

**IN THE UNITED STATES DISTRICT COURT
FOR THE NORTHERN DISTRICT OF OHIO
EASTERN DIVISION**

**IN RE: NATIONAL PRESCRIPTION
OPIATE LITIGATION**

This document relates to:

*The County of Summit, Ohio, et al. v. Purdue
Pharma L.P., et al.*
Case No. 18-op-45090

and

*The County of Cuyahoga v. Purdue Pharma
L.P., et al.*
Case No. 1:18-op-45004

MDL No. 2804

Case No. 17-md-2804

Hon. Judge Dan A. Polster

THE JANSSEN DEFENDANTS' TRIAL EXHIBIT LIST

The Janssen Defendants¹ submit the following trial exhibit list pursuant to the Civil Jury Trial Order, ECF No. 1598, entered in *In re National Prescription Opiate Litigation* (MDL 2804) on May 1, 2019 (as amended on July 29, 2019), and the Parties' Joint Trial Exhibit Stipulation and Template submitted to the Court on August 16, 2019. The Janssen Defendants submit this trial exhibit list subject to the following reservation of rights:

1. To withdraw at any time any exhibit identified on these lists;
2. To use admissible exhibits identified or used by Plaintiffs or any other party;
3. To supplement and/or amend these lists upon receipt of Plaintiffs' exhibit list(s), witness list(s) and/or amendments and changes to Plaintiffs' or Defendants' deposition designations or counter-designations;
4. To supplement and/or to amend these lists in the event that additional relevant documents or materials are produced in this action, identified in subsequent supplemental expert reports, or are discovered subsequent to the date of service of these exhibit lists;
5. To supplement these lists with any medical or scientific literature, other data, or regulatory findings or communications issued or published after the date of this submission;
6. To supplement and/or to amend these exhibit lists to use additional unlisted documents and/or data at trial as required for rebuttal, cross examination, demonstrative purposes, impeachment purposes, or to cure an evidentiary objection, or to the extent Plaintiffs proffer any documents which Plaintiffs have not listed or to

¹ Janssen Pharmaceuticals, Inc., Johnson & Johnson, Janssen Pharmaceutica, Inc. n/k/a Janssen Pharmaceuticals, Inc., and Ortho-McNeil-Janssen Pharmaceuticals, Inc. n/k/a Janssen Pharmaceuticals, Inc.

- the extent that Plaintiffs purport to pursue claims or theories not set forth in their pleadings to date;
7. To object to the introduction and/or admissibility of any document listed on the exhibit lists;
 8. That the inclusion of any exhibit on any exhibit list does not waive or affect any prior confidentiality designations in this litigation;
 9. That the inclusion of a particular document on the Janssen Defendants' exhibit list is not intended to be a waiver of the right to object to the introduction and/or admissibility of that document for any purpose;
 10. To use alternative copies of exhibits where appropriate, including but not limited to physical, color, redacted, and/or native documents, or copies, without deposition exhibit stickers;
 11. To use trial demonstrative exhibits, including without limitation: charts, graphs, photographs, animations, timelines, objects, models, PowerPoint slides, drawings, graphics, and other demonstrative aids;
 12. To offer enlargements of any exhibits on the lists or on any party's exhibit lists;
 13. To supplement and/or to amend these lists in response to rulings of the Court on pretrial motions, including any Daubert motions, Motions for Summary Judgment, or motions in limine, or any other Court decisions that affect the scope of evidence in this trial; and
 14. To supplement and/or amend these lists as necessary based on the Court's order regarding the severing of particular party and/or as necessary based on future severance, settlement, and/or dismissal of any other party.

Dated: September 25, 2019

Respectfully Submitted,

/s/ Charles C. Lifland

Charles C. Lifland
Sabrina H. Strong
O'MELVENY & MYERS LLP
400 S. Hope Street
Los Angeles, CA 90071
Tel: (213) 430-6000
clifland@omm.com
sstrong@omm.com

Daniel M. Petrocelli
Amy R. Lucas
O'MELVENY & MYERS LLP
1999 Avenue of the Stars, 8th Floor
Los Angeles, CA 90067-6035
Tel: (310) 553-6700 dpetrocelli@omm.com
alucas@omm.com

*Attorneys for Defendants Janssen
Pharmaceuticals, Inc., Johnson & Johnson,
Janssen Pharmaceutica, Inc. n/k/a Janssen
Pharmaceuticals, Inc., and Ortho-McNeil-Janssen
Pharmaceuticals, Inc. n/k/a Janssen
Pharmaceuticals, Inc.*

CERTIFICATE OF SERVICE

I, Charles C. Lifland, hereby certify that the foregoing document was served on September 25, 2019 via electronic transfer to all counsel of record, consistent with the Court's order.

/s/ Charles C. Lifland
Charles C. Lifland
Sabrina H. Strong
O'MELVENY & MYERS LLP
400 S. Hope Street
Los Angeles, CA 90071
Tel: (213) 430-6000
clifland@omm.com

Janssen Defendants' Trial Exhibit List (09/25/19)											
Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-00001	06/22/2016	Augustine J, et al., Ability and Use of Comparative Effectiveness Research by P&T Committee Members and Support Staff: A 1-Year Follow-up, Journal of Managed Care & Specialty Pharmacy, Vol. 22(6), pp. 618-625, 2016 Jun	JAN-TREX-00000001	JAN-TREX-00000007							
JA-00002	08/08/2017	Banken R, et al., Abuse Deterrent Formulations of Opioids: Effectiveness and Value, Institute for Clinical and Economic Review, 2007	JAN-TREX-00000008	JAN-TREX-00000217							
JA-00003	07/10/1905	American Society of Addiction Medicine Presentation: Treatment of Opioid Use Disorder Course	JAN-TREX-00000218	JAN-TREX-00000245							
JA-00004	11/05/2018	Avalere Health Press Release, re: Access to Abuse-Deterrent Opioid Formulations Tied to Reduced Risk of Opioid Abuse and Overdose	JAN-TREX-00149907	JAN-TREX-00149907							
JA-00005	01/23/2008	Tyler LS, et. al., American Society of Health-System Pharmacists, (ASHP), Statement on the Pharmacy and Therapeutics Committee and the Formulary System, Am J Health-Syst Pharm., 65: 2384-6, pp. 215-7, 2008	JAN-TREX-00000246	JAN-TREX-00000248							
JA-00006	07/10/1905	CareSource Website: Caresource Implements Quantity Limits on Opioids for Ohio Medicaid, available at https://www.caresource.com/documents/oh-p-1413 spring2018-providersource-insert-mcd-opioid-04042018/	JAN-TREX-00000249	JAN-TREX-00000250							
JA-00007	09/01/2015	Substance Abuse and Mental Health Services Administration (SAMHSA), U.S. Department of Health and Human Services Website: Behavioral Health Trends in the United States: Results from the 2014 National Survey on Drug Use and Health, available at https://www.samhsa.gov/data/sites/default/files/NSDUH-FRR1-2014/NSDUH-FRR1-2014.pdf	JAN-TREX-00149908	JAN-TREX-00149908							
JA-00008	03/18/2016	Dowell D, et al., CDC Guideline for Prescribing Opioids for Chronic Pain — United States, 2016, Centers for Disease Control and Prevention MMWR, Vol 65(1), pp. 1-49, Mar. 18, 2016	JAN-TREX-00000251	JAN-TREX-00000302							
JA-00009	03/18/2016	Dowell D, et al., CDC Guideline for Prescribing Opioids for Chronic Pain — United States, 2016, Centers for Disease Control and Prevention MMWR, Vol 65(1), pp. 1-49, Mar. 18, 2016	JAN-TREX-00000303	JAN-TREX-00000354							
JA-00010	07/28/2011	HealthLeaders Website: States to get Drug Rebates Even Under Managed Care, available at https://www.healthleadersmedia.com/finance/states-get-drug-rebates-even-under-managed	JAN-TREX-00000355	JAN-TREX-00000359							
JA-00011	01/28/2016	Centers For Medicare & Medicaid Services, CMCS Informational Bulletin re: Best Practices for Addressing Prescription Opioid Overdoses, Misuse and Addiction	JAN-TREX-00000360	JAN-TREX-00000374							
JA-00012	04/01/2008	Cohen J, et al., Role of Budget Impact in Drug Reimbursement Decisions, Journal of Health Politics, Policy and Law, Vol. 33(20), pp. 225- 247, April 2008	JAN-TREX-00000375	JAN-TREX-00000398							
JA-00013	01/23/2019	Forbes Website: The Importance of Patient-Centric Opioid Prescribing Guidelines, Cohen, J, available at https://www.forbes.com/sites/joshuacohen/2019/01/23/the-importance-of-patient-centric-opioid-prescribing-guidelines/#4b9df9df1b7a	JAN-TREX-00000399	JAN-TREX-00000401							
JA-00014	02/12/2019	Hartung D., et al., Research Letter: Buprenorphine Coverage in the Medicare Part D Program for 2007 to 2018, JAMA, 321(6), pp. 607-9, Feb. 12, 2019	JAN-TREX-00000402	JAN-TREX-00000404							
JA-00015	04/21/2016	Frieden T, et al., Reducing the Risks of Relief — The CDC Opioid-Prescribing Guideline, New England Journal of Medicine, 374(16) pp. 1501-1504, April 21, 2016	JAN-TREX-00000405	JAN-TREX-00000408							
JA-00016	05/23/2017	Palanker D et al., Responding to the Opioid Crisis: Insurers Balance Stepped up Monitoring, Restrictions with Need for Appropriate Pain Treatment, Georgetown University Health Policy Institute Center on Health Insurance Reforms. May 23, 2017, available at http://chirblog.org/responding-opioid-crisis-insurers-balance-stepped-monitoring-restrictions-need-appropriate-pain-treatment/	JAN-TREX-00000409	JAN-TREX-00000412							
JA-00017	07/08/1905	Kaiser Family Foundation, Health Insurance Coverage of the Total Population, 2016, available at https://www.kff.org/other/state-indicator/total-population/?currentTimeframe=0&sortModel=%7B%22colId%22%22%22Location%22%22sort%22%22asc%22%7D	JAN-TREX-00000413	JAN-TREX-00000414							
JA-00018	07/10/1905	Kaiser Family Foundation, States Reporting Medicaid FFS Pharmacy Benefit Management Strategies for Opioids In Place. 2017, available at https://www.kff.org/medicaid/state-indicator/states-reporting-medicaid-ffs-pharmacy-benefit-management-strategies-for-opioids-in-place/?currentTimeframe=0&sortModel=%7B%22colId%22%22Location%22%22sort%22%22asc%22%7D	JAN-TREX-00000415	JAN-TREX-00000416							
JA-00019	02/01/2018	Kaiser Family Foundation, Medicaid's Role In Addressing The Opioid Epidemic, February 2018, available at https://www.kff.org/infographic/medicaids-role-in-addressing-opioid-epidemic/	JAN-TREX-00000417	JAN-TREX-00000418							
JA-00020	06/22/2018	Lin D, et al., Prescription Drug Coverage for Treatment of Low Back Pain Among US Medicaid, Medicare Advantage, and Commercial Insurers, JAMA Network Open 2018;1(2):e180235, available at https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2685625	JAN-TREX-00000419	JAN-TREX-00000431							
JA-00021	09/07/2016	Martin S, et al., Neat, Plausible, and Generally Wrong: A Response to the CDC Recommendations for Chronic Opioid Use. Medium. 2016, available at https://medium.com/@stmartin/neat-plausible-and-generally-wrong-a-response-to-the-cdc-recommendation-for-opioid-use-5c9d9d319f71	JAN-TREX-00000432	JAN-TREX-00000455							
JA-00022	06/26/2018	Ohio Auditor of State Website: The Opioid Crisis: The impact on the Medicaid population is stretching the state's safety net, available at https://www.ohioauditor.gov/publications/Special_Report_The_Opioid_Crisis.pdf	JAN-TREX-00000456	JAN-TREX-00000472							
JA-00023	01/04/2017	Penm J, et al., Strategies and policies to address the opioid epidemic: A case study of Ohio, Journal of the American Pharmacists Association, 57(2), pp. 5148-5153, 2017	JAN-TREX-00000473	JAN-TREX-00000478							
JA-00024	02/14/2014	Rossiter L, et al., Medical cost savings associated with an extended-release opioid with abuse-deterrent technology in the US, Journal of Medical Economics, 17(4), pp. 279-287, 14 Feb 2014	JAN-TREX-00000479	JAN-TREX-00000495							
JA-00025	10/02/2018	Sandoe E, et al., Policy Levers That States Can Use To improve Opioid Addiction Treatment And Address The Opioid Epidemic, Health Affairs Blog, October 2, 2018, available at https://www.healthaffairs.org/doi/10.1377/hblog20180927.51221/full/	JAN-TREX-00000496	JAN-TREX-00000506							
JA-00026	07/01/2018	U.S. Department Of Health & Human Services Office of Inspector General Data Brief, re: Opioids in Ohio Medicaid: Review of Extreme Use and Prescribing, July 2018.	JAN-TREX-00000507	JAN-TREX-00000539							
JA-00027	2015 - 2016	Allergan Spreadsheet detailing total monthly prescriptions of products by State and Specialty	ALLERGAN-MDL-00327296	ALLERGAN-MDL-00327305							
JA-00028	01/2016-12/2017	Allergan Spreadsheet detailing MSA Smart Regional Audit from December 2015 to November 2017 Fiorinal with Codeine and Reprexain	ALLERGAN-MDL-01095284	ALLERGAN-MDL-01095289							
JA-00029	No Date	Allergan spreadsheet tracking products by market, price and manufacturer	ALLERGAN-MDL-03320303	ALLERGAN-MDL-03320311							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-00030	N/A	IQVIA national prescription data	ALLERGAN_MDL_02485011	ALLERGAN_MDL_02485011							
JA-00031	N/A	IQVIA national prescription data	ALLERGAN_MDL_03281086	ALLERGAN_MDL_03281086							
JA-00032	01/03/2019	Par Pharmaceutical Spreadsheet with Monthly Integrated Views of Endo and Par Prescriptions	PAR_OPIOID_MDL_0002016786	PAR_OPIOID_MDL_0002016786							
JA-00033	01/18/2017	Insys Spreadsheet detailing Total Prescriptions by Product and Prescriber	INSYS-MDL-015010545	INSYS-MDL-015010756							
JA-00034	07/27/2000	Janssen Spreadsheet: Duragesic DDD-Xponent Sales	JAN-MS-02393502	JAN-MS-02393502							
JA-00035	10/16/2001	Janssen Spreadsheet: August xponent data, 24 Months	JAN-MS-00787237	JAN-MS-00787237							
JA-00036	07/16/2003	Janssen Spreadsheet: related to Duragesic Growth Contest analysis	JAN-MS-00781210	JAN-MS-00781210							
JA-00037	09/01/2010	Janssen Spreadsheets: SAO CII MARKET TRx, NUCYNTA TRx - Sum Breakout Target 03/21/2010 - 09/03/2010	JAN-MS-02947176	JAN-MS-02947190							
JA-00038	04/01/2001	Spreadsheet: Average RX size for Duragesic April 2001	JAN-MS-00305682	JAN-MS-00305682							
JA-00039	08/01/2002	Spreadsheet: IMS Health: NPA 20K-Monthly Rx Audit	JAN-MS-01058369	JAN-MS-01058370							
JA-00040	06/25/2004	Spreadsheet: IMS Health: NPA+7-Monthly Rx Audit	JAN-MS-04199447	JAN-MS-04199447							
JA-00041	01/20/2005	Spreadsheet: IMS Health NPA: Duragesic: TRx Volume 3Q04-1Q01	JAN-MS-01966908	JAN-MS-01966908							
JA-00042	05/10/2005	Spreadsheet: IMS health NPA: Duragesic TRx Volume 3Q04-1Q01	JAN-MS-00576268	JAN-MS-00576268							
JA-00043	06/27/1905	Spreadsheet: NPA Data-July (2005)	JAN-MS-03076681	JAN-MS-03076681							
JA-00044	06/27/1905	Spreadsheet: NPA Data-September	JAN-MS-03076692	JAN-MS-03076692							
JA-00045	06/27/1905	Spreadsheet: NPA Data-October	JAN-MS-03076703	JAN-MS-03076703							
JA-00046	06/27/1905	Spreadsheet: IMS NPA-All Specialties	JAN-MS-00596312	JAN-MS-00596312							
JA-00047	06/27/1905	Spreadsheet: NPA Data-May	JAN-MS-02017065	JAN-MS-02017065							
JA-00048	06/28/1905	Janssen Spreadsheet: IMS Health: NPA+7-Monthly Rx Audit	JAN-MS-00775284	JAN-MS-00775284							
JA-00049	06/28/1905	Spreadsheet: IMS Health: NPA+7-Monthly RxAudit	JAN-MS-02307427	JAN-MS-02307427							
JA-00050	07/20/2007	Spreadsheet: Trx, Layer 1/2	JAN-MS-01104313	JAN-MS-01104313							
JA-00051	08/23/2007	Spreadsheet: All Channels Retail Mail Order Long term Care	JAN-MS-01105655	JAN-MS-01105655							
JA-00052	06/29/1905	Spreadsheet: IMS Health: NPA-Weekly RX	JAN-MS-00591746	JAN-MS-00591746							
JA-00053	10/23/2007	Spreadsheet: LAO-CRA Template	JAN-MS-00475711	JAN-MS-00475711							
JA-00054	01/04/2008	Spreadsheet: IMS Product News: NPA Projected Guidance for mail Service Channel	JAN-MS-03858080	JAN-MS-03858080							
JA-00055	06/29/1905	Spreadsheet: December 2007 IMS NPA Data	JAN-MS-01104123	JAN-MS-01104123							
JA-00056	06/30/1905	Spreadsheet: Long Acting Opioid Market	JAN-MS-02005678	JAN-MS-02005678							
JA-00057	08/01/2008	Spreadsheet: Tapentadol IR-Oral Solution Forecast: Historical Market Growth & Share	JAN-MS-00441684	JAN-MS-00441684							
JA-00058	06/30/1905	Spreadsheet: IMS NPA Audit	JAN-MS-01104099	JAN-MS-01104099							
JA-00059	12/17/2008	Spreadsheet: IMS NPA Audit	JAN-MS-00593346	JAN-MS-00593346							
JA-00060	07/01/1905	Spreadsheet: NPA TRx (2009)	JAN-MS-01105401	JAN-MS-01105401							
JA-00061	07/01/1905	Spreadsheet: IMS Health NPA-Weekly Rx	JAN-MS-01106787	JAN-MS-01106787							
JA-00062	12/07/2009	Spreadsheet: IMS Health NPA-Weekly Rx	JAN-MS-02919982	JAN-MS-02919982							
JA-00063	07/01/1905	Spreadsheet: IMS Health NPA-Monthly Rx	JAN-MS-00590953	JAN-MS-00590953							
JA-00064	07/02/1905	Spreadsheet: IMS Health: NPA-Weekly Rx	JAN-MS-02008829	JAN-MS-02008829							
JA-00065	07/02/1905	Spreadsheet: IMS Health: NPA-Weekly TRx	JAN-MS-02002959	JAN-MS-02002959							
JA-00066	07/02/1905	Spreadsheet: IMS Health; NPA-Weekly Trx	JAN-MS-02749960	JAN-MS-02749960							
JA-00067	04/13/2010	Spreadsheet: IMS health; NPA-Monthly Rx	JAN-MS-02920042	JAN-MS-02920042							
JA-00068	07/19/2010	Janssen Spreadsheet FentPavZ	JAN-MS-01977233	JAN-MS-01977234							
JA-00069	07/02/1905	Spreadsheet: 2010 BP IMS-NPA: Levaquin Tabs-Retail	JAN-MS-03872290	JAN-MS-03872290							
JA-00070	10/12/2010	Spreadsheet with Launch Analog Data	JAN-MS-02921425	JAN-MS-02921426							
JA-00071	11/12/2010	Spreadsheet: IMS Health: NPA-Weekly TRx	JAN-MS-00293633	JAN-MS-00293633							
JA-00072	11/26/2010	Spreadsheet: IMS Health: NPA-Weekly TRx	JAN-MS-01977983	JAN-MS-01977983							
JA-00073	01/24/2011	Spreadsheet with Duragesic 2010 TrX Mix	JAN-MS-00580102	JAN-MS-00580102							
JA-00074	03/01/2011	Spreadsheet with CII_weekly volumes	JAN-MS-02920344	JAN-MS-02920344							
JA-00075	04/11/2011	Spreadsheet with CII LAO Market TRx - 2004 to 2011 (Oxy Gr Analysis)	JAN-MS-02920425	JAN-MS-02920425							
JA-00076	06/21/2011	Spreadsheet with Reporting\Weekly Tracking Metrics\2011\Data Files	JAN-MS-02947572	JAN-MS-02947572							
JA-00077	06/28/2011	Spreadsheet with Duragesic Historical Weekly by Strength data	JAN-MS-00580607	JAN-MS-00580607							
JA-00078	09/30/2011	Spreadsheet with CII Opioid Mthly NPA Spec (Jan06-Aug11)	JAN-MS-02934491	JAN-MS-02934493							
JA-00079	10/17/2011	Spreadsheet with CII Mthly NPA Spec by SKU (Jan11-Sep11)	JAN-MS-02934489	JAN-MS-02934489							
JA-00080	10/21/2011	Spreadsheet with CII LAO Market TRx - 2004 to 2011 (Oxy Gr Analysis)	JAN-MS-02920554	JAN-MS-02920554							
JA-00081	10/26/2011	Spreadsheet: 2010 and 2011 Prescription Data	JAN-MS-02920587	JAN-MS-02920587							
JA-00082	11/03/2011	Spreadsheet: Opioid Prescription Data	JAN-MS-02947971	JAN-MS-02947971							
JA-00083	11/07/2011	Spreadsheet: IMS Opioid Prescription Data	JAN-MS-02947584	JAN-MS-02947584							
JA-00084	12/16/2011	Spreadsheet: IMS Prescription data for Nucynta	JAN-MS-02934260	JAN-MS-02934260							
JA-00085	01/23/2012	Spreadsheet: Prescription Data for Nucynta	JAN-MS-02933586	JAN-MS-02933586							
JA-00086	01/23/2012	Spreadsheet: IMS National Prescription Audit Data for Nucynta	JAN-MS-02933588	JAN-MS-02933588							
JA-00087	01/23/2012	Spreadsheet: IMS National Prescription Audit Data For Nucynta	JAN-MS-02545691	JAN-MS-02545691							
JA-00088	01/23/2012	Spreadsheet: IMS National Prescription Audit Data	JAN-MS-02545689	JAN-MS-02545689							
JA-00089	01/23/2012	Spreadsheet: Nucynta Prescriber Data for Period Jan - Dec 2011	JAN-MS-02669052	JAN-MS-02669052							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-00090	01/30/2012	Janssen Spreadsheet: NPA Summary Data	JAN-MS-02932779	JAN-MS-02932779							
JA-00091	07/03/1905	Janssen Spreadsheet: Nucynta prescription sales comparison for 2010 to 2011	JAN-MS-02933552	JAN-MS-02933552							
JA-00092	07/04/1905	Janssen Spreadsheet: Prescription data for 2006 to 2011 and projections	JAN-MS-02920809	JAN-MS-02920809							
JA-00093	07/04/1905	Janssen Spreadsheet: Nucynta prescription sales 2011 to 2012	JAN-MS-02947054	JAN-MS-02947054							
JA-00094	02/01/2012	Janssen Spreadsheet: Opioid prescription sales and market share 2011 to 02/2012	JAN-MS-02948348	JAN-MS-02948348							
JA-00095	02/01/2012	Janssen Spreadsheet: Opioid prescription market share data 2011 to 02/2012	JAN-MS-02948361	JAN-MS-02948361							
JA-00096	01/30/2012	Janssen Spreadsheet: Opana - IMS NPA Spec - LTD thru Dec11	JAN-MS-02932780	JAN-MS-02932780							
JA-00097	06/01/2012	Janssen Spreadsheet: Nucynta sales data for 01/2012 to 05/2012	JAN-MS-02920999	JAN-MS-02920999							
JA-00098	05/01/2012	Janssen Spreadsheet: Nucynta prescription sales comparison for 2011	JAN-MS-02948346	JAN-MS-02948346							
JA-00099	05/01/2012	Janssen Spreadsheet: Share percentages and DACON information for Drug Cost Calculator 2011	JAN-MS-00354503	JAN-MS-00354503							
JA-00100	07/06/1905	Janssen Spreadsheet: Nucynta prescription sales data and weekly average 2012 to 2013	JAN-MS-02921037	JAN-MS-02921037							
JA-00101	07/20/2012	Janssen Spreadsheet: Nucynta prescription sales data 2011 and 2012	JAN-MS-02933555	JAN-MS-02933555							
JA-00102	07/20/2012	Janssen Spreadsheet: Nucynta IR and ER prescription sales data 2011 and 2012	JAN-MS-02933589	JAN-MS-02933590							
JA-00103	03/12/2013	Janssen Spreadsheet: Duragesic & Fentanyl (37 mcg project) data and charts 2011 to 2013	JAN-MS-01986956	JAN-MS-01986956							
JA-00104	03/15/2013	Janssen Spreadsheet: Duragesic TRx market share among all fentanyl patch products	JAN-MS-00585450	JAN-MS-00585450							
JA-00105	04/10/2013	Janssen Spreadsheet: Duragesic Fentanyl Patch Volume History Through February 2013	JAN-MS-01988352	JAN-MS-01988353							
JA-00106	04/15/2013	Janssen Spreadsheet: Duragesic Fentanyl Weekly Monthly Report 04/05/13	JAN-MS-01987152	JAN-MS-01987152							
JA-00107	07/05/1905	Janssen Spreadsheet: Nucynta and other prescription opioids sales data for 2004 to 2013	JAN-MS-02933118	JAN-MS-02933118							
JA-00108	04/15/2013	Janssen Spreadsheet: Duragesic Fentanyl Weekly Monthly Report 04/05/13 with March 2013	JAN-MS-01987190	JAN-MS-01987190							
JA-00109	04/22/2013	Janssen Spreadsheet: Duragesic Fentanyl NPA Weekly Monthly Report 04/12/13 with March 2013	JAN-MS-00582474	JAN-MS-00582474							
JA-00110	04/29/2013	Janssen Spreadsheet: Duragesic Fentanyl NPA Weekly Monthly Report 04/19/13 with March 2013	JAN-MS-00582486	JAN-MS-00582486							
JA-00111	05/06/2013	Janssen Spreadsheet: Duragesic Fentanyl NPA Weekly Monthly Report 04/26/13 with March 2013	JAN-MS-00582495	JAN-MS-00582495							
JA-00112	03/29/2013	Janssen Spreadsheet: Opioid prescription sales data for 2004 to 2013	JAN-MS-02933149	JAN-MS-02933149							
JA-00113	05/13/2013	Janssen Spreadsheet: Duragesic Fentanyl NPA Weekly Monthly Report 05/03/13 with March 2013	JAN-MS-00582504	JAN-MS-00582504							
JA-00114	05/13/2013	Janssen Spreadsheet: Duragesic Fentanyl NPA Weekly Monthly Report 05/03/13 with April 2013	JAN-MS-00582509	JAN-MS-00582509							
JA-00115	05/20/2013	Janssen Spreadsheet: Duragesic Fentanyl NPA Weekly Monthly Report 05/10/13 with April 2013	JAN-MS-00582511	JAN-MS-00582511							
JA-00116	06/10/2013	Janssen Spreadsheet: Duragesic Fentanyl NPA Weekly Monthly Report 05/31/13 with April 2013	JAN-MS-00582572	JAN-MS-00582572							
JA-00117	06/10/2013	Janssen Spreadsheet: Duragesic Fentanyl NPA Weekly Monthly Report 05/31/13 with April 2013	JAN-MS-01992729	JAN-MS-01992729							
JA-00118	06/18/2013	Janssen Spreadsheet: Duragesic Fentanyl NPA Weekly Monthly Report 06/07/13 with May 2013	JAN-MS-00582579	JAN-MS-00582579							
JA-00119	06/24/2013	Janssen Spreadsheet: Duragesic/Fentanyl Patch Weekly/Monthly IMS Data Report	JAN-MS-01992734	JAN-MS-01992734							
JA-00120	07/02/2013	Janssen Spreadsheet: Duragesic/Fentanyl Patch Weekly/Monthly IMS Data Report (Week-Ending 6/21/13)	JAN-MS-01992737	JAN-MS-01992737							
JA-00121	07/08/2013	Janssen Spreadsheet: Duragesic/Fentanyl Patch Weekly/Monthly IMS Data	JAN-MS-01992740	JAN-MS-01992740							
JA-00122	07/15/2013	Janssen Spreadsheet: Duragesic Fentanyl NPA Weekly Monthly Report 07/05/13 with May 2013	JAN-MS-01992743	JAN-MS-01992743							
JA-00123	07/23/2013	Janssen Spreadsheet: Duragesic/Fentanyl Patch Weekly/Monthly IMS Data Report (Week-Ending 7/12/13)	JAN-MS-01992746	JAN-MS-01992746							
JA-00124	07/29/2013	Janssen Spreadsheet: Duragesic/Fentanyl Patch Weekly/Monthly IMS Data Report (Week-Ending 7/19/13)	JAN-MS-01992749	JAN-MS-01992749							
JA-00125	12/01/2014	Janssen Spreadsheet: Nucynta sales data 2004 to 2014	JAN-MS-02921129	JAN-MS-02921129							
JA-00126	07/31/2013	Janssen Spreadsheet: Duragesic Fentanyl NPA Monthly TRx Vol and Share June 2013	JAN-MS-00582669	JAN-MS-00582669							
JA-00127	08/05/2013	Janssen Spreadsheet: Duragesic/Fentanyl Patch Weekly/Monthly IMS Data Report (Week-Ending 7/26/13)	JAN-MS-01992752	JAN-MS-01992752							
JA-00128	08/12/2013	Janssen Spreadsheet: Duragesic/Fentanyl Patch Weekly/Monthly IMS Data Report (Week-Ending 8/2/13)	JAN-MS-00582683	JAN-MS-00582683							
JA-00129	08/19/2013	Janssen Spreadsheet: Duragesic/Fentanyl Patch Weekly/Monthly IMS Data Report (Week-Ending 8/9/13)	JAN-MS-00582695	JAN-MS-00582695							
JA-00130	08/26/2013	Janssen Spreadsheet: Duragesic/Fentanyl Patch Weekly/Monthly IMS Data Report (Week-Ending 8/16/13)	JAN-MS-00582703	JAN-MS-00582703							
JA-00131	09/03/2013	Janssen Spreadsheet: Duragesic/Fentanyl Patch Weekly/Monthly IMS Data Report (Week-Ending 8/23/13)	JAN-MS-00582717	JAN-MS-00582717							
JA-00132	09/10/2013	Janssen Spreadsheet: Duragesic/Fentanyl Patch Weekly/Monthly IMS Data Report (Week-Ending 8/30/13)	JAN-MS-00582724	JAN-MS-00582724							
JA-00133	09/18/2013	Janssen Spreadsheet: Duragesic/Fentanyl Patch Weekly/Monthly IMS Data Report (Week-Ending 09/6/13)	JAN-MS-00582742	JAN-MS-00582742							
JA-00134	09/23/2013	Janssen Spreadsheet: Duragesic/Fentanyl Patch Weekly/Monthly IMS Data Report (Week-Ending 9/13/13)	JAN-MS-00582747	JAN-MS-00582747							
JA-00135	09/30/2013	Janssen Spreadsheet: Duragesic/Fentanyl Patch Weekly/Monthly IMS Data Report (Week-Ending 9/20/13)	JAN-MS-00582752	JAN-MS-00582752							
JA-00136	10/07/2013	Janssen Spreadsheet: Duragesic/Fentanyl Patch Weekly/Monthly IMS Data Report (Week-Ending 9/27/13)	JAN-MS-00582788	JAN-MS-00582788							
JA-00137	10/15/2013	Janssen Spreadsheet: Duragesic/Fentanyl Patch Weekly/Monthly IMS Data Report (Week-Ending 10/4/13)	JAN-MS-00582824	JAN-MS-00582824							
JA-00138	10/30/2013	Janssen Spreadsheet: Duragesic/Fentanyl Patch Weekly/Monthly IMS Data Report (Week-Ending 10/18/13)	JAN-MS-00582839	JAN-MS-00582839							
JA-00139	11/12/2013	Janssen Spreadsheet: Duragesic/Fentanyl Patch Weekly/Monthly IMS Data Report (Week-Ending 11/1/13)	JAN-MS-00582859	JAN-MS-00582859							
JA-00140	11/18/2013	Janssen Spreadsheet: Duragesic/Fentanyl Patch Weekly/Monthly IMS Data Report (Week-Ending 11/8/13)	JAN-MS-00582875	JAN-MS-00582875							
JA-00141	12/06/2013	Janssen Spreadsheet: Duragesic/Fentanyl Patch Weekly/Monthly IMS Data Report (Week-Ending 11/22/13)	JAN-MS-00582907	JAN-MS-00582907							
JA-00142	12/11/2013	Janssen Spreadsheet: Duragesic/Fentanyl Patch Weekly/Monthly IMS Data Report (Week-Ending 11/29/13)	JAN-MS-00582919	JAN-MS-00582919							
JA-00143	12/20/2013	Janssen Spreadsheet: Duragesic/Fentanyl Patch Weekly/Monthly IMS Data Report (Week-Ending 12/6/13)	JAN-MS-00582930	JAN-MS-00582930							
JA-00144	12/23/2013	Janssen Spreadsheet: Duragesic/Fentanyl Patch Weekly/Monthly IMS Data Report (Week-Ending 12/13/13)	JAN-MS-00582943	JAN-MS-00582943							
JA-00145	12/20/2013	Spreadsheet: DuragesicFentanyl_NPAWeeklyMonthlyReport_122013_withNovember2013.xlsx	JAN-MS-00582949	JAN-MS-00582949							
JA-00146	12/27/2013	Spreadsheet: DuragesicFentanyl_NPAWeeklyMonthlyReport_122713_withNovember2013.xlsx	JAN-MS-00582958	JAN-MS-00582958							
JA-00147	12/01/2013	Spreadsheet: DuragesicFentanyl_NPAWeeklyMonthlyReportwithDecember2013.xlsx	JAN-MS-00582977	JAN-MS-00582977							
JA-00148	01/10/2014	Spreadsheet: DuragesicFentanyl_NPAWeeklyMonthlyReport_1-10-14.xlsx	JAN-MS-00582996	JAN-MS-00582996							
JA-00149	01/17/2014	Spreadsheet: DuragesicFentanyl_NPAWeeklyMonthlyReport_1-17-14.xlsx	JAN-MS-00583014	JAN-MS-00583014							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-00150	12/01/2013	Spreadsheet: Fentanyl12mcgNPAPharmacy&RetailDollarsDecember2013.xlsx	JAN-MS-00583009	JAN-MS-00583009							
JA-00151	12/01/2013	Spreadsheet: Fentanyl12mcgTRxSharesDec2013.xlsx	JAN-MS-00583011	JAN-MS-00583011							
JA-00152	01/24/2014	Spreadsheet: DuragesicFentanyl_NPAWeeklyMonthlyReport_1-24-14.xlsx	JAN-MS-01992993	JAN-MS-01992993							
JA-00153	02/05/2014	Spreadsheet: FentanylExplanations.xlsx	JAN-MS-01988225	JAN-MS-01988225							
JA-00154	02/08/2014	Janssen spreadsheet: Fentanyl Explanations	JAN-MS-01988280	JAN-MS-01988280							
JA-00155	01/31/2014	Spreadsheet: DuragesicFentanyl_NPAWeeklyMonthlyReport_1-31-14.xlsx	JAN-MS-01993014	JAN-MS-01993014							
JA-00156	02/07/2014	Spreadsheet: DuragesicFentanyl_NPAWeeklyMonthlyReport_2-7-14.xlsx	JAN-MS-00583101	JAN-MS-00583101							
JA-00157	02/14/2014	Spreadsheet: DuragesicFentanyl_NPAWeeklyMonthlyReport_2-14-14.xlsx	JAN-MS-00583105	JAN-MS-00583105							
JA-00158	02/21/2014	Spreadsheet: DuragesicFentanyl_NPAWeeklyMonthlyReport_2-21-14.xlsx	JAN-MS-00583113	JAN-MS-00583113							
JA-00159	02/28/2014	Spreadsheet: DuragesicFentanyl_NPAWeeklyMonthlyReport_2-28-14.xlsx	JAN-MS-01988472	JAN-MS-01988472							
JA-00160	03/07/2014	Spreadsheet: DuragesicFentanyl_NPAWeeklyMonthlyReport_3-7-14.xlsx	JAN-MS-00583144	JAN-MS-00583144							
JA-00161	03/14/2014	Spreadsheet: DuragesicFentanyl_NPAWeeklyMonthlyReport_3-14-14.xlsx	JAN-MS-00583149	JAN-MS-00583149							
JA-00162	03/21/2014	Spreadsheet: DuragesicFentanyl_NPAWeeklyMonthlyReport_3-21-14.xlsx	JAN-MS-00583162	JAN-MS-00583162							
JA-00163	03/28/2014	Spreadsheet: DuragesicFentanyl_NPAWeeklyMonthlyReport_3-28-14.xlsx	JAN-MS-00583169	JAN-MS-00583169							
JA-00164	04/04/2014	Spreadsheet: DuragesicFentanyl_NPAWeeklyMonthlyReport_4-4-14.xlsx	JAN-MS-00583183	JAN-MS-00583183							
JA-00165	04/15/2014	Spreadsheet: Fentanyl_Patch_U.S._VeterinaryOnly_MAT_TRx_TRx\$_Totals.xlsx	JAN-MS-01989075	JAN-MS-01989075							
JA-00166	04/11/2014	Spreadsheet: DuragesicFentanyl_NPAWeeklyMonthlyReport_4-11-14.xlsx	JAN-MS-00583192	JAN-MS-00583192							
JA-00167	04/18/2014	Spreadsheet: DuragesicFentanyl_NPAWeeklyMonthlyReport_4-18-14.xlsx	JAN-MS-00583202	JAN-MS-00583202							
JA-00168	04/25/2014	Spreadsheet: DuragesicFentanyl_NPAWeeklyMonthlyReport_4-25-14.xlsx	JAN-MS-00583216	JAN-MS-00583216							
JA-00169	05/02/2014	Spreadsheet: DuragesicFentanyl_NPAWeeklyMonthlyReport_5-2-14.xlsx	JAN-MS-00583237	JAN-MS-00583237							
JA-00170	05/09/2014	Spreadsheet: DuragesicFentanyl_NPAWeeklyMonthlyReport_5-9-14	JAN-MS-00583248	JAN-MS-00583248							
JA-00171	05/16/2014	Spreadsheet: DuragesicFentanyl_NPAWeeklyMonthlyReport_5-16-14.xlsx	JAN-MS-00583261	JAN-MS-00583261							
JA-00172	05/23/2014	Spreadsheet: DuragesicFentanyl_NPAWeeklyMonthlyReport_5-23-14.xlsx	JAN-MS-00583268	JAN-MS-00583268							
JA-00173	06/06/2014	Spreadsheet: DuragesicStengthMOPCoPay.xlsx	JAN-MS-00583279	JAN-MS-00583279							
JA-00174	05/30/2014	Spreadsheet: DuragesicFentanyl_NPAWeeklyMonthlyReport_5-30-14.xlsx	JAN-MS-00583284	JAN-MS-00583284							
JA-00175	06/06/2014	Spreadsheet: DuragesicFentanyl_NPAWeeklyMonthlyReport_6-6-14.xlsx	JAN-MS-01989371	JAN-MS-01989371							
JA-00176	04/01/2014	Spreadsheet: Duragesic Trx Sizes April 2014.xlsx	JAN-MS-00583294	JAN-MS-00583294							
JA-00177	06/20/2014	Spreadsheet: DuragesicRetailBreakout.xlsx	JAN-MS-01989394	JAN-MS-01989394							
JA-00178	06/13/2014	Spreadsheet: DuragesicFentanyl_NPAWeeklyMonthlyReport_6-13-14.xlsx	JAN-MS-00583297	JAN-MS-00583297							
JA-00179	05/01/2014	Spreadsheet: FentanylPatchMarketTRxVol&SharebyStrenghtthruMay2014.xlsx	JAN-MS-01989438	JAN-MS-01989438							
JA-00180	06/20/2014	Spreadsheet: DuragesicFentanyl_NPAWeeklyMonthlyReport_6-20-14.xlsx	JAN-MS-00583306	JAN-MS-00583306							
JA-00181	06/27/2014	Spreadsheet: DuragesicFentanyl_NPAWeeklyMonthlyReport_6-27-14.xlsx	JAN-MS-00583321	JAN-MS-00583321							
JA-00182	07/04/2014	Spreadsheet: DuragesicFentanyl_NPAWeeklyMonthlyReport_7-4-14.xlsx	JAN-MS-00583349	JAN-MS-00583349							
JA-00183	07/11/2014	Spreadsheet: DuragesicFentanyl_NPAWeeklyMonthlyReport_7-11-14.xlsx	JAN-MS-00583364	JAN-MS-00583364							
JA-00184	07/18/2014	Spreadsheet: DuragesicFentanyl_NPAWeeklyMonthlyReport_7-18-14.xlsx	JAN-MS-00583369	JAN-MS-00583369							
JA-00185	06/01/2014	Spreadsheet: JUNE 2014 NPA.xlsx	JAN-MS-01101961	JAN-MS-01101961							
JA-00186	07/25/2014	Spreadsheet: DuragesicFentanyl_NPAWeeklyMonthlyReport_7-25-14.xlsx	JAN-MS-00583413	JAN-MS-00583413							
JA-00187	04/11/2016	Spreadsheet: Oxybutynin CL ER WeeklyTRx Data Udate through April latest week.xlsx	JAN-MS-01995951	JAN-MS-01995951							
JA-00188	08/01/2014	Spreadsheet: DuragesicFentanyl_NPAWeeklyMonthlyReport_8-1-14.xlsx	JAN-MS-00583449	JAN-MS-00583449							
JA-00189	08/08/2014	Spreadsheet: DuragesicFentanyl_NPAWeeklyMonthlyReport_8-8-14.xlsx	JAN-MS-00583458	JAN-MS-00583458							
JA-00190	08/15/2014	Spreadsheet: DuragesicFentanyl_NPAWeeklyMonthlyReport_8-15-14.xlsx	JAN-MS-00583474	JAN-MS-00583474							
JA-00191	08/22/2014	Spreadsheet: DuragesicFentanyl_NPAWeeklyMonthlyReport_8-22-14.xlsx	JAN-MS-00583486	JAN-MS-00583486							
JA-00192	08/29/2014	Spreadsheet: DuragesicFentanyl_NPAWeeklyMonthlyReport_8-29-14.xlsx	JAN-MS-00583495	JAN-MS-00583495							
JA-00193	09/05/2014	Spreadsheet: DuragesicFentanyl_NPAWeeklyMonthlyReport_9-5-14.xlsx	JAN-MS-00583519	JAN-MS-00583519							
JA-00194	09/19/2014	Spreadsheet: DuragesicFentanyl_NPAWeeklyMonthlyReport_9-19-14.xlsx	JAN-MS-00583528	JAN-MS-00583528							
JA-00195	09/26/2014	Spreadsheet: DuragesicFentanyl_NPAWeeklyMonthlyReport_9-26-14.xlsx	JAN-MS-00583553	JAN-MS-00583553							
JA-00196	10/06/2014	Spreadsheet: NER & NUC plus Mkt - TRx and Sales\$ (Launch thru Jul14).xlsx	JAN-MS-01413592	JAN-MS-01413592							
JA-00197	10/03/2014	Spreadsheet: DuragesicFentanyl_NPAWeeklyMonthlyReport	JAN-MS-00583560	JAN-MS-00583560							
JA-00198	10/10/2014	Spreadsheet: DuragesicFentanyl_NPAWeeklyMonthlyReport	JAN-MS-00583567	JAN-MS-00583567							
JA-00199	10/17/2014	Spreadsheet: DuragesicFentanyl_NPAWeeklyMonthlyReport	JAN-MS-00583653	JAN-MS-00583653							
JA-00200	07/06/1905	Projected Monthly Actual 2014 Market and Brand TRx Summary	JAN-MS-00583665	JAN-MS-00583665							
JA-00201	07/06/1905	Projected Monthly Actual 2014 Market and Brand TRx Summary	JAN-MS-00583735	JAN-MS-00583735							
JA-00202	07/06/1905	Projected Monthly Actual 2014 Market and Brand TRx Summary	JAN-MS-00583742	JAN-MS-00583742							
JA-00203	07/03/1905	NPA Extended Insights Audit from November 2011 to October 2014	JAN-MS-01990022	JAN-MS-01990022							
JA-00204	07/06/1905	Projected Monthly Actual Forecast Data	JAN-MS-00583758	JAN-MS-00583758							
JA-00205	07/06/1905	Projected Monthly Actual 2014 Market and Brand TRx Summary	JAN-MS-00583768	JAN-MS-00583768							
JA-00206	07/06/1905	Projected Monthly Actual 2014 Market and Brand TRx Summary	JAN-MS-00583779	JAN-MS-00583779							
JA-00207	07/06/1905	Projected Monthly Actual 2014 Market and Brand TRx Summary	JAN-MS-00583811	JAN-MS-00583811							
JA-00208	07/06/1905	Projected Monthly Actual 2014 Market and Brand TRx Summary	JAN-MS-00583833	JAN-MS-00583833							
JA-00209	07/06/1905	Projected Monthly Actual 2014 Market and Brand TRx Summary	JAN-MS-00583841	JAN-MS-00583841							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-00210	07/06/1905	Projected Monthly Actual 2014 Market and Brand TRx Summary	JAN-MS-00583849	JAN-MS-00583849							
JA-00211	07/06/1905	Projected Monthly Actual 2014 Market and Brand TRx Summary	JAN-MS-00583853	JAN-MS-00583853							
JA-00212	07/06/1905	Projected Monthly Actual 2014 Market and Brand TRx Summary	JAN-MS-00583864	JAN-MS-00583864							
JA-00213	07/07/1905	Projected Monthly Actual 2015 Market and Brand TRx Summary	JAN-MS-00583881	JAN-MS-00583881							
JA-00214	07/07/1905	Projected Monthly Actual 2015 Market and Brand TRx Summary	JAN-MS-00583892	JAN-MS-00583892							
JA-00215	12/01/2014	EPG Portfolio Genericized Molecules Report December 2014, NPA Extended Insights	JAN-MS-01990390	JAN-MS-01990391							
JA-00216	07/07/1905	Projected Monthly Actual 2015 Market and Brand TRx Summary	JAN-MS-00583913	JAN-MS-00583913							
JA-00217	07/07/1905	Projected Monthly Actual 2015 Market and Brand TRx Summary	JAN-MS-00583920	JAN-MS-00583920							
JA-00218	07/06/1905	NPA Data Value	JAN-MS-00825922	JAN-MS-00825922							
JA-00219	07/07/1905	Projected Monthly Data 2015 Market and Brand Trx Summary	JAN-MS-00583927	JAN-MS-00583927							
JA-00220	07/07/1905	Projected Monthly Actual 2015 Market and Brand TRx Summary	JAN-MS-00583934	JAN-MS-00583934							
JA-00221	07/07/1905	Projected Monthly Actual 2015 Market and Brand TRx Summary	JAN-MS-00583948	JAN-MS-00583948							
JA-00222	07/07/1905	Projected Monthly Actual 2015 Market and Brand TRx Summary	JAN-MS-00583972	JAN-MS-00583972							
JA-00223	03/20/2015	Projected Monthly Actual 2015 Market and Brand TRx Summary	JAN-MS-00583976	JAN-MS-00583976							
JA-00224	03/27/2015	IMS Health NPA- Weekly Rx	JAN-MS-00577556	JAN-MS-00577556							
JA-00225	03/27/2015	Projected Monthly Actual 2015 Market and Brand TRx Summary	JAN-MS-00583985	JAN-MS-00583985							
JA-00226	04/03/2015	Projected Monthly Actual 2015 Market and Brand TRx Summary	JAN-MS-00583993	JAN-MS-00583993							
JA-00227	04/10/2015	Projected Monthly Actual 2015 Market and Brand TRx Summary	JAN-MS-00584002	JAN-MS-00584002							
JA-00228	04/17/2015	Projected Monthly Actual 2015 Market and Brand TRx Summary	JAN-MS-00584024	JAN-MS-00584024							
JA-00229	04/30/2015	NPA Extended Insights Audit; April 2012-March 2015	JAN-MS-01990811	JAN-MS-01990811							
JA-00230	04/24/2015	Projected Monthly Actual 2015 Market and Brand TRx Summary	JAN-MS-00584029	JAN-MS-00584029							
JA-00231	05/01/2015	Projected Monthly Actual 2015 Market and Brand TRx Summary	JAN-MS-00584038	JAN-MS-00584038							
JA-00232	05/08/2015	Projected Monthly Actual 2015 Market and Brand TRx Summary	JAN-MS-00584045	JAN-MS-00584045							
JA-00233	05/15/2015	Projected Monthly Actual 2015 Market and Brand TRx Summary	JAN-MS-00584080	JAN-MS-00584080							
JA-00234	05/22/2015	Projected Monthly Actual 2015 Market and Brand TRx Summary	JAN-MS-00584087	JAN-MS-00584087							
JA-00235	05/29/2015	Projected Monthly Actual 2015 Market and Brand TRx Summary	JAN-MS-00584098	JAN-MS-00584098							
JA-00236	06/05/2015	Projected Monthly Actual 2015 Market and Brand TRx Summary	JAN-MS-00584107	JAN-MS-00584107							
JA-00237	06/12/2015	Projected Monthly Actual 2015 Market and Brand TRx Summary	JAN-MS-00584114	JAN-MS-00584114							
JA-00238	06/19/2015	Projected Monthly Actual 2015 Market and Brand TRx Summary	JAN-MS-00584121	JAN-MS-00584121							
JA-00239	06/26/2015	Projected Monthly Actual 2015 Market and Brand TRx Summary	JAN-MS-00584130	JAN-MS-00584130							
JA-00240	07/10/2015	NPA Extended Insights Audit; June 2012 to May 2015	JAN-MS-00584132	JAN-MS-00584132							
JA-00241	07/03/2015	Projected Monthly Actual 2015 Market and Brand TRx Summary	JAN-MS-01991114	JAN-MS-01991114							
JA-00242	07/10/2015	Projected Monthly Actual 2015 Market and Brand TRx Summary	JAN-MS-01991134	JAN-MS-01991134							
JA-00243	07/24/2015	Projected Monthly Actual 2015 Market and Brand TRx Summary	JAN-MS-01991626	JAN-MS-01991626							
JA-00244	07/31/2015	Projected Monthly Actual 2015 Market and Brand TRx Summary	JAN-MS-01991638	JAN-MS-01991638							
JA-00245	08/07/2015	Projected Monthly Actual 2015 Market and Brand TRx Summary	JAN-MS-01991705	JAN-MS-01991705							
JA-00246	08/14/2015	Projected Monthly Actual 2015 Market and Brand TRx Summary	JAN-MS-01991764	JAN-MS-01991764							
JA-00247	08/21/2015	Projected Monthly Actual 2015 Market and Brand TRx Summary	JAN-MS-01991772	JAN-MS-01991772							
JA-00248	08/28/2015	Projected Monthly Actual 2015 Market and Brand Trx Summary	JAN-MS-01991782	JAN-MS-01991782							
JA-00249	09/04/2015	Projected Monthly Actual 2015 Market and Brand TRx Summary	JAN-MS-01991789	JAN-MS-01991789							
JA-00250	09/11/2015	Projected Monthly Actual 2015 Market and Brand TRx Summary	JAN-MS-01993816	JAN-MS-01993816							
JA-00251	09/28/2015	Projected Monthly Actual 2015 Market and Brand TRx Summary	JAN-MS-01993823	JAN-MS-01993823							
JA-00252	09/25/2015	Projected Monthly Actual 2015 Market and Brand TRx Summary	JAN-MS-01993828	JAN-MS-01993828							
JA-00253	10/02/2015	Projected Monthly Actual 2015 Market and Brand TRx Summary	JAN-MS-01993832	JAN-MS-01993832							
JA-00254	10/30/2015	Market and Brand TRx Summary; January 2013-December 2015	JAN-MS-01994007	JAN-MS-01994007							
JA-00255	11/20/2015	Janssen Spreadsheet: 2015 EPG Reporting Workbook IMS Data NPA Weekly	JAN-MS-01994035	JAN-MS-01994035							
JA-00256	12/09/2015	Janssen Spreadsheet: FentanylPatchMoleculeMonthlyIMSNPAbystrengthbychannelbyproductv	JAN-MS-00586185	JAN-MS-00586185							
JA-00257	01/01/2016	Janssen Spreadsheet: 2015 EPG Reporting Workbook IMS Data NPA Weekly 1-1-2016 Duragesic Fentanyl wMonthly	JAN-MS-01994156	JAN-MS-01994156							
JA-00258	01/18/2016	Spreadsheet: 2015 EPG Reporting Workbook IMS Data NPA Weekly 1-18-2016DuragesicFentanylwMonthlycorrected	JAN-MS-01994172	JAN-MS-01994172							
JA-00259	01/25/2016	Spreadsheet: 2015 EPG Reporting Workbook IMS Data NPA Weekly 1-25-2016DuragesicFentanylwMonthly	JAN-MS-01994201	JAN-MS-01994201							
JA-00260	02/01/2016	Spreadsheet: 2015 EPG Reporting Workbook IMS Data NPA Weekly 2-1-2016DuragesicFentanylwMonthly	JAN-MS-01994207	JAN-MS-01994207							
JA-00261	02/08/2016	Spreadsheet: 2015 EPG Reporting Workbook IMS Data NPA Weekly 2-8-2016DuragesicFentanylwMonthly	JAN-MS-01994213	JAN-MS-01994213							
JA-00262	02/29/2016	Spreadsheet: 2015 EPG Reporting Workbook IMS Data NPA Weekly 2-29-2016DuragesicFentanylwMonthly	JAN-MS-01994454	JAN-MS-01994454							
JA-00263	03/11/2016	Spreadsheet: IMS NPA WeeklyMonthly Report Data Week Ending 031116 DuragesicFentanyl	JAN-MS-01994480	JAN-MS-01994480							
JA-00264	03/18/2016	Spreadsheet: IMS NPA WeeklyMonthly Report Data Week Ending 031816 DuragesicFentanyl	JAN-MS-01994663	JAN-MS-01994663							
JA-00265	03/25/2016	Spreadsheet: IMS NPA WeeklyMonthly Report Data Week Ending 032516 DuragesicFentanyl	JAN-MS-01994961	JAN-MS-01994961							
JA-00266	02/01/2016	Spreadsheet: DuragesicFentanylRefreshofEuTRxEuTRxshareTRxTRxshareTRxsize	JAN-MS-00586806	JAN-MS-00586806							
JA-00267	04/01/2016	Spreadsheet: IMS NPA WeeklyMonthly Report Data Week Ending 040116 DuragesicFentanyl	JAN-MS-01995048	JAN-MS-01995048							
JA-00268	04/08/2016	spreadsheet: IMS NPA WeeklyMonthly Report Data Week Ending 041516 DuragesicFentanyl	JAN-MS-01995060	JAN-MS-01995060							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-00269	04/15/2016	Spreadsheet: IMS NPA WeeklyMonthly Report Data Week Ending 041516 DuragesicFentanyl	JAN-MS-01995075	JAN-MS-01995075							
JA-00270	04/22/2016	Spreadsheet: IMS NPA WeeklyMonthly Report Data Week Ending 042216 DuragesicFentanyl	JAN-MS-01995090	JAN-MS-01995090							
JA-00271	04/29/2016	Spreadsheet: IMS NPA WeeklyMonthly Report Data Week Ending 042216 DuragesicFentanyl	JAN-MS-01995093	JAN-MS-01995093							
JA-00272	05/11/2016	Spreadsheet: Duragesic CoPay Breakouts by MOP MAT for last 3 years 051116	JAN-MS-00586942	JAN-MS-00586942							
JA-00273	05/06/2016	Spreadsheet: IMS NPA WeeklyMonthly Report Data Week Ending 050616 DuragesicFentanyl w April Actuals	JAN-MS-01995104	JAN-MS-01995104							
JA-00274	05/13/2016	Spreadsheet: IMS NPA WeeklyMonthly Report Data Week Ending 051316 DuragesicFentanyl	JAN-MS-01995108	JAN-MS-01995108							
JA-00275	05/20/2016	Spreadsheet: IMS NPA WeeklyMonthly Report Data Week Ending 052016 DuragesicFentanyl	JAN-MS-01995153	JAN-MS-01995153							
JA-00276	05/27/2016	Spreadsheet: IMS NPA WeeklyMonthly Report Data Week Ending 052716 DuragesicFentanyl	JAN-MS-01995156	JAN-MS-01995156							
JA-00277	06/03/2016	Spreadsheet: IMS NPA WeeklyMonthly Report Data Week Ending 052716 DuragesicFentanyl	JAN-MS-01995159	JAN-MS-01995159							
JA-00278	05/01/2016	Spreadsheet:IMS NPA WeeklyMonthly Report_ May 2016_ DuragesicFentanyl	JAN-MS-01995162	JAN-MS-01995162							
JA-00279	07/08/1905	Spreadsheet: IMS NPA TRX and Market Share	JAN-MS-01997020	JAN-MS-01997020							
JA-00280	03/22/2019	Spreadsheet: IMS NPA TRX and Market Share	JAN-MS-01995200	JAN-MS-01995200							
JA-00281	08/01/2016	Spreadsheet: NPA Ext. Insights - Durageisc by MoP through August 2016.xlsx	JAN-MS-01995484	JAN-MS-01995484							
JA-00282	01/01/2016	Spreadsheet: 2015 EPG Reporting Workbook IMS Data NPA Weekly 1-1-2016ConcertaMolecule	JAN-MS-02983716	JAN-MS-02983716							
JA-00283	01/18/2016	Spreadsheet: 2015 EPG Reporting Workbook IMS Data NPA Weekly 1-18-2016ConcertaMolecule	JAN-MS-02983767	JAN-MS-02983767							
JA-00284	01/25/2016	Spreadsheet: 2015 EPG Reporting Workbook IMS Data NPA Weekly 1-25-2016ConcertaMolecule	JAN-MS-02983719	JAN-MS-02983719							
JA-00285	03/11/2016	Spreadsheet:IMS Data NPA Monthly Weekly Report Data Week Ending 031116 ConcertaBrandAG	JAN-MS-02983708	JAN-MS-02983708							
JA-00286	03/18/2016	Spreadsheet: IMS Data NPA Monthly Weekly Report Data Week Ending 031816 ConcertaBrandAG	JAN-MS-03062908	JAN-MS-03062908							
JA-00287	04/08/2016	Spreadsheet: IMS Data NPA Monthly Weekly Report Data Week Ending 040816 ConcertaBrandAG	JAN-MS-02964753	JAN-MS-02964753							
JA-00288	04/25/2016	Janssen spreadsheet: Concerta Brand & AG Weekly/Monthly IMS Data Reports (week ending 04/16/2016).	JAN-MS-02964728	JAN-MS-02964728							
JA-00289	05/02/2016	Janssen spreadsheet: Concerta Brand & AG Weekly/Monthly IMS Data Reports (week ending 4/22/2016).	JAN-MS-02964725	JAN-MS-02964725							
JA-00290	05/16/2016	Janssen spreadsheet: Concerta Brand & AG Weekly/Monthly IMS Data Reports (week ending 5/6/2016).	JAN-MS-02964734	JAN-MS-02964734							
JA-00291	05/23/2016	Janssen spreadsheet: Concerta Brand & AG Weekly/Monthly IMS Data Reports (week ending 5/13/2016).	JAN-MS-02964708	JAN-MS-02964708							
JA-00292	06/06/2016	Janssen spreadsheet: Concerta Brand & AG Weekly/Monthly IMS Data Reports (week ending 5/27/2016).	JAN-MS-02964699	JAN-MS-02964699							
JA-00293	06/13/2016	Janssen spreadsheet: Concerta Brand & AG Weekly/Monthly IMS Data Reports (week ending 6/3/2016).	JAN-MS-02964711	JAN-MS-02964711							
JA-00294	02/08/2016	Janssen spreadsheet: Concerta Brand & AG Weekly/Monthly IMS Data Reports (week ending 1/29/2016).	JAN-MS-02983689	JAN-MS-02983689							
JA-00295	09/04/2007	Janssen spreadsheet: Brand Highlight Sheets.	JAN-MS-01105538	JAN-MS-01105538							
JA-00296	11/04/2007	Janssen spreadsheet: Tapentadol IMS Market Basket 11/13/2007.	JAN-MS-01016125	JAN-MS-01016125							
JA-00297	10/27/2008	Janssen spreadsheet: Sandoz Monthly NSP 2008.	JAN-MS-00593264	JAN-MS-00593264							
JA-00298	06/30/1905	Janssen spreadsheet: Duragesic SIC GP Analysis.	JAN-MS-01112508	JAN-MS-01112508							
JA-00299	06/30/1905	Janssen spreadsheet: Duragesic SIC GP Analysis.	JAN-MS-01105395	JAN-MS-01105395							
JA-00300	09/19/2011	Janssen spreadsheet: Tapentadol Sales and Marketing by year.	JAN-MS-02947973	JAN-MS-02947975							
JA-00301	09/04/2012	Spreadsheet with CII & NUC Mix - NPA & NSP (12mos thru Jul12) - 09.04.12	JAN-MS-02921467	JAN-MS-02921467							
JA-00302	03/29/2013	Spreadsheet with CII SAO & LAO NSP Sales\$ - Jan13	JAN-MS-02933150	JAN-MS-02933150							
JA-00303	12/01/2013	Spreadsheet: Fentanyl12mcgNSP\$December2013	JAN-MS-00583010	JAN-MS-00583010							
JA-00304	06/01/2014	Spreadsheet: JUNE 2014 NSP	JAN-MS-01101962	JAN-MS-01101962							
JA-00305	04/01/2014	Spreadsheet: NSP Audit from May 2008 to April 2014	JAN-MS-02737034	JAN-MS-02737034							
JA-00306	11/19/2003	Spreadsheet with CP Weekly November 7	JAN-MS-03862826	JAN-MS-03862826							
JA-00307	07/26/2005	Spreadsheet with MERIGROUP_1Q2005_IOM product shares	JAN-MS-02565938	JAN-MS-02565938							
JA-00308	12/15/2009	JAN-OH-00102515 Ohio Nucynta TRX Trend, Sales and Marketing.	JAN-OH-00102515	JAN-OH-00102515							
JA-00309	10/11/2011	Spreadsheet with Duragesic PlanTrak Data_Jun 2011	JAN-MS-01981024	JAN-MS-01981024							
JA-00310	10/21/2011	Janssen spreadsheet: Duragesic PlanTrak Data August 2011.	JAN-MS-01981070	JAN-MS-01981070							
JA-00311	12/08/2011	Johnson & Johnson spreadsheet: Duragesic PlanTrak Data	JAN-MS-00581022	JAN-MS-00581022							
JA-00312	10/30/2006	Janssen spreadsheet: Duragesic Erosion from 2005 forward	JAN-MS-02009771	JAN-MS-02009771							
JA-00313	05/24/2011	Johnson&Johnson spreadsheet: summary of share of voice & competitor journal spend	JAN-MS-01130492	JAN-MS-01130492							
JA-00314	01/06/2012	Janssen spreadsheet: IMS audited Share of Voice for Nucynta/Nucynta ER and Xarelto	JAN-MS-01095895	JAN-MS-01095895							
JA-00315	04/02/2012	Johnson & Johnson spreadsheet: % of Minutes for all of J&J	JAN-MS-02934035	JAN-MS-02934036							
JA-00316	11/12/2012	Spreadsheet: Monthly figures for various medical areas	JAN-MS-02934044	JAN-MS-02934044							
JA-00317	03/29/2013	Janssen spreadsheet: Contact and call volume	JAN-MS-02934038	JAN-MS-02934040							
JA-00318	08/07/2013	Janssen spreadsheet: Nucynta vs Exalgo/National chart calls	JAN-MS-02934057	JAN-MS-02934057							
JA-00319	11/07/2006	Janssen spreadsheet: Duragesic All State by Payor Type	JAN-MS-02013475	JAN-MS-02013475							
JA-00320	11/25/2002	Janssen spreadsheet: Duragesic Business Information Report for November 2002	JAN-MS-00784557	JAN-MS-00784557							
JA-00321	09/25/2003	Janssen spreadsheet: Xponent vs NPA by Drug	JAN-MS-00787880	JAN-MS-00787880							
JA-00322	03/03/2005	Janssen spreadsheet: Fentanyl Pricing Comparison	JAN-MS-00784020	JAN-MS-00784020							
JA-00323	02/01/2006	Janssen spreadsheet: Vortex IR Base - Q4 08 launch	JAN-MS-00441596	JAN-MS-00441596							
JA-00324	08/17/2009	Janssen spreadsheet: BF Data dictionary; In scope vendor programs with communication timelines status	JAN-MS-03858731	JAN-MS-03858731							
JA-00325	04/13/2010	Janssen spreadsheet: Weekly Oncology Tracking Report	JAN-MS-01043678	JAN-MS-01043678							
JA-00326	10/11/2010	Janssen spreadsheet: Aetna Nucynta Targets	JAN-MS-02472410	JAN-MS-02472410							
JA-00327	10/14/2011	Janssen spreadsheet: IMS Xponent Data	JAN-MS-03878395	JAN-MS-03878395							
JA-00328	10/21/2011	JAN-OH-00017579 High Value Nucynta Targets, Unique to New CSO Territories.	JAN-OH-00017579	JAN-OH-00017579							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-00329	01/31/2012	Janssen presentation: Nucynta Monthly Review, IMS Xponent Data thru 1/13/2012	JAN-MS-03879478	JAN-MS-03879478							
JA-00330	01/17/2012	Trinity Partners Janssen presentation: Nucynta Xponent Data Analysis	JAN-MS-02935325	JAN-MS-02935325							
JA-00331	07/05/1905	Janssen presentation: TRx&EU-updated (IMS NPA), Nucynta & Nucynta ER Weekly TRx	JAN-MS-02947983	JAN-MS-02947983							
JA-00332	10/01/2012	Ohio Medicaid Fee-For-Service Pharmacy Benefit Management Program Preferred Drug List	JAN-OH-00080030	JAN-OH-00080114							
JA-00333	11/01/2013	Ohio Medicaid Fee-For-Service Pharmacy Benefit Management Program Preferred Drug List	JAN-OH-00142663	JAN-OH-00142755							
JA-00334	04/08/2015	Ohio Department of Medicaid P&T Committee Meeting Minutes	ODM-002-0012815	ODM-002-0012835							
JA-00335	06/10/2015	Ohio Department of Medicaid P&T Committee Meeting Minutes	ODM-002-0012897	ODM-002-0013127							
JA-00336	10/01/2012	Ohio Department of Medicaid Preferred Drug List	ODM-002-0014039	ODM-002-0014123							
JA-00337	11/01/2013	Ohio Medicaid Preferred Drug List	ODM-002-0014124	ODM-002-0014216							
JA-00338	06/11/2014	Ohio Department of Medicaid P&T Committee Meeting Minutes	ODM-002-0013128	ODM-002-0013312							
JA-00339	10/01/2014	Ohio Department of Medicaid Preferred Drug List	ODM-002-0014217	ODM-002-0014308							
JA-00340	09/20/2016	Ohio Department of Medicaid Drug Utilization Review Board Meeting Minutes	ODM-002-0013810	ODM-002-0013811							
JA-00341	10/01/2015	Ohio Department of Medicaid Preferred Drug List	ODM-002-0014521	ODM-002-0014620							
JA-00342	05/20/2014	Ohio Department of Medicaid Drug Utilization Review Board Meeting Minutes	ODM-002-0013875	ODM-002-0013876							
JA-00343	01/01/2017	Ohio Department of Medicaid Preferred Drug List	ODM-002-0015110	ODM-002-0015213							
JA-00344	10/01/2009	Ohio Medicaid Fee-For-Service Pharmacy Benefit Management Program Preferred Drug List	ODM-035445	ODM-035446							
JA-00345	10/01/2009	Ohio Medicaid Fee-For-Service Pharmacy Benefit Management Program Preferred Drug List	ODM-036290	ODM-036293							
JA-00346	10/01/2007	Ohio Medicaid Fee-For-Service Pharmacy Benefit Management Program Preferred Drug List	ODM-036294	ODM-036297							
JA-00347	10/01/2006	Ohio Medicaid Fee-For-Service Pharmacy Benefit Management Program Preferred Drug List	ODM-036298	ODM-036301							
JA-00348	07/13/2018	Change Healthcare draft presentation: Fiscal Analysis to Remove Prior Authorization Barriers to Medication Assisted Treatment (MAT) of Opioid Addiction	ODM-040866_Clawback	ODM-040872							
JA-00349	10/01/2017	Ohio Medicaid Fee-For-Service Pharmacy Benefit Management Program Preferred Drug List	CUYAH-013963829	CUYAH-013963935							
JA-00350	09/19/2012	Email from Thomas Gilson to Terry Allan et al.	CUYAH-014304430	CUYAH-014304431							
JA-00351	12/07/2016	Ohio Legislative Service Commission Impact Statement re: Bill S.B. 319 of the 131st G.A.	SUMMIT_000170790	SUMMIT_000170798							
JA-00352	01/01/2019	Jody Lutz, Opioid prescribing guidelines, AffirmHealth, 01/01/2019	JAN-TREX-00000540	JAN-TREX-00000559							
JA-00353	12/18/2017	Comprehensive Preferred Drug List, Buckeye Health Plan, Envolve Pharmacy Solutions, 12/18/2017, available at https://www.buckeyehealthplan.com/content/dam/centene/Buckeye/mcicaid/pdfs/Medicaid-PDL-2018.pdf	JAN-TREX-00000560	JAN-TREX-00000752							
JA-00354	04/01/2019	CareSource Ohio Medicaid Preferred Drug List, April 2019, available at https://www.caresource.com/documents/ohio-mcicaid-preferred-medication-list/	JAN-TREX-00000753	JAN-TREX-00000827							
JA-00355	10/08/2018	Ohio Medicaid will cover more withdrawal medicine, October 2018, available at https://www.wvxu.org/post/ohio-mcicaid-will-cover-more-opioid-withdrawl-medicine#stream/0	JAN-TREX-00000828	JAN-TREX-00000829							
JA-00356	08/15/2017	Medicaid's Opioid Fix: Evidence suggests the program may contribute to the epidemic. Wall Street Journal. August 2017, available at https://www.wsj.com/articles/mcicaids-opioid-fix-1502838645	JAN-TREX-00000830	JAN-TREX-00000831							
JA-00357	04/01/2019	Molina Healthcare of South Carolina Preferred Drug List, Molina Healthcare, Healthy Connections, April 2019, available at https://www.molinahealthcare.com/providers/oh/mcicaid/medication/PDF/RxInfo_OH_MolinaHealthcareOhioFormulary.pdf	JAN-TREX-00000832	JAN-TREX-00000986							
JA-00358	07/11/1905	Drug Coverage Information, Ohio Department of Medicaid, https://pharmacy.mcicaid.ohio.gov/medication-coverage	JAN-TREX-00149909	JAN-TREX-00149909							
JA-00359	04/01/2019	Preferred Drug Lists, Fee-for-Service Preferred Drug List, Effective April 2019, Ohio Department of Medicaid, available at https://pharmacy.mcicaid.ohio.gov/sites/default/files/OH%20PDL%20Effective%202019-04-01_0.pdf	JAN-TREX-00000987	JAN-TREX-00001100							
JA-00360	07/11/1905	Ohio Department of Medicaid Drug Utilization Review (DUR) Board, available at https://pharmacy.mcicaid.ohio.gov/medication-utilization-review-board	JAN-TREX-00001101	JAN-TREX-00001102							
JA-00361	07/11/1905	Opioid Prescribing Guidelines, Ohio Mental Health and Addiction Services, available at https://mha.ohio.gov/News/-/GCOAT-Opiate-Action-Team/Opioid-Prescribing-Guidelines	JAN-TREX-00149910	JAN-TREX-00149910							
JA-00362	05/01/2019	Paramount Advantage Preferred Drug List. 05/01/2019, available at https://www.paramounthealthcare.com/assets/documents/advantage/preferred-medication-list-advantage.pdf	JAN-TREX-00001103	JAN-TREX-00001162							
JA-00363	04/01/2019	Preferred Drug List (PDL), Ohio, Effective date 4/1/19, UnitedHealthcare, available at https://www.uhccommunityplan.com/assets/plandocuments/findamedication/OH-PDL/OH-Mcicaid-PDL.pdf	JAN-TREX-00001163	JAN-TREX-00001297							
JA-00364	07/11/1905	State Drug Utilization Data, Centers for Medicare and Medicaid Services, available at https://www.mcicaid.gov/mcicaid/prescription-drugs/state-drug-utilization-data/index.html .	JAN-TREX-00001298	JAN-TREX-00001300							
JA-00365	09/01/2018	Oral Morphine Milligram Equivalents, Centers for Disease Control and Prevention, available at https://www.cdc.gov/drugoverdose/resources/data.html	JAN-TREX-00149911	JAN-TREX-00149911							
JA-00366	04/01/2019	Preferred Drug Lists: Fee-for-Service Preferred Drug List, Effective April 1, 2019, Ohio Department of Medicaid, available at https://pharmacy.mcicaid.ohio.gov/sites/default/files/OH%20PDL%20Effective%202019-04-01_0.pdf	JAN-TREX-00001301	JAN-TREX-00001414							
JA-00367	07/10/1905	Information About Medication-Assisted Treatment (MAT), U.S. Food & Drug Administration, available at https://www.fda.gov/drugs/information-drug-class/information-about-medication-assisted-treatment-mat .	JAN-TREX-00001415	JAN-TREX-00001417							
JA-00368	04/19/2019	Deborah Dowell, Tamara Haegerich, Roger Chou, No Shortcuts to Safer Opioid Prescribing, New England Journal of Medicine, April 24, 2019, available at https://www.nejm.org/doi/10.1056/NEJMp1904190?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=c_r_pub%3Dwww.ncbi.nlm.nih.gov	JAN-TREX-00001418	JAN-TREX-00001420							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-00369	12/28/2018	U.S. Department of Health & Human Services, Draft Report on Pain Management Best Practices: Updates, Gaps, Inconsistencies, and Recommendations, December 28, 2018, available at https://www.hhs.gov/ash/advisory-committees/pain/reports/2018-12-draft-report-on-updates-gaps-inconsistencies-recommendations/index.html	JAN-TREX-00001421	JAN-TREX-00001528							
JA-00370	07/08/1905	Total Number of Medicare Beneficiaries, The Henry J. Kaiser Family Foundation, 2016. https://www.kff.org/medicare/state-indicator/total-medicare-beneficiaries/?currentTimeframe=2&sortModel=%7B%22colId%22:%22Location%22,%22sort%22:%22asc%22%7D	JAN-TREX-00001529	JAN-TREX-00001530							
JA-00371	02/01/2019	February 2019 Medicaid & CHIP Enrollment Data Highlights, Medicaid.gov, https://www.medicaid.gov/medicaid/program-information/medicaid-and-chip-enrollment-data/report-highlights/index.html	JAN-TREX-00001531	JAN-TREX-00001558							
JA-00372	12/03/2004	MediMedia Information Technologies Group: Formulary Compass Proposal for Alpharma	ALLERGAN_MDL_02453417	ALLERGAN_MDL_02453423							
JA-00373	N/A	CV of Josh Cohen	JAN-TREX-00188455	JAN-TREX-00188466							
JA-00374	11/01/2016	USDOJ, 2016 National Drug Threat Assessment	JAN-TREX-00004061	JAN-TREX-00004254							
JA-00375	10/01/2017	USDOJ, 2017 National Drug Threat Assessment	JAN-TREX-00004255	JAN-TREX-00004436							
JA-00376	03/01/2018	U.S. Government Accountability Office, Illicit Opioids: While Greater Attention Given to Combating Synthetic Opioids, Agencies Need to Better Assess Their Efforts, Mar. 2018	JAN-TREX-00004793	JAN-TREX-00004886							
JA-00377	06/06/2018	Martin R, "In Rural Ohio, An Opioid Crisis Becomes a Meth Crisis," National Public Radio, Available at: https://www.npr.org/2018/06/06/617422943/in-rural-ohio-anopioid-crisis-becomes-a-methamphetamine-crisis	JAN-TREX-00005280	JAN-TREX-00005291							
JA-00378	06/07/2018	DeMio T, "Fentanyl deaths up 1,000% since 2013, so much so that even heroin's supply is dwarfed," The Cincinnati Enquirer. Available at: https://www.cincinnati.com/story/news/2018/06/06/opioid-fentanyl-dwarfs-heroin-cincinnati-drug-supply-killing-more/610804002/	JAN-TREX-00005294	JAN-TREX-00005298							
JA-00379	07/09/1905	Anne Case & Angus Deaton, "Mortality and Morbidity in the 21st Century," Brookings Papers on Economic Activity, Spring 2017.	JAN-TREX-00008684	JAN-TREX-00008763							
JA-00380	06/25/1905	Janssen Pharmaceutica, Progress Note, Pain Assessment and Documentation Tool (PADT)	JAN-TREX-00008764	JAN-TREX-00008765							
JA-00381	06/26/1905	Passik SD et al. "A New Tool to Assess and Document Pain Outcomes in Chronic Pain Patients Receiving Opioid Therapy," Clinical Therapeutics, 26,4, pp. 552-561.	JAN-TREX-00008766	JAN-TREX-00008775							
JA-00382	05/04/2005	Kosinski MR et al. "An observational study of health-related quality of life and pain outcomes in chronic low back pain patients treated with fentanyl transdermal system," Current Medical Research and Opinion,21,6, pp. 849-862.	JAN-TREX-00008776	JAN-TREX-00008790							
JA-00383	06/30/1905	Fishbain DA, et al. "What Percentage of Chronic Nonmalignant Pain Patients Exposed to Chronic Opioid Analgesic Therapy Develop Abuse/Addiction and/or Aberrant Drug-Related Behaviors? A Structured Evidence-Based Review," Pain Medicine, 9(4), pp. 444-459	JAN-TREX-00008791	JAN-TREX-00008806							
JA-00384	07/02/1905	Noble M et al., "Long-term opioid management for chronic noncancer pain" (Review), Cochrane Database of Systematic Reviews	JAN-TREX-00008807	JAN-TREX-00008876							
JA-00385	06/01/2014	Galia E et al. "Evaluation of the tamper-resistant properties of tapentadol extended-release tablets: Results of in vitro laboratory analyses," Journal of Opioid Management 10(3), pp. 149-158	JAN-TREX-00008877	JAN-TREX-00008886							
JA-00386	07/01/1905	Annual U.S. OxyContin Prescriptions (Millions) Chart, U.S. Food and Drug Administration	JAN-TREX-00008887	JAN-TREX-00008889							
JA-00387	01/01/2017	U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER) Assessment of Abuse Potential of Drugs: Guidance for Industry,	JAN-TREX-00008890	JAN-TREX-00008926							
JA-00388	08/25/2011	U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research Application Number: 200533Orig1s000 Summary Review Reference ID:3006373	JAN-TREX-00008927	JAN-TREX-00008974							
JA-00389	07/11/1905	Code of Federal Regulations. Schedules, https://www.deadiversion.usdoj.gov/schedules/	JAN-TREX-00008975	JAN-TREX-00009048							
JA-00390	05/28/2009	Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research Meeting Transcript	JAN-TREX-00009049	JAN-TREX-00009440							
JA-00391	08/01/1990	Duragesic Label	JAN-TREX-00009441	JAN-TREX-00009451							
JA-00392	01/01/1991	Duragesic Label	JAN-TREX-00009452	JAN-TREX-00009462							
JA-00393	06/01/1991	Duragesic Label	JAN-TREX-00009463	JAN-TREX-00009473							
JA-00394	04/01/1992	Duragesic Label	JAN-TREX-00009474	JAN-TREX-00009484							
JA-00395	03/01/1993	Duragesic Label	JAN-TREX-00009485	JAN-TREX-00009496							
JA-00396	08/01/1993	Duragesic Label	JAN-TREX-00009497	JAN-TREX-00009508							
JA-00397	01/01/1994	Duragesic Label	JAN-TREX-00009509	JAN-TREX-00009520							
JA-00398	06/01/1994	Duragesic Label	JAN-TREX-00009521	JAN-TREX-00009532							
JA-00399	06/01/1997	Duragesic Label	JAN-TREX-00009533	JAN-TREX-00009544							
JA-00400	04/01/1998	Duragesic Label	JAN-TREX-00009545	JAN-TREX-00009547							
JA-00401	11/01/1999	Duragesic Label	JAN-TREX-00009548	JAN-TREX-00009555							
JA-00402	01/01/2000	Duragesic Label	JAN-TREX-00009556	JAN-TREX-00009557							
JA-00403	02/01/2001	Duragesic Label (1-2000, 2-2001)	JAN-TREX-00009558	JAN-TREX-00009561							
JA-00404	05/01/2003	Duragesic Label	JAN-TREX-00009562	JAN-TREX-00009589							
JA-00405	05/20/2003	Letter from Bob Rappaport to Janne Wissel	JAN-TREX-00009590	JAN-TREX-00009593							
JA-00406	06/25/1905	Duragesic Label	JAN-TREX-00009594	JAN-TREX-00009637							
JA-00407	06/27/1905	Duragesic Label	JAN-TREX-00009638	JAN-TREX-00009685							
JA-00408	07/01/2009	Duragesic Label	JAN-TREX-00009686	JAN-TREX-00009731							
JA-00409	10/01/2011	Duragesic Label	JAN-TREX-00009732	JAN-TREX-00009774							
JA-00410	10/01/2011	Duragesic Label	JAN-TREX-00009775	JAN-TREX-00009818							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-00411	04/01/2014	Duragesic Label	JAN-TREX-00009819	JAN-TREX-00009864							
JA-00412	04/01/2014	Duragesic Label	JAN-TREX-00009865	JAN-TREX-00009920							
JA-00413	01/01/2018	Duragesic Label	JAN-TREX-00009921	JAN-TREX-00009976							
JA-00414	08/01/1990	Duragesic Original Approval Package	JAN-TREX-00009977	JAN-TREX-00009987							
JA-00415	05/20/2003	US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Approval Package.	JAN-TREX-00009988	JAN-TREX-00010156							
JA-00416	06/01/2015	Extended-Release (ER) And Long-Acting (LA) Opioid Analgesics Risk Evaluation and Mitigation Strategy (REMS)	JAN-TREX-00010157	JAN-TREX-00010201							
JA-00417	07/22/2010	US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Joint Meeting of the Anesthetic and Life Support Drugs Advisory Committee (ALSDAC) & Drug Safety and Risk Management Advisory Committee (DSaRM) Meeting Transcript	JAN-TREX-00010202	JAN-TREX-00010564							
JA-00418	07/23/2010	US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Joint Meeting of the Anesthetic and Life Support Drugs Advisory Committee (ALSDAC) & Drug Safety and Risk Management Advisory Committee (DSaRM) Meeting Transcript	JAN-TREX-00010565	JAN-TREX-00010887							
JA-00419	07/23/2010	US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Joint Meeting of the Anesthetic and Life Support Drugs Advisory Committee (ALSDAC) & Drug Safety and Risk Management Advisory Committee (DSaRM) Meeting Agenda.	JAN-TREX-00010888	JAN-TREX-00011210							
JA-00420	07/23/2010	US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Joint Meeting of the Anesthetic and Life Support Drugs Advisory Committee (ALSDAC) & Drug Safety and Risk Management Advisory Committee (DSaRM) Draft Agenda	JAN-TREX-00011211	JAN-TREX-00011533							
JA-00421	05/01/2017	FDA Blueprint for Prescriber Education for Extended-Release and Long-Acting Opioid Analgesics	JAN-TREX-00011534	JAN-TREX-00011554							
JA-00422	04/09/2019	FDA Statement by Douglas Throckmorton, M.D. Deputy Center Director, Center for Drug Evaluation and Research (CDER), on new opioid analgesic labeling changes to give providers better information for how to properly taper patients who are physically dependent on opioids.	JAN-TREX-00011555	JAN-TREX-00011558							
JA-00423	02/09/2009	FDA Website: A Guide to Safe Use of Pain Medication, available at https://www.fda.gov/consumers/consumer-updates/guide-safe-use-pain-medicine	JAN-TREX-00011559	JAN-TREX-00011564							
JA-00424	05/07/2019	FDA Website: Development & Approval Process (Drugs), available at https://www.fda.gov/drugs/development-approval-process-drugs	JAN-TREX-00011565	JAN-TREX-00011568							
JA-00425	07/09/1905	FDA Website, FDA Enforcement Statistics:Summary, Fiscal Year 2017. https://www.fda.gov/media/71878/download	JAN-TREX-00011569	JAN-TREX-00011582							
JA-00426	04/01/2019	US Department of Health and Human Services, Food and Drug Administration. Regulatory Procedures Manual. FDA Website: https://www.fda.gov/media/110196/download	JAN-TREX-00011583	JAN-TREX-00011643							
JA-00427	07/23/2010	US Department of Health and Human Services, Food and Drug Administration, Joint Meeting of the Anesthetic and Life Support Drugs and Drug Safety and Risk Management Advisory Committees, Risk Evaluation and Mitigation Strategies (REMS) for Extended-Release and Long-Acting Opioid Products	JAN-TREX-00011644	JAN-TREX-00011690							
JA-00428	12/04/2009	US Department of Health and Human Services, Food and Drug Administration, Risk Evaluation and Mitigation Strategies for Certain Opioid Drugs Public Meeting	JAN-TREX-00011691	JAN-TREX-00011796							
JA-00429	02/04/2005	Letter from Bob Rappaport to Susan Rinne	JAN-TREX-00011797	JAN-TREX-00011800							
JA-00430	02/07/2008	Letter from Bob Rappaport to Michael H. Kaufman	JAN-TREX-00011801	JAN-TREX-00011804							
JA-00431	07/09/2012	Letter from Bob Rappaport to Mary Mulligan	JAN-TREX-00011805	JAN-TREX-00011808							
JA-00432	12/16/2016	Letter from Sharon Hertz to Kelly Rudnick	JAN-TREX-00011809	JAN-TREX-00011813							
JA-00433	04/16/2014	Letter from Judith Racoosin to Mary Mulligan	JAN-TREX-00011814	JAN-TREX-00011818							
JA-00434	08/25/2011	Letter from Bob A. Rappaport to Kathleen F. Dusek	JAN-TREX-00011819	JAN-TREX-00011825							
JA-00435	07/09/2012	Letter from Bob A. Rappaport to Tania Miller	JAN-TREX-00011826	JAN-TREX-00011836							
JA-00436	08/28/2012	Letter from Bob A. Rappaport to Tania Hillmer	JAN-TREX-00011837	JAN-TREX-00011842							
JA-00437	04/16/2014	Letter from Judith A. Racoosin to Tania Hillmer	JAN-TREX-00011843	JAN-TREX-00011847							
JA-00438	04/10/2019	Letter from Robert R. Redfield to Daniel Alford	JAN-TREX-00011848	JAN-TREX-00011852							
JA-00439	04/01/2011	Letter from Philomena McArthur to Thomas Abrams	JAN-TREX-00011853	JAN-TREX-00011870							
JA-00440	03/01/2009	Nucynta Highlights of Prescribing Information 03/2009	JAN-TREX-00011871	JAN-TREX-00011896							
JA-00441	10/01/2010	Nucynta Highlights of Prescribing Information 10/2010	JAN-TREX-00011897	JAN-TREX-00011922							
JA-00442	11/01/2008	Unnamed opioid analgesic Label 2008-11-20	JAN-TREX-00011923	JAN-TREX-00011949							
JA-00443	03/01/2009	Nucynta Label 2009-11-09	JAN-TREX-00011950	JAN-TREX-00011975							
JA-00444	10/01/2010	Nucynta Label 2010-11-01	JAN-TREX-00011976	JAN-TREX-00012001							
JA-00445	07/01/2013	Nucynta Label 2013-07-11	JAN-TREX-00012002	JAN-TREX-00012029							
JA-00446	10/01/2013	Nucynta Label 2013-10-31	JAN-TREX-00012030	JAN-TREX-00012057							
JA-00447	12/01/2016	Nucynta Tablet Label 2016-12-16	JAN-TREX-00012058	JAN-TREX-00012090							
JA-00448	10/01/2012	Nucynta IR Oral Solution Label 2012-10-15	JAN-TREX-00012091	JAN-TREX-00012121							
JA-00449	11/01/2014	Nucynta Oral Solution Label 2014-11-17	JAN-TREX-00012122	JAN-TREX-00012159							
JA-00450	12/01/2016	Nucynta Oral Solution Label 2016-12-16	JAN-TREX-00012160	JAN-TREX-00012198							
JA-00451	08/01/2011	Nucynta ER tablets label 2011-08-25	JAN-TREX-00012199	JAN-TREX-00012237							
JA-00452	07/01/2012	Nucynta ER tablet label 2012-07-09	JAN-TREX-00012238	JAN-TREX-00012272							
JA-00453	08/01/2012	Nucynta ER tablet label 2012-08-28	JAN-TREX-00012273	JAN-TREX-00012309							
JA-00454	04/01/2014	Nucynta ER tablet label 2014-04-16	JAN-TREX-00012310	JAN-TREX-00012344							
JA-00455	12/01/2016	Nucynta tablet label 2016-12-16	JAN-TREX-00012345	JAN-TREX-00012377							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-00456	07/22/2010	Covidien Presentation: Our Experience in EXALGO Risk Management, U.S. Food and Drug Administration, Joint Meeting of the Anesthetic and Life Support Drugs Advisory and Drug Safety and Risk Management Advisory Committees	JAN-TREX-00012378	JAN-TREX-00012388							
JA-00457	07/22/2010	FDA Presentation: Outpatient Prescription Opioid Utilization in the U.S., Years 2000 – 2009	JAN-TREX-00012389	JAN-TREX-00012544							
JA-00458	12/28/2018	U.S. Department of Health and Human Services, Draft Report on Pain Management Best Practices: Updates, Gaps, Inconsistencies, and Recommendations, December 28, 2018	JAN-TREX-00012545	JAN-TREX-00012612							
JA-00459	10/15/2014	Prescribe Responsibly Website, available at www.prescriberesponsibly.com	JAN-TREX-00012613	JAN-TREX-00012721							
JA-00460	01/07/2015	FDA presentation: Selected FDA Activities on Opioids	JAN-TREX-00012722	JAN-TREX-00012752							
JA-00461	07/23/2010	Joint Meeting of the Anesthetic and Life Support Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee summary minutes; risk evaluation and mitigation strategies for extended-release and long-acting opioid analgesics	JAN-TREX-00012753	JAN-TREX-00012763							
JA-00462	11/01/2008	Unnamed drug highlights of prescribing information 11/2008	JAN-TREX-00012764	JAN-TREX-00012790							
JA-00463	12/21/2015	Transmucosal Immediate Release Fentanyl (TIRF) Risk Evaluation and Mitigation Strategy (REMS) (Dec. 2014)	JAN-TREX-00012791	JAN-TREX-00012923							
JA-00464	09/23/2001	ABT-MDL-KY-0025968 American Pain Foundation Pain Action Guide: Reading this could help ease your pain	ABT-MDL-KY-0025968	ABT-MDL-KY-0025974							
JA-00465	07/27/2010	Nucynta 2011 Business Plan	JAN-MS-00010379	JAN-MS-00010432							
JA-00466	06/06/2011	Nucynta ER Launch Plan	JAN-MS-00022131	JAN-MS-00022164							
JA-00467	07/03/1905	Nucynta ER Frequently Asked Questions List	JAN00073184	JAN00073195							
JA-00468	06/26/1905	Spreadsheet: Duragesic Account ARC Call Details	JAN00118955	JAN00118955							
JA-00469	06/26/1905	Spreadsheet: Duragesic Sales Call Information	JAN00118956	JAN00118956							
JA-00470	06/12/2017	Spreadsheet: Nucynta sales call data	JAN00118960	JAN00118960							
JA-00471	06/12/2007	Spreadsheet: Nucynta sales call data	JAN00118971	JAN00118971							
JA-00472	06/13/2009	JAN-0014-0021012	JAN-0014-0021012	JAN-0014-0021012							
JA-00473	10/20/1994	Letter from Elizabeth A. Clark to Robert Bedford	JAN00221820	JAN00221820							
JA-00474	06/30/2003	Letter from Susan Merchant to Victor Raczkowski	JAN00221849	JAN00221849							
JA-00475	06/25/2004	Letter from Kathleen Dusek to Victor Raczkowski	JAN00221868	JAN00221868							
JA-00476	02/01/2005	Duragesic Label: Full Prescribing Information	JAN00222123	JAN00222123							
JA-00477	04/22/2011	Letter from Mathilda Fienkeng to Philomena McArthur	JAN-IN-000132297	JAN-IN-000132300							
JA-00478	05/02/2011	Global Medical Safety J&J: NUCYNTA® (Tapentadol Hydrochloride) Immediate Release: Third Safety Surveillance Plan Progress Report	JAN-MS-00235238	JAN-MS-00235238							
JA-00479	11/08/2017	Promotional Platform: Physician & Payers	JAN-MS-00010752	JAN-MS-00010796							
JA-00480	12/12/2012	Nucynta & Nucynta ER 2012 Business Plan	JAN-MS-00010801	JAN-MS-00010885							
JA-00481	07/20/2012	Janssen Presentation: Nucynta 2013 Preliminary Business Plan	JAN-MS-00011318	JAN-MS-00011370							
JA-00482	07/04/1905	Training manual for Nucynta ER	JAN-MS-00118938	JAN-MS-00118983							
JA-00483	No Date	Presentation: Video 1: Introduction Video	JAN-MS-00131172	JAN-MS-00131156							
JA-00484	01/14/2008	Benefit Risk Management, Division of Johnson & Johnson Pharmaceutical Research & Development, L.L.C.: DURAGESIC Progress Report Covering the Period 01 January 2004 to 31 March 2007	JAN-MS-00132845	JAN-MS-00132845							
JA-00485	03/18/2008	Duragesic Third Risk Management Plan Progress Report	JAN-MS-00132850	JAN-MS-00132850							
JA-00486	06/17/2008	Janssen Fentanyl and Fentanyl citrate Periodic Safety Update Report 05/01/2007 to 04/30/2008	JAN-MS-00132853	JAN-MS-00151773							
JA-00487	06/16/2008	Johnson & Johnson Duragesic (fentanyl transdermal system): Fourth Risk Management Plan Progress Report	JAN-MS-00151777	JAN-MS-00151777							
JA-00488	09/26/2008	Letter from Michael Kaufman to Bob A. Rappaport	JAN-MS-00151803	JAN-MS-00151803							
JA-00489	09/26/2008	Johnson & Johnson Duragesic (fentanyl transdermal system): Revised Risk Management Plan	JAN-MS-00151804	JAN-MS-00151804							
JA-00490	12/02/2011	Johnson & Johnson Duragesic (fentanyl transdermal system): Eleventh Risk Management Progress Report	JAN-MS-00291163	JAN-MS-00291163							
JA-00491	06/25/2015	Janssen Periodic Benefit Risk Evaluation Report/Periodic Safety Update Report	JAN-MS-00291192	JAN-MS-00291192							
JA-00492	06/23/2016	Janssen Periodic Benefit Risk Evaluation Report/Periodic Safety Update Report	JAN-MS-00291230	JAN-MS-00291230							
JA-00493	06/15/2017	Janssen Periodic Benefit Risk Evaluation Report/Periodic Safety Update Report	JAN-MS-00291322	JAN-MS-00291322							
JA-00494	09/02/2004	Letter from Thomas W. Abrams to Ajit Shetty	JAN-MS-00291331	JAN-MS-00291331							
JA-00495	09/17/2004	Letter from James Burros to Thomas W. Abrams	JAN-MS-00291332	JAN-MS-00291332							
JA-00496	06/17/2010	Janssen Fentanyl Periodic Safety Update Report 05/01/2009 to 04/30/2010	JAN-MS-00165630	JAN-MS-00185346							
JA-00497	11/22/2010	Duragesic: 9th Risk Management Plan Progress Report	JAN-MS-00185379	JAN-MS-00185379							
JA-00498	05/23/2011	Duragesic: 10th Risk Management Plan Progress Report	JAN-MS-00185384	JAN-MS-00185384							
JA-00499	06/15/2011	Janssen Fentanyl and Fentanyl citrate Periodic Safety Update Report 05/01/2010 to 04/30/2011	JAN-MS-00185387	JAN-MS-00198440							
JA-00500	06/01/2012	Duragesic: 10th Risk Management Plan Progress Report	JAN-MS-00198521	JAN-MS-00198521							
JA-00501	06/18/2012	Janssen Fentanyl and Fentanyl citrate Periodic Safety Update Report 05/01/2011 to 04/30/2012	JAN-MS-00198542	JAN-MS-00207023							
JA-00502	06/21/2013	Janssen Fentanyl and Fentanyl citrate Periodic Safety Update Report 05/01/2012 to 04/30/2013	JAN-MS-00207095	JAN-MS-00213411							
JA-00503	06/17/2014	Janssen Fentanyl and Fentanyl citrate Periodic Safety Update Report 05/01/2013 to 04/30/2014	JAN-MS-00213464	JAN-MS-00213464							
JA-00504	04/11/1990	Alza Safety Update - Long and Short Term Use of Transdermal Therapeutic System (fentanyl)	JAN-MS-00213588	JAN-MS-00213588							
JA-00505	12/21/1987	ALZA New Drug Application: Transdermal Therapeutic System (fentanyl)	JAN-MS-00213627	JAN-MS-00213627							
JA-00506	06/09/1905	Alza Stability Studies for Transdermal Therapeutic System (fentanyl)	JAN-MS-00213680	JAN-MS-00213680							
JA-00507	07/01/1992	ALZA Bibliography of Clinical Studies and Data for Transdermal Therapeutic System (fentanyl)	JAN-MS-00213683	JAN-MS-00213683							
JA-00508	08/31/1994	Janssen Research Non-clinical Pharmacokinetics Report for fentanyl formulation	JAN-MS-00213688	JAN-MS-00213688							
JA-00509	12/15/1995	ALZA Annual Report for NDA 19-813 Duragesic (fentanyl transdermal system)	JAN-MS-00213692	JAN-MS-00213692							
JA-00510	11/02/1994	Duragesic Stability Studies Schedule	JAN-MS-00213695	JAN-MS-00213695							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-00511	02/24/1997	Duragesic Stability Studies Schedule	JAN-MS-00213699	JAN-MS-00213699							
JA-00512	01/15/1998	Duragesic Stability Studies Schedule	JAN-MS-00213702	JAN-MS-00213702							
JA-00513	06/06/1999	ALZA Annual Report for Duragesic (fentanyl transdermal system)	JAN-MS-00213705	JAN-MS-00213705							
JA-00514	06/30/2003	Letter from Susan Merchant to FDA	JAN-MS-00213714	JAN-MS-00213714							
JA-00515	06/25/2004	Letter from Kathleen Dusek to FDA	JAN-MS-00213733	JAN-MS-00213733							
JA-00516	07/22/2005	Letter from Mary Christian to Bob Rappaport	JAN-MS-00213750	JAN-MS-00213750							
JA-00517	06/15/2007	Letter from Michael Kaufman to Bob Rappaport	JAN-MS-00213780	JAN-MS-00213780							
JA-00518	06/14/2007	Johnson & Johnson Duragesic Risk Management Plan (Draft)	JAN-MS-00213784	JAN-MS-00213784							
JA-00519	06/29/2007	FDA Periodic Safety Update Report Fentanyl and Fentanyl Citrate Medically Unconfirmed Adverse Reactions; May 1, 2006-April 30, 2007	JAN-MS-00213785	JAN-MS-00213785							
JA-00520	06/29/2007	Letter from Michael Kaufman to FDA	JAN-MS-00213795	JAN-MS-00213795							
JA-00521	09/01/2011	Letter from Bob Rappaport to Kathleen Dusek	JAN-MS-00214315	JAN-MS-00214315							
JA-00522	11/17/2009	Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Benefit Risk Management Tapentadol ER	JAN-MS-00214423	JAN-MS-00214423							
JA-00523	11/10/2009	Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Clinical Overview Tapentadol HCl	JAN-MS-00214445	JAN-MS-00214445							
JA-00524	03/16/2011	Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Global Medical Safety Tapentadol ER Safety Surveillance Plan	JAN-MS-00228228	JAN-MS-00228228							
JA-00525	07/30/2012	Nucynta (Tapentadol) Extended-Release: First Safety Surveillance Plan Progress Report	JAN-MS-00228466	JAN-MS-00228466							
JA-00526	03/01/2018	JRD Reg Affairs; Status of Post-Marketing Study Commitments	JAN-MS-00228476	JAN-MS-00228476							
JA-00527	10/17/2012	JRD Reg Affairs Annual Reports; Summary of Clinical Pharmacology Information	JAN-MS-00228477	JAN-MS-00228477							
JA-00528	08/29/2012	JRD Reg Affairs Annual Reports; Summary of Other Significant New Information	JAN-MS-00228481	JAN-MS-00228481							
JA-00529	12/20/2012	Naureckiene S, et al., Nucynta (Tapentadol) Extended-Release: Second Safety Surveillance Plan Progress Report, 2012	JAN-MS-00228506	JAN-MS-00228506							
JA-00530	04/26/2013	Naureckiene S, et al., NUCYNTA®(Tapentadol) Extended-Release: Third Safety Surveillance Plan Progress Report, 2013	JAN-MS-00228517	JAN-MS-00228517							
JA-00531	10/08/2013	JRD Reg Affairs Annual Reports; Status of Other Post-Marketing Studies	JAN-MS-00228537	JAN-MS-00228537							
JA-00532	10/08/2013	JRD Reg Affairs Annual Reports; Status of Other Post-Marketing Studies	JAN-MS-00228538	JAN-MS-00228538							
JA-00533	10/07/2013	JRD Reg Affairs Annual Reports; Status of Other Post-Marketing Studies	JAN-MS-00228539	JAN-MS-00228539							
JA-00534	12/02/2013	Naureckiene, S et al., Nucynta (Tapentadol) Extended-Release: FourthSafety Surveillance Plan Progress Report, 2013	JAN-MS-00228548	JAN-MS-00228548							
JA-00535	08/25/2011	Status of Post-Marketing Study Commitments.	JAN-MS-00228619	JAN-MS-00228619							
JA-00536	07/06/1905	Summary of Clinical Pharmacology Information.	JAN-MS-00228622	JAN-MS-00228622							
JA-00537	10/21/2014	Janssen, Summary of Other Significant New Information, 2014	JAN-MS-00228623	JAN-MS-00228623							
JA-00538	02/01/2013	Presentation: Nucynta ER Powerful Pain Management: Proven Across Multiple Acute and Chronic Pain Models.	JAN-MS-00229171	JAN-MS-00229171							
JA-00539	03/31/2014	Nucynta ER Safety Label	JAN-MS-00229217	JAN-MS-00229217							
JA-00540	04/01/2012	Presentation: A Different Option for Chronic Pain Management, Nucynta ER	JAN-MS-00229314	JAN-MS-00229314							
JA-00541	09/01/2011	New Nucynta ER, Pharmacy Stocking Request Tool.	JAN-MS-00229607	JAN-MS-00229607							
JA-00542	08/01/2012	Schwartz, Sherwyn et al, Nucynta ER, Safety and efficacy of tapentadol ER in patient with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial.	JAN-MS-00229655	JAN-MS-00229655							
JA-00543	07/01/2011	Nucynta Infosite on Medscape.	JAN-MS-00229930	JAN-MS-00229930							
JA-00544	08/26/2011	Letter from Mathilda Fienkeng to Roxanne O. McGregor-Beck	JAN-MS-00230366	JAN-MS-00230366							
JA-00545	09/12/2011	Letter from Roxanne O. McGregor-Beck to Mathilda K. Fienkeng	JAN-MS-00230368	JAN-MS-00230368							
JA-00546	01/11/2008	Tapentadol IR Safety Surveillance Plan	JAN-MS-00230429	JAN-MS-00230429							
JA-00547	01/11/2008	Tapentadol IR in the Treatment of Moderate to Severe Acute Pain	JAN-MS-00230459	JAN-MS-00230459							
JA-00548	01/12/2010	Status of Other Post-Marketing Studies.	JAN-MS-00235142	JAN-MS-00235142							
JA-00549	01/12/2010	Status of Postmarketing Study Commitments.	JAN-MS-00235143	JAN-MS-00235143							
JA-00550	01/19/2010	Summary of Clinical Pharmacology Information on Tapentadol	JAN-MS-00235144	JAN-MS-00235144							
JA-00551	04/26/2010	Janssen report on safety plan of Nucynta IR	JAN-MS-00235160	JAN-MS-00235160							
JA-00552	01/14/2011	Status of Other Post-Marketing Studies.	JAN-MS-00235204	JAN-MS-00235204							
JA-00553	01/03/2011	Status of Postmarketing Study Commitments.	JAN-MS-00235205	JAN-MS-00235205							
JA-00554	01/13/2011	Summary of Clinical Pharmacology Information.	JAN-MS-00235206	JAN-MS-00235206							
JA-00555	01/05/2011	Summary of Other Significant New Information.	JAN-MS-00235210	JAN-MS-00235210							
JA-00556	05/02/2011	Janssen third safety report on Nucynta IR	JAN-MS-00235238	JAN-MS-00235238							
JA-00557	05/02/2011	Janssen third safety report on Nucynta IR	JAN-MS-00235239	JAN-MS-00235239							
JA-00558	01/12/2012	Status of Other Post-Marketing Studies.	JAN-MS-00235264	JAN-MS-00235264							
JA-00559	01/12/2012	Status of Postmarketing Study Commitments.	JAN-MS-00235265	JAN-MS-00235265							
JA-00560	01/05/2012	Janssen report on Clinical Pharmacology Information for Tapentadol	JAN-MS-00235266	JAN-MS-00235266							
JA-00561	01/05/2012	Summary of Other Significant New Information.	JAN-MS-00235270	JAN-MS-00235270							
JA-00562	01/19/2012	Janssen fourth safety surveillance plan for Nucynta IR	JAN-MS-00235278	JAN-MS-00235278							
JA-00563	08/06/2003	Janssen draft presentation: 2004 Business Plan	JAN-MS-00723375	JAN-MS-00723375							
JA-00564	06/23/2003	Email from Detlef Albrecht to Amy Stephenson et al	JAN-MS-00723911	JAN-MS-00723911							
JA-00565	01/16/2004	Janssen draft presentation: Public Safety	JAN-MS-00724843	JAN-MS-00724851							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-00566	09/06/2011	Janssen report on call feedback	JAN-MS-00074061	JAN-MS-00074062							
JA-00567	11/15/2007	Report from Vince Brett on Duragesic	JAN-MS-00747497	JAN-MS-00747504							
JA-00568	02/14/2008	Letter from PriCara to customers	JAN-MS-00747681	JAN-MS-00747681							
JA-00569	06/06/2012	Janssen report on Nucynta ER	JAN-MS-00774016	JAN-MS-00774024							
JA-00570	03/03/2003	Janssen draft presentation: Public Relations Activities	JAN-MS-00776219	JAN-MS-00776219							
JA-00571	05/22/2002	Email from Adrienne Minecci to Kati Chupa	JAN-MS-00776446	JAN-MS-00776446							
JA-00572	05/22/2002	Janssen presentation: Self-study Guide	JAN-MS-00776447	JAN-MS-00776456							
JA-00573	09/05/2001	Janssen report on Duragesic	JAN-MS-00776565	JAN-MS-00776570							
JA-00574	09/02/2004	Letter from Thomas Abrams to James Burns	JAN-MS-00779345	JAN-MS-00779350							
JA-00575	09/24/2004	Email from Joseph Cannavo to Kati Chupa	JAN-MS-00779353	JAN-MS-00779353							
JA-00576	06/20/2003	Email from Susan Merchant to Elizabeth Turek	JAN-MS-00779572	JAN-MS-00779572							
JA-00577	06/18/2003	Janssen draft label for Duragesic	JAN-MS-00779573	JAN-MS-00779573							
JA-00578	06/20/2003	Janssen draft label for Duragesic	JAN-MS-00779574	JAN-MS-00779574							
JA-00579	06/27/2001	Discovery presentation: Growing Market Share in 2002	JAN-MS-00780131	JAN-MS-00780131							
JA-00580	07/01/2002	Janssen draft presentation: Operation Business Plan	JAN-MS-00780336	JAN-MS-00780336							
JA-00581	07/22/2002	Janssen presentation: Business Planning 2003	JAN-MS-00780354	JAN-MS-00780354							
JA-00582	11/30/2001	Scientific Advisory Board minutes; determine research projects on Duragesic	JAN-MS-00782617	JAN-MS-00782626							
JA-00583	06/24/1905	Presentation: Duragesic Green Sales Force District Meeting Cycle II	JAN-MS-00246939	JAN-MS-00246939							
JA-00584	02/07/2005	Email from James Burrus to Ravi Desiraju et al.	JAN-MS-00257412	JAN-MS-00257412							
JA-00585	06/26/1905	Summary of Duragesic labeling history and proposed additions to label for Duragesic 12 mcg	JAN-MS-00262153	JAN-MS-00262153							
JA-00586	01/17/2015	Email from American Pain Society to Ron Kuntz	JAN-MS-00264775	JAN-MS-00264776							
JA-00587	08/31/2007	Email from Greg Panico to Chris Handler et al.	JAN-MS-00275814	JAN-MS-00275815							
JA-00588	12/02/2011	Duragesic Eleventh Risk Management Plan Progress Report	JAN-MS-00291163	JAN-MS-00291163							
JA-00589	06/19/2015	Global Medical Safety, Periodic Benefit Risk Evaluation Report/Periodic Safety Update Report, Fentanyl and Fentanyl Citrate.	JAN-MS-00291192	JAN-MS-00291192							
JA-00590	04/30/2016	Global Medical Safety, Periodic Benefit Risk Evaluation Report/Periodic Safety Update Report, Fentanyl and Fentanyl Citrate.	JAN-MS-00291230	JAN-MS-00291230							
JA-00591	04/30/2017	Global Medical Safety, Periodic Benefit Risk Evaluation Report/Periodic Safety Update Report, Fentanyl.	JAN-MS-00291322	JAN-MS-00291322							
JA-00592	09/02/2004	Letter from Thomas Abram to Ajit Shetty.	JAN-MS-00291331	JAN-MS-00291331							
JA-00593	09/17/2004	Facsimile letter from James Burrus to Thomas Abrams, FDA.	JAN-MS-00291332	JAN-MS-00291332							
JA-00594	10/01/2004	Letter from Brenda Marques to James Burrus.	JAN-MS-00291333	JAN-MS-00291333							
JA-00595	10/15/2004	Letter from James Burrus to Brenda Marques	JAN-MS-00291335	JAN-MS-00291335							
JA-00596	01/03/2005	Letter from Brenda Marques to James Burrus.	JAN-MS-00291339	JAN-MS-00291339							
JA-00597	01/13/2005	Letter from James Burrus to Brenda Marques	JAN-MS-00291340	JAN-MS-00291340							
JA-00598	05/12/2005	Facsimile letter from Jialynn Wang, FDA/HHS to James Burrus.	JAN-MS-00291349	JAN-MS-00291349							
JA-00599	06/24/2005	Letter from Mary Christian to US Food and Drug Administration,.Center for Drug Evaluation and Research	JAN-MS-00291420	JAN-MS-00291420							
JA-00600	06/21/2008	Letter from Michael Kaufman to .US Food and Drug Administration,.Center for Drug Evaluation and Research	JAN-MS-00291442	JAN-MS-00291442							
JA-00601	07/31/2008	Letter from Bob Rappaport to Harindra Abeyasinghe.	JAN-MS-00292753	JAN-MS-00292807							
JA-00602	03/01/2004	Presentation: Duragesic, Work, Uninterrupted.	JAN-MS-00299212	JAN-MS-00299218							
JA-00603	06/30/2003	AP-48 D-TRANS fentanyl system with naltrexone HCl, Executive Summary	JAN-MS-00299535	JAN-MS-00299535							
JA-00604	09/09/2003	FDA Advisory Committee Meeting Media Response Document	JAN-MS-00303831	JAN-MS-00303835							
JA-00605	09/16/2003	Duragesic PhysPulse Brand Monitoring and Performance Enhancement Study, Summary of Wave 1 Results	JAN-MS-00306124	JAN-MS-00306124							
JA-00606	06/16/2003	Duragesic Positioning/Message/Campaign Evolution Overview	JAN-MS-00306327	JAN-MS-00306327							
JA-00607	03/05/2003	Email from Cheryl Pavia to Jim Eckhardt et al.	JAN-MS-00306415	JAN-MS-00306415							
JA-00608	06/26/1905	Draft Duragesic Labeling Scenarios, FDA Proposed and J&J Alternatives	JAN-MS-00306425	JAN-MS-00306455							
JA-00609	03/24/2004	Email from Susan Merchant to Peter Bridge et al.	JAN-MS-00306483	JAN-MS-00306483							
JA-00610	07/26/2001	Duragesic 2002 Business Plan	JAN-MS-00306718	JAN-MS-00306718							
JA-00611	10/07/2005	J&J Cumulative Review of Death Cases With the Use of Fentanyl Transdermal System	JAN-MS-00309203	JAN-MS-00309349							
JA-00612	06/01/2002	Duragesic Positioning Evolution Overview	JAN-MS-00309606	JAN-MS-00309606							
JA-00613	08/01/2001	Milligan K et al., "Evaluation of Long-term Efficacy and Safety of Transdermal Fentanyl in the Treatment of Chronic Noncancer Pain," The Journal of Pain, 2(4), pp. 197-204.	JAN-MS-00311759	JAN-MS-00311766							
JA-00614	No Date	Duragesic Detail Role Play	JAN-MS-00313051	JAN-MS-00313053							
JA-00615	02/23/2009	Janssen Nucynta Suggested Presentation	JAN-MS-00327255	JAN-MS-00327263							
JA-00616	05/01/2009	Nucynta (IR and ER) 2010 Business Plan	JAN-MS-00350627	JAN-MS-00350627							
JA-00617	03/11/2008	Email from Ravi Desiraju to Steven Silber	JAN-MS-00351356	JAN-MS-00351357							
JA-00618	06/23/2010	Email from David Lin to Lisa Ferguson et al.	JAN-MS-00362016	JAN-MS-00362049							
JA-00619	10/01/2004	Spreadsheet:Contact Dates with FDA.	JAN-MS-00375054	JAN-MS-00375054							
JA-00620	07/01/2005	Duragesic NDA Annual Report, section on labeling	JAN-MS-00379100	JAN-MS-00379104							
JA-00621	05/12/2003	Email from Juergen Haeussler to David Upmalis	JAN-MS-00385872	JAN-MS-00385873							
JA-00622	06/23/2010	Citizen Petition from Alza to US Food and Drug Administration	JAN-MS-00386726	JAN-MS-00386736							
JA-00623	02/16/2005	Email from Kimberly Gaumer to Sue Rinne	JAN-MS-00392372	JAN-MS-00392373							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-00624	06/30/1905	Tapentadol Business Plan 2008	JAN-MS-00443233	JAN-MS-00443233							
JA-00625	No Date	Highlights of Prescribing Information	JAN-MS-00445032	JAN-MS-00445055							
JA-00626	07/02/1905	Memo from Mike Hanlon to David Lin	JAN-MS-00448838	JAN-MS-00448838							
JA-00627	08/15/2000	Email from Michael Grissinger to Ron Kuntz et al.	JAN-MS-00456650	JAN-MS-00456651							
JA-00628	No Date	Presentation: Tapentadol Global Commercial Team	JAN-MS-00457581	JAN-MS-00457581							
JA-00629	02/08/2011	Copy Review Approval Form for Nucynta Formulary Pricing Flashcard	JAN-MS-00464131	JAN-MS-00464131							
JA-00630	03/27/2008	Presentation: Welcome, Tapentadol E-learning Project Kickoff	JAN-MS-00469584	JAN-MS-00469584							
JA-00631	01/07/2009	Email from Tanya Nelson to Chris Cho et al.	JAN-MS-00469968	JAN-MS-00469970							
JA-00632	08/25/2010	Presentation: Nucynta ER Payer and Physician Research	JAN-MS-00473858	JAN-MS-00473858							
JA-00633	06/01/2008	Presentation: 2009 Tapentadol Business Plan Situation Assessment.	JAN-MS-00477361	JAN-MS-00477361							
JA-00634	09/10/2004	Presentation: Differences Between the Duragesic Fentanyl Reservoir Patch and Fentanyl Matrix Patches, Potential Drug Safety and Abuse Liability Implications	JAN-MS-00478361	JAN-MS-00478361							
JA-00635	09/15/2000	Record of FDA Contact	JAN-MS-00479781	JAN-MS-00479783							
JA-00636	06/08/2000	Record of FDA Contact	JAN-MS-00479784	JAN-MS-00479785							
JA-00637	05/10/2000	Record of FDA Contact	JAN-MS-00479787	JAN-MS-00479788							
JA-00638	05/10/2000	Record of FDA Contact	JAN-MS-00480543	JAN-MS-00480543							
JA-00639	04/26/2006	Letter from Bob Rappaport to Michael Kaufman.	JAN-MS-00480894	JAN-MS-00480899							
JA-00640	09/27/2004	Email from Michael Kafrissen to Bruce Moskovitz et al.	JAN-MS-00482680	JAN-MS-00482683							
JA-00641	03/09/2009	"FDA Kicks Off Opioid Class REMS Discussion; Asks for Industry Collaboration," F-D-C Reports, 7(10)	JAN-MS-00484776	JAN-MS-00484777							
JA-00642	10/22/2003	Email from Bruce Moskovitz to Susan Merchant	JAN-MS-00492672	JAN-MS-00492673							
JA-00643	12/05/2003	Email from Bruce Moskovitz to Kati Chupa et al.	JAN-MS-00492752	JAN-MS-00492752							
JA-00644	08/07/1990	Letter from Carl Peck to Virgil Place	JAN-MS-00551711	JAN-MS-00552054							
JA-00645	06/13/2005	J&J Fentanyl and Fentanyl Citrate Periodic Safety Update Report	JAN-MS-00553427	JAN-MS-00553787							
JA-00646	03/02/2005	Presentation: Proposed CCDS Revisions for fentanyl TTS, Duragesic/Durogesic	JAN-MS-00564021	JAN-MS-00564026							
JA-00647	03/02/2005	Draft Table of Proposed CCDS Revisions for Fentanyl TTS	JAN-MS-00564028	JAN-MS-00564039							
JA-00648	12/11/2012	Work Order #6724, Pain Management Sales Team	JAN-MS-00576727	JAN-MS-00576746							
JA-00649	07/18/2016	Janssen R&D White Paper: Matrix Fentanyl Transdermal Drug Delivery System: Review of Available Evidence to Inform Reformulation Needs of the Matrix Patch Outside of the United States	JAN-MS-00587189	JAN-MS-00587202							
JA-00650	10/01/1997	Simpson, Richard K. et al., "Transdermal Fentanyl as Treatment for Chronic Low Back Pain," Journal of Pain and Symptom Management, Vol. 14, No. 4, pp. 218-224.	JAN-MS-00591572	JAN-MS-00591578							
JA-00651	08/02/2006	PriCara Quarterly Report, Assessment of the Abuse of Ultram ER and Fentanyl Products.	JAN-MS-00613857	JAN-MS-00613888							
JA-00652	09/17/2003	Email from Hetal V. Patel to Mekre Senbetta et al.	JAN-MS-00616428	JAN-MS-00616429							
JA-00653	08/01/2000	Duragesic 2001 Business Plan	JAN-MS-00618253	JAN-MS-00618253							
JA-00654	12/15/2000	Letter from Janne Wissel to Cynthia McCormick	JAN-MS-00642115	JAN-MS-00642135							
JA-00655	01/04/2001	Record of FDA Contact	JAN-MS-00654881	JAN-MS-00654883							
JA-00656	04/16/2013	Update on Recent FDA Ruling Regarding Abuse-Deterrent Formulations (ADF)	JAN-MS-00658452	JAN-MS-00658452							
JA-00657	06/19/2012	Letter from Mary Mulligan to Bob Rappaport, FDA.	JAN-MS-00700680	JAN-MS-00700681							
JA-00658	08/06/2003	Presentation: AP 48, 2004 Business Plan	JAN-MS-00723375	JAN-MS-00723375							
JA-00659	06/23/2003	Email from Detlef Albrecht to Amy Stephenson et al.	JAN-MS-00723911	JAN-MS-00723911							
JA-00660	06/26/1905	Public Safety Script for Duragesic	JAN-MS-00724843	JAN-MS-00724851							
JA-00661	09/06/2011	Janssen report on sales feedback	JAN-MS-00074061	JAN-MS-00074062							
JA-00662	11/15/2007	Comment on draft Duragesic KOL Slide Deck	JAN-MS-00747497	JAN-MS-00747504							
JA-00663	12/01/2009	Urgent Drug Recall	JAN-MS-00747681	JAN-MS-00747681							
JA-00664	06/06/2012	Cycle 2 Update: Video Walk-Through	JAN-MS-00774016	JAN-MS-00774024							
JA-00665	03/03/2003	2003 Duragesic Public Relations Activities	JAN-MS-00776219	JAN-MS-00776219							
JA-00666	05/22/2002	Email from Adrienne Minecci to Kati Chupa	JAN-MS-00776446	JAN-MS-00776446							
JA-00667	No Date	Sales Representative Self-Study Guide	JAN-MS-00776447	JAN-MS-00776456							
JA-00668	09/01/2001	Product News Update, Medical Services, Product Management & Sales Training	JAN-MS-00776565	JAN-MS-00776570							
JA-00669	09/02/2004	Faxed letter from Thomas Abrams, HHS to Ajit Sherry.	JAN-MS-00779345	JAN-MS-00779350							
JA-00670	09/24/2004	Email from Joseph Cannavo to Kati Chupa	JAN-MS-00779353	JAN-MS-00779353							
JA-00671	06/20/2003	Email from Susan Merchant to Elizabeth Turek et al.	JAN-MS-00779572	JAN-MS-00779572							
JA-00672	05/01/2003	Duragesic Full Prescribing Information.	JAN-MS-00779573	JAN-MS-00779573							
JA-00673	05/01/2003	Duragesic Patient Information leaflet.	JAN-MS-00779574	JAN-MS-00779574							
JA-00674	06/27/2001	Presentation: Growing Market Share in 2002, Medical Education Tactics in Support of Duragesic	JAN-MS-00780131	JAN-MS-00780131							
JA-00675	No Date	Presentation: CP \$\$ Market Breakdown by Specialty	JAN-MS-00780336	JAN-MS-00780336							
JA-00676	07/22/2002	Presentation: Duragesic Business Planning 2003	JAN-MS-00780354	JAN-MS-00780354							
JA-00677	11/30/2001	Executive Summary Chronic Pain Scientific Advisory Board	JAN-MS-00782617	JAN-MS-00782626							
JA-00678	11/30/2005	Email from Sujata Manam to Kati Chupa	JAN-MS-00783443	JAN-MS-00783443							
JA-00679	08/01/2000	Presentation: Duragesic 2001 Business Plan	JAN-MS-00785798	JAN-MS-00785798							
JA-00680	02/01/2002	Presentation: Duragesic 340 Sales Force, Cycle 1 Presentation	JAN-MS-00785983	JAN-MS-00785983							
JA-00681	06/28/2002	Presentation: Duragesic, Analysis of Duragesic Brand Prescribing.	JAN-MS-00787243	JAN-MS-00787243							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-00682	01/26/2005	Email from Stephen Cornwell to Laura Vaughan et al.	JAN-MS-00787900	JAN-MS-00787900							
JA-00683	06/10/2003	Duragesic Full Prescribing Information.	JAN-MS-00787901	JAN-MS-00787964							
JA-00684	No Date	Coleman, John et al., "Assessment of the Abuse of Transdermal Fentanyl."	JAN-MS-00789392	JAN-MS-00789402							
JA-00685	11/29/2004	Email from Cindy Knowlton to Kati Chupa et al.	JAN-MS-00790075	JAN-MS-00790077							
JA-00686	09/19/2003	Regulatory Agency Contact Report, FDA, Anesthetic, Critical Care & Addiction Drug Products Division, September 19, 2003.	JAN-MS-00790757	JAN-MS-00790759							
JA-00687	01/20/2010	Email from David Lin to Frank Demiro et al.	JAN-MS-00837195	JAN-MS-00837198							
JA-00688	10/11/2004	Email from Carolyn Kong to Hans Wormann et al.	JAN-MS-00848410	JAN-MS-00848410							
JA-00689	08/29/2003	NDA History from 12/21/1987 to 08/29/2003.	JAN-MS-00884728	JAN-MS-00884739							
JA-00690	08/24/2004	Email from Elizabeth Turek to Jay Audett et al.	JAN-MS-00884751	JAN-MS-00884751							
JA-00691	08/09/2004	Duragesic Global Regulatory Team Meeting Minutes	JAN-MS-00884794	JAN-MS-00884796							
JA-00692	03/30/2009	Marketing Plan for the Transition of Duragesic Reservoir Patch to the Duragesic Matrix Patch	JAN-MS-00885848	JAN-MS-00885850							
JA-00693	02/17/2010	Email from Marjo Janssen to Regi Van Genechten et al.	JAN-MS-00888210	JAN-MS-00888211							
JA-00694	01/26/2005	Email from William Randolph to Hank Avallone et al.	JAN-MS-00890282	JAN-MS-00890285							
JA-00695	12/21/2004	FDA Citizen Petition: EMEA Risk Management Responses	JAN-MS-00891010	JAN-MS-00891012							
JA-00696	01/07/2003	Regulatory Agency Contact Report, FDA Dockets Management Branch.	JAN-MS-00896355	JAN-MS-00896359							
JA-00697	08/22/2001	Email from Elizabeth Turek to Simon Arnold et al.	JAN-MS-00899137	JAN-MS-00899137							
JA-00698	08/14/2001	Memorandum from Ed Rady et al. to Dennis Fitzgerlad et al.	JAN-MS-00899138	JAN-MS-00899142							
JA-00699	03/02/2000	Email from Jack Grebb to Ira Katz et al.	JAN-MS-00901266	JAN-MS-00901266							
JA-00700	02/29/2000	Letter from Cynthia Chianese to Spencer Salis, FDA.	JAN-MS-00901267	JAN-MS-00901269							
JA-00701	05/16/2000	Canada Reply	JAN-MS-00901369	JAN-MS-00901384							
JA-00702	05/22/2001	Email from Brigitte Kuperwasser to Joseph Guarnieri.	JAN-MS-00901946	JAN-MS-00901948							
JA-00703	02/19/2001	Janssen Research Foundation: Duragesic Tolerance and Tolerability: Long term Duragesic Treatment Tolerance Probability and Tolerability	JAN-MS-00901949	JAN-MS-00901965							
JA-00704	04/01/1998	Duragesic Administration Instructions.	JAN-MS-00907134	JAN-MS-00907152							
JA-00705	11/10/2004	Email from Jennifer Ekelund to Michael Chester et al.	JAN-MS-00914206	JAN-MS-00914207							
JA-00706	12/07/2004	Email from Cindy Knowlton to Kim Gaumer et al.	JAN-MS-00914223	JAN-MS-00914225							
JA-00707	02/01/2005	Email from Cindy Knowlton to Kim Gaumer et al.	JAN-MS-00914240	JAN-MS-00914244							
JA-00708	02/08/2005	Email from Cindy Knowlton to Larry Morra et al.	JAN-MS-00914263	JAN-MS-00914265							
JA-00709	08/04/2004	Email from Cindy Knowlton to Dawne Hom et al.	JAN-MS-00914600	JAN-MS-00914600							
JA-00710	08/05/2004	Email from Susan Merchant to Bruce Moskovitz et al.	JAN-MS-00914601	JAN-MS-00914604							
JA-00711	08/11/2004	Email from Susan Merchant to Cindy Knowlton et al.	JAN-MS-00914640	JAN-MS-00914640							
JA-00712	07/01/2003	Draft letter from sue Rinne to Bob Rappaport, FDA.	JAN-MS-00914641	JAN-MS-00914643							
JA-00713	08/11/2004	J & J PRD Regulatory Affairs Label Change Request Approval./Notification Form.	JAN-MS-00914671	JAN-MS-00914671							
JA-00714	11/30/2004	Email from Cindy Knowlton to Raymond Hernandez	JAN-MS-00914787	JAN-MS-00914788							
JA-00715	02/11/2002	Duragesic Labeling History.	JAN-MS-00914802	JAN-MS-00914802							
JA-00716	01/12/2001	Letter from Janne Wissel, Alza to Cynthia McCormick, FDA.	JAN-MS-00914803	JAN-MS-00914805							
JA-00717	09/26/2001	Letter Cynthia McCormick, FDA./HHS to Janne Wissel, Alza Corporation.	JAN-MS-00914806	JAN-MS-00914808							
JA-00718	02/11/2002	Letter from Janne Wissel to Cynthia McCormick, FDA.	JAN-MS-00914809	JAN-MS-00914814							
JA-00719	06/06/2004	Duragesic NDA Annual Report, Section C, Labeling.	JAN-MS-00914818	JAN-MS-00914819							
JA-00720	08/10/2005	Email from Kimberly Compton to Mary Christian et al.	JAN-MS-00914938	JAN-MS-00914941							
JA-00721	05/08/2008	J&J Pharmaceutical R&D: Draft Report: Seven Studies of Tapentadol Immediate Release For Acute Pain To Be Presented at 2008 American Pain Society Annual Meeting.	JAN-MS-00928656	JAN-MS-00928656							
JA-00722	05/09/2008	J&J Pharmaceutical R&D: Draft Report: Results Of Phase 3 Study Show Tapentadol IR Relieves Acute Pain And Offers Favorable Gastrointestinal Tolerability Profile.	JAN-MS-00928658	JAN-MS-00928658							
JA-00723	No Date	Extended-Release and Long-Acting Opioid Analgesics, Risk Evaluation and Mitigation Strategy (REMS) Supporting Document	JAN-MS-00935481	JAN-MS-00935534							
JA-00724	01/28/2005	Letter from Steven Galson, FDA/HHS to Sue Rinne, Alza Corp.	JAN-MS-00950449	JAN-MS-00950461							
JA-00725	06/20/2006	Email from Dawn Sanderson-Bongiovanni to Kenneth Kostenbader	JAN-MS-00957863	JAN-MS-00957864							
JA-00726	No Date	Pain Force District Manager's Meetings with Pharmacy District/Regional Directors	JAN-MS-00982914	JAN-MS-00982914							
JA-00727	12/16/2013	Letter from David Lin to Community Anti-Drug Coalitions of America (CADCA).	JAN-MS-00984287	JAN-MS-00984295							
JA-00728	01/25/2008	Tapentadol HCl bunionectomy JMA-51492 Second Draft Comments.	JAN-MS-01011449	JAN-MS-01011449							
JA-00729	03/19/2008	Upmalis, David, et al, Bunionectomy Phase III Manuscript, "Analgesic Efficacy of Multiple Doses of Tapendtadol Immediate Release in Postsurgical Orthopedic (Bunionectomy) Pain; Results of a Phase III, Randomized, Dobule-blind, Placebo-Controlled Study," Anesthesiology..	JAN-MS-01011479	JAN-MS-01011509							
JA-00730	No Date	Presentation: Goals for Publication of the Phase III Manuscript.	JAN-MS-01011585	JAN-MS-01011585							
JA-00731	12/11/2003	Letter from Lisa Basham-Cruz, HHS to Richard Paul, Grunenthal USA.	JAN-MS-01031602	JAN-MS-01031613							
JA-00732	08/17/2011	Email from Tania Hillmer to Janet Peterson et al.	JAN-MS-01047546	JAN-MS-01047547							
JA-00733	01/21/2010	Email from David Lin to Carole Carter-Cleaver et al.	JAN-MS-01049657	JAN-MS-01049658							
JA-00734	12/09/2012	Email from David Lin to Patricia Yap et al.	JAN-MS-01049919	JAN-MS-01049920							
JA-00735	No Date	Presentation: Project Pearl Internal Discussion Guide	JAN-MS-01051754	JAN-MS-01051754							
JA-00736	No Date	Presentation:Tapentadol Launch Process	JAN-MS-01053692	JAN-MS-01053692							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-00737	02/02/2012	Email from Frank Demiro to Vandana Kataria et al.	JAN-MS-01079820	JAN-MS-01079820							
JA-00738	01/09/2012	Email from DocAlert to Michael McIntire	JAN-MS-01090372	JAN-MS-01090379							
JA-00739	No Date	Marketing Presentation: Nucynta ER, Unleashing The Power.	JAN-MS-01114237	JAN-MS-01114237							
JA-00740	01/09/2012	Email from Christopher Flores to Roxanne O. McGregor-Beck	JAN-MS-01122345	JAN-MS-01122348							
JA-00741	04/17/2008	Email from Edward Benson to Paul Kramer et al.	JAN-MS-01124775	JAN-MS-01124782							
JA-00742	01/07/2009	Email from Tanya Nelson to Lori Lonczak et al.	JAN-MS-01124841	JAN-MS-01124842							
JA-00743	01/06/2009	Email from Tanya Nelson to Chris Cho et al.	JAN-MS-01124843	JAN-MS-01124844							
JA-00744	01/08/2009	Email from Tanya Nelson to Michele Scott et al.	JAN-MS-01124847	JAN-MS-01124848							
JA-00745	09/16/2008	Email from Christine Rauschkolb to Greg Panico	JAN-MS-01124875	JAN-MS-01124879							
JA-00746	11/20/2008	Letter from Curtis Rosebraugh to Kathleen F. Dusek	JAN-MS-01130740	JAN-MS-01130779							
JA-00747	09/10/2004	Duragesic and fentanyl matrix patches Regulatory Strategy Meeting, September 10, 2004.	JAN-MS-01139472	JAN-MS-01139477							
JA-00748	02/03/2005	Letter from Susan Rinne to Robert Rappaport, FDA.	JAN-MS-01144045	JAN-MS-01144047							
JA-00749	11/12/2002	Janssen draft report on Duragesic use	JAN-MS-01145538	JAN-MS-01145538							
JA-00750	06/26/2009	IWG Submission to FDA Docket.	JAN-MS-01152859	JAN-MS-01152876							
JA-00751	06/23/2004	Email from Bruce Moskovitz to Hetal V. Patel	JAN-MS-01197219	JAN-MS-01197222							
JA-00752	07/06/2004	Email from Bruce Moskovitz to Elizabeth Turek et al.	JAN-MS-01197354	JAN-MS-01197355							
JA-00753	No Date	Duragesic: NDA-19-813. S-039.	JAN-MS-01197356	JAN-MS-01197356							
JA-00754	07/20/2004	Email from Bruce Moskovitz to Sheryne Duncombe	JAN-MS-01197375	JAN-MS-01197375							
JA-00755	10/01/2003	Janssen-Cilag Report: An assessment of the potential for prescription analgesic abuse, misuse, and diversion in Europe.	JAN-MS-01200052	JAN-MS-01200132							
JA-00756	04/25/2008	Email from Bruce Moskovitz to Ravi Desiraju	JAN-MS-01200479	JAN-MS-01200480							
JA-00757	04/25/2008	Janssen report on fentanyl patch	JAN-MS-01200481	JAN-MS-01200495							
JA-00758	11/20/2008	Letter from Curtis Rosebraugh, FDA/HHS to Kathleen Dusek.	JAN-MS-01232317	JAN-MS-01232356							
JA-00759	06/22/2009	Janssen label for Nucynta	JAN-MS-01249732	JAN-MS-01249757							
JA-00760	04/21/2009	Janssen draft press release on Transition from Reservoir to Matrix patch	JAN-MS-01250151	JAN-MS-01250151							
JA-00761	02/10/2004	Email from Peter Bridge to Henry M. Richards	JAN-MS-01305627	JAN-MS-01305630							
JA-00762	03/25/2005	Email from Michael Damask to Patricia Robinson et al.	JAN-MS-01317286	JAN-MS-01317287							
JA-00763	02/04/2005	Email from Henry M. Richards to Patricia Robinson	JAN-MS-01317778	JAN-MS-01317781							
JA-00764	03/22/2005	Report: Richards, Henry, J&J Benefit Risk Management Medical Group; Cumulative post-marketing adverse event experience with fentanyl-containing medicinal products and exposure to monoamine oxidase inhibitors as concomitant medications.	JAN-MS-01318449	JAN-MS-01318459							
JA-00765	02/20/2007	Mark J. Edlund, Diane Steffick, Teresa Hudson, Katherine M. Harris, Mark Sullivan, Risk factors for clinically recognized opioid abuse and dependence among veterans using opioids for chronic non-cancer pain, Elsevier B.V., Pain 129, pp. 355-362, 2007	JAN-MS-01466935	JAN-MS-01466942							
JA-00766	05/10/2012	Janssen study on REMS for Nucynta ER	JAN-MS-01489228	JAN-MS-01489275							
JA-00767	03/24/2008	Email from Bruce Moskovitz to Ravi Desiraju et al	JAN-MS-02005184	JAN-MS-02005185							
JA-00768	01/29/2008	Email from Scott Trembley to Ravi Desiraju et al	JAN-MS-02007690	JAN-MS-02007692							
JA-00769	06/12/2008	Copy Review Approval Form for Duragesic.com interim website	JAN-MS-02008330	JAN-MS-02008330							
JA-00770	08/27/2013	Janssen Research & Development, Record of Contact.	JAN-MS-02043301	JAN-MS-02043308							
JA-00771	No Date	Duragesic Labeling Scenarios Without Opioid-Naive Test.	JAN-MS-02105411	JAN-MS-02105411							
JA-00772	No Date	Duragesic Labeling Scenarios.	JAN-MS-02105412	JAN-MS-02105412							
JA-00773	05/20/2003	Email from Samuel Maldonado to Elizabeth Turek et al.	JAN-MS-02109774	JAN-MS-02109775							
JA-00774	07/21/2003	"Drugs In Development," Monthly Report, Johnson & Johnson, July 21, 2003.	JAN-MS-02110875	JAN-MS-02110884							
JA-00775	11/20/2003	Email from Bruce Mokovitz to Susan Merchant et al.	JAN-MS-02111027	JAN-MS-02111028							
JA-00776	06/07/2004	Assessment of Abuse Potential of the Matrix Formulation of Fentanyl Transdermal System: Update of the 2001 Pinney Associates' Report, June 7, 2004.	JAN-MS-02119824	JAN-MS-02119863							
JA-00777	04/04/2003	Email from Kim Kuehne to Linda Carducci et al.	JAN-MS-02123297	JAN-MS-02123297							
JA-00778	07/26/2004	Email from Susan Merchant to Susan Merchant et al.	JAN-MS-02123444	JAN-MS-02123445							
JA-00779	06/10/2003	Duragesic Full Prescribing Information.	JAN-MS-02123446	JAN-MS-02123446							
JA-00780	04/08/2004	Email from Susan Merchant to Bruce Moskovitz et al.	JAN-MS-02124857	JAN-MS-02124858							
JA-00781	01/06/2005	Email from Gary J. Vorsanger to Donna Jordan	JAN-MS-02131265	JAN-MS-02131266							
JA-00782	02/11/2005	Email from Gary J. Vorsanger to Donna Jordan	JAN-MS-02131380	JAN-MS-02131381							
JA-00783	No Date	Letter from Bob Rappaort, FDA/HHS to Janne Wissel.	JAN-MS-02133207	JAN-MS-02133207							
JA-00784	06/27/1905	Questions and Answers, Duragesic DDL: Package Insert Update.	JAN-MS-02134565	JAN-MS-02134566							
JA-00785	09/01/2005	Freyenhagen, Rainer et al, "Switching from Reservoir to Matrix Systems for the Transdermal Delivery of Fentanyl: A Prospective Mutlicenter Pilot Study in Outpatients with Chronic Pain," Journal of Pain and Symptom Management, Vol. 30, No.3, September 2005, pp. 289-297.	JAN-MS-02135033	JAN-MS-02135041							
JA-00786	05/31/2005	Prescription Drug Research Center: Duragesic Surveillance Program	JAN-MS-02136209	JAN-MS-02136226							
JA-00787	05/31/2005	Prescription Drug Research Center: Duragesic Surveillance Program	JAN-MS-02136227	JAN-MS-02136238							
JA-00788	03/04/2009	Email from Roxanne O. McGregor-Beck to Carole Carter-Cleaver et al.	JAN-MS-02202032	JAN-MS-02202033							
JA-00789	01/05/2012	Email from Gary Vorsanger to Myoung Kim	JAN-MS-02299539	JAN-MS-02299541							
JA-00790	05/09/2005	Janssen draft presentation: Risk Management Plan for Our Products	JAN-MS-02321524	JAN-MS-02321524							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-00791	06/15/2001	Janssen Report: Periodic Safety Update Report for Fentanyl Intravenous Solution and Transdermal Patches.	JAN-MS-02338206	JAN-MS-02338279							
JA-00792	04/23/2014	Janssen draft presentation: Pain Business Review	JAN-MS-02389698	JAN-MS-02389698							
JA-00793	05/25/2004	Presentation: Duragesic Grow and Defend Strategy, Market Research Summary, May 25, 2004.	JAN-MS-02391035	JAN-MS-02391101							
JA-00794	05/03/2005	Janssen report on label changes for Duragesic	JAN-MS-02392749	JAN-MS-02392814							
JA-00795	01/21/2004	Draft Janssen Presentation: Duragesic Business Update	JAN-MS-02396626	JAN-MS-02396705							
JA-00796	04/02/2004	Email from Elizabeth Turek to Ravi Desiraju	JAN-MS-02409987	JAN-MS-02409988							
JA-00797	No Date	Safety Review of TTS-Fentanyl in Opioid Naive Subjects	JAN-MS-02409989	JAN-MS-02410000							
JA-00798	01/05/2010	Email from Ravi Desiraju to Steven Silber	JAN-MS-02410536	JAN-MS-02410537							
JA-00799	07/31/2002	Change Document # (5715)-(063003) Amendment #9	JAN-MS-02461232	JAN-MS-02461234							
JA-00800	01/07/2003	Letter from Janne Wissel to FDA	JAN-MS-02477437	JAN-MS-02477437							
JA-00801	09/06/2004	Email from Juergen Haessler to David Upmalis	JAN-MS-02478753	JAN-MS-02478754							
JA-00802	10/02/2013	Email from Teodora Doherty to Teodora Doherty et al.	JAN-MS-02525303	JAN-MS-02525304							
JA-00803	07/03/1905	Nucynta ER NDA Approval Letter from Bob Rappaport, FDA to Kathleen Dusek	JAN-MS-02543460	JAN-MS-02543567							
JA-00804	08/25/2011	Janssen label for Nucynta ER	JAN-MS-02544901	JAN-MS-02544939							
JA-00805	09/09/2004	Email from Jeff Schein to James Burrus et al.	JAN-MS-02567590	JAN-MS-02567593							
JA-00806	01/17/2000	Email from Michelle Sheridan to Kent Bockes et al.	JAN-MS-02727829	JAN-MS-02727829							
JA-00807	No Date	Oxycontin Backgrounder Family Feud Questions	JAN-MS-02727830	JAN-MS-02727831							
JA-00808	01/21/1998	Janssen letter to sales team	JAN-MS-02728460	JAN-MS-02728461							
JA-00809	11/12/1999	Janssen letter to sales team	JAN-MS-02728546	JAN-MS-02728546							
JA-00810	09/06/2006	Janssen draft report on Duragesic	JAN-MS-02754767	JAN-MS-02754783							
JA-00811	12/01/2003	Janssen report on Duragesic	JAN-MS-02757583	JAN-MS-02757588							
JA-00812	08/01/2002	Janssen report on Duragesic	JAN-MS-02757589	JAN-MS-02757596							
JA-00813	06/01/2003	Presentation: Duragesic, Work, Uninterrupted.	JAN-MS-02757751	JAN-MS-02757760							
JA-00814	11/01/2001	Patient Booklet: Answers to Your Questions, Duragesic.	JAN-MS-02757826	JAN-MS-02757857							
JA-00815	03/01/2001	Janssen Presentationnn: Duragesic, Life Uninterrupted.	JAN-MS-02757939	JAN-MS-02757951							
JA-00816	05/05/2003	Email from Susan Merchant to Susan Merchant et al.	JAN-MS-02775248	JAN-MS-02775249							
JA-00817	05/15/2003	Duragesic Pediatric Labeling Alza/J&J PRD Counterproposal, May 15, 2003.	JAN-MS-02775250	JAN-MS-02775251							
JA-00818	04/02/2004	Email from Gary Vorsanger to Elizabeth Turek et al.	JAN-MS-02776297	JAN-MS-02776297							
JA-00819	07/01/2003	Draft letter from Sue Rinne to Bob Rappaport, FDA.	JAN-MS-02832530	JAN-MS-02832532							
JA-00820	10/22/2002	Email from Elizabeth Turek to Gary Vorsanger	JAN-MS-02855934	JAN-MS-02855936							
JA-00821	08/29/1989	Regulatory Agency Contact Report	JAN-MS-02908031	JAN-MS-02908032							
JA-00822	02/21/1990	FDA-DEA-NIDA Meeting Minutes	JAN-MS-02909945	JAN-MS-02909949							
JA-00823	07/02/1905	Training manual for Nucynta	JAN-OH-00075426	JAN-OH-00075432							
JA-00824	10/02/1993	Duragesic Annual Report	JAN-MS-03087739	JAN-MS-03087739							
JA-00825	05/26/1996	Duragesic Schedule for Stability Study	JAN-MS-03087746	JAN-MS-03087746							
JA-00826	06/23/1905	Duragesic Stability Study Schedule	JAN-MS-03087748	JAN-MS-03087748							
JA-00827	06/24/1905	Duragesic Stability Study Schedule	JAN-MS-03087753	JAN-MS-03087753							
JA-00828	11/01/2008	Highlights of and Full Prescribing Information, Tapendatol.	JAN-MS-03088032	JAN-MS-03088058							
JA-00829	11/09/2009	Letter from Bob Rappaport to Kathleen Dusek.	JAN-MS-03088059	JAN-MS-03088061							
JA-00830	07/11/2013	Letter from Bob Rappaport to Tania Hillmer.	JAN-MS-03088088	JAN-MS-03088092							
JA-00831	10/31/2013	Letter from Bob Rappaport to Tania Hillmer.	JAN-MS-03088121	JAN-MS-03088123							
JA-00832	10/15/2012	Letter from Sharon Hertz to Peggy Ferrone.	JAN-MS-03088183	JAN-MS-03088187							
JA-00833	07/03/1905	Highlights of Prescribing Information, Nucynta	JAN-MS-03088195	JAN-MS-03088233							
JA-00834	06/30/1905	Highlights of Prescribing Information, Nucynta	JAN-MS-03088286	JAN-MS-03088322							
JA-00835	11/01/2010	Letter from Sharon Hertz to Kathleen Dusek.	JAN-MS-03088539	JAN-MS-03088441							
JA-00836	08/25/2011	Center for Drug Evaluation and Research, Nucynta ER tablets	JAN-MS-03088737	JAN-MS-03088784							
JA-00837	11/20/2008	Center for Drug Evaluation and Research, Summary Basis for Regulatory Action, Tapentadol Tablet	JAN-MS-03089129	JAN-MS-03089142							
JA-00838	10/15/2012	Summary Review for Regulatory Action	JAN-MS-03089143	JAN-MS-030150							
JA-00839	11/17/2014	Letter from Sharon Hertz to Tania Hillmer.	JAN-MS-03089151	JAN-MS-03089153							
JA-00840	04/15/2009	Letter from Kathleen Dusek to Bob Rappaport, FDA.	JAN-MS-03089421	JAN-MS-03089421							
JA-00841	07/06/1905	Article: "What a Prescriber Should Know Before Writing the First Prescription"	JAN-MS-03090578	JAN-MS-03090583							
JA-00842	03/18/1998	Letter from Elizabeth Turek to Stephen Sherman, FDA.	JAN-MS-03090755	JAN-MS-03090851							
JA-00843	04/16/1998	Letter from FDA/.HHS to Elizabeth Turek.	JAN-MS-03090859	JAN-MS-03090861							
JA-00844	04/21/1998	Record of FDA Contact, April 21, 1998.	JAN-MS-03090863	JAN-MS-03090863							
JA-00845	01/30/2009	Letter from Harindra Abeyasinghe to Bob Rappaport	JAN-MS-04230555	JAN-MS-04230556							
JA-00849	08/01/2001	Fine, Perry, "Opioid Selection: Plaudits, Pitfalls, and Possibilities," The Journal of Pain, 2(4), pp. 195-196.	PPLPC020000014935	PPLPC020000014936							
JA-00850	05/23/2016	Abdel Shaheed, et al., Efficacy,Tolerability, and Dose-Dependent Effects of Opioid Analgesics for Low Back Pain A Systematic Review and Meta-analysis, JAMA Internal Medicine, 176(7)	JAN-TREX-00012924	JAN-TREX-00012936							
JA-00851	02/01/2004	Ackerman, SJ, et al., Risk of Constipation in Patients Prescribed Fentanyl Transdermal System or Oxycodone Hydrochloride Controlled-Release in a California Medicaid Population, The Consultant Pharmacist, 19(2)	JAN-TREX-00012937	JAN-TREX-00012945							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-00852	05/01/2006	Adams EH, et al., A Comparison of the Abuse Liability of Tramadol, NSAIDs, and Hydrocodone in Patients with Chronic Pain, Journal of Pain and Symptom Management, 31(5), pp. 465-476	JAN-TREX-00012946	JAN-TREX-00012952							
JA-00853	06/01/1905	Advances in Pain Research and Therapy (J. Bonica, ed. 1979)	JAN-TREX-00012953	JAN-TREX-00012966							
JA-00854	01/01/2013	Afilalo, M et al., Efficacy of Tapentadol ER for Managing Moderate to Severe Chronic Pain, Pain Physician Journal, Vol. 16	JAN-TREX-00012967	JAN-TREX-00012974							
JA-00855	07/02/1905	Al, F, et al., MR Imaging of Knee Osteoarthritis and Correlation of Findings with Reported Patient Pain, J Huazhong Univ Sci Technol [Med Sci] (2010) 30(2)	JAN-TREX-00012975	JAN-TREX-00012981							
JA-00856	05/01/2003	Alexander, J , Underuse of Analgesia in Very Young Pediatric Patients With Isolated Painful Injuries, Ann Emerg Med (2003) 41(5)	JAN-TREX-00012982	JAN-TREX-00012985							
JA-00857	05/12/2001	Allan, L, et al., Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain, BMJ, Vol.322	JAN-TREX-00012986	JAN-TREX-00012992							
JA-00858	06/27/1905	Allan L, et al., Transdermal Fentanyl Versus Sustained Release Oral Morphine in Strong-Opioid Naive Patients With Chronic Low Back Pain, SPINE (2005) 30(22)	JAN-TREX-00012993	JAN-TREX-00012998							
JA-00859	06/19/1905	The Use of Opioids for the Treatment of Chronic Pain: A Consensus Statement From the American Academy of Pain Medicine and the American Pain Society, The Chronicle Journal of Pain, 13(1)	JAN-TREX-00012999	JAN-TREX-00013002							
JA-00860	09/01/2000	American College of Rheumatology Subcommittee on Osteoarthritis Guidelines, Recommendations For the Medical Management of Osteoarthritis of the Hip and Knee, Arthritis and Rheumatism, 43(9)	JAN-TREX-00013003	JAN-TREX-00013008							
JA-00861	07/01/1905	American Pain Foundation, Pain Resource Guide: Getting the Help You Need (2009)	JAN-TREX-00013009	JAN-TREX-00013017							
JA-00862	06/23/1905	American Pain Society, Pain: Current Understanding of Assessment, Management, and Treatments (2001)	JAN-TREX-00013018	JAN-TREX-00013078							
JA-00863	06/26/1905	American Pain Foundation, Pain Notebook	JAN-TREX-00013079	JAN-TREX-00013080							
JA-00864	08/15/2011	American Society of Addiction Medicine (ASAM) Public Policy Statement: Definition of Addiction	JAN-TREX-00013081	JAN-TREX-00013083							
JA-00865	02/01/1999	Anderson VC, et al., A Prospective Study of Long-term Intrathecal Morphine in the Management of Chronic Nonmalignant Pain, Neurosurgery (1999) 44(2)	JAN-TREX-00013084	JAN-TREX-00013097							
JA-00866	01/14/1982	Angell, M., The Quality of Mercy, NJM (1982) 306(2)	JAN-TREX-00013098	JAN-TREX-00013099							
JA-00867	07/01/2009	Argoff C, et al., A Comparison of Long- and Short-Acting Opioids for the Treatment of Chronic Noncancer Pain: Tailoring Therapy to Meet Patient Needs, Mayo Clin Proc. (2009) 84(7)	JAN-TREX-00013100	JAN-TREX-00013109							
JA-00869	06/17/1905	Arkinstall W et al., Efficacy of controlled-release codeine in chronic non-malignant pain: a randomized, placebo-controlled clinical trial, Pain (1995) 62	JAN-TREX-00013120	JAN-TREX-00013127							
JA-00870	03/15/1989	Arkinstall W, et al., Control of severe pain with sustained-release morphine tablets v. oral morphine solution, CMAJ (1989), 140	JAN-TREX-00013128	JAN-TREX-00013133							
JA-00871	07/02/1905	Attal N, et al., EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision, European Journal of Neurology (2010), Vol. 17	JAN-TREX-00013134	JAN-TREX-00013158							
JA-00872	06/26/1905	Audette J, Principles and Practice of Pain Medicine, 2d edition. New York: McGraw-Hill, 2004	JAN-TREX-00013159	JAN-TREX-00013167							
JA-00873	07/08/1905	Badiola I, Can Chronic Pain Be Prevented?, Anesthesiology Clin (2016), 34	JAN-TREX-00013168	JAN-TREX-00013174							
JA-00874	11/13/2003	Ballantyne JC, et al., Opioid Therapy for Chronic Pain, New England Journal of Medicine, 349(20)	JAN-TREX-00013175	JAN-TREX-00013189							
JA-00875	07/04/1905	Bannwarth B, Will Abuse-Deterrent Formulations of Opioid Analgesics Be Successful in Achieving Their Purpose?, Drugs, 72 (13)	JAN-TREX-00013190	JAN-TREX-00013197							
JA-00876	07/01/1905	Banta-Green CJ, Opioid use behaviors, mental health and pain- Development of a typology of chronic pain patients, Drug and Alcohol Dependence (2009), Vol. 104	JAN-TREX-00013198	JAN-TREX-00013204							
JA-00877	07/09/1905	Baron R, et al., Tapentadol Prolonged Release for Chronic Pain: A Review of Clinical Trials and 5 Years of Routine Clinical Practice Data, Pain Practice (2017), 17(5)	JAN-TREX-00013205	JAN-TREX-00013220							
JA-00879	07/01/1905	Bell K, et al., Pain, physical dependence and pseudoaddiction: Redefining addiction for 'nice' people?, International Journal of Drug Policy (2009), Vol. 20	JAN-TREX-00013221	JAN-TREX-00013226							
JA-00882	06/20/1905	Bernabei R, et al., Management of Pain in Elderly Patients with Cancer, JAMA (1998), 279(23)	JAN-TREX-00013227	JAN-TREX-00013233							
JA-00883	07/09/1905	Berube, M, et al., Acute to chronic pain transition in extremity trauma: A narrative review for future preventive interventions (part 2), International Journal of Orthopaedic and Trauma Nursing (2017), Vol. 24	JAN-TREX-00013234	JAN-TREX-00013238							
JA-00884	01/01/2018	Bhatia A, et al., Radiofrequency procedures to relieve chronic hip pain: An Evidence-Based Narrative Review, Regional Anesthesia and Pain Medicine, 43(1)	JAN-TREX-00013239	JAN-TREX-00013250							
JA-00885	07/07/1905	Bicket M, et al., Epidural injections for spinal pain: systematic review and meta-analysis evaluating need for surgery in randomized controlled trials. The Spine Journal, Vol. 15	JAN-TREX-00013251	JAN-TREX-00013261							
JA-00886	07/07/1905	Bicket, MC, et al., Epidural steroid injections: an updated review on recent trends in safety and complications, Pain Management (2015), 5(2)	JAN-TREX-00013262	JAN-TREX-00013279							
JA-00887	07/02/1905	Binsfield H, et al., A Randomized Study to Demonstrate Noninferiority of Once-Daily OROS Hydromorphone with Twice-Daily Sustained-Release Oxycodone for Moderate to Severe Chronic Noncancer Pain, Pain Practice, Volume 10, Issue 5, (2010)	JAN-TREX-00013280	JAN-TREX-00013287							
JA-00888	No Date	Biondi D, et al., Abstract: A post hoc pooled data analysis to evaluate blood pressure (BP) and heart rate (HR) measurements in patients with a current or prior history of hypertension who received tapentadol ER, oxycodone CR, or placebo in chronic pain studies, Journal of Pain	JAN-TREX-00149920	JAN-TREX-00149920							
JA-00890	07/10/1905	Boland JW, et al., Influence of opioids on immune function in patients with cancer pain: from bench to bedside, British Journal of Pharmacology (2018), Vol.175	JAN-TREX-00013288	JAN-TREX-00013294							
JA-00891	07/02/1905	Boscarino JA, et al., Risk factors for drug dependence among out-patients on opioid therapy in a large US health-care system, Addiction, Vol. 105	JAN-TREX-00013295	JAN-TREX-00013302							
JA-00892	07/11/2011	Boscarino JA, et al., Prevalence of Prescription Opioid-Use Disorder Among Chronic Pain Patients: Comparison of the DSM-5 vs. DSM-4 Diagnostic Criteria, Journal of Addictive Diseases, Vol. 30	JAN-TREX-00013303	JAN-TREX-00013313							
JA-00893	06/29/1905	Brennan F, et al., Pain Management: A Fundamental Human Right, Pain Medicine (2007), 108(1)	JAN-TREX-00013314	JAN-TREX-00013324							
JA-00894	02/01/2013	Bruehl SA, et al., Personalized Medicine and Opioid Analgesic Prescribing for Chronic Pain: Opportunities and Challenges, The Journal of Pain, Vol 14, No 2 (Feb. 2013)	JAN-TREX-00013325	JAN-TREX-00013332							
JA-00896	07/05/1905	Brummett CB et al., Pathogenesis, diagnosis, and Treatment of Zygapophyseal (Facet) Joint Pain, Raj's Practical Management of Pain, 5th edition. London: Mosby Elsevier, 2013	JAN-TREX-00013333	JAN-TREX-00013363							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-00897	02/05/2019	Brutcher RE, et al., Compounded Topical Pain Creams to Treat Localized Chronic Pain: A Randomized Controlled Trial, Annals of Internal Medicine 2019; Feb 5 (e-pub ahead of print; with multiple news releases from Reuters, Medscape, Science Daily, NPR, etc).	JAN-TREX-00013364	JAN-TREX-00013373							
JA-00898	06/09/2018	Buchbinder R, et al., Low back pain: A call for action, Lancet (2018), Vol. 39	JAN-TREX-00013374	JAN-TREX-00013378							
JA-00899	07/09/1905	Bueno-Gomez N, Conceptualizing suffering and pain, Philosophy, Ethics, and Humanities in Medicine (2017), 12:7	JAN-TREX-00013379	JAN-TREX-00013385							
JA-00900	09/01/2016	Burgstaller JM, Is There an Association Between Pain and Magnetic Resonance Imaging Parameters in Patients With Lumbar Spinal Stenosis?, Spine (2016) 41(17)	JAN-TREX-00013386	JAN-TREX-00013395							
JA-00901	07/08/1905	Burgstaller JM, et al., The Impact of Obesity on the Outcome of Decompression Surgery in Degenerative Lumbar Spinal Canal Stenosis: Analysis of the Lumbar Spinal Outcome Study (LSOS): A Swiss Prospective, Multicenter Cohort Study, Spine, 41(1)	JAN-TREX-00013396	JAN-TREX-00013403							
JA-00902	12/18/2018	Busse JW, et al., Opioids for Chronic Noncancer Pain: A Systematic Review and Meta-analysis, JAMA (2018), 320(23)	JAN-TREX-00013404	JAN-TREX-00013415							
JA-00903	07/07/1905	Butler SF, et al., Tapentadol Abuse Potential: A Postmarketing Evaluation Using a Sample of Individuals Evaluated for Substance Abuse Treatment, Pain Medicine (2015) Vol. 16	JAN-TREX-00013416	JAN-TREX-00013423							
JA-00905	07/07/1905	Buynak R, et al., Long-term Safety and Efficacy of Tapentadol Extended Release Following up to 2 Years of Treatment in Patients With Moderate to Severe, Chronic Pain: Results of an Open-label Extension Trial, Clinical Therapeutics (2015), Volume 37, Number 11	JAN-TREX-00013424	JAN-TREX-00013433							
JA-00906	04/01/2002	Caldwell JR, et al., Efficacy and Safety of a Once-Daily Morphine Formulation in Chronic, Moderate-to-Severe Osteoarthritis Pain: Results from a Randomized, Placebo-Controlled, Double-Blind Trial and an Open-Label Extension Trial. Journal of Pain and Symptom Management (2002), Vol. 23, No. 4	JAN-TREX-00013434	JAN-TREX-00013442							
JA-00907	06/21/1905	Caldwell J, et al., Treatment of Osteoarthritis Pain with Controlled Release Oxycodone or Fixed Combination Oxycodone Plus Acetaminophen Added to Nonsteroidal Antiinflammatory Drugs: A Double Blind, Randomized, Multicenter, Placebo Controlled Trial, Journal of Rheumatology (1999), Vol. 26, No. 4	JAN-TREX-00013443	JAN-TREX-00013450							
JA-00908	07/07/1905	Campbell CM. Dynamic pain phenotypes are associated with spinal cord stimulation-induced reduction in pain: A repeated measures observational pilot study. Pain Med 2015; 16: 1349-60.	JAN-TREX-00013451	JAN-TREX-00013462							
JA-00909	02/01/2019	Caputi, F., et al., "Tapentadol: an analgesic that differs from classic opioids due to its noradrenergic mechanism of action," Edizioni Minerva Medica 2019; 110(1); 62-78	JAN-TREX-00013463	JAN-TREX-00013479							
JA-00910	07/07/1905	Chang D. Emerging targets in treating pain. Curr Opin Anaesthesiol 2015; 28: 379-97.	JAN-TREX-00013480	JAN-TREX-00013492							
JA-00911	07/09/1905	Chaparro, L. E., A. D. Furlan, A. Deshpande, A. Mailis-Gagnon, S. Atlas, and D. C. Turk. 2013. Opioids compared to placebo or other treatments for chronic low-back pain, Cochrane Database Syst Rev, 8: CD004959.	JAN-TREX-00013493	JAN-TREX-00013519							
JA-00912	04/01/1974	Charache S. The Treatment of Sickle Cell Anemia. Arch Intern Med. 1974;133(4):698-705.	JAN-TREX-00013520	JAN-TREX-00013527							
JA-00913	07/05/1905	Chen L. Opioids. In: Brummett CM, Cohen SP. Managing Pain. Oxford University Press, New York, 3-34.	JAN-TREX-00149921	JAN-TREX-00149921							
JA-00914	12/01/2014	Chen, L., et al., Clinical interpretation of opioid tolerance versus opioid-induced hyperalgesia, Journal of Opioid Management 10:6 (Nov./Dec. 2014) 383-93.	JAN-TREX-00013528	JAN-TREX-00013535							
JA-00915	06/29/1905	Chou, R., "Nonpharmacologic Therapies for Acute and Chronic Low Back Pain: A Review of the Evidence for an American Pain Society/American College of Physicians Clinical Practice Guideline," Ann Intern Med. 2007; 147:492-504	JAN-TREX-00013536	JAN-TREX-00013569							
JA-00916	02/01/2009	R. Chou, Opioid Treatment Guidelines, Clinical Guidelines for the Use of Chronic Opioid Therapy in Chronic Noncancer Pain, 10 Journal of Pain 113 (2009)	JAN-TREX-00013570	JAN-TREX-00013609							
JA-00917	07/10/1905	Christiansen S. Chronic Pain: Pathophysiology and Mechanisms. In: Manchikanti L, Kaye AD, Falco FJ, Hirsch JA. Essentials of Interventional Techniques in Managing Chronic Pain. ASIPP Publishing, Paducah, KY, 2018, 15-25.	JAN-TREX-00013610	JAN-TREX-00013615							
JA-00918	07/07/1905	Clauw, D. J. 2015. Diagnosing and treating chronic musculoskeletal pain based on the underlying mechanism(s), Best Practice & rResearch Clinical Rheumatology, 29: 6-19.	JAN-TREX-00013616	JAN-TREX-00013621							
JA-00919	02/11/2019	Clauw, D., "Reframing chronic pain as a disease, not a symptom: rationale and implications for pain management," Postgraduate Medicine (2019)	JAN-TREX-00013622	JAN-TREX-00013632							
JA-00920	07/09/1905	Cochrane Library, Paracetamol for low back pain (Review), Cochrane Database of Systematic Reviews 2016, Issue 6. Art. No.: CD012230.	JAN-TREX-00013633	JAN-TREX-00013683							
JA-00921	06/24/1905	Cohen S. Central pain. Curr Opin Anaesthesiol 2002; 15: 575-81.	JAN-TREX-00013684	JAN-TREX-00013690							
JA-00922	06/30/1905	Cohen SP. Management of low back pain. BMJ 2008; 337: a2718.	JAN-TREX-00013691	JAN-TREX-00013697							
JA-00923	06/30/1905	Cohen SP. Randomized, placebo-controlled study evaluating lateral branch radiofrequency denervation for sacroiliac joint pain. Anesthesiology 2008; 109: 279-88 (with editorial).	JAN-TREX-00013698	JAN-TREX-00013707							
JA-00924	07/05/1905	Cohen SP. A call to arms: The credibility gap in interventional pain medicine and recommendations for future research. Pain Med 2013; 14: 1280-3.	JAN-TREX-00013708	JAN-TREX-00013711							
JA-00925	06/29/1905	Cohen SP. A double-blind, placebo-controlled, dose-response pilot study evaluating intradiscal etanercept in patients with chronic discogenic low back pain or lumbosacral radiculopathy. Anesthesiology 2007; 107: 99-105.	JAN-TREX-00013712	JAN-TREX-00013718							
JA-00926	04/01/2009	Cohen SP. An intravenous ketamine test as a predictive response tool in opioid-exposed patients with persistent pain. J Pain Symptom Manage 2009; 37: 698-708.	JAN-TREX-00013719	JAN-TREX-00013729							
JA-00927	07/02/1905	Cohen SP. Benzodiazepines for back pain: When the cure is worse than the disease. Pain 2010; 149: 424-5.	JAN-TREX-00013730	JAN-TREX-00013731							
JA-00928	07/01/2015	Cohen SP. Botulinum toxin type B for chronic pain: Panacea or snake oil? The need for more and better preclinical studies. Anesth Analg 2015; 121: 20-21.	JAN-TREX-00013732	JAN-TREX-00013733							
JA-00929	01/27/2008	Cohen SP. Cannabinoids for chronic pain. BMJ 2008; 336: 167-8.	JAN-TREX-00013734	JAN-TREX-00013740							
JA-00930	07/05/2018	Cohen SP. Consensus guidelines on the use of intravenous ketamine infusions for chronic pain from the American Society of Regional Anesthesia and Pain Medicine (ASRA), American Academy of Pain Medicine (AAPM) and the American Society of Anesthesiologists (ASA). Reg Anesth Pain Med 2018; 43: 521-46.	JAN-TREX-00013741	JAN-TREX-00013766							
JA-00931	06/28/1905	Cohen SP. Drug delivery methods. In: Mao J, ed. Translational Pain Research. Current Status and Trends. Volume I. New York: Nova Publishers, 2006: 415-52.	JAN-TREX-00013767	JAN-TREX-00013805							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-00932	02/01/2007	Cohen SP. Epidemics, evolution and sacroiliac joint pain. Reg Anesth Pain Med 2007; 32: 3-6.	JAN-TREX-00013806	JAN-TREX-00013809							
JA-00933	07/07/1905	Cohen SP. Epidemiology, diagnosis and treatment of neck Pain. Mayo Clin Proc 2015; 90: 284-99.	JAN-TREX-00013810	JAN-TREX-00013825							
JA-00934	07/03/1905	Cohen SP. Epidural steroid injections for low back pain: The evidence is weak, but may benefit some. BMJ 2011; 343:d5310.	JAN-TREX-00013826	JAN-TREX-00013827							
JA-00935	06/29/1905	Cohen SP. Intrathecal Analgesia. Anesthesiol Clin 2007; 25: 863-82.	JAN-TREX-00013828	JAN-TREX-00013847							
JA-00936	06/29/1905	Cohen SP. Intrathecal Analgesia. Med Clin North Am 2007; 91: 251-70.	JAN-TREX-00013848	JAN-TREX-00013867							
JA-00937	07/01/1905	Cohen SP. Intravenous Infusions tests have limited utility for selecting long-term drug therapy in patients with chronic pain: A systematic review. Anesthesiology 2009; 111: 416-31.	JAN-TREX-00013868	JAN-TREX-00013883							
JA-00939	07/03/1905	Cohen SP. Ketamine in pain management. Adv Psychosom Med 2011; 30: 139-61.	JAN-TREX-00013898	JAN-TREX-00013920							
JA-00940	07/05/1905	Cohen SP. Low back pain. In: Brummett CM, Cohen SP. Managing Pain. Oxford University Press: New York, 2013, 183-211.	JAN-TREX-00013921	JAN-TREX-00013952							
JA-00941	06/26/1905	Cohen SP. Low Back Pain. In: Warfield C, Bajwa Z, eds. Principles and Practice of Pain Medicine, 2nd edition. New York: McGraw-Hill, 2004: 273-284.	JAN-TREX-00013953	JAN-TREX-00013966							
JA-00942	06/30/1905	Cohen SP. Lumbar zygapophysial (facet) joint radiofrequency denervation success as a function of pain relief during diagnostic medial branch blocks: a multi-center analysis. The Spine Journal, 2008; 8: 498-504 (with editorial).	JAN-TREX-00013967	JAN-TREX-00013973							
JA-00943	07/06/1905	Cohen SP. Mechanisms of neuropathic pain and their clinical implications. BMJ 2014; 348:f7656	JAN-TREX-00013974	JAN-TREX-00013985							
JA-00944	No date	Cohen SP. Neck pain: Advances in the diagnosis and management of neck pain. BMJ 2017; 358: j3221.	JAN-TREX-00013986	JAN-TREX-00014004							
JA-00945	06/23/1905	Cohen SP. New developments in the use of tricyclic antidepressants for the management of pain. Current Opinion in Anesthesiology, 2001; 14: 505-11.	JAN-TREX-00014005	JAN-TREX-00014011							
JA-00946	02/01/2004	Cohen SP. Pain management in trauma patients. Am J Phys Med Rehabil 2004; 83: 142-61.	JAN-TREX-00014012	JAN-TREX-00014031							
JA-00947	07/03/1905	Cohen SP. Pain. In: Goldman L, Schafer A, Golfmen-Cecil Textbook of Medicine, 24th edition. Philadelphia: Saunders, 2011, 133-9.	JAN-TREX-00014032	JAN-TREX-00014044							
JA-00948	12/01/2014	Cohen SP. Precision targeting for neuroablative therapy: The future of interventional pain medicine. Reg Anesth Pain Med 2014; 39: 447-9.	JAN-TREX-00014045	JAN-TREX-00014047							
JA-00949	08/01/2007	Cohen SP. The efficacy of repeat intradiscal electrothermal therapy (IDET) for discogenic low back pain Anesth Analg 2007; 495-8.	JAN-TREX-00014048	JAN-TREX-00014051							
JA-00950	06/01/2006	Cohen SP. The IV ketamine test predicts subsequent response to an oral dextromethorphan treatment regimen in fibromyalgia patients. J Pain 2006; 7: 391-8.	JAN-TREX-00014052	JAN-TREX-00014059							
JA-00951	06/26/1905	Cohen SP. The IV ketamine test: a predictive response tool for an oral dextromethorphan treatment regimen in neuropathic pain. Anesth Analg 2004; 99: 1753-9.	JAN-TREX-00014060	JAN-TREX-00014066							
JA-00952	11/01/2006	Cohen SP. The middle way: a practical approach to prescribing opioids. Nature Clinical Practice Neurology 2006; 2: 580-1.	JAN-TREX-00014067	JAN-TREX-00014068							
JA-00953	08/14/2003	Cohen SP. The pharmacological treatment of complex regional pain syndromes. Curr Rev Clin Anesth 2003; 24: 35-41.	JAN-TREX-00014069	JAN-TREX-00014077							
JA-00954	06/26/1905	Cohen SP. The pharmacological treatment of muscle pain. Anesthesiology 2004; 101: 495-526.	JAN-TREX-00014078	JAN-TREX-00014109							
JA-00955	02/12/2013	Cohen, M., "Issues in implementing a treat-to-target approach in RA," Nat. Rev. Rheumatol. (2013) 9:137–138	JAN-TREX-00014110	JAN-TREX-00014111							
JA-00956	02/01/2013	Cohen, S., "Facet joint pain—advances in patient selection and treatment," Rheumatology (2013) 9:101	JAN-TREX-00014112	JAN-TREX-00014127							
JA-00957	07/06/1905	Cohen, S., "Neuropathic pain: mechanisms and their clinical implications," BMJ (2014) 348:f7656	JAN-TREX-00014128	JAN-TREX-00014139							
JA-00958	07/04/1905	Cohen, S., "Spine-area pain in military personnel: a review of epidemiology, etiology, diagnosis, and treatment," The Spine Journal (2012) 12:833-842	JAN-TREX-00014140	JAN-TREX-00014149							
JA-00959	07/09/1905	Coluzzi, F., et al "From acute to chronic pain: tapentadol in the progressive stages of this disease entity," European Review for Medical and Pharmacological Sciences 21:1672-1683 (2017)	JAN-TREX-00014150	JAN-TREX-00014161							
JA-00960	07/07/1905	Coluzzi, F., et al "Tapentadol prolonged release for patients with multiple myeloma suffering from moderate-to-severe cancer pain due to bone disease," Journal of Pain Research (2015) 8:229-238	JAN-TREX-00014162	JAN-TREX-00014171							
JA-00961	07/03/1905	Committee on Advancing Pain Research, Care, and Education; Board on Health Sciences Policy; Institute of Medicine, Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research (2011)	JAN-TREX-00014172	JAN-TREX-00014553							
JA-00962	07/09/1905	Cooper, T., et al "Morphine for chronic neuropathic pain in adults (Review)" Cochrane Library: Cochrane Database of Systematic Reviews (2017)	JAN-TREX-00014554	JAN-TREX-00014607							
JA-00963	06/27/1905	Cowan DT, et al "A randomized, double-blind, placebo-controlled, cross-over pilot study to assess the effects of long-term opioid drug consumption and subsequent abstinence in chronic noncancer pain patients receiving controlled-release morphine." Pain Med. (2005).	JAN-TREX-00014608	JAN-TREX-00014616							
JA-00964	08/01/2014	Dart, R., "Nonmedical Use of Tapentadol Immediate Release by College Students," Clin J Pain (2014)	JAN-TREX-00014617	JAN-TREX-00014624							
JA-00965	07/06/1905	da Costa BR, Nuesch E, Kasteler R, et al. Oral or transdermal opioids for osteoarthritis of the knee or hip (Cochrane Review). 2014	JAN-TREX-00149922	JAN-TREX-00149922							
JA-00966	09/14/2018	Dahlhamer, J., et al "Prevalence of Chronic Pain and High-Impact Chronic Pain Among Adults — United States, 2016," MMWR (Sept. 14, 2018)	JAN-TREX-00014625	JAN-TREX-00014630							
JA-00967	08/01/2011	Dalacorte, R., et al "Pain management in the elderly at the end of life," N Am J Med Sci. 2011 Aug; 3(8): 348–354	JAN-TREX-00014631	JAN-TREX-00014645							
JA-00968	07/01/1905	Daniels, S., et al "A randomized, double-blind, phase III study comparing multiple doses of tapentadol IR, oxycodone IR, and placebo for postoperative (bunionectomy) pain," CMRO 2009; 25(3); 765-776	JAN-TREX-00014646	JAN-TREX-00014657							
JA-00969	07/01/1905	Daniels, S., et al "A randomized, double-blind, placebo-controlled phase 3 study of the relative efficacy and tolerability of tapentadol IR and oxycodone IR for acute pain," CMRO 2009; 25(6); 1551-1561	JAN-TREX-00014658	JAN-TREX-00014668							
JA-00970	07/08/1905	Dart., R., et al "Diversion and Illicit Sale of Extended Release Tapentadol in the United States," Pain Medicine 2016; 17: 1490–1496	JAN-TREX-00014669	JAN-TREX-00014675							
JA-00971	07/10/1905	David, M., "Cancer-Related Neuropathic Pain: Review and Selective Topics," Hematol Oncol Clin N Am 2018; 32: 417-431	JAN-TREX-00014676	JAN-TREX-00014690							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-00972	10/01/1998	Dellemijn, P., et al "Prolonged Treatment with Transdermal Fentanyl in Neuropathic Pain," Journal of Pain and Symptom Management 16:220 (1998)	JAN-TREX-00014691	JAN-TREX-00014700							
JA-00973	07/10/1905	Deer, T., et al "Success Using Neuromodulation With BURST (SUNBURST) Study: Results From a Prospective, Randomized Controlled Trial Using a Novel Burst Waveform," Neuromodulation 2018; 21: 56-66	JAN-TREX-00014701	JAN-TREX-00014711							
JA-00974	06/28/1905	Deyo, R., et al "Trends and Variations in the Use of Spine Surgery," CLINICAL ORTHOPAEDICS AND RELATED RESEARCH (2006) 443:139-146	JAN-TREX-00014712	JAN-TREX-00014719							
JA-00976	12/01/2016	DiJulio, B., et al Henry J. Kaiser Family Foundation, "The Washington Post/Kaiser Family Foundation Survey of Long-Term Prescription Painkiller Users and Their Household Members," (Dec. 2016)	JAN-TREX-00014720	JAN-TREX-00014737							
JA-00977	06/18/1905	Donner, B., et al, "Direct conversion from oral morphine to transdermal fentanyl: a multicenter study in patients with cancer pain," Pain, 64 (1996) 527-534	JAN-TREX-00014738	JAN-TREX-00014745							
JA-00978	06/09/1905	Donovan, M., "Incidence and characteristics of pain in a sample of medical-surgical inpatients." Pain. 30 (1987): 69-78.	JAN-TREX-00014746	JAN-TREX-00014755							
JA-00979	07/11/1905	Dowell, D., et al "No Shortcuts to Safer Opioid Prescribing," NEJM (2019)	JAN-TREX-00014756	JAN-TREX-00014758							
JA-00980	06/05/2013	Dowell, D., et al "Opioid Analgesics--Risky Drugs, Not Risky Patients," JAMA (June 5, 2013)	JAN-TREX-00014759	JAN-TREX-00014760							
JA-00981	07/02/1905	Stannard C, et al, eds. "Treatment modalities: the evidence; In Evidence-based Chronic Pain Management. Wiley-Blackwell, BMJ Books, Oxford, UK, 2010, 369-99	JAN-TREX-00014761	JAN-TREX-00014792							
JA-00982	07/04/1905	Dragovich A., et al "Pain in the battlefield injured." In: Moore RJ, ed. Handbook of Pain & Palliative Care: Biobehavioral Approaches for the Life Course. New York: Springer, 195-212. (2012)	JAN-TREX-00014793	JAN-TREX-00014810							
JA-00983	07/01/1905	Dragovich A., et al "Spinal analgesia." In: Smith HS, editor. Current Therapy in Pain, 2nd edition. Saunders Elsevier, Philadelphia, 2009, 640-51	JAN-TREX-00014811	JAN-TREX-00014822							
JA-00984	07/01/1905	Dreyfuss P., "Is immediate pain relief after a spinal injection procedure enhanced by intravenous sedation?" Phys Med Rehabil. 1: 60-3, (January 2009)	JAN-TREX-00014823	JAN-TREX-00014826							
JA-00985	06/29/1905	Dworkin, R. "Pharmacologic management of neuropathic pain: Evidence-based recommendations," Pain 132 (2007) 237-251	JAN-TREX-00014827	JAN-TREX-00014835							
JA-00986	06/30/1905	Dworkin, R., "Interpreting the Clinical Importance of Treatment Outcomes in Chronic Pain Clinical Trials: IMMPACT Recommendations," Journal of Pain (2008) 9(2):105-121	JAN-TREX-00014836	JAN-TREX-00014848							
JA-00987	07/06/1905	Edlund MJ, Martin BC, Russo JE, Devries A, Braden JB, Sullivan MD. The Role of Opioid Prescription in Incident Opioid Abuse and Dependence Among Individuals With Chronic Noncancer Pain. Clin J Pain. 2014;30(7):557-564	JAN-TREX-00014849	JAN-TREX-00014855							
JA-00988	06/28/1905	Edlund MJ, Sullivan M, Steffick D, Harris KM, Wells KB. Do users of regularly prescribed opioids have higher rates of substance use problems than nonusers? Pain Med. 2007. doi:10.1111/j.1526-4637.2006.00200.x	JAN-TREX-00014856	JAN-TREX-00014862							
JA-00989	06/27/1905	Eichenbaum, G., "Does tapentadol affect sex hormone concentrations differently from morphine and oxycodone? An initial assessment and possible implications for opioid-induced androgen deficiency," Journal of Opioid Management (2005) 11:3	JAN-TREX-00014863	JAN-TREX-00014873							
JA-00990	07/07/1905	Eisenach, J. C., C. Tong, and R. S. Curry. 2015. Failure of intrathecal ketorolac to reduce remifentanyl-induced postinfusion hyperalgesia in humans, Pain, 156: 81-7	JAN-TREX-00014874	JAN-TREX-00014879							
JA-00991	06/28/1905	Elander, J., Factors Affecting Hospital Staff Judgments About Sickle Cell Disease Pain, Journal of Beahioral Medicine (2006) 29(2):203-214	JAN-TREX-00014880	JAN-TREX-00014885							
JA-00992	06/28/1905	Elander, J., "Pain management and symptoms of substance dependence among patients with sickle cell disease," Social Science & Medicine 57:1683 (2006)	JAN-TREX-00149923	JAN-TREX-00149923							
JA-00993	06/26/1905	Elander, J., "Understanding the Causes of Problematic Pain Management in Sickle Cell Disease: Evidence That Pseudoaddiction Plays a More Important Role Than Genuine Analgesic Dependence," Journal of Pain & Symptom Management (2004)	JAN-TREX-00014886	JAN-TREX-00014894							
JA-00994	07/06/1905	Etropolski, M. "Safety and Tolerability of Tapentadol Extended Release in Moderate to Severe Chronic Osteoarthritis or Low Back Pain Management: Pooled Analysis of Randomized Controlled Trials," Adv Ther 31:604 (2014)	JAN-TREX-00014895	JAN-TREX-00014904							
JA-00995	07/01/1905	Etropolski, M., "Efficacy and Safety of Tapentadol Extended Release Versus Oxycodone Controlled Release in Opioid-Naïve and Opioid-Experienced Patients with Chronic Pain Associated with Osteoarthritis of the Knee," Osteoarthritis and Cartilage 17:S175 (2009)	JAN-TREX-00149924	JAN-TREX-00149924							
JA-00996	08/29/2012	FDA Approves Nucynta for Pain Associated with Diabetic Peripheral Neuropathy, Physician's Weekly (8/29/2012)	JAN-TREX-00149925	JAN-TREX-00149925							
JA-00997	04/01/2017	Federation of State Medical Boards, Guidelines for the Chronic Use of Opioid Analgesics (Apr. 2017)	JAN-TREX-00014905	JAN-TREX-00014912							
JA-00998	05/01/2004	Federation of State Medical Boards of the United States, Inc., Model Guidelines for the Use of Controlled Substances for the Treatment of Pain (May 2004)	JAN-TREX-00014913	JAN-TREX-00014917							
JA-00999	06/28/1905	Fejer, R., "The prevalence of neck pain in the world population: a systematic critical review of the literature," Eur Spine J (2006) 15:834-848	JAN-TREX-00014918	JAN-TREX-00014929							
JA-01000	06/11/1905	Ferrell, B., "Effects of Controlled-Release Morphine on Quality of Life for Cancer Pain," Oncology Nursing Forum (1989) 16(4):521-526	JAN-TREX-00014930	JAN-TREX-00014936							
JA-01001	06/17/1905	Ferrell, B., "Pain in Cognitively Impaired Nursing Home Patients" J Pain Symptom Manage (1995)10:591-598.	JAN-TREX-00014937	JAN-TREX-00014945							
JA-01002	06/10/1905	Fields, H. "Letter to the Editor: Can Opiates Relieve Neuropathic Pain?"Pain (1988) 35:365	JAN-TREX-00149926	JAN-TREX-00149926							
JA-01003	07/09/1905	Fillingim, R., "Individual differences in pain: understanding the mosaic that makes pain personal," Pain (2017) 158(4):S11-S18	JAN-TREX-00014946	JAN-TREX-00014953							
JA-01004	No date	Fillingim, R., "Sex, Gender, and Pain: A Review of Recent Clinical and Experimental Findings," Journal of Pain 10(5):447-485	JAN-TREX-00014954	JAN-TREX-00014985							
JA-01005	06/29/1905	Finnerup, N.B., et al., An Evidence-Based Algorithm for the Treatment of Neuropathic Pain, MedGenMed. 2007; 9(2): 36, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1994866/?report=printable .	PMC1994866	PMC1994866							
JA-01006	02/01/2015	Finnerup, N.B., et al., Pharmacotherapy for neuropathic pain in adults: systematic review, meta-analysis and updated NeuPSIG recommendations, Lancet Neurol. 2015 February; 14(2): 162-173	JAN-TREX-00014986	JAN-TREX-00014993							
JA-01007	06/24/1905	Fishbain, D., "Medico-legal Rounds: Medico-legal Issues and Breaches of Standards of Medical Care in Opioid Tapering for Alleged Opioid Addiction," Pain Medicine (2002)	JAN-TREX-00014994	JAN-TREX-00015001							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-01008	06/30/1905	Fishbain, D., "What Percentage of Chronic Nonmalignant Pain Patients Exposed to Chronic Opioid Analgesic Therapy Develop Abuse/Addiction and/or Aberrant Drug-Related Behaviors? A Structured Evidence-Based Review," Pain Medicine (2008)	JAN-TREX-00015002	JAN-TREX-00015012							
JA-01009	06/14/1905	Fishbain DA, Rosomoff HL, Rosomoff RS. Drug abuse, dependence, and addiction in chronic pain patients. Clin J Pain. 1992. doi:10.1097/00002508-199206000-00003	JAN-TREX-00015013	JAN-TREX-00015019							
JA-01010	07/01/1905	Fishbain, D., et al., "Alleged Breaches of 'Standards of Medical Care' in a Patient Overdose Death Possibly Related to Chronic Opioid Analgesic Therapy, Application of the Controlled Substances Model Guidelines: Case Report," Pain Medicine 2009; 10(3)	JAN-TREX-00015020	JAN-TREX-00015028							
JA-01011	07/01/1905	Fishbain, D., et al., "Alleged Medical Abandonment in Chronic Opioid Analgesic Therapy: Case Report," Pain Medicine 2009; 10(4)	JAN-TREX-00015029	JAN-TREX-00015032							
JA-01012	07/01/1905	Fishbain, D., et al., "Are Chronic Low Back Pain Patients Who Smoke at Greater Risk for Suicide Ideation?" Pain Medicine 2009; 10(2)	JAN-TREX-00015033	JAN-TREX-00015036							
JA-01013	06/19/1905	Fishbain, D., et al., "Chronic Pain-Associated Depression: Antecedent or Consequence of Chronic Pain? A Review," The Clinical Journal of Pain (1997) 13:116-137	JAN-TREX-00015037	JAN-TREX-00015059							
JA-01014	07/01/1905	Fishbain, D., et al., "Correlates of Self-Reported Violent Ideation Against Physicians in Acute- and Chronic-Pain Patients," Pain Medicine 2009; 10(3)	JAN-TREX-00015060	JAN-TREX-00015067							
JA-01015	07/01/1905	Fishbain, D., et al., "Do Opioids Induce Hyperalgesia in Humans? An Evidence-Based Structured Review," Pain Medicine 2009; 10(5)	JAN-TREX-00015068	JAN-TREX-00015073							
JA-01016	07/01/1905	Fishbain, D., et al., "Risk for Five Forms of Suicidality in Acute Pain Patients and Chronic Pain Patients vs Pain-Free Community Controls," Pain Medicine 2009; 10(6)	JAN-TREX-00015074	JAN-TREX-00015079							
JA-01017	07/02/1905	Furlan, A., "Opioids for chronic noncancer pain: a new Canadian practice guideline," CMAJ 2010; 182(9):923-930	JAN-TREX-00015080	JAN-TREX-00015085							
JA-01018	03/01/1998	Gajraj, N., Letter to the Editor: Opiate Abuse or Undertreatment, The Clinical Journal of Pain (Mar. 1998)	JAN-TREX-00015086	JAN-TREX-00015089							
JA-01019	07/06/1905	Galia, E., "Evaluation of the tamper-resistant properties of tapentadol extended-release tablets: Results of in vitro laboratory analyses," Journal of Opioid Management (2014) 10(3):149	JAN-TREX-00015090	JAN-TREX-00015096							
JA-01020	07/05/1905	Galvez, R., "Tapentadol Prolonged Release Versus Strong Opioids for Severe, Chronic Low Back Pain: Results of an Open-Label, Phase 3b Study," Adv Ther 30:229 (2013)	JAN-TREX-00015097	JAN-TREX-00015114							
JA-01021	08/01/2012	Gaskin, The Journal of Pain, Vol 13, No 8 (August), 2012: 715-724	JAN-TREX-00015115	JAN-TREX-00015122							
JA-01022	07/08/1905	GBD 2015, "Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015," Lancet (2016) 388:1545–602	JAN-TREX-00015123	JAN-TREX-00015261							
JA-01023	07/10/1905	GBD 2017, "Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017," Lancet (2018) 392:1789-858	JAN-TREX-00015262	JAN-TREX-00015331							
JA-01024	07/01/1905	Gibbs, M., The role of transdermal fentanyl patches in the effective management of cancer pain, International Journal of Palliative Nursing (2009) 15(7):354-59	JAN-TREX-00015332	JAN-TREX-00015335							
JA-01025	06/28/1905	Gottschalk A. Preventing and treating pain after thoracic surgery. Anesthesiology 2006; 104: 594-600	JAN-TREX-00015336	JAN-TREX-00015341							
JA-01026	07/01/1997	Graziotti, P. and Goucke, C Roger, "The use of oral opioids in patients with chronic non-cancer pain." Clinical Practice 1997 July; 167	JAN-TREX-00015342	JAN-TREX-00015345							
JA-01027	07/04/1905	Greenberg, E., The Consequences of Chronic Pain, Journal of Pain & Palliative Care Pharmacotherapy, (2012) 26:64-67	JAN-TREX-00015346	JAN-TREX-00015347							
JA-01028	06/23/1905	Haentzchel, H., "Fentanyl-TTS (Durogesic) reduces pain and improves day-time activity and night-time sleep quality in patients with pain associated with rheumatoid arthritis," 60 Z. Rheumatol. (Suppl. 1) 81 (2001)	JAN-TREX-00149927	JAN-TREX-00149927							
JA-01029	07/01/1905	Hale, M., "Tolerability of tapentadol immediate release in patients with lower back pain or osteoarthritis of the hip or knee over 90 days: a randomized, double-blind study," CURRENT MEDICAL RESEARCH AND OPINION (2009) 25(5):1095-1104	JAN-TREX-00015348	JAN-TREX-00015355							
JA-01030	07/09/1905	Han B, Compton WM, Blanco C, Crane E, Lee J, Jones CM. Prescription Opioid Use, Misuse, and Use Disorders in U.S. Adults: 2015 National Survey on Drug Use and Health. Annals of internal medicine. 2017;167(5):293-301. Epub 2017/08/02. doi: 10.7326/m17-0865. PubMed PMID: 28761945	JAN-TREX-00015356	JAN-TREX-00015363							
JA-01031	No date	Harper, D., "Misuse of 'Hyperalgesia' to Limit Care," Practical Pain Management; 10(8)	JAN-TREX-00015364	JAN-TREX-00015368							
JA-01032	07/01/1905	Hartrick, C., "Efficacy and Tolerability of Tapentadol Immediate Release and Oxycodone HCl Immediate Release in Patients Awaiting Primary Joint Replacement Surgery for End-Stage Joint Disease: A to-Day, Phase III, Randomized, Double-Blind, Active- and Placebo-Controlled Study," Clinical Therapeutics (2009) 31:260	JAN-TREX-00015369	JAN-TREX-00015375							
JA-01033	07/03/1905	Hartrick, C., CNS Drugs 2011; 25 (5): 359-370	JAN-TREX-00015376	JAN-TREX-00015387							
JA-01034	07/10/1905	Hartvigsen J. What low back pain is and why we need to pay attention. Lancet 2018; 391: 2356-67.	JAN-TREX-00015388	JAN-TREX-00015400							
JA-01035	07/07/1905	Häuser W, Bernardy K, Maier C. Long-term opioid therapy in chronic noncancer pain: A systematic review and meta-analysis of efficacy, tolerability and safety in open-label extension trials with study duration of at least 26 weeks. Schmerz. 2015. doi:10.1007/s00482-014-1452-0	JAN-TREX-00015401	JAN-TREX-00015410							
JA-01036	06/25/1905	Heit, H., "Addiction, Physical Dependence, and Tolerance: Precise Definitions to Help Clinicians Evaluate and Treat Chronic Pain Patients,"17 Journal of Pain & Palliative Care Pharmacotherapy 15 (2003)	JAN-TREX-00015411	JAN-TREX-00015425							
JA-01037	06/23/1905	Heit, H., European Journal of Pain (2001) 5 (Suppl. A): 27-29	JAN-TREX-00015426	JAN-TREX-00015427							
JA-01038	07/10/1905	Higgins C, Smith BH, Matthews K. Incidence of iatrogenic opioid dependence or abuse in patients with pain who were exposed to opioid analgesic therapy: a systematic review and meta-analysis. Br J Anaesth. 2018;120(6):1335-1344. doi:10.1016/j.bja.2018.03.009	JAN-TREX-00015428	JAN-TREX-00015434							
JA-01039	07/10/1905	Higgins C., Smith B.H., and Matthews, K., "Evidence of opioid-induced hyperalgesia in clinical populations after chronic opioid exposure: a systematic review and meta-analysis," BJA 2018; 1-13	JAN-TREX-00015435	JAN-TREX-00015443							
JA-01040	07/02/1905	Højsted J, Nielsen PR, Guldstrand SK, Frich L, Sjøgren P. Classification and identification of opioid addiction in chronic pain patients. Eur J Pain. 2010;14(10):1014-1020	JAN-TREX-00015444	JAN-TREX-00015449							
JA-01041	07/02/1905	Hoy, D., "Measuring the global burden of low back pain," Best Practice & Research Clinical Rheumatology (2010) 24:155–165	JAN-TREX-00015450	JAN-TREX-00015455							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-01042	07/02/1905	Hoy, D., "The Epidemiology of low back pain," Best Practice & Research Clinical Rheumatology (2010) 24:769–781	JAN-TREX-00015456	JAN-TREX-00015463							
JA-01043	04/01/2012	Ikeda, M., et al., "A Pilot Study of the Reduced Effects of Adverse Events Caused by Oral Morphine and Oxycodone After Rotating to Fentanyl Patch in Patients with Metastatic Breast Cancer," Japanese Journal of Cancer and Chemotherapy 2012 April; 39(4); 599-603	JAN-TREX-00015464	JAN-TREX-00015470							
JA-01044	07/10/1905	Illgen, M., "Pain, Opioids, and Suicide Mortality in the United States," Annals of Internal Medicine 2018; 169(7): 498-499	JAN-TREX-00015471	JAN-TREX-00015472							
JA-01045	07/10/1905	Jamison DE. Intrathecal therapy for chronic pain. In: Benzon H, Raja SN, Fishman SM, Liu SS, Cohen SP, eds. Essentials of Pain Medicine & Regional Anesthesia,4th edition. Philadelphia: Elsevier Churchill Livingstone, 2018, 693-702	JAN-TREX-00015473	JAN-TREX-00015481							
JA-01046	07/16/2009	Jamison RN, Butler SF, Budman SH, Edwards RR, Wasan AD. Gender Differences in Risk Factors for Aberrant Prescription Opioid Use. J Pain. 2010. doi:10.1016/j.jpain.2009.07.016	JAN-TREX-00015482	JAN-TREX-00015488							
JA-01047	06/25/1905	Jovey, R., et al., "Use of opioid analgesics for the treatment of chronic noncancer pain-A consensus statement and guidelines from the Canadian Pain Society," Pain Res Manage 2003; 8; 3A-14A	JAN-TREX-00015489	JAN-TREX-00015497							
JA-01048	06/30/1905	Katz W, Opioids for Nonmalignant Pain. Rheum Dis Clin N Am (2008) 34:387-413	JAN-TREX-00015498	JAN-TREX-00015506							
JA-01049	07/09/1905	Kaye A, Jones M, Kaye A, et al. No Prescription Opioid Abuse in Chronic Pain: An Updated Review of Opioid Abuse Predictors and Strategies to Curb Opioid Abuse: Part 1.Title. Pain Physician J. 2017	JAN-TREX-00015507	JAN-TREX-00015524							
JA-01050	07/06/1905	Kennedy, J. "Prevalence of Persistent Pain in the U.S. Adult Population: New Data From the 2010 National Health Interview Survey," Journal of Pain (2014) 15(10):979-984	JAN-TREX-00015525	JAN-TREX-00015529							
JA-01051	06/30/1905	Kleinert, R., "Single Dose Analgesic Efficacy of Tapentadol in Postsurgical Dental Pain: The Results of a Randomized, Double-Blind, Placebo-Controlled Study," Anesthesia & Analgesics (2008) 107(6):2048	JAN-TREX-00015530	JAN-TREX-00015535							
JA-01052	07/08/1905	Krashin, D., N. Murinova, and M. Sullivan. 2016. Challenges to Treatment of Chronic Pain and Addiction During the 'Opioid Crisis', Curr Pain Headache Rep, 20: 65	JAN-TREX-00015536	JAN-TREX-00015537							
JA-01053	07/02/1905	Lange, B., "Efficacy and Safety of Tapentadol Prolonged Release for Chronic Osteoarthritis Pain and Low Back Pain," Adv Ther 27:381 (2010)	JAN-TREX-00015538	JAN-TREX-00015548							
JA-01054	07/04/1905	Lembke A. Why Doctors Prescribe Opioids to Known Opioid Abusers. N Engl J Med. 2012;367(17):1580-1581	JAN-TREX-00015549	JAN-TREX-00015550							
JA-01055	06/01/2018	Lin, D., "Prescription Drug Coverage for Treatment of Low Back Pain Among US Medicaid, Medicare Advantage, and Commercial Insurers," JAMA Network OPen 2018 June; 1(2):e180235	JAN-TREX-00015551	JAN-TREX-00015558							
JA-01056	06/28/1905	Lusher, J., "Analgesic Addiction and Pseudoaddiction in Painful Chronic Illness," Clin/Pain (2006)	JAN-TREX-00015559	JAN-TREX-00015565							
JA-01057	06/25/1905	Manchikanti et.al Prevalence of prescription drug abuse and dependency in patients with chronic pain in western Kentucky. J Ky Med Assoc 2003;101:511–17	JAN-TREX-00015566	JAN-TREX-00015570							
JA-01058	07/11/1905	Manchikanti, L., "Letter to the Editor: Comments on Space Randomized Clinical Trial by Krebs et al.," Pain Physician (2019) 22:E139-E146	JAN-TREX-00149928	JAN-TREX-00149928							
JA-01059	07/11/1905	Manchikanti, L., "Letter to the Editor: Need for Reframing of Prevention Strategies to Combat Opioid Epidemic," Pain Physician (2019) 22:E139-E146	JAN-TREX-00149929	JAN-TREX-00149929							
JA-01060	07/11/1905	Manchikanti, L., "Letter to the Editor: Reforming Approaches to Curb Drug Overdose Deaths," Pain Physician (2019) 22:E139-E146	JAN-TREX-00149930	JAN-TREX-00149930							
JA-01061	07/02/1905	Marcum, Z.A., Recognizing the Risks of Chronic Nonsteroidal Anti-Inflammatory Drug Use in Older Adults, Annals of Long-Term Care: Clinical Care and Aging (2010) 18(9):24-27	JAN-TREX-00015571	JAN-TREX-00015573							
JA-01062	05/26/1905	Marks, R., "Undertreatment of Medical Inpatiernrts with Narcotic Analgesics," Annals of Internal Medicine (1973) 78(2):173	JAN-TREX-00015574	JAN-TREX-00015583							
JA-01063	04/01/1979	Maruta T., Swanson D., Finlayson, R. Drug Abuse and Dependence in Patients with Chronic Pain. Mayo Clin. Proc. 1979 (April):241-244	JAN-TREX-00015584	JAN-TREX-00015592							
JA-01064	06/12/1905	Max, M., "Improving Outcomes of Analgesic Treatment: Is Education Enough?" Annals of Internal Medicine (1990) 113:885-889	JAN-TREX-00015593	JAN-TREX-00015597							
JA-01065	05/29/1905	McCaffery M, Hart LL. Undertreatment of acute pain with narcotics. Am J Nurs. 1976 Oct;76(10)1586-91.	JAN-TREX-00015598	JAN-TREX-00015603							
JA-01066	06/23/1905	McCarberg, B.H., Long-Acting Opioids for Chronic Pain: Pharmacotherapeutic Opportunities to Enhance Compliance, Quality of Life, and Analgesia, American Journal of Therapeutics (2001) 9(3) 181-186.	JAN-TREX-00015604	JAN-TREX-00015607							
JA-01067	06/27/1905	McIlwain H, Ahdieh H. Safety, Tolerability, and Effectiveness of Oxymorphone Extended Release for Moderate to Severe Osteoarthritis Pain: A One-Year Study. Am J Ther. 2005;112:106-112	JAN-TREX-00015608	JAN-TREX-00015612							
JA-01068	07/07/1905	McNaughton, E., Assessing Abuse Potential of New Analgesic Medications Following Market Release: An Evaluation of Internet Discussion of Tapentadol Abuse, Pain Medicine (2015) 16:131-140	JAN-TREX-00015613	JAN-TREX-00015619							
JA-01069	07/09/1905	Meacham, K., et al., "Neuropathic Pain: Central vs. Peripheral Mechanisms," Curr Pain headache Rep 2017; 21:28	JAN-TREX-00015620	JAN-TREX-00015626							
JA-01070	06/12/1905	Melzack, "The Tragedy of Needleless Pain," Scientific American (1990) 262(2):27	JAN-TREX-00015627	JAN-TREX-00015633							
JA-01071	05/18/1905	Melzack, R., "Pain Mechanisms: A New Theory," 150 Science 972 (1965)	JAN-TREX-00015634	JAN-TREX-00015642							
JA-01072	06/24/1905	Menten, J., "Longitudinal Follow-up of TTS-Fentanyl Use in Patients with Cancer-Related Pain: Results of a Compassionate-Use Study with Special Focus on Elderly Patients," Current Medical Research & Opinion 18:488 (2002)	JAN-TREX-00015643	JAN-TREX-00015649							
JA-01073	06/24/1905	Mercadante, S., "Episodic (Breakthrough) Pain: Consensus Conference of an Expert Working Group of the European Association for Palliative Care," Cancer (2002) 94(2):832-839	JAN-TREX-00015650	JAN-TREX-00015654							
JA-01074	07/10/1905	Meske DS, Lawal OD, Elder H, Langberg V, Paillard F, Katz N. Efficacy of opioids versus placebo in chronic pain: A systematic review and meta-analysis of enriched enrollment randomized withdrawal trials. J Pain Res. 2018. doi:10.2147/JPR.S160255	JAN-TREX-00015655	JAN-TREX-00015664							
JA-01075	06/23/1905	Milligan K, Lanteri-minet M, Borchert K, et al. Evaluation of Long-term Efficacy and Safety of Transdermal Fentanyl in the Treatment of Chronic Noncancer Pain. 2001;2(4):197-204. doi:10.1054/jpai.2001.25352	JAN-TREX-00015665	JAN-TREX-00015670							
JA-01076	07/04/1905	Minozzi, S., Development of dependence following treatment with opioid analgesics for pain relief: a systematic review. Addiction Review (2012)	JAN-TREX-00015671	JAN-TREX-00015676							
JA-01077	06/30/1905	Mogull SA. Chronology of Direct-to-Consumer Advertising Regulation in the United States. Am. Med. Writers Ass’n J. (2008) 23(3):106-109	JAN-TREX-00015677	JAN-TREX-00015706							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-01078	07/06/1905	Moore, "Nonsteroidal Anti-Inflammatory Drugs, Gastroprotection, and Benefit–Risk," Pain Practice (2014) 14(4):378-395	JAN-TREX-00015707	JAN-TREX-00015718							
JA-01079	07/09/1905	Moore, R., "Gabapentin for chronic neuropathic pain and fibromyalgia in adults (Review)," Cochrane Database of Systematic Reviews (2017)	JAN-TREX-00015719	JAN-TREX-00015774							
JA-01080	06/08/1905	Morgan, John, American Opiophobia: Customary Underutilization of Opioid Analgesics, In: Controversies in Alcoholism and Substance Abuse 1986, Haworth Press	JAN-TREX-00015775	JAN-TREX-00015785							
JA-01081	06/30/1905	Motov, S.M., Is there a Limit to the Analgesic Effect of Pain Medications, 2008, Medscape, https://www.medscape.com/viewarticle/574279_print	JAN-TREX-00015786	JAN-TREX-00015787							
JA-01082	07/10/1905	Murphy, L., et al., "Intravenous Lipid Emulsion Use for Severe Hydroxychloroquine Toxicity," American Journal of Therapeutics 2018; 25: e273-e275	JAN-TREX-00015788	JAN-TREX-00015789							
JA-01083	06/25/1905	Mystakidou, Kyriaki, Parpa, Efi, Tsilika, Eleni, Mavromati A, Smyrniotis V, Georgaki, Stavroula, Vlahos L. Long-Term Management of Noncancer Pain With Transdermal Therapeutic System-Fentanyl. J Pain. 2003;4(6):298-306. doi:10.1016/S1526-5900(03)00632-1	JAN-TREX-00015790	JAN-TREX-00015797							
JA-01084	06/26/1905	Nagda J, Bajwa Z., Definitions and Classification of Pain In: Warfield CA, Bajwa ZH,, eds. Principles and Practice of Pain Medicine, 2d edition. New York: McGraw-Hill, 2004	JAN-TREX-00015798	JAN-TREX-00015804							
JA-01085	07/07/1905	Nahin, R., "Estimates of Pain Prevalence and Severity in Adults: United States, 2012," Journal of Pain 16:769-780 (2015)	JAN-TREX-00015805	JAN-TREX-00015811							
JA-01086	07/03/1905	National Academies of Science, Engineering & Medicine, Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research (2011)	JAN-TREX-00015812	JAN-TREX-00016194							
JA-01087	06/26/1905	Neighbor, "Factors Affecting Emergency Department Opioid Administration to Severely Injured Patients," Journal of the Academy of Emergency Medicine (2004) 11(12):1290	JAN-TREX-00016195	JAN-TREX-00016200							
JA-01088	06/30/1905	Nicholson, B., et al., Randomized trial comparing polymer-coated extended release morphine sulfate to controlled-release oxycodone HCl in moderate to severe nonmalignant pain, Current Medical Research and Opinion, Vol. 22, No. 8 (2008) 1503-1514.	JAN-TREX-00016201	JAN-TREX-00016213							
JA-01089	07/01/1905	Nielsen, C., "Individual Differences in Pain Sensitivity: Measurement, Causation, and Consequences," 10 Journal of Pain 231 (2009)	JAN-TREX-00016214	JAN-TREX-00016218							
JA-01090	07/01/1905	Norrbrink, C., "Tramadol in Neuropathic Pain After Spinal Cord Injury A Randomized, Double-blind, Placebo-controlled Trial," Clinical Journal of Pain (2009) 25(3):177	JAN-TREX-00016219	JAN-TREX-00016224							
JA-01091	06/23/1905	Nugent, M., Long-Term Observations of Patients Receiving Transdermal Fentanyl After a Randomized Trial, Journal of Pain and Symptom Management (2001) 21(5):385-391	JAN-TREX-00016225	JAN-TREX-00016232							
JA-01092	07/04/1905	Onyewu O. An update of appraisal of accuracy and utility of cervical discography in chronic neck pain. Pain Physician 2012; 15: E777-806.	JAN-TREX-00016233	JAN-TREX-00016252							
JA-01093	09/01/2018	Orhurhu V. Ketamine for chronic pain: A systematic review and meta-analysis. Accepted to Anesth Analg 9/2018 (with editorial).	JAN-TREX-00016253	JAN-TREX-00016264							
JA-01094	07/11/1905	Orhurhu VJ. Ketamine in acute and chronic pain management. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2019 Jan– 2019 Apr 5.	JAN-TREX-00016265	JAN-TREX-00016276							
JA-01095	06/20/1905	Pappagallo, Marco, The Concept of Pseudotolerance to Opioids, Journal of Pharmaceutical Care in Pain & Symptom Control (1998) 6(2):95-98	JAN-TREX-00016277	JAN-TREX-00016280							
JA-01096	06/29/1905	Pascual, M., Open-label study of the safety and effectiveness of long-term therapy with extended-release tramadol in the management of chronic nonmalignant pain. Current Medical Research and Opinion (2007) 23(10):2531-2542	JAN-TREX-00016281	JAN-TREX-00016292							
JA-01097	06/28/1905	Passik, S., "An Opioid Screening Instrument: Long-Term Evaluation of the Utility of the Pain Medication Questionnaire by Holmes et al.," Pain Practice (2006)	JAN-TREX-00016293	JAN-TREX-00016294							
JA-01098	07/01/1905	Passik, S., "Current Risk Assessment and Management Paradigms: Snapshots in the Life of the Pain Specialist," Pain Medicine (2009)	JAN-TREX-00016295	JAN-TREX-00016302							
JA-01099	07/03/1905	Passik, S., "Pseudoaddiction revisited: a commentary on clinical and historical considerations," Pain Management (2011)	JAN-TREX-00016303	JAN-TREX-00016308							
JA-01100	06/27/1905	Passik SD, Kirsh KL, Whitcomb L, et al. Monitoring outcomes during long-term opioid therapy for noncancer pain: Results with the Pain Assessment and Documentation Tool. J Opioid Manag. 2005	JAN-TREX-00016309	JAN-TREX-00016315							
JA-01101	07/03/1905	Passik SD, Messina J, Golsorkhi A, Xie F. Aberrant drug-related behavior observed during clinical studies involving patients taking chronic opioid therapy for persistent pain and fentanyl buccal tablet for breakthrough pain. J Pain Symptom Manage. 2011;41(1):116-125	JAN-TREX-00016316	JAN-TREX-00016321							
JA-01102	07/10/1905	Pergolizzi, J., "Abuse-deterrent opioids: an update on current approaches and considerations," Currnet Medical Research and Opinion (2018) 34(4):711-723	JAN-TREX-00016322	JAN-TREX-00016334							
JA-01103	07/08/1905	Pergolizzi, J., "Evolution to low-dose NSAID therapy," Pain Management (2016) 6(2):175-189	JAN-TREX-00016335	JAN-TREX-00016348							
JA-01104	05/26/1905	Pert, "Opiate Receptor: Demonstration in Nervous Tissue," Science (1973) 179:1011	JAN-TREX-00016349	JAN-TREX-00016352							
JA-01105	02/01/2019	Pitcher, M., "Prevalence and Profile of High-Impact Chronic Pain in the United States," Journal of Pain 20:146-160 (Feb. 2019)	JAN-TREX-00016353	JAN-TREX-00016361							
JA-01106	06/11/1905	Plezia, P., Transdermal Fentanyl: Pharmacokinetics and Preliminary Clinical Evaluation Pharmacotherapy (1989) 9(1):2-9	JAN-TREX-00016362	JAN-TREX-00016370							
JA-01107	07/09/1905	Plunkett A. Acupuncture for the treatment of chronic pain in the military population: Factors associated with treatment outcomes. Clin J Pain 2017; 33: 939-43	JAN-TREX-00016371	JAN-TREX-00016375							
JA-01108	06/26/1905	Portenoy, "Population-Based Survey of Pain in the United States: Differences Among White, African American, and Hispanic Subjects," The Journal of Pain (2004) 5(6):317-328	JAN-TREX-00016376	JAN-TREX-00016384							
JA-01109	06/29/1905	Portenoy, et al., Long Term Use of Controlled-release Oxycodone for Noncancer Pain: Results of a 3-year Registry Study. Clin. J. Pain 2007; 23: 287-299	JAN-TREX-00016385	JAN-TREX-00016395							
JA-01110	06/08/1905	Portenoy, R. K., and K. M. Foley. 1986. Chronic use of opioid analgesics in non-malignant pain: report of 38 cases, Pain, 25: 171-86	JAN-TREX-00016396	JAN-TREX-00016416							
JA-01111	06/11/1905	Portenoy, R. K., Breakthrough Pain: Definition and Management, Oncology (Supplement) Vol. 3, No. 8 (1989) 25-29	JAN-TREX-00149931	JAN-TREX-00149931							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-01112	06/26/1905	Portenoy, R.K. et al., Acute and Chronic Pain, In: Lowinson JH et al., eds., Substance Abuse: A Comprehensive Textbook, 4th ed. Philadelphia: Lippincott, 2004	JAN-TREX-00016417	JAN-TREX-00016439							
JA-01113	01/10/1980	Jane Porter and Herschel Jick, MD, Addiction Rare in Patients Treated with Narcotics, 302(2) N Engl J Med. 123 (Jan. 10, 1980)	JAN-TREX-00149932	JAN-TREX-00149932							
JA-01114	06/25/1905	Porter-Williamson, K., "Pseudoaddiction," Journal of Palliative Medicine 6:937 (2003)	JAN-TREX-00016440	JAN-TREX-00016443							
JA-01115	08/21/2017	Raffaeli, W., "Pain as a Disease: An Overview," Journal of Pain Research (Aug. 21, 2017)	JAN-TREX-00016444	JAN-TREX-00016449							
JA-01116	07/11/1905	Rainer, F., et al., "Current understanding of the mixed pain concept: a brief narrative review," CMRO 2019; 35(6); 1011-1018	JAN-TREX-00016450	JAN-TREX-00016457							
JA-01117	07/06/1905	Rauck RL. Treatment of post-amputation pain with peripheral nerve stimulation. Neuromodulation 2014; 17: 188-97	JAN-TREX-00016458	JAN-TREX-00016464							
JA-01118	07/03/1905	Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education and Research (2011); National Academies Press. https://doi.org/10.17226/13172	JAN-TREX-00016465	JAN-TREX-00016600							
JA-01119	06/25/1905	Rosenblum, Andrew, et al., Prevalence and Characteristics of Chronic Pain Among Chemically Dependent Patients in Methadone Maintenance and Residential Treatment Facilities, JAMA 2003; 289(18):2370-2378	JAN-TREX-00016601	JAN-TREX-00016609							
JA-01120	06/13/1905	Rowbotham, Michael C., et al., Both intravenous lidocaine and morphine reduce the pain of postherpetic neuralgia, Neurology 1991; 41:1024-1028	JAN-TREX-00016610	JAN-TREX-00016614							
JA-01121	07/01/1905	Rupert MP. Evaluation of sacroiliac joint interventions: a systematic appraisal of the literature. Pain Physician 2009; 12: 399-418.	JAN-TREX-00016615	JAN-TREX-00016625							
JA-01122	01/01/1996	Sackett, David L., et al., Evidence based medicine: what it is and what it isn't, BMJ Volume 312, 13 January 1996, pp. 71-72	JAN-TREX-00016626	JAN-TREX-00016627							
JA-01123	01/01/2013	Sauver, Jennifer L., et al., Why do patients visit their doctors? Assessing the most prevalent conditions in a defined US population, Mayo Clin Proc. 2013 January ; 88(1): 56–67. doi:10.1016/j.mayocp.2012.08.020	JAN-TREX-00016628	JAN-TREX-00016633							
JA-01124	07/03/1905	Schwartz, S., "Safety and Efficacy of Tapentadol ER in Patients with Painful Diabetic Peripheral Neuropathy: Results of a Randomized-Withdrawal, Placebo-Controlled Trial," Current Medical Research & Opinion 27:151 (2011)	JAN-TREX-00016634	JAN-TREX-00016642							
JA-01125	07/10/1905	Schwenk E. Consensus guidelines on the use of intravenous ketamine infusions for acute pain management from the American Society of Regional Anesthesia and Pain Medicine (ASRA), American Academy of Pain Medicine (AAPM) and the American Society of Anesthesiologists (ASA). Reg Anesth Pain Med 2018; 43: 456-66 (with editorial; listed as "most downloaded" article on pain by Pain Medicine News).	JAN-TREX-00016643	JAN-TREX-00016652							
JA-01126	10/04/2012	Schwittay, A., "Tapentadol Prolonged Release for Severe Chronic Pain: Results of a Noninterventional Study Involving General Practitioners and Internists, MMWFortschr Med., 154, pp. 85-93, October 4, 2012	JAN-TREX-00016653	JAN-TREX-00016658							
JA-01127	07/03/1905	Seminowicz, D., "Effective Treatment of Chronic Low Back Pain in Humans Reverses Abnormal Brain Anatomy and Function," Journal of Neuroscience (2011) 31(20):7450-7550	JAN-TREX-00016659	JAN-TREX-00016665							
JA-01128	07/09/1905	Serrie, A., Lange, B., and Steup, A., "Tapentadol prolonged-release for moderate-to-severe chronic osteoarthritis knee pain: a double-blind, randomized, placebo-and oxycodone controlled release-controlled study," CMRO 2017; 33(8); 1423-1432	JAN-TREX-00016666	JAN-TREX-00016675							
JA-01129	06/22/1905	Siddall, Philip J., et al., The Efficacy of Intrathecal Morphine and Clonidine in the Treatment of Pain After Spinal Cord Injury, Anesth Analg 2000;91:1493–8	JAN-TREX-00016676	JAN-TREX-00016679							
JA-01130	07/05/1905	Siminoff, L., "Incorporating patient and family preferences into evidence-based medicine," (2013) 13(Suppl 3):S6	JAN-TREX-00016680	JAN-TREX-00016683							
JA-01131	06/14/1905	Simmonds, M., "Transdermal Fentanyl: Long-Term Analgesic Studies," J of Paine & Symptom Mgmt (1992) 7(3)(Suppl.):S36	JAN-TREX-00016684	JAN-TREX-00016685							
JA-01132	06/29/1905	Simpson, David M., et al., Fentanyl Buccal Tablet for the Relief of Breakthrough Pain in Opioid-Tolerant Adult Patients with Chronic Neuropathic Pain: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study, Clinical Therapeutics/Volume 29, Number 4, 2007	JAN-TREX-00016686	JAN-TREX-00016694							
JA-01133	06/19/1905	Simpson, R., "Transdermal Fentanyl as Treatment for Chronic Low Back Pain," Journal of Pain & Symptom Management 14:218 (1997)	JAN-TREX-00016695	JAN-TREX-00016701							
JA-01134	07/03/1905	Sinha N. Pain management for trauma. In: Vadivelu N, Urman RD, Hines R, eds. Essentials of Pain Management. New York: Springer Press, 2011, 401-16.	JAN-TREX-00016702	JAN-TREX-00016716							
JA-01135	07/08/1905	Sluka, K. A., and D. J. Clauw. 2016. Neurobiology of fibromyalgia and chronic widespread pain, Neuroscience.	JAN-TREX-00016717	JAN-TREX-00016732							
JA-01136	07/05/1905	Soledad Cepeda, M., "Comparison of Opioid Doctor Shopping for Tapentadol and Oxycodone: A Cohort Study," Journal of Pain 14:1227 (2013)	JAN-TREX-00016733	JAN-TREX-00016739							
JA-01137	07/05/1905	Soledad Cepeda, M., "Comparison of the Risks of Opioid Abuse or Dependence Between Tapentadol and Oxycodone: Results From a Cohort Study," Journal of Pain 14:158 (2013)	JAN-TREX-00016740	JAN-TREX-00016754							
JA-01138	06/29/1905	Somogyi, A. "Pharmacogenetics of Opioids," Clinical Pharmacology & Therapeutics (2007) 81(3):429	JAN-TREX-00016755	JAN-TREX-00016770							
JA-01139	06/23/1905	Staats, P., et al., "The Additive Impact of Anxiety and a Placebo on Pain," Pain Medicine 2001; 2(4); 267-279	JAN-TREX-00016771	JAN-TREX-00016783							
JA-01140	03/01/2001	Staats, P., et al., "The Effects of Alcohol Celiac Plexus Block, Pain, and Mood on Longevity in Patients with Unresectable Pancreatic Cancer: A double-mind, randomized, placebo-controlled study, Pain Med., 2, pp. 28-34, March 2001	JAN-TREX-00016784	JAN-TREX-00016796							
JA-01141	02/01/2004	Staats, Peter S., et al., Incidence of Constipation Associated with Long-acting Opioid Therapy: A Comparative Study, Southern Medial Journal • Volume 97, Number 2, February 2004	JAN-TREX-00016797	JAN-TREX-00016803							
JA-01142	07/01/1905	Stanos, S., "Pain Management with Opioid Analgesics Balancing Risk & Benefit," Am. J. Phys. Med. Rehabil. 88:S69 (2009)	JAN-TREX-00016804	JAN-TREX-00016834							
JA-01143	06/30/1905	Stegmann, Jens-Ulrich, et al., The efficacy and tolerability of multiple-dose tapentadol immediate release for the relief of acute pain following orthopedic (bunionectomy) surgery, of Orthopedic Surgeons, March 5–9, 2008, San Francisco, CA, USA, The World Institute of Pain , VOL. 24, NO. 11, 2008, 3185–3196	JAN-TREX-00149933	JAN-TREX-00149933							
JA-01144	07/11/1905	Stonington, S., "Structural Iatrogenesis — A 43-Year-Old Man with 'Opioid Misuse'," New England Journal of Medicine 380:701 (2019)	JAN-TREX-00016835	JAN-TREX-00016838							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-01145	07/05/1905	Stoops, William W., Miotic and Subject-Rated Effects of Therapeutic Doses of Tapentadol, Tramadol and Hydromorphone in Occasional Opioid Users, Psychopharmacology (Berl). 2013 July ; 228(2): 255–262. doi:10.1007/s00213-013-3031-y.	JAN-TREX-00016839	JAN-TREX-00016849							
JA-01146	06/29/1905	Stovner, L., "The global burden of headache: a documentation of headache prevalence and disability worldwide," Cephalalgia (2007) 27:193-210	JAN-TREX-00195100	JAN-TREX-00195117							
JA-01147	07/06/1905	Strick, Volker, Management of severe chronic pain with tapentadol prolonged release - long-term data from pain specialists, Current Medical Research & Opinion Vol. 30, No. 10, 2014, 2085–2092, Article ST-0108.R1/939166	JAN-TREX-00016850	JAN-TREX-00016857							
JA-01148	07/09/1905	Sullivan MD, Turner JA, DiLodovico C, D'Appollonio A, Stephens K, Chan Y-F. Prescription Opioid Taper Support for Outpatients With Chronic Pain: A Randomized Controlled Trial. J Pain. 2017. doi:10.1016/j.jpain.2016.11.003	JAN-TREX-00016858	JAN-TREX-00016880							
JA-01149	07/08/1905	Tayeb BO, Barreiro AE, Bradshaw YS, Chui KKH, Carr DB. Durations of opioid, nonopioid drug, and behavioral clinical trials for chronic pain: Adequate or inadequate? Pain Med (United States). 2016. doi:10.1093/PM/PNW245	JAN-TREX-00016881	JAN-TREX-00016891							
JA-01150	07/09/1905	Thornton, D.J., et al., Health-related quality of life in patients receiving long-term opioid therapy: a systematic review with meta-analysis, Qual Life Res (2017) 26:1955-1967.	JAN-TREX-00016892	JAN-TREX-00016904							
JA-01151	07/11/1905	Treede, Rolf-Detlef, et al., Chronic pain as a symptom or a disease: the IASP Classification of Chronic Pain for the International Classification of Diseases (ICD-11) , PAIN 160 (2019) 19–27	JAN-TREX-00016905	JAN-TREX-00016913							
JA-01152	06/28/1905	Trescot, A., "Opioid Guidelines in the Management of Chronic Non-Cancer Pain," Pain Physician (2006) 9:1-40	JAN-TREX-00016914	JAN-TREX-00016953							
JA-01153	06/30/1905	Trescot, A.M., et al., Opioid Pharmacology, Pain Physician 2008: Opioid Special Issue: 11: S133-S153.	JAN-TREX-00016954	JAN-TREX-00016975							
JA-01154	06/25/1905	Turk, Dennis C., et al., Core outcome domains for chronic pain clinical trials: IMMPACT recommendations; Pain 106 (2003) 337-345	JAN-TREX-00016976	JAN-TREX-00016984							
JA-01155	05/28/1905	Twycross, R.G., The use of narcotic analgesics in terminal illness. Journal of Medical Ethics. 1(1) : 7-10 (1975)	JAN-TREX-00016985	JAN-TREX-00016992							
JA-01156	07/01/1905	Tzchentke, Thomas M., et al., Tapentadol Hydrochloride: A Next-Generation, Centrally Acting Analgesic with Two Mechanisms of action in a Single Molecule, Drugs of Today 2009, 45(7): 483-496	JAN-TREX-00016993	JAN-TREX-00017006							
JA-01157	07/09/1905	Vadivelu, N., et al., "Ketorolac, Oxymorphone, Tapentadol, and Tramadol: A Comprehensive Review," Anesthesiology Clin 2017; 35; e1-e20	JAN-TREX-00017007	JAN-TREX-00017026							
JA-01158	06/25/1905	Vallerance, A., "The use of long-acting opioids in chronic pain management," Nurs Clin N Am (2003) 38:435–445	JAN-TREX-00017027	JAN-TREX-00017037							
JA-01159	07/02/1905	Van der Weijden, "How to integrate individual patient values and preferences in clinical practice guidelines? A research protocol," Implementation Science (2010) 5:10	JAN-TREX-00017038	JAN-TREX-00017046							
JA-01160	07/04/1905	Vieira, EMB, et al., "Chronic pain, associated factors, and impact on daily life: are there differences between the sexes?" Cad. Saude Publica, Rio de Janeiro 2012; 28(8): 1459-1467	JAN-TREX-00017047	JAN-TREX-00017055							
JA-01161	07/04/1905	Vinik, A. "Abstract: Efficacy and tolerability of tapentadol extended release (ER) in patients with chronic, painful diabetic peripheral neuropathy (DPN): results of a phase 3, randomized-withdrawal, placebo-controlled study," Journal of Pain (Supp.) 13:S72 (2012)	JAN-TREX-00149934	JAN-TREX-00149934							
JA-01162	07/08/1905	Volkow, N., "Opioid Abuse in Chronic Pain—Misconceptions and Mitigation Strategies," 374 N Engl J Med 13 (2016)	JAN-TREX-00017056	JAN-TREX-00017066							
JA-01163	07/09/1905	Voon et al. Substance Abuse Treatment, Prevention, and Policy (2017) 12:36	JAN-TREX-00017067	JAN-TREX-00017075							
JA-01164	07/02/1905	Vorsanger, G., Abstract: Tolerability of tapentadol immediate release (IR) versus oxycodone IR in elderly patients with low back pain or osteoarthritis pain of the hip or knee; Journal of Pain (2010) 11(4):S42	JAN-TREX-00149935	JAN-TREX-00149935							
JA-01165	07/02/1905	Vorsanger, G. , "Evaluation of study discontinuations with tapentadol immediate release and oxycodone immediate release in patients with low back or osteoarthritis pain," Journal of Opioid Management 6:169 (2010)	JAN-TREX-00017076	JAN-TREX-00017086							
JA-01166	07/07/1905	Vowles, K.E., et al., Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis, J Pain, 156(4) (2015) 569-576.	JAN-TREX-00017087	JAN-TREX-00017094							
JA-01167	07/10/1905	Wang DD, Ma TT, Zhu HD, Peng CB. Transdermal fentanyl for cancer pain: Trial sequential analysis of 3406 patients from 35 randomized controlled trials. J Can Res Ther 2018;14:S14-21.	JAN-TREX-00017095	JAN-TREX-00017103							
JA-01168	06/23/1905	Way, W., Opioid Analgesics & Antagonists in Basic & Clinical Pharmacology (8th ed., 2001) (B. Katzung, ed.)	JAN-TREX-00017104	JAN-TREX-00017126							
JA-01169	06/11/1905	Weissman, Davie E. and Haddox, J. David, Opioid pseudoaddiction - an iatrogenic syndrome; Pain, 36 (1989) 363-366 Elsevier	JAN-TREX-00017127	JAN-TREX-00017130							
JA-01170	07/04/1905	Wilkinson I. Epidural steroid injections for chronic back pain: Piecing the puzzle together. Pain Manag 2012; 2: 307-9.	JAN-TREX-00017131	JAN-TREX-00017133							
JA-01171	06/26/1905	Winner, P., "Overview of Pediatric Headache," Current Treatment Options in Neurology (2004) 6:471–487	JAN-TREX-00017134	JAN-TREX-00017150							
JA-01172	07/07/1905	Yi, P., and P. Prybylkowski. 2015. Opioid Induced Hyperalgesia, Pain Med, 16 Suppl 1: S32-6	JAN-TREX-00017151	JAN-TREX-00017155							
JA-01173	06/14/1905	Zenz, Michael; Strumpf, Michael; Tryba M. Long Term Oral Opioid Therapy in Patients with Chronic Nonmalignant Pain. 1992:69-77	JAN-TREX-00017156	JAN-TREX-00017164							
JA-01174	06/29/1905	Zernikow, B., Transdermal Fentanyl in Childhood and Adolescence: A Comprehensive Literature Review, The Journal of Pain (2007) 8(3):187-207	JAN-TREX-00017165	JAN-TREX-00017185							
JA-01175	07/10/1905	American Medical Association House of Delegates Resolution on CDC Guidelines, 2018	JAN-TREX-00017186	JAN-TREX-00017222							
JA-01176	07/08/1905	American Medical Association’s Letter to CDC on Comments to CDC Guidelines, 2016	JAN-TREX-00017223	JAN-TREX-00017234							
JA-01177	01/01/2017	Assessment of Abuse Potential of Drugs: Guidance for Industry, U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER) , Jan. 2017 https://www.fda.gov/regulatory-information/search-fda-guidance-documents/assessment-abuse-potential-drugs	JAN-TREX-00017235	JAN-TREX-00017271							
JA-01178	07/01/2009	Australian National Health and Medical Research Council, Guideline for the non-surgical management of hip and knee osteoarthritis, July 2009	JAN-TREX-00017272	JAN-TREX-00017341							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-01179	No date	Biotechnology Innovation Organization, Toolkit, available at: https://www.bio.org/sites/default/files/docs/toolkit/IGP15.pdf	JAN-TREX-00149936	JAN-TREX-00149936							
JA-01180	02/28/2019	Centers for Disease Control and Prevention Letter on CDC Guidelines Clarification, Feb. 28, 2019	JAN-TREX-00017342	JAN-TREX-00017343							
JA-01181	07/08/1905	Centers for Disease Control Letter on CDC Guideline for Prescribing Opioids for Chronic Pain--United States, 2016, Apr. 10, 2019	JAN-TREX-00017344	JAN-TREX-00017348							
JA-01182	03/18/2016	Centers for Disease Control and Prevention, "CDC Guideline for Prescribing Opioids for Chronic Pain — United States, 2016," MMWR, Mar. 18, 2016	JAN-TREX-00017349	JAN-TREX-00017400							
JA-01183	02/01/2018	Centers for Medicare & Medicaid Services, Opioid Oral Morphine Milligram Equivalent (MME) Conversion Factors, Feb. 2018, https://www.cms.gov/Medicare/Prescription-Drug-Coverage/PrescriptionDrugCovContra/Downloads/Oral-MME-CFs-vFeb-2018.pdf	JAN-TREX-00017401	JAN-TREX-00017402							
JA-01184	06/28/1905	DEA, Practitioner's Manual: AN Informational Outline of the Controlled Substances Act, 2006 ed.	JAN-TREX-00017403	JAN-TREX-00017464							
JA-01186	04/09/2019	FDA, Consumer Updates > A Guide to Safe Use of Pain Medicine, 4/9/2019, https://www.fda.gov/ForConsumers/ConsumerUpdates/ucm095673.htm	JAN-TREX-00017465	JAN-TREX-00017469							
JA-01187	05/01/2004	Federation of State Medical Boards of the United States, Inc., Model Guidelines for the Use of Controlled Substances for the Treatment of Pain, May 2004	JAN-TREX-00017470	JAN-TREX-00017477							
JA-01188	04/01/2017	Federation of State Medical Boards, Guidelines for the Chronic Use of Opioid Analgesics, Apr. 2017	JAN-TREX-00017478	JAN-TREX-00017499							
JA-01189	11/01/2017	Food & Drug Administration, HHS, General Principles for Evaluating the Abuse Deterrence of Generic Solid Oral Opioid Drug Products Guidance for Industry, Nov. 2017	JAN-TREX-00017500	JAN-TREX-00017532							
JA-01190	07/22/2010	Food and Drug Administration Center for Drug Evaluation and Research (CDER), Joint Meeting of the Anesthetic and Life Support Drugs Advisory Committee (ALSDAC) & Drug Safety and Risk Management Advisory Committee (DSaRM) Meeting Transcript, Jul. 22, 2010	JAN-TREX-00017533	JAN-TREX-00017543							
JA-01191	07/23/2010	Food and Drug Administration Center for Drug Evaluation and Research (CDER), Joint Meeting of the Anesthetic and Life Support Drugs Advisory Committee (ALSDAC) & Drug Safety and Risk Management Advisory Committee (DSaRM) Meeting Transcript, Jul. 23, 2010	JAN-TREX-00017544	JAN-TREX-00017554							
JA-01192	03/06/2019	Health Professionals for Patients in Pain (HP3) Letter, Health Professionals Call on the CDC to Address Misapplication of its Guideline on Opioids for Chronic Pain through Public Clarification and Impact Evaluation, Mar. 6, 2019	JAN-TREX-00017555	JAN-TREX-00017557							
JA-01193	No date	IASP Terminology, https://www.iasp-pain.org/Education/Content.aspx?ItemNumber=1698	JAN-TREX-00017558	JAN-TREX-00017565							
JA-01194	No date	Institute of Health Economics of Alberta Canada, Toward Optimized Practice: Clinical Assessment of Psychosocial Yellow Flags	JAN-TREX-00017566	JAN-TREX-00017568							
JA-01195	No date	Institute of Health Economics of Alberta Canada, Toward Optimized Practice: Management of Psychosocial Yellow Flags	JAN-TREX-00017569	JAN-TREX-00017570							
JA-01196	07/01/1905	Institute of Health Economics of Alberta Canada, Toward Optimized Practice: What You Should Know About Your Acute Low Back Pain, 2009, revised 2011, 2015	JAN-TREX-00149937	JAN-TREX-00149937							
JA-01197	07/01/1905	Institute of Health Economics of Alberta Canada, Toward Optimized Practice: What You Should Know About Your Chronic Low Back Pain, 2009, revised 2011, 2015	JAN-TREX-00149938	JAN-TREX-00149938							
JA-01198	08/28/2012	Letter from FDA Center for Drug Evaluation & Research to Janssen Research & Development, LLC re Supplemental New Drug Application 200533/S-001	JAN-TREX-00017571	JAN-TREX-00017576							
JA-01199	06/22/2004	Letter from FDA Center for Drug Evaluation & Research to Mylan Technologies Inc. re Abbreviated New Drug Application 76-258	JAN-TREX-00017577	JAN-TREX-00017579							
JA-01200	08/15/2012	Letter from American Academy of Pain Medicine to FDA re Petition of Physicians for Responsible Opioid Prescribing for Label Changes	JAN-TREX-00017580	JAN-TREX-00017590							
JA-01201	04/30/2019	Lister Hill National Center for Biomedical Communications, U.S. Nat'l Library of Medicine, NIH, Genetics Home Reference: Help Me Understand Precision Medicine, Apr. 30, 2019	JAN-TREX-00017591	JAN-TREX-00017602							
JA-01202	02/01/2011	National Center for Health Statistics, Health, United States, 2010: With Special Feature on Death and Dying, Feb. 2011	JAN-TREX-00017603	JAN-TREX-00018165							
JA-01203	06/01/2009	National Center for Health Statistics, The National Nursing Home Survey: 2004 Overview, June 2009	JAN-TREX-00018166	JAN-TREX-00018223							
JA-01204	No date	Opioid Oral Morphine Milligram Equivalent (MME) Conversion Factors	JAN-TREX-00018224	JAN-TREX-00018225							
JA-01205	03/06/2009	Press Release: Health Professionals for Patients in Pain, Professionals Call on the CDC to Address Misapplication of its Guideline on Opioids for Chronic Pain through Clarification and Impact Evaluation, Mar. 6, 2009	JAN-TREX-00018226	JAN-TREX-00018229							
JA-01206	02/12/2014	U.K. National Institute for Health and Care Excellence, Osteoarthritis: care and management, Feb. 12, 2014	JAN-TREX-00018230	JAN-TREX-00018259							
JA-01207	12/28/2018	U.S. Dept. of Health and Human Services, Office of the Assistant Secretary for Health, Draft Report on Pain Management Best Practices: Updates, Gaps, Inconsistencies, and Recommendations, Dec. 28, 2018	JAN-TREX-00018260	JAN-TREX-00018362							
JA-01208	05/03/2003	U.S. Dept. of Veterans Affairs, Pain Management, VHA Directive 2003-021, May 3, 2003	JAN-TREX-00018363	JAN-TREX-00018367							
JA-01209	No date	U.S. Food and Drug Administration. Abuse-Deterrent Opioid Analgesics. Available at: https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/abuse-deterrent-opioid-analgesics	JAN-TREX-00018368	JAN-TREX-00018370							
JA-01211	03/01/2003	VA/DOD Clinical Practice Guideline for the Management of Opioid Therapy for Chronic Pain, Mar. 2003	JAN-TREX-00018371	JAN-TREX-00018450							
JA-01212	05/01/2017	FDA Blueprint for Prescriber Education for Extended-Release and Long-Acting Opioid Analgesics, May 2017	JAN-TREX-00018451	JAN-TREX-00018471							
JA-01213	08/01/1990	Duragesic Label 1990-08	JAN-TREX-00018472	JAN-TREX-00018482							
JA-01214	05/20/2003	Duragesic Label 2003-05-20	JAN-TREX-00018483	JAN-TREX-00018493							
JA-01215	02/04/2005	Duragesic Label 2005-02-04	JAN-TREX-00018494	JAN-TREX-00018507							
JA-01216	07/09/2012	Duragesic Label 2012-07-09	JAN-TREX-00018508	JAN-TREX-00018531							
JA-01217	12/16/2016	Duragesic Label 2016-12-16	JAN-TREX-00018532	JAN-TREX-00018554							
JA-01218	01/24/2018	Duragesic Label 2018-01-24	JAN-TREX-00018555	JAN-TREX-00018586							
JA-01219	09/18/2018	Duragesic Label 2018-09-18	JAN-TREX-00018587	JAN-TREX-00018610							
JA-01220	08/25/2011	Nucynta ER Label 2011-08-25	JAN-TREX-00018611	JAN-TREX-00018634							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-01221	08/28/2011	Nucynta ER Label 2011-08-28	JAN-TREX-00018635	JAN-TREX-00018673							
JA-01222	07/09/2012	Nucynta ER Label 2012-07-09	JAN-TREX-00018674	JAN-TREX-00018692							
JA-01223	08/28/2012	Nucynta ER Label 2012-08-28	JAN-TREX-00018693	JAN-TREX-00018710							
JA-01224	12/16/2016	Nucynta ER Label 2016-12-16	JAN-TREX-00018711	JAN-TREX-00018724							
JA-01225	07/10/1905	Nucynta ER Label 2018 Label	JAN-TREX-00018725	JAN-TREX-00018739							
JA-01226	07/10/1905	Nucynta IR Label 2018	JAN-TREX-00018740	JAN-TREX-00018768							
JA-01227	11/17/2014	Nucynta IR Oral Solution Label 2014-11-17	JAN-TREX-00018769	JAN-TREX-00018789							
JA-01228	11/20/2008	Nucynta IR Tablet Label 2008-11-20	JAN-TREX-00018790	JAN-TREX-00018807							
JA-01229	07/01/1905	Nucynta IR Tablet Label 2009-11-09	JAN-TREX-00018808	JAN-TREX-00018825							
JA-01230	07/02/1905	Nucynta IR Tablet Label 2010-10	JAN-TREX-00018826	JAN-TREX-00018841							
JA-01231	07/11/2013	Nucynta IR Tablet Label 2013-07-11	JAN-TREX-00018842	JAN-TREX-00018857							
JA-01232	10/31/2013	Nucynta IR Tablet Label 2013-10-31	JAN-TREX-00018858	JAN-TREX-00018873							
JA-01233	12/01/2016	Nucynta IR Tablet Label 2016-12	JAN-TREX-00018874	JAN-TREX-00018886							
JA-01234	09/01/2018	Nucynta IR Tablet Label 2018-09	JAN-TREX-00018887	JAN-TREX-00018920							
JA-01235	04/10/2006	Janssen Websitel: Duragesic-Welcome. What is Duragesic? (2006), available at http://jomhp1d3.na.jnj.com:6640?host=www.duragesic.com	JAN00222151	JAN00222151							
JA-01236	08/01/1990	Duragesic fentanyl transdermal system serum fentanyl concentrations	JAN-MS-00238727	JAN-MS-00238737							
JA-01237	07/01/2013	Nucynta: Highlights of Prescribing Information	JAN-MS-01229368	JAN-MS-01229395							
JA-01238	05/14/2008	Draft of Let's Talk Pain Coalition Web Site Content	JAN-MS-01241348	JAN-MS-01241348							
JA-01239	No date	The France Foundation Presentation: Addressing the Barriers to Effective Pain Management and Issues of Opioid Misuse and Abuse	JAN-MS-01509021	JAN-MS-01509021							
JA-01240	10/19/2009	Email from Ravi Desiraju to Bruce Moskowitz et al.	JAN-MS-02001916	JAN-MS-02001918							
JA-01241	06/22/2010	Joint Meeting Of The Anesthetic and Life Support Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee July 22 and 23, 2010: Risk Evaluation and Mitigation Strategies (REMS) for Extended-Release and Long-Acting Opioid Analgesics	JAN-MS-02233933	JAN-MS-02233306							
JA-01242	08/25/2011	Letter from Bob Rappaport, FDA/HHS to Kathleen Dusek.	JAN-MS-02543460	JAN-MS-02543567							
JA-01243	03/18/2010	Memorandum from Endo, King, Janssen and Purdue to Participating IWG Companies	JAN-MS-02569643	JAN-MS-02569644							
JA-01244	07/04/1905	The 2012 Johnson Medal for Research and Development, Nomination-Full Application, Nucynta/Nucynta ER	JAN-MS-02604007	JAN-MS-02604012							
JA-01245	04/06/2010	Email from Karen Naim to Phillip Pierce	JAN-MS-02605687	JAN-MS-02605689							
JA-01246	11/29/1988	Alza Corporation, Rational for the Development, Therapeutic Use, and Clinical Program for Transdermal Therapeutic System (Fentanyl),1988	JAN-MS-02908137	JAN-MS-02908151							
JA-01247	11/29/1988	Alza Corporation, Rational for the Development, Therapeutic Use, and Clinical Program for Transdermal Therapeutic System (Fentanyl)	JAN-MS-02908285	JAN-MS-02908296							
JA-01248	05/14/2010	Email from Fraank Strzelecki to Marsha Lash, et al	JAN-OH-00076245	JAN-OH-00076245							
JA-01249	05/14/2010	Janssen Meeting Minutes; Nucynta Ask The Expert Call	JAN-OH-00076246	JAN-OH-00076248							
JA-01250	11/07/2010	Email from Amy Maddox to Jeffrey Chapman, et al	JAN-OH-00116003	JAN-OH-00116004							
JA-01251	09/27/2004	Email from Michael Kafissen to Bruce Moskowitz	JAN-MS-00482680	JAN-MS-00482683							
JA-01252	04/10/2019	PLTF_2804_000018913 (Claims data relating to Track 1 Plaintiffs' "High MME Patients")	PLTF_2804_000018913	PLTF_2804_000018913							
JA-01254	06/09/1905	Goleman, D., "Health: Patient Care; Physicians Said to Persist in Undertreating Pain and Ignoring the Evidence," N.Y. Times (Dec. 31, 1987)	JAN-TREX-00018921	JAN-TREX-00018923							
JA-01255	06/27/1905	Libby, R., Treating Doctors as Drug Dealers: The DEA's War on Prescription Painkillers, Policy Analysis (2005) 545:1-28	JAN-TREX-00018924	JAN-TREX-00018951							
JA-01256	07/09/1905	Pain Management and the Opioid Epidemic: Balancing Societal and Individual Benefits and Risks of Prescription Opioid Use (Bonnie, R., ed.) (2017)	JAN-TREX-00018952	JAN-TREX-00019434							
JA-01258	05/18/2018	Corrected Second Amended Complaint	JAN-TREX-00019456	JAN-TREX-00019584							
JA-01259	05/18/2018	Second Amended Complaint	JAN-TREX-00019585	JAN-TREX-00019948							
JA-01265	04/12/2019	National Oceanic and Atmospheric Administration Atmospheric ESRL data	JAN-TREX-00019949	JAN-TREX-00019961							
JA-01266	09/01/2018	Centers for Disease Control (CDC) opioid morphine conversion factors data, cdc_mme_table_sept2018.sas7bdat, https://www.cdc.gov/drugoverdose/resources/data.html (accessed May 3, 2019).	JAN-TREX-00019962	JAN-TREX-00020257							
JA-01267	04/01/2017	Centers for Medicaid and Medicare Services opioid morphine conversion factors data, https://www.cms.gov/Medicare/Prescription-Drug-Coverage/PrescriptionDrugCovContra/Downloads/Opioid-Morphine-EQ-Conversion-Factors-April-2017.pdf (accessed May 3, 2019).	JAN-TREX-00020258	JAN-TREX-00020259							
JA-01268	07/04/1905	The American Hospital Formulary Service (AHFS) Pharmacologic-Therapeutic Classification, http://www.mgh.org/Content/Uploads/UP%20Health%20System%20-%20Marquette/files/formulary/AHFS%20Pharmacologic-Therapeutic%20Classification%20(2012).pdf (accessed May 3, 2019).	JAN-TREX-00020260	JAN-TREX-00020269							
JA-01269	05/03/2019	Federal Drug Administration (FDA) National Drug Code (NDC) / National Health Related Items Code (NHRIC) labeler codes, ndc_nhric_labeler_codes_05_03_2019.xlsx, https://www.fda.gov/industry/structured-product-labeling-resources/ndcnhric-labeler-codes (accessed May 3, 2019).	JAN-TREX-00149914	JAN-TREX-00149914							
JA-01270	08/01/1997	U.S. DOJ, Drug Enforcement Agency, Automation of Reports and Consolidated Orders System (ARCOS) Registrant Handbook, August 1997	JAN-TREX-00020270	JAN-TREX-00020460							
JA-01272	08/20/2019	Ohio Automated Prescription Reporting System (OARRS) https://www.ohiopmp.gov/State.aspx (accessed May 3, 2019).	JAN-TREX-00020461	JAN-TREX-00020463							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-01273	02/21/2019	Confidential Ohio Automated Prescription Reporting System (OARRS) data created by the State of Ohio Board of Pharmacy. Ohio BOP 20190221 Vol 1 & 2.zip: BOP_MDL 5th Production_000001.txt ... BOP_MDL 5th Production_000044.txt	BOP_MDL 5th Production_000044	BOP_MDL 5th Production_000044							
JA-01274	04/02/2015	Depomed Announcement April 2, 2015; https://www.jnj.com/media-center/press-releases/janssen-pharmaceuticals-inc-completes-divestiture-of-us-license-rights-to-nucynta-tapentadol-nucynta-er-tapentadol-extended-release-tablets-and-nucynta-tapentadol-oral-solution-to-depomed-inc (accessed May 3, 2019) ; https://www.prnewswire.com/news-releases/depomed-announces-closing-of-acquisition-of-us-rights-to-nucynta-tapentadol-nucynta-er-tapentadol-extended-release-tablets-and-nucynta-tapentadol-oral-solution-from-janssen-pharmaceuticals-inc-for-105-billion-300060453.html (accessed May 3, 2019).	JAN-TREX-00020464	JAN-TREX-00020469							
JA-01275	07/03/1905	Allen et al., "Reference Guide on the Estimation of Economic Damages," in Reference Manual on Scientific Evidence, 3rd ed., Federal Judicial Center, 2011.	JAN-TREX-00020470	JAN-TREX-00020547							
JA-01276	11/01/1966	Box GEP, Use and Abuse of Regression, Technometrics, Vol. 8, No. 4, pp. 625--629, 1966.	JAN-TREX-00020548	JAN-TREX-00020552							
JA-01277	05/27/1905	Granger CWJ, et al., Spurious Regressions in Econometrics, Journal of Econometrics 2, pp. 111-120, 1974.	JAN-TREX-00020553	JAN-TREX-00020562							
JA-01278	07/03/1905	Kaye, David H. and Freedman, David A., "Reference Guide on Statistics" Reference Manual on Scientific Evidence, 3rd ed., Federal Judicial Center, 2011.	JAN-TREX-00020563	JAN-TREX-00020654							
JA-01279	06/29/1905	Noriega AE, et al., Spurious Regression and Trending Variables, Oxford Bulletin of Economics and Statistics, Vol. 69, No. 3, pp. 439-444, 2007	JAN-TREX-00020655	JAN-TREX-00020660							
JA-01280	06/08/1905	Phillips PCB, Understanding Spurious Regressions in Econometrics, Journal of Econometrics, Vol. 33, pp. 311-340, 1986.	JAN-TREX-00020661	JAN-TREX-00020690							
JA-01281	07/03/1905	Rubinfeld, Daniel L., "Reference Guide on Multiple Regression" Reference Manual on Scientific Evidence, 3rd ed., Federal Judicial Center, 2011.	JAN-TREX-00020691	JAN-TREX-00020746							
JA-01282	01/01/1926	Yule GU, Why Do We Sometimes Get Nonsense-Correlations Between Time-Series?, Journal of the Royal Statistical Society, Vol. 89, No. 1, pp. 1--63, January 1926	JAN-TREX-00020747	JAN-TREX-00020810							
JA-01284	01/28/2016	Alford DP., Opioid Prescribing for Chronic Pain — Achieving the Right Balance through Education, The New England Journal of Medicine, 374(4), pp. 301-3, January 28, 2016	JAN-TREX-00020846	JAN-TREX-00020848							
JA-01285	01/30/2014	Atluri S, et al., Assessment of the Trends in Medical Use and Misuse of Opioid Analgesics from 2004 to 2011, Pain Physician Journal, 17, pp. E119-28, 2014	JAN-TREX-00021420	JAN-TREX-00021429							
JA-01286	07/09/1905	Case A, et al., Mortality and Morbidity in the 21st Century, Brookings Papers on Economic Activity, pp. 397-476, Spring 2017	JAN-TREX-00021562	JAN-TREX-00021641							
JA-01287	07/07/1905	Greene M and Chambers A, Pseudoaddiction: Fact or Fiction? An Investigation of the Medical Literature, Curr Addict Report, 2, pp. 310-317, 2015	JAN-TREX-00023354	JAN-TREX-00023361							
JA-01288	11/21/2016	Krashin D, et al., Challenges to Treatment of Chronic Pain and Addiction During the "Opioid Crisis", Curr Pain Headache Rep, 20: 65, 2016.	JAN-TREX-00024487	JAN-TREX-00024489							
JA-01289	03/06/2018	Krebs EE, et al., Effect of Opioid vs Nonopioid Medications on Pain-Related Function in Patients with Chronic Back Pain or Hip or Knee Osteoarthritis Pain, JAMA, Vol. 319, No. 9, pp. 872-882, March 6, 2018.	JAN-TREX-00024490	JAN-TREX-00024500							
JA-01290	06/30/1905	Manchikanti L. and Singh, A., "Therapeutic Opioids: a Ten Year Perspective on the Complexities and Complications of the Escalating Use, Abuse, and Nonmedical Use of Opioids," Pain Physician, 11: pp. 563-588.	JAN-TREX-00024617	JAN-TREX-00024642							
JA-01291	03/01/2018	Rummans, T., et al., "How Good Intentions Contributed to Bad Outcomes: The Opioid Crisis", Mayo Clinic Proceedings, 93 (3), pp. 344-350.	JAN-TREX-00025297	JAN-TREX-00025303							
JA-01292	11/01/2017	Soelberg C, et al., The US Opioid Crisis: Current Federal and State Legal Issues, International Anesthesia Research Society, Vol. 125 (5), 2017	JAN-TREX-00025544	JAN-TREX-00025550							
JA-01293	04/30/2019	Dr. Steven Cohen CV	JAN-TREX-00028869	JAN-TREX-00028886							
JA-01294	N/A	CV of Frank Torti	JAN-TREX-00196948	JAN-TREX-00196981							
JA-01295	07/01/2018	Typewritten notes	JAN-TREX-00181977	JAN-TREX-00181981							
JA-01296	06/23/2004	Bruce Moskovitz Presentation: Primary Care Franchise Update	JAN-MS-00492868	JAN-MS-00492868							
JA-01297	08/07/2008	Email From Bruce Moskovitz to Faith Sarioz	JAN-MS-01204898	JAN-MS-01204899							
JA-01298	07/04/1905	Janssen Presentation: Cycle 1 Meeting	JAN00085130	JAN00085232							
JA-01299	08/17/2015	Surveying Ohio physicians on opiate prescribing behaviors,	SUMMIT_000839795	SUMMIT_000839813							
JA-01300	06/29/1905	Ohio HIDTA, Annual Report, 2007	OH-HIDTA_000534	OH-HIDTA_000564							
JA-01301	06/30/1905	Ohio High Intensity Drug Trafficking Area, CY 2008 Annual Report Ohio	OH-HIDTA_000565	OH-HIDTA_000615							
JA-01302	07/01/1905	Ohio High Intensity Drug Trafficking Area, CY 2009 Annual Report Ohio	OH-HIDTA_000616	OH-HIDTA_000655							
JA-01303	07/02/1905	Ohio High Intensity Drug Trafficking Area, CY 2010 Annual Report Ohio	OH-HIDTA_000656	OH-HIDTA_000700							
JA-01304	07/03/1905	Ohio High Intensity Drug Trafficking Area, CY 2011 Annual Report Ohio	OH-HIDTA_000701	OH-HIDTA_000750							
JA-01305	07/04/1905	Ohio High Intensity Drug Trafficking Area, CY 2012 Annual Report Ohio	OH-HIDTA_000751	OH-HIDTA_000804							
JA-01306	07/05/1905	Ohio High Intensity Drug Trafficking Area, CY 2013 Annual Report Ohio	OH-HIDTA_000805	OH-HIDTA_000850							
JA-01307	07/06/1905	Ohio High Intensity Drug Trafficking Area, CY 2014 Annual Report Ohio	OH-HIDTA_000851	OH-HIDTA_000891							
JA-01308	07/07/1905	Ohio High Intensity Drug Trafficking Area, CY 2015 Annual Report Ohio	OH-HIDTA_000892	OH-HIDTA_000936							
JA-01309	07/08/1905	Ohio High Intensity Drug Trafficking Area, CY 2016 Annual Report Ohio	OH-HIDTA_000937	OH-HIDTA_000988							
JA-01310	07/09/1905	Ohio High Intensity Drug Trafficking Area, 2017 Annual Report Ohio	OH-HIDTA_000989	OH-HIDTA_001030							
JA-01311	06/27/1905	Ohio HIDTA 2005 Threat Assessment	OH-HIDTA_002167	OH-HIDTA_002233							
JA-01312	06/15/2013	Threat Assessment & Strategy Program Year 2013, Ohio High Intensity Drug Trafficking Area	OH-HIDTA_002863	OH-HIDTA_002908							
JA-01313	06/15/2014	Threat Assessment & Strategy Program Year 2014, Ohio High Intensity Drug Trafficking Area	OH-HIDTA_002909	OH-HIDTA_002960							
JA-01314	06/15/2015	Threat Assessment & Strategy Program Year 2015, Ohio High Intensity Drug Trafficking Area	OH-HIDTA_002961	OH-HIDTA_003018							
JA-01315	06/15/2016	Threat Assessment & Strategy Program Year 2016, Ohio High Intensity Drug Trafficking Area	OH-HIDTA_003019	OH-HIDTA_003084							
JA-01316	06/15/2017	Threat Assessment & Strategy Program Year 2017, Ohio High Intensity Drug Trafficking Area	OH-HIDTA_003085	OH-HIDTA_003156							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-01317	07/10/1905	Threat Assessment & Strategy Program Year 2018, Ohio High Intensity Drug Trafficking Area	OH-HIDTA_003157	OH-HIDTA_003230							
JA-01318	03/03/1999	Letter from Emily Sweeney to Joseph Peters enclosing Ohio's HIDTA Proposal	OH-HIDTA_003369	OH-HIDTA_003406							
JA-01319	07/08/1999	Northern Ohio High Intensity Drug Trafficking Area, Mission Statement, 1999	OH-HIDTA_003455	OH-HIDTA_003473							
JA-01320	06/24/1905	Ohio HIDTA, 2002 Threat Assessment	OH-HIDTA_003501	OH-HIDTA_003557							
JA-01321	06/25/1905	Ohio HIDTA, 2003 Threat Assessment	OH-HIDTA_003558	OH-HIDTA_003616							
JA-01322	06/26/1905	Ohio HIDTA, 2004 Threat Assessment	OH-HIDTA_003617	OH-HIDTA_003653							
JA-01323	02/28/2010	Waidley, E, Ohio Diversion Intelligence Summary-February, 2010	OH-HIDTA_000142	OH-HIDTA_000143							
JA-01324	06/01/2010	Ohio High Intensity Drug Trafficking Area, Ohio Diversion Intelligence Summary, 2010	OH-HIDTA_000221	OH-HIDTA_000224							
JA-01325	03/01/2010	Ohio High Intensity Drug Trafficking Area, Ohio Diversion Intelligence Summary, 2010	OH-HIDTA_000225	OH-HIDTA_000227							
JA-01326	05/01/2010	Ohio High Intensity Drug Trafficking Area, Ohio Diversion Intelligence Summary, 2010	OH-HIDTA_000228	OH-HIDTA_000231							
JA-01327	06/28/1905	National Drug Threat Survey 2006, U.S. Department of Justice National Drug Intelligence Center	OH-HIDTA_002531	OH-HIDTA_002536							
JA-01328	04/01/2010	U.S. Department of Justice, National Drug Intelligence Center, Ohio High Intensity Drug Trafficking Area, 2010	OH-HIDTA_000010	OH-HIDTA_000028							
JA-01329	07/03/1905	Ohio High Intensity Drug Trafficking Area, Drug Market Analysis (Draft), 2011	OH-HIDTA_000232	OH-HIDTA_000250							
JA-01330	07/03/1905	Ohio High Intensity Drug Trafficking Area, Drug Market Analysis, 2011	OH-HIDTA_000251	OH-HIDTA_000265							
JA-01331	06/01/2006	Ohio High Intensity Drug Trafficking Area Drug Market Analysis, National Drug Intelligence Center, 2006	OH-HIDTA_002236	OH-HIDTA_002251							
JA-01332	06/01/2007	Ohio High Intensity Drug Trafficking Area Drug Market Analysis, U.S. Department of Justice, 2007	OH-HIDTA_002635	OH-HIDTA_002646							
JA-01333	05/01/2008	Ohio High Intensity Drug Trafficking Area, National Drug Intelligence Center, U.S Department of Justice, 2008	OH-HIDTA_002665	OH-HIDTA_002683							
JA-01334	06/29/1905	Ohio High Intensity Drug Trafficking Area Drug Market Analysis, 2007	OH-HIDTA_002697	OH-HIDTA_002711							
JA-01335	06/29/1905	Ohio High Intensity Drug Trafficking Area Drug Market Analysis, 2007	OH-HIDTA_002712	OH-HIDTA_002725							
JA-01336	06/29/1905	Ohio High Intensity Drug Trafficking Area Drug Market Analysis, 2007	OH-HIDTA_002726	OH-HIDTA_002739							
JA-01337	04/01/2009	Ohio High Intensity Drug Trafficking Area Drug Market Analysis 2009, National Drug Intelligence Center U.S. Department of Justice	OH-HIDTA_002753	OH-HIDTA_002774							
JA-01338	07/01/1905	Ohio High Intensity Drug Trafficking Area Drug Market Analysis-2009,	OH-HIDTA_002776	OH-HIDTA_002792							
JA-01339	07/01/1905	Ohio High Intensity Drug Trafficking Area Drug Market Analysis, 2009	OH-HIDTA_002793	OH-HIDTA_002809							
JA-01340	04/01/2010	Ohio High Intensity Drug Trafficking Area, National Drug Intelligence Center U.S. Department of Justice, 2010	OH-HIDTA_002840	OH-HIDTA_002858							
JA-01341	07/03/1905	Ohio High Intensity Drug Trafficking Area, Drug Market Analysis 2011	OH-HIDTA_004228	OH-HIDTA_004245							
JA-01342	06/28/1905	Ohio High Intensity Drug Trafficking Area, 2006 Strategy	OH-HIDTA_001054	OH-HIDTA_001081							
JA-01343	06/29/1905	Ohio High Intensity Drug Trafficking Area, 2007 Strategy	OH-HIDTA_001082	OH-HIDTA_001111							
JA-01344	06/30/1905	Ohio High Intensity Drug Trafficking Area, 2008 Strategy	OH-HIDTA_001112	OH-HIDTA_001143							
JA-01345	07/01/1905	Ohio High Intensity Drug Trafficking Area, 2009 Strategy	OH-HIDTA_001144	OH-HIDTA_001175							
JA-01346	07/02/1905	Ohio High Intensity Drug Trafficking Area, 2010 Strategy	OH-HIDTA_001176	OH-HIDTA_001208							
JA-01347	07/03/1905	Ohio High Intensity Drug Trafficking Area, CY 2011 Strategy Ohio	OH-HIDTA_001209	OH-HIDTA_001242							
JA-01348	07/04/1905	Ohio High Intensity Drug Trafficking Area, CY 2012 Strategy Ohio	OH-HIDTA_001243	OH-HIDTA_001275							
JA-01349	07/05/1905	Ohio High Intensity Drug Trafficking Area, CY 2013 Strategy Ohio	OH-HIDTA_001276	OH-HIDTA_001312							
JA-01350	06/29/1905	Ohio High Intensity Drug Trafficking Area , 2007 Strategy	OH-HIDTA_001671	OH-HIDTA_001699							
JA-01351	06/15/2018	Threat Assessment & Strategy Program Year 2018	OH-HIDTA-00013430	OH-HIDTA-00013459							
JA-01352	06/24/1905	Janssen presentataion: The Drug Development Process and the Integration of R&D and Commercial presentation	JAN-TREX-00028902	JAN-TREX-00028932							
JA-01353	11/12/2004	Alza Citizen Petition	JAN-MS-02508937	JAN-MS-02508948							
JA-01354	No Date	Review and Conclusion of the RADARS Report Summarizing Abuse and Diversion Data for Transdermal Fentanyl Products in the United States	JAN-MS-02578637	JAN-MS-02578638							
JA-01355	04/28/2008	Email from Bruce Moskowitz to Ravi Desiraju et al.	JAN-MS-02484172	JAN-MS-02484172							
JA-01356	02/03/2012	Feb Retail ST 101 Agenda, Janssen, 2012	JAN-MS-00060275	JAN-MS-00060277							
JA-01357	08/10/2011	Mike Burzcak, Welcome to Sales training 101, Janssen, G02-256 CSS, 2011	JAN-MS-00061140	JAN-MS-00061166							
JA-01358	03/07/2011	Janssen Presentation: Sales Training 101 Preparation, Ortho-McNeil Janssen,Pharmaceuatical services,	JAN-MS-00061971	JAN-MS-00062005							
JA-01359	03/07/2011	New Representative Training, Administrative Activities	JAN-MS-00062006	JAN-MS-00062006							
JA-01360	07/03/1905	Class Materials List, Pri Cara ST 101-PAIN	JAN-MS-00062908	JAN-MS-00062908							
JA-01361	07/26/2011	Janssen Presentation: Retail Sales Training 101 Preparation, Ortho-McNeil Janssen Training & Development	JAN-MS-00063475	JAN-MS-00063516							
JA-01362	08/29/2011	Janssen Presentation: Nucynta ER, Train-the-Trainer, August 29, 2011	JAN-MS-00064792	JAN-MS-00064878							
JA-01363	09/04/2009	Nucynta Competition Advisor Guide, For Pricara Training Use Only	JAN-MS-00067422	JAN-MS-00067424							
JA-01364	09/04/2009	Nucynta Pain Advisor Guide, For Pricara Training Use Only	JAN-MS-00067450	JAN-MS-00067450							
JA-01365	09/04/2009	Nucynta Package Insert Advisor Guide	JAN-MS-00067561	JAN-MS-00067564							
JA-01366	09/04/2009	Nucynta Visual Aid Advisor Guide, For Pricara Training Use Only	JAN-MS-00067601	JAN-MS-00067602							
JA-01367	07/02/2010	Nucynta Clinical Reprints Leader's Guide, For Pricara Training Use Only	JAN-MS-00067603	JAN-MS-00067614							
JA-01368	09/04/2009	Nucynta Competition Leader's Guide, For Pricara Training Use Only	JAN-MS-00067668	JAN-MS-00067679							
JA-01369	07/02/2010	Nucynta Disease State Leader's Guide	JAN-MS-00067687	JAN-MS-00067691							
JA-01370	07/02/2010	Nucynta Package Insert Leader's Guide, For Pricara Training Use Only	JAN-MS-00067813	JAN-MS-00067830							
JA-01371	07/02/2010	Nucynta Visual Aid Leader's Guide, For Pricara Training Use Only	JAN-MS-00067861	JAN-MS-00067868							
JA-01372	03/03/2011	Janssen Presentation: Tapentadol ER Training Plan	JAN-MS-00086658	JAN-MS-00086681							
JA-01373	07/12/2013	Home Study Training Calendar Nucynta, Sales Learning, Janssen	JAN-MS-00093415	JAN-MS-00093430							
JA-01374	08/01/2011	Janssen Presentation: Sales training Standards and Certification Process, New Hires, Transfers, New Products & Co-Promotions, Janssen, August 2011	JAN-MS-00093624	JAN-MS-00093643							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-01375	09/22/2011	Janssen Presentation: New Representative Training Process, Janssen, September 22, 2011	JAN-MS-00093656	JAN-MS-00093673							
JA-01376	05/05/2008	Janssen Training & Development Material Review	JAN-MS-00094435	JAN-MS-00094446							
JA-01377	09/02/2008	Janssen Training & Development Material Review	JAN-MS-00098904	JAN-MS-00098916							
JA-01378	03/01/2013	Janssen Training & Development Material Review	JAN-MS-00099423	JAN-MS-00099435							
JA-01379	04/28/2011	Training & Development Material Review, MRC Review Process, Ortho McNeil Janssen Pharmaceutical Services	JAN-MS-00102203	JAN-MS-00102204							
JA-01380	01/17/2011	Janssen Training & Development Material Review	JAN-MS-00102578	JAN-MS-00102580							
JA-01381	12/16/2008	Janssen Training & Development Material Review	JAN-MS-00105395	JAN-MS-00105401							
JA-01382	06/05/2009	Training & Development Material Review, MRC Review Process, Ortho-McNeil Janssen Pharmaceutical Services	JAN-MS-00105719	JAN-MS-00105724							
JA-01383	06/01/2009	Janssen Presentation: OMCV Nucynta Training	JAN-MS-00106322	JAN-MS-00106392							
JA-01384	01/17/2011	Training & Development Material Review, MRC Review Process, Ortho-McNeil Janssen Pharmaceutical Services	JAN-MS-00107544	JAN-MS-00107546							
JA-01385	09/17/2009	Janssen Training & Development Material Review	JAN-MS-00107852	JAN-MS-00107855							
JA-01386	04/14/2010	Janssen Training & Development Material Review	JAN-MS-00107978	JAN-MS-00107987							
JA-01387	08/16/2010	Janssen Training & Development Material Review	JAN-MS-00109557	JAN-MS-00109559							
JA-01388	01/13/2014	Report: List of training material,	JAN-MS-00118403	JAN-MS-00118405							
JA-01389	03/31/2009	Janssen Presentation: Best Practices / Project Traps, Tapentadol Launch Training Project	JAN-MS-00126983	JAN-MS-00127002							
JA-01390	07/10/1905	Summit County Sheriff's Department Crime Statistics 2006-2018 Spreadsheet	SUMMIT_000064914	SUMMIT_000064914							
JA-01391	05/15/2018	Cuyahoga County, Medical Eaminer's Office presentation: Heroin/Fentanyl/Cocaine Related Deaths in Cuyahoga County (2017 April Update)	CLEVE_000249000	CLEVE_000249010							
JA-01392	07/10/1905	Cuyahoga County Prosecutor Crime Database 2007-2018	CUYAH_000097414	CUYAH_000097414							
JA-01393	07/08/1905	Cuyahoga County Sheriff's Office Annual Report; 2016; State of Ohio	CUYAH_000114691	CUYAH_000114743							
JA-01394	07/07/1905	Cuyahoga County Sheriff's Office Annual Report; 2015; State of Ohio	CUYAH_000120708	CUYAH_000120760							
JA-01395	07/01/2003	AGS Organizational Overview (July 2003). Discusses membership composition, history, major activities and accomplishments, and J&J sponsorship of (but no evidence of influence/control over) educational materials on urinary incontinence.	CHI_000566672	CHI_000566680							
JA-01396	08/23/2011	Email from Kate Paxton to Chartese Day	CHI_002377058	CHI_002377059							
JA-01397	08/03/2011	Email from Jeffrey Christensen to Chartese Day	CHI_002378197	CHI_002378198							
JA-01398	08/19/2011	Email from D. Dusek to Gary Eichenbaum et al.	CHI_002380257	CHI_002380258							
JA-01399	11/14/2008	Email from Greg Panico to Nithya Desikan et al.	CHI_002427878	CHI_002427878							
JA-01400	07/09/1905	Kearn's Analysis of Summit County Children Services cost categories impacted by opioids, 2012-2017	SUMMIT_000344091	SUMMIT_000344091							
JA-01401	03/09/2017	Email from Hugh Shannon to Gary Gingell et al.	CLEVE_000273471	CLEVE_000273622							
JA-01402	04/19/2018	Email from Gary Gingell to Harold Pretel et al.	CLEVE_000273938	CLEVE_000273966							
JA-01403	03/19/2018	Email from Charles Brown to Kenneth Ball et al.	AKRON_000236205	AKRON_000236205							
JA-01404	07/02/2012	Email from Ohio EMS General Announcements to ListServ	AKRON_000241989	AKRON_000241989							
JA-01405	01/01/2012	Ohio Substance Abuse Monitoring Network, Surveillance of Drug Abuse Trends in the State of Ohio, January 2011 - January 2012, OSAM-O-Gram, Ohio Department of Alcohol and Drug Addiction Services	AKRON_000241990	AKRON_000241997							
JA-01406	08/17/2016	Cuyahoga County Medical Examiner's Office, Fentanyl Bulletin 03-16	AKRON_000243583	AKRON_000243583							
JA-01407	07/07/1905	2015 Ohio Drug Overdose Data General Findings	AKRON_000271921	AKRON_000271932							
JA-01408	08/30/2017	Email from Eric Wandersleben to Gertrude Williams	AKRON_000272350	AKRON_000272353							
JA-01409	07/10/1905	Summit County Alcohol, Drug Addiction & Mental Health Services Board Cash Balance Forecast Summary 2009-2020	SUMMIT_001103655	SUMMIT_001103655							
JA-01410	07/10/1905	Cuyahoga County Revenue Source Detail by Fund Spreadsheet 2006-2017	CUYAH_001714459	CUYAH_001714459							
JA-01411	02/12/2016	Cuyahoga County Medical Examiner's Office Press Release, re: Heroin-Related Deaths Decrease for the first time since 2007; Fentanyl-Related Deaths finiah at all-time high in 2015	CUYAH_001976551	CUYAH_001976552							
JA-01412	07/10/1905	Cuyahoga County Department of Children and Family Services Removals Spreadsheet 2006-2018	CUYAH_002442182	CUYAH_002442182							
JA-01413	07/13/2016	Email from Trista Piccola to Cynthia Weiskittel	CUYAH_002479896	CUYAH_002479897							
JA-01414	07/08/1905	Comparison of SACWIS Data with PCSAO's April 2016 Survey Results	CUYAH_002479899	CUYAH_002479899							
JA-01415	07/08/1905	PCSAO Survey Instructions	CUYAH_002479900	CUYAH_002479901							
JA-01416	07/10/1905	Sheriff Jail Bookings Data 2001-2018	CUYAH_002503213	CUYAH_002503213							
JA-01417	01/11/2017	Ohio Department of Medicaid Pharmacy & Therapeutics Committee Meeting Minutes	ODM-002-0012540	ODM-002-0012549							
JA-01418	04/12/2017	Ohio Department of Medicaid Pharmacy & Therapeutics Committee Meeting Minutes	ODM-002-0012551	ODM-002-0012554							
JA-01419	07/12/2017	Ohio Department of Medicaid Pharmacy & Therapeutics Committee Meeting Minutes	ODM-002-0012556	ODM-002-0012592							
JA-01420	10/04/2017	Ohio Department of Medicaid Pharmacy & Therapeutics Committee Meeting Minutes	ODM-002-0012594	ODM-002-0012601							
JA-01421	01/11/2012	Ohio Department of Medicaid Pharmacy & Therapeutics Committee Meeting Minutes	ODM-002-0012787	ODM-002-0012789							
JA-01422	01/27/2010	Ohio Department of Medicaid Pharmacy & Therapeutics Committee Meeting Minutes	ODM-002-0012813	ODM-002-0012814							
JA-01423	04/09/2014	Ohio Department of Medicaid Pharmacy & Therapeutics Committee Meeting Minutes	ODM-002-0012836	ODM-002-0012843							
JA-01424	04/13/2011	Ohio Department of Medicaid Pharmacy & Therapeutics Committee Meeting Minutes	ODM-002-0012876	ODM-002-0012886							
JA-01425	04/13/2016	Ohio Department of Medicaid Pharmacy & Therapeutics Committee Meeting Minutes	ODM-002-0012887	ODM-002-0012892							
JA-01426	06/12/2013	Ohio Department of Medicaid Pharmacy & Therapeutics Committee Meeting Minutes	ODM-002-0013313	ODM-002-0013397							
JA-01427	06/27/2012	Ohio Department of Medicaid Pharmacy & Therapeutics Committee Meeting Minutes	ODM-002-0013398	ODM-002-0013581							
JA-01428	06/29/2011	Ohio Department of Medicaid Pharmacy & Therapeutics Committee Meeting Minutes	ODM-002-0013582	ODM-002-0013668							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-01429	07/07/2010	Ohio Department of Medicaid Pharmacy & Therapeutics Committee Meeting Minutes	ODM-002-0013669	ODM-002-0013733							
JA-01430	11/14/2017	Ohio Department of Medicaid Drug Utilization Review Board Meeting Minutes	ODM-002-0013794	ODM-002-0013795							
JA-01431	09/15/2015	Ohio Department of Medicaid Drug Utilization Review Board Meeting Minutes	ODM-002-0013804	ODM-002-0013805							
JA-01432	02/16/2016	Ohio Department of Medicaid Drug Utilization Review Board Meeting Minutes	ODM-002-0013806	ODM-002-0013807							
JA-01433	05/17/2016	Ohio Department of Medicaid Drug Utilization Review Board Meeting Minutes	ODM-002-0013808	ODM-002-0013809							
JA-01434	05/08/2012	Ohio Department of Medicaid Drug Utilization Review Board Meeting Minutes	ODM-002-0013831	ODM-002-0013850							
JA-01435	05/19/2010	Ohio Department of Medicaid Drug Utilization Review Board Meeting Minutes	ODM-002-0013854	ODM-002-0013856							
JA-01436	05/19/2015	Ohio Department of Medicaid Drug Utilization Review Board Meeting Minutes	ODM-002-0013857	ODM-002-0013874							
JA-01437	05/21/2013	Ohio Department of Job and Family Services Drug Utilization Review Board Meeting Minutes	ODM-002-0013877	ODM-002-0013886							
JA-01438	09/15/2010	Ohio Department of Job and Family Services Drug Utilization Review Board Meeting Minutes	ODM-002-0013890	ODM-002-0013892							
JA-01439	09/16/2014	Ohio Department of Medicaid Drug Utilization Review Board Meeting Minutes	ODM-002-0013893	ODM-002-0013894							
JA-01440	11/13/2012	Ohio Department of Job and Family Services Drug Utilization Review Board Meeting Minutes	ODM-002-0013898	ODM-002-0013899							
JA-01441	11/15/2011	Ohio Department of Job and Family Services Drug Utilization Review Board Meeting Minutes	ODM-002-0013900	ODM-002-0013902							
JA-01442	11/18/2014	Ohio Department of Medicaid Drug Utilization Review Board Meeting Minutes	ODM-002-0013905	ODM-002-0013906							
JA-01443	11/19/2013	Ohio Department of Medicaid Drug Utilization Review Board Meeting Minutes	ODM-002-0013907	ODM-002-0013924							
JA-01444	07/01/2018	Ohio Department of Medicaid Preferred Drug List for Pharmacy Benefit Management Program	ODM-002-0013925	ODM-002-0014038							
JA-01445	04/01/2017	Ohio Department of Medicaid Preferred Drug List for Pharmacy Benefit Management Program	ODM-002-0014309	ODM-002-0014414							
JA-01446	07/01/2017	Ohio Department of Medicaid Preferred Drug List for Pharmacy Benefit Management Program	ODM-002-0014415	ODM-002-0014520							
JA-01447	04/01/2018	Ohio Department of Medicaid Preferred Drug List for Pharmacy Benefit Management Program	ODM-002-0014621	ODM-002-0014733							
JA-01448	01/01/2018	Ohio Department of Medicaid Preferred Drug List for Pharmacy Benefit Management Program	ODM-002-0014734	ODM-002-0014846							
JA-01449	10/01/2017	Ohio Department of Medicaid Preferred Drug List for Pharmacy Benefit Management Program	ODM-002-0014847	ODM-002-0014953							
JA-01450	10/01/2010	Ohio Department of Job and Family Services Preferred Drug List for Pharmacy Benefit Management Program	ODM-002-0014954	ODM-002-0015024							
JA-01451	10/01/2011	Ohio Department of Job and Family Services Preferred Drug List for Pharmacy Benefit Management Program	ODM-002-0015025	ODM-002-0015109							
JA-01452	12/12/1991	Order of the Ohio State Board of Pharmacy, In the Matter of Fred St. Clair	Ohio BOP 0000327	Ohio BOP 00000334							
JA-01453	07/07/1998	Settlement Agreement with the Ohio State Board of Pharmacy, In the Matter of Jerry H. Starr	Ohio BOP 00000353	Ohio BOP 00000356							
JA-01454	01/07/2007	Order of the Ohio State Board of Pharmacy, In the Matter of Frank L. Dusini	Ohio BOP 00000362	Ohio BOP 00000492							
JA-01455	04/04/2000	Order of the Ohio State Board of Pharmacy, In the Matter of Michael Popovich	Ohio BOP 00000493	Ohio BOP 00000503							
JA-01456	04/21/1997	Order of the Ohio State Board of Pharmacy, In the Matter of Anthony Savoca	Ohio BOP 00000690	Ohio BOP 00000701							
JA-01457	01/09/2001	Order of the Ohio State Board of Pharmacy, In the Matter of Dennis L. Carey	Ohio BOP 00001006	Ohio BOP 00001020							
JA-01458	02/03/2009	Order of the Ohio State Board of Pharmacy, In the Matter of Steven Holtel	Ohio BOP 00002012	Ohio BOP 00002215							
JA-01459	04/06/2015	Order of the Ohio State Board of Pharmacy, In the Matter of	Ohio BOP 00002267	Ohio BOP 00002272							
JA-01460	01/09/2008	Ohio State Medical Board Agenda, Meeting Minutes, and Exhibits	Ohio_State_Medical_Board_00000003	Ohio_State_Medical_Board_00000829							
JA-01461	02/13/2008	Ohio State Medical Board Agenda, Meeting Minutes, and Exhibits	Ohio_State_Medical_Board_00000830	Ohio_State_Medical_Board_00002225							
JA-01462	03/12/2008	Ohio State Medical Board Agenda, Meeting Minutes, and Exhibits	Ohio_State_Medical_Board_00002226	Ohio_State_Medical_Board_00003768							
JA-01463	04/09/2008	Ohio State Medical Board Agenda, Meeting Minutes, and Exhibits	Ohio_State_Medical_Board_00003769	Ohio_State_Medical_Board_00005248							
JA-01464	05/14/2008	Ohio State Medical Board Agenda, Meeting Minutes, and Exhibits	Ohio_State_Medical_Board_00005249	Ohio_State_Medical_Board_00006564							
JA-01465	06/11/2008	Ohio State Medical Board Agenda, Meeting Minutes, and Exhibits	Ohio_State_Medical_Board_00006565	Ohio_State_Medical_Board_00007728							
JA-01466	07/09/2008	Ohio State Medical Board Agenda, Meeting Minutes, and Exhibits	Ohio_State_Medical_Board_00007729	Ohio_State_Medical_Board_00009059							
JA-01467	08/13/2008	Ohio State Medical Board Agenda, Meeting Minutes, and Exhibits	Ohio_State_Medical_Board_00009060	Ohio_State_Medical_Board_00012583							
JA-01468	09/10/2018	Ohio State Medical Board Agenda, Meeting Minutes, and Exhibits	Ohio_State_Medical_Board_00012584	Ohio_State_Medical_Board_00014071							
JA-01469	10/08/2008	Ohio State Medical Board Agenda, Meeting Minutes, and Exhibits	Ohio_State_Medical_Board_00014072	Ohio_State_Medical_Board_00015193							
JA-01470	11/12/2008	Ohio State Medical Board Agenda, Meeting Minutes, and Exhibits	Ohio_State_Medical_Board_00015194	Ohio_State_Medical_Board_00016486							
JA-01471	12/10/2008	Ohio State Medical Board Agenda, Meeting Minutes, and Exhibits	Ohio_State_Medical_Board_00016487	Ohio_State_Medical_Board_00017928							
JA-01472	01/14/2009	Ohio State Medical Board Agenda, Meeting Minutes, and Exhibits	Ohio_State_Medical_Board_00017929	Ohio_State_Medical_Board_00018961							
JA-01473	02/11/2009	Ohio State Medical Board Agenda, Meeting Minutes, and Exhibits	Ohio_State_Medical_Board_00018962	Ohio_State_Medical_Board_00020860							
JA-01474	03/11/2009	Ohio State Medical Board Agenda, Meeting Minutes, and Exhibits	Ohio_State_Medical_Board_00020861	Ohio_State_Medical_Board_00023024							
JA-01475	04/08/2009	Ohio State Medical Board Agenda, Meeting Minutes, and Exhibits	Ohio_State_Medical_Board_00023025	Ohio_State_Medical_Board_00024273							
JA-01476	05/13/2009	Ohio State Medical Board Agenda, Meeting Minutes, and Exhibits	Ohio_State_Medical_Board_00024274	Ohio_State_Medical_Board_00026404							
JA-01477	06/10/2009	Ohio State Medical Board Agenda, Meeting Minutes, and Exhibits	Ohio_State_Medical_Board_00026405	Ohio_State_Medical_Board_00028422							
JA-01478	07/08/2009	Ohio State Medical Board Agenda, Meeting Minutes, and Exhibits	Ohio_State_Medical_Board_00028423	Ohio_State_Medical_Board_00029515							
JA-01479	08/12/2009	Ohio State Medical Board Agenda, Meeting Minutes, and Exhibits	Ohio_State_Medical_Board_00029516	Ohio_State_Medical_Board_00031039							
JA-01480	09/09/2009	Ohio State Medical Board Agenda, Meeting Minutes, and Exhibits	Ohio_State_Medical_Board_00031040	Ohio_State_Medical_Board_00032732							
JA-01481	10/14/2009	Ohio State Medical Board Agenda, Meeting Minutes, and Exhibits	Ohio_State_Medical_Board_00032733	Ohio_State_Medical_Board_00034117							
JA-01482	11/12/2009	Ohio State Medical Board Agenda, Meeting Minutes, and Exhibits	Ohio_State_Medical_Board_00034118	Ohio_State_Medical_Board_00035279							
JA-01483	12/09/2009	Ohio State Medical Board Agenda, Meeting Minutes, and Exhibits	Ohio_State_Medical_Board_00035280	Ohio_State_Medical_Board_00037274							
JA-01484	01/13/2010	Ohio State Medical Board Agenda, Meeting Minutes, and Exhibits	Ohio_State_Medical_Board_00037275	Ohio_State_Medical_Board_00038879							
JA-01485	03/10/2010	Ohio State Medical Board Agenda, Meeting Minutes, and Exhibits	Ohio_State_Medical_Board_00038880	Ohio_State_Medical_Board_00040492							
JA-01486	04/14/2010	Ohio State Medical Board Agenda, Meeting Minutes, and Exhibits	Ohio_State_Medical_Board_00040493	Ohio_State_Medical_Board_00041152							
JA-01487	05/12/2010	Ohio State Medical Board Agenda, Meeting Minutes, and Exhibits	Ohio_State_Medical_Board_00041153	Ohio_State_Medical_Board_00041985							
JA-01488	06/09/2010	Ohio State Medical Board Agenda, Meeting Minutes, and Exhibits	Ohio_State_Medical_Board_00041986	Ohio_State_Medical_Board_00042380							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-01549	07/08/2015	Ohio State Medical Board Agenda, Meeting Minutes, and Exhibits	Ohio_State_Medical_Board_00076761	Ohio_State_Medical_Board_00077213							
JA-01550	08/12/2015	Ohio State Medical Board Agenda, Meeting Minutes, and Exhibits	Ohio_State_Medical_Board_00077214	Ohio_State_Medical_Board_00077634							
JA-01551	09/09/2015	Ohio State Medical Board Agenda, Meeting Minutes, and Exhibits	Ohio_State_Medical_Board_00077635	Ohio_State_Medical_Board_00078160							
JA-01552	10/14/2015	Ohio State Medical Board Agenda, Meeting Minutes, and Exhibits	Ohio_State_Medical_Board_00078161	Ohio_State_Medical_Board_00078676							
JA-01553	11/04/2015	Ohio State Medical Board Agenda, Meeting Minutes, and Exhibits	Ohio_State_Medical_Board_00078677	Ohio_State_Medical_Board_00079014							
JA-01554	12/09/2015	Ohio State Medical Board Agenda, Meeting Minutes, and Exhibits	Ohio_State_Medical_Board_00079015	Ohio_State_Medical_Board_00079442							
JA-01555	01/13/2016	Ohio State Medical Board Agenda, Meeting Minutes, and Exhibits	Ohio_State_Medical_Board_00079443	Ohio_State_Medical_Board_00079876							
JA-01556	02/10/2016	Ohio State Medical Board Agenda, Meeting Minutes, and Exhibits	Ohio_State_Medical_Board_00079877	Ohio_State_Medical_Board_00080122							
JA-01557	03/09/2016	Ohio State Medical Board Agenda, Meeting Minutes, and Exhibits	Ohio_State_Medical_Board_00080123	Ohio_State_Medical_Board_00080693							
JA-01558	04/13/2016	Ohio State Medical Board Agenda, Meeting Minutes, and Exhibits	Ohio_State_Medical_Board_00080694	Ohio_State_Medical_Board_00080959							
JA-01559	05/11/2016	Ohio State Medical Board Agenda, Meeting Minutes, and Exhibits	Ohio_State_Medical_Board_00080960	Ohio_State_Medical_Board_00081621							
JA-01560	06/08/2016	Ohio State Medical Board Agenda, Meeting Minutes, and Exhibits	Ohio_State_Medical_Board_00081622	Ohio_State_Medical_Board_00081923							
JA-01561	07/13/2016	Ohio State Medical Board Agenda, Meeting Minutes, and Exhibits	Ohio_State_Medical_Board_00081924	Ohio_State_Medical_Board_00082356							
JA-01562	08/102016	Ohio State Medical Board Agenda, Meeting Minutes, and Exhibits	Ohio_State_Medical_Board_00082357	Ohio_State_Medical_Board_00082714							
JA-01563	09/14/2016	Ohio State Medical Board Agenda, Meeting Minutes, and Exhibits	Ohio_State_Medical_Board_00082715	Ohio_State_Medical_Board_00083058							
JA-01564	10/19/2016	Ohio State Medical Board Agenda, Meeting Minutes, and Exhibits	Ohio_State_Medical_Board_00083059	Ohio_State_Medical_Board_00083376							
JA-01565	11/09/2016	Ohio State Medical Board Agenda, Meeting Minutes, and Exhibits	Ohio_State_Medical_Board_00083377	Ohio_State_Medical_Board_00083740							
JA-01566	12/14/2016	Ohio State Medical Board Agenda, Meeting Minutes, and Exhibits	Ohio_State_Medical_Board_00083741	Ohio_State_Medical_Board_00084018							
JA-01567	01/11/2017	Ohio State Medical Board Agenda, Meeting Minutes, and Exhibits	Ohio_State_Medical_Board_00084019	Ohio_State_Medical_Board_00084508							
JA-01568	02/08/2017	Ohio State Medical Board Agenda, Meeting Minutes, and Exhibits	Ohio_State_Medical_Board_00084509	Ohio_State_Medical_Board_00084809							
JA-01569	03/08/2017	Ohio State Medical Board Agenda, Meeting Minutes, and Exhibits	Ohio_State_Medical_Board_00084810	Ohio_State_Medical_Board_00085068							
JA-01570	04/12/2017	Ohio State Medical Board Agenda, Meeting Minutes, and Exhibits	Ohio_State_Medical_Board_00085069	Ohio_State_Medical_Board_00085568							
JA-01571	04/13/2017	Ohio State Medical Board Board Retreat Agenda, Meeting Minutes	Ohio_State_Medical_Board_00085569	Ohio_State_Medical_Board_00085577							
JA-01572	05/10/2017	Ohio State Medical Board Agenda, Meeting Minutes, and Exhibits	Ohio_State_Medical_Board_00085578	Ohio_State_Medical_Board_00085919							
JA-01573	07/12/2017	Ohio State Medical Board Agenda, Meeting Minutes, and Exhibits	Ohio_State_Medical_Board_00086291	Ohio_State_Medical_Board_00086902							
JA-01574	08/09/2017	Ohio State Medical Board Agenda, Meeting Minutes, and Exhibits	Ohio_State_Medical_Board_00086903	Ohio_State_Medical_Board_00087497							
JA-01575	09/13/2017	Ohio State Medical Board Agenda, Meeting Minutes, and Exhibits	Ohio_State_Medical_Board_00087498	Ohio_State_Medical_Board_00088090							
JA-01576	10/11/2017	Ohio State Medical Board Agenda, Meeting Minutes, and Exhibits	Ohio_State_Medical_Board_00088091	Ohio_State_Medical_Board_00088368							
JA-01577	11/08/2017	Ohio State Medical Board Agenda, Meeting Minutes, and Exhibits	Ohio_State_Medical_Board_00088369	Ohio_State_Medical_Board_00088708							
JA-01578	12/13/2017	Ohio State Medical Board Agenda, Meeting Minutes, and Exhibits	Ohio_State_Medical_Board_00088709	Ohio_State_Medical_Board_00089027							
JA-01579	07/11/2018	Ohio State Medical Board Agenda, Meeting Minutes, and Exhibits	Ohio_State_Medical_Board_00089028	Ohio_State_Medical_Board_00089409							
JA-01580	01/10/2018	Ohio State Medical Board Agenda, Meeting Minutes, and Exhibits	Ohio_State_Medical_Board_00089410	Ohio_State_Medical_Board_00089678							
JA-01581	02/14/2018	Ohio State Medical Board Agenda, Meeting Minutes, and Exhibits	Ohio_State_Medical_Board_00089679	Ohio_State_Medical_Board_00089900							
JA-01582	03/14/2018	Ohio State Medical Board Agenda, Meeting Minutes, and Exhibits	Ohio_State_Medical_Board_00089901	Ohio_State_Medical_Board_00090139							
JA-01583	04/11/2018	Ohio State Medical Board Agenda, Meeting Minutes, and Exhibits	Ohio_State_Medical_Board_00090140	Ohio_State_Medical_Board_00090869							
JA-01584	05/09/2018	Ohio State Medical Board Agenda, Meeting Minutes, and Exhibits	Ohio_State_Medical_Board_00090870	Ohio_State_Medical_Board_00091142							
JA-01585	06/13/2018	Ohio State Medical Board Agenda, Meeting Minutes, and Exhibits	Ohio_State_Medical_Board_00091143	Ohio_State_Medical_Board_00091474							
JA-01586	08/13/2018	Ohio State Medical Board Prescribing Resources	Ohio_State_Medical_Board_00091475	Ohio_State_Medical_Board_00091762							
JA-01587	02/01/2008	Ohio State Medical Board Formal Action Report	Ohio_State_Medical_Board_00092504	Ohio_State_Medical_Board_00092586							
JA-01588	02/18/2009	Ohio State Medical Board Formal Action Report	Ohio_State_Medical_Board_00092587	Ohio_State_Medical_Board_00092677							
JA-01589	03/08/2010	Ohio State Medical Board Formal Action Report	Ohio_State_Medical_Board_00092678	Ohio_State_Medical_Board_00092763							
JA-01590	02/22/2011	Ohio State Medical Board Formal Action Report	Ohio_State_Medical_Board_00092764	Ohio_State_Medical_Board_00092866							
JA-01591	02/02/2012	Ohio State Medical Board Formal Action Report	Ohio_State_Medical_Board_00092867	Ohio_State_Medical_Board_00092975							
JA-01592	01/18/2013	Ohio State Medical Board Formal Action Report	Ohio_State_Medical_Board_00092976	Ohio_State_Medical_Board_00093094							
JA-01593	01/29/2014	Ohio State Medical Board Formal Action Report	Ohio_State_Medical_Board_00093095	Ohio_State_Medical_Board_00093213							
JA-01594	02/17/2015	Ohio State Medical Board Formal Action Report	Ohio_State_Medical_Board_00093214	Ohio_State_Medical_Board_00093330							
JA-01595	02/11/2016	Ohio State Medical Board Formal Action Report	Ohio_State_Medical_Board_00093331	Ohio_State_Medical_Board_00093439							
JA-01596	02/24/2017	Ohio State Medical Board Formal Action Report	Ohio_State_Medical_Board_00093440	Ohio_State_Medical_Board_00093530							
JA-01597	02/12/2018	Ohio State Medical Board Formal Action Report	Ohio_State_Medical_Board_00093531	Ohio_State_Medical_Board_00093579							
JA-01598	2007-2015	OSMB Your Report From the State Medical Board of Ohio	Ohio_State_Medical_Board_00093580	Ohio_State_Medical_Board_00093803							
JA-01599	07/09/1905	The State Medical Board of Ohio Board Actions	Ohio_State_Medical_Board_00098231	Ohio_State_Medical_Board_00098257							
JA-01600	07/10/1905	The State Medical Board of Ohio Board Actions	Ohio_State_Medical_Board_00098258	Ohio_State_Medical_Board_00098269							
JA-01601	06/30/1905	The State Medical Board of Ohio Disciplinary Sanctions	Ohio_State_Medical_Board_00098270	Ohio_State_Medical_Board_00098300							
JA-01602	07/02/1905	The State Medical Board of Ohio Disciplinary Sanctions	Ohio_State_Medical_Board_00098301	Ohio_State_Medical_Board_00098324							
JA-01603	07/01/1905	The State Medical Board of Ohio Disciplinary Sanctions	Ohio_State_Medical_Board_00098325	Ohio_State_Medical_Board_00098352							
JA-01604	07/03/1905	The State Medical Board of Ohio Disciplinary Sanctions	Ohio_State_Medical_Board_00098353	Ohio_State_Medical_Board_00098384							
JA-01605	07/04/1905	The State Medical Board of Ohio Disciplinary Sanctions	Ohio_State_Medical_Board_00098385	Ohio_State_Medical_Board_00098415							
JA-01606	07/05/1905	The State Medical Board of Ohio Disciplinary Sanctions	Ohio_State_Medical_Board_00098416	Ohio_State_Medical_Board_00098444							
JA-01607	07/08/1905	The State Medical Board of Ohio Disciplinary Sanctions	Ohio_State_Medical_Board_00098445	Ohio_State_Medical_Board_00098471							
JA-01608	07/06/1905	The State Medical Board of Ohio Disciplinary Sanctions	Ohio_State_Medical_Board_00098472	Ohio_State_Medical_Board_00098491							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-01609	07/07/1905	The State Medical Board of Ohio Disciplinary Sanctions	Ohio_State_Medical_Board_00098492	Ohio_State_Medical_Board_00098515							
JA-01610	06/30/1905	Ohio State Medical Board Annual Reports, Years 2008 -2018	Ohio_State_Medical_Board_00100791	Ohio_State_Medical_Board_00101036							
JA-01611	05/31/2017	Correspondence from American Association of Nurse Practitioners to J&J, thanking J&J for membership on Corporate Council	AANP 0001824	AANP 0001825							
JA-01612	No Date	AAPA Press Release, re: Physician assistant foundation awards two \$25,000 Johnson & Johnson scholarships to underrepresented minority students	AAPA0000481	AAPA0000481							
JA-01613	06/01/2013	University of Wisconsin Pain & Policy Studies Group (2012) publication entitled "Achieving Balance in Federal and State Pain Policy: A Guide to Evaluation." The document, which was sponsored by the American Cancer Society, will help legitimize PPSG.	WIS_PPSG_004248	WIS_PPSG_004248							
JA-01614	07/01/2013	FSMB's Model Policy on the Use of Opioid Analgesics in the Treatment of Chronic Pain. The Policy notes that the DEA, National Associations of State Controlled Substances Authorities, and the 57 of 70 State Medical Boards have endorsed FSMB's Model Guidelines. This will help legitimize FSMB.	WIS_PPSG_015646	WIS_PPSG_015646							
JA-01615	05/23/2017	Email from Hugh Shannon to Redacted Recipients	CLEVE_001504363	CLEVE_001504364							
JA-01616	05/25/2017	Thomas P. Gilson, MD, Final Drug Deaths Report, Cuyahoga County Medical Examiners Office, 2017	CLEVE_001504365	CLEVE_001504388							
JA-01617	06/15/2015	Ohio HIDTA: Threat Assessment & Strategy (Program Year 2015)	CLEVE_001506114	CLEVE_001506171							
JA-01618	03/01/2009	Nucynta Label (2009)	JAN-MS-03088062	JAN-MS-03088087							
JA-01619	07/01/2013	Nucynta Label (07-2013)	JAN-MS-03088093	JAN-MS-03088120							
JA-01620	10/01/2013	Nucynta Label (10-2013)	JAN-MS-03088124	JAN-MS-03088151							
JA-01621	07/01/2012	Nucynta ER Label (07-2012)	JAN-MS-03088245	JAN-MS-03088279							
JA-01622	04/01/2014	Nucynta ER Label (2014)	JAN-MS-03088328	JAN-MS-03088362							
JA-01623	01/01/2003	Duragesic, Fentanyl Transdermal System, Full Prescribing Information, 2003	JAN-MS-03088363	JAN-MS-03088390							
JA-01624	07/01/2009	Duragesic CII, Fentanyl Transdermal System), Full Prescribing Information, 2009	JAN-MS-03088395	JAN-MS-03088440							
JA-01625	07/01/2012	Full Prescribing Information, Duragesic, 2012	JAN-MS-03088496	JAN-MS-03088538							
JA-01626	11/01/2010	Nucynta Label (2010)	JAN-MS-03088542	JAN-MS-03088567							
JA-01627	06/27/1905	Duragesic, Fentanyl Transdermal System, Full Prescribing Information, Janssen, 2005	JAN-MS-03089240	JAN-MS-03089287							
JA-01628	12/01/2016	Duragesic Fentanyl Transdermal System, Full Prescribing Information, Janssen, 2016	JAN-MS-03089292	JAN-MS-03089347							
JA-01629	08/01/1993	Duragesic Label: Full Prescribing Information, March 1993, August 1993	JAN-MS-03089370	JAN-MS-03089381							
JA-01630	06/01/1994	Duragesic Label: Full Prescribing Information, January 1994, June 1994	JAN-MS-03089382	JAN-MS-03089393							
JA-01631	11/01/1999	Duragesic Label, Full Prescribing Information, April 1998, November 1999	JAN-MS-03089394	JAN-MS-03089401							
JA-01632	01/01/1994	Duragesic Label, Full Prescribing Information, August 1993, January 1994	JAN-MS-03089407	JAN-MS-03089418							
JA-01633	04/12/2000	Letter from Janssen to DDMAC re: 03/30/2000 Untitled Letter	JAN-MS-03090751	JAN-MS-03090751							
JA-01634	03/05/1998	Untitled Letter from DDMAC to Janssen re: Duragesic	JAN-MS-03090752	JAN-MS-03090754							
JA-01635	04/08/1998	Letter from Janssen to DDMAC re: 03/05/1998 Untitled Letter	JAN-MS-03090852	JAN-MS-03090858							
JA-01636	07/10/1905	Cuyahoga Prosecutor Database 2005-2017	CUYAH_014627783	CUYAH_014627783							
JA-01637	01/28/1998	Ohio State Dental Board Compliance/ Investigation File re: D. Specht, DDS	OSDB_MDL 1st Production_001620	OSDB_MDL 1st Production_001627							
JA-01638	11/04/2004	Ohio State Dental Board Compliance/ Investigation File re: N. Tomasi, DDS	OSDB_MDL 1st Production_003050	OSDB_MDL 1st Production_003063							
JA-01639	06/02/2004	Ohio State Dental Board Compliance/ Investigation File re: H. Woith, DDS	OSDB_MDL 1st Production_005081	OSDB_MDL 1st Production_005088							
JA-01640	11/03/2004	Ohio State Dental Board Compliance/ Investigation File re: N. Zagunis, DDS (Cuy Cty)	OSDB_MDL 1st Production_006838	OSDB_MDL 1st Production_006845							
JA-01641	07/01/1997	Ohio State Dental Board Compliance/ Investigation File re: K. Bram, DDS	OSDB_MDL 1st Production_007368	OSDB_MDL 1st Production_007451							
JA-01642	05/27/2014	Ohio State Dental Board Compliance/ Investigation File re: C. Schmidt, DDS (Cuy Cty)	OSDB_MDL 1st Production_008648	OSDB_MDL 1st Production_008687							
JA-01643	01/07/2004	Ohio State Dental Board Compliance/ Investigation File re: S. Province, DDS	OSDB_MDL 1st Production_008797	OSDB_MDL 1st Production_008815							
JA-01644	04/23/2014	Ohio State Dental Board Meeting Minutes	OSDB_MDL 1st Production_000026	OSDB_MDL 1st Production_000079							
JA-01645	06/25/2014	Ohio State Dental Board Meeting Minutes	OSDB_MDL 1st Production_011720	OSDB_MDL 1st Production_011747							
JA-01646	11/07/2012	Ohio State Dental Board Meeting Minutes	OSDB_MDL 1st Production_000080	OSDB_MDL 1st Production_000109							
JA-01647	02/07/2018	Ohio State Dental Board Meeting Minutes	OSDB_MDL 1st Production_000110	OSDB_MDL 1st Production_000148							
JA-01648	04/11/2012	Ohio State Dental Board Meeting Minutes	OSDB_MDL 1st Production_011886	OSDB_MDL 1st Production_011917							
JA-01649	07/27/2016	Ohio State Dental Board Meeting Minutes	OSDB_MDL 1st Production_012072	OSDB_MDL 1st Production_012118							
JA-01650	05/15/2013	Ohio State Dental Board Meeting Minutes	OSDB_MDL 1st Production_013065	OSDB_MDL 1st Production_013084							
JA-01651	05/23/2012	Ohio State Dental Board Meeting Minutes	OSDB_MDL 1st Production_013157	OSDB_MDL 1st Production_013186							
JA-01652	11/01/2008	Ohio Board of Nursing Compliance/Investigation Files	OBN_MDL 1st Production 000001	OBN_MDL 1st Production 001827							
JA-01653	04/17/2015	RADARS System Report, 2014 Annual Data, Fentanyl Data, Janssen Scientific Affairs, LLC	DenverHealth_015635	DenverHealth_015840							
JA-01654	04/13/2015	RADARS System Report, 4th Quarter 2014 Annual Data, Fentanyl Data, Janssen Scientific Affairs, LLC	DenverHealth_016044	DenverHealth_016250							
JA-01655	05/01/2018	Ohio State Dental Board E-Bulletin	OSDB_MDL 2nd Production 013779	OSDB_MDL 2nd Production 013787							
JA-01656	07/01/2011	Ohio Board of Nursing Momentum Magazine	OBN_MDL_0219675	OBN_MDL_0219706							
JA-01657	07/01/2007	Ohio Board of Nursing Momentum Magazine	OBN_MDL_0236039	OBN_MDL_0236065							
JA-01658	07/01/2010	Ohio Board of Nursing Momentum Magazine	OBN_MDL_0236636	OBN_MDL_0236659							
JA-01659	07/01/2013	Ohio Board of Nursing Momentum Magazine	OBN_MDL_0236813	OBN_MDL_0236844							
JA-01660	01/01/2013	Ohio Board of Nursing Momentum Magazine	OBN_MDL_0236965	OBN_MDL_0236996							
JA-01661	07/01/2012	Ohio Board of Nursing Momentum Magazine	OBN_MDL_0237025	OBN_MDL_0237056							
JA-01662	10/01/2013	Ohio Board of Nursing Momentum Magazine	OBN_MDL_0237121	OBN_MDL_0237152							
JA-01663	10/01/2011	Ohio Board of Nursing Momentum Magazine	OBN_MDL_0237185	OBN_MDL_0237216							
JA-01664	01/01/2011	Ohio Board of Nursing Momentum Magazine	OBN_MDL_0237313	OBN_MDL_0237336							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-01665	01/01/2019	Summit County Children Services Board Historical Revneues and Expenditures 2006-2018	SUMMIT_002054603	SUMMIT_002054603							
JA-01666	12/31/2018	Summit County Children Services Operating Forecast	SUMMIT_002057610	SUMMIT_002057610							
JA-01667	12/312014	Summit County Children Services Carry Forward Analysis	SUMMIT_002057852	SUMMIT_002057852							
JA-01668	06/30/1905	Summit County Children Services Carry Forward Analysis	SUMMIT_002058218	SUMMIT_002058218							
JA-01669	07/01/2013	Email from Ron Kuntz to Michelle Dempsey	JAN-MS-04201134	JAN-MS-04201134							
JA-01670	07/07/1905	National Diversion Survey Annual Report (January 1, 2015 - December 31, 2015)	CLEVE_002518251	CLEVE_002518287							
JA-01671	05/24/2012	Email from Katherine Cruz to Mark Adams et al.	CLEVE_002599515	CLEVE_002599517							
JA-01672	05/01/2012	Office of the Ohio Attorney General, Ohio Bureau of Criminal Investigation re: Heroin In Ohio: "Falling Out of the Sky."	CLEVE_002599518	CLEVE_002599540							
JA-01673	03/28/2018	Email from Gary Gingell to Matthew Baeppler	CLEVE_002609714	CLEVE_002609714							
JA-01674	09/29/2016	CDP Heroin/Fentanyl Strategy	CLEVE_002715524	CLEVE_002715528							
JA-01675	06/15/2016	OH HIDTA: Threat Assessment & Strategy (Program Year 2016)	CLEVE_002715831	CLEVE_002715893							
JA-01676	06/22/2013	Combating Pharmaceutical Diversion: Targeting "Rogue Pain Clinics" & "Pill Mills"	US-DEA-00001434	US-DEA-00001434							
JA-01677	06/15/2016	OH HIDTA: Program Year 2015 Annual Report (Ohio)	CLEVE_004063977	CLEVE_004064021							
JA-01678	05/05/2017	Email from Edna Orozco to Jennifer Ciaccia	CLEVE_003969859	CLEVE_003969860							
JA-01679	07/19/2018	Email from Zina Martinez to Dornat Drummond et al.	CLEVE_003976656	CLEVE_003976657							
JA-01680	06/01/2018	Ohio Attorney General's Office - Bureau of Criminal Investigation (BCI) re: Quarterly Laboratory Drug Cases Report - Q2 2018	CLEVE_003976658	CLEVE_003976659							
JA-01681	08/01/2018	Fentanyl Proliferation Worsens Cocaine Comeback's Effects by Fueling Overdose Deaths	CLEVE_003976891	CLEVE_003976907							
JA-01682	02/28/2018	Email from Ohio Department of Health to Persis Sosiak	CLEVE_004245092	CLEVE_004245096							
JA-01683	10/01/2005	Ohio Department of Job and Family Services Preferred Drug List for Pharmacy Benefit Management Program	ODM_035447	ODM_035465							
JA-01684	10/01/2007	Ohio Department of Job and Family Services Preferred Drug List for Pharmacy Benefit Management Program	ODM_035769	ODM_035789							
JA-01685	10/01/2009	Ohio Department of Job and Family Services Preferred Drug List for Pharmacy Benefit Management Program	ODM_035863	ODM_035935							
JA-01686	10/01/2008	Ohio Department of Job and Family Services Preferred Drug List for Pharmacy Benefit Management Program	ODM_036009	ODM_036076							
JA-01687	11/11/2015	Ohio Department of Medicaid SmartPA Criteria Proposal for Medication Assisted Treatment of Opioid Addiction	ODM_036377	ODM_036389							
JA-01688	03/04/2010	Ohio Medicaid Pharmacy Prior Authorization List	ODM_036504	ODM_036504							
JA-01689	09/01/2010	Draft Letter from Jill RK Griffith & Margaret Scott to Opiate Physicians	ODM_038660	ODM_038660							
JA-01690	07/29/2010	Letter from Margaret A. Scott to Michael C. Barnes	ODM_038848	ODM_038848							
JA-01691	11/09/2015	Ohio Department of Medicaid SmartPA Criteria Proposal for Opioids	ODM_038869	ODM_038902							
JA-01692	10/01/2015	Ohio Department of Medicaid Comments on Sprague Draft Opioid Legislation	ODM_038964	ODM_038966							
JA-01693	01/22/2016	Ohio Department of Medicaid SmartPA Criteria Proposal for Opioids	ODM_038967	ODM_039001							
JA-01694	09/01/2007	Ohio Medicaid Pharmacy and Therapeutics Committee Therapeutic Class Review Summary	ODM_039078	ODM_039080							
JA-01695	09/01/2012	DUR Program Drug Utilization Review of Duplicative Long-Acting Opiate Use	ODM_039326	ODM_039327							
JA-01696	03/01/2019	Envolve Pharmacy Solutions Comprehensive Preferred Drug List for the Buckeye Health Plan	Buckeye_000020	Buckeye_000235							
JA-01697	07/11/1905	Summit County Child Services Board Removals Spreadsheet 2006-2019	SUMMIT_002103952	SUMMIT_002103952							
JA-01698	07/06/1905	OptumRx Your 2014 Prescription Drug List	OPTUMRX-OPI-JJ00000029	OPTUMRX-OPI-JJ00000056							
JA-01699	07/07/1905	OptumRx Your 2015 Prescription Drug List	OPTUMRX-OPI-JJ00000225	OPTUMRX-OPI-JJ00000252							
JA-01700	01/01/2016	OptumRx Your 2016 Prescription Drug List	OPTUMRX-OPI-JJ00000533	OPTUMRX-OPI-JJ00000560							
JA-01701	11/07/2017	Correspondence from Janssen Consumer Council to American Chronic Pain Association, agreeing to sponsorship.	ACPA_MDL_000000059	ACPA_MDL_000000059.0004							
JA-01702	08/25/2016	JCAHO, Joint Commission Health Care Association Forum booklet. Discusses JCAHO's functions, personnel, accomplishments, etc., many of which have nothing to do with opioids or even pain care. This document will help legitimize JCAHO.	AAPA_MDL_000000692	AAPA_MDL_000000692.0411							
JA-01703	03/05/2011	NAVIPPRO Drug Abuse Surveillance Report Q4 2010	JAN-MS-00008999	JAN-MS-00009045							
JA-01704	09/02/2011	NAVIPPRO Surveillance Report Q2 2011	JAN-MS-00009046	JAN-MS-00009103							
JA-01705	12/06/2011	NAVIPPRO Surveillance Report Q3 2011	JAN-MS-00009104	JAN-MS-00009169							
JA-01706	03/07/2012	NAVIPPRO Surveillance Report Q4 2011	JAN-MS-00009170	JAN-MS-00009237							
JA-01707	06/10/2011	NAVIPPRO Surveillance Report Q1 2011	JAN-MS-00009238	JAN-MS-00009295							
JA-01708	11/07/2012	NAVIPPRO Surveillance Report P2 2012	JAN-MS-00009296	JAN-MS-00009409							
JA-01709	03/06/2013	NAVIPPRO Surveillance Report P3 2012	JAN-MS-00009410	JAN-MS-00009530							
JA-01710	07/03/2012	NAVIPPRO Surveillance Report P1 2012	JAN-MS-00009531	JAN-MS-00009620							
JA-01711	07/25/2013	NAVIPPRO Surveillance Report P1 2013	JAN-MS-00009621	JAN-MS-00009742							
JA-01712	11/04/2013	NAVIPPRO Surveillance Report P2 2013	JAN-MS-00009743	JAN-MS-00009862							
JA-01713	03/07/2014	NAVIPPRO Surveillance Report P3 2013	JAN-MS-00009863	JAN-MS-00009984							
JA-01714	08/15/2014	NAVIPPRO Surveillance Report P1 2014	JAN-MS-00009985	JAN-MS-00010110							
JA-01715	12/09/2014	NAVIPPRO Surveillance Report P2 2014	JAN-MS-00010111	JAN-MS-00010233							
JA-01716	04/15/2015	NAVIPPRO Surveillance Report P3 2014	JAN-MS-00010234	JAN-MS-00010360							
JA-01717	10/02/2009	RADARS System Tapentadol Report (Q2 2009)	JAN-MS-00042434	JAN-MS-00042566							
JA-01718	01/05/2010	RADARS System Tapentadol Report (Q3 2009)	JAN-MS-00042567	JAN-MS-00042834							
JA-01719	04/05/2010	RADARS System Tapentadol Report (Q4 2009)	JAN-MS-00042835	JAN-MS-00043110							
JA-01720	07/01/2010	RADARS System Tapentadol Report (Q1 2010)	JAN-MS-00043111	JAN-MS-00043387							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-01721	10/04/2010	RADARS System Tapentadol Report (Q2 2010)	JAN-MS-00043388	JAN-MS-00043661							
JA-01722	01/10/2011	RADARS System Tapentadol Report (Q3 2010)	JAN-MS-00043662	JAN-MS-00043937							
JA-01723	04/05/2011	RADARS System Tapentadol Report (Q4 2010)	JAN-MS-00043938	JAN-MS-00044269							
JA-01724	04/18/2011	RADARS System Tapentadol Report (2010 Annual)	JAN-MS-00044270	JAN-MS-00044578							
JA-01725	07/08/2011	RADARS System Tapentadol Report (Q1 2011)	JAN-MS-00044579	JAN-MS-00044889							
JA-01726	10/05/2011	RADARS System Tapentadol Report (Q2 2011)	JAN-MS-00044890	JAN-MS-00045160							
JA-01727	01/09/2012	RADARS System Tapentadol Report (Q3 2011)	JAN-MS-00045161	JAN-MS-00045351							
JA-01728	04/04/2012	RADARS System Tapentadol Report (Q4 2011)	JAN-MS-00045352	JAN-MS-00045543							
JA-01729	04/17/2012	RADARS System Tapentadol Report (2011 Annual)	JAN-MS-00045544	JAN-MS-00045734							
JA-01730	07/09/2012	RADARS System Tapentadol Report (Q1 2012)	JAN-MS-00045744	JAN-MS-00045936							
JA-01731	10/01/2012	RADARS System Tapentadol Report (Q2 2012)	JAN-MS-00045937	JAN-MS-00046126							
JA-01732	01/02/2013	RADARS System Tapentadol Report (Q3 2012)	JAN-MS-00046127	JAN-MS-00046323							
JA-01733	04/03/2013	RADARS System Tapentadol Report (Q4 2012)	JAN-MS-00046324	JAN-MS-00046524							
JA-01734	08/28/2009	Training & Development Materials Review Project Cover Sheet Sign-Off Form	JAN-MS-00105725	JAN-MS-00105731							
JA-01735	11/30/2009	Application to Market a New Drug, Nucynta ER	JAN-MS-00214352	JAN-MS-00214352							
JA-01736	11/30/2009	Letter from Kathleen Dusek to Bob Rappaport	JAN-MS-00214374	JAN-MS-00214374							
JA-01737	11/24/2009	Reviewer's Guide for Tapentadol Extended-Release Tablets	JAN-MS-00214419	JAN-MS-00214419							
JA-01738	11/12/2009	Clinical Summary - Summary of Biopharmaceutic Studies and Associated Analytical Methods	JAN-MS-00214447	JAN-MS-00214447							
JA-01739	10/29/2009	Clinical Summary - Summary of Clinical Pharmacology Studies	JAN-MS-00214448	JAN-MS-00214448							
JA-01740	11/24/2009	Janssen Clinical Study Report comparing OxyContin and Tapentadol TRF	JAN-MS-00214470	JAN-MS-00214470							
JA-01741	11/24/2009	Janssen Clinical Study Report comparing OxyContin and Tapentadol TRF	JAN-MS-00214471	JAN-MS-00214471							
JA-01742	11/01/2009	Nucynta ER Tamper Resistant Formulation Summary (SUPP 1)	JAN-MS-00214472	JAN-MS-00214472							
JA-01743	11/24/2009	List of Clinical Studies for Nucynta ER NDA	JAN-MS-00214585	JAN-MS-00214585							
JA-01744	08/01/2007	Phase I Clinical Trial Report - HP5503/08/A	JAN-MS-00214586	JAN-MS-00214586							
JA-01745	03/30/2007	Phase 1 Clinical Study Report - R331333-PAI-1003 (HP5503/17)	JAN-MS-00214588	JAN-MS-00214588							
JA-01746	07/17/2007	Phase 1 Clinical Study Report - R331333-PAI-1020 (H P5503/28)	JAN-MS-00214590	JAN-MS-00214590							
JA-01747	11/08/2007	Phase 1 Clinical Study Report - R331333-PAI-1021 (HP5503/27)	JAN-MS-00214592	JAN-MS-00214592							
JA-01748	10/26/2009	Phase 1 Clinical Study Report - R331333-PAI-1047 (HP5503/62)	JAN-MS-00214594	JAN-MS-00214594							
JA-01749	08/01/2007	Phase 1 Clinical Trial Report - HP5503/12/A	JAN-MS-00214598	JAN-MS-00214598							
JA-01750	03/03/2009	Phase 1 Clinical Trial Report - HP5503/33	JAN-MS-00214600	JAN-MS-00214600							
JA-01751	02/25/2009	Phase 1 Clinical Trial Report - HP5503/52	JAN-MS-00214602	JAN-MS-00214602							
JA-01752	03/03/2009	Phase 1 Clinical Trial Report - HP5503/53	JAN-MS-00214604	JAN-MS-00214604							
JA-01753	03/09/2009	Phase I Clinical Trial Report - HP5503/54	JAN-MS-00214606	JAN-MS-00214606							
JA-01754	07/25/2007	Phase 1 Clinical Study Report - R331333-PAI-1004 (HP5503/18)	JAN-MS-00214608	JAN-MS-00214608							
JA-01755	02/20/2009	Phase 1 Clinical Study Report - R331333-PAI-1022 (HP5503/41)	JAN-MS-00214610	JAN-MS-00214610							
JA-01756	02/06/2008	Phase 1 Clinical Study Report - R331333-PAI-1023 (HP5503/36)	JAN-MS-00214612	JAN-MS-00214612							
JA-01757	04/21/2008	Phase 1 Clinical Study Report - R331333-PAI-1024 (HP5503/35)	JAN-MS-00214614	JAN-MS-00214614							
JA-01758	04/17/2009	Phase 1 Clinical Study Report - R331333-PAI-1033 (HP5503/31)	JAN-MS-00214616	JAN-MS-00214616							
JA-01759	05/14/2009	Phase 1 Clinical Study Report - R331333-PAI-1034 (HP5503/42)	JAN-MS-00214618	JAN-MS-00214618							
JA-01760	05/27/2009	Phase 1 Clinical Study Report - R331333-PAI-1037 (HP5503/57)	JAN-MS-00214620	JAN-MS-00214620							
JA-01761	07/10/2009	Phase 1 Clinical Study Report - R331333-PAI-1046 (HP5503/61)	JAN-MS-00214622	JAN-MS-00214622							
JA-01762	10/28/2009	Phase 1 Clinical Study Report - R331333-PAI-1055 (HP5503/67)	JAN-MS-00214624	JAN-MS-00214624							
JA-01763	12/02/2008	Phase 1 Clinical Study Report - R331333-PAI-1012 (HP5503/32)	JAN-MS-00214628	JAN-MS-00214628							
JA-01764	06/23/2008	Phase 1 Clinical Study Report - R331333-PAI-1025 (HP5503/29)	JAN-MS-00214630	JAN-MS-00214630							
JA-01765	06/03/2009	Phase 1 Clinical Study Report - R331333-PAI-1035 (HP5503/39)	JAN-MS-00214632	JAN-MS-00214632							
JA-01766	06/10/2009	Phase 1 Clinical Study Report - R331333-PAI-1038 (HP5503/58)	JAN-MS-00214634	JAN-MS-00214634							
JA-01767	01/30/2008	Phase 1 Clinical Study Report - R331333-PAI-10246	JAN-MS-00214647	JAN-MS-00214647							
JA-01768	04/29/2009	Phase 1 Clinical Study Report - R331333-PAI-1036 (HP5503/38)	JAN-MS-00214649	JAN-MS-00214649							
JA-01769	05/14/2009	Phase 1 Clinical Study Report - R331333-PAI-1028 (HP5503/44)	JAN-MS-00214651	JAN-MS-00214651							
JA-01770	11/03/2009	Population Pharmacokinetic Analysis of Tapentadol Extended Release	JAN-MS-00214653	JAN-MS-00214653							
JA-01771	08/01/2007	Phase 1 Clinical Trial Report HP5503/10	JAN-MS-00214654	JAN-MS-00214654							
JA-01772	02/27/2009	Phase 2B Clinical Trial Report - KF5503/09/B	JAN-MS-00214657	JAN-MS-00214657							
JA-01773	08/17/2007	Phase 2b Clinical Trial Report - KF5503/10/A	JAN-MS-00214659	JAN-MS-00214659							
JA-01774	12/07/2007	Phase 2b Clinical Study Report - R331333-PAI-2001 (HP5503/19)	JAN-MS-00214661	JAN-MS-00214661							
JA-01775	12/10/2007	Phase 2B Clinical Study Report - R331333-PAI-2002 (KF5503/20)	JAN-MS-00214664	JAN-MS-00214664							
JA-01776	01/22/2009	Phase 3 Clinical Study Report - R331333-PAI-3008 (KF5503/11)	JAN-MS-00214666	JAN-MS-00214666							
JA-01777	01/22/2009	Phase 3 Clinical Study Synopsis - R331333-PAI-3008 (KF5503/11)	JAN-MS-00214669	JAN-MS-00214669							
JA-01778	02/27/2009	Phase 3 Clinical Study Report - R331333-PAI-3009 (KF5503/12)	JAN-MS-00214670	JAN-MS-00214670							
JA-01779	02/27/2009	Phase 3 Clinical Study Synopsis - R331333-PAI-3009 (KF5503/12)	JAN-MS-00214671	JAN-MS-00214671							
JA-01780	02/12/2009	Phase 3 Clinical Study Report - R331333-PAI-3011 (KF5503/23)	JAN-MS-00214672	JAN-MS-00214672							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-01781	01/26/2009	Phase 3 Clinical Study Synopsis - R331333-PAI-3011 (KF5503/23)	JAN-MS-00214675	JAN-MS-00214675							
JA-01782	03/10/2009	Phase 3 Clinical Study Report - R331333-PAI-3015 (KF5503/36)	JAN-MS-00214676	JAN-MS-00214676							
JA-01783	03/10/2009	Phase 3 Clinical Study Synopsis - R331333-PAI-3015 (KF5503/36)	JAN-MS-00214678	JAN-MS-00214678							
JA-01784	01/27/2009	Phase 3 Clinical Study Report - R331333-PAI-3019 (KF5503/39)	JAN-MS-00214679	JAN-MS-00214679							
JA-01785	01/27/2009	Phase 3 Clinical Study Synopsis - R331333-PAI-3019 (KF5503/39)	JAN-MS-00214680	JAN-MS-00214680							
JA-01786	03/13/2009	Phase 3 Clinical Study Report - R331333-PAI-3007 (KF5503/24)	JAN-MS-00214681	JAN-MS-00214681							
JA-01787	03/13/2009	Phase 3 Clinical Study Synopsis - R331333-PAI-3007 (KF5503/24)	JAN-MS-00214682	JAN-MS-00214682							
JA-01788	08/31/2009	Clinical Summary - Summary of Clinical Efficacy	JAN-MS-00214683	JAN-MS-00214683							
JA-01789	11/09/2009	Clinical Summary - Summary of Clinical Safety	JAN-MS-00214688	JAN-MS-00214688							
JA-01790	02/05/2009	Phase 1 Clinical Study Report - R331333-PAI-1030; HP5503/50	JAN-MS-00214692	JAN-MS-00214692							
JA-01791	10/15/2008	Phase 3 Clinical Trial Report Amendment - KF5503/35/A	JAN-MS-00214694	JAN-MS-00214694							
JA-01792	10/15/2008	Phase 3 Clinical Trial Synopsis - KF5503/35/A	JAN-MS-00214695	JAN-MS-00214695							
JA-01793	05/05/2009	Phase 3 Clinical Study Report - R331333-PAI-3018 (KF5503/38)	JAN-MS-00214696	JAN-MS-00214696							
JA-01794	05/05/2009	Phase 3 Clinical Study Synopsis - R331333-PAI-3018 (KF5503/38)	JAN-MS-00214697	JAN-MS-00214697							
JA-01795	12/21/1987	Duragesic NDA 12-21-1987 VOL 10	JAN-MS-00213628	JAN-MS-00213628							
JA-01796	12/21/1987	Duragesic NDA 12-21-1987 VOL 11	JAN-MS-00213629	JAN-MS-00213629							
JA-01797	12/21/1987	Duragesic NDA 12-21-1987 VOL 12	JAN-MS-00213630	JAN-MS-00213630							
JA-01798	12/21/1987	Duragesic NDA 12-21-1987 VOL 13	JAN-MS-00213631	JAN-MS-00213631							
JA-01799	12/21/1987	Duragesic NDA 12-21-1987 VOL 14	JAN-MS-00213632	JAN-MS-00213632							
JA-01800	12/21/1987	Duragesic NDA 12-21-1987 VOL 15	JAN-MS-00213633	JAN-MS-00213633							
JA-01801	12/21/1987	Duragesic NDA 12-21-1987 VOL 16	JAN-MS-00213634	JAN-MS-00213634							
JA-01802	12/21/1987	Duragesic NDA 12-21-1987 VOL 17	JAN-MS-00213635	JAN-MS-00213635							
JA-01803	12/21/1987	Duragesic NDA 12-21-1987 VOL 18	JAN-MS-00213636	JAN-MS-00213636							
JA-01804	12/21/1987	Duragesic NDA 12-21-1987 VOL 19	JAN-MS-00213637	JAN-MS-00213637							
JA-01805	12/21/1987	Duragesic NDA 12-21-1987 VOL 2	JAN-MS-00213638	JAN-MS-00213638							
JA-01806	12/21/1987	Duragesic NDA 12-21-1987 VOL 20	JAN-MS-00213639	JAN-MS-00213639							
JA-01807	12/21/1987	Duragesic NDA 12-21-1987 VOL 21	JAN-MS-00213640	JAN-MS-00213640							
JA-01808	12/21/1987	Duragesic NDA 12-21-1987 VOL 22	JAN-MS-00213641	JAN-MS-00213641							
JA-01809	12/21/1987	Duragesic NDA 12-21-1987 VOL 23	JAN-MS-00213642	JAN-MS-00213642							
JA-01810	12/21/1987	Duragesic NDA 12-21-1987 VOL 24	JAN-MS-00213643	JAN-MS-00213643							
JA-01811	12/21/1987	Duragesic NDA 12-21-1987 VOL 25	JAN-MS-00213644	JAN-MS-00213644							
JA-01812	12/21/1987	Duragesic NDA 12-21-1987 VOL 26	JAN-MS-00213645	JAN-MS-00213645							
JA-01813	10/01/1987	Section 314.50 (d)(5)(ii) Clinical Data - Controlled Clinical Studies, Final Report Protocol C-85-038, Study II Postoperative Analgesic Efficacy Delivered Transdermally, ALZA Corporation,1987	JAN-MS-00213646	JAN-MS-00213646							
JA-01814	09/01/1987	Section 314.50 (d)(5)(ii) Clinical Data – Controlled Clinical Studies, Final Report Protocol C-85-042, Study II Postoperative Analgesic Efficacy of Transdermally Administered Fentanyl, ALZA Corporation,1987	JAN-MS-00213647	JAN-MS-00213647							
JA-01815	06/09/1905	Duragesic NDA 12-21-1987 VOL 29	JAN-MS-00213648	JAN-MS-00213648							
JA-01816	06/09/1905	Duragesic NDA 12-21-1987 VOL 3	JAN-MS-00213649	JAN-MS-00213649							
JA-01817	06/09/1905	Duragesic NDA 12-21-1987 VOL 30	JAN-MS-00213650	JAN-MS-00213650							
JA-01818	06/09/1905	Duragesic NDA 12-21-1987 VOL 31	JAN-MS-00213651	JAN-MS-00213651							
JA-01819	06/09/1905	Duragesic NDA 12-21-1987 VOL 32	JAN-MS-00213652	JAN-MS-00213652							
JA-01820	06/09/1905	Duragesic NDA 12-21-1987 VOL 33	JAN-MS-00213653	JAN-MS-00213653							
JA-01821	06/09/1905	Duragesic NDA 12-21-1987 VOL 34	JAN-MS-00213654	JAN-MS-00213654							
JA-01822	06/09/1905	Duragesic NDA 12-21-1987 VOL 35	JAN-MS-00213655	JAN-MS-00213655							
JA-01823	06/09/1905	Duragesic NDA 12-21-1987 VOL 36	JAN-MS-00213656	JAN-MS-00213656							
JA-01824	06/09/1905	Duragesic NDA 12-21-1987 VOL 37	JAN-MS-00213657	JAN-MS-00213657							
JA-01825	12/14/1987	Alza Corporation, Summary of Fentanyl Clinical Literature 1987 VOL 38	JAN-MS-00213658	JAN-MS-00213658							
JA-01826	08/12/1985	Stanski D, et al., The Efficacy and Safety of a Continuous Intravenous Fentanyl Infusion as Analgesia Following Surgery, Vol. 5	JAN-MS-00213659	JAN-MS-00213659							
JA-01827	12/11/1987	Prevo, M, Nonclinical Pharmacology and Toxicology, Vol. 4	JAN-MS-00213660	JAN-MS-00213660							
JA-01828	06/09/1905	Duragesic NDA 12-21-1987 VOL 40	JAN-MS-00213661	JAN-MS-00213661							
JA-01829	06/09/1905	Curriculum Vitae Peter Armstrong	JAN-MS-00213662	JAN-MS-00213662							
JA-01830	04/13/1987	Curriculum Vitaie Chassem Larijani	JAN-MS-00213663	JAN-MS-00213663							
JA-01831	07/01/1985	Alza Corporation, Clinical Literature References, Clinical Pharmacy, Vol. 4 July 1985	JAN-MS-00213664	JAN-MS-00213664							
JA-01832	01/01/1985	Literature References Clinical Protocols and Reports, 1985, Vol. 44	JAN-MS-00213665	JAN-MS-00213665							
JA-01833	06/06/1905	Alza Corporation, Literature References Clinical Protocols and Reports Duragesic NDA 12-21-1987 VOL 45	JAN-MS-00213666	JAN-MS-00213666							
JA-01834	12/21/1987	Duragesic NDA 12-21-1987 VOL 46	JAN-MS-00213667	JAN-MS-00213667							
JA-01835	12/21/1987	Duragesic NDA 12-21-1987 VOL 47	JAN-MS-00213668	JAN-MS-00213668							
JA-01836	12/21/1987	Duragesic NDA 12-21-1987 VOL 48	JAN-MS-00213669	JAN-MS-00213669							
JA-01837	12/21/1987	Duragesic NDA 12-21-1987 VOL 49	JAN-MS-00213670	JAN-MS-00213670							
JA-01838	12/21/1987	Duragesic NDA 12-21-1987 VOL 5	JAN-MS-00213671	JAN-MS-00213671							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-01839	12/21/1987	Duragesic NDA 12-21-1987 VOL 6	JAN-MS-00213672	JAN-MS-00213672							
JA-01840	12/21/1987	Duragesic NDA 12-21-1987 VOL 62	JAN-MS-00213673	JAN-MS-00213673							
JA-01841	12/21/1987	Duragesic NDA 12-21-1987 VOL 63	JAN-MS-00213674	JAN-MS-00213674							
JA-01842	12/21/1987	Duragesic NDA 12-21-1987 VOL 64	JAN-MS-00213675	JAN-MS-00213675							
JA-01843	12/21/1987	Duragesic NDA 12-21-1987 VOL 7	JAN-MS-00213676	JAN-MS-00213676							
JA-01844	12/21/1987	Duragesic NDA 12-21-1987 VOL 8	JAN-MS-00213677	JAN-MS-00213677							
JA-01845	12/21/1987	Duragesic NDA 12-21-1987 VOL 9	JAN-MS-00213678	JAN-MS-00213678							
JA-01846	06/19/2003	Duragesic PSUR May 2002-Apr 2003	JAN-MS-00213707	JAN-MS-00213707							
JA-01847	06/19/2003	Duragesic PSUR May 2002-Apr 2003	JAN-MS-00213708	JAN-MS-00213708							
JA-01848	06/20/2003	Duragesic PSUR May 2002-Apr 2003	JAN-MS-00213709	JAN-MS-00213709							
JA-01849	06/20/2003	Duragesic PSUR May 2002-Apr 2003	JAN-MS-00213710	JAN-MS-00213710							
JA-01850	06/20/2003	Duragesic PSUR May 2002-Apr 2003	JAN-MS-00213711	JAN-MS-00213711							
JA-01851	06/20/2003	Duragesic PSUR May 2002-Apr 2003	JAN-MS-00213712	JAN-MS-00213712							
JA-01852	06/20/2003	Duragesic PSUR May 2002-Apr 2003	JAN-MS-00213713	JAN-MS-00213713							
JA-01853	06/19/2003	Duragesic PSUR May 2002-Apr 2003	JAN-MS-00213715	JAN-MS-00213715							
JA-01854	06/19/2003	Duragesic PSUR May 2002-Apr 2003	JAN-MS-00213716	JAN-MS-00213716							
JA-01855	06/19/2003	Duragesic PSUR May 2002-Apr 2003	JAN-MS-00213717	JAN-MS-00213717							
JA-01856	06/19/2003	Duragesic PSUR May 2002-Apr 2003	JAN-MS-00213718	JAN-MS-00213718							
JA-01857	06/19/2003	Duragesic PSUR May 2002-Apr 2003	JAN-MS-00213719	JAN-MS-00213719							
JA-01858	06/19/2003	Duragesic PSUR May 2002-Apr 2003	JAN-MS-00213720	JAN-MS-00213720							
JA-01859	06/19/2003	Duragesic PSUR May 2002-Apr 2003	JAN-MS-00213721	JAN-MS-00213721							
JA-01860	06/19/2003	Duragesic PSUR May 2002-Apr 2003	JAN-MS-00213722	JAN-MS-00213722							
JA-01861	06/15/2004	Duragesic PSUR May 2003-Apr 2004	JAN-MS-00213723	JAN-MS-00213723							
JA-01862	06/15/2004	Duragesic PSUR May 2003-Apr 2004	JAN-MS-00213724	JAN-MS-00213724							
JA-01863	06/15/2004	Duragesic PSUR May 2003-Apr 2004	JAN-MS-00213725	JAN-MS-00213725							
JA-01864	06/15/2004	Duragesic PSUR May 2003-Apr 2004	JAN-MS-00213726	JAN-MS-00213726							
JA-01865	06/15/2004	Duragesic PSUR May 2003-Apr 2004	JAN-MS-00213727	JAN-MS-00213727							
JA-01866	06/15/2004	Duragesic PSUR May 2003-Apr 2004	JAN-MS-00213728	JAN-MS-00213728							
JA-01867	06/15/2004	Duragesic PSUR May 2003-Apr 2004	JAN-MS-00213729	JAN-MS-00213729							
JA-01868	06/15/2004	Duragesic PSUR May 2003-Apr 2004	JAN-MS-00213730	JAN-MS-00213730							
JA-01869	06/15/2004	Duragesic PSUR May 2003-Apr 2004	JAN-MS-00213731	JAN-MS-00213731							
JA-01870	06/15/2004	Duragesic PSUR May 2003-Apr 2004	JAN-MS-00213732	JAN-MS-00213732							
JA-01871	06/15/2004	Duragesic PSUR May 2003-Apr 2004	JAN-MS-00213734	JAN-MS-00213734							
JA-01872	06/15/2004	Duragesic PSUR May 2003-Apr 2004	JAN-MS-00213735	JAN-MS-00213735							
JA-01873	06/15/2004	Duragesic PSUR May 2003-Apr 2004	JAN-MS-00213736	JAN-MS-00213736							
JA-01874	06/15/2004	Duragesic PSUR May 2003-Apr 2004	JAN-MS-00213737	JAN-MS-00213737							
JA-01875	06/15/2004	Duragesic PSUR May 2003-Apr 2004	JAN-MS-00213738	JAN-MS-00213738							
JA-01876	06/15/2004	Duragesic PSUR May 2003-Apr 2004	JAN-MS-00213739	JAN-MS-00213739							
JA-01877	06/15/2004	Duragesic PSUR May 2003-Apr 2004	JAN-MS-00213740	JAN-MS-00213740							
JA-01878	06/15/2004	Duragesic PSUR May 2003-Apr 2004	JAN-MS-00213741	JAN-MS-00213741							
JA-01879	06/12/2004	Duragesic PSUR May 2003-Apr 2004	JAN-MS-00213742	JAN-MS-00213742							
JA-01880	06/26/1905	Duragesic PSUR May 2003-Apr 2004	JAN-MS-00213743	JAN-MS-00213743							
JA-01881	06/26/1905	Duragesic PSUR May 2003-Apr 2004	JAN-MS-00213744	JAN-MS-00213744							
JA-01882	06/01/2004	Duragesic PSUR May 2003-Apr 2004	JAN-MS-00213745	JAN-MS-00213745							
JA-01883	06/12/2004	Duragesic PSUR May 2003-Apr 2004	JAN-MS-00213746	JAN-MS-00213746							
JA-01884	06/12/2004	Duragesic PSUR May 2003-Apr 2004	JAN-MS-00213747	JAN-MS-00213747							
JA-01885	06/15/2004	Duragesic PSUR May 2003-Apr 2004	JAN-MS-00213748	JAN-MS-00213748							
JA-01886	06/15/2004	Duragesic PSUR May 2003-Apr 2004	JAN-MS-00213749	JAN-MS-00213749							
JA-01887	11/11/1997	Janssen Research Foundation: Clinical Research Report	JAN-MS-00213773	JAN-MS-00213773							
JA-01888	05/01/2007	Duragesic PSUR May 2006-Apr 2007	JAN-TREX-00149906	JAN-TREX-00149906							
JA-01889	06/12/2007	Duragesic PSUR May 2006-Apr 2007	JAN-MS-00213787	JAN-MS-00213787							
JA-01890	06/12/2007	Duragesic PSUR May 2006-Apr 2007	JAN-MS-00213788	JAN-MS-00213788							
JA-01891	06/12/2007	Duragesic PSUR May 2006-Apr 2007	JAN-MS-00213789	JAN-MS-00213789							
JA-01892	06/12/2007	Duragesic PSUR May 2006-Apr 2007	JAN-MS-00213790	JAN-MS-00213790							
JA-01893	06/12/2007	Duragesic PSUR May 2006-Apr 2007	JAN-MS-00213791	JAN-MS-00213791							
JA-01894	06/12/2007	Duragesic PSUR May 2006-Apr 2007	JAN-MS-00213792	JAN-MS-00213792							
JA-01895	06/12/2007	Duragesic PSUR May 2006-Apr 2007	JAN-MS-00213793	JAN-MS-00213793							
JA-01896	06/12/2007	Duragesic PSUR May 2006-Apr 2007	JAN-MS-00213794	JAN-MS-00213794							
JA-01897	06/12/2007	Duragesic PSUR May 2006-Apr 2007	JAN-MS-00213796	JAN-MS-00213796							
JA-01898	06/12/2007	Duragesic PSUR May 2006-Apr 2007	JAN-MS-00213797	JAN-MS-00213797							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-01899	06/12/2007	Duragesic PSUR May 2006-Apr 2007	JAN-MS-00213798	JAN-MS-00213798							
JA-01900	06/12/2007	Duragesic PSUR May 2006-Apr 2007	JAN-MS-00213799	JAN-MS-00213799							
JA-01901	06/12/2007	Duragesic PSUR May 2006-Apr 2007	JAN-MS-00213800	JAN-MS-00213800							
JA-01902	06/12/2007	Duragesic PSUR May 2006-Apr 2007	JAN-MS-00213801	JAN-MS-00213801							
JA-01903	06/12/2007	Duragesic PSUR May 2006-Apr 2007	JAN-MS-00213802	JAN-MS-00213802							
JA-01904	06/12/2007	Duragesic PSUR May 2006-Apr 2007	JAN-MS-00213803	JAN-MS-00213803							
JA-01905	06/12/2007	Duragesic PSUR May 2006-Apr 2007	JAN-MS-00213804	JAN-MS-00213804							
JA-01906	06/29/1905	Duragesic PSUR May 2006-Apr 2007	JAN-MS-00213805	JAN-MS-00213805							
JA-01907	06/29/1905	Duragesic PSUR May 2006-Apr 2007	JAN-MS-00213806	JAN-MS-00213806							
JA-01908	06/29/1905	Duragesic PSUR May 2006-Apr 2007	JAN-MS-00213807	JAN-MS-00213807							
JA-01909	06/29/1905	Duragesic PSUR May 2006-Apr 2007	JAN-MS-00213808	JAN-MS-00213808							
JA-01910	06/29/1905	Duragesic PSUR May 2006-Apr 2007	JAN-MS-00213809	JAN-MS-00213809							
JA-01911	06/29/1905	Duragesic PSUR May 2006-Apr 2007	JAN-MS-00213810	JAN-MS-00213810							
JA-01912	06/29/1905	Duragesic PSUR May 2006-Apr 2007	JAN-MS-00213811	JAN-MS-00213811							
JA-01913	06/29/1905	Duragesic PSUR May 2006-Apr 2007	JAN-MS-00213812	JAN-MS-00213812							
JA-01914	05/01/2005	Duragesic visual aid	JAN-MS-00214174	JAN-MS-00214174							
JA-01915	03/30/2000	Untitled Letter from DDMAC to Janssen re: Duragesic	JAN-MS-00238346	JAN-MS-00238353							
JA-01916	08/01/2003	Duragesic File Card	JAN-MS-00238370	JAN-MS-00238378							
JA-01917	04/01/2014	Duragesic Label (2014)	JAN-MS-00238420	JAN-MS-00238465							
JA-01918	12/01/2016	Nucynta ER Label (2016)	JAN-MS-00238604	JAN-MS-00238636							
JA-01919	12/01/2016	Nucynta Label (2016)	JAN-MS-00238666	JAN-MS-00238698							
JA-01920	01/01/2001	Duragesic Label (08-1999, 01-2001)	JAN-MS-00304304	JAN-MS-00304309							
JA-01921	11/01/2002	Duragesic visual aid	JAN-MS-00306286	JAN-MS-00306293							
JA-01922	04/01/2004	Duragesic visual aid	JAN-MS-00306376	JAN-MS-00306380							
JA-01923	10/21/2004	Brookoff Citizen Petition	JAN-MS-00306548	JAN-MS-00306568							
JA-01924	10/21/2001	Letter from Susan Rinne to Gary Buehler	JAN-MS-00306569	JAN-MS-00306576							
JA-01925	07/02/2009	Email from Susan Nicholson to Christopher Guiton et al.	JAN-MS-00677128	JAN-MS-00677128							
JA-01926	06/29/2009	IWG Submission to FDA Docket	JAN-MS-00677129	JAN-MS-00677143							
JA-01927	06/01/2005	Dear Doctor Letter	JAN-MS-00683408	JAN-MS-00683412							
JA-01928	03/22/2012	Nucynta Formulation Video	JAN-MS-00271467	JAN-MS-00271467							
JA-01929	06/08/2008	Dear Doctor Letter	JAN-MS-00291141	JAN-MS-00291141							
JA-01930	06/27/1994	Letter from Elizabeth Clark to FDA	JAN-MS-00291329	JAN-MS-00291329							
JA-01931	10/07/1994	Letter from Elizabeth Clark to FDA	JAN-MS-00291330	JAN-MS-00291330							
JA-01932	06/25/2015	ER/LA REMS Modification	JAN-MS-00291357	JAN-MS-00291357							
JA-01933	11/08/1995	Letter from Mirka Dunn to FDA	JAN-MS-00291365	JAN-MS-00291365							
JA-01934	11/08/1995	Duragesic PADER Aug 1994-Jul 1995	JAN-MS-00291366	JAN-MS-00291366							
JA-01935	10/18/1996	Letter from Melody Eble to FDA	JAN-MS-00291367	JAN-MS-00291367							
JA-01936	06/18/1905	Duragesic PADER Aug 1995-Jul 1996	JAN-MS-00291368	JAN-MS-00291368							
JA-01937	09/30/1997	Letter from Jacqueline Brown to FDA	JAN-MS-00291369	JAN-MS-00291369							
JA-01938	06/19/1905	Duragesic PADER Aug 1996-Jul 1997	JAN-MS-00291370	JAN-MS-00291370							
JA-01939	10/05/1998	Letter from Elizabeth Turek to FDA	JAN-MS-00291371	JAN-MS-00291371							
JA-01940	06/20/1905	Duragesic PADER Aug 1997-Jul 1998	JAN-MS-00291372	JAN-MS-00291372							
JA-01941	06/20/1905	Duragesic PADER Aug 1997-Jul 1998	JAN-MS-00291373	JAN-MS-00291373							
JA-01942	10/01/1999	Letter from Cynthia Chianese to FDA	JAN-MS-00291374	JAN-MS-00291374							
JA-01943	06/21/1905	Duragesic PADER Aug 1998-Jul 1999	JAN-MS-00291375	JAN-MS-00291375							
JA-01944	06/21/1905	Duragesic PADER Aug 1998-Jul 1999	JAN-MS-00291376	JAN-MS-00291376							
JA-01945	06/21/1905	Duragesic PADER Aug 1998-Jul 1999	JAN-MS-00291377	JAN-MS-00291377							
JA-01946	06/21/1905	Duragesic PADER Aug 1998-Jul 1999	JAN-MS-00291378	JAN-MS-00291378							
JA-01947	06/21/1905	Duragesic PADER Aug 1998-Jul 1999	JAN-MS-00291379	JAN-MS-00291379							
JA-01948	06/21/1905	Duragesic PADER Aug 1998-Jul 1999	JAN-MS-00291380	JAN-MS-00291380							
JA-01949	09/20/2000	Letter from Cynthia Chianese to FDA	JAN-MS-00291381	JAN-MS-00291381							
JA-01950	06/22/1905	Duragesic PADER Aug 1999-Jul 2000	JAN-MS-00291382	JAN-MS-00291382							
JA-01951	06/22/1905	Duragesic PADER Aug 1999-Jul 2000	JAN-MS-00291383	JAN-MS-00291383							
JA-01952	06/22/1905	Duragesic PADER Aug 1999-Jul 2000	JAN-MS-00291384	JAN-MS-00291384							
JA-01953	06/22/1905	Duragesic PADER Aug 1999-Jul 2000	JAN-MS-00291385	JAN-MS-00291385							
JA-01954	06/22/1905	Duragesic PADER Aug 1999-Jul 2000	JAN-MS-00291386	JAN-MS-00291386							
JA-01955	06/22/1905	Duragesic PADER Aug 1999-Jul 2000	JAN-MS-00291387	JAN-MS-00291387							
JA-01956	06/21/1905	Duragesic PADER Aug 1999-Jul 2000	JAN-MS-00291388	JAN-MS-00291388							
JA-01957	06/21/1905	Duragesic PADER Aug 1999-Jul 2000	JAN-MS-00291389	JAN-MS-00291389							
JA-01958	06/21/1905	Duragesic PADER Aug 1999-Jul 2000	JAN-MS-00291390	JAN-MS-00291390							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-01959	06/21/1905	Duragesic PADER Aug 1999-Jul 2000	JAN-MS-00291391	JAN-MS-00291391							
JA-01960	06/22/1905	Duragesic PADER Aug 1999-Jul 2000	JAN-MS-00291392	JAN-MS-00291392							
JA-01961	06/22/1905	Duragesic PADER Aug 1999-Jul 2000	JAN-MS-00291393	JAN-MS-00291393							
JA-01962	06/22/1905	Duragesic PADER Aug 1999-Jul 2000	JAN-MS-00291394	JAN-MS-00291394							
JA-01963	06/22/1905	Duragesic PADER Aug 1999-Jul 2000	JAN-MS-00291395	JAN-MS-00291395							
JA-01964	09/14/2001	Duragesic PADER Aug 2000-Jul 2001	JAN-MS-00291396	JAN-MS-00291396							
JA-01965	07/31/2001	Duragesic PADER Aug 2000-Jul 2001	JAN-MS-00291397	JAN-MS-00291397							
JA-01966	07/31/2001	Duragesic PADER Aug 2000-Jul 2001	JAN-MS-00291398	JAN-MS-00291398							
JA-01967	07/31/2001	Duragesic PADER Aug 2000-Jul 2001	JAN-MS-00291399	JAN-MS-00291399							
JA-01968	07/31/2001	Duragesic PADER Aug 2000-Jul 2001	JAN-MS-00291400	JAN-MS-00291400							
JA-01969	07/31/2001	Duragesic PADER Aug 2000-Jul 2001	JAN-MS-00291401	JAN-MS-00291401							
JA-01970	07/31/2001	Duragesic PADER Aug 2000-Jul 2001	JAN-MS-00291402	JAN-MS-00291402							
JA-01971	08/27/2001	Duragesic PADER Aug 2000-Jul 2001	JAN-MS-00291403	JAN-MS-00291403							
JA-01972	06/27/2002	Duragesic PADER Aug 2001-Apr 2002	JAN-MS-00291404	JAN-MS-00291404							
JA-01973	04/30/2002	Duragesic PADER Aug 2001-Apr 2002	JAN-MS-00291405	JAN-MS-00291405							
JA-01974	04/30/2002	Duragesic PADER Aug 2001-Apr 2002	JAN-MS-00291406	JAN-MS-00291406							
JA-01975	04/30/2002	Duragesic PADER Aug 2001-Apr 2002	JAN-MS-00291407	JAN-MS-00291407							
JA-01976	04/30/2002	Duragesic PADER Aug 2001-Apr 2002	JAN-MS-00291408	JAN-MS-00291408							
JA-01977	06/12/2002	Duragesic PADER Aug 2001-Apr 2002	JAN-MS-00291409	JAN-MS-00291409							
JA-01978	06/24/2005	Duragesic PSUR May 2004-Apr 2005	JAN-MS-00291410	JAN-MS-00291410							
JA-01979	06/24/2005	Duragesic PSUR May 2004-Apr 2005	JAN-MS-00291411	JAN-MS-00291411							
JA-01980	06/24/2005	Duragesic PSUR May 2004-Apr 2005	JAN-MS-00291412	JAN-MS-00291412							
JA-01981	06/24/2005	Duragesic PSUR May 2004-Apr 2005	JAN-MS-00291413	JAN-MS-00291413							
JA-01982	06/24/2005	Duragesic PSUR May 2004-Apr 2005	JAN-MS-00291414	JAN-MS-00291414							
JA-01983	06/24/2005	Duragesic PSUR May 2004-Apr 2005	JAN-MS-00291415	JAN-MS-00291415							
JA-01984	06/24/2005	Duragesic PSUR May 2004-Apr 2005	JAN-MS-00291416	JAN-MS-00291416							
JA-01985	06/24/2005	Duragesic PSUR May 2004-Apr 2005	JAN-MS-00291417	JAN-MS-00291417							
JA-01986	06/24/2005	Duragesic PSUR May 2004-Apr 2005	JAN-MS-00291418	JAN-MS-00291418							
JA-01987	06/24/2005	Duragesic PSUR May 2004-Apr 2005	JAN-MS-00291419	JAN-MS-00291419							
JA-01988	06/24/2005	Duragesic PSUR May 2004-Apr 2005	JAN-MS-00291421	JAN-MS-00291421							
JA-01989	06/24/2005	Duragesic PSUR May 2004-Apr 2005	JAN-MS-00291422	JAN-MS-00291422							
JA-01990	06/24/2005	Duragesic PSUR May 2004-Apr 2005	JAN-MS-00291423	JAN-MS-00291423							
JA-01991	06/24/2005	Duragesic PSUR May 2004-Apr 2005	JAN-MS-00291424	JAN-MS-00291424							
JA-01992	06/24/2005	Duragesic PSUR May 2004-Apr 2005	JAN-MS-00291425	JAN-MS-00291425							
JA-01993	06/24/2005	Duragesic PSUR May 2004-Apr 2005	JAN-MS-00291426	JAN-MS-00291426							
JA-01994	06/24/2005	Duragesic PSUR May 2004-Apr 2005	JAN-MS-00291427	JAN-MS-00291427							
JA-01995	06/24/2005	Duragesic PSUR May 2004-Apr 2005	JAN-MS-00291428	JAN-MS-00291428							
JA-01996	06/24/2005	Duragesic PSUR May 2004-Apr 2005	JAN-MS-00291429	JAN-MS-00291429							
JA-01997	06/24/2005	Duragesic PSUR May 2004-Apr 2005	JAN-MS-00291430	JAN-MS-00291430							
JA-01998	06/24/2005	Duragesic PSUR May 2004-Apr 2005	JAN-MS-00291431	JAN-MS-00291431							
JA-01999	06/21/2006	Duragesic PSUR May 2005-Apr 2006	JAN-MS-00291432	JAN-MS-00291432							
JA-02000	06/21/2006	Duragesic PSUR May 2005-Apr 2006	JAN-MS-00291433	JAN-MS-00291433							
JA-02001	06/21/2006	Duragesic PSUR May 2005-Apr 2006	JAN-MS-00291434	JAN-MS-00291434							
JA-02002	06/21/2006	Duragesic PSUR May 2005-Apr 2006	JAN-MS-00291435	JAN-MS-00291435							
JA-02003	06/21/2006	Duragesic PSUR May 2005-Apr 2006	JAN-MS-00291436	JAN-MS-00291436							
JA-02004	06/21/2006	Duragesic PSUR May 2005-Apr 2006	JAN-MS-00291437	JAN-MS-00291437							
JA-02005	06/21/2006	Duragesic PSUR May 2005-Apr 2006	JAN-MS-00291438	JAN-MS-00291438							
JA-02006	06/21/2006	Duragesic PSUR May 2005-Apr 2006	JAN-MS-00291439	JAN-MS-00291439							
JA-02007	06/21/2006	Duragesic PSUR May 2005-Apr 2006	JAN-MS-00291440	JAN-MS-00291440							
JA-02008	06/21/2006	Duragesic PSUR May 2005-Apr 2006	JAN-MS-00291441	JAN-MS-00291441							
JA-02009	06/21/2006	Duragesic PSUR May 2005-Apr 2006	JAN-MS-00291443	JAN-MS-00291443							
JA-02010	06/21/2006	Duragesic PSUR May 2005-Apr 2006	JAN-MS-00291444	JAN-MS-00291444							
JA-02011	06/21/2006	Duragesic PSUR May 2005-Apr 2006	JAN-MS-00291445	JAN-MS-00291445							
JA-02012	06/21/2006	Duragesic PSUR May 2005-Apr 2006	JAN-MS-00291446	JAN-MS-00291446							
JA-02013	06/21/2006	Duragesic PSUR May 2005-Apr 2006	JAN-MS-00291447	JAN-MS-00291447							
JA-02014	06/21/2006	Duragesic PSUR May 2005-Apr 2006	JAN-MS-00291448	JAN-MS-00291448							
JA-02015	06/21/2006	Duragesic PSUR May 2005-Apr 2006	JAN-MS-00291449	JAN-MS-00291449							
JA-02016	06/21/2006	Duragesic PSUR May 2005-Apr 2006	JAN-MS-00291450	JAN-MS-00291450							
JA-02017	06/21/2006	Duragesic PSUR May 2005-Apr 2006	JAN-MS-00291451	JAN-MS-00291451							
JA-02018	10/06/2010	Email from Bruce Moskovitz to Christine Rauschkolb et al.	JAN-MS-01977572	JAN-MS-01977574							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-02019	10/23/2011	Letter from Tania Hillmer to Bob A. Rappaport	JAN-MS-01046321	JAN-MS-01046322							
JA-02020	06/08/2012	Letter from the ER/LA Opioid Analgesic REMS Companies to DEA-Registered Prescriber re REMS ER/LA Precriber Letter #1	JAN-MS-01047964	JAN-MS-01047965							
JA-02021	05/26/2009	Susan Nicholson to Christopher Guiton and others	JAN-MS-01048368	JAN-MS-01048368							
JA-02022	05/01/2009	U.S. FDA REMS for Certain Opioid Drugs Public Meeting presentation	JAN-MS-01048380	JAN-MS-01048380							
JA-02023	07/08/2010	Email from Bruce Moskovitz to Dr. David Biondi et al.	JAN-MS-01048566	JAN-MS-01048567							
JA-02024	07/07/2010	Draft ER/LA REMS	JAN-MS-01048568	JAN-MS-01048684							
JA-02025	07/07/2010	Draft ER/LA REMS	JAN-MS-01048685	JAN-MS-01048693							
JA-02026	08/06/2009	Email from Shoko Nakazawa to Takashi Takeshita et al.	JAN-MS-00353439	JAN-MS-00353440							
JA-02027	07/10/1998	Clinical Expert Report on Durogesic in chronic pain of non-malignant origin	JAN-MS-00353441	JAN-MS-00353480							
JA-02028	03/31/2010	CME Presentation: High Stakes, Young Lives: Prescription Medications in Our Communities	JAN-MS-00394607	JAN-MS-00394622							
JA-02029	03/19/2010	CME Program: High Stakes Young Lives: Prescription Drug Diversion in the Adolescent Community	JAN-MS-00409816	JAN-MS-00409839							
JA-02030	08/19/2011	Email from Susan Nicholson to Ron Kuntz et al.	JAN-MS-00454121	JAN-MS-00454122							
JA-02031	04/10/2008	Email from Lynn Leonard to Matthew Wick	JAN-MS-00476406	JAN-MS-00476406							
JA-02032	03/01/2008	NEO Pathways Booth Panel re: Undertreatment of Pain	JAN-MS-00476407	JAN-MS-00476408							
JA-02033	03/01/2008	NEO Pathways Booth Panel re: Consequences of Undertreated Pain	JAN-MS-00476409	JAN-MS-00476410							
JA-02034	03/01/2008	NEO Pathways Brochure	JAN-MS-00476418	JAN-MS-00476419							
JA-02035	05/07/2002	Update Bulletin re Revised DAWN statistics	JAN-MS-00776682	JAN-MS-00776686							
JA-02036	02/04/2005	Duragesic Label (2005)	JAN-MS-00780841	JAN-MS-00780888							
JA-02037	02/01/2005	Letter from Norman Rosenthal, MD to Dear Healthcare Professional re Important Correction of Drug Information	JAN-MS-00780903	JAN-MS-00780904							
JA-02038	04/05/2004	Letter from Susan Rinne to Robert Rappaport, FDA re letter of Certification of submission of electronic supplemental NDA	JAN-MS-00781142	JAN-MS-00781146							
JA-02039	07/16/2002	Email from Pam Dotter to Adrienne Minecci et al.	JAN-MS-00781332	JAN-MS-00781332							
JA-02040	07/16/2002	DRAFT Questions and Answers re Potential for Misuse Duragesic	JAN-MS-00781333	JAN-MS-00781333							
JA-02041	09/06/2002	Email from Adrienne Minecci to Cheryl Pavia et al.	JAN-MS-00781338	JAN-MS-00781339							
JA-02042	06/04/2013	Nucynta ER Abuse Deterrent Labeling Change Briefing Document	JAN-MS-02051874	JAN-MS-02051874							
JA-02043	04/13/2013	RADARS System Tapentadol Report (2012 Annual)	JAN-MS-02061476	JAN-MS-02061676							
JA-02044	09/01/2013	Duragesic Label (2013)	JAN-MS-00583030	JAN-MS-00583073							
JA-02045	05/30/2014	The Street Prices of Immediate Release and Extended Release Tapentadol are Lower than Other Schedule II Opioid Tablets/Capsules	JAN-MS-02092151	JAN-MS-02092151							
JA-02046	06/10/2002	Final Clinical Research Report FEN-USA-72	JAN-MS-02104259	JAN-MS-02104359							
JA-02047	06/07/2002	Final Clinical Research Report FEN-USA-71	JAN-MS-02104361	JAN-MS-02104455							
JA-02048	01/19/2006	Duragesic Media Monitoring Pilot Program Summary Report (Q4 2005)	JAN-MS-02107248	JAN-MS-02107256							
JA-02049	06/07/2006	Examination of Transdermal Fentanyl Patch Systems Postings on Internet Bulletin Boards	JAN-MS-02107443	JAN-MS-02107632							
JA-02050	01/14/2015	Vadivelu et al., Tapentadol extended release in the management of peripheral diabetic neuropathic pain, Therapeutics and Clinical Risk Management 2015:11 95-105.	JAN-MS-00599070	JAN-MS-00599080							
JA-02051	09/26/2006	RADARS System Methadone Clinic Signal Detection System (Q2 2006)	JAN-MS-02108253	JAN-MS-02108325							
JA-02052	10/02/2006	RADARS System Drug Diversion Signal Detection System (Q2 2006)	JAN-MS-02108327	JAN-MS-02108440							
JA-02053	10/05/2006	RADARS System Poison Control Center Signal Detection System (Q2 2006)	JAN-MS-02108442	JAN-MS-02108565							
JA-02054	05/21/2013	FDA Draft Guidance Abuse Deterrent Opioids Evaluation and Labeling, Implications for Nucynta ER prepared by Pinney Associates	JAN-MS-00604220	JAN-MS-00604248							
JA-02055	06/10/2005	PDRC Duragesic Surveillance Program Sentinel Network & Media Review Post-Baseline Update	JAN-MS-00620634	JAN-MS-00620658							
JA-02056	04/02/2015	Letter from Tania Hillmer to Sharon Hertz re IND 61345	JAN-MS-02119925	JAN-MS-02119926							
JA-02057	04/02/2015	Letter from Tania Hillmer to Sharon Hertz re Janssen Pharmaceuticals NDA	JAN-MS-02119929	JAN-MS-02119930							
JA-02058	04/02/2015	Letter from Tania Hillmer to Sharon Hertz re Janssen Pharmaceuticals NDA	JAN-MS-02119931	JAN-MS-02119932							
JA-02059	05/21/2010	Phase Clinical Study Report - R331333-PAI-3010 (KF5503/18)	JAN-MS-00227808	JAN-MS-00227808							
JA-02060	02/15/2011	Clinical Summary - Complete Response Safety Update	JAN-MS-00227810	JAN-MS-00227810							
JA-02061	09/27/2004	Assessment of Abuse Potential of Fentanyl Transdermal Systems in the US	JAN-MS-02130500	JAN-MS-02130546							
JA-02062	11/01/2007	CME Overview: Individualizing Analgesic Regimens: Strategies to Reduce Abuse and Diversion An Internet CME/CE Initiative	JAN-MS-00640233	JAN-MS-00640245							
JA-02063	11/01/2007	CME Overview: Individualizing Analgesic Regimens: Strategies to Reduce Abuse and Diversion An Internet CME/CE Initiative (Module 3)	JAN-MS-00640246	JAN-MS-00640252							
JA-02064	05/31/2005	PDRC Duragesic Surveillance Program Sentinel Network & Media Review Baseline Update Part II	JAN-MS-02130849	JAN-MS-02130884							
JA-02065	01/15/2008	RADARS System Fentanyl Data (Q3 2007)	JAN-MS-02146501	JAN-MS-02146515							
JA-02066	04/01/2008	RADARS System Fentanyl Data (Q4 2007)	JAN-MS-02146542	JAN-MS-02146553							
JA-02067	12/13/2011	Nucynta ER PADER Aug 2011-Nov 2011	JAN-MS-00228332	JAN-MS-00228332							
JA-02068	03/15/2012	Nucynta ER PADER Nov 2011-Feb 2012	JAN-MS-00228427	JAN-MS-00228427							
JA-02069	06/15/2012	Nucynta ER PADER Feb 2012-May 2012	JAN-MS-00228450	JAN-MS-00228450							
JA-02070	07/01/2012	ER/LA REMS	JAN-MS-00228462	JAN-MS-00228462							
JA-02071	09/18/2012	Nucynta ER PADER May 2012-Aug 2012	JAN-MS-00228469	JAN-MS-00228469							
JA-02072	12/18/2012	Nucynta ER PADER Aug 2012-Nov 2012	JAN-MS-00228497	JAN-MS-00228497							
JA-02073	03/18/2013	Nucynta ER PADER Nov 2013-Feb 2013	JAN-MS-00228509	JAN-MS-00228509							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-02074	06/17/2013	Nucynta ER PADER Feb 2013-May 2013	JAN-MS-00228521	JAN-MS-00228521							
JA-02075	09/12/2013	Nucynta ER PADER May 2013-Aug 2013	JAN-MS-00228530	JAN-MS-00228530							
JA-02076	12/18/2013	Nucynta ER PADER Aug 2013-Nov 2013	JAN-MS-00228552	JAN-MS-00228552							
JA-02077	03/18/2014	Nucynta ER PADER Nov 2013-Feb 2014	JAN-MS-00228556	JAN-MS-00228556							
JA-02078	06/16/2014	Nucynta ER PADER Feb 2014-May 2014	JAN-MS-00228583	JAN-MS-00228583							
JA-02079	09/17/2014	Nucynta ER PADER May 2014-Aug 2014	JAN-MS-00228611	JAN-MS-00228611							
JA-02080	05/01/2013	Powerful Chronic and Acute Pain Management Nucynta presentation	JAN-MS-00229356	JAN-MS-00229356							
JA-02081	12/05/2014	FDA Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use (Form 2253)	JAN-MS-00230015	JAN-MS-00230015							
JA-02082	11/01/2014	Nucynta ER Patient Brochure	JAN-MS-00230017	JAN-MS-00230017							
JA-02083	06/11/2012	Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use (Form 2253)	JAN-MS-00230154	JAN-MS-00230154							
JA-02084	05/01/2012	Speaker Slide Deck - A New Perspective for Moderate to Severe Acute Pain Relief	JAN-MS-00230157	JAN-MS-00230157							
JA-02085	01/22/2008	Letter from Kathleen Dusek to Bob Rappaport	JAN-MS-00230389	JAN-MS-00230389							
JA-02086	01/23/2008	Application to Market a New Drug, Nucynta	JAN-MS-00230390	JAN-MS-00230390							
JA-02087	01/21/2008	Reviewer's Guide For Tapentadol HCl	JAN-MS-00230438	JAN-MS-00230438							
JA-02088	12/21/2007	Clinical Summary - Summary of Biopharmaceutic Studies and Associated Analytical Methods	JAN-MS-00230495	JAN-MS-00230495							
JA-02089	01/04/2008	Clinical Summary - Summary of Clinical Efficacy	JAN-MS-00230496	JAN-MS-00230496							
JA-02090	01/09/2008	Clinical Summary - Summary of Clinical Pharmacology	JAN-MS-00230497	JAN-MS-00230497							
JA-02091	09/19/2009	Tapentadol Clinical Review Integrated Review of Safety by Ellen Fields	JAN-MS-02214038	JAN-MS-02214159							
JA-02092	01/21/2008	List of Nucynta (IR) Clinical Studies	JAN-MS-00230753	JAN-MS-00230753							
JA-02093	06/29/2007	Phase 1 Clinical Study Report - HP5503/03	JAN-MS-00230754	JAN-MS-00230754							
JA-02094	06/29/2007	Phase 1 Clinical Study Report - HP5503/04	JAN-MS-00230756	JAN-MS-00230756							
JA-02095	08/08/2007	Phase 1 Clinical Trial Report - HP5503/07/A	JAN-MS-00230758	JAN-MS-00230758							
JA-02096	10/09/2007	Phase 1 Clinical Study Report - R331333-PAI-1014 (HP5503/34)	JAN-MS-00230760	JAN-MS-00230760							
JA-02097	08/08/2007	Phase 1 Clinical Trial Report - HP5503/05	JAN-MS-00230782	JAN-MS-00230782							
JA-02098	08/08/2007	Phase 1 Clinical Trial Report - HP5503/11/A	JAN-MS-00230784	JAN-MS-00230784							
JA-02099	07/31/2007	Phase 1 Clinical Study Report - R331333-PAI-1005 (HP5503/13)	JAN-MS-00230786	JAN-MS-00230786							
JA-02100	07/27/2007	Phase 1 Clinical Study Report - R331333-PAI-1006 (HP5503/15)	JAN-MS-00230788	JAN-MS-00230788							
JA-02101	06/29/2007	Phase 1 Clinical Study Report - R331333-PAI-1002 (HP5503/16)	JAN-MS-00230790	JAN-MS-00230790							
JA-02102	10/01/2007	Phase 1 Clinical Study Report - R331333-PAI-1019 (HP5503/30)	JAN-MS-00230792	JAN-MS-00230792							
JA-02103	11/21/2007	Phase 1 Clinical Study Report - R331333-PAI-1027	JAN-MS-00230794	JAN-MS-00230794							
JA-02104	09/18/2007	Phase 1 Clinical Study Report - R331333-PAI-1008 (HP5503/19)	JAN-MS-00230796	JAN-MS-00230796							
JA-02105	07/17/2007	Phase 1 Clinical Study Report - R331333-PAI-1009 (HP5503/20)	JAN-MS-00230798	JAN-MS-00230798							
JA-02106	07/25/2007	Phase 1 Clinical Study Report - R331333-PAI-1010 (HP5503/21)	JAN-MS-00230800	JAN-MS-00230800							
JA-02107	09/20/2007	Phase 1 Clinical Study Report - R331333-PAI-1011 (HP5503/22)	JAN-MS-00230802	JAN-MS-00230802							
JA-02108	07/09/2007	Phase 1 Clinical Study Report - R331333-PAI-1013 (HP5503/23)	JAN-MS-00230804	JAN-MS-00230804							
JA-02109	01/10/2008	Population Pharmacokinetics and Exposure-Response of Tapentadol Immediate Release	JAN-MS-00230806	JAN-MS-00230806							
JA-02110	08/01/2007	Phase 1 Clinical Trial Report - HP5503/09	JAN-MS-00230807	JAN-MS-00230807							
JA-02111	08/31/2007	Phase 1 Clinical Study Report - R331333-PAI-1007 (HP5503/14)	JAN-MS-00230809	JAN-MS-00230809							
JA-02112	12/12/2007	Phase 1 Clinical Study Report - R331333-PAI-1018 (HP5503/25)	JAN-MS-00230811	JAN-MS-00230811							
JA-02113	08/07/2007	Phase 2 Clinical Trial Report - KF5503/01/A	JAN-MS-00230813	JAN-MS-00230813							
JA-02114	08/03/2007	Phase 2 Clinical Trial Report - KF5503/02/A	JAN-MS-00230814	JAN-MS-00230814							
JA-02115	08/03/2007	Phase 2 Clinical Trial Report - KF5503/04/A	JAN-MS-00230815	JAN-MS-00230815							
JA-02116	08/03/2007	Phase 2 Clinical Trial Report - KF5503/05/A	JAN-MS-00230816	JAN-MS-00230816							
JA-02117	08/03/2007	Phase 2A Clinical Trial Report - KF5503/08/A	JAN-MS-00230817	JAN-MS-00230817							
JA-02118	08/07/2007	Phase 2 Clinical Trial Report - KF5503/21/A	JAN-MS-00230822	JAN-MS-00230822							
JA-02119	03/07/2007	Phase 2B Clinical Study Report - R331333-PAI-2003 (KF5503/22)	JAN-MS-00230823	JAN-MS-00230823							
JA-02120	11/08/2007	Phase 3 Clinical Study Report - R331333-PAI-3003 (KF5503/32)	JAN-MS-00230824	JAN-MS-00230824							
JA-02121	12/20/2007	Phase 3 Clinical Study Report - R331333-PAI-3002 (KF5503/33)	JAN-MS-00230825	JAN-MS-00230825							
JA-02122	12/04/2007	Phase 3 Clinical Study Report - R331333-PAI-3004 (KF5503/34)	JAN-MS-00230826	JAN-MS-00230826							
JA-02123	06/29/2010	Email from Bruce Moskowitz to Christine Rauschkolb et al.	JAN-MS-02233931	JAN-MS-02233932							
JA-02124	01/05/2008	Module 2.7.4 Summary of Clinical Safety / Integrated Summary of Safety	JAN-MS-00230827	JAN-MS-00230827							
JA-02125	08/13/2007	Phase 1 Clinical Trial Report - HP5503/01	JAN-MS-00230829	JAN-MS-00230829							
JA-02126	08/16/2007	Phase 1 Clinical Trial Report - HP5503/02/A	JAN-MS-00230830	JAN-MS-00230830							
JA-02127	08/01/2007	Phase 1 Clinical Trial Report - HP5503/06/A	JAN-MS-00230831	JAN-MS-00230831							
JA-02128	04/29/2010	RADARS System Tapentadol Report (2009 Annual)	JAN-MS-02237460	JAN-MS-02237734							
JA-02129	09/15/2011	Email from Myoung Kim to Gary Vorsanger et al.	JAN-MS-02267889	JAN-MS-02267889							
JA-02130	09/14/2011	Key Characteristics of NAVIPPRO, RADARS, SKIP, and RADARS OTP Surveillance Systems	JAN-MS-02267890	JAN-MS-02267898							
JA-02131	10/16/2012	Email from Jadwiga Martynowicz to Jacqueline Brown et al.	JAN-MS-02283803	JAN-MS-02283803							
JA-02132	10/15/2012	PhRMA Perspective white paper, re: Controlled substances scheduling process	JAN-MS-02283804	JAN-MS-02283823							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-02133	08/28/2012	Letter from Bob A. Rappaport to Tania Hillmer	JAN-MS-02285274	JAN-MS-02285359							
JA-02134	08/03/2012	Presentation: RADARS System Overview	JAN-MS-02296262	JAN-MS-02296313							
JA-02135	04/20/2007	Bruce Moskovitz Presentation - Duragesic Risk Management Overview	JAN-MS-02305132	JAN-MS-02305132							
JA-02136	07/22/2014	RADARS Presentation: Janssen Pharmaceutical, Inc.: RADARS System	JAN-MS-02319754	JAN-MS-02319754							
JA-02137	09/17/2014	NAVIPPRO: Abuse Liability of Tapentadol: The NAVIPPRO Perspective	JAN-MS-02319755	JAN-MS-02319755							
JA-02138	08/05/2014	Nucynta 21st Century Technology	JAN-MS-02319887	JAN-MS-02319887							
JA-02139	05/20/2003	Letter from Bob Rappaport to Janne Wissel re Received approval letter for the pediatric supplement	JAN-MS-00909266	JAN-MS-00909269							
JA-02140	11/13/2007	Nucynta Annual Report 2011 Clinical Summary	JAN-MS-00234206	JAN-MS-00234206							
JA-02141	06/30/2009	Letter from Harinda Abeysinghe to Bob A. Rappaport re NDA 19-813 for Duragesic (fentanyl transdermal system).	JAN-MS-02371562	JAN-MS-02371563							
JA-02142	02/04/2005	Letter from Bob Rappaport to Susan P. Rinne	JAN-MS-02371740	JAN-MS-02371787							
JA-02143	02/01/2013	Nucynta ER program presentation	JAN-MS-01080235	JAN-MS-01080235							
JA-02144	12/17/2001	D-trans (fentanyl) Summary of Benefits and Risks: Abuse and Diversion prepared by Pinney Associates	JAN-MS-01139518	JAN-MS-01139597							
JA-02145	08/16/2004	Transdermal Fentanyl Systems: Reduced Safety and Increased Societal Risk of Matrix Patch Formulations, White Paper prepared by Mudskipper	JAN-MS-04307987	JAN-MS-04308090							
JA-02146	06/04/2009	Draft Charter of the Opioid REMS Industry Working Group	JAN-MS-01152825	JAN-MS-01152828							
JA-02147	04/21/2011	Bruce Moskovitz Presentation: The Drug Development Process and the Integration of R&D and Commercial	JAN-MS-01183244	JAN-MS-01183244							
JA-02148	07/09/2008	Phase 3 Clinical Study Report - R331333-PAI-3001 (KF5503/31)	JAN-MS-04434400	JAN-MS-04436002							
JA-02149	11/20/2008	Letter from Bob Rappaport to Kathleen Dusek	JAN-MS-01232317	JAN-MS-01232356							
JA-02150	11/17/2009	Email from Phillip Pierce to Jadwiga Martynowicz et al.	JAN-MS-01264809	JAN-MS-01264809							
JA-02151	07/02/1905	Phase 2 Clinical Study Report - JNS024PR-JPN-C01	JAN-MS-01344495	JAN-MS-01344650							
JA-02152	07/01/2014	RADARS System Tapentadol Report (Q1 2014)	JAN-MS-01368470	JAN-MS-01368671							
JA-02153	10/04/2013	RADARS System Tapentadol Report (Q2 2013)	JAN-MS-01368672	JAN-MS-01368868							
JA-02154	10/07/2014	RADARS System Tapentadol Report (Q2 2014)	JAN-MS-01368869	JAN-MS-01369061							
JA-02155	01/02/2014	RADARS System Tapentadol Report (Q3 2013)	JAN-MS-01369062	JAN-MS-01369264							
JA-02156	04/04/2014	RADARS System Tapentadol Report (Q4 2013)	JAN-MS-01369265	JAN-MS-01369466							
JA-02157	04/07/2015	RADARS System Tapentadol Report (Q4 2014)	JAN-MS-01439894	JAN-MS-01440096							
JA-02158	06/01/2012	Dear Doctor Letter	JAN-MS-01461550	JAN-MS-01461551							
JA-02159	08/01/2011	Janssen Presentation: Nucynta ER - New Perspectives in the Management of Moderate to Severe Chronic Pain	JAN-MS-02406964	JAN-MS-02406964							
JA-02160	01/01/2012	Janssen Presentation: Nucynta - A New Perspective for Moderate to Severe Acute Pain Relief: A Focus on the Balance of Efficacy and Tolerability	JAN-MS-02406966	JAN-MS-02406966							
JA-02161	08/25/2011	Dear Doctor Letter	JAN-MS-01476308	JAN-MS-01476311							
JA-02162	08/13/2013	RADARS System Tapentadol Report (Q1 2013)	JAN-MS-01529805	JAN-MS-01530005							
JA-02163	07/05/2011	RADARS Fentanyl Data (Q1 2011)	JAN-MS-01545296	JAN-MS-01545597							
JA-02164	01/29/2010	Phase 3 Clinical Trial Report - KF5503/16	JAN-MS-01547500	JAN-MS-01550427							
JA-02165	10/05/2011	RADARS System Fentanyl Data (Q2 2011)	JAN-MS-01551506	JAN-MS-01551800							
JA-02166	04/04/2011	RADARS Fentanyl Data (Q4 2010)	JAN-MS-01595930	JAN-MS-01596236							
JA-02167	01/07/2015	RADARS System Tapentadol Report (Q3 2014)	JAN-MS-01597449	JAN-MS-01597652							
JA-02168	04/17/2015	RADARS System Tapentadol Report (2014 Annual)	JAN-MS-01598670	JAN-MS-01598870							
JA-02169	04/16/2014	RADARS System Tapentadol Report (2013 Annual)	JAN-MS-01598871	JAN-MS-01599071							
JA-02170	07/15/2008	Phase 3 Clinical Trial Report - KF5503/37	JAN-MS-01744111	JAN-MS-01746217							
JA-02171	05/25/2010	Phase 3b Clinical Study Report - R331333-PAI-3020 (KF5503/41)	JAN-MS-01772718	JAN-MS-01775485							
JA-02172	08/25/2011	Letter from Bob A. Rappaport to Kathleen Dusek	JAN-MS-02558181	JAN-MS-02558288							
JA-02173	08/30/2005	Email from State Government Affairs Update to ListServe	JAN-MS-02565925	JAN-MS-02565929							
JA-02174	03/18/2010	Email from Susan Nicholson to Karen Naim et al.	JAN-MS-02569642	JAN-MS-02569642							
JA-02175	10/04/1997	Simpson, et al, Transdermal Fentanyl as Treatment for Chronic Low Back Pain, Journal of Pain and Symptom Management, Vol 14, No. 4, p.218-224 (1997)	JAN-MS-02580183	JAN-MS-02580190							
JA-02176	04/24/2002	FEN-OUT-45 Clinical Trial Protocol	JAN-MS-02590047	JAN-MS-02590116							
JA-02177	09/28/2004	FEN-OUT-45 Clinical Research Report	JAN-MS-02592520	JAN-MS-02592592							
JA-02178	07/31/2009	Letter from Bob A. Rappaport to Harindra Abeysinghe	JAN-MS-02749196	JAN-MS-02749250							
JA-02179	01/01/2000	Duragesic visual aid	JAN-MS-02757604	JAN-MS-02757615							
JA-02180	01/01/2003	Duragesic visual aid	JAN-MS-02757742	JAN-MS-02757750							
JA-02181	02/18/2005	Duragesic (fentanyl transdermal system) Internet Monitoring Methodology	JAN-MS-02777561	JAN-MS-02777580							
JA-02182	03/10/2009	Nucynta PADER Nov 2008-Feb 2009	JAN-MS-00235114	JAN-MS-00235114							
JA-02183	06/05/2009	Nucynta PADER Feb 2009-May 2009	JAN-MS-00235118	JAN-MS-00235118							
JA-02184	09/15/2009	Nucynta PADER May 2009-Aug 2009	JAN-MS-00235122	JAN-MS-00235122							
JA-02185	12/11/2009	Nucynta PADER Aug 2009-Nov 2009	JAN-MS-00235126	JAN-MS-00235126							
JA-02186	03/15/2010	Nucynta PADER Nov 2009-Feb 2010	JAN-MS-00235155	JAN-MS-00235155							
JA-02187	06/08/2010	Nucynta PADER Feb 2010-May 2010	JAN-MS-00235169	JAN-MS-00235169							
JA-02188	09/10/2010	Nucynta PADER May 2010-Aug 2010	JAN-MS-00235190	JAN-MS-00235190							
JA-02189	12/10/2010	Nucynta PADER Aug 2010-Nov 2010	JAN-MS-00235193	JAN-MS-00235193							
JA-02190	03/11/2011	Nucynta PADER Nov 2010-Feb 2011	JAN-MS-00235219	JAN-MS-00235219							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-02191	06/09/2011	Nucynta PADER Feb 2011-May 2011	JAN-MS-00235242	JAN-MS-00235242							
JA-02192	09/12/2011	Nucynta PADER May 2011-Aug 2011	JAN-MS-00235245	JAN-MS-00235245							
JA-02193	12/12/2011	Nucynta PADER Aug 2011-Nov 2011	JAN-MS-00235252	JAN-MS-00235252							
JA-02194	01/02/2013	Nucynta PADER Nov 2011-Nov 2012	JAN-MS-00235281	JAN-MS-00235281							
JA-02195	01/17/2013	Nucynta Annual Report 2013 Clinical Summary	JAN-MS-00235292	JAN-MS-00235292							
JA-02196	12/30/2013	Nucynta PADER Nov 2012-Nov 2013	JAN-MS-00235302	JAN-MS-00235302							
JA-02197	01/17/2014	Nucynta Annual Report 2014 Clinical Summary	JAN-MS-00235315	JAN-MS-00235315							
JA-02198	01/08/2015	Nucynta PADER Nov 2013-Nov 2014	JAN-MS-00235324	JAN-MS-00235324							
JA-02199	12/29/2010	Nucynta Speaker Direct NewsChannel Presentation	JAN-MS-00235864	JAN-MS-00235864							
JA-02200	06/19/2009	Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use (Form 2253)	JAN-MS-00236013	JAN-MS-00236013							
JA-02201	04/01/2009	Nucynta Pharmacist Branded Visual Aid	JAN-MS-00236015	JAN-MS-00236015							
JA-02202	04/01/2009	Nucynta Pharmacist Leave Behind	JAN-MS-00236016	JAN-MS-00236016							
JA-02203	04/01/2009	Nucynta Dosing and Administration Guide	JAN-MS-00236017	JAN-MS-00236017							
JA-02204	02/01/2009	Hartrick C, et al., Efficacy and Tolerability of Tapentadol Immediate Release and Oxycodone HCl Immediate Release in Patients Awaiting Primary Joint Replacement Surgery for End-State Joint Disease: A 10-Day, Phase III, Randomized, Double-Blind, Active- and Placebo-Controlled Study, Clinical Therapeutics, Vol. 31 No. 2, pp. 260-271	JAN-MS-00236018	JAN-MS-00236018							
JA-02205	04/01/2009	Hartrick Reprint Carrier	JAN-MS-00236019	JAN-MS-00236019							
JA-02206	10/07/2010	Janssen presentation: Leadership in Compliance	JAN-OH-00038521	JAN-OH-00038521							
JA-02207	03/09/2011	Janssen Nucynta Surveillance Report: National Addictions Vigilance Intervention and Prevention Program (NAVIPPRO); November 2010 to December 2010	JAN-MS-00008953	JAN-MS-00008998							
JA-02208	06/25/1905	Duragesic Full Prescribing Information	JAN-MS-03089192	JAN-MS-03089235							
JA-02209	03/05/2019	Samples, Hillary et al., "Opioid use and Misuse and Suicidal Behaviors in a Nationally Representative Sample of US Adults," American Journal of Epidemiology, Vol. 188, No. 7, pp. 1245-1253.	JAN-TREX-00028933	JAN-TREX-00028941							
JA-02212	07/09/1905	National Automobile Dealers Association (NADA) data including the Annual Financial Profile of America's Franchised New-Car Dealerships Report for 2017, https://www.nada.org/2017NADAdata/ (accessed August 19, 2019) and electronic file "2017 NADA State Data Sheets.xlsx" received from NADA Economist, Patrick Manzi, August 13, 2019.	JAN-TREX-00149915	JAN-TREX-00149915							
JA-02213	1996-2017	Polk confidential light-vehicle registrations from R.L. Polk & Co., a foundation of IHS Markit automotive solutions, 1996–2017.	JAN-TREX-00028942	JAN-TREX-00028957							
JA-02214	07/11/1905	U.S. Department of Justice, National Institute of Justice, Law Enforcement Records Management System (LERMS) data. Electronic files received August 19, 2019, and "Standard Functional Specifications for Law Enforcement Records Management Systems (RMS)," https://it.ojp.gov/documents/LEITSC_Law_Enforcement_RMS_Systems.pdf (accessed August 19, 2019). 33. U.S. Department of Transportation, National Highway Traffic Safety Administration, Traffic Safety Facts 1996-Traffic Safety Facts 2016, https://crashstats.nhtsa.dot.gov/#/DocumentTypeList/11 (accessed July 31, 2019).	JAN-TREX-00028958	JAN-TREX-00029024							
JA-02215	1996-2016	U.S. Department of Transportation, National Highway Traffic Safety Administration, Traffic Safety Facts 1996-Traffic Safety Facts 2016, https://crashstats.nhtsa.dot.gov/#/DocumentTypeList/11 (accessed July 31, 2019).	JAN-TREX-00029025	JAN-TREX-00029240							
JA-02216	07/02/1905	Nucynta ER FAQ List	JAN-TREX-00029241	JAN-TREX-00029252							
JA-02217	01/25/2010	Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use, Nucynta IR	JAN-MS-00236191	JAN-MS-00236191							
JA-02218	01/11/2008	Email from Ron Kuntz to Roxanne McGregor-Beck et al.	JAN-MS-01018739	JAN-MS-01018740							
JA-02219	07/11/2009	Email from HCC Communications to Terry Arnold-Collins et al.	JAN-MS-02000333	JAN-MS-02000336							
JA-02220	11/01/2008	Full Prescribing Information	JAN-TREX-00149693	JAN-TREX-00149693							
JA-02221	03/01/2009	Full Prescribing Information	JAN-TREX-00149694	JAN-TREX-00149694							
JA-02222	01/12/2012	Introductory Presentation: Nucynta PR Meeting - Welcome Weber Shandwick	JAN-MS-00018068	JAN-MS-00018180							
JA-02223	01/12/2012	Introductory Presentation: Nucynta PR Meeting - Welcome Weber Shandwick	JAN-TREX-00029253	JAN-TREX-00029362							
JA-02224	03/18/2016	CDC Guideline for Prescribing Opioids for Chronic Pain -- United States, 2016	JAN-TREX-00029363	JAN-TREX-00029414							
JA-02225	08/01/2011	Analgesic treatment for moderate-to-severe acute pain in the United States: Patients' perspectives in the Physicians Partnering Against Pain (P3) Survey, B. Moskovitz and others	JAN-TREX-00029415	JAN-TREX-00029424							
JA-02226	03/08/2002	Medical Affairs Pain Mycology Monthly Status Report, February 23, 2002	JAN-MS-02326363	JAN-MS-02326387							
JA-02227	12/13/2005	Investigator Initiated Studies-Duragesic, Ongoing/Completed/Terminated Studies	JAN-MS-00274787	JAN-MS-00274789							
JA-02228	07/06/2006	Substance Use Disorders in a Primary Care Sample Receiving Daily Opioid Therapy, Michael Fleming and others	JAN-TREX-00029425	JAN-TREX-00029434							
JA-02229	12/05/2008	Opioid use behaviors, mental health and pain--Development of a typology of chronic pain patients, Caleb Banta-Green and others	JAN-TREX-00029435	JAN-TREX-00029443							
JA-02230	09/28/2009	Risk factors for drug dependence among out-patients on opioid therapy in a large US health-care system, Joseph Boscarino and others	JAN-TREX-00029444	JAN-TREX-00029451							
JA-02231	06/30/1905	What Percentage of Chronic Nonmalignant Pain Patients Exposed to Chronic Opioid Analgesic Therapy Develop Abuse/Addiction and/or Aberrant Drug-Related Behaviors? A Structured Evidence-Based Review, David Fishbain and others	JAN-TREX-00029452	JAN-TREX-00029467							
JA-02232	07/02/1905	Cochrane Library Long-term opioid management for chronic noncancer pain (Review), Treadwell and others	JAN-TREX-00029468	JAN-TREX-00029537							
JA-02233	04/28/2005	Evaluation of Abuse of Prescription and Illicit Drugs in Chronic Pain Patients Receiving Short-Acting (Hydrocodone) or Long-Acting (Methadone) Opioids	JAN-TREX-00029538	JAN-TREX-00029542							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-02234	07/01/1905	ScienceDirect website on Hydrocodone, available at https://www.sciencedirect.com/topics/medicine-and-dentistry/hydrocodone	JAN-TREX-00029543	JAN-TREX-00029548							
JA-02235	04/20/2007	Duragesic Risk Management Overview	JAN-MS-00493882	JAN-MS-00493882							
JA-02236	09/01/2018	2018 Duragesic Label and Prescription Guide	JAN-TREX-00029549	JAN-TREX-00029608							
JA-02237	1987 - 2014	Selected Studies, Research, and Analysis of Safety and Efficacy of Duragesic and Nucynta	JAN-TREX-00029609	JAN-TREX-00029636							
JA-02238	2009-2014	Selected Support for Statements and Representations Regarding Pseudoadddiction	JAN-TREX-00029637	JAN-TREX-00029748							
JA-02239	No Date	Sources of Knowledge Regarding Abuse, Misuse, Dependence or Addiction	JAN-TREX-00029749	JAN-TREX-00030320							
JA-02240	No Date	PrescribeResponsibly.com References	JAN-TREX-00030321	JAN-TREX-00031746							
JA-02241	No Date	Let's Talk Pain References	JAN-TREX-00149695	JAN-TREX-00149695							
JA-02242	07/02/1905	Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind placebo and active-controlled Phase III Study, Robert Buynak and others	JAN-TREX-00031747	JAN-TREX-00031764							
JA-02243	05/01/2007	FDA Periodic Safety Update Report Fentanyl and Fentanyl Citrate	JAN-MS-00213786	JAN-MS-00213786							
JA-02244	02/06/2014	Journal of Opioid Management: Evaluation of the Tamper-Resistant Properties of Tapentadol Extended-Release Tablets: Results of In Vitro Laboratory Analyses, Eric Galia et al.	JAN-TREX-00031765	JAN-TREX-00031774							
JA-02245	07/07/1905	Pain Medicine Wiley Periodicals, Inc.: Tapentadol Abuse Potential: A Postmarketing Evaluation Using a Sample of Individuals Evaluated for Substance Abuse Treatment, Stephen Butler et al.	JAN-TREX-00031775	JAN-TREX-00031786							
JA-02246	07/07/1905	Pain Medicine Wiley Periodicals, Inc.: Assessing Abuse Potential of New Analgesic Medications Following Market Release: An Evaluation of Internet Discussion of Tapentadol Abuse, Emily McNaughton et al.	JAN-TREX-00031787	JAN-TREX-00031796							
JA-02247	07/05/1905	Pain Physician Journal: Efficacy of Tapentadol ER for Managing Moderate to Severe Chronic Pain, Marc Afialo et al.	JAN-TREX-00031797	JAN-TREX-00031810							
JA-02248	07/08/1905	Pain Medicine: Diversion and Illicit Sale of Extended Release of Tapentadol in the United States, Richard C. Dart et al.	JAN-TREX-00031811	JAN-TREX-00031817							
JA-02249	No Date	APF: Pain Resource Guide, pp. 1,7 (Tab 2 of Ex. 21 from 1/9/19 depo)	JAN-TREX-00031818	JAN-TREX-00031820							
JA-02250	No Date	APF: Pain Notebook, p. 6 (Tab 3 of Ex. 21 from 1/9/19 depo)	JAN-TREX-00031821	JAN-TREX-00031822							
JA-02251	No Date	APS Glossary of Pain Terms (Tab 4 of Ex. 21 from 1/9/19 depo)	JAN-TREX-00149696	JAN-TREX-00149696							
JA-02252	06/16/2005	Treating Doctors as Drug Dealers; The DEA's War on Prescription Painkillers; Ronald T. Libby (Tab 6 of Ex. 21 from 1/9/19 depo)	JAN-TREX-00031823	JAN-TREX-00031850							
JA-02253	10/12/2018	NEJM: Opioid Therapy for Chronic Pain Article (Tab 7 of Ex. 21 from 1/9/19 depo)	JAN-TREX-00031851	JAN-TREX-00031861							
JA-02254	06/27/1905	Portenoy RK, Payne R, Passik SK. Lowinson JH, Ruz P, Millman RB, Langrod JG. Substance Abuse: A Comprehensive Textbook. 4th ed. Philadelphia: Lippincott, William & Wilkens; 2004. Acute and Chronic Pain (Tab 8 of Ex. 21 from 1/9/19 depo)	JAN-TREX-00031862	JAN-TREX-00031905							
JA-02255	05/01/2003-04/30/2004	DUR 16, 2003-2004 Duragesic PSUR Studies	JAN-MS-002133773	JAN-MS-002133773							
JA-02256	2009-2010	DUR 22, 2009-2010 Duragesic PSUR	JAN-MS-0165630	JAN-MS-0165630							
JA-02257	01/15/2013	IR 14, 2013 Nucynta IR Annual Report Other Significant Information	JAN-MS-00235296	JAN-MS-00235296							
JA-02258	01/15/2013	IR 15, 2013 Nucynta IR Annual Report PMR Commitments	JAN-MS-00235291	JAN-MS-00235291							
JA-02259	01/12/2013	IR 16, 2014 Nucynta IR Annual PMR Commitments	JAN-MS-00235314	JAN-MS-00235314							
JA-02260	01/07/2013	IR 18, 2014 Nucynta IR Annual Report Other Significant Information	JAN-MS-00235318	JAN-MS-00235318							
JA-02261	01/02/2013	IR 19, 2015 Nucynta IR Annual Report Clinical Summary	JAN-MS-00235335	JAN-MS-00235335							
JA-02262	01/07/2013	IR 20, 2015 Nucynta IR Annual Report Other Significant Info	JAN-MS-00235340	JAN-MS-00235340							
JA-02263	01/12/2013	IR 21, 2015 Nucynta IR Annual Report PMR Commitments	JAN-MS-00235334	JAN-MS-00235334							
JA-02264	02/17/2012	ER 3, 2012 Nucynta ER Annual Report Other PMR Studies	JAN-MS-00228474	JAN-MS-00228474							
JA-02265	06/26/1905	Steven Passik, et. al., A New Tool to Assess and Document Pain Outcomes in Chronic Pain Patients Receiving Opioid Therapy, 26(4), pp.552 - 562, 2004	JAN-MS-02312280	JAN-MS-02312289							
JA-02266	05/04/2005	SUPP 8, An observational study of health-related quality of life and pain outcomes in chronic low back pain patients treated with fentanyl transdermal system, Mark Kosinski and others	JAN-TREX-00031906	JAN-TREX-00031920							
JA-02267	10/01/1997	SUPP 9, Transdermal Fentanyl as Treatment for Chronic Low Back Pain, Richard Simpson and others	JAN-TREX-00031921	JAN-TREX-00031927							
JA-02268	05/05/2005	Email from G. Vorsanger to K. Naim et al.	JAN-MS-00619620	JAN-MS-00619620							
JA-02269	02/11/2005	Prescription Drug Research Center "How To Manual" for Duragesic Surveillance Program	JAN-MS-02777505	JAN-MS-02777546							
JA-02270	02/11/2005	Prescription Drug Research Center "How To Manual" for Duragesic Surveillance Program Appendix	JAN-MS-02777547	JAN-MS-02777560							
JA-02271	04/09/2019	Statement by Douglas Throckmorton, M.D., Deputy Center Director for Regulatory Programs in FDA Regarding New Opioid Analgesic Labeling Changes	JAN-TREX-00031928	JAN-TREX-00031931							
JA-02272	06/20/1905	Opioid tolerance: the clinical perspective, B-J Collett	JAN-TREX-00031932	JAN-TREX-00031942							
JA-02273	09/14/2018	CDC Morbidity and Mortality Weekly Report, Prevalence of Chronic Pain and High-Impact Chronic Pain Among Adults -- United States, 2016	JAN-TREX-00031943	JAN-TREX-00031950							
JA-02274	04/28/2008	Janssen RADARS Report	JAN-MS-00483327	JAN-MS-00483328							
JA-02275	No Date	NIDA: Pain Assessment and Documentation Tool (PADT)	JAN-TREX-00031951	JAN-TREX-00031953							
JA-02276	06/11/2014	Letter from Judith Racoosin to Tania Hillmer re approving ER/LA REMS with REMS attached	JAN-MS-02099676	JAN-MS-02099723							
JA-02277	07/02/2015	Prescribe Responsibly home page	JAN-TREX-00149697	JAN-TREX-00149697							
JA-02278	07/02/2015	Prescribe Responsibly full website, unavailable online	JAN-TREX-00031954	JAN-TREX-00031964							
JA-02279	01/10/2008	Ortho-McNeil presentation: Smart Moves, Smart Choices 2008 Rollout Plan presentation	JAN-MS-00275603	JAN-MS-00275603							
JA-02280	07/02/1905	NASN and PriCara presentation: Overview of Smart Moves, Smart Choices	JAN-MS-00343143	JAN-MS-00343143							
JA-02281	07/06/1905	Smart Moves, Smart Choices About page	JAN-TREX-00149698	JAN-TREX-00149698							
JA-02282	07/06/1905	Smart Moves, Smart Choices Elementary Smart Start Tools webpage	JAN-TREX-00031965	JAN-TREX-00031966							
JA-02283	07/06/1905	Smart Moves, Smart Choices Tool Kit for Middle and High Schools webpage	JAN-TREX-00031967	JAN-TREX-00031968							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-02284	07/06/1905	Smart Moves, Smart Choices Choices video webpage	JAN-TREX-00031969	JAN-TREX-00031970							
JA-02285	05/04/2012	Email from Bruce Colligen to Robyn Kohn et al.	JAN-MS-00916797	JAN-MS-00916798							
JA-02286	03/25/2014	Start Smart Program Overview	JAN-MS-00428464	JAN-MS-00428466							
JA-02287	03/25/2014	Smart Moves, Smart Choices Animated Video Discussion Guide	JAN-MS-00428467	JAN-MS-00428473							
JA-02288	04/29/2019	Nurse.com Website: Confronting the Opioid Epidemic	JAN-TREX-00149699	JAN-TREX-00149699							
JA-02289	04/29/2019	About Nurse.com Webpage	JAN-TREX-00031971	JAN-TREX-00031973							
JA-02290	08/31/2018	Nurse.com Opioid Use Course Description	JAN-TREX-00031974	JAN-TREX-00031978							
JA-02291	08/31/2018	Nurse.com Health Literacy Course Description	JAN-TREX-00031979	JAN-TREX-00031983							
JA-02292	08/31/2018	Nurse.com Patient Counseling Course Description	JAN-TREX-00031984	JAN-TREX-00031988							
JA-02293	01/01/2003	Nurse.com Meeting the Challenge Course Description	JAN-TREX-00031989	JAN-TREX-00031995							
JA-02294	01/17/2014	Nurse.com Responsible Opioid Prescribing Course Description	JAN-TREX-00031996	JAN-TREX-00032001							
JA-02295	09/09/2002	Nurse.com Prescription Drug Abuse Course Description	JAN-TREX-00032002	JAN-TREX-00032007							
JA-02296	02/22/2018	Nurse.com Pain Management Course Description	JAN-TREX-00032008	JAN-TREX-00032013							
JA-02297	01/17/2014	Nurse.comChronic Pain Course Description	JAN-TREX-00032014	JAN-TREX-00032019							
JA-02298	06/28/2018	Nurse.com Effective Pain Management Course Description	JAN-TREX-00032020	JAN-TREX-00032025							
JA-02299	12/16/2002	Nurse.com Substance Abuse Course Description	JAN-TREX-00032026	JAN-TREX-00032032							
JA-02300	03/25/2013	Nurse.com Medical Non-Adherence Course Description	JAN-TREX-00032033	JAN-TREX-00032038							
JA-02301	07/16/2007	Nurse.com Knocking Out Course Description	JAN-TREX-00032039	JAN-TREX-00032044							
JA-02302	10/18/1999	Nurse.com Recognizing Course Description	JAN-TREX-00032045	JAN-TREX-00032050							
JA-02303	05/08/2018	Nurse.com Evidence-Based Course Description	JAN-TREX-00032051	JAN-TREX-00032055							
JA-02304	07/28/2015	Nurse.com Motivational Course Description	JAN-TREX-00032056	JAN-TREX-00032062							
JA-02305	04/24/2019	About BabyCenter Webpage	JAN-TREX-00032063	JAN-TREX-00032070							
JA-02306	04/24/2019	BabyCenter.com Editorial and Advertising Policy Webpage at https://www.babycenter.com/editorial-advertising-policy	JAN-TREX-00032071	JAN-TREX-00032075							
JA-02307	04/24/2019	BabyCenter.com Advisory Board webpage	JAN-TREX-00032076	JAN-TREX-00032085							
JA-02308	06/01/2018	BabyCenter.com What Are Opioids Webpage	JAN-TREX-00032086	JAN-TREX-00032090							
JA-02309	06/01/2018	BabyCenter.com Which Medicines Contain Opioids Webpage	JAN-TREX-00032091	JAN-TREX-00032096							
JA-02310	06/01/2018	BabyCenter.com Is It Safe to Take Opioids During Pregnancy Webpage	JAN-TREX-00032097	JAN-TREX-00032102							
JA-02311	06/01/2018	BabyCenter.com Is It Safe to Take Opioids While Breastfeeding Webpage	JAN-TREX-00032103	JAN-TREX-00032108							
JA-02312	06/01/2018	BabyCenter.com Is It Safe to Take Opioids During Labor Webpage	JAN-TREX-00032109	JAN-TREX-00032114							
JA-02313	06/01/2018	BabyCenter.com What Is My Risk Webpage	JAN-TREX-00032115	JAN-TREX-00032120							
JA-02314	06/01/2018	BabyCenter.com How Can I Minimize my Risk Webpage	JAN-TREX-00032121	JAN-TREX-00032126							
JA-02315	06/01/2018	BabyCenter.com What Are The Signs Webpage	JAN-TREX-00032127	JAN-TREX-00032133							
JA-02316	09/01/2018	FDA's Opioid Analgesic REMS Education Blueprint	JAN-TREX-00032134	JAN-TREX-00032146							
JA-02317	09/18/2018	Approved Risk Evaluation and Mitigation Strategies Opioid Analgesic REMS	JAN-TREX-00032147	JAN-TREX-00032183							
JA-02318	07/25/2012	PROP Petition	JAN-TREX-00032184	JAN-TREX-00032190							
JA-02319	09/10/2013	FDA Response to PROP Petition	JAN-TREX-00032191	JAN-TREX-00032208							
JA-02320	12/21/2009	Smart Moves, Smart Choices 2009 Program Success PPT	JAN-MS-02403095	JAN-MS-02403095							
JA-02321	04/16/2008	National Association of School Nurses Launches Educational Program to Address Surge of Prescription Drug Abuse by America's Youth	JAN-MS-00500040	JAN-MS-00500041							
JA-02322	01/01/2018	Duragesic Label 2018-01	JAN-TREX-00032209	JAN-TREX-00032264							
JA-02323	10/01/2012	Nucynta Oral Solution Label 2012-10	JAN-MS-01248173	JAN-MS-01248215							
JA-02324	12/01/2016	Nucynta Oral Solution Label 2016-12	JAN-TREX-00032265	JAN-TREX-00032303							
JA-02325	12/15/2011	Letter from Peggy Ferrone to Dr. Bob Rappaport, FDA re Nucynta Oral Solution NDA Cover Letter	JAN-MS-00230206	JAN-MS-00230206							
JA-02326	12/15/2011	Nucynta Oral Solution Application to Market a New Drug	JAN-MS-00230193	JAN-MS-00230193							
JA-02327	12/13/2011	Nucynta Oral Solution Cross-Reference to Nucynta IR Clinical Overview	JAN-MS-00230207	JAN-MS-00230207							
JA-02328	No Date	Janssen presentation: Nucynta ER (tapentadol) Extended-Release Oral Tablets	JAN-MS-00244576	JAN-MS-00244717							
JA-02329	05/27/2009	Agenda for May 27, 2009 meeting with FDA	JAN-MS-01048370	JAN-MS-01048379							
JA-02330	07/22/2010	Joint Meeting of the Anesthetic and Life Support Drugs Advisory Committe and the Drug Safety and Risk Management Advisory Committees July 22-23, 2010 PPT	JAN-TREX-00032304	JAN-TREX-00032350							
JA-02331	04/06/2004	ALZA sNDA for Duragseic for 12 mcg/h dosage strength	JAN-MS-00781142	JAN-MS-00781146							
JA-02332	01/30/2009	Johnson & Johnson sNDA for Duragesic matrix patch	JAN-MS-02371562	JAN-MS-023715623							
JA-02333	07/31/2009	FDA Approval Duragesic sNDA for matrix patch	JAN-MS-02749196	JAN-MS-02749250							
JA-02334	No Date	Opioid Risk Tool	JAN-TREX-00032351	JAN-TREX-00032352							
JA-02335	03/26/2002	D-trans sufentanil + antagonist work plan and cost estimate	JAN-MS-01032303	JAN-MS-01032312							
JA-02336	03/04/2005	Email from E. Huang to Eric Huang et al.	JAN-MS-01032284	JAN-MS-01032285							
JA-02337	12/12/2012	Press release - Marketing clearance for post-surgical pain candidate IONSYS expected in early 2014	JAN-TREX-00032353	JAN-TREX-00032355							
JA-02338	01/29/2002	Email from L. Atkinson to Detlef Albrecht et al.	JAN-MS-00618585	JAN-MS-00618585							
JA-02339	01/22/2002	AP-44 Clinical Development Plan Draft	JAN-MS-00618586	JAN-MS-00618589							
JA-02340	06/12/2001	OROS Oxycodone HCI Clinical Development Plan	JAN-MS-00618599	JAN-MS-00618611							
JA-02341	09/15/2003	Email from T. Queli to Tina Queli et al.	JAN-MS-00423424	JAN-MS-00423425							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-02342	09/15/2003	Presentation: Developmental Alternatives for backup during AP-23 discussion	JAN-MS-00423428	JAN-MS-00423428							
JA-02343	08/17/2004	Email from L. Fedow to William Foster et al.	JAN-MS-01235425	JAN-MS-01235428							
JA-02344	05/24/2003	Email from E. Mutisya to Joyce Babecki et al.	JAN-MS-02536039	JAN-MS-025360040							
JA-02345	05/20/2003	Janssen Presentation: R331333 NPDC Meeting	JAN-MS-02536041	JAN-MS-02536056							
JA-02346	10/17/2001	Email from Dorothy Bermudez to Detlef Albrecht et al.	JAN-MS-02462097	JAN-MS-02462097							
JA-02347	10/22/2001	ALZZA AP-48 D-TRANS fentanyl + naltrexone PPT	JAN-MS-02462099	JAN-MS-02462122							
JA-02348	10/17/2001	D-TRANS AP-48 work plan and cost estimate	JAN-MS-02462123	JAN-MS-02462147							
JA-02349	12/23/2003	Email from S. Lande to M. McDonald	JAN-MS-03067302	JAN-MS-03067302							
JA-02350	10/18/2011	Janssen Presentation: Nucynta OS (Tapentadol HCI)	JAN-MS-02920800	JAN-MS-02920800							
JA-02351	02/27/2012	Email from R. Kuntz to K. Burns	JAN-MS-01040851	JAN-MS-01040851							
JA-02352	02/27/2012	Janssen Presentation: Nucynta Oral Solution	JAN-MS-01040852	JAN-MS-01040852							
JA-02353	10/18/2012	Email from F. Demiro to P. Yap	JAN-MS-00336388	JAN-MS-00336388							
JA-02354	10/18/2012	Nucynta (tapentadol) oral souldion Q & A	JAN-MS-00336389	JAN-MS-00336390							
JA-02355	04/02/2015	Email from GMS Support Desk to T. Hillmer et al.	JAN-MS-02119923	JAN-MS-02119924							
JA-02356	04/02/2015	Letter from Tania Hillmer to Sharon Hertz, FDA re Transfer of IND 108134 Ownership to Depomed - tapentadol oral solution	JAN-MS-02119927	JAN-MS-02119928							
JA-02357	04/02/2015	Letter from Tania Hillmer to Sharon Hertz, FDA re Transfer of NDA 203794 Ownership to Depomed - Nucynta oral solution	JAN-MS-02119933	JAN-MS-02119934							
JA-02358	07/03/1905	Allen et al ., "Reference Guide on the Estimation of Economic Damages," in Reference Manual on Scientific Evidence, 3rd ed.,, Federal Judicial Center, 2011.	JAN-TREX-00032356	JAN-TREX-00032436							
JA-02359	No Date	Finding Relief References	JAN-TREX-00032437	JAN-TREX-00033378							
JA-02360	05/04/2005	An observational study of health-related quality of life and pain outcomes in chronic low back pain patients treated with fentanyl transdermal system, Mark Kosinski and others	JAN-TREX-00033379	JAN-TREX-00033393							
JA-02361	10/04/1997	Transdermal Fentanyl as Treatment for Chronic Low Back Pain, Richard Simpson and others	JAN-TREX-00033394	JAN-TREX-00033400							
JA-02362	08/29/2005	Email from D. Hewitt to B. Moskovitz et al.	JAN-MS-02136846	JAN-MS-02136846							
JA-02363	07/01/2005	Draft Response to July 29, 2005 FDA letter received on IONSYS RiskMAP	JAN-TREX-00033401	JAN-TREX-00033405							
JA-02364	04/28/1998	Food and Drug Administration Center for Drug Evaluation and Research Drug Abuse Advisory Committee	JAN-MS-00890718	JAN-MS-00890888							
JA-02365	02/27/2007	Email from G. Vorsanger to Jean Farrell et al.	JAN-MS-02310916	JAN-MS-02310917							
JA-02366	11/12/1991	Duragesic Status Report of Post Marketing Studies part of NDA (1991-1992)	JAN-MS-00213684	JAN-MS-00213684							
JA-02367	12/19/2003	Email from A. Stephenson to B. Moskovitz	JAN-MS-01195546	JAN-MS-01195546							
JA-02368	07/07/2003	Pharmacodynamic Study to Evaluate AP-58 in Opioid-experienced non-dependent volunteers	JAN-MS-01195547	JAN-MS-01195562							
JA-02369	11/06/2002	Email from S. Roman to K. Chupa	JAN-MS-00314078	JAN-MS-00314078							
JA-02370	12/01/2002	NPEC presentation on clinical management of pain	JAN-MS-00314079	JAN-MS-00314079							
JA-02371	09/27/2007	Email from L. Wilton to Linda Bell-Powell et al.	JAN-MS-02003147	JAN-MS-02003147							
JA-02372	09/26/2007	Duragesic Patient Pak Folder	JAN-MS-02003178	JAN-MS-02003181							
JA-02373	11/01/1966	Box, George E.P., "Use and Abuse of Regression," Technometrics, 8:4, 625-629, 1966.	JAN-TREX-00033406	JAN-TREX-00033411							
JA-02374	08/14/2007	Duragesic Patient Pak Letter	JAN-MS-0200176	JAN-MS-0200177							
JA-02375	05/31/1905	Box, George E.P., Hunter, William G., and Hunter, J. Stuart, Statistics for Experimenters: An Introduction to Design, Data Analysis, and Model Building, New York: John Wiley & Sons, 1978.	JAN-TREX-00149700	JAN-TREX-00149700							
JA-02376	08/01/2007	Patient Pak Q&A Booklet	JAN-MS-02003148	JAN-MS-02003175							
JA-02377	05/30/1905	Cochran, William G., Sampling Techniques, 3rd ed., New York: John Wiley & Sons, 1977.	JAN-TREX-00033412	JAN-TREX-00033421							
JA-02378	09/26/2007	Duragesic Patient Pak Box	JAN-MS-02003182	JAN-MS-02003183							
JA-02379	05/01/2007	Patient Pak Coupon	JAN-MS-02003184	JAN-MS-02003185							
JA-02380	06/20/1905	Freedman, David, Pisani, Robert and Purves, Roger, Statistics, New York: W. W. Norton & Company, 1998.	JAN-TREX-00149701	JAN-TREX-00149701							
JA-02381	11/27/2001	Promoting Pain Relief and Preventing Abuse of Pain Medications: A Critical Balancing Act	JAN-TREX-00149702	JAN-TREX-00149702							
JA-02382	05/27/1905	Granger, C.W.J. and Newbold, P., "Spurious Regressions in Econometrics," Journal of Econometrics, 2, 111-120, 1974.	JAN-TREX-00033422	JAN-TREX-00033431							
JA-02383	07/03/1905	Kaye, David H. and Freedman, David A., "Reference Guide on Statistics" Reference Manual on Scientific Evidence, 3rd ed., Federal Judicial Center, 2011.	JAN-TREX-00033432	JAN-TREX-00034465							
JA-02384	07/02/1905	Lohr, Sharon L. Sampling: Design and Analysis, 2nd ed., Boston: Brooks Cole, 2010.	JAN-TREX-00149703	JAN-TREX-00149703							
JA-02385	04/10/2019	National Drug Code (NDC) descriptions from various sources; www.cdc.gov/drugoverdose/resources/data.html/CDC_Oral_Morphine_Milligram_Equivalents_sept_2018.xlsx www.accessdata.fda.gov www.rxlist.com	JAN-TREX-00034466	JAN-TREX-00034467							
JA-02386	06/08/1905	Phillips, P.C.B., "Understanding Spurious Regressions in Econometrics," Journal of Econometrics, 33, 311-340, 1986.	JAN-TREX-00034468	JAN-TREX-00034497							
JA-02387	07/03/1905	Rubinfeld, Daniel L., "Reference Guide on Multiple Regression" Reference Manual on Scientific Evidence, 3rd ed., Federal Judicial Center, 2011.	JAN-TREX-00034498	JAN-TREX-00034555							
JA-02388	06/16/1905	Snedecor, G. W., and Cochran, W. G., Statistical Methods, 8th ed., Ames: Iowa State University Press, Ames, 1994.	JAN-TREX-00149704	JAN-TREX-00149704							
JA-02389	06/13/1905	Stuart, Alan and Keith J. Ord. Kendall's Advanced Theory of Statistics, 5th ed. Oxford University Press,	JAN-TREX-00034556	JAN-TREX-00034557							
JA-02390	06/24/1905	UN International Narcotics Control Board ("INCB"): Estimated World Requirements for 2001	JAN-TREX-00034558	JAN-TREX-00034835							
JA-02391	06/24/1905	UN International Narcotics Control Board ("INCB"): Estimated World Requirements for 2002	JAN-TREX-00034836	JAN-TREX-00035173							
JA-02392	06/25/1905	UN International Narcotics Control Board ("INCB"): Estimated World Requirements for 2003	JAN-TREX-00035174	JAN-TREX-00035529							
JA-02393	06/26/1905	UN International Narcotics Control Board ("INCB"): Estimated World Requirements for 2004	JAN-TREX-00035530	JAN-TREX-00035869							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-02394	06/27/1905	UN International Narcotics Control Board ("INCB"): Estimated World Requirements for 2005	JAN-TREX-00035870	JAN-TREX-00036233							
JA-02395	06/28/1905	UN International Narcotics Control Board ("INCB"): Estimated World Requirements for 2006	JAN-TREX-00036234	JAN-TREX-00036601							
JA-02396	06/29/1905	UN International Narcotics Control Board ("INCB"): Estimated World Requirements for 2007	JAN-TREX-00036602	JAN-TREX-00037023							
JA-02397	06/30/1905	UN International Narcotics Control Board ("INCB"): Estimated World Requirements for 2008	JAN-TREX-00037024	JAN-TREX-00037452							
JA-02398	07/01/1905	UN International Narcotics Control Board ("INCB"): Estimated World Requirements for 2009	JAN-TREX-00037453	JAN-TREX-00037867							
JA-02399	07/02/1905	UN International Narcotics Control Board ("INCB"): Estimated World Requirements for 2010	JAN-TREX-00037868	JAN-TREX-00038301							
JA-02400	07/03/1905	UN International Narcotics Control Board ("INCB"): Estimated World Requirements for 2011	JAN-TREX-00038302	JAN-TREX-00038745							
JA-02401	07/05/1905	UN International Narcotics Control Board ("INCB"): Estimated World Requirements for 2013	JAN-TREX-00038746	JAN-TREX-00039206							
JA-02402	07/08/1905	UN International Narcotics Control Board ("INCB"): Estimated World Requirements for 2016	JAN-TREX-00039207	JAN-TREX-00039678							
JA-02403	07/09/1905	UN International Narcotics Control Board ("INCB"): Estimated World Requirements for 2017	JAN-TREX-00039679	JAN-TREX-00040154							
JA-02404	07/10/1905	UN International Narcotics Control Board ("INCB"): Estimated World Requirements for 2018	JAN-TREX-00040155	JAN-TREX-00040648							
JA-02405	05/08/2019	FDA Drug Master File List	JAN-TREX-00040649	JAN-TREX-00040664							
JA-02406	05/08/2019	Proposed and final aggregate production quota for scheduled II controlled substances for years 1990-2018	JAN-TREX-00040665	JAN-TREX-00040669							
JA-02407	06/29/1905	2007 FDA "Orange Book"	JAN-TREX-00040670	JAN-TREX-00041738							
JA-02408	06/30/1905	2008 FDA "Orange Book"	JAN-TREX-00041739	JAN-TREX-00042840							
JA-02409	05/14/1905	UN Single Convention on Narcotic Drugs, 1961	JAN-TREX-00042841	JAN-TREX-00042884							
JA-02410	05/24/1905	UN Convention on Psychotropic Substances, 1971	JAN-TREX-00042885	JAN-TREX-00042912							
JA-02411	07/05/1905	UN Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances, 1988	JAN-TREX-00042913	JAN-TREX-00043080							
JA-02412	06/29/2016	DEA form 189 - application for individual manufacturing quota (blank)	JAN-TREX-00149705	JAN-TREX-00149705							
JA-02413	06/29/2016	DEA form 250 - application for procurement quota for controlled substance (blank)	JAN-TREX-00149706	JAN-TREX-00149706							
JA-02414	No Date	DEA form 236 - controlled substances import/export declaration (blank)	JAN-TREX-00149707	JAN-TREX-00149707							
JA-02415	No Date	DEA form 357 - application for permit to import controlled substances or domestic and/or scientific purposes (blank)	JAN-TREX-00149708	JAN-TREX-00149708							
JA-02416	No Date	DEA form 161 - application for permit to export controlled substances pursuant to Section 1003(a), (b), (c) & (d), Title III, PL 91-513 (blank)	JAN-TREX-00149709	JAN-TREX-00149709							
JA-02417	No Date	DEA form 161R - application for permit to export controlled substances for subsequent reexport (blank)	JAN-TREX-00149710	JAN-TREX-00149710							
JA-02418	10/07/2014	2014 Notice of Registration, Bulk Manufacturer of Controlled Substances Application, Noramco, Inc.	JAN-TREX-00043081	JAN-TREX-00043082							
JA-02419	07/04/1905	Janssen presentation: Understanding DEA Requirements in the Controlled Substance Supply Chain	JAN-MS-02283774	JAN-MS-02283774							
JA-02420	01/16/2019	Email from Brad Beckworth to Amy Spencer	JAN-TREX-00149711	JAN-TREX-00149711							
JA-02421	10/10/2012	Nucynta and Nucynta ER Speaker Training	JAN-MS-00027221	JAN-MS-00027347							
JA-02422	12/01/2010	Nucynta Resource Guide	JAN-MS-00364042	JAN-MS-00364091							
JA-02423	04/25/2002	Email from Molly McDonald to Kati Chupa et al.	JAN-MS-00312486	JAN-MS-00312486							
JA-02424	No Date	Data and Analytics Summary Sheet	JAN-TREX-00149712	JAN-TREX-00149712							
JA-02425	06/29/1905	Fishman, SM, Responsible Opioid Prescribing: A Physician's Guide	JAN-TREX-00043083	JAN-TREX-00043086							
JA-02426	03/09/2012	Presentation: Nucynta Training Workshop	JAN-MS-00668921	JAN-MS-00668921							
JA-02427	No Date	Medical Education and Medical Communication Summary Sheet	JAN-TREX-00043087	JAN-TREX-00043088							
JA-02428	12/19/2018	Medical Science Liaisons Summary Sheet	JAN-TREX-00149713	JAN-TREX-00149713							
JA-02429	03/26/2001	Email from Cheryl Pavia to Bill Whyte	JAN-MS-00304252	JAN-MS-00304252							
JA-02430	03/26/2001	Email from Cheryl Pavia to Bill Whyte	JAN-MS-00304253	JAN-MS-00304253							
JA-02431	01/16/2019	Johnson & Johnson Overview & Meeting Objectives	JAN-TREX-00043089	JAN-TREX-00043099							
JA-02432	02/04/2019	Growing Pains Website - Accepting the Pain, available at http://growingpains.org/accept-the-pain	JAN-TREX-00043100	JAN-TREX-00043101							
JA-02433	02/04/2019	Growing Pains Website - Know Your Emotions, available at http://growingpains.org/know-your-emotions	JAN-TREX-00043102	JAN-TREX-00043103							
JA-02434	02/04/2019	Growing Pains Website - Communicating to Others, available at http://growingpains.org/communicating-to-others	JAN-TREX-00043104	JAN-TREX-00043105							
JA-02435	02/04/2019	Growing Pains Website - Family, available at http://growingpains.org/family	JAN-TREX-00043106	JAN-TREX-00043107							
JA-02436	02/04/2019	Growing Pains Website - Family, available at http://growingpains.org/parents	JAN-TREX-00043108	JAN-TREX-00043109							
JA-02437	02/04/2019	Growing Pains Website - Family, available at http://growingpains.org/know-your-rights	JAN-TREX-00043110	JAN-TREX-00043113							
JA-02438	No Date	Growing Pains Website - Family, available at http://growingpains.org/assert-your-rights	JAN-TREX-00043114	JAN-TREX-00043115							
JA-02439	02/04/2019	Growing Pains Website - Family, available at http://growingpains.org/ask-for-what-you-want	JAN-TREX-00043116	JAN-TREX-00043118							
JA-02440	03/04/2010	A Call to Revolutionize Chronic Pain Care in America: An Opportunity in Health Care Reform	JAN-TREX-00043119	JAN-TREX-00043135							
JA-02441	07/01/1905	Finding Relief: Pain Management in Older Adults	JAN-TREX-00043136	JAN-TREX-00043156							
JA-02442	07/04/1905	American Academy of Pain Medicine Response to PROP Petition to the FDA That Seeks to Limit Pain Medications for Legitimate Noncancer Pain Sufferers	JAN-TREX-00043157	JAN-TREX-00043162							
JA-02443	01/23/2004	Draft Guidance for Industry: Help-Seeking and Other Disease Awareness Communications by or on behalf of Drug and Device Firms	JAN-TREX-00043163	JAN-TREX-00043172							
JA-02444	12/06/2010	Email from Bonnie Weissfeld to David Gerould	JAN-MS-00250471	JAN-MS-00250471							
JA-02445	12/06/2010	Email from Bonnie Weissfeld to David Gerould	JAN-MS-00250472	JAN-MS-00250473							
JA-02446	05/20/2008	Email from Greg Panico to Michael Heinley	JAN-MS-00276491	JAN-MS-00276492							
JA-02447	01/14/2008	Email from Scott Trembley to Cathy Amato	JAN-MS-00281494	JAN-MS-00281494							
JA-02448	12/06/2002	Email from Karen Bates to Bill Whyte	JAN-MS-00304926	JAN-MS-00304926							
JA-02449	12/06/2002	Proposal for the Duragesic Regional Advisory Board Meetings to be held in 2003	JAN-MS-00304927	JAN-MS-00304935							
JA-02450	08/05/2011	Email from Kimberly Deem-Eshleman to Roxanne McGregor-Beck et al.	JAN-MS-00319588	JAN-MS-00319588							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-02451	03/28/2011	Email from Laura Flannery to Kimberly Deem-Eshleman	JAN-MS-00320771	JAN-MS-00320771							
JA-02452	06/01/2009	Pain Resource Guide	JAN-MS-00320772	JAN-MS-00320803							
JA-02453	12/06/2010	Email from Bonnie Weissfeld to David Gerould	JAN-MS-00329331	JAN-MS-00329331							
JA-02454	12/06/2010	Email from Bonnie Weissfeld to David Gerould	JAN-MS-00329332	JAN-MS-00329337							
JA-02455	12/06/2010	Email from Bonnie Weissfeld to David Gerould	JAN-MS-00329343	JAN-MS-00329343							
JA-02456	12/06/2010	Email from Bonnie Weissfeld to David Gerould	JAN-MS-00329344	JAN-MS-00329381							
JA-02457	07/02/2009	Beth Israel Medical Center Invoice to Ortho-McNeil Janssen	JAN-MS-00394853	JAN-MS-00394853							
JA-02458	09/15/2009	Beth Israel Medical Center Invoice to Ortho-McNeil Janssen	JAN-MS-00395835	JAN-MS-00395835							
JA-02459	08/30/2012	PAINS Project - 2012 Annual Meeting - Invitees	JAN-MS-00411906	JAN-MS-00411907							
JA-02460	07/21/2009	Nucynta IR & ER 2010 Business Plan	JAN-MS-00454883	JAN-MS-00454883							
JA-02461	07/08/2003	Email from Marina Riajenova to Bruce Moskovitz	JAN-MS-00481527	JAN-MS-00481531							
JA-02462	12/21/2009	Smart Moves, Smart Choices: A Prescription Drug Abuse Prevention Program	JAN-MS-00508121	JAN-MS-00508121							
JA-02463	10/18/2010	Grant Request to PriCara: Pain Management Strategies for the Hospital-Based Care Team: Focus on Pain Related Osteoarthritis, Diabetic Neuropathy, and Cancer	JAN-MS-00626860	JAN-MS-00626893							
JA-02464	11/30/2001	Executive Summary: Chronic Pain Scientific Advisory Board	JAN-MS-00654435	JAN-MS-00654444							
JA-02465	06/25/1905	Duragesic (Fentanyl transdermal system) CII- 2003 Business Plan Summary	JAN-MS-00726353	JAN-MS-00726386							
JA-02466	11/23/2011	Email from Oliver Bock to David Lin et al.	JAN-MS-00775681	JAN-MS-00775682							
JA-02467	11/06/2003	Marketing Research Briefing Document	JAN-MS-00778989	JAN-MS-00778990							
JA-02468	11/05/2002	Email from Cheryl Pavia to Bill Amberg	JAN-MS-00786434	JAN-MS-00786434							
JA-02469	03/09/2001	2001 Pain Management Experts Panel Agenda	JAN-MS-00786821	JAN-MS-00786823							
JA-02470	06/02/2004	Grow and Defend to Build for the Future - 2005 Business Plan	JAN-MS-00788386	JAN-MS-00788386							
JA-02471	04/11/2003	Email from Molly McDonald to Kip Pritchard	JAN-MS-00789592	JAN-MS-00789593							
JA-02472	04/11/2003	Duragesic Direct-to-Patient Pilot Program Introduction	JAN-MS-00789594	JAN-MS-00789595							
JA-02473	01/07/2011	Copy Review Cover Sheet - NEO Chronic	JAN-MS-00804624	JAN-MS-00804655							
JA-02474	05/08/2012	Summary of payments made 1997-2012, in response to Senate Finance Committee request	JAN-MS-00000001	JAN-MS-00000010							
JA-02475	01/16/2013	Email from Frank Demiro to David Lin et al.	JAN-MS-00826110	JAN-MS-00826113							
JA-02476	11/01/2011	Mutual Accountability for Pain - Driving Demand for NUCYNTA and NUCYNTA ER	JAN-MS-00937860	JAN-MS-00937904							
JA-02477	11/14/2012	Email from Robyn Kohn to Ron Kuntz	JAN-MS-00948094	JAN-MS-00948094							
JA-02478	11/14/2012	List of Companies that Contributed to Develop PAINS	JAN-MS-00948095	JAN-MS-00948095							
JA-02479	01/01/2013	Pain Care Forum - Participating Organizations	JAN-MS-00992093	JAN-MS-00992093							
JA-02480	06/19/2014	Email from Oliver Bock to Michelle Goodridge et al.	JAN-MS-00996343	JAN-MS-00996344							
JA-02481	06/19/2014	Competitive Intelligence Bi-Weekly Brief	JAN-MS-00996345	JAN-MS-00996345							
JA-02482	08/13/2008	Copy Review Approval Form for Let's Talk Pain Video/Transcript - Getting Started	JAN-MS-00007215	JAN-MS-00007221							
JA-02483	08/20/2008	Copy Review Approval Form for Let's Talk Pain Video/Transcript - Myth v. Reality	JAN-MS-00007320	JAN-MS-00007326							
JA-02484	07/01/2004	Medical Affairs Agenda - Medical Science Liaison Report	JAN-MS-01203019	JAN-MS-01203030							
JA-02485	07/04/1905	2012 Incentive Compensation and Recognition Plan	JAN-MS-00089006	JAN-MS-00089037							
JA-02486	11/06/2014	Email from Frederick Tewell to Oliver Bock	JAN-MS-01969185	JAN-MS-01969185							
JA-02487	10/01/2015	Email from Frederick Tewell to Robin Adkins	JAN-MS-01974211	JAN-MS-01974213							
JA-02488	12/16/2009	Janssen Script: Nucynta Video	JAN-MS-00131175	JAN-MS-00131179							
JA-02489	12/16/2009	Janssen Script: Nucynta Video	JAN-MS-00131180	JAN-MS-00131181							
JA-02490	12/16/2009	Janssen Script: Nucynta Video	JAN-MS-00131155	JAN-MS-00131156							
JA-02491	07/27/2010	NUCYNTA 2011 Business Plan (Draft)	JAN-MS-00132333	JAN-MS-00132386							
JA-02492	07/19/2001	Janssen presentation: Medical Affairs Pain and Mycology Franchise	JAN-MS-02321925	JAN-MS-02321925							
JA-02493	10/01/2014	Vortex II Post Diligence Questions	JAN-MS-02733172	JAN-MS-02733172							
JA-02494	09/08/2014	Draft Janssen presentation to management: Nucynta and Nucynta ER	JAN-MS-02735018	JAN-MS-02735110							
JA-02495	07/02/2015	Candiotti, Keith, Use of Opioid Analgesics in Pain Management, PrescribeResponsibly.com,	JAN-MS-03090610	JAN-MS-03090613							
JA-02496	06/24/1905	ACCME Standards for Commercial Support of Continuing Medical Education Presentation	JAN-MS-04211271	JAN-MS-04211271							
JA-02497	03/07/2002	Email from Peter Christ to K. Chupa	JAN-MS-04211270	JAN-MS-04211270							
JA-02498	11/12/2010	NDA #022304: NUCYNTA (tapentadol) immediate-release oral tablets	JAN-MS-05456115	JAN-MS-05456123							
JA-02499	06/06/2008	Draft June 6, 2008; Neo Pathways: New Directions in Pain	JAN-MS-01136210	JAN-MS-01136210							
JA-02500	04/24/2008	Let's Talk Pain Web Manuscript Draft	JAN-MS-01234242	JAN-MS-01234257							
JA-02501	08/11/2011	Nucynta and Nucynta ER REMS Webpage Links	JAN-MS-01047105	JAN-MS-01047106							
JA-02502	01/07/2008	Efficacy and Safety of Tapentadol IR Over 90 Days for Relief of Low Back Pain or Osteoarthritis Pain	JAN-MS-01018741	JAN-MS-01018742							
JA-02503	01/07/2008	Safety of Tapentadol IR for Opioid-experienced and Non-experienced Patient Populations after 90 Days of Exposure in Patients with Low Back Pain or Osteoarthritis Pain	JAN-MS-01018743	JAN-MS-01018745							
JA-02504	01/07/2008	Long-term Use of Tapentadol Immediate Release for the Treatment of Low Back Pain and Osteoarthritis Pain: A Safety Study	JAN-MS-01018746	JAN-MS-01018748							
JA-02505	01/07/2008	Tapentadol Immediate Release Provides Effective Analgesia of Acute Pain Following Orthopedic Surgery in a Randomized, Double-Blind, Placebo-controlled, Phase III Study	JAN-MS-01018749	JAN-MS-01018751							
JA-02506	01/07/2008	Effective Relief of Acute Pain Following Orthopedic Surgery: Efficacy and Tolerability of Tapentadol Immediate Release in a Randomized, Double-blind, Placebo-Controlled, Phase III Study	JAN-MS-01018752	JAN-MS-01018754							
JA-02507	01/07/2008	Janssen Clinical Study: Tapentadol Bunionectomy	JAN-MS-01018755	JAN-MS-01018757							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-02508	01/07/2008	Efficacy and Tolerability Data Supporting the Use of Tapentadol Immediate Release for the Relief of Pain from End-Stage Joint Disease	JAN-MS-01018758	JAN-MS-01018760							
JA-02509	01/07/2008	Tapentadol Immediate Release Provides Effective Pain Relief in Patients Awaiting Primary Joint Replacement Surgery in a Randomized, Double Blind, Active- and Placebo-Controlled, Phase III Study	JAN-MS-01018761	JAN-MS-01018763							
JA-02510	01/07/2008	Efficacy and Tolerability Data for Tapentadol Immediate Release: Pain Relief in Patients suffering from End-Stage Joint Disease	JAN-MS-01018764	JAN-MS-01018766							
JA-02511	05/16/2018	Effect of a high dosage opioid prior authorization policy on prescription opioid use, misuse, and overdose outcomes	JAN-TREX-00043173	JAN-TREX-00043180							
JA-02512	06/22/1905	Drug Diplomacy in the Twentieth Century by William B. McAllister	JAN-TREX-00043181	JAN-TREX-00043364							
JA-02513	03/14/2019	Zhu, et al., NEJM, Initial Opioid Prescriptions among US Commercially Insured Patients, 2012-2017, New England Journal of Medicine 380:11, pp. 1043-52	JAN-TREX-00043365	JAN-TREX-00043374							
JA-02514	05/26/2009	C. Banta-Green, "Opioid use behaviors, mental health and pain—Development of a typology of chronic pain patients," 104 Drug and Alcohol Dependence 34	JAN-TREX-00043375	JAN-TREX-00043383							
JA-02515	09/11/2018	"Editorial: Pain, Opioids, and Suicide Mortality in the United States," Annals of Internal Medicine	JAN-TREX-00043384	JAN-TREX-00043385							
JA-02516	07/08/1905	American Medical Association House of Delegates Resolution on CDC Guidelines	JAN-TREX-00043386	JAN-TREX-00043425							
JA-02517	03/18/2016	D. Dowell, CDC Guideline for Prescribing Opioids for Chronic Pain--United States, 2016, MMWR (Mar. 18, 2016) and Errata (Mar. 26, 2016)	JAN-TREX-00043426	JAN-TREX-00043478							
JA-02518	06/24/1905	D. Fishbain, "What Percentage of Chronic Nonmalignant Pain Patients Exposed to Chronic Opioid Analgesic Therapy Develop Abuse/Addiction and/or Aberrant Drug-Related Behaviors? A Structured Evidence-Based Review," Pain Medicine	JAN-TREX-00043479	JAN-TREX-00043494							
JA-02519	06/24/1905	D. Fishbain, "Medico-legal Rounds: Medico-legal Issues and Breaches of Standards of Medical Care in Opioid Tapering for Alleged Opioid Addiction," Pain Medicine	JAN-TREX-00043495	JAN-TREX-00043503							
JA-02520	07/08/1905	American Medical Association House of Delegates Resolution on CDC Guidelines	JAN-TREX-00043504	JAN-TREX-00043543							
JA-02521	03/20/2019	Further Explanation of Certain Disclosed Expert Opinion Testimony of Laurentius Marais, Ph.D.	JAN-TREX-00043544	JAN-TREX-00043545							
JA-02522	09/01/2002	Charles E. Argoff, M.D., Pharmacologic Management of Chronic Pain, JAOA Supplement 3 Vol. 102 No. 9	JAN-TREX-00043546	JAN-TREX-00043551							
JA-02523	07/02/1905	Bradley S. Galin, M.D. and Charles E. Argoff, M.D., "Defeat Chronic Pain Now!"	JAN-TREX-00043552	JAN-TREX-00043560							
JA-02524	06/24/2009	Tapentadol Team Status - 2008/2009 Acute Pain Publications	JAN-MS-00323309	JAN-MS-00323309							
JA-02525	07/22/2018	InSight Crime interview, Federal Police officials, 22 July 2018	JAN-TREX-00149835	JAN-TREX-00149835							
JA-02526	06/02/2018	InSight Crime interview, high ranking official, Mexico's Attorney General's Office, 2 June 2018.	JAN-TREX-00149836	JAN-TREX-00149836							
JA-02527	08/09/2016	13 WHAM ABC, "WNY drug bust operation lands \$2.5 million in cocaine, heroin, fentanyl," 9 August 2016.	JAN-TREX-00043561	JAN-TREX-00043572							
JA-02528	11/01/2016	2016 National Drug Threat Assessment	JAN-TREX-00043573	JAN-TREX-00043766							
JA-02529	10/01/2017	2017 National Drug Threat Assessment	JAN-TREX-00043767	JAN-TREX-00043948							
JA-02530	06/26/1905	Michael K. Steinberg, Joseph J. Hobbs and Kent Mathewson, eds., Dangerous Harvest: Drug Plants and the Transformation of Indigenous Landscapes (2004)	JAN-TREX-00149837	JAN-TREX-00149837							
JA-02531	07/01/1905	A.G., Schaefer, B. Bahney, and K. J. Riley, Security in Mexico: Implications for U.S. policy Options. Santa Monica California: Rand Corporation, 2009.	JAN-TREX-00043949	JAN-TREX-00044054							
JA-02532	05/14/2018	Alison Fox, "China's fentanyl production, export fueling US opioid crisis, Schumer says," AM New York, 14 May 2018. https://www.amny.com/news/china-fentanyl-schumer-1.18531808 14 US-China Economic and Security Review Commission, "Fentanyl: China's Deadly Export to the United States," February 2017.	JAN-TREX-00044055	JAN-TREX-00044073							
JA-02533	05/08/2019	Bebinger, Martha - "Fentanyl-Linked Deaths: The U.S. Opioid Epidemic's Third Wave Begins" (21 Mar. 2019).	JAN-TREX-00044074	JAN-TREX-00044078							
JA-02534	06/07/2017	Brown University. Feared by drug users but hard to avoid, fentanyl takes a mounting toll. June 7, 2017.	JAN-TREX-00044079	JAN-TREX-00044083							
JA-02535	08/01/2012	Bruce Bagley, Bruce, "Drug Trafficking and Organized Crime in Latin America: Major Trends in the 21st Century." Washington, D.C: Latin American Program, Woodrow Wilson Center, 2012. 36 p.	JAN-TREX-00044084	JAN-TREX-00044105							
JA-02536	06/11/1905	Bruce Michael Bagley, Bruce, "The New Hundred Years War?: U.S. National securituy and the War on Drugs in Latin America," in Donald J. Mabry, ed., The Latin American Narcotics Trade and U.S. National Security. New York: Greenwood Press, Contributions in Political Science, Number 240, 1989, pp. 43-58	JAN-TREX-00044106	JAN-TREX-00044123							
JA-02537	01/22/2018	Burns, Gus - "Detroit Police Join Task Force in Response to 383 Opioid-Related Deaths in 2017" (22 Jan. 2018)	JAN-TREX-00044124	JAN-TREX-00044126							
JA-02538	10/26/2015	CDC - "CDC Health Advisory: Increases in Fentanyl Drug Confiscations and Fentanyl-Related Overdose Fatalities" (26 Oct. 2015)	JAN-TREX-00044127	JAN-TREX-00044133							
JA-02539	04/17/2019	CDC. Provisional Drug Overdose Death Counts.	JAN-TREX-00044134	JAN-TREX-00044140							
JA-02540	12/20/2016	Centers for Disease Control and Prevention, "Drugs most frequently involved in drug overdose deaths. National Vital Statistics Reports - United States, 2010-2014," December 2016.	JAN-TREX-00044141	JAN-TREX-00044155							
JA-02541	03/30/2018	Centers for Disease Control and Prevention, "Overdose Deaths Involving Opioids, Cocaine, and Psychostimulants - United States, 2015-2016," March 2018.	JAN-TREX-00044156	JAN-TREX-00044172							
JA-02542	03/30/2018	Centers for Disease Control and Prevention, "Overdose Deaths Involving Opioids, Cocaine, and Psychostimulants - United States, 2015-2016," March 2018.	JAN-TREX-00044173	JAN-TREX-00044189							
JA-02543	04/17/2019	Centers for Disease Control and Prevention, "Provisional drug overdose death counts. National Center for Health Statistics," December 2018.	JAN-TREX-00044190	JAN-TREX-00044196							
JA-02544	03/06/2018	Centers for Disease Control and Prevention, "Vital Signs: Trends in Emergency Department Visits for Suspected Opioid Overdoses — United States, July 2016–September 2017", March 2018.	JAN-TREX-00044197	JAN-TREX-00044207							
JA-02545	09/01/2017	Centers for Disease Control and Prevention. Morbidity and Mortality Weekly Report Weekly / Vol. 66 / No. 34 September 1, 2017.	JAN-TREX-00044208	JAN-TREX-00044231							
JA-02546	09/01/2017	Centers for Disease Control and Prevention. Morbidity and Mortality Weekly Report Weekly / Vol. 66 / No. 34 September 1, 2017.	JAN-TREX-00044232	JAN-TREX-00044255							
JA-02547	06/25/2018	CNBC, "China says the US domestic opioid market is the crux of the crisis," 25 June 2018.	JAN-TREX-00044256	JAN-TREX-00044259							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-02548	07/01/2016	Commission on Security and Cooperation in Europe: US Helsinki Commission, "The Opioid Crisis and Drug Enforcement Administration, "Counterfeit Prescription Pills Containing Fentanyl: A Global Threat," July 2016.	JAN-TREX-00044260	JAN-TREX-00044268							
JA-02549	03/28/2018	Commission on Security and Cooperation in Europe: US Helsinki Commission, "The Opioid Crisis and the Dark Web: How Transnational Criminal Devastate US Communities," 28 March 2018.	JAN-TREX-00044269	JAN-TREX-00044295							
JA-02550	01/14/2016	Compton, Wilson M. - "Relationship Between Nonmedical Prescription-Opioid Use and Heroin Use" (14 Jan. 2016)	JAN-TREX-00044296	JAN-TREX-00044305							
JA-02551	03/01/2018	Connecticut Accidental Drug Intoxication Deaths Office of the Chief Medical Examiner.	JAN-TREX-00149838	JAN-TREX-00149838							
JA-02552	04/19/2018	Coscarelli, J. - "Prince's Overdose Death Results in No Criminal Charges" (19 April 2018)	JAN-TREX-00044306	JAN-TREX-00044311							
JA-02553	07/17/2018	Dan Goldberg, "Evolving Opioid Epidemic Poses Challenge for Public Health Officials," Politico, 17 July 2018.	JAN-TREX-00044312	JAN-TREX-00044314							
JA-02554	06/24/1905	David F. Musto and Pamela Korsmeyer, The Quest for Drug Control: Politics and Federal Policy in a Period of Increasing Substance Abuse, 1963-1981. New Haven: Yale University Press, 1983, 303p.	JAN-TREX-00044315	JAN-TREX-00044316							
JA-02555	06/21/1905	David F. Musto, The American Disease: Origins of Narcotics Control (New Haven: Yale U. Press, 1999), pp. 1-244.	JAN-TREX-00149839	JAN-TREX-00149839							
JA-02556	06/22/1905	David Musto, ed., One Hundred Years of Heroin. Westport, Conn.: Auburn House, 2000, 236 p.	JAN-TREX-00149840	JAN-TREX-00149840							
JA-02557	03/18/2015	DEA - "DEA Issues Nationwide Alert on Fentanyl as Threat to Health and Public Safety" (18 Mar. 2015)	JAN-TREX-00044317	JAN-TREX-00044318							
JA-02558	05/01/2015	DEA, 2018 Fentanyl Remains the Most Significant Synthetic Opioid Threat in US. May 01, 2018.	JAN-TREX-00044319	JAN-TREX-00044321							
JA-02559	09/06/2018	Department of Justice. Tackling Fentanyl: The China Connection, presented September 6, 2018.	JAN-TREX-00044322	JAN-TREX-00044332							
JA-02560	08/02/2018	Department of Justice. U.S. Attorney's Office. Southern District of California. 19-Year-Old Charged With Importation of 11,490 Fentanyl Pills,61 Pounds of Methamphetamine, and 14 Pounds of Heroin at San Ysidro Port of Entry. August 2, 2018.	JAN-TREX-00044333	JAN-TREX-00044334							
JA-02561	08/08/2018	Department of Justice. U.S. Attorney's Office. Southern District of California. Defendant Charged with Importation of More than 20,000 Fentanyl Pills at the San Ysidro Port of Entry. August 8, 2018.	JAN-TREX-00044335	JAN-TREX-00044336							
JA-02562	07/07/2018	DW. Mexico Extradites El Chapo Drug Cartel Lieutenant to US.	JAN-TREX-00044337	JAN-TREX-00044339							
JA-02563	01/07/2017	DW. Murder Rate Rises in Mexico as Drug Cartels Argue over Leadership and Profits.	JAN-TREX-00044340	JAN-TREX-00044342							
JA-02564	08/22/2018	El Espectador. Así se mueve la heroína por las carreteras del país Judicial. Catalina Vargas Vergara. August 22, 2018.	JAN-TREX-00044343	JAN-TREX-00044349							
JA-02565	07/30/2010	El Mundo, "Muere 'Nacho' Coronel, uno de los narcos más buscados y poderosos de México," 30 July 2010. https://www.elmundo.es/america/2010/07/30/mexico/1280446951.html	JAN-TREX-00044350	JAN-TREX-00044351							
JA-02566	08/22/2017	El tiempo. Un jefe del Eln es el gran capo de la heroína en el país. Justicia. August 22, 2017.	JAN-TREX-00044352	JAN-TREX-00044359							
JA-02567	04/01/2014	Emergency Medicine News. InFocus: Fentanyl-Laced Heroin A Deadly Combination. Roberts, James R. MD. April 2014 - Volume 36 - Issue 4 - p 13–15.	JAN-TREX-00044360	JAN-TREX-00044362							
JA-02568	10/16/2018	Ezequiel Flores Contreras, "Sierra de Guerrero: la amapola a la baja, la violencia al alza," Proceso, 16 October 2018.	JAN-TREX-00044363	JAN-TREX-00044370							
JA-02569	05/24/2018	FDA - "FDA Commissioner Scott Gottlieb, M.D., Invites Internet Stakeholders to Opioid Summit" (27 June 2018)	JAN-TREX-00149841	JAN-TREX-00149841							
JA-02570	06/05/2018	FDA - "FDA takes action against 53 websites marketing unapproved opioids as part of a comprehensive effort to target illegal online sales" (5 June 2018)	JAN-TREX-00044371	JAN-TREX-00044373							
JA-02571	09/14/2018	Fox 5. 3 die from fentanyl-laced cocaine in beach areas. Sandra Phillips, September 14, 2018	JAN-TREX-00044374	JAN-TREX-00044382							
JA-02572	02/16/2017	Frank, Richard G. - "Addressing the Fentanyl Threat to Public Health" (16 Feb. 2017)	JAN-TREX-00044383	JAN-TREX-00044385							
JA-02573	07/01/1905	George W. Grayson, Mexico's Struggle with 'Drugs and Thugs'. Foreign Policy Association, Headline Series, No. 331, Winter 2009, 96 p.	JAN-TREX-00044386	JAN-TREX-00044389							
JA-02574	08/26/2016	CDC Report: "Fentanyl Law Enforcement Submissions and Increases in Synthetic Opioid-Involved Overdose Deaths"	JAN-TREX-00044390	JAN-TREX-00044396							
JA-02575	07/09/2018	Gottlieb, Scott - "Statement by FDA Commissioner Scott Gottlieb, M.D., on balancing access to appropriate treatment for patients with chronic and end-of-life pain with need to take steps to stem misuse and abuse of opioids" (9 July 2018)	JAN-TREX-00044397	JAN-TREX-00044401							
JA-02576	No Date	Harm Reduction Coalition. Fentanyl	JAN-TREX-00044402	JAN-TREX-00044405							
JA-02577	09/28/2018	Hindustan Times, "Three including Mexican arrested with drugs worth over Rs 100 crore in MP," 28 September 2018.	JAN-TREX-00044406	JAN-TREX-00044411							
JA-02578	08/02/2017	House of Representatives Committee on Energy and Commerce, Subcommittee on Oversight and Investigations, "The next wave of the opioid crisis," March 2017.	JAN-TREX-00044412	JAN-TREX-00044420							
JA-02579	08/14/2018	How Oxycodone Gets Laced With Fentanyl. August 14, 2018.	JAN-TREX-00044421	JAN-TREX-00044432							
JA-02580	08/16/2016	Huntington Police Respond to 26 Overdoses in 4 Hours. Clark Davis. August 16, 2016.	JAN-TREX-00044433	JAN-TREX-00044438							
JA-02581	09/01/2018	IBISWorld, "Pharmaceutical Manufacturing Industry in China: Industry Market Research Report," September 2018.	JAN-TREX-00044439	JAN-TREX-00044443							
JA-02582	10/26/2015	Increases in Fentanyl Drug Confiscations and Fentanyl-related Overdose Fatalities Archived: October 26, 2015	JAN-TREX-00044444	JAN-TREX-00044450							
JA-02583	10/01/2018	US Drug Enforcement Administration, "2018 National Drug Threat Assessment," October 2018.	JAN-TREX-00044451	JAN-TREX-00044614							
JA-02584	11/26/2018	InSight Crime interview, Kentucky law enforcement official, 17 July 2018. 128 US-China Economic and Security Review Commission, "Fentanyl Flows from China: An Update since 2017," 26 November 2018.	JAN-TREX-00044615	JAN-TREX-00044622							
JA-02585	05/25/2017	InSight Crime interview, Public Health advocate, 12 June 2018. 132 US Department of Homeland Security, "Testimony of Robert E. Perez, Executive Assistant Commissioner," 25 May 2017.	JAN-TREX-00044623	JAN-TREX-00044631							
JA-02586	08/28/2017	InSightCrime. Bolivian, Peru Cocaine Figures Show Colombia Driving Andean Boom. Parker Asmann. August 28, 2017.	JAN-TREX-00044632	JAN-TREX-00044633							
JA-02587	07/06/2018	Puerta, Felipe, Cocaine Leaving Ecuador Shows Flaws Anti-Drug Strategies, InSightCrime.org, July 6, 2018.	JAN-TREX-00044634	JAN-TREX-00044639							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-02588	06/26/2018	InSightCrime. Colombia Coca Production Hits New Record High US Figures Say. Parker Asmann. June 26, 2018.	JAN-TREX-00044640	JAN-TREX-00044645							
JA-02589	09/19/2018	InSightCrime. Colombia Production Breaks New Record Levels: UNODC Report. Parker Asmann. September 19, 2018.	JAN-TREX-00044646	JAN-TREX-00044650							
JA-02590	03/22/2018	InSightCrime. Colombia's Last Guerrillas Escalate Battle Contol. Angelika Albaladejo. March 22, 2018.	JAN-TREX-00044651	JAN-TREX-00044652							
JA-02591	12/03/2013	InSightCrime. Is Colombia Still a Major Heroin Producer? Marguerite Cawley. December 3, 2013.	JAN-TREX-00044653	JAN-TREX-00044656							
JA-02592	07/27/2016	Mike LaSusa, Mexico, China are Key Nodes in Fentanyl Trade: DEA, InSight Crime, July 27, 2016	JAN-TREX-00044657	JAN-TREX-00044660							
JA-02593	01/19/2018	InSightCrime. News Analysis European Cocaine Seizures Hint at New Possibilities for Colombia Traffickers. James Bargent. January 19, 2018.	JAN-TREX-00044661	JAN-TREX-00044663							
JA-02594	10/18/2018	InSightCrime. Peru Drug Trafficking Expanding European Markets. Anna Grace. October 18, 2018.	JAN-TREX-00044664	JAN-TREX-00044665							
JA-02595	10/11/2016	InSightCrime. Peru Renews Military Operations in Vraem Coca Hub. Tristan Clavel. October 11, 2016	JAN-TREX-00044666	JAN-TREX-00044667							
JA-02596	07/17/2017	InSightCrime. Record Cocaine Production Colombia Fuels New Criminal Generation. Jeremy McDermott. July 17, 2017.	JAN-TREX-00044668	JAN-TREX-00044676							
JA-02597	08/23/2018	InSightCrime. Shifting Ex Farc Mafia Alliances Fuel Colombia Criminal Shakeup. Parker Asmann and James Bargent. August 23, 2018	JAN-TREX-00044677	JAN-TREX-00044679							
JA-02598	03/15/2018	InSightCrime. The "Invisibles": Colombia's New Generation of Drug Traffickers. Jeremy McDermott. March 15, 2018.	JAN-TREX-00044680	JAN-TREX-00044682							
JA-02599	03/01/2018	InSightCrime. UN Drug Control Board Emphasizes Prevention Treatment in New Report. Mike LaSusa. March 1, 2018.	JAN-TREX-00044683	JAN-TREX-00044685							
JA-02600	09/13/2016	InSightCrime. US Singles Out Bolivia Venezuela Counternarcotic Failures. Venezuela Investigative Unit. September 13, 2016.	JAN-TREX-00044686	JAN-TREX-00044687							
JA-02601	05/29/2017	InSightCrime. What Can Bolivia Teach Post Conflict Colombia About Coca Reduction? David Gagne. Mayo 29, 2017.	JAN-TREX-00044688	JAN-TREX-00044689							
JA-02602	08/13/2013	International Drug Control Policy: Background and U.S. Responses, Liana Sun Wyler, August 13, 2013.	JAN-TREX-00044690	JAN-TREX-00044736							
JA-02603	07/10/1905	Jalal, Hawre - "Changing Dynamics of drug overdose epidemic in the United States from 1979 through 2016" (2018)	JAN-TREX-00044737	JAN-TREX-00044743							
JA-02604	02/01/2017	Joji Suzuki and Saria El-Haddad, "A review: Fentanyl and non-pharmaceutical fentanyls," Drug and Alcohol Dependence, Vol. 171 (February 2017), pp. 107-116.	JAN-TREX-00044744	JAN-TREX-00044753							
JA-02605	06/28/1905	Julia Buxton, The Political Economy of Narcotics: Production, Consumption and Global Markets. London and New York: Zed Books, 2006, 246 p	JAN-TREX-00149842	JAN-TREX-00149842							
JA-02606	07/03/2018	June S. Beittel, "Mexico: Organized Crime and Drug Trafficking Organizations," Congressional Research Service, 3 July 2018.	JAN-TREX-00044754	JAN-TREX-00044785							
JA-02607	06/10/1905	Kevin Healy, "Coca, the State and the Peasantry in Bolivia," in Bruce Bagley, Bruce, ed. Assessing the America's War on Drugs, Special Issue Journal of InterAmerican Studies and World Affairs (JISWA), Vol. 30, Nos. 2 & 3, (Summer/Fall 1988) pp. 105-126.	JAN-TREX-00044786	JAN-TREX-00044807							
JA-02608	12/21/2017	Lopez, G. - "How fentanyl became America's leading cause of overdose deaths" (21 Dec. 2017).	JAN-TREX-00044808	JAN-TREX-00044817							
JA-02609	05/04/2018	Lopez, G. - "Why America's cocaine problem is now a fentanyl problem too" (4 May 2018).	JAN-TREX-00044818	JAN-TREX-00044826							
JA-02610	07/20/2018	Luis Herrera, "El Cartel de los Océanos," Reporte Índigo, 20 July 2018.	JAN-TREX-00044827	JAN-TREX-00044838							
JA-02611	08/04/2014	Marguerite Cawley, "Meth Trafficker Sentence Highlights Asia Ties to Mexico's Sinaloa Cartel," InSight Crime, 4 August 2014.	JAN-TREX-00044839	JAN-TREX-00044840							
JA-02612	07/03/1905	Mark A. R. Kleiman, Jonathan P. Caulkins, Angela Hawken, Drugs and Drug Policy: What Everyone Needs to Know. New York: Oxford University press, 2011, 234p.	JAN-TREX-00149843	JAN-TREX-00149843							
JA-02613	06/21/2018	Mark Stevenson, "Mexico opium poppy growers see price drop, turn to marijuana," AP News, 21 June 2018	JAN-TREX-00044841	JAN-TREX-00044857							
JA-02614	06/13/2018	Martin, James - "Effect of Restricting the Legal Supply of Prescription Opioids on Buying Through Online Illicit Marketplaces: Interrupted Time Series Analysis" (13 June 2018)	JAN-TREX-00044858	JAN-TREX-00044864							
JA-02615	12/12/2018	Mexico Attorney General's Office, "Inicia PGR investigación por aseguramiento de laboratorio clandestino en Sinaloa," 23 November 2017. 79 Procuraduría General de la República, "Comunicado PGR 34/18. PGR asegura en la Ciudad de México laboratorio clandestino para elaborar fentanilo," 12 December 2018.	JAN-TREX-00044865	JAN-TREX-00044870							
JA-02616	01/29/2019	Mexico Cartels Forecast 2019	JAN-TREX-00044871	JAN-TREX-00044881							
JA-02617	02/14/2017	Mike Gallagher, "The Cartels Next Door: 'Mayor of Mexico' ran a slick operation," Albuquerque Journal, 14 February 2017.	JAN-TREX-00044882	JAN-TREX-00044890							
JA-02618	05/25/2016	Mimi Yagoub, "Why a 900% Spike in Murders in West Mexico State," InSight Crime, 25 May 2016.	JAN-TREX-00044891	JAN-TREX-00044892							
JA-02619	08/01/2013	Muhuri, Pradip K. - "Associations of Nonmedical Pain Reliever Use and Initiation of Heroin Use in the United States" (Aug. 2013)	JAN-TREX-00044893	JAN-TREX-00044909							
JA-02620	08/31/2018	MySA. An Ordinary Couple Who Drove Raggedy Cars. Guillermo Contreras. August 31, 2018.	JAN-TREX-00044910	JAN-TREX-00044912							
JA-02621	01/01/2018	National Institute on Drug Abuse. Increased drug availability is associated with increased use and overdose. January 2018.	JAN-TREX-00044913	JAN-TREX-00044914							
JA-02622	01/01/2019	National Institute on Drug Abuse. Overdose Death Rates. January, 2019.	JAN-TREX-00044915	JAN-TREX-00044922							
JA-02623	06/01/2018	National Institute on Drug Abuse. What is heroin, Revised on June 2018.	JAN-TREX-00044923	JAN-TREX-00044929							
JA-02624	02/13/2018	New York Times. Meth, the Forgotten Killer, is Back. And It's Everywhere. Frances Robles. February 13, 2018. Available at: https://www.nytimes.com/2018/02/13/us/meth-crystal-drug.html	JAN-TREX-00044930	JAN-TREX-00044934							
JA-02625	12/25/1988	New York Times. Synthetic Heroin Seen As Cause in 18 Deaths. December 25, 1988.	JAN-TREX-00044935	JAN-TREX-00044937							
JA-02626	01/01/2019	NIH - "Opioid Overdose Crisis" (Jan. 2019)	JAN-TREX-00044938	JAN-TREX-00044941							
JA-02627	03/29/2018	NPR. Fentanyl-Laced Cocaine Becoming A Deadly Problem Among Drug Users. March 29, 2018.	JAN-TREX-00044942	JAN-TREX-00044954							
JA-02628	05/01/2018	NYC Health. Health Department Pilots Awareness Campaign in Lower East Side Bars and Nightclubs on Risk of Fentanyl in Cocaine Supply. May 23, 2018.	JAN-TREX-00044955	JAN-TREX-00044956							
JA-02629	03/01/2017	NYPD findings January – March 2017	JAN-TREX-00149844	JAN-TREX-00149844							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-02630	11/03/2017	O'Donnell, Julie K. - "Deaths Involving Fentanyl, Fentanyl Analogs, and U-47700—10 States, July-December 2016" (3 Nov. 2017)	JAN-TREX-00044957	JAN-TREX-00044965							
JA-02631	07/11/1905	ODC. Observatorio de Drogas de Colombia.	JAN-TREX-00044966	JAN-TREX-00044968							
JA-02632	05/01/2018	Office of the Special Narcotics Prosecutor for the City of New York, "2017 Annual Report," May 2018. Available at: http://www.snpsc.org/wp-content/uploads/2018/05/SNP-AR2017.pdf	JAN-TREX-00044969	JAN-TREX-00045016							
JA-02633	11/02/2018	ONDCP. ONDCP Releases Data on Coca Cultivation and Cocaine Production in Peru and Bolivia. November 2, 2018.	JAN-TREX-00045017	JAN-TREX-00045019							
JA-02634	07/26/2018	Parker Asmann, "Mexico Organized Crime-Related Executions Hit Record High: Report," 26 July 2018.	JAN-TREX-00045020	JAN-TREX-00045023							
JA-02635	07/01/1905	Paul Gootenberg "Talking About the Flow: Drugs, Borders, and the Discourse of Drug Control," Cultural Critique, 71, Winter 2009, 13-49.	JAN-TREX-00045024	JAN-TREX-00045061							
JA-02636	02/26/2017	Pedro Villa y Caña, "Puertos. Marina recupera el control de capitanías," El Universal	JAN-TREX-00045062	JAN-TREX-00045071							
JA-02637	07/01/1905	Peter Andreas, Border Games: Policing the U.S.-Mexican Divide. Cornell, 2nd edition, 2009.	JAN-TREX-00045072	JAN-TREX-00045073							
JA-02638	07/03/1905	Peter Chalk, The Latin American Drug Trade: Scope, Dimensions, Impact and Response. Santa Monica, CA: Rand Corporation, Prepared for the United States Air Force, 2011, 87 p.	JAN-TREX-00045074	JAN-TREX-00045186							
JA-02639	06/01/1990	Peter Reuter and David Rondfeldt, Quest for Integrity: The Mexican-U.S. Drug Problem. Santa Monica, CA: The Rand Corporation, June 1990, 62 p.	JAN-TREX-00045187	JAN-TREX-00045264							
JA-02640	05/08/2017	Pew, As Fentanyl Spreads, States Step Up Responses	JAN-TREX-00045265	JAN-TREX-00045270							
JA-02641	08/23/2017	Phil Fairbanks, "New indictment ups the ante for WNY drug network linked to Mexican cartel," The Buffalo News	JAN-TREX-00045271	JAN-TREX-00045275							
JA-02642	06/06/2018	Rachel Martin, "In Rural Ohio, An Opioid Crisis Becomes a Methamphetamine Crisis," National Public Radio	JAN-TREX-00045276	JAN-TREX-00045287							
JA-02643	07/10/1905	Rolling Stones	JAN-TREX-00045288	JAN-TREX-00045291							
JA-02644	08/15/2011	Sam Quinones, "Dreamland: The True Tale of America's Opiate Epidemic" (New York 2015). 3 American Society of Addiction Medicine, "Definition of Addiction,"	JAN-TREX-00045292	JAN-TREX-00045302							
JA-02645	09/07/2018	SAMHSA. 2017 National Survey on Drug Use and Health (NSDUH)	JAN-TREX-00045303	JAN-TREX-00048173							
JA-02646	01/31/2019	Sands, Geneva - "US customs announces largest fentanyl seizure in its history". Available at: https://www.cnn.com/2019/01/31/health/fentanyl-customs-bn/index.html	JAN-TREX-00048174	JAN-TREX-00048175							
JA-02647	01/24/2018	Scott, D. - "This is how easy it is to order deadly opioids over the internet". Available at: https://www.vox.com/policy-and-politics/2018/1/24/16928986/fentanyl-online-orders-postal-service	JAN-TREX-00048176	JAN-TREX-00048182							
JA-02648	05/01/2010	Steven S. Dudley, "Drug Trafficking Organizations in Central America: Transportistas, Mexican Cartels and Maras." Woodrow Wilson International Center for Scholars Mexico Institute: Working Paper Series on U.S. Mexico Security Collaboration and the University of San Diego Trans-Border Institute. http://wilsoncenter.org/topics/pubs/Drug%20Trafficking%20Organizations%20in%20Central%20America.%20Dudley.pdf	JAN-TREX-00048183	JAN-TREX-00048214							
JA-02649	05/09/2019	Substance Abuse & Mental Health Service Administration, "Treatment Episode Data Set."	JAN-TREX-00048215	JAN-TREX-00048217							
JA-02650	05/02/2018	The Atlantic. The Hard-to-Trace Ingredient Behind Skyrocketing Cocaine Deaths. Joseph Frankel	JAN-TREX-00048218	JAN-TREX-00048224							
JA-02651	06/25/1905	Thoumi, Francisco E. Illegal Drugs, Economy and Society in the Andes. Baltimore: The Johns Hopkins University Press, 2003. ISBN 0-8018-7854-3 (pbk).	JAN-TREX-00048225	JAN-TREX-00048226							
JA-02652	10/12/2018	U.S. Attorney's Office, US Northern District of Ohio, "Twenty people indicted in conspiracy that brought large amounts of heroin, cocaine and fentanyl to Northeast Ohio,"	JAN-TREX-00048227	JAN-TREX-00048229							
JA-02653	07/12/2018	U.S. Attorney's Office, US Southern District of California, "Former Border Patrol Agency Pleads Guilty to Conspiracy to Distribute 4ANPP Used in the Manufacturing of Fentanyl,"	JAN-TREX-00048230	JAN-TREX-00048231							
JA-02654	03/08/2018	U.S. Attorney's Office, US Southern District of Ohio, "Twelve Charged in Cincinnati in Connection to Mexico-Based Sinaloa Drug Cartel,"	JAN-TREX-00048232	JAN-TREX-00048235							
JA-02655	08/09/2019	U.S. Attorney's Office, US Western District of New York, "17 Defendants Indicted In International Drug Trafficking Ring,"	JAN-TREX-00048236	JAN-TREX-00048238							
JA-02656	12/20/2018	U.S. Attorney's Office, US Western District of New York, "Federal Jury Convicts Two Defendants of Narcotics Conspiracy Tied To The El Chapo Mexican Drug Cartel,"	JAN-TREX-00048239	JAN-TREX-00048242							
JA-02657	01/25/2018	U.S. Senate, Permanent Subcommittee on Investigations - "Combatting the Opioid Crisis: Exploiting Vulnerabilities in International Mail"	JAN-TREX-00048243	JAN-TREX-00048244							
JA-02658	05/09/2019	Global Research Project Study: Heroin in Transition	JAN-TREX-00149845	JAN-TREX-00149845							
JA-02659	03/01/2018	United States Department of State. Bureau for International Narcotics and Law Enforcement Affairs. International Narcotics Control Strategy Report. Volume I. Drug and Chemical Control. Available at: https://www.state.gov/documents/organization/278759.pdf	JAN-TREX-00048245	JAN-TREX-00048538							
JA-02660	03/01/2018	United States Department of State. Bureau of International Narcotics and Law Enforcement Affairs. International Narcotics Control Strategy Report. Volume I Drug and Chemical Control.	JAN-TREX-00048539	JAN-TREX-00048832							
JA-02661	05/10/2018	United States Senate Committee on Homeland Security and Governmental Affairs, Minority Staff Report, "Combatting the Opioid Epidemic: Intercepting Illicit Opioids at Ports of Entry,"	JAN-TREX-00048833	JAN-TREX-00048849							
JA-02662	05/09/2019	UNODC. Statistics and Data. Available at: https://data.unodc.un.org/drugs/heroin_and_cocaine_prices_in_eu_and_usa	JAN-TREX-00149846	JAN-TREX-00149846							
JA-02663	05/09/2019	UPI. Andres Manuel Obrador. Available at: https://www.upi.com/topic/Andres_Manuel_Lopez_Obrador/?tps=1	JAN-TREX-00048850	JAN-TREX-00048856							
JA-02664	06/28/2018	US Customs and Border Protection, "Philadelphia CBP Seizes Nearly \$1.7 Million in Fentanyl Shipped from Chin,"	JAN-TREX-00048857	JAN-TREX-00048859							
JA-02665	05/09/2019	US Customs and Border Protection. CBP Enforcement Statistics FY 2019.	JAN-TREX-00048860	JAN-TREX-00048865							
JA-02666	10/17/2017	US Department of Justice, "Justice Department announces indictments against Chinese manufacturers of fentanyl and other opiate Substances,"	JAN-TREX-00048866	JAN-TREX-00048868							
JA-02667	10/23/2018	US Department of Justice, "Thirty-Two Kilos of Fentanyl Worth \$28.8 Million Seized and Two Dominican Nationals Arrested for Trafficking," 23 October 2018.	JAN-TREX-00048869	JAN-TREX-00048870							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-02668	03/01/2014	US Department of State, Bureau of International Narcotics and Law Enforcement Affairs, "2014 International Narcotics Control Strategy Report (INCSR)," March 2014	JAN-TREX-00048871	JAN-TREX-00048875							
JA-02669	03/01/2018	US Department of State: Bureau of International Narcotics and Law Enforcement Affairs, "2018 International Narcotics Control Strategy Report (INCSR)," March 2018	JAN-TREX-00048876	JAN-TREX-00048878							
JA-02670	10/01/2017	US Drug Enforcement Administration, "2017 National Drug Threat Assessment," 1 October 2017	JAN-TREX-00048879	JAN-TREX-00049060							
JA-02671	10/01/2017	US Drug Enforcement Administration, "2017 National Drug Threat Assessment," October 2017.	JAN-TREX-00049061	JAN-TREX-00049242							
JA-02672	10/01/2018	US Drug Enforcement Administration, "2018 National Drug Threat Assessment," October 2018.	JAN-TREX-00049243	JAN-TREX-00049406							
JA-02673	07/10/1905	US Drug Enforcement Administration, "National Forensic Laboratory Information System: NFLIS-Drug Annual Report 2017," 2018.	JAN-TREX-00049407	JAN-TREX-00049438							
JA-02674	07/10/1905	US Drug Enforcement Administration, "National Forensic Laboratory Information System: NFLISDrug Annual Report 2017," 2018.	JAN-TREX-00049439	JAN-TREX-00049470							
JA-02675	07/10/1905	US Drug Enforcement Administration, "National Forensic Laboratory Information System: NFLISDrug Midyear Report 2017," 2018.	JAN-TREX-00049471	JAN-TREX-00049498							
JA-02676	07/10/1905	US Drug Enforcement Administration, "National Forensic Laboratory Information System: NFLISDrug Midyear Report 2017," 2018.	JAN-TREX-00049499	JAN-TREX-00049526							
JA-02677	11/15/2017	US House Committee on Energy and Commerce, "Bipartisan E&C Leaders Press DEA on Use of Pill Presse in Fentanyl Pill Mills," 15 November 2017.	JAN-TREX-00149847	JAN-TREX-00149847							
JA-02678	11/01/2017	US President's Office, "The President's Commission on Combating Drug Addiction and the Opioid Crisis," 1 November 2017.	JAN-TREX-00049527	JAN-TREX-00049664							
JA-02679	05/10/2018	US Senate Committee on Homeland Security and Governmental Affairs, Minority Staff Report, "Combatting the Opioid Epidemic: Intercepting Illicit Opioids at Ports of Entry," 10 May 2018.	JAN-TREX-00049665	JAN-TREX-00049681							
JA-02680	01/23/2018	US Senate Committee on Homeland Security and Governmental Affairs, Permanent Subcommittee on Investigations: Staff Report, "Combatting the Opioid Crisis: Exploiting Vulnerabilities in International Mail," 23 January 2018.	JAN-TREX-00049682	JAN-TREX-00049781							
JA-02681	03/01/2018	US State Department, Bureau of International Narcotics and Law Enforcement Affairs, "International Narcotics Control Strategy Report Vol. 1,"March 2018.	JAN-TREX-00049782	JAN-TREX-00050075							
JA-02682	11/01/2014	US-China Economic and Security Review Commission, "2014 Report to Congress," November 2014.	JAN-TREX-00050076	JAN-TREX-00050686							
JA-02683	02/01/2017	US-China Economic and Security Review Commission, "Fentanyl: China's Deadly Export to the United States," February 2017.	JAN-TREX-00050687	JAN-TREX-00050703							
JA-02684	05/04/2018	Why America's cocaine problem is now a fentanyl problem too., Vox Media, German Lopez, May 4, 2018	JAN-TREX-00050704	JAN-TREX-00050713							
JA-02685	02/01/2014	What America's Users Spend on Illegal Drugs: 2000-2010, Prepared by RAND Corporation for the Office of National Drug Control Policy.	JAN-TREX-00050714	JAN-TREX-00050837							
JA-02686	07/10/1905	World Drug Report 2018.	JAN-TREX-00050838	JAN-TREX-00050878							
JA-02687	06/04/2018	Wynn, R.L. - "Nonmedical Prescription Opioid Users Transitioning to Heroin: Incidence and Predictors"	JAN-TREX-00050879	JAN-TREX-00050887							
JA-02688	10/12/2011	Email from Margaret Quinn to Malcolm Monaghan	JAN-MS-00935073	JAN-MS-00935076							
JA-02689	04/24/2019	Kaiser Family Foundation website. State Health Facts: Health Insurance Coverage of the Total Population, available at www.kff.org/other/state-indicator/total-population/?currentTimeframe=0&sortModel=%7B"colId": "Location", "sort": "asc"%7D	JAN-TREX-00050888	JAN-TREX-00050891							
JA-02690	07/01/2008	ASHP guidelines on the pharmacy and therapeutics committee and the formulary system, ASHP Reports, Am J Health-Syst Pharm, Vol. 65, pp. 1272-83, 2008	JAN-TREX-00050892	JAN-TREX-00050903							
JA-02691	04/24/2019	JMCP.org website: Jill Augustine, PharmD, et al., Ability and Use of Comparative Effectiveness Research by P&T Committee Members and Support Staff: A 1-Year Follow-up, Journal of Managed Care & Specialty Pharmacy, Vol. 22, Issue 6, pp. 618–625, June 2016, available at https://www.jmcp.org/doi/full/10.18553/jmcp.2016.22.6.618	JAN-TREX-00050904	JAN-TREX-00050911							
JA-02692	04/24/2019	Medium.com website: Stephen A. Martin, MD, et al., Neat, Plausible, and Generally Wrong: A Response to the CDC Recommendations for Chronic Opioid Use, September 7, 2016, available at https://medium.com/@stmartin/neat-plausible-and-generally-wrong-a-response-to-the-cdc-recommendations-for-chronic-opioid-use-5c9d9d319f71	JAN-TREX-00050912	JAN-TREX-00050935							
JA-02693	04/24/2019	International Anesthesia Research Society website: Frank Brennan, MBBS, et al., The Role of Opioids in Pain Management, Anesthesia & Analgesia, Vol. 105, Issue 6, pp. 1865-1866, available at https://journals.lww.com/anesthesia-analgesia/fulltext/2007/12000/The_Role_of_Opioids_in_Pain_Management.65.aspx	JAN-TREX-00050936	JAN-TREX-00050937							
JA-02694	05/10/2016	Scientific American website: Maia Szalavitz, Opioid Addiction Is a Huge Problem, but Pain Prescriptions Are Not the Cause, Scientific American, May 10, 2016, available at https://blogs.scientificamerican.com/mind-guest-blog/opioid-addiction-is-a-huge-problem-but-pain-prescriptions-are-not-the-cause/	JAN-TREX-00050938	JAN-TREX-00050945							
JA-02695	04/24/2019	SAMHSA website: Results from the 2014 National Survey on Drug Use and Health: Detailed Tables, U.S. Department of Health and Human Services, Substance Abuse and Mental Health Service Administrations, available at https://www.samhsa.gov/data/sites/default/files/NSDUH-DetTabs2014/NSDUH-DetTabs2014.htm#tab6-47b	JAN-TREX-00050946	JAN-TREX-00052504							
JA-02696	03/18/2016	CDC website: Deborah Dowell, MD, et al., CDC Guideline for Prescribing Opioids for Chronic Pain — United States, 2016, Morbidity and Mortality Weekly Report, Centers for Disease Control and Prevention, Vol. 65, No. 1, pp. 1–49, available at https://www.cdc.gov/mmwr/volumes/65/rr/rr6501e1.htm	JAN-TREX-00052505	JAN-TREX-00052586							
JA-02697	05/01/2016	HHS website: Total US expenditures for opioid pain relievers, by insurance type and year, available at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4955937/figure/F1/	PMC4955937	PMC4955937							
JA-02698	02/24/2014	Taylor & Francis website: Louis F. Rossiter, Medical cost savings associated with an extended-release opioid with abuse-deterrent technology in the US, Journal of Medical Economics, Vol. 17, No. 4, February 24, 2014, available at https://www.tandfonline.com/doi/full/10.3111/13696998.2014.897628	JAN-TREX-00052587	JAN-TREX-00052595							
JA-02699	02/05/2018	Massachusetts Department of Public Health, Drug Formulary Commission, minutes of meeting on February 5, 2018, available at https://www.mass.gov/files/documents/2018/05/11/dfc-minutes-2-5-18-approved.pdf	JAN-TREX-00052596	JAN-TREX-00052602							
JA-02700	01/17/2018	Drugs for dollars: How Medicaid helps fuel the opioid epidemic, Majority Media	JAN-TREX-00052603	JAN-TREX-00052605							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-02701	03/27/2018	Medicare is Cracking Down on Opioids. Doctors Fear Pain Patients Will Suffer, New York Times	JAN-TREX-00052606	JAN-TREX-00052615							
JA-02702	03/27/2019	Kaiser Family Foundation. States Reporting Medicaid FFS Pharmacy Benefit Management Strategies for Opioids In Place. 2017	JAN-TREX-00052616	JAN-TREX-00052617							
JA-02703	07/07/1905	RADARS 3rd Quarter 2015 Technical Report. Abuse Prevalence and Preference of Immediate Release versus Extended Release Opioids	JAN-TREX-00052618	JAN-TREX-00052621							
JA-02704	05/23/2017	Georgetown University Center on Health Insurance Reforms Website: http://chirblog.org/responding-opioid-crisis-insurers-balance-stepped-monitoring-restrictions-need-appropriate-pain-treatment/ "	JAN-TREX-00052622	JAN-TREX-00052626							
JA-02705	04/21/2016	Frieden T, Houry D., Reducing the Risks Relief —The CDC's Opioid-Prescribing Guideline. New England Journal of Medicine, 374(16), 1501–1504, 2016	JAN-TREX-00052644	JAN-TREX-00052647							
JA-02706	04/11/2018	Henry J. Kaiser Family Foundation Website: https://www.kff.org/medicaid/issue-brief/the-opioid-epidemic-and-medicoids-role-in-facilitating-access-to-treatment/	JAN-TREX-00052648	JAN-TREX-00052657							
JA-02707	07/10/1905	Medicaid Benefits: Prescription Drugs, State Health Facts, Henry J. Kaiser Family Foundation	JAN-TREX-00052658	JAN-TREX-00052659							
JA-02708	02/12/2019	D. Hartung, Buprenorphine Coverage in the Medicare Part D Program for 2007 to 2018, JAMA, 321(6), pp. 607-609, 2019	JAN-TREX-00052660	JAN-TREX-00052662							
JA-02709	04/01/2018	Cohen J, Stolk E, Niezen M. Role of Budget Impact in role of Drug Reimbursement Decisions. Journal of Health Politics, Policy and Law, Vol. 33, No. 2. April 2008.	JAN-TREX-00052663	JAN-TREX-00052686							
JA-02710	12/10/2018	Alexandra Duncan, Why Those With Opioid Use Disorder May Not Receive Treatment, Pew Charitable Trusts (Dec. 10, 2018),	JAN-TREX-00052687	JAN-TREX-00052690							
JA-02711	06/30/1905	American Society of Health-System Pharmacists. ASHP guidelines on the pharmacy and therapeutics committee and the formulary system. Am J Health-Syst Pharm. 2008; 65:1272-83	JAN-TREX-00052691	JAN-TREX-00052702							
JA-02712	07/10/1905	CARESOURCE Implements Quantity Limits on Opioids for Ohio Medicaid, 2018	JAN-TREX-00052703	JAN-TREX-00052704							
JA-02713	07/06/1905	Center for Behavioral Health Statistics and Quality (CBHSQ), Substance Abuse and Mental Health Services Administration (SAMHSA), U.S. Department of Health and Human Services. Results from the 2014 National Survey on Drug Use and Health: Detailed Tables. 2014.	JAN-TREX-00052705	JAN-TREX-00054262							
JA-02714	03/18/2016	Centers for Disease Control and Prevention, "CDC Guideline for Prescribing Opioids for Chronic Pain — United States, 2016," MMWR (Mar. 18, 2016)	JAN-TREX-00054263	JAN-TREX-00054344							
JA-02715	03/18/2016	Centers for Disease Control and Prevention. Dowell D, Haegerich T, Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain — United States. MMWR Food and Drug Administration. FDA Opioids Action Plan. February 2016	JAN-TREX-00054345	JAN-TREX-00054396							
JA-02716	01/28/2016	CMCS Bulletin. Best Practices for Addressing Prescription Opioid Overdoses, Misuse and Addiction https://www.medicaid.gov/federal-policy-guidance/downloads/cib-02-02-16	JAN-TREX-00054397	JAN-TREX-00054411							
JA-02717	08/01/2018	Cohen J, El Khoury C, Milne C, Peters S. Rising Drug Costs Drives the Growth of Pharmacy Benefit Managers Exclusion Lists: Are Exclusion Decisions Value-Based? Health Services Research. Aug. 2018.	JAN-TREX-00054412	JAN-TREX-00054423							
JA-02718	04/04/2014	Cohen J, Felix A. Personalized Medicine's Bottleneck: Diagnostic Test Evidence and Reimbursement. Journal of Personalized Medicine 2014.	JAN-TREX-00054424	JAN-TREX-00054436							
JA-02719	02/01/2018	Cohen J, Mendoza M, Roland C. Challenges Involved in the Development and Delivery of Abuse-deterrent Formulations of Opioid Analgesics. Clinical Therapeutics 2018; 40(2):334 – 344.	JAN-TREX-00054437	JAN-TREX-00054438							
JA-02720	04/01/2008	Cohen J, Stolk E, Niezen M. Role of Budget Impact in role of bDrug Reimbursement Decisions. Journal of Health Politics, Policy and Law, Vol. 33, No. 2. April 2008.	JAN-TREX-00054439	JAN-TREX-00054462							
JA-02721	07/05/1905	Cohen J, Wilson A, Manzollillo K. Clinical and economic challenges facing pharmacogenomics. The Pharmacogenomics Journal (2013) 13, 378-388.	JAN-TREX-00054463	JAN-TREX-00054473							
JA-02722	06/26/1905	Cohen J. Are clinical practice guidelines impartial? International Journal of Technology Assessment in Health Care, 20:4 (2004), 415-420.	JAN-TREX-00054474	JAN-TREX-00054479							
JA-02723	07/19/2018	Cohen J. 'Diseases of Despair' Contribute To Declining U.S. Life Expectancy. Forbes. Jul. 19, 2018.	JAN-TREX-00054480	JAN-TREX-00054483							
JA-02724	05/07/2018	Cohen J. Guest Commentary: Aligning price and value for drugs—potential disrupters of the PBM model. Modern Healthcare. May 7, 2018.	JAN-TREX-00054484	JAN-TREX-00054487							
JA-02725	12/19/2018	Cohen J. Looking Into A Crystal Ball: Some Healthcare Predictions For 2019. Forbes. Dec. 19, 2018.	JAN-TREX-00054488	JAN-TREX-00054492							
JA-02726	09/04/2018	Cohen J. Medicaid To Introduce Value-Based Drug Pricing. Forbes. Sep. 4, 2018.	JAN-TREX-00054493	JAN-TREX-00054497							
JA-02727	09/24/2018	Cohen J. To Include Or Not Include Drug Prices In DTC Ads. Sep. 24, 2018.	JAN-TREX-00054498	JAN-TREX-00054501							
JA-02728	01/23/2019	Cohen, Joshua The Importance of Patient-Centric Opioid Prescribing Guidelines. Forbes. Jan. 23, 2019.	JAN-TREX-00054502	JAN-TREX-00054504							
JA-02729	02/12/2019	D. Hartung, Buprenorphine Coverage in the Medicare Part D Program for 2007 to 2018. JAMA.	JAN-TREX-00054505	JAN-TREX-00054509							
JA-02730	01/01/2018	Duragesic Label	JAN-TREX-00054510	JAN-TREX-00054565							
JA-02731	02/01/2016	Food and Drug Administration. FDA Opioids Action Plan. February 2016	JAN-TREX-00054566	JAN-TREX-00054567							
JA-02732	04/21/2016	Frieden T, Houry D. Reducing the Risks of Relief — The CDC's Opioid-Prescribing Guideline. New England Journal of Medicine 2016; 374(16):1501-1504	JAN-TREX-00054568	JAN-TREX-00054571							
JA-02733	05/23/2017	Georgetown University Center on Health Insurance Reforms. Palanker D. Ahn S, Corlette S. Responding to the Opioid Crisis: Insurers Balance Stepped up Monitoring, Restrictions with Need for Appropriate Pain Treatment. May 23, 2017	JAN-TREX-00054572	JAN-TREX-00054576							
JA-02734	03/27/2018	Hoffman J. Medicare is Cracking Down on Opioids. Doctors Fear Pain Patients Will Suffer. New York Times. March 27, 2018	JAN-TREX-00054577	JAN-TREX-00054586							
JA-02735	06/22/2018	Prescription Drug Coverage for Treatment of Low Back Pain Among US Medicaid, Medicare Advantage and Commercial Insurers	JAN-TREX-00054587	JAN-TREX-00054599							
JA-02736	01/13/2019	Curriculum Vitae Joshua P. Cohen	JAN-TREX-00054600	JAN-TREX-00054611							
JA-02737	06/01/2016	Journal of Managed Care & Specialty Pharmacy 2016 22:6: 618-625	JAN-TREX-00054612	JAN-TREX-00054619							
JA-02738	04/11/2018	Julia Zur, Jennifer Tolbert, The Opioid Epidemic and Medicaid's Role in Facilitating Access to Treatment, Henry J. Kaiser Family Foundation (Apr. 11, 2018)	JAN-TREX-00054620	JAN-TREX-00054629							
JA-02739	03/29/2018	Kacik. A. Blue Cross and Blue Shield Discourages Use of Opioids in Primary Care Treatment. Modern Healthcare. March 2018.	JAN-TREX-00054630	JAN-TREX-00054636							
JA-02740	07/09/1905	Kaiser Family Foundation. State Health Facts: Health Insurance Coverage of the Total Population. 2017	JAN-TREX-00054637	JAN-TREX-00054640							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-02741	07/09/1905	Kaiser Family Foundation. States Reporting Medicaid FFS Pharmacy Benefit Management Strategies for Opioids In Place. 2017	JAN-TREX-00054641	JAN-TREX-00054642							
JA-02742	07/09/1905	Kaye A, Jones M, Ripoll J, Jones D, Galan V, Beakly B, Calixto F, Bolden J, Urman R, Manchikanti L, Prescription Opioid Abuse in Chronic Pain: An Updated Review of Opioid Abuse Predictors and Strategies to Curb Opioid Abuse (Part 2). Pain Physician 2017; 20:S111-E133	JAN-TREX-00054643	JAN-TREX-00054666							
JA-02743	07/10/1905	Lin D, Jones C, Compton W, et al. Prescription Drug Coverage for Treatment of Low Back Pain Among US Medicaid, Medicare Advantage, and Commercial Insurers.	JAN-TREX-00054667	JAN-TREX-00054679							
JA-02744	06/22/2018	Lin D, Jones C, Compton W, et al. Prescription Drug Coverage for Treatment of Low Back Pain Among US Medicaid, Medicare Advantage, and Commercial Insurers.	JAN-TREX-00054680	JAN-TREX-00054702							
JA-02745	02/05/2018	Massachusetts Public Health Commission (Formulary) minutes; on abuse-deterrent formulations of opioid analgesics	JAN-TREX-00054703	JAN-TREX-00054709							
JA-02746	02/05/2018	Massachusetts Public Health Commission (Formulary) minutes; on abuse-deterrent formulations of opioid analgesics	JAN-TREX-00054710	JAN-TREX-00054716							
JA-02747	07/10/1905	Milliman. Davenport S, Matthews K. 2018. Opioid use disorder in the United States: Diagnosed prevalence by payer, age; sex; and state	JAN-TREX-00054717	JAN-TREX-00054725							
JA-02748	07/10/1905	Milliman. Davenport S, Matthews K. 2018. Opioid use disorder in the United States: Diagnosed prevalence by payer, age; sex; and state	JAN-TREX-00054726	JAN-TREX-00054731							
JA-02749	01/01/2019	National Institute on Drug Abuse. Overdose Death Rates. August 2018	JAN-TREX-00054732	JAN-TREX-00054739							
JA-02750	02/12/2019	JAMA Program for 2007 to 2018	JAN-TREX-00054740	JAN-TREX-00054742							
JA-02751	04/01/2018	Puja Seth et al., Quantifying the Epidemic of Prescription Opioid Overdose Deaths. American Journal of Public Health 2018; 108(4):500-502	JAN-TREX-00054743	JAN-TREX-00054746							
JA-02752	03/18/2016	CDC Recommendations and Reports Vol 65 (1): CDC Guideline for Prescribing Opioids for Chronic Pain - United States, 2016	JAN-TREX-00054747	JAN-TREX-00054798							
JA-02753	07/06/1905	Rossiter L, Kirson ets., Medical cost savings associated with an extended-release opioid with abuse-deterrent technology in the US. Journal of Medical Economics 2014; 17(4):279-287	JAN-TREX-00054799	JAN-TREX-00054822							
JA-02754	12/01/2007	Saidman L, Brennan et al.,. The Role of Opioids in Pain Management. Anesthesia & Analgesia 2007; 105(6):1865-1866	JAN-TREX-00054823	JAN-TREX-00054826							
JA-02755	10/02/2018	Sandoe E, Fry C, Frank R. Policy Levers That States Can Use To improve Opioid Addiction Treatment And Address The Opioid Epidemic, Health Affairs Blog	JAN-TREX-00054827	JAN-TREX-00054837							
JA-02756	08/01/2013	Substance Abuse and Mental Health Services Administration (SAMHSA). Muhiri P, Gfoerer J, Davies C. Associations of Nonmedical Pain Reliever Use and Initiation of Heroin Use in the United States	JAN-TREX-00054838	JAN-TREX-00054851							
JA-02757	05/10/2016	Szalavitz M. Opioid Addiction Is a Huge Problem, but Pain Prescriptions Are Not the Cause. MIND Guest Blog. Scientific American	JAN-TREX-00054852	JAN-TREX-00054859							
JA-02758	02/28/2017	Szalavitz M. The Feds Are About to Stick It to Pain Patients in a Big Way. Vice	JAN-TREX-00054860	JAN-TREX-00054875							
JA-02759	03/14/2018	FDA presentation: FDA's Actions to Address the Opioid Epidemic	JAN-TREX-00054876	JAN-TREX-00054901							
JA-02760	05/01/2018	Weiss A, Heslin K. Healthcare Cost and Utilization Project Payers of Opioid-Related Inpatient Stays and Emergency Department Visits Nationally and by State, 2010 and 2015. .	JAN-TREX-00054902	JAN-TREX-00054929							
JA-02761	05/01/2016	Zhou C. "Payments For Opioids Shifted Substantially To Public And Private Insurers While Consumer Spending Declined, 1999-2012" Health Affairs (Project Hope) 2016; 35(5):824-831.	JAN-TREX-00054930	JAN-TREX-00054937							
JA-02762	09/12/1994	U.S. vs. Clary, 34F.3d 709 (1994)	JAN-TREX-00054938	JAN-TREX-00054942							
JA-02763	03/22/2019	Courtwright David T., Dark Paradise: A History of Opiate Addiction in America, Excerpt pp. 6-7	JAN-TREX-00054943	JAN-TREX-00054945							
JA-02764	03/22/2019	Courtwright David T., Dark Paradise: A History of Opiate Addiction in America, Excerpt pp. 260-261	JAN-TREX-00054946	JAN-TREX-00054948							
JA-02765	12/26/2000	News releases; Healthbeat: Hospitals Told to Treat Patients' Pain, New Efforts Against an Old Foe: Pain by Laurie Tarkan	JAN-MS-00311736	JAN-MS-00311741							
JA-02766	11/01/2017	The President's Commission on Combating Drug Addiction and The Opioid Crisis	JAN-TREX-00054949	JAN-TREX-00055086							
JA-02767	12/19/2018	Chronology of the Declaration of the Fifth Vital Sign - Chronology of the Declaration of the Fifth Vital Sign	JAN-TREX-00149848	JAN-TREX-00149848							
JA-02768	10/08/2002	Duragesic: The Tipping Point 2003 Tactical Plan	JAN-TREX-00055087	JAN-TREX-00055141							
JA-02769	04/26/2006	Treating Pain in the 21st Century: How to Reduce Abuse and Diversion - Proposal for a CME/CE Initiative	JAN-MS-00411490	JAN-MS-00411496							
JA-02770	No Date	Johnson & Johnson Code of Business Conduct / Live Our Credo, Know Our Code by Alex Gorsky	JAN-TREX-00055142	JAN-TREX-00055176							
JA-02771	08/25/2004	Pain Therapeutic Area Strategy - New Product DevelopmentCommittee	JAN-TREX-00055177	JAN-TREX-00055214							
JA-02772	02/27/2004	A New Tool to Assess and Document Pain Outcomes in Chronic Pain Patients Receiving Opioid Therapy	JAN-TREX-00055215	JAN-TREX-00055224							
JA-02773	05/01/2019	Only together can we improve the relief of pain; American Pain Society	JAN-TREX-00055225	JAN-TREX-00055226							
JA-02774	05/01/2019	ASPMN Mission Statement & Goals	JAN-TREX-00055227	JAN-TREX-00055229							
JA-02775	05/01/2019	ASPMN Formation & Early History	JAN-TREX-00055230	JAN-TREX-00055232							
JA-02776	03/20/2019	US Pain Foundation About Us	JAN-TREX-00055233	JAN-TREX-00055234							
JA-02777	05/01/2011	APF Pain Resource Locator	JAN-TREX-00055235	JAN-TREX-00055236							
JA-02778	04/09/2011	APF Welcome to PainAid page	JAN-TREX-00055237	JAN-TREX-00055238							
JA-02779	01/30/2019	Pain & Policy Studies website, available at https://web.archive.org/web/20190130031524/http://www.painpolicy.wisc.edu/about-ppsg	JAN-TREX-00055239	JAN-TREX-00055241							
JA-02780	05/01/2019	Cancer Action Network About page	JAN-TREX-00055242	JAN-TREX-00055244							
JA-02781	05/01/2019	Cancer Action Network Corporate Members page	JAN-TREX-00055245	JAN-TREX-00055248							
JA-02782	05/01/2019	Cancer Action Network Pain Relief page	JAN-TREX-00055249	JAN-TREX-00055251							
JA-02783	05/01/2019	Video: Smart Moves Smart Choices: http://www.smartmovesmartchoices.org/animated-video	JAN-TREX-00149849	JAN-TREX-00149849							
JA-02784	05/01/2019	Smart Moves Smart Choices Video Presentation: Dr. Drew Haley, Kyle's Story	JAN-TREX-00149850	JAN-TREX-00149850							
JA-02785	05/01/2019	Smart Moves Smart Choices Video Presentation: Dr. Drew School Nurses and Educators Take Action	JAN-TREX-00149851	JAN-TREX-00149851							
JA-02786	05/01/2019	Smart Moves Smart Choices Video Presentation: Q & A with Dr. Drew	JAN-TREX-00149852	JAN-TREX-00149852							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-02787	05/01/2019	Smart Moves Smart Choices Video Presentation: Dr. Drew Q & A with Kyle	JAN-TREX-00149853	JAN-TREX-00149853							
JA-02788	05/01/2019	Dr. Drew Smart Moves for Teens Video Link	JAN-TREX-00149854	JAN-TREX-00149854							
JA-02789	05/01/2019	Smart Moves Smart Choices Video Presentation: Dr. Drew Pinsky - Teen Prescription Drug Abuse, http://www.smartmovessmartchoices.org/dr-drew-videos#teen-prescription-abuse	JAN-TREX-00149855	JAN-TREX-00149855							
JA-02790	05/01/2019	Smart Moves Smart Choices Video Presentation: Dr. Drew Pinsky: What is Addiction, http://www.smartmovessmartchoices.org/dr-drew-videos#what-is-addiction	JAN-TREX-00149856	JAN-TREX-00149856							
JA-02791	05/01/2019	Smart Moves Smart Choices Video Presentation: Dr. Drew Pinsky: What Parents Can Do, http://www.smartmovessmartchoices.org/dr-drew-videos#what-is-addiction : http://www.smartmovessmartchoices.org/dr-drew-videos#what-parents-can-do	JAN-TREX-00149857	JAN-TREX-00149857							
JA-02792	05/01/2019	Smart Moves Smart Choices Video Presentation: Dr. Drew Pinsky: Why Teen Abuse, http://www.smartmovessmartchoices.org/dr-drew-videos#why-teens-abuse	JAN-TREX-00149858	JAN-TREX-00149858							
JA-02793	08/01/2016	Smart Moves, Smart Choices Poster	JAN-TREX-00149859	JAN-TREX-00149859							
JA-02794	08/01/2016	Smart Moves Assembly Flier: http://www.smartmovessmartchoices.org/pdfs/SmartMoves_SchoolToolkit_AssemblyFlier_Web.pdf	JAN-TREX-00149860	JAN-TREX-00149860							
JA-02795	08/01/2016	Educator Survey: http://www.smartmovessmartchoices.org/pdfs/SmartMoves_SchoolToolkit_EducatorSurvey_Web.pdf	JAN-TREX-00055252	JAN-TREX-00055253							
JA-02796	08/01/2011	Smart Moves Parent Flier: http://www.smartmovessmartchoices.org/pdfs/SmartMoves_SchoolToolkit_ParentFlier_Web.pdf	JAN-TREX-00149861	JAN-TREX-00149861							
JA-02797	08/01/2016	Student Post-Test: http://www.smartmovessmartchoices.org/pdfs/SmartMoves_SchoolToolkit_Post-Test_Web.pdf	JAN-TREX-00055254	JAN-TREX-00055257							
JA-02798	08/01/2016	Student Pre-Test: http://www.smartmovessmartchoices.org/pdfs/SmartMoves_SchoolToolkit_Pre-Test_Web.pdf	JAN-TREX-00055258	JAN-TREX-00055261							
JA-02799	08/01/2016	Small Things Can Be Deadly Poster: http://www.smartmovessmartchoices.org/pdfs/SmartMoves_SchoolToolkit_SmallThingsPoster_Web.pdf	JAN-TREX-00149862	JAN-TREX-00149862							
JA-02800	08/01/2016	Small Things Can Be Deadly Poster: http://www.smartmovessmartchoices.org/pdfs/SmartMoves_SchoolToolkit_SpeakerNotes_AssemblyUsingSpeakers_Web.pdf	JAN-TREX-00055262	JAN-TREX-00055266							
JA-02801	08/01/2016	Poster Small Things Can Be Deadly: http://www.smartmovessmartchoices.org/pdfs/SmartMoves_SchoolToolkit_SpeakerNotes_AssemblyUsingVideos_Web.pdf	JAN-TREX-00149863	JAN-TREX-00149863							
JA-02802	08/01/2016	Teen Prescription (Rx) Drug Abuse Awareness School Tool Kit: http://www.smartmovessmartchoices.org/pdfs/SmartMoves_SchoolToolKit_Web_HiRes.pdf	JAN-TREX-00055267	JAN-TREX-00055296							
JA-02803	08/01/2016	Video Discussion Guide: http://www.smartmovessmartchoices.org/pdfs/SmartMovesSmartChoices_AnimatedVideo_DiscussionGuide.pdf	JAN-TREX-00055297	JAN-TREX-00055303							
JA-02804	04/01/2014	Smart Moves Smart Choices Website: Start Smart Medication Safety Basics, available at http://www.smartmovessmartchoices.org/pdfs/Start%20Smart_BasicsPoster.pdf	JAN-TREX-00149864	JAN-TREX-00149864							
JA-02805	04/01/2014	Start Smart Infographic 1: http://www.smartmovessmartchoices.org/pdfs/Start%20Smart_Infographic1.pdf	JAN-TREX-00149865	JAN-TREX-00149865							
JA-02806	04/01/2014	Start Smart Infographic 1: http://www.smartmovessmartchoices.org/pdfs/Start%20Smart_Infographic2.pdf	JAN-TREX-00149866	JAN-TREX-00149866							
JA-02807	04/01/2014	Start Smart Infographic 1: http://www.smartmovessmartchoices.org/pdfs/Start%20Smart_KidsArePricelessPoster.pdf	JAN-TREX-00149867	JAN-TREX-00149867							
JA-02808	08/01/2016	Start Smart Medicine Safety Tips: http://www.smartmovessmartchoices.org/pdfs/Start%20Smart_MedicineSafetyTips.pdf	JAN-TREX-00055304	JAN-TREX-00055305							
JA-02809	04/01/2014	Start Smart Parent Fact Sheet: http://www.smartmovessmartchoices.org/pdfs/Start%20Smart_ParentFactSheet.pdf	JAN-TREX-00055306	JAN-TREX-00055307							
JA-02810	08/01/2016	Start Smart Program Overview: http://www.smartmovessmartchoices.org/pdfs/Start%20Smart_ProgramOverview.pdf	JAN-TREX-00055308	JAN-TREX-00055310							
JA-02811	04/01/2014	Smart Moves Smart Choices Website: Start Smart Their Drug of Choice, available at http://www.smartmovessmartchoices.org/pdfs/Start%20Smart_TheirDrugOfChoice_Poster.pdf	JAN-TREX-00149868	JAN-TREX-00149868							
JA-02812	04/01/2014	Smart Moves Smart Choices Website: Start Smart Their Drug of Choice, available at http://www.smartmovessmartchoices.org/pdfs/Start%20Smart_Workbook_3-5.pdf	JAN-TREX-00055311	JAN-TREX-00055322							
JA-02813	04/01/2014	Start Smart K-2 Workbook: http://www.smartmovessmartchoices.org/pdfs/Start%20Smart_Workbook_K-2.pdf	JAN-TREX-00055323	JAN-TREX-00055332							
JA-02814	06/27/1905	Opioid Risk Tool	JAN-TREX-00055333	JAN-TREX-00055334							
JA-02815	05/01/2019	Prescription Opioids - Drug Overdose - CDC Injury Center: www.cdc.gov/drugoverdose/opioids/prescribed.html	JAN-TREX-00055335	JAN-TREX-00055338							
JA-02816	06/01/2018	Drug Facts: Prescription Opioids, National Institute on Drug Abuse (NIDA): www.drugabuse.gov/publications/drugfacts/prescription-opioids	JAN-TREX-00055339	JAN-TREX-00055349							
JA-02817	06/26/1905	Passik, SD, et al., A New Tool to Assess and Document Pain Outcomes in Chronic Pain Patients Receiving Opioid Therapy, <i>Clinical Therapeutics</i> , Vol. 26, No.4, 2004	JAN-TREX-00055350	JAN-TREX-00055359							
JA-02818	05/01/2019	ASPMN Website: Formation & Early History of ASPMN, available at http://www.aspmn.org/whoweare/pages/history.aspx	JAN-TREX-00055360	JAN-TREX-00055362							
JA-02819	03/21/2019	APF Website: About APF, available at https://web.archive.org/web/20110223040453/http://www.painfoundation.org/about/	JAN-TREX-00055363	JAN-TREX-00055364							
JA-02820	03/21/2019	AIPM Website: Our Mission, available at https://www.integrativepainmanagement.org/page/about	JAN-TREX-00149869	JAN-TREX-00149869							
JA-02821	04/01/2019	AIPM Website: Policy & Advocacy, available at https://www.integrativepainmanagement.org/page/policyandadvocacy#	JAN-TREX-00055365	JAN-TREX-00055368							
JA-02822	10/17/2003	RESOLVE (Randomized Enrollment Study of Opioid Long-term use to eValuate Efficacy)	JAN-TREX-00055369	JAN-TREX-00055370							
JA-02823	10/29/2001	Janssen Marketing Best Practices Council Meeting Minutes re: Duragesic Advisory Boards	JAN-MS-00780199	JAN-MS-00780208							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-02824	02/28/2011	Janssen Presentation: Incentive Plan Feedback	JAN-MS-00868424	JAN-MS-00868424							
JA-02825	06/06/2008	Email from Michelle Wanat to David Moore	JAN-MS-01136209	JAN-MS-01136209							
JA-02826	04/30/2019	How to Talk to Your Healthcare Professional	JAN-TREX-00055371	JAN-TREX-00055373							
JA-02827	04/30/2019	How to Talk to Your Healthcare Professional	JAN-TREX-00055374	JAN-TREX-00055376							
JA-02828	11/07/2007	Duragesic Promotional Material	JAN-TREX-00149870	JAN-TREX-00149870							
JA-02829	06/27/1905	"Write What You Know" Ad	JAN-TREX-00055377	JAN-TREX-00055383							
JA-02830	05/06/2014	Nucynta Marketing Materials	JAN-MS-02387666	JAN-MS-02387675							
JA-02831	11/21/2018	Community Connect Discussion Guide	JAN-MS-03745431	JAN-MS-03745444							
JA-02832	11/08/2013	AAPM Grant Request; Promoting Inter-professional cooperation in Pain Care: Reconciling the Roles of Prescribers and Dispensers	JAN-MS-02347089	JAN-MS-02347094							
JA-02833	07/22/2008	Guidance Document on Educational Support	JAN-MS-05457397	JAN-MS-05457445							
JA-02834	10/04/2010	Let's Talk Pain Video Series: Segment 6: Safe Use of Medical Devices (PainSAFE)	JAN-TREX-00149871	JAN-TREX-00149871							
JA-02835	10/04/2010	Let's Talk pain Video Series: Segment 5: Safe Use of Medical Devices (PainSAFE)	JAN-TREX-00149872	JAN-TREX-00149872							
JA-02836	09/20/2010	Let's Talk Pain Video Series: Segment 4: Safe Use of Over-the-Counter Medicines (PainSAFE)	JAN-TREX-00149873	JAN-TREX-00149873							
JA-02837	09/29/2010	Let's Talk Pain Video Series: Segment 3: Safe Use of Over-the-Counter Medications (PainSAFE)	JAN-TREX-00149874	JAN-TREX-00149874							
JA-02838	09/29/2010	Let's Talk Pain Video Series: Segment 2: Safe Use of Opioids	JAN-TREX-00149875	JAN-TREX-00149875							
JA-02839	No Date	Let's Talk Pain Video Series: Segment 1: Safe Use of Opioids (PainSAFE)	JAN-TREX-00149876	JAN-TREX-00149876							
JA-02840	09/26/2010	Lets Talk Pain Video Presentation: Pain Medication Safety Series Introduction (PainSAFE)	JAN-TREX-00149877	JAN-TREX-00149877							
JA-02841	04/07/2010	Let's Talk Pain Coalition Video Presentation: Profile of Denise Colman - Patient Advocate	JAN-TREX-00149878	JAN-TREX-00149878							
JA-02842	04/07/2010	Let's Talk Pain Coalition Video Series: Segment 4: Thinking and Feeling About Pain	JAN-TREX-00149879	JAN-TREX-00149879							
JA-02843	04/07/2010	Let's Talk Pain Coalition Video Series: Segment 5 - Maintaining an Active Life with Pain: Integrative Pain Management	JAN-TREX-00149880	JAN-TREX-00149880							
JA-02844	11/02/2009	Let's Talk Pain Video Series: Segment 3: Communicating about Pain: For People with Pain	JAN-TREX-00149881	JAN-TREX-00149881							
JA-02845	09/29/2009	Let's Talk Pain Video Series: Segment 2: Communicating about Pain for Healthcare Practitioners	JAN-TREX-00149882	JAN-TREX-00149882							
JA-02846	09/16/2009	Let's Talk Pain Video Series: Segment 1: Tackling the Challenges of Pain and Pain Management	JAN-TREX-00149883	JAN-TREX-00149883							
JA-02847	09/16/2009	Let's Talk Pain Video Presentation: Kathy Church: In Depth Profile	JAN-TREX-00149884	JAN-TREX-00149884							
JA-02848	12/15/2011	Email from Penney Cowan to Peg Forrestel et al.	JAN-MS-00396535	JAN-MS-00396536							
JA-02849	02/01/2007	Smart Moves, Smart Choices - A Prescription Drug Abuse Prevention Program	JAN-MS-00275522	JAN-MS-00275522							
JA-02850	02/01/2014	Start Smart Medication Safety Basics	JAN-MS-00428531	JAN-MS-00428533							
JA-02851	10/28/2000	Public Law 106-386: Victims of Trafficking and Violence Protection Act of 2000	JAN-TREX-00055384	JAN-TREX-00055469							
JA-02852	01/01/2011	Prescribe Responsibly Overview	JAN-MS-00318469	JAN-MS-00318494							
JA-02853	01/27/2011	Email from Deem-Eshelman to Carissa Hornbeck	JAN-MS-00318468	JAN-MS-00318468							
JA-02854	10/11/2018	Nurse.Com Website - Confronting the Opioid Epidemic, available at https://resources.nurse.com/opioid-epidemic	JAN-TREX-00055470	JAN-TREX-00055478							
JA-02855	05/05/2014	Email from Frederick Tewell to Christine Lenthe	JAN-MS-01967941	JAN-MS-01967942							
JA-02856	05/01/2006	Ortho-McNeill Janssen Presentation, R331333 Market Definition Research - Final Report	JAN-MS-02358785	JAN-MS-02358831							
JA-02857	02/01/2014	Draft Janssen presentation: Nucynta: Overview of Tapentadol Abuse	JAN-MS-00418497	JAN-MS-00418497							
JA-02858	02/01/2006	The Resolutions Group Presentation for Ortho-McNeil Janssen Pharmaceutical Services: Prescribing Decisions for Short-Acting Opioids	JAN-MS-00435726	JAN-MS-00435726							
JA-02859	05/16/2007	Ortho-McNeil Janssen Pharmaceutical Services Presentation: Emotive Drivers Qualitative Physician and Patient Research	JAN-MS-00504451	JAN-MS-00504451							
JA-02860	08/21/2014	Email from Gary Vorsanger to Frederick Tewell et al.	JAN-MS-00577454	JAN-MS-00577454							
JA-02861	09/01/2009	Nucynta Ad - David's Patient Profile	JAN-MS-00235897	JAN-MS-00235897							
JA-02862	10/23/2002	Email from Marc Porter to Kati Chupa et al.	JAN-MS-00305468	JAN-MS-00305468							
JA-02863	03/1991 - Present	Duragesic Journal Advertising Overview March 1991 - Present	JAN-MS-00305469	JAN-MS-00305469							
JA-02864	10/11/2018	Nurse.com OnCourse Learning: About Nurse.com, available at https://www.nurse.com/about-us	JAN-TREX-00055479	JAN-TREX-00055480							
JA-02865	10/11/2018	Nurse.com OnCourse Learning: Responsible Opioid Prescribing, Chronic Pain and addiction CME, available at https://www.nurse.com	JAN-TREX-00055481	JAN-TREX-00055488							
JA-02866	10/10/2018	Nurse.com OnCourse Learning: Prescription Drug Abuse CME, available at https://www.nurse.com	JAN-TREX-00055489	JAN-TREX-00055496							
JA-02867	10/10/2018	Nurse.com OnCourse Learning: Pain Management and Ethics: What's the Right thing to do Webinar, available at https://www.nurse.com/ce/pain-management-and-ethics-what-s-the-right-thing-to-do	JAN-TREX-00055497	JAN-TREX-00055503							
JA-02868	10/10/2018	Nurse.com On Course Learning: Chronic Pain: How Do We Treat it in an Era of Increasing Prescription Medication Misuse and Abuse, available at https://www.nurse.com	JAN-TREX-00055504	JAN-TREX-00055509							
JA-02869	11/01/2013	Nucynta/Nucynta ER Pharmacy Guide	JAN-MS-00577291	JAN-MS-00577302							
JA-02870	12/01/2013	Nucynta ER Brochure: Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo-and active-controlled Phase III study	JAN-MS-00577303	JAN-MS-00577308							
JA-02871	11/01/2013	Nucynta Brochure: Efficacy and Tolerability of Tapentadol Immediate Release and Oxycodone HCL Immediate Release in Patients Awaiting Primary Joint Replacement Surgery for End-Stage Joint Disease: A 10-Day, Phase III, Randomized Double-Blind, Active-and Placebo-Controlled Study	JAN-MS-00577309	JAN-MS-00577313							
JA-02872	11/01/2013	Nucynta Brochure: A randomized, double-blind, placebo-controlled phase 3 study of the relative efficacy and tolerability of tapentadol IR and oxycodone IR for acute pain	JAN-MS-00577314	JAN-MS-00577321							
JA-02873	11/01/2013	Nucynta Brochure: A randomized, double-blind, phase III study comparing multiple doses of tapentadol IR, oxycodone IR, and placebo for postoperative (bunionectomy) pain	JAN-MS-00577322	JAN-MS-00577326							
JA-02874	11/07/2007	Duragesic Marketing Materials	JAN-MS-02376708	JAN-MS-02376708							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-02875	05/01/2005	"Write What You Know" Duragesic Ad	JAN-MS-02013574	JAN-MS-02013580							
JA-02876	05/01/2005	"Write What you Know" Ad - Variation	JAN-MS-00588646	JAN-MS-00588655							
JA-02877	10/01/2004	"Duragesic - A Trusted Choice" Ad	JAN-MS-03073317	JAN-MS-03073317							
JA-02878	07/13/2012	Janssen Presentation: Nucynta Sales Promotion	JAN-MS-00466843	JAN-MS-00466843							
JA-02879	08/04/2009	Presentation: Duragesic Matrix: CCC/MC Training Module	JAN-MS-02002550	JAN-MS-02002550							
JA-02880	12/04/2012	2012 Schedule of Home Study Test 01 for New Hires and New Products	JAN-MS-00337392	JAN-MS-00337413							
JA-02881	04/01/2005	Duragesic: Duragesic 12mcg Dosage Frequently Asked Questions (April 2005)	JAN-MS-00314292	JAN-MS-00314295							
JA-02882	04/01/2005	Duragesic: Prescribing Information Label Revision Backgrounder and FAQs (April 2005)	JAN-MS-00314356	JAN-MS-00314362							
JA-02883	07/06/2010	E-Learning Courses for Pain	JAN-MS-00273068	JAN-MS-00273080							
JA-02884	02/13/2009	Janssen presentation: Tapentadol IR Training	JAN-MS-00468261	JAN-MS-00468261							
JA-02885	07/02/1905	Janssen presentation: Health Care Compliance (Cycle 2 - 2010)	JAN-MS-00857332	JAN-MS-00857332							
JA-02886	07/02/1905	PriCara Presentation: Frequently Asked HCC Questions Health Care Compliance Cycle 1 - 2010	JAN-MS-00877293	JAN-MS-00877293							
JA-02887	01/08/2013	Appendix A: Home Study Training Calendar for Nucynta and Nucynta ER (for inside sales team)	JAN-MS-00668766	JAN-MS-00668775							
JA-02888	05/01/2010	Nucynta 2010 AI/GI Home Study and Meeting Agendas (May 2010)	JAN-MS-03870226	JAN-MS-03870226							
JA-02889	05/01/2019	Chemical Handler's Manual, Appendix E-3, United States Department of Justice Drug Enforcement Administration	JAN-TREX-00149885	JAN-TREX-00149885							
JA-02890	06/28/1905	Who Uses DAWN?—Federal Agenices	JAN-TREX-00055510	JAN-TREX-00055511							
JA-02891	06/01/2004	WHO USES DATA FROM THE NEW DAWN?	JAN-TREX-00055512	JAN-TREX-00055513							
JA-02892	05/09/2019	Department of Health and Human Services: Final Pain Management Best Practices Inter-Agency Task Force Report	JAN-TREX-00055514	JAN-TREX-00055629							
JA-02893	05/14/2014	05/06/2014 America's Addiction to Opioids	JAN-TREX-00055630	JAN-TREX-00055695							
JA-02894	06/22/2017	06/22/2017 Transcript: Addiction in America	JAN-TREX-00055696	JAN-TREX-00055728							
JA-02895	06/23/2019	Prescription Drug Abuse Prevention Module	JAN-TREX-00055729	JAN-TREX-00055731							
JA-02896	07/09/1905	2016-2017 National Surveys on Drug Use and Health: Model-Based Estimated Totals (in Thousands) 50 States and the District of Columbia)	JAN-TREX-00055732	JAN-TREX-00055795							
JA-02897	03/01/2013	Dear Doctor Letter re Important Change in Duragesic for Transdermal Administration CII, Complete Prescribing Information	JAN-MS-03945918	JAN-MS-03945921							
JA-02898	06/24/1905	Inspector General's Final Report, Review of the DEA's Investigations of the Diversion Controlled Pharmaceuticals, Report No. I-2002-010	JAN-TREX-00055796	JAN-TREX-00055834							
JA-02899	01/31/2019	KOLD News 13, CBP Seizes Record-Breaking Amount of Fentanyl	JAN-TREX-00055835	JAN-TREX-00055841							
JA-02900	04/01/2012	DEA Form 225 - Application for Registration Under the Controlled Substances Act	JAN-TREX-00055842	JAN-TREX-00055845							
JA-02901	10/01/2017	National IMS Data: NPS Audit from January 1992 to October 2017	JAN-MS-03108026	JAN-MS-03108026							
JA-02902	01/01/2010	Nucynta Visual Aid	JAN-MS-00236198	JAN-MS-00236198							
JA-02903	01/22/2019	Action Chart	JAN-TREX-00149912	JAN-TREX-00149912							
JA-02904	12/31/2013	Denver Health RADARS System Presentation Slide: Diversion and Illicit Sale of Extended-Release Tapentadol in the United States	JAN-MS-05365400	JAN-MS-05365400							
JA-02905	06/19/2009	Letter from Tania Hillmer to Bob Rappaport, FDA	JAN-MS-002200676	JAN-MS-002200678							
JA-02906	02/01/1973	R. Marks & E. Sachar, Annals of Internal Medicine, Undertreatment of Medical Inpatients with Narcotic Analgesics	JAN-TREX-00055846	JAN-TREX-00055850							
JA-02907	04/01/1975	R. Twycross, The Use of Narcotic Analgesics in Terminal Illness	JAN-TREX-00055851	JAN-TREX-00055854							
JA-02908	11/12/2003	M. Meldrum, A Capsule History of Pain Management, Am. Medical Assoc.	JAN-TREX-00055855	JAN-TREX-00055860							
JA-02909	06/01/2005	Duragesic Dosage Guide:Tailor Your Chronic Pain Therapy With Expanded Dosing Options	JAN-MS-01997111	JAN-MS-01997114							
JA-02910	01/07/2008	Dear Healthcare Professional Letter re: Duragesic - Write What You Know	JAN-MS-00591645	JAN-MS-00591649							
JA-02911	08/08/2015	Chronic Opioid Analgesic Therapy for Chronic Low Back Pain	JAN-TREX-00055861	JAN-TREX-00055874							
JA-02912	02/06/2013	Email from Gary Baker to Sarah Chamberlain et al.	JAN-MS-02057424	JAN-MS-02057426							
JA-02913	07/04/1905	Imagine the Possibilities Pain Coalition Totality Closeout Documentation Meeting Agendas	JAN-MS-02057427	JAN-MS-02057429							
JA-02914	07/01/2011	Imagine the Possibilities Pain Coalition presentation: Next Steps Key Slides	JAN-MS-02057430	JAN-MS-02057430							
JA-02915	02/01/2012	February 2012 Meeting Summary Slides	JAN-MS-02057432	JAN-MS-02057432							
JA-02916	05/04/2012	May 4, 2012 Meeting Output	JAN-MS-02057433	JAN-MS-02057433							
JA-02917	01/17/2013	Manuscript Draft	JAN-MS-02057434	JAN-MS-02057434							
JA-02918	10/01/2015	AH Vallerand, P Cosler, JE Henningfield, P Galassini. Pain management strategies and lessons from the military: A narrative review	JAN-TREX-00055875	JAN-TREX-00055882							
JA-02919	05/06/2019	Pain Management Best Practices Inter-Agency Task Force Report	JAN-TREX-00055883	JAN-TREX-00055996							
JA-02920	02/10/2019	Controlled Substances Act from DOJ website	JAN-TREX-00055997	JAN-TREX-00056004							
JA-02921	01/25/2019	Office-Based Acute Guidelines	JAN-TREX-00056005	JAN-TREX-00056006							
JA-02922	01/25/2019	Office-Based Chronic Guidelines	JAN-TREX-00056007	JAN-TREX-00056010							
JA-02923	08/29/2005	Incomplete Draft Response to 2005 FDA Letter re IONSYS	JAN-MS-02136847	JAN-MS-02136851							
JA-02924	01/01/2018	2018 Abridged Formulary, Silverscript	JAN-TREX-00056011	JAN-TREX-00056086							
JA-02925	07/11/2008	Email from Michael Heinley to Jeff Smith	JAN-MS-00500229	JAN-MS-00500230							
JA-02926	07/10/2008	Let's Talk Pain Survey Messages	JAN-MS-00500231	JAN-MS-00500231							
JA-02927	04/18/2002	Email String Re: Dr. Laski Being Interviewed by Channel 12 Following the Newsweek Article	JAN-TREX-00056087	JAN-TREX-00056088							
JA-02928	02/09/2005 - 03/09/2013	Web Archive: Drug Abuse Warning Network: "Who Uses DAWN--Federal Agencies"	JAN-TREX-00056089	JAN-TREX-00056090							
JA-02929	06/01/2004	Website: Drug Abuse Warning Network: "Who Uses Data From The New Dawn?"	JAN-TREX-00056091	JAN-TREX-00056092							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-02930	12/18/2000	Janssen Research Foundation: Record Of FDA Contact regarding the decision not to proceed with the Direct to Consumer advertising campaign for Duragesic	JAN-TREX-00149913	JAN-TREX-00149913							
JA-02931	10/22/2008	PRC Approval Forms for Finding Relief Brochure and associated DVD	JAN-MS-00000330	JAN-MS-00000343							
JA-02932	12/17/2008	PRC Approval Forms for Finding Relief Brochure and associated DVD	JAN-MS-00000344	JAN-MS-00000372							
JA-02933	01/09/2009	PRC Approval Forms for Finding Relief Brochure and associated DVD	JAN-MS-00000405	JAN-MS-00000432							
JA-02934	07/29/2011	Janssen Pain Management Project, Institutional Direction Memo	JAN-MS-00001024	JAN-MS-00001037							
JA-02935	08/02/2010	Copy Review Submission Cover Sheet for Let's Talk Pain Medication Safety Series: Segment 1: Safe Use of Opioids	JAN-MS-00006663	JAN-MS-00006686							
JA-02936	08/01/2008	The Neo Pathways Campaign: An Annotated Guide	JAN-MS-00126905	JAN-MS-00126932							
JA-02937	04/07/2009	Training & Development Material Review Project Cover Sheet, Nucynta	JAN-MS-00131044	JAN-MS-00131049							
JA-02938	03/08/2008	Johnson & Johnson Report: Duragsic (fentanyl transdermal system): Third Risk Management Plan Progress Report	JAN-TREX-00056093	JAN-TREX-00056200							
JA-02939	10/28/2010	FDA Form, OMB No. 0910-0001, Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use - DURAGESIC	JAN-MS-00214154	JAN-MS-00214154							
JA-02940	02/03/2012	Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use, Nucynta ER	JAN-MS-00228657	JAN-MS-00228657							
JA-02941	01/01/2013	Nucynta ER Reimbursement Status Prepared for Southeast Pain Care	JAN-MS-00229101	JAN-MS-00229101							
JA-02942	01/01/2013	Nucynta ER: Dosing and Titration Guide	JAN-MS-00229192	JAN-MS-00229192							
JA-02943	09/01/2011	Nucynta ER - Powerful Pain Management: Now Approved: FDA Approval Announcement	JAN-MS-00229644	JAN-MS-00229644							
JA-02944	09/01/2009	Nucynta Savings Card	JAN-MS-00236318	JAN-MS-00236318							
JA-02945	11/01/2010	Email from e-Pharm/alert to ListServe	JAN-MS-00236319	JAN-MS-00236319							
JA-02946	06/08/2011	Email from Christopher Sikes to Antoun Nader	JAN-MS-00241364	JAN-MS-00241365							
JA-02947	03/16/2011	Email from Michael Genus to Kati Chupa, et al.	JAN-MS-00246666	JAN-MS-00246666							
JA-02948	07/15/2011	Email from Cheryl Iannaccone to David Lin, et al.	JAN-MS-00246670	JAN-MS-00246670							
JA-02949	12/16/2002	Email from Kelly Calandro to Bill White	JAN-MS-00246792	JAN-MS-00246792							
JA-02950	07/24/2002	Email from Carmen St. John to Adrienne Minecci et al.	JAN-MS-00246834	JAN-MS-00246834							
JA-02951	06/24/2002	Email from Molly Mcdonald to Kati Chupa.	JAN-MS-00246878	JAN-MS-00246879							
JA-02952	06/18/2002	Email from Bill Amberg to Kati Chupa	JAN-MS-00247230	JAN-MS-00247230							
JA-02953	06/25/1905	Janssen Spreadsheet: DURAGESIC Brand Team, 2003 Responsibilities	JAN-MS-00247407	JAN-MS-00247407							
JA-02954	03/17/2010	Contract: Tapentadol 'Prescribe Responsibly' 2010 PR Activities (V. submitted March 17, 2010)	JAN-MS-00252455	JAN-MS-00252457							
JA-02955	07/02/1905	PriCara presentation: Nucynta 2010 Speakers Bureau	JAN-MS-00252465	JAN-MS-00252465							
JA-02956	01/19/2010	Contract: Tapentadol 'Prescribe Responsibly' 2010 PR Activities (V. submitted Jan. 19, 2010)	JAN-MS-00252578	JAN-MS-00252579							
JA-02957	02/10/2011	Email from Frank Demiro to Rob Gibney	JAN-MS-00254912	JAN-MS-00254912							
JA-02958	08/03/2011	Email from Frank Demiro to Lynda Mack et al.	JAN-MS-00255873	JAN-MS-00255874							
JA-02959	01/22/2010	Email from Frank Demiro to Lisa Ferguson, et al.	JAN-MS-00258804	JAN-MS-00258805							
JA-02960	11/09/2009	Email from Jennifer Gropper to Robyn Kohn	JAN-MS-00262924	JAN-MS-00262924							
JA-02961	01/06/2009	Email from Robyn Kohn to Greg Panico	JAN-MS-00264010	JAN-MS-00264011							
JA-02962	11/20/2012	Email from Ron Kuntz to Eric Bloesch.	JAN-MS-0270442	JAN-MS-0270443							
JA-02963	10/16/2009	Janssen presentation: NeoPathways Appointment Flashcard	JAN-MS-00274436	JAN-MS-00274436							
JA-02964	02/01/2010	Draft brochure on Nucynta and Treating moderate to severe acute pain	JAN-MS-00274525	JAN-MS-00274539							
JA-02965	01/14/2009	Pain Franchise "Digital Deployment Strategy" 2009 PR Activities	JAN-MS-00277462	JAN-MS-00277463							
JA-02966	11/03/2008	Pain Management Advisory Board, PriCara, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc - Executive Summary	JAN-MS-00278194	JAN-MS-00278203							
JA-02967	08/17/2009	Email from IReview to Scott Trembley	JAN-MS-00280637	JAN-MS-00280638							
JA-02968	05/01/2012	Janssen Sales Rep "How To" Guide - Improving Pain Management in the Institution, May 2012	JAN-MS-00290395	JAN-MS-00290398							
JA-02969	03/09/2011	Email from Judith Burns to John Peterkins.	JAN-MS-00303265	JAN-MS-00303265							
JA-02970	07/28/2012	Email from Kati Chupa to David Lin.	JAN-MS-00303382	JAN-MS-00303382							
JA-02971	06/24/1905	Johnson & Johnson Presentation: Duragesic 2002/2003 US Public Relations Overview.	JAN-MS-00303807	JAN-MS-00303807							
JA-02972	09/09/2003	Email from Susan Roman to Molly McDonald et al.	JAN-MS-00303861	JAN-MS-00303861							
JA-02973	09/09/2003	KOLs in Chronic Pain Management.	JAN-MS-00303862	JAN-MS-00303891							
JA-02974	04/13/2001	Email from Bruce Ritchie to Robert Hutchinson et al.	JAN-MS-00304764	JAN-MS-00304764							
JA-02975	03/29/2003	Duragesic Regional Advisory Board Meeting Materials - Perry Fine, MD, "Megatrends in Healthcare"	JAN-MS-00304961	JAN-MS-00304962							
JA-02976	03/29/2003	Duragesic Regional Advisory Board Meeting Materials - Perry Fine, MD, "Optimizing DURAGESIC in Chronic Pain Patients"	JAN-MS-00304963	JAN-MS-00304964							
JA-02977	12/17/2002	Email from Scott Ferrell to Kati Chupa et al.	JAN-MS-00305065	JAN-MS-00305065							
JA-02978	12/01/2002	Janssesn draft report on Major Changes in Market Place	JAN-MS-00305066	JAN-MS-00305066							
JA-02979	06/26/1905	Spreadsheet: 2004 Pain Team Roles and Responsibilities	JAN-MS-00305129	JAN-MS-00305129							
JA-02980	02/12/2002	NPEC Draft Press Release, re: National Pain Education Council (NPEC) To Educate Healthcare Professionals on Use of Opioids In Clinical Practice	JAN-MS-00305220	JAN-MS-00305221							
JA-02981	03/10/2004	Email from Todd Walker to Stephen Cornwell et al.	JAN-MS-0306371	JAN-MS-0306371							
JA-02982	02/16/2006	Janssen Sales Material for Duragesic	JAN-MS-00306393	JAN-MS-00306393							
JA-02983	02/16/2006	Janssen Sales Material for Duragesic	JAN-MS-00306394	JAN-MS-00306394							
JA-02984	02/16/2006	Janssen Sales Material for Duragesic	JAN-MS-00306395	JAN-MS-00306395							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-02985	03/01/2004	Work, Uninterrupted	JAN-MS-00306396	JAN-MS-00306402							
JA-02986	06/24/1905	Johnson & Johnson Presentation: Life, Uninterrupted.	JAN-MS-00306403	JAN-MS-00306409							
JA-02987	02/16/2006	Janssen Sales Material for Duragesic	JAN-MS-00306410	JAN-MS-00306410							
JA-02988	02/16/2006	Janssen Sales Material for Duragesic	JAN-MS-00306411	JAN-MS-00306411							
JA-02989	02/09/2001	Email from Ram Moorthy to Kati Chupa	JAN-MS-00309786	JAN-MS-00309786							
JA-02990	11/29/2000	ZS Associates Presentation: Duragesic Promotion Response Modeling Project, Final Recommendations Meeting - Janssen Pharmaceutica & ZS Associates	JAN-MS-00309787	JAN-MS-00309787							
JA-02991	10/01/2003	Email from Tricia Haertlein to Tricia Haertlein et al.	JAN-MS-00310361	JAN-MS-00310361							
JA-02992	06/23/1905	Optimizing Chronic Pain Management With Duragesic	JAN-MS-00310474	JAN-MS-00310474							
JA-02993	11/03/2001	National Pain Education Council Meeting Minutes; Planning Session	JAN-MS-00312149	JAN-MS-00312151							
JA-02994	05/23/2019	NPEC Case Study Cancer Pain	JAN-MS-00312364	JAN-MS-00312364							
JA-02995	05/23/2019	NPEC Case Study Low Back Pain	JAN-MS-00312365	JAN-MS-00312365							
JA-02996	02/22/2002	Duragesic Speakers Training Meeting	JAN-MS-00312487	JAN-MS-00312487							
JA-02997	03/07/2002	Duragesic Promotional Speaker Agreement -- Ongoing	JAN-MS-00312493	JAN-MS-00312496							
JA-02998	10/03/2002	Email from Bill Amberg to Kati Chupa	JAN-MS-00312784	JAN-MS-00312785							
JA-02999	06/24/1905	Spreadsheet: Duragesic Team Status Report - Active Promotional Programs 2002	JAN-MS-00312933	JAN-MS-00312945							
JA-03000	03/28/2002	Email from Chris de Vries to Nadim Yacteen, et al.	JAN-MS-00313720	JAN-MS-00313720							
JA-03001	03/27/2002	Best Practices Council meeting minutes; Speakers' Bureau discussion	JAN-MS-00313721	JAN-MS-00313723							
JA-03002	03/01/2002	Performance Update for OBP/ Janssen	JAN-MS-00313831	JAN-MS-00313831							
JA-03003	01/01/2003	Duragesic Team Status Report	JAN-MS-00314706	JAN-MS-00314712							
JA-03004	01/24/2003	NPEC 2003 Faculty Honoraria Budget Proposal	JAN-MS-00314815	JAN-MS-00314815							
JA-03005	09/01/2011	Janssen Presentation: A Different Approach to Chronic Pain Management Nucynta ER	JAN-MS-00319589	JAN-MS-00319589							
JA-03006	02/11/2011	Copy Review Submission Cover Sheet, Project: Website Prescribe Responsibly	JAN-MS-00320418	JAN-MS- 00320426							
JA-03007	03/30/2011	Report, Prescribe Responsibly Survey Results	JAN-MS-00320529	JAN-MS-00320532							
JA-03008	12/21/2010	Email from Carissa Hornbeck to Kimberly Deem-Eshleman	JAN-MS-00320642	JAN-MS-00320642							
JA-03009	12/01/2010	Prescribe Responsibly Slide Deck	JAN-MS-00320643	JAN-MS-00320668							
JA-03010	12/20/2010	Spreadsheet Nucynta Status Report Updated 12.20.10	JAN-MS-00323117	JAN-MS-00323117							
JA-03011	11/17/2009	Email from R. Kuntz to H. Taitel et al.	JAN-MS-00323768	JAN-MS-00323769							
JA-03012	12/18/2008	Email from Ron Kuntz to Bruce Moskovitz, et al.	JAN-MS-00327211	JAN-MS-00327212							
JA-03013	12/12/2008	TAPENTADOL Professional ISI Final (12-12--08)	JAN-MS-00327213	JAN-MS-00327214							
JA-03014	06/30/1905	Exhibit B - Work Order Template (B1) To Be Used When Quoting And Submitting Project Estimates and Change Orders (B2) To The Client Pricing In Accordance With Rate Card (B3)	JAN-MS-00328672	JAN-MS-00328675							
JA-03015	01/27/2011	J&J Services Inc. Work Order for Nucynta Speaker Training Webcasts	JAN-MS-00339158	JAN-MS-00339165							
JA-03016	07/03/1905	Recommended description: Janssen Activities Summary	JAN-MS-00339823	JAN-MS-00339824							
JA-03017	01/13/2012	2012 Trained Nucynta ER Speakers	JAN-MS-00340750	JAN-MS-00340750							
JA-03018	06/26/2012	Email from Frank Demiro to Cheryl Iannaccone	JAN-MS-00341645	JAN-MS-00341646							
JA-03019	07/01/2012	Janssen Nucynta ER Presentation: New Perspectives in the Management of Moderate to Severe Chronic Pain	JAN-MS-00341647	JAN-MS-00341647							
JA-03020	08/08/2012	Nucynta iPad Materials	JAN-MS-00341809	JAN-MS-00341809							
JA-03021	08/10/2010	Copy Review Submission form for Smart Moves Smart Choice School Assembly Messaging	JAN-MS-00342997	JAN-MS-00343022							
JA-03022	02/09/2011	Janssen presentation: Nucynta ER Launch Readiness Promotion Strategy 2011	JAN-MS-00344263	JAN-MS-00344263							
JA-03023	03/17/2011	Email from Frank Demiro to Michael Paulik	JAN-MS-00344652	JAN-MS-00344653							
JA-03024	04/27/2011	Email from Frank Demiro to Roxanne McGregor-Beck	JAN-MS-00345073	JAN-MS-00345074							
JA-03025	04/27/2011	Janssen Sales Materials for Nucynta	JAN-MS-00345075	JAN-MS-00345075							
JA-03026	11/23/2011	Email from David Lin to Kati Chupa, et al	JAN-MS-00346687	JAN-MS-00346688							
JA-03027	11/22/2011	Nucynta and Nucynta ER Latest Thinking Tracker Spreadsheet	JAN-MS-00346689	JAN-MS-00346689							
JA-03028	01/19/2010	Project contract proposal from Ketchum Public Relations	JAN-MS-00346877	JAN-MS-00346878							
JA-03029	01/19/2010	Project contract proposal from Ketchum Public Relations	JAN-MS-00346879	JAN-MS-00346880							
JA-03030	02/19/2009	Project contract proposal from Ketchum Public Relations	JAN-MS-00350790	JAN-MS-00350792							
JA-03031	07/22/2013	Email from Matthew Stella to Lisa Ferguson	JAN-MS-00353873	JAN-MS-00353873							
JA-03032	07/06/1905	Janssen presentation: 2014 National Advocacy Business Planning: INVOKANA Advocacy Relations Presentation	JAN-MS-00353874	JAN-MS-00353874							
JA-03033	12/14/2010	Email from Lynda Mack to Frank Demiro et al.	JAN-MS-00364041	JAN-MS-00364041							
JA-03034	03/24/2000	Email from Bruce Moskovitz to Juergen Haeussler et al.	JAN-MS-00385987	JAN-MS-00385987							
JA-03035	03/24/2000	Executive Summary - Duragesic Advisory Board Questions	JAN-MS-00385988	JAN-MS-00385988							
JA-03036	02/22/2008	Email from Winifred Schein to Robyn Kohn et al.	JAN-MS-00392809	JAN-MS-00392809							
JA-03037	02/22/2008	Proposed Budget: Beth Israel Medical Center, Department of Pain Medicine and Palliative Care for APT-EM training	JAN-MS-00392810	JAN-MS-00392810							
JA-03038	02/21/2008	Report of Beth Israel Medical Center Department of Pain Medicine and Palliative Care - APT-EM: Advanced Pain Treatment & Training in Emergency Medicine	JAN-MS-00392811	JAN-MS-00392813							
JA-03039	06/01/2009	Optimizing Chronic Pain Management: Integrating Pharmacokinetics and Pharmacodynamics, Clinical Courier	JAN-MS-00393681	JAN-MS-00393692							
JA-03040	05/26/2009	Email from Robyn Kohn to Jana Pines	JAN-MS-00394146	JAN-MS-00394147							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-03041	05/22/2009	Emerging Solutions in Pain, Educational Initiative Overview Report	JAN-MS-00394148	JAN-MS-00394171							
JA-03042	07/02/2009	Three-Party CE Educational Grant Agreement (Re Grant ID #29040)	JAN-MS-00394196	JAN-MS-00394200							
JA-03043	09/24/2009	CME/CE Dinner Symposium Invitation- High Stakes, Young Lives: Prescription Medications in Our Communities: Insights from Recovering Teens on Preventing Prescription Drug Diversion	JAM-MS-00394550	JAM-MS-00394554							
JA-03044	09/18/2009	Email from Scott Weber to Robyn Kohn	JAN-MS-00395012	JAN-MS-00395012							
JA-03045	07/01/1905	AAPM, U.S. Medicine and Med-IQ presentation: Practical Strategies for the Management of Pain: Virtual Roundtable of Clinical Experts with Enduring Print & Online Publication	JAN-MS-00395013	JAN-MS-00395013							
JA-03046	12/04/2009	Memorandum from Linda Saunders to PriCara, Educational Grant Committee	JAN-MS-00395594	JAN-MS-00395595							
JA-03047	07/02/1905	Letter from the American Chronic Pain Association to Robyn Kohn	JAN-MS-00396166	JAN-MS-00396170							
JA-03048	02/23/2010	Email from Ellen Conway to Robyn Kohn	JAN-MS-00396768	JAN-MS-00396768							
JA-03049	12/18/2009	INROADS into Pain Management: Meeting the Challenges of Managing Patients with Complex Pain Syndromes	JAN-MS-00396769	JAN-MS-00396793							
JA-03050	03/17/2010	Email from E. Conway to R. Kohn	JAN-MS-00396799	JAN-MS-00396799							
JA-03051	03/16/2010	Continuing Education Grant Proposal, Overcoming Disparities in Pain Management: Beyond the Decade of Pain	JAN-MS-00396800	JAN-MS-00396835							
JA-03052	05/27/2010	Email from Michael Wolfe to Melia Becker et al.	JAN-MS-00399853	JAN-MS-00399853							
JA-03053	05/27/2010	NHPAQ National Advocacy Partner Opportunities	JAN-MS-00399854	JAN-MS-00399854							
JA-03054	07/13/2010	Email from Michael Wolfe to Robert Cagungun	JAN-MS-00399863	JAN-MS-00399863							
JA-03055	07/13/2010	HPAQ National Advocacy Plan	JAN-MS-00399865	JAN-MS-00399865							
JA-03056	07/13/2010	National Advocacy Opportunities	JAN-MS-00399866	JAN-MS-00399866							
JA-03057	08/20/2010	Email from Robyn Kohn to Michael Wolfe	JAN-MS-00399873	JAN-MS-00399873							
JA-03058	07/02/1905	National Advocacy Directors presentation: Mission, Vision Goal - Strategies and Tactics for Success	JAN-MS-00399877	JAN-MS-00399877							
JA-03059	10/07/2011	Email from Jeffrey Christensen to Robyn Kohn	JAN-MS-00400401	JAN-MS-00400401							
JA-03060	07/02/1905	Janssen speaker training presentation: Janssen Commitment to Pain	JAN-MS-00400402	JAN-MS-00400402							
JA-03061	10/14/2011	Janssen Pharmaceuticals, Inc. Fact Sheet	JAN-MS-00400407	JAN-MS-00400408							
JA-03062	09/13/2010	Email from Michael Wolfe to Robert Cagungun et al.	JAN-MS-00400705	JAN-MS-00400705							
JA-03063	09/12/2010	Draft National Advocacy Directors presentation: Mission, Vision Goal - Strategies and Tactics for Success	JAN-MS-00400707	JAN-MS-00400707							
JA-03064	07/03/1905	Janssen Nucynta presentation: Advocacy, Policy, Quality Activities - Engage advocacy partners to help define patient treatment success & access pain management options	JAN-MS-00400878	JAN-MS-00400878							
JA-03065	04/12/2011	Email from Erin Parsons to Mary Ambruzs	JAN-MS-00402652	JAN-MS-00402654							
JA-03066	01/05/2012	Email from Kimberly Evanyo to Samina Ali et al.	JAN-MS-00403818	JAN-MS-00403820							
JA-03067	01/11/2012	Email from Kimberly Evanyo to Samina Ali et al.	JAN-MS-00403821	JAN-MS-00403822							
JA-03068	01/10/2012	Email from Kimberly Evanyo to Samina Ali et al.	JAN-MS-00403823	JAN-MS-00403825							
JA-03069	06/26/2008	Email from Ellen Conway to Robyn Kohn	JAN-MS-00406423	JAN-MS-00406423							
JA-03070	06/20/2008	Concepts in Acute Pain Management: A Nurse's Guide to Multimodal Approaches to Drug Therapy , part of the INROADS into Pain Management series	JAN-MS-00406424	JAN-MS-00406431							
JA-03071	06/26/2008	Presentation: "Optimizing Medication Therapy for Pain The Science and Practice of Analgesic Care"	JAN-MS-00406432	JAN-MS-00406463							
JA-03072	03/10/2008	Ortho-McNeil Janssen Scientific Affairs, Medical Education Department Monthly Report	JAN-MS-00407639	JAN-MS-00407641							
JA-03073	09/11/2007	Three-Party Educational Grant Agreement Regarding a Continuing Education or Independent Education Grant	JAN-MS-00408253	JAN-MS-00408257							
JA-03074	04/14/2009	PharmaCon Group Information	JAN-MS-00408968	JAN-MS-00408970							
JA-03075	09/08/2006	Brochure for CME Symposium Challenging Cases in Chronic Pain for the Frontline Clinician	JAN-MS-00411372	JAN-MS-00411373							
JA-03076	02/19/2015	Home Study Training Calendar Nucynta ER and Nucynta	JAN-MS-00417287	JAN-MS-00417297							
JA-03077	No Date	Janssen Presentation: Nucynta Brand Playbook: Key Internal Initiatives	JAN-MS-00418781	JAN-MS-00418781							
JA-03078	11/15/2013	Statement of Work Community Connect Public Health Pain Management Initiative	JAN-MS-00423093	JAN-MS-00423104							
JA-03079	07/27/2013	Email from Patricia Yap to Keith Hofbeck et al.	JAN-MS-00426174	JAN-MS-00426174							
JA-03080	07/05/1905	Spreadsheet: National, Regional and Local Speaker Honoraria Details	JAN-MS-00426175	JAN-MS-00426175							
JA-03081	02/12/2013	AAPM Letter of Agreement for Commercial Support	JAN-MS-00426700	JAN-MS-00426701							
JA-03082	03/31/2014	Smart Moves Materials_Final Review	JAN-MS-00428521	JAN-MS-00428521							
JA-03083	03/31/2014	Start Smart: Protect our Kids from Medication Accidents	JAN-MS-00428522	JAN-MS-00428522							
JA-03084	01/14/2015	Email from Terry Davidson to Dominic Lazzaro et al.	JAN-MS-00430527	JAN-MS-00430528							
JA-03085	07/07/1905	Janssen presentation: Nucynta Brand Playbook - Key Internal Initiatives	JAN-MS-00430529	JAN-MS-00430529							
JA-03086	02/04/2015	Email from JP Brassil to Jill Brasacchio et al.	JAN-MS-00430562	JAN-MS-00430563							
JA-03087	11/30/2012	Prescribe Responsibly PRC Summary Letter	JAN-MS-00452372	JAN-MS-00452372							
JA-03088	06/15/2012	High Level Overview of Suspicious Order Monitoring	JAN-MS-00454958	JAN-MS-00454958							
JA-03089	01/24/2013	Email from Roxanne McGregor-Beck to Dominic Lazzaro	JAN-MS-00468984	JAN-MS-00468984							
JA-03090	01/23/2013	Letter from L. Shenée' Toombs to Martha Propsner	JAN-MS-00468985	JAN-MS-00468993							
JA-03091	10/01/2008	NEO Pathways web conference brochure - Acute Pain Control Concerns & Consequences	JAN-MS-00471121	JAN-MS-00471122							
JA-03092	09/08/2008	NEO Pathways Speaker NewsChannel Segment #2 submission to CRC	JAN-MS-00472000	JAN-MS-00472010							
JA-03093	05/16/2008	Sponsorship Agreement	JAN-MS-00474423	JAN-MS-00474429							
JA-03094	01/17/2008	PMLC Steering Committee Meeting - 01/17/2008	JAN-MS-00475321	JAN-MS-00475324							
JA-03095	11/01/2007	Draft Letter re: Tapentadol Pain Leadership Steering Committee Meeting	JAN-MS-00475325	JAN-MS-00475325							
JA-03096	01/18/2008	Project Brief Meeting Title: Pain Management Leadership Council: Chronic Pain	JAN-MS-00475394	JAN-MS-00475394							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-03097	09/16/2008	Email from Michelle Wanat to David Moore	JAN-MS-00476487	JAN-MS-00476487							
JA-03098	08/02/2008	PriCara Post Operative Pan Management in Gynecology Surgery Advisory Board Meeting, 08/02/2008	JAN-MS-00476488	JAN-MS-00476504							
JA-03099	10/02/2008	Email from Gina Conrad to David Moore	JAN-MS-00476730	JAN-MS-00476730							
JA-03100	10/02/2008	PriCara Price Sheet	JAN-MS-00476731	JAN-MS-00476731							
JA-03101	10/17/2008	Email from Gina Conrad to David Moore	JAN-MS-00476732	JAN-MS-00476732							
JA-03102	10/17/2008	PriCara Price Sheet	JAN-MS-00476733	JAN-MS-00476734							
JA-03103	01/16/2009	Tapentadol "Let's Talk Pain" 2009 PR Activities	JAN-MS-00500042	JAN-MS-00500043							
JA-03104	10/27/2008	Smart Moves, Smart Choices A Prescription Drug Abuse Education Program: Program Success & Looking Ahead	JAN-MS-00500333	JAN-MS-00500333							
JA-03105	01/21/2009	Work Order between Pricara and Ketchum Public Relations, 01/21/2009	JAN-MS-00500405	JAN-MS-00500406							
JA-03106	07/03/2007	Email from Greg Panico to Diane Kelly	JAN-MS-00501425	JAN-MS-00501427							
JA-03107	06/29/1905	Work Order between PiCara and Ruder Finn, 01/01/2007	JAN-MS-00501429	JAN-MS-00501429							
JA-03108	10/31/2007	Pain Management Health Education Program Project Brief	JAN-MS-00503337	JAN-MS-00503340							
JA-03109	01/23/2009	Email from Tina Pinto to Renee McKenna	JAN-MS-00507008	JAN-MS-00507008							
JA-03110	01/21/2009	Work order between Ketchum P.R. and Janssen regarding tapentadol presentation.	JAN-MS-00507009	JAN-MS-00507009							
JA-03111	04/16/2009	"Let's Talk Pain" Talk Show Key Messages	JAN-MS-00507596	JAN-MS-00507598							
JA-03112	08/25/2009	Facing Pain Blog	JAN-MS-00507646	JAN-MS-00507647							
JA-03113	01/26/2015	Email from Frederick Tewell to Tyler Bergen et al.	JAN-MS-00576833	JAN-MS-00576833							
JA-03114	03/24/2014	Email from Kanitha Burns to Laura Glauda et al.	JAN-MS-00577277	JAN-MS-00577277							
JA-03115	No Date	Resume: Kimberly Deem Eshleman	JAN-MS-00578100	JAN-MS-00578101							
JA-03116	02/07/2005	Speaker Analysis Summary 2004	JAN-MS-00588903	JAN-MS-00588903							
JA-03117	06/29/1905	Duragesic Defend and Grow Goals and Actualy, July-December 2007	JAN-MS-00591674	JAN-MS-00591674							
JA-03118	12/05/2008	Duragesic Product Risk Management Team Contact Information	JAN-MS-00593374	JAN-MS-00593374							
JA-03119	09/16/2005	Email from Gary Vorsanger to Cynthia Crowley	JAN-MS-00619652	JAN-MS-00619652							
JA-03120	08/18/2010	Email from Robyn Kohn to Walter Fox et al.	JAN-MS-00628296	JAN-MS-00628297							
JA-03121	08/09/2012	Johnson & Johnson Presentation: Pain Team Preliminary Targeting View: Potential Impacts to Forecast	JAN-MS-00664179	JAN-MS-00664179							
JA-03122	01/01/2014	Janssen Training Presentation: Compliance Guidelines for Promotional Speaker Bureau	JAN-MS-00670087	JAN-MS-00670087							
JA-03123	05/22/2006	Email from Vincent Brett to Caren Perry	JAN-MS-00747381	JAN-MS-00747383							
JA-03124	09/23/2014	FOR APPROVAL: Copy Revision Recommendations	JAN-MS-00753040	JAN-MS-00753043							
JA-03125	07/06/1905	FOR APPROVAL: Copy Revision Recommendations - PRC Comments	JAN-MS-00753047	JAN-MS-00753059							
JA-03126	02/06/2013	Email from Kanitha Burns to Ron Kuntz	JAN-MS-00753246	JAN-MS-00753248							
JA-03127	06/10/2013	Email from Kanitha Burns to Lori Goddard	JAN-MS-00754655	JAN-MS-00754656							
JA-03128	10/02/2013	Email from Kanitha Burns to Martha Propsner et al.	JAN-MS-00755157	JAN-MS-00755158							
JA-03129	10/02/2013	Presentation: Nucynta and Nucynta ER Label Update	JAN-MS-00755159	JAN-MS-00755159							
JA-03130	06/18/2014	Janssen Script: Nucynta Dosing and Titration Video	JAN-MS-00758508	JAN-MS-00758510							
JA-03131	09/21/2012	Email from Simone Fuge to Lori Goddard, et al.	JAN-MS-00759762	JAN-MS-00759762							
JA-03132	10/01/2011	Janssen Nucynta ER presentation: Unleashing the POWER	JAN-MS-00761749	JAN-MS-00761749							
JA-03133	04/01/2012	Nucynta and Nucynta ER Presentation: Patient Strategy Recommendation	JAN-MS-00772406	JAN-MS-00772406							
JA-03134	06/01/2012	PRC Comments on Nucynta ER Patient Brochure	JAN-MS-00772441	JAN-MS-00772452							
JA-03135	04/05/2011	Email from Robyn Hand to Michael Paulik	JAN-MS-00775541	JAN-MS-00775542							
JA-03136	07/01/2012	Nucynta ER Highlights of Prescribing Information, Revised 07/2012	JAN-MS-00775738	JAN-MS-00775772							
JA-03137	07/13/2012	Email from Kati Chupa to Joseph Doyle	JAN-MS-00775819	JAN-MS-00775820							
JA-03138	07/26/2012	Email from Kati Chupa from Robyn Hand	JAN-MS-00775844	JAN-MS-00775844							
JA-03139	01/01/2012	Nucynta Roles - Primary and Business Interface Staffing Scenarios	JAN-MS-00775845	JAN-MS-00775847							
JA-03140	09/01/2012	Spreadsheet: Nucynta Roles - Staffing Scenarios	JAN-MS-00775849	JAN-MS-00775850							
JA-03141	08/02/2012	Email from Kati Chupa to Melissa Friedman	JAN-MS-00775877	JAN-MS-00775878							
JA-03142	01/23/2003	Email from Bill Whyte to Molly McDonald et al.	JAN-MS-00777401	JAN-MS-00777401							
JA-03143	06/24/1905	Pain Management Communicator: Janssen Key Advisor Communication Program	JAN-MS-00777042	JAN-MS-00777042							
JA-03144	03/24/2004	Email from Bruce Ritchie to Kati Chupa	JAN-MS-00777087	JAN-MS-00777087							
JA-03145	09/12/2003	Janssen Presentation: Welcome & Introduction Pain Franchise & Market Overview	JAN-MS-00777088	JAN-MS-00777088							
JA-03146	02/11/2003	Email from Molly McDonald to Kati Chupa et al.	JAN-MS-00778806	JAN-MS-00778806							
JA-03147	11/16/2001	Email from Brian Goff to Nadim Yacteen et al	JAN-MS-00780198	JAN-MS-00780198							
JA-03148	06/25/1905	National Pain Education Center Presentation: 2003 Tactical Plan NPEC Objectives	JAN-MS-00780331	JAN-MS-00780331							
JA-03149	06/07/2002	Email from Kati Chupa to Adrienne Minecci	JAN-MS-00781930	JAN-MS-00781931							
JA-03150	12/06/2001	Email from Surya Vangala to Christine DeVries	JAN-MS-00782627	JAN-MS-00782627							
JA-03151	02/10/2002	Memorandum from Surya Vangala to Bruce Moskovitz	JAN-MS-00784996	JAN-MS-00785015							
JA-03152	01/08/2001	Email from Ramiro Roman to Kati Chupa	JAN-MS-00785623	JAN-MS-00785623							
JA-03153	04/11/2002	Email from Michelle Meola to Kati Chupa	JAN-MS-00786128	JAN-MS-00786128							
JA-03154	04/11/2002	Draft contract between DI and Alza	JAN-MS-00786129	JAN-MS-00786131							
JA-03155	09/13/2002	Email from Pam Dotter to Gary Pruden	JAN-MS-00787261	JAN-MS-00787262							
JA-03156	12/14/2001	Email from Christine DeVries to Brian Goff et al.	JAN-MS-00787306	JAN-MS-00787306							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-03157	09/27/2002	Email from Doug Dickson to Gary Grazioso et al.	JAN-MS-00787515	JAN-MS-00787515							
JA-03158	01/09/2004	Email from David Randal to Dominic La Selva et al.	JAN-MS-00788573	JAN-MS-00788573							
JA-03159	01/09/2004	2004 Primary Care Incentive Targets	JAN-MS-00788574	JAN-MS-00788574							
JA-03160	08/19/2003	Email from Joseph Cannavo to Kati Chupa et al.	JAN-MS-00789518	JAN-MS-00789518							
JA-03161	11/18/2004	American Academy of Pain management Corporate Membership Application	JAN-MS-00790017	JAN-MS-00790018							
JA-03162	07/04/1905	2012 Performance Planning & Review	JAN-MS-00790365	JAN-MS-00790372							
JA-03163	04/27/2012	Tapentadol ER Puerto Rico Advisory Board with KOLs	JAN-MS-00793861	JAN-MS-00793879							
JA-03164	06/15/2010	Email from Kimberly Deem-Eshleman to Roxanne McGregor-Beck	JAN-MS-00798399	JAN-MS-00798401							
JA-03165	08/04/2001	Email from Kimberly Deem-Eshleman to Roxanne McGregor-Beck et al.	JAN-MS-00802141	JAN-MS-00802142							
JA-03166	08/01/2011	Johnson & Johnson Presentation: Nucynta ER Contract Training	JAN-MS-00802143	JAN-MS-00802143							
JA-03167	04/20/2011	PrescribeResponsibly.com Tools	JAN-MS-00804401	JAN-MS-00804401							
JA-03168	01/14/2011	Email from Tanya Nelson to Kimberly Deem-Eshleman	JAN-MS-00804623	JAN-MS-00804623							
JA-03169	12/18/2009	Email from Greg Panico to David Lin et al.	JAN-MS-00809240	JAN-MS-00809240							
JA-03170	07/10/2010	Email from Ruth Tumbokon to Chris Cho et al.	JAN-MS-00810234	JAN-MS-00810234							
JA-03171	07/10/2008	Training Material: Courses on Pain and NEO Pathways	JAN-MS-00810235	JAN-MS-00810296							
JA-03172	05/09/2005	Broad Experience with Pain Sparks a Search for Relief, ABC News/USA Today/Stanford Medical Center Pain Poll	JAN-MS-00813494	JAN-MS-00813507							
JA-03173	05/06/2008	NeoPathwaysInPain submission-soft copies	JAN-MS-00813526	JAN-MS-00813526							
JA-03174	04/16/2008	Copy Review Approval Form and Cover Sheet - NEOPathways	JAN-MS-00813527	JAN-MS-00813543							
JA-03175	03/23/2011	Email from Frank Demiro to Tara Blackman	JAN-MS-00823489	JAN-MS-00823490							
JA-03176	03/17/2010	Email from Jennifer Statham to Frank Demiro et al.	JAN-MS-00824694	JAN-MS-00824694							
JA-03177	03/17/2010	Tapentadol "Prescribe Responsibly" 2010 PR Activities	JAN-MS-00824695	JAN-MS-00824697							
JA-03178	02/07/2010	Executive Summary Highlights: PMLC Advisory Board Meeting	JAN-MS-00825435	JAN-MS-00825435							
JA-03179	02/03/2011	Work Order for Tapentadol KOL Advisory Board program with decile.ten communications	JAN-MS-00825437	JAN-MS-00825444							
JA-03180	02/25/2015	Janssen Presentation: Speaker Compliance Guidelines	JAN-MS-00825728	JAN-MS-00825728							
JA-03181	03/01/2011	Memorandum from Nucynta (tapentadol) Brand Team to Pain, AIGI, CVI & COBI Sales Force	JAN-MS-00826670	JAN-MS-00826670							
JA-03182	02/02/2011	Ketchum contract for "2011 Public Relations Activities"	JAN-MS-00826997	JAN-MS-00826000							
JA-03183	12/01/2011	Work Order for Nucynta promotional speakers Slide Deck with decile.ten communications	JAN-MS-00828369	JAN-MS-00828375							
JA-03184	12/12/2011	Work Order for Nucynta Product Theater at APS Annual Conference with decile.ten communications	JAN-MS-00828376	JAN-MS-00828382							
JA-03185	12/12/2011	Work Order for Nucynta promotional presentation at AAMP Annual Conference with decile.ten communications	JAN-MS-00828398	JAN-MS-00828404							
JA-03186	11/05/2010	Email from Frank Demiro to Lynda Mack et al.	JAN-MS-00832888	JAN-MS-00832889							
JA-03187	08/01/2010	Janssen presentation: Nycynta Resource Guide	JAN-MS-00832890	JAN-MS-00832939							
JA-03188	02/02/2011	Email from Frank Demiro to Hye Yoon Park	JAN-MS-00833974	JAN-MS-00833975							
JA-03189	05/03/2011	Email from Frank Demiro to Roxanne O. McGregor-Beck	JAN-MS-00834291	JAN-MS-00834292							
JA-03190	07/05/2011	2011 Let's Talk Pain Partner Fees	JAN-MS-00835556	JAN-MS-00835557							
JA-03191	07/15/2011	Email from Frank Demiro to David Lin	JAN-MS-00835577	JAN-MS-00835578							
JA-03192	08/23/2011	Email from Frank Demiro to Dominic Lazzaro et al.	JAN-MS-00836143	JAN-MS-00836144							
JA-03193	08/22/2011	Janssen Presentation: NUCYNTA ER Launch Playbook	JAN-MS-00836145	JAN-MS-00836145							
JA-03194	02/02/2009	Email from Carole Carter-Cleaver to Frank Demiro	JAN-MS-00836973	JAN-MS-00836975							
JA-03195	01/26/2009	Janssen Presentation: Tapentadol Pivotal Trials	JAN-MS-00836976	JAN-MS-00836976							
JA-03196	08/07/2009	Dr. Amirdelfan: Speaker Removal	JAN-MS-00837173	JAN-MS-00837173							
JA-03197	11/13/2008	Medscape presentation: Pharmacologic Management of Pain Resource Center and Components Update	JAN-MS-00841491	JAN-MS-00841491							
JA-03198	05/04/2012	Email from Jeffrey Christensen to Lisa Ferguson	JAN-MS-00868261	JAN-MS-00868262							
JA-03199	04/24/2012	Agreement for Revision to Statement of Work	JAN-MS-00868265	JAN-MS-00868267							
JA-03200	07/09/2012	Email from Brad Updegrove to Lisa Ferguson	JAN-MS-00868297	JAN-MS-00868298							
JA-03201	06/13/2012	Agreement for Revision to Statement of Work	JAN-MS-00868299	JAN-MS-00868300							
JA-03202	10/11/2010	Email from the American Pain Society to Robyn Kohn	JAN-MS-00916363	JAN-MS-00916367							
JA-03203	08/09/2012	Email from Patricia Yap to Christopher Horn et al.	JAN-MS-00916719	JAN-MS-00916722							
JA-03204	03/19/2009	Two-Party CE Educational Grant Agreement (Re Grant ID #25601)	JAN-MS-00918175	JAN-MS-00918180							
JA-03205	07/13/2009	Email from Robyn Kohn to Peter VanPelt et al.	JAN-MS-00918763	JAN-MS-00918765							
JA-03206	02/25/2010	Email from Christina Culbert to Robyn Kohn et al.	JAN-MS-00919038	JAN-MS-00919038							
JA-03207	11/12/2009	Three-Party CE Educational Grant Agreement (Re Grant ID #36072)	JAN-MS-00919312	JAN-MS-00919316							
JA-03208	02/01/2010	Pain Care Forum 2010 Meetings Schedule	JAN-MS-00922357	JAN-MS-00922368							
JA-03209	04/13/2010	Chart, Let's Talk Pain Medication Safety Series Filming Schedule	JAN-MS-00923090	JAN-MS-00923091							
JA-03210	03/27/2010	Email from Robyn Kohn to Samantha Miller et al.	JAN-MS-00923941	JAN-MS-00923941							
JA-03211	07/23/2012	Totality Request ID: 128665	JAN-MS-00926528	JAN-MS-00926538							
JA-03212	07/04/1905	Janssen presentation: Advocacy Partners Update in Support of Appropriate Analgesia Therapy	JAN-MS-00926857	JAN-MS-00926857							
JA-03213	04/06/2009	Email from Lenore Duensing to Erin C. Sexton et al.	JAN-MS-00929254	JAN-MS-00929254							
JA-03214	12/03/2010	Marketing Sponsorship Agreement	JAN-MS-00929428	JAN-MS-00929428							
JA-03215	06/09/2009	Email from Greg Panico to Cassie Hallberg	JAN-MS-00930038	JAN-MS-00930038							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-03216	06/10/2009	Email from Greg Panico to lauren.hoffman@kethchum	JAN-MS-00930049	JAN-MS-00930049							
JA-03217	06/15/2009	Prescribe Responsibly Web Site Manuscript, For Review	JAN-MS-00930063	JAN-MS-00930064							
JA-03218	08/12/2009	Bruce Moskowitz Transcript	JAN-MS-00930203	JAN-MS-00930203							
JA-03219	09/02/2009	Email from Greg Panico to Haya Taitel et al.	JAN-MS-00930256	JAN-MS-00930256							
JA-03220	09/16/2009	Exclusive Health Interview Opportunity Announcement: Making Sense of Pain Medicine Confusion	JAN-MS-00930257	JAN-MS-00930257							
JA-03221	09/02/2009	SMT/RMT: Making Sense of Pain Medicine Confusion Key Messages and Questions	JAN-MS-00930258	JAN-MS-00930260							
JA-03222	03/04/2010	Three-Party CE Educational Grant Agreement (Re Grant ID #46393)	JAN-MS-00931407	JAN-MS-00931413							
JA-03223	10/22/2009	Letter from Kay Weigand to Donna Barnickel	JAN-MS-00932484	JAN-MS-00932486							
JA-03224	11/23/2010	Top Things Advocacy Partners/Pain Communities Care Most About	JAN-MS-00933198	JAN-MS-00933199							
JA-03225	11/05/2010	Email from Robyn Kohn to Malcolm Monaghan	JAN-MS-00933929	JAN-MS-00933929							
JA-03226	11/05/2010	Janssen Presentation: Pain Management	JAN-MS-00933930	JAN-MS-00933930							
JA-03227	02/09/2010	The Center for Practical Bioethics 2010 Annual Dinner Proposal	JAN-MS-00934165	JAN-MS-00934194							
JA-03228	08/12/2009	Email from Lauren Kashtan to Greg Panico	JAN-MS-00934351	JAN-MS-00934352							
JA-03229	06/02/2010	Email from Jeffrey Christensen to David Biondi et al.	JAN-MS-00937839	JAN-MS-00937839							
JA-03230	06/03/2010	PriCara/Ketchum NUCYNTA Message Mapping Workshop	JAN-MS-00937840	JAN-MS-00937841							
JA-03231	07/13/2011	Draft Prescribe Responsibly Press Release	JAN-MS-00939635	JAN-MS-00939635							
JA-03232	03/26/2012	Email from Lynda Mack to Jeffrey Christensen et al.	JAN-MS-00940779	JAN-MS-00940781							
JA-03233	04/18/2011	2011 Smart Moves Toolkit PRC coversheet.	JAN-MS-00940782	JAN-MS-00940784							
JA-03234	07/03/1905	Advocacy, Policy, Quality Activities	JAN-MS-00940794	JAN-MS-00940794							
JA-03235	12/05/2008	Email from Kathy Cousins to Robyn Kohn	JAN-MS-00943833	JAN-MS-00943833							
JA-03236	01/08/2009	SynerMed Communications Presentation: Abuse, Addition, and Pain Relief - Time for Change: Year in Review	JAN-MS-00943834	JAN-MS-00943834							
JA-03237	01/16/2009	Tapentadol "Prescribe Responsibly" 2009 PR Activities	JAN-MS-00944802	JAN-MS-00944803							
JA-03238	02/27/2009	Prescribe Responsibly Conference Call Summary	JAN-MS-00944824	JAN-MS-00944825							
JA-03239	03/24/2009	Email from Greg Panico to Lori Lonczak	JAN-MS-00944828	JAN-MS-00944829							
JA-03240	03/24/2009	PriCara Prescribe Responsibly Web Site Content Outline	JAN-MS-00944830	JAN-MS-00944832							
JA-03241	06/01/2007	Medical Education Department Monthly Report	JAN-MS-00944920	JAN-MS-00944925							
JA-03242	06/01/2008	"The Current State of Teenage Drug Abuse: Trend Toward Prescription Drugs."	JAN-MS-00945246	JAN-MS-00945263							
JA-03243	12/10/2007	Letter from Carol Tsiamas to Robyn Kohn	JAN-MS-00945651	JAN-MS-00945652							
JA-03244	04/02/2009	Email from Greg Panico to Nithya Desikan, et al.	JAN-MS-00946007	JAN-MS-00946007							
JA-03245	01/08/2008	CME/CE-Certified Workshop Announcement: Individualizing Analgesic Regimens ,Strategies to Reduce Abuse and Diversion	JAN-MS-00946480	JAN-MS-00946481							
JA-03246	01/08/2008	CME/CE-Certified Workshop Announcement: Individualizing Analgesic Regimens - Strategies to Reduce Abuse and Diversion	JAN-MS-00946482	JAN-MS-00946482							
JA-03247	10/06/2008	Email from Colleen Moran to Gary Baker et al.	JAN-MS-00947213	JAN-MS-00947213							
JA-03248	10/03/2008	Slide Deck Outcomes Inc. Identifying Unmet Educational and Informational Needs in Pain Management	JAN-MS-00947214	JAN-MS-00947214							
JA-03249	08/14/2008	Email from Joan Wilk on behalf of Colleen Moran to Lawrence Walsh et al.	JAN-MS-00947215	JAN-MS-00947215							
JA-03250	08/12/2008	Outcomes Inc. Needs Assessment Survey	JAN-MS-00947216	JAN-MS-00947216							
JA-03251	03/04/2009	EDGR Meeting: Medical Affairs Comments	JAN-MS-00947602	JAN-MS-00947603							
JA-03252	03/30/2015	Email from Ron Kuntz to Robert Kelso, et al.	JAN-MS-00981690	JAN-MS-00981691							
JA-03253	03/26/2015	Community Connect Programs Sheet	JAN-MS-00981697	JAN-MS-00981698							
JA-03254	07/25/2013	Simponi 100mg (UC) Distribution Strategy - Updated	JAN-MS-00982828	JAN-MS-00982828							
JA-03255	02/06/2013	Prescribe Responsibly Slide Deck.pptx	JAN-MS-00985075	JAN-MS-00985075							
JA-03256	07/01/2011	Prescribe Responsibly: A Suite of Resources to Help Improve Pain Management in Any Healthcare Setting	JAN-MS-00985076	JAN-MS-00985076							
JA-03257	03/10/2014	Community Connect: Mock Panel Discussion	JAN-MS-00988467	JAN-MS-00988488							
JA-03258	04/24/2014	Email from Ron Kuntz to Nicole Barsamian	JAN-MS-00989212	JAN-MS-00989217							
JA-03259	12/01/2014	Email from Ron Kuntz to Christopher Tippet	JAN-MS-00990298	JAN-MS-00990300							
JA-03260	11/25/2014	Work Order Project: 2014 NUCYNTA/NUCYNTA ER Spear Bureau Vetting	JAN-MS-00990301	JAN-MS-00990304							
JA-03261	12/05/2012	Email from Burt Rosen to Aaron Gilson et al.	JAN-MS-00992073	JAN-MS-00992074							
JA-03262	04/15/2014	Email from Michele Dempsey to Tim Gribbin et al.	JAN-MS-00995310	JAN-MS-00995311							
JA-03263	09/09/2014	PRC Meeting Agenda	JAN-MS-00997372	JAN-MS-00997372							
JA-03264	10/06/2014	PRC Meeting Agenda	JAN-MS-00997695	JAN-MS-00997696							
JA-03265	10/14/2014	PRC Meeting Agenda	JAN-MS-00997880	JAN-MS-00997880							
JA-03266	04/29/2002	Johnson & Johnson presentation: Duragesic Disease Modeling-Presentation to the GOC	JAN-MS-01003931	JAN-MS-01003931							
JA-03267	06/26/1905	Ortho-McNeil Policy Guidelines: Advisory Boards/Consultant Meetings	JAN-MS-01008639	JAN-MS-01008639							
JA-03268	04/19/2005	Email from Anna Bayer on behalf of Kate Van Arsdale to Trenton Gardner et al.	JAN-MS-01015525	JAN-MS-01015526							
JA-03269	04/18/2005	Janssen Sales Training Materials Reviewer Grid	JAN-MS-01015527	JAN-MS-01015527							
JA-03270	10/01/2007	Janssen Presentation: Tapentadol Clinical Trial Recommendations	JAN-MS-01027709	JAN-MS-01027709							
JA-03271	03/10/2010	Email from David Lin to Carole Carter-Cleaver et al.	JAN-MS-01044623	JAN-MS-01044623							
JA-03272	08/11/2011	Email from Janet Peterson to Ron Kuntz	JAN-MS-01047103	JAN-MS-01047104							
JA-03273	12/17/2014	Email from Dominic Lazzaro to Lisa Waltz	JAN-MS-01069033	JAN-MS-01069035							
JA-03274	09/01/2012	Nucynta ohio medicaid card	JAN-MS-01076874	JAN-MS-01076875							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-03275	05/07/2012	Dr. Li Handout	JAN-MS-01078132	JAN-MS-01078133							
JA-03276	05/07/2012	Email from Frank Demiro to Dominic Lazzaro	JAN-MS-01078132	JAN-MS-01078133							
JA-03277	08/13/2014	FMV Analysis.pptx	JAN-MS-01082758	JAN-MS-01082758							
JA-03278	08/12/2014	2015 FMV & Speaker Honoraria Analysis 2015 BP	JAN-MS-01082759	JAN-MS-01082759							
JA-03279	07/16/2012	Email from Hillary Murdock to Dominic Lazzaro et al.	JAN-MS-01094764	JAN-MS-01094764							
JA-03280	07/01/2012	Nucynta Field Sales Memo	JAN-MS-01094765	JAN-MS-01094765							
JA-03281	12/10/2014	Email from Robert Kelso to Lori Goddard et al.	JAN-MS-01102536	JAN-MS-01102537							
JA-03282	10/07/2013	Nucynta ER TrainingDirect 2013 Work Order	JAN-MS-01114585	JAN-MS-01114588							
JA-03283	06/30/1905	Ortho-McNeil Chart: New Representative 30-Day Self Study Training Calendar	JAN-MS-01117062	JAN-MS-01117075							
JA-03284	06/30/1905	Janssen Outline: Draft Submitting Materials for Sales Training Review	JAN-MS-01124776	JAN-MS-01124777							
JA-03285	04/17/2008	Draft Compliance Guidance for Sales Training Materials	JAN-MS-01124778	JAN-MS-01124782							
JA-03286	01/05/2009	Email from Ruth Tumbokon to Chris Cho et al.	JAN-MS-01124828	JAN-MS-01124828							
JA-03287	11/01/2008	Janssen Spreadsheet: Tapentadol Product Launch-Training Project Management Roles & Responsibilities	JAN-MS-01124829	JAN-MS-01124829							
JA-03288	01/08/2009	Email from Tanya Nelson to Chris Cho et al.	JAN-MS-01124830	JAN-MS-01124831							
JA-03289	10/05/2006	Centocor Sales Training Materials Reviewer Procedure	JAN-MS-01124853	JAN-MS-01124857							
JA-03290	07/01/1905	PriCara Presentation: 1st Half 2009 Pain Team Targeting & Call Plan Strategy	JAN-MS-01128769	JAN-MS-01128769							
JA-03291	07/14/2008	PriCara Presentation: Neo Pathways, Program Objectives	JAN-MS-01136251	JAN-MS-01136251							
JA-03292	09/23/2008	Introducing Nucynta: Redefining Success in Pain Management	JAN-MS-01136399	JAN-MS-01136404							
JA-03293	03/27/2011	AAPM 27th Annual Meeting Overview	JAN-MS-01149255	JAN-MS-01149264							
JA-03294	03/22/2005	Chart: Risk Management Tools Planned or In-Place for Marketed or To-Be Marketed Pain Products	JAN-MS-01160464	JAN-MS-01160464							
JA-03295	08/12/2003	CME Task Force Meeting August 6, 2003	JAN-MS-01195296	JAN-MS-01195297							
JA-03296	10/15/2008	Copy Review Approval Form for Let's Talk Pain MAT Releases	JAN-MS-01233375	JAN-MS-01233378							
JA-03297	04/11/2008	Email from Kate Paxton to Greg Panico.	JAN-MS-01234042	JAN-MS-01234045							
JA-03298	04/24/2008	Email from Andrea Iraheta to Greg Panico et al.	JAN-MS-01234241	JAN-MS-01234241							
JA-03299	06/30/2008	Tapentadol Copy Review Meeting Agenda-July 9, 2008	JAN-MS-01234739	JAN-MS-01234740							
JA-03300	06/29/1905	Tapentadol Insider - Springboard Internal Communications Article: Smart Moves, Smart Choices	JAN-MS-01234772	JAN-MS-01234773							
JA-03301	04/22/2008	Email from Greg Panico to Bruce Moskovitz	JAN-MS-01237304	JAN-MS-01237306							
JA-03302	03/12/2008	Mechanical Stat Review for Physician Survey - Tapentadol	JAN-MS-01239438	JAN-MS-01239448							
JA-03303	01/18/2008	Ortho-McNeil Presentation: Smart Moves, Smart Choices, A Prescription Drug Abuse Prevention Program 2008: Roll Out Plan	JAN-MS-01240300	JAN-MS-01240300							
JA-03304	03/19/2008	Email from Roxanne O. McGregor-Beck to Greg Panico et al.	JAN-MS-01241634	JAN-MS-01241634							
JA-03305	05/09/2008	Johnson & Johnson Draft Report: Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile	JAN-MS-01241635	JAN-MS-01241635							
JA-03306	03/19/2008	Email from Roxanne O. McGregor-Beck to Greg Panico et al.	JAN-MS-01241636	JAN-MS-01241636							
JA-03307	05/09/2008	Johnson & Johnson Draft Report: Ne Study Suggests Tapentadol IR for Acute Pain is Associated with Improved Gastrointestinal Tolerability Compared to Oxycodone IR	JAN-MS-01241637	JAN-MS-01241637							
JA-03308	05/11/2007	Email from Leonard Lynn to Greg Panico	JAN-MS-01241845	JAN-MS-01241845							
JA-03309	05/02/2007	Tapentadol Pain Clinician Advisory Board Executive Summary	JAN-MS-01241846	JAN-MS-01241850							
JA-03310	07/17/2007	Memorandum from Chris Handler et al. to Greg Panico	JAN-MS-01244657	JAN-MS-01244659							
JA-03311	01/23/2009	Email from Greg Panico to Nithya Desikan	JAN-MS-01246700	JAN-MS-01246703							
JA-03312	01/22/2009	Tapentadol "Prescribe Responsibly" 2009 PR Activities	JAN-MS-01246704	JAN-MS-01246705							
JA-03313	03/07/2013	Nucynta ER Patient Brochure	JAN-MS-01387186	JAN-MS-01387186							
JA-03314	07/04/1905	Janssen Brochure: Nucynta ER	JAN-MS-01387187	JAN-MS-01387197							
JA-03315	09/10/2014	EOS Task Assignment Reminder: Review Submission Due in 1 Day	JAN-MS-01390669	JAN-MS-01390669							
JA-03316	07/04/1905	Totality Form RFP for Vendor Contract: Nucynta Prescribing Practice Ad Board	JAN-MS-01453488	JAN-MS-01453491							
JA-03317	04/02/2009	Letter from Gary Vorsanger to Tilak Raj, MD	JAN-MS-01456438	JAN-MS-01456439							
JA-03318	04/05/2014	Email from Frederick Tewell to Terry Davidson	JAN-MS-01967614	JAN-MS-01967614							
JA-03319	12/01/2013	CNS Pain Team 2014 Call Plan Strategy	JAN-MS-01968557	JAN-MS-01968561							
JA-03320	12/01/2014	CNS Pain Team 2015 Call Plan Strategy	JAN-MS-01969372	JAN-MS-01969372							
JA-03321	01/29/2015	Email from Frederick Tewell to Michelle Goodridge	JAN-MS-01969583	JAN-MS-01969583							
JA-03322	07/07/1905	Nucynta IR and ER 2015 Transition Bonus Program	JAN-MS-01969584	JAN-MS-01969584							
JA-03323	09/01/2012	Janssen Presentation: Nucynta ER, A Different Option for Chronic Pain Management	JAN-MS-01969690	JAN-MS-01969690							
JA-03324	03/13/2015	Email from Frederick Tewell to Terry Davidson et al.	JAN-MS-01969722	JAN-MS-01969726							
JA-03325	09/29/2014	Email from Stephanie Mello to David Mosher et al.	JAN-MS-01971128	JAN-MS-01971128							
JA-03326	09/26/2014	Janssen Presentation: Medical Information Presented by Phung Quach and Lew Manera	JAN-MS-01971129	JAN-MS-01971154							
JA-03327	01/27/2015	Email from John Monacchio to Frederick Tewell et al.	JAN-MS-01971363	JAN-MS-01971364							
JA-03328	09/01/2014	Fifth Change Order for Work Order #6724	JAN-MS-01971368	JAN-MS-01971372							
JA-03329	12/11/2012	Work Order #6724	JAN-MS-01971374	JAN-MS-01971393							
JA-03330	02/21/2014	Third Change Order for Work Order #6724	JAN-MS-01971394	JAN-MS-01971399							
JA-03331	01/02/2013 - 03/29/2013	Internal Medicine Pain Sales Force - 1st Quarter 2013 Call Plan	JAN-MS-01973127	JAN-MS-01973128							
JA-03332	08/29/2014	Memorandum from Michelle Goodridge to Steve Bariahtaris, et al.	JAN-MS-01973590	JAN-MS-01973592							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-03333	07/06/1905	Janssen draft Presentation: Nucynta Brand Overview	JAN-MS-01975159	JAN-MS-01975159							
JA-03334	11/22/2009	PriCara Presentation: Executive Summary Highlights Understanding Schedule III Analgesic Usage Advisory Board Meeting	JAN-MS-01975567	JAN-MS-01975567							
JA-03335	11/01/2013	Duragesic Concomitant Strength Use Analysis	JAN-MS-01976589	JAN-MS-01976589							
JA-03336	06/26/2006	Duragesic "Preliminary Strategies: Preliminary Working Draft, June 20, 2006": draft of Duragesic business strategies slide deck	JAN-MS-01997062	JAN-MS-01997062							
JA-03337	06/01/2009	Training Materials Review - Integration of PGHCC Functions	JAN-MS-02000338	JAN-MS-02000350							
JA-03338	05/31/2007	Copy Review Approval Form for Duragesic S50 Trade Coupon	JAN-MS-02011314	JAN-MS-02011319							
JA-03339	11/04/2003	Key Opinion Leader Advisory Board: defining Relative Abuse Liability for modified release opioid analgesics (MROs) for chronic pain	JAN-MS-02105453	JAN-MS-02105628							
JA-03340	02/01/2002	Optimizing Product Strategy Through Disease Modeling	JAN-MS-02110740	JAN-MS-02110744							
JA-03341	09/12/2001	Email from Christine DeVries to Adrienne Minecci et al.	JAN-MS-02125588	JAN-MS-02125589							
JA-03342	08/26/2009	Email from Greg Panico to David Biondi et al.	JAN-MS-02206691	JAN-MS-02206691							
JA-03343	04/21/2009	Email from Gary Vorsanger to Roxanne McGregor-Beck et al.	JAN-MS-02214196	JAN-MS-02214197							
JA-03344	05/01/2009	Inside the Data	JAN-MS-02214198	JAN-MS-02214206							
JA-03345	04/29/2010	Email from David Lin to Lynda Mack et al.	JAN-MS-02236444	JAN-MS-02236444							
JA-03346	05/25/2010	Email from Roxanne O. McGregor-Beck to Frank Demiro et al.	JAN-MS-02248336	JAN-MS-02248337							
JA-03347	05/25/2010	Draft letter from Paula to Dave	JAN-MS-02248338	JAN-MS-02248338							
JA-03348	05/01/2010	Ortho-McNeil Janssen Presentation: Nucynta Tapentadol, An Advance in Multimodal Analgesic Therapy	JAN-MS-02254932	JAN-MS-02254932							
JA-03349	10/10/2011	Email from Dominic Lazzaro to Gary Vorsanger et al.	JAN-MS-02266298	JAN-MS-02266301							
JA-03350	09/28/2011	Janssen Nucynta ER Frequently Asked Questions	JAN-MS-02266302	JAN-MS-02266324							
JA-03351	01/13/2011	Email from Gary Vorsanger to Lauren Wilton et al.	JAN-MS-02275256	JAN-MS-02275257							
JA-03352	07/21/2011	Email from Gary Vorsanger to Jeffrey Christensen et al.	JAN-MS-02278334	JAN-MS-02278336							
JA-03353	03/19/2012	Email from Diann Hoedl to Jill McCollam	JAN-MS-02287901	JAN-MS-02287901							
JA-03354	01/31/2012	Email from Jack Henningfield to Patricia Cosler et al.	JAN-MS-02293087	JAN-MS-02293089							
JA-03355	06/25/1905	Jansen Extramural Research Program	JAN-MS-02326351	JAN-MS-02326351							
JA-03356	01/01/2014	Partnership Renewal Invitation Template for 2014 Speakers Bureau	JAN-MS-02342126	JAN-MS-02342128							
JA-03357	06/01/2012	Email from Michael Magera to Bruce Ritchie et al.	JAN-MS-02355236	JAN-MS-02355240							
JA-03358	07/17/2012	Janssen Presentation: Sales Representative Training	JAN-MS-02360240	JAN-MS-02360240							
JA-03359	03/14/2003	Email from Beverly Ernst to Cindy Chao	JAN-MS-02390400	JAN-MS-02390400							
JA-03360	04/03/2001	Email from Sarah Rubenstein to Dennis Fitzgerald et al.	JAN-MS-02395023	JAN-MS-02395023							
JA-03361	03/15/2001	Janssen Presentation: Sales Force Training	JAN-MS-02395029	JAN-MS-02395038							
JA-03362	03/28/2001	Contact Report 3/28.doc	JAN-MS-02395040	JAN-MS-02395042							
JA-03363	04/03/2001	Faxed Letter from Dennis Fitzgerald to Sarah Rubenstein	JAN-MS-02395043	JAN-MS-02395045							
JA-03364	04/01/2002	Email from Dawne McClendon to Kati Chupa	JAN-MS-02395189	JAN-MS-02395192							
JA-03365	01/01/2006	Policy on Sales Representative Interactions with Health Care Professionals (OMJPS HCC)	JAN-MS-02400223	JAN-MS-02400239							
JA-03366	08/26/2010	Email from Frank Demiro to David Lin et al.	JAN-MS-02401998	JAN-MS-02402000							
JA-03367	08/16/2010	Nucynta ER Message Map	JAN-MS-02402001	JAN-MS-02402001							
JA-03368	06/03/2008	Email from David Moore to Kimberly Deem-Eshleman	JAN-MS-02402894	JAN-MS-02402894							
JA-03369	05/01/2003	Slide Deck Neo Pathways Barriers to Effective Pain Management	JAN-MS-02402896	JAN-MS-02402899							
JA-03370	05/01/2008	Slide Deck Neo Pathways Consequences of Undertreatment	JAN-MS-02402900	JAN-MS-02402903							
JA-03371	05/01/2008	Slide Deck Clinical Challenge: Addressing the Limitations of Opioid Analgesics	JAN-MS-02402904	JAN-MS-02402907							
JA-03372	05/01/2008	Slide Deck Undertreatment of Pain: The Evidence is Compelling	JAN-MS-02402908	JAN-MS-02402911							
JA-03373	11/16/2010	Email from Frank Demiro to Hye Yoon Park	JAN-MS-02407423	JAN-MS-02407423							
JA-03374	11/12/2010	Fax and letter from Twyla Thompson to Roxanne McGregor-Beck	JAN-MS-02407424	JAN-MS-02407433							
JA-03375	01/27/2011	Email from Frank Demiro to Mary Griffin	JAN-MS-02407510	JAN-MS-02407511							
JA-03376	01/14/2011	Proposal for Understanding Acute Pain Wall Chart & Pocket Guide	JAN-MS-02407513	JAN-MS-02407516							
JA-03377	01/14/2011	Proposal for Understanding Chronic Pain Anatomical Resources Wall Chart, Pocket Guide, Tear-Pad	JAN-MS-02407517	JAN-MS-02407519							
JA-03378	08/06/2010	Email from Samantha Miller to Frank Demiro et al.	JAN-MS-02407789	JAN-MS-02407790							
JA-03379	08/05/2010	Ketchum Public Relations, Pain Awareness Month Video Series and Internal Awareness Campaign Budget / Proposal	JAN-MS-02407791	JAN-MS-02407794							
JA-03380	12/03/2009	Janssen PADT Guidebook	JAN-MS-02493626	JAN-MS-02493627							
JA-03381	03/18/2010	Email from Robyn Kohn to Susan Nicholson	JAN-MS-02494145	JAN-MS-02494146							
JA-03382	08/09/2012	Janssen Pharmaceuticals Contributions Committee meeting Minutes	JAN-MS-02496824	JAN-MS-02496844							
JA-03383	03/19/2008	Email from Roxanne O. McGregor-Beck to Greg Panico et al.	JAN-MS-02498895	JAN-MS-02498895							
JA-03384	05/08/2008	Johnson & Johnson draft press release on TAPENTADOL IMMEDIATE RELEASE EFFECTIVE IN RELIEVING ACUTE PAIN FROM COMMON FOOT SURGERY	JAN-MS-02498896	JAN-MS-02498896							
JA-03385	12/14/2007	Email from Lauren Hartmann to Diane McCracken et al.	JAN-MS-02498955	JAN-MS-02498956							
JA-03386	12/14/2007	Letter from Cyndi Grimes to Robyn Kohn	JAN-MS-02498957	JAN-MS-02498963							
JA-03387	09/11/2007	Three-Party CE Educational Grant Agreement (Re Grant ID #5505)	JAN-MS-02498981	JAN-MS-02498981							
JA-03388	01/01/2006	OMJPS Health Care Compliance Reference Guide	JAN-MS-02508522	JAN-MS-02508805							
JA-03389	03/25/2014	Statement of Work - Community Connect National Program Rollout	JAN-MS-02522549	JAN-MS-02522553							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-03390	07/01/2013	2013-2014 Corporate Membership: Totality Request ID: 160671	JAN-MS-02525626	JAN-MS-02525631							
JA-03391	05/01/2014	PAIN Rep Master Table May 2014	JAN-MS-02527268	JAN-MS-02527268							
JA-03392	10/24/2014	Scheduled or Completed Programs	JAN-MS-02529910	JAN-MS-02529910							
JA-03393	01/15/2007	Email from Haya Taitel to Gregory J. Imber et al.	JAN-MS-02533808	JAN-MS-02533810							
JA-03394	10/01/2014	Email from Frederick Tewell to Christine Damico et al.	JAN-MS-02733170	JAN-MS-02733171							
JA-03395	10/06/2014	Email from MaryAnn Sicurella to Frederick Tewell	JAN-MS-02734351	JAN-MS-02734352							
JA-03396	03/01/2013	Janssen draft presentation: CNS Pain Team Q2-Q4 Call Plan Strategy	JAN-MS-02734353	JAN-MS-02734357							
JA-03397	03/29/2013	Internal Medicine PAIN Sales Force 1st Quarter 2013 Call Plan	JAN-MS-02734358	JAN-MS-02734359							
JA-03398	09/01/2012	Approved Specialties for Nucynta and Nucynta ER	JAN-MS-02734360	JAN-MS-02734360							
JA-03399	06/27/2014	2014 Program Budget and Assessment	JAN-MS-02734788	JAN-MS-02734788							
JA-03400	11/09/2014	MediMedia Health Proposal: Duragesic Web \$50 Coupon 2015 Program	JAN-MS-02737011	JAN-MS-02737017							
JA-03401	09/04/2007	Email from Paul Simms to Wesley Dorey et al.	JAN-MS-02750931	JAN-MS-02750932							
JA-03402	10/22/2007	Email from Wesley Dorey to Scott Trembley et al.	JAN-MS-02751055	JAN-MS-02751057							
JA-03403	11/15/2010	Email from Gary Vorsanger to Bruce Moskovitz et al.	JAN-MS-02819785	JAN-MS-02819787							
JA-03404	08/26/2011	Presentation: Nucynta ER Messaging	JAN-MS-02823191	JAN-MS-02823191							
JA-03405	07/03/1905	NUCYNTA ER (tapentadol extended-release tablets) FDA Action Response Document for APPROVAL	JAN-MS-02823192	JAN-MS-02823199							
JA-03406	11/22/2011	Nucynta ER Opioid Dose Conversion Web Advisory Board	JAN-MS-02827954	JAN-MS-02827986							
JA-03407	12/26/2012	Work Order Project: Xponent Analysis	JAN-MS-02935308	JAN-MS-02935313							
JA-03408	11/01/2011	Pharmacor: Pain Management Study - Chronic Pain Nov. 2011	JAN-MS-02948933	JAN-MS-02949151							
JA-03409	08/01/2012	Nucynta and Nucynta ER Dual Dosing Guides	JAN-MS-02958779	JAN-MS-02958836							
JA-03410	12/01/2010	PriCara Presentation: Nucynta RBD Meeting	JAN-MS-02959725	JAN-MS-02959725							
JA-03411	04/07/2015	Form Letter from Michael Levitt to "valued business partners"	JAN-MS-02960561	JAN-MS-02960569							
JA-03412	05/01/2015	2015 Suspicious Order Monitoring, JOM SOM Program	JAN-MS-02960646	JAN-MS-02960646							
JA-03413	01/10/2017	JOM 2017 Suspicious Order Monitoring	JAN-MS-02964344	JAN-MS-02964345							
JA-03414	04/01/2014	2015 Completed SOM Questionnaire by Anda, Inc.	JAN-MS-02966146	JAN-MS-02966146							
JA-03415	04/01/2014	JOM SOM Questionnaire in Preparation for On-Site Visit	JAN-MS-02966794	JAN-MS-02966795							
JA-03416	01/02/2013	Internal Medicine PAIN Sales Force 1st Quarter 2013 Call Plan	JAN-MS-02979844	JAN-MS-02979845							
JA-03417	01/28/2015	Email from Michele Dempsey to John Daly	JAN-MS-02984602	JAN-MS-02984607							
JA-03418	01/02/2015	Product Promotion Policy	JAN-MS-02989735	JAN-MS-00789755							
JA-03419	06/23/1905	Janssen 2001 Product Business Plan Summary	JAN-MS-02992128	JAN-MS-02992130							
JA-03420	02/01/2006	General Policy and Procedure for the Review and Approval of Advertising, Promotional and Field Sales Force Training Materials	JAN-MS-02994505	JAN-MS-02994505							
JA-03421	06/28/1905	PriCara Frequently Asked Questions, 1st Half 2006 Call Plan	JAN-OH-00138847	JAN-OH-00138847							
JA-03422	05/30/2014	Suspicious Order Monitoring Due Diligence Visit Report	JAN-MS-03054664	JAN-MS-03054666							
JA-03423	11/12/2004	Email from Joseph Cannavo to Richard Grant et al.	JAN-MS-03072697	JAN-MS-03072698							
JA-03424	06/26/1905	Janssen Duragesic Patient Coupon Program Guide	JAN-MS-03072699	JAN-MS-03072700							
JA-03425	12/03/2004	Chronic Pain: DURAGESIC Speaker Training Meeting	JAN-MS-03074478	JAN-MS-03074481							
JA-03426	01/23/2004	DURAGESIC Speakers Bureau 2004 Speaker Training Details & Justification (Draft)	JAN-MS-03074511	JAN-MS-03074511							
JA-03427	09/22/2003	Duragesic Product Suite - Course 1: Understanding Pain	JAN-MS-03075212	JAN-MS-03075296							
JA-03428	10/28/2003	Duragesic Product Suite - Course 7: Selling Duragesic	JAN-MS-03075299	JAN-MS-03075299							
JA-03429	11/03/2003	Duragesic Product Suite - Course 6: Competition	JAN-MS-03075301	JAN-MS-03075301							
JA-03430	09/22/2004	Janssen Storyboard: Duragesic Product Suite	JAN-MS-03075308	JAN-MS-03075308							
JA-03431	10/09/2003	Duragesic Product Suite - Course 4: Disease States	JAN-MS-03075309	JAN-MS-03075408							
JA-03432	09/22/2003	Duragesic Product Suite - Course 3: Treatment Options	JAN-MS-03075417	JAN-MS-03075529							
JA-03433	09/22/2003	Duragesic Product Suite - Course 2: Pain Assessment	JAN-MS-03075534	JAN-MS-03075586							
JA-03434	12/01/2004	Duragesic Speaker Bureau: December 2004 Speaker Training Details & Justification	JAN-MS-03076038	JAN-MS-03076038							
JA-03435	01/23/2015	Standard Operating Procedure for the Management of the Copy Review Process	JAN-MS-03087769	JAN-MS-03087785							
JA-03436	11/04/2018	Janssen Presentation: JOM Suspicious Order Monitoring	JAN-MS-03089466	JAN-MS-03089483							
JA-03437	07/01/2017	Quintiles IMS Fifteenth Amendment to Information Services Agreement No. COBS-0608-1213	JAN-MS-03108831	JAN-MS-03108833							
JA-03438	12/31/2016	Quintiles IMS Thirteenth Amendment to Information Services Agreement No. COBS-0608-1213	JAN-MS-03108834	JAN-MS-03108835							
JA-03439	01/01/2017	Quintiles IMS Fourteenth Amendment to Information Services Agreement No. COBS-0608-1213	JAN-MS-03108836	JAN-MS-03108858							
JA-03440	06/18/2008	IMS HEALTH Information Services Agreement AGREEMENT No.: COBS- SFE0608-1213	JAN-MS-03108859	JAN-MS-03108872							
JA-03441	06/18/2008	IMS HEALTH Information Services Agreement AGREEMENT No.: COBS- SFE0608-1213	JAN-MS-03108873	JAN-MS-03108886							
JA-03442	01/01/2010	Amendment to Information Services Agreement Dated 6/18/2008	JAN-MS-03108887	JAN-MS-03108904							
JA-03443	01/01/2010	IMS HEALTH AMENDMENT TO INFORMATION SERVICES AGREEMENT No. COBS-0608-1213 DATED JUNE 18, 2008 BETWEEN IMS HEALTH INCORPORATED ("IMS") AND CENTOCOR ORTHO BIOTECH SERVICES, LLC ("CLIENT")	JAN-MS-03108905	JAN-MS-03108922							
JA-03444	01/01/2007	IMS Health Information Services Agreement (J&J Master Agreement)	JAN-MS-03108923	JAN-MS-03108974							
JA-03445	01/01/2007	IMS HEALTH Information Services Agreement AGREEMENT No.: J&J-MasterAgreement07-09	JAN-MS-03108975	JAN-MS-03109026							
JA-03446	01/01/2010	Quintiles IMS 14th Amendment to Information Services Agreement No COBS-0608-1213	JAN-MS-03109027	JAN-MS-03109044							
JA-03447	12/31/2016	Quintiles IMS Thirteenth Amendment to Information Services Agreement No. COBS-0608-1213	JAN-MS-03109045	JAN-MS-03109046							
JA-03448	07/01/2007	Quintiles IMS Fifteenth Amendment to Information Services Agreement No. COBS-0608-1213	JAN-MS-03109070	JAN-MS-03109072							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-03449	06/18/2008	IMS HEALTH Information Services Agreement AGREEMENT No.: COBS- SFE0608-1213	JAN-MS-03109073	JAN-MS-03109086							
JA-03450	01/01/2007	"IMS HEALTH Information Services Agreement AGREEMENT No.: J&J-MasterAgreement07-09"	JAN-MS-03109087	JAN-MS-03109138							
JA-03451	01/28/2014	Janssen Suspicious Order Monitoring Program Questionnaire	JAN-MS-03116127	JAN-MS-03116127							
JA-03452	06/19/2017	JOM Customer Service New Customer Pre Application	JAN-MS-03121163	JAN-MS-03121165							
JA-03453	01/24/2013	JOM Customer Service New Customer Post-Application	JAN-MS-03121166	JAN-MS-03121170							
JA-03454	07/05/2018	JOM Customer Support Services DEA Questionable Order Report and Monitoring Process	JAN-MS-03121171	JAN-MS-03121185							
JA-03455	10/01/2018	JOM Distribution Shipping Process	JAN-MS-03121186	JAN-MS-03121244							
JA-03456	05/17/2018	JOM Customer Support Services Schedule II CS Order Process	JAN-MS-03121245	JAN-MS-03121264							
JA-03457	10/24/2018	JOM Customer Support Services Monthly Metric Report for Scheduled Orders	JAN-MS-03121265	JAN-MS-03121283							
JA-03458	08/10/2017	JOM Customer Support Services New Customer Request Process	JAN-MS-03121284	JAN-MS-03121290							
JA-03459	10/06/2017	JOM Customer Support Services - Business Manager: Release Orders	JAN-MS-03121291	JAN-MS-03121311							
JA-03460	09/07/2018	JOM Controlled Substance Compliance Maintaining DEA and State Reporting	JAN-MS-03121312	JAN-MS-03121326							
JA-03461	11/19/2018	JOM Customer Service Customer Master Data Process	JAN-MS-03121327	JAN-MS-03121359							
JA-03462	05/04/2018	JOM Customer Support Services Schedule 11-V Order Processing and Investigating Questionable Order Quantities	JAN-MS-03121360	JAN-MS-03121368							
JA-03463	No Date	JOM Controlled Substance Compliance Suspicious Order Monitoring	JAN-MS-03121369	JAN-MS-03121378							
JA-03464	04/02/2002	Spreadsheets: Speaker Bureau Programs	JAN-MS-0312397	JAN-MS-03124005							
JA-03465	07/30/2013	Email from Martha Wick to Maryann Gribbin et al.	JAN-MS-03123994	JAN-MS-03123996							
JA-03466	12/20/2017	Email from Robert Helfrick to Stephanie Dixon et al.	JAN-MS-03124006	JAN-MS-03124007							
JA-03467	12/20/2017	Checklist for Importer and Exporter inspections	JAN-MS-03124008	JAN-MS-03124009							
JA-03468	12/28/2017	Email from Robert Helfrick to Stephanie Dixon et al.	JAN-MS-03124010	JAN-MS-03124011							
JA-03469	12/04/2008	Attendee list for Dec. 2008 FDLI Conference	JAN-MS-03124015	JAN-MS-03124015							
JA-03470	05/14/2008-04/11/2014	DEA conference attendance certificates	JAN-MS-03124016	JAN-MS-03124021							
JA-03471	04/15/2015	DEA Distributors Conference Documents -2015	JAN-MS-03124022	JAN-MS-03124047							
JA-03472	01/29/2018	ACI Summit on Controlled Substances Agenda	JAN-MS-03124048	JAN-MS-03124049							
JA-03473	03/22/2017	Email from DEA Conference Registration to Michelle Dempsey	JAN-MS-03124050	JAN-MS-03124052							
JA-03474	04/04/2016	Email from DEA Conference Registration to Michele Dempsey	JAN-MS-03124053	JAN-MS-03124055							
JA-03475	04/12/2016	April 2016 DEA Pharma Training Seminar	JAN-MS-03124056	JAN-MS-03124058							
JA-03476	08/19/2015	Email from DEA Conference Registration to Michele Dempsey	JAN-MS-03124059	JAN-MS-03124062							
JA-03477	07/06/1905	2014 Specialty Pharma Supply Chain Issues & Trends Seminar attendees list	JAN-MS-03124063	JAN-MS-03124063							
JA-03478	07/30/2013	Email from DEA Conference Registration to Michele Dempsey	JAN-MS-03124064	JAN-MS-03124065							
JA-03479	07/19/2013	DEA Manufacturers, Importers, Exports Conference agenda, topics, and roster	JAN-MS-03124066	JAN-MS-03124069							
JA-03480	02/13/2012	DEA Conference Attendees List	JAN-MS-03124070	JAN-MS-03124070							
JA-03481	04/19/2011	DEA Pharma Training Seminar Cert of Participation	JAN-MS-03124071	JAN-MS-03124073							
JA-03482	10/14/2009	DEA Pharma Conference Attendees List	JAN-MS-03124074	JAN-MS-03124075							
JA-03483	01/07/2019	Regulatory Agency Contact Report 2019-002	JAN-MS-03124076	JAN-MS-03124079							
JA-03484	12/12/2007	Regulatory Agency Contact Report	JAN-MS-03124082	JAN-MS-03124087							
JA-03485	08/03/2011	JOM Standard Operating Procedure: License Management	JAN-MS-03124088	JAN-MS-03124100							
JA-03486	07/24/2013	JOM Standard Operating Procedure: Customer Service Suspicious or Excessive Orders	JAN-MS-03124101	JAN-MS-03124110							
JA-03487	01/24/2013	JOM Standard Operating Procedure: Customer Service New Customer Post Application	JAN-MS-03124141	JAN-MS-03124145							
JA-03488	01/24/2013	JOM Standard Operating Procedure: Customer Service New Customer Pre-Application	JAN-MS-03124146	JAN-MS-03124148							
JA-03489	04/08/2009	Email from Cassie Hallberg to Robyn Kohn et al.	JAN-MS-03613638	JAN-MS-03613639							
JA-03490	09/16/2005	JOM Customer Service Suspicious or Excessive Narcotic Orders.	JAN-MS-03741170	JAN-MS-03741176							
JA-03491	09/19/2005	JOM Standard Operating Procedure: Customer Service Order Processing of Controlled Substances	JAN-MS-03741177	JAN-MS-03741200							
JA-03492	11/17/2005	JOM Standard Operating Procedure: Customer JOM Standard Operating Procedure: Customer Service Schedule II-V Order Processing and Investigating Suspicious or Excessive Narcotics Orders	JAN-MS-03741201	JAN-MS-03741205							
JA-03493	01/07/2019	Controlled Substances Suspicious Order Monitoring Program Questionnaire	JAN-MS-03741206	JAN-MS-03741211							
JA-03494	06/01/2012	Copy Review Submission Cover Sheet - Nucynta ER Patient Brochure	JAN-MS-03768436	JAN-MS-03768447							
JA-03495	04/01/2009	Advertisement: Opioid Efficacy Meets Unexpected Tolerability.	JAN-MS-03769903	JAN-MS-03769914							
JA-03496	04/16/2008	Copy Review Approval Form for Tapentadol KOL NewsChannel	JAN-MS-03778931	JAN-MS-03778931							
JA-03497	04/03/2008	Copy Review Approval Form - NEO Pathways KOL NewsChannel	JAN-MS-03778932	JAN-MS-03778932							
JA-03498	07/01/2011	Janssen Presentation: Nucynta Dosing and Administration Guide	JAN-MS-03797063	JAN-MS-03797077							
JA-03499	09/02/2014	EOS Project Initiation: Nucynta Updates	JAN-MS-03830441	JAN-MS-03830444							
JA-03500	10/25/2013	Form 2253 - Transmittal of Advertisements and Promotional Labeling For Drugs and Biologics for Human Use	JAN-MS-03830495	JAN-MS-03830495							
JA-03501	09/02/2014	EOS Project Initiation: Nucynta Updates	JAN-MS-03844401	JAN-MS-03844409							
JA-03502	04/07/2014	EOS record of PRC approved Start Smart materials	JAN-MS-03857633	JAN-MS-03857638							
JA-03503	07/02/1905	Smart Moves, Smart Choices fact sheet.	JAN-MS-03917731	JAN-MS-039177312							
JA-03504	06/21/2012	CRC Meeting Agenda; Advertising & Promotion	JAN-MS-03966966	JAN-MS-03966966							
JA-03505	07/28/2010	AI/GI (sales force) tablet materials	JAN-MS-04022231	JAN-MS-04022292							
JA-03506	07/01/2009	Nucynta representative resource guide	JAN-MS-04105807	JAN-MS-04105810							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-03507	06/01/2012	Copy Review Approval Form for Nucynta ER Patient Brochure	JAN-MS-04145965	JAN-MS-04145965							
JA-03508	06/01/2012	Copy Review Submission Package - Nucynta ER Patient Brochure	JAN-MS-04145969	JAN-MS-04145969							
JA-03509	06/01/2012	lReview Item # Request Form - Nucynta ER Patient Brochure	JAN-MS-04145970	JAN-MS-04145970							
JA-03510	12/05/2008	Nucynta pharmacy leave behind	JAN-MS-04146535	JAN-MS-04146541							
JA-03511	06/01/2009	Nucynta pharmacy vis aid annotated	JAN-MS-04157172	JAN-MS-04157191							
JA-03512	09/01/2010	Nucynta dosing and administration guide	JAN-MS-04181502	JAN-MS-04181512							
JA-03513	07/01/1905	Nucynta eRep assets	JAN-MS-04183671	JAN-MS-04183740							
JA-03514	03/16/2011	Nucynta website	JAN-MS-04190903	JAN-MS-04191187							
JA-03515	07/02/2013	Email from Michael Levitt to Michele Dempsey	JAN-MS-04201132	JAN-MS-04201133							
JA-03516	01/08/2003	Email from Robert Lisicki to Kati Chupa et al.	JAN-MS-04211256	JAN-MS-04211256							
JA-03517	07/15/2002	Guidance Document: Support of Continuing Medical Education (CME) Activities	JAN-MS-04211257	JAN-MS-04211269							
JA-03518	10/15/2013	Email from Arnold Doyle to Scott McKenzie et al.	JAN-MS-04215700	JAN-MS-04215701							
JA-03519	04/08/2011	Email from Frank Demiro to Beth Rathburn et al.	JAN-MS-04218304	JAN-MS-04218308							
JA-03520	04/12/2011	Email from Frank Demiro to Tara Blackman	JAN-MS-04218321	JAN-MS-04218327							
JA-03521	03/08/2011	Email from Frank Demiro to Linda Hurchins.	JAN-MS-04219749	JAN-MS-04219749							
JA-03522	07/02/1905	Ortho-McNeil Status Grid_03-07-11 to Client	JAN-MS-04219750	JAN-MS-04219750							
JA-03523	08/01/2013	Email from ValueTrak Report Administrator to Shweta Raval	JAN-MS-05332010	JAN-MS-05332010							
JA-03524	12/13/2010	Letter from Tracy Allgier-Baker (Penn State) to Ortho-McNeil Janssen Scientific Affairs, LLC, Educational Grants	JAN-MS-05399338	JAN-MS-05399339							
JA-03525	05/16/2012	Email from Maryann Gribbin to David E. Johnson et al.	JAN-MS-05433721	JAN-MS-05433722							
JA-03526	05/17/2012	Email from Maryann Gribbin to Maryann Gribbin et al.	JAN-MS-05433723	JAN-MS-05433725							
JA-03527	05/18/2012	Email from Maryann Gribbin to Maryann Gribbin et al.	JAN-MS-05433726	JAN-MS-05433727							
JA-03528	05/21/2012	Email from Maryann Gribbin to Maryann Gribbin et al.	JAN-MS-05433728	JAN-MS-05433729							
JA-03529	01/22/2019	Email from Robert Helfrick to Stephanie Dixon	JAN-MS-05433730	JAN-MS-05433730							
JA-03530	11/16/2017	JOM Customer Support Services DEA Unusual Order Report and Monitoring Process	JAN-MS-05433731	JAN-MS-05433740							
JA-03531	01/22/2019	Email from Robert Helfrick to Stephanie Dixon	JAN-MS-05433741	JAN-MS-05433741							
JA-03532	08/04/2015	Email from Robert Helfrick to Martha Wick et al.	JAN-MS-05433744	JAN-MS-05433745							
JA-03533	09/25/2018	Email from George Guralnik to Cindy Maiolino et al.	JAN-MS-05433746	JAN-MS-05433747							
JA-03534	10/22/2008	Email from Maryann Gribbin to Jill Lavitsky et al.	JAN-MS-05433748	JAN-MS-05433749							
JA-03535	12/17/2018	Regulatory Agency Contact Report - 2018-77	JAN-MS-05433750	JAN-MS-05433753							
JA-03536	01/02/2018	YTD Monitored Orders (Kentucky Distribution Center)	JAN-MS-05433754	JAN-MS-05433754							
JA-03537	06/26/2018	Questionable Order Justification Release Form	JAN-MS-05433755	JAN-MS-05433755							
JA-03538	06/14/2018	Questionable Order Justification Release Form	JAN-MS-05433757	JAN-MS-05433757							
JA-03539	01/24/2019	Email from Belinda Corum to Michele Dempsey	JAN-MS-05433758	JAN-MS-05433760							
JA-03540	05/05/2011	Email from Robyn Hand to Kati Chupa et al.	JAN-MS-05435624	JAN-MS-05435624							
JA-03541	No Date	Order Management FRS Document	JAN-MS-05441988	JAN-MS-05442211							
JA-03542	No Date	Mercury Order Management User Requirements Specifications	JAN-MS-05442212	JAN-MS-05442253							
JA-03543	06/28/1905	Handwritten Notes	JAN-MS-05444824	JAN-MS-05446674							
JA-03544	11/23/2013	JOM Standard Operating Procedure: Customer Service Customer Master Data Process	JAN-MS-05457234	JAN-MS-05457247							
JA-03545	04/04/2006	Guidance Document on Support for Promotional and Educational Programs and Materials	JAN-MS-05457296	JAN-MS-05457337							
JA-03546	07/05/2012	July Sales Impact Pull-Through Guide, Learning and Exploring with you PCP and Specialists	JAN-MS-00091517	JAN-MS-00091519							
JA-03547	07/04/1905	Janssen Presentation: Training Workshops, Nucynta and Nucynta ER	JAN-MS-00091555	JAN-MS-00091611							
JA-03548	07/04/1905	Janssen Presentation:Training Workshops, Nucynta and Nucynta ER	JAN-MS-00091615	JAN-MS-00091672							
JA-03549	07/04/1905	Janssen Presentation on Nucynta and Nucynta ER: Cycle 1 Meeting	JAN-MS-00091704	JAN-MS-00091806							
JA-03550	07/04/1905	Janssen Presentation: Value Based Selling: A Consultative Approach with Nucynta ER	JAN-MS-00092138	JAN-MS-00092167							
JA-03551	01/07/2011	Nucynta Home Study Training Calendar	JAN-MS-00092190	JAN-MS-00092192							
JA-03552	05/18/2009	Daniels, Stephen, et al., A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Relative Efficacy and Tolerability of Tapentadol IR and Oxycodone IR for Acute Pain, Current Medical Research and Opinion, Vol. 25, No.6, pp. 1551-1561, 2009.	JAN-MS-00092203	JAN-MS-00092213							
JA-03553	02/09/2009	Daniels, Stephem, et al;., A Randomized, Double-Blind, Phase III Study Comparing Multiple Doses of Tapentadol IR, Oxycodone IR, and Placebos for Postoperative (Bunionectomy) Pain, Current Medical Research and Opinions, Vol. 26, No. 3, 2009, pp. 765-776.	JAN-MS-00092214	JAN-MS-00092225							
JA-03554	02/01/2009	Hartrick, Craig et al., Efficacy and Tolerability of Tapentadol Immediate Release and Oxycodone HC1 Immediate Release in Patients Awaiting Primary Joint Replacement Surgery for End-Stage Joint Disease: A 10-Day, Phase III, Randomized, Double-Blind, Active- and Placebo-Controlled Study, Clinical Therpaeutics, Vol, 31, No. 2, 2009.	JAN-MS-00092226	JAN-MS-00092237							
JA-03555	04/10/2012	Nucynta ER FAQs	JAN-MS-00093748	JAN-MS-00093774							
JA-03556	10/01/2011	Janssen Presentation: Risk Management (REMS) for Tapentadol ER, Chapter 2: The REMS Programs for Nucynta ER	JAN-MS-00093821	JAN-MS-00093880							
JA-03557	11/01/2013	Janssen Presentation: Value Based Selling: A Consultative Approach with Nucynta ER	JAN-MS-00105838	JAN-MS-00105868							
JA-03558	05/14/2010	FAQ: Ask the Nucynta Team	JAN-MS-00120596	JAN-MS-00120610							
JA-03559	07/05/1905	Janssen Presentation: Retail Training Workshops, Nucynta, Nucynta ER	JAN-MS-00122286	JAN-MS-00122357							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-03560	07/05/1905	Janssen Presentation: Retail Training Workshops, Nucynta, Nucynta ER	JAN-MS-00122577	JAN-MS-00122648							
JA-03561	10/01/2011	Janssen Presentation: Risk Management {REMS} for Tapentadol ER, Chapter 2: The REMS Programs for Nucynta ER	JAN-MS-00123331	JAN-MS-00123390							
JA-03562	02/12/2019	Spreadsheet re Mkt Res - Reg KOL	JAN-MS-02533814	JAN_MS_02533814							
JA-03563	02/06/2014	Evaluation of the tamper-resistant properties of tapentadol extended-release tablets: Results of in vitro laboratory analyses by Eric Galia, PhD, Yinka Williams, Ben Van Hove, et al.	JAN-TREX-00056201	JAN-TREX-00056210							
JA-03564	07/07/1905	Tapentadol Abuse Potential: A Postmarketing Evaluation Using a Sample of Individuals Evaluated for Substance Abuse by Stephen F. Butler, Emily C. McNaughton, MPH and Ryan A. Black, PhD	JAN-TREX-00056211	JAN-TREX-00056222							
JA-03565	07/07/1905	Pain Medicine Wiley Periodicals, Inc.: Assessing Abuse Potential of New Analgesic Medications Following Market Release: An Evaluation of Internet Discussion of Tapentadol Abuse, Emily McNaughton et al.	JAN-TREX-00056223	JAN-TREX-00056232							
JA-03566	07/05/1905	Pain Physician Journal: Efficacy of Tapentadol ER for Managing Moderate to Severe Chronic Pain, Marc Afialo et al.	JAN-TREX-00056233	JAN-TREX-00056246							
JA-03567	07/08/1905	Pain Medicine: Diversion and Illicit Sale of Extended Release of Tapentadol in the United States, Richard C. Dart et al	JAN-TREX-00056247	JAN-TREX-00056253							
JA-03568	06/10/2004	APF: Pain Notebook	JAN-TREX-00056254	JAN-TREX-00056255							
JA-03569	06/16/2005	Treating Doctors as Drug Dealers; The DEA's War on Prescription Painkillers; Ronald T. Libby	JAN-TREX-00056256	JAN-TREX-00056283							
JA-03570	06/26/1905	Substance Abuse: A Comphrensive Textbook. 4th ed.: Joyce H. Lowinson, M.D., Pedro Ruiz, M.D., Robert B. Millman, M.D., et al.	JAN-TREX-00056284	JAN-TREX-00056327							
JA-03571	04/09/2019	Statement by Douglas Throckmorton, M.D., Deputy Center Director for Regulatory Programs in FDA's Center for Drug Evaluation and Research, on new opioid analgesic labeling changes to give providers better information for how to properly taper patients who are physically dependent on opioids	JAN-TREX-00056328	JAN-TREX-00056331							
JA-03572	06/20/1905	British Journal of Anaesthesia Opioid tolerance: the clinical perspective, B-J Collett	JAN-TREX-00056332	JAN-TREX-00056342							
JA-03573	09/14/2018	CDC Morbidity and Mortality Weekly Report, Prevalence of Chronic Pain and High-Impact Chronic Pain Among Adults -- United States, 2016	JAN-TREX-00056343	JAN-TREX-00056350							
JA-03574	06/25/1905	NIDA: Pain Assessment and Documentation Tool (PADT)	JAN-TREX-00056351	JAN-TREX-00056353							
JA-03575	07/02/2015	Prescribe Responsibly home page	JAN-TREX-00149916	JAN-TREX-00149916							
JA-03576	07/02/2015	Prescribe Responsibly full website	JAN-TREX-00056354	JAN-TREX-00056364							
JA-03577	07/06/1905	Smart Moves, Smart Choices About page	JAN-TREX-00149917	JAN-TREX-00149917							
JA-03578	07/06/1905	Smart Moves, Smart Choices Elementary Smart Start Tools webpage	JAN-TREX-00056365	JAN-TREX-00056366							
JA-03579	07/06/1905	Smart Moves, Smart Choices Tool Kit for Middle and High Schools webpage	JAN-TREX-00056367	JAN-TREX-00056368							
JA-03580	07/06/1905	Smart Moves, Smart Choices Tool Kit for Middle and High Schools webpage	JAN-TREX-00056369	JAN-TREX-00056370							
JA-03581	04/29/2019	Nurse.com Confronting the Opioid Epidemic Webpage	JAN-TREX-00149918	JAN-TREX-00149918							
JA-03582	04/29/2019	About Nurse.com Webpage	JAN-TREX-00056371	JAN-TREX-00056373							
JA-03583	08/31/2018	Nurse.com Opioid Use Disorder and Pregnancy: What Does Evidence-Based Care Look Like?	JAN-TREX-00056374	JAN-TREX-00056378							
JA-03584	08/31/2018	Nurse.com Health Literacy and Discharge Education: I Didn't Understand	JAN-TREX-00056379	JAN-TREX-00056383							
JA-03585	08/31/2018	Nurse.com Patient Counseling: Preventing and Combating Opioid Misuse	JAN-TREX-00056384	JAN-TREX-00056388							
JA-03586	08/24/2018	Nurse.com Meeting the Challenge of Pediatric Pain Management	JAN-TREX-00056389	JAN-TREX-00056395							
JA-03587	08/21/2018	Nurse.com Responsible Opioid Prescribing, Chronic Pain, and Addiction	JAN-TREX-00056396	JAN-TREX-00056401							
JA-03588	05/07/2018	Nurse.com Prescription Drug Abuse	JAN-TREX-00056402	JAN-TREX-00056407							
JA-03589	02/22/2019	Nurse.com website: Pain Management and Ethics: What's the Right Thing To Do?, available at www.nuse.com/ce/pain-managementy-and-ethics-what-s-the-right-thing-to-do	JAN-TREX-00056408	JAN-TREX-00056413							
JA-03590	06/29/2018	Nurse.com website: Chronic Pain: How Do We Treat It in an Era of Increasing Prescription Medication Misuse and Abuse?, available at www.nurse.com/ce/chronic-pain	JAN-TREX-00056414	JAN-TREX-00056419							
JA-03591	06/28/2018	Nurse.com website: Effective Pain Management Is More than Just a Number, available at www.nurse.com/ce/effective-pain-management-is-more-than-just-a-number	JAN-TREX-00056420	JAN-TREX-00056425							
JA-03592	01/05/2018	Nurse.com website: Substance Abuse: Helping Women and Their Children, available at www.nurse.com/ce/substance-abuse-helping-women-and-their-children	JAN-TREX-00056426	JAN-TREX-00056432							
JA-03593	11/02/2017	Nurse.com website: Medication Nonadherence: America's Other Drug Problem, available at www.nurse.com/ce/medication-nonadherence	JAN-TREX-00056433	JAN-TREX-00056438							
JA-03594	03/05/2018	Nurse.com website: Knocking Out Pain Safely with PCA, available at www.nurse.com/ce/knocking-out-pain-safely-with-pca	JAN-TREX-00056439	JAN-TREX-00056444							
JA-03595	08/27/2018	Nurse.com website: Recognizing Drug-Seeking Behavior, available at www.nurse.com/ce/recognizing-drugseeking-behavior	JAN-TREX-00056445	JAN-TREX-00056450							
JA-03596	05/08/2018	Nurse.com website: Evidence-Based Approaches to Pain Control, available at www.nurse.com/ce/evidence-based-approaches-to-pain-control	JAN-TREX-00056451	JAN-TREX-00056455							
JA-03597	08/28/2018	Nurse.com website: Motivational Interviewing, available at www.nurse.com/ce/motivational-interviewing	JAN-TREX-00056456	JAN-TREX-00056462							
JA-03598	04/24/2019	BabyCenter.com website: About BabyCenter, LLC, available at www.babycenter.com/about	JAN-TREX-00056463	JAN-TREX-00056470							
JA-03599	04/24/2019	Babycenter.com website: Editorial and Advertising Policy, available at www.babycenter.com/editorial-advertising-policy	JAN-TREX-00056471	JAN-TREX-00056475							
JA-03600	04/24/2019	Babycenter.com website: BabyCenter Medical Advisory Board, available at www.babycenter.com/prkit-advisoryboard	JAN-TREX-00056476	JAN-TREX-00056485							
JA-03601	04/24/2019	Babycenter.com website: What Are Opioids?, available at www.babycenter.com/0_what-are-opioids_20004416.bc	JAN-TREX-00056486	JAN-TREX-00056490							
JA-03602	04/24/2019	Babycenter.com website: Chart: Which medicines contain opioids?, available at www.babycenter/0_chart-which-medicines-contain-opioids_20000902.bc	JAN-TREX-00056491	JAN-TREX-00056496							
JA-03603	04/24/2019	Babycenter.com website: Is it safe to take opioids during pregnancy?, available at www.babycenter.com/0_is-it-safe-to-take-opioids-during-pregnancy_20004418.bc	JAN-TREX-00056497	JAN-TREX-00056502							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-03604	04/24/2019	Babycenter.com website: Is it safe to take opioids while breastfeeding?, available at www.babycenter.com/0_is-it-safe-to-take-opioids-while-breastfeeding_20004424.bc	JAN-TREX-00056503	JAN-TREX-00056508							
JA-03605	04/24/2019	Babycenter.com website: Is it safe to take opioids during labor?, available at www.babycenter.com/0_is-it-safe-to-take-opioids-during-labor_20004422.bc	JAN-TREX-00056509	JAN-TREX-00056514							
JA-03606	04/24/2019	Babycenter.com website: What is my risk of becoming addicted if I take opioids?, available at www.babycenter.com/0_what-is-my-risk-of-becoming-addicted-if-i-take-opioids_20004430.bc	JAN-TREX-00056515	JAN-TREX-00056520							
JA-03607	06/01/2018	Babycenter.com website: How can I minimize my risk of addiction when I'm taking opioids?, available at www.babycenter.xom/0_how-can-i-minimize-my-risk-of-addiction-when-im-taking-opioi_20004432.bc	JAN-TREX-00056521	JAN-TREX-00056526							
JA-03608	04/24/2019	Babycenter.com website: What are the signs that someone is becoming addicted to opioids?, available at www.babycenter.com/0_what-are-the-signs-that-someone-is-becoming-addicted-to-opio_20004428.bc	JAN-TREX-00056527	JAN-TREX-00056533							
JA-03609	09/01/2018	FDA Education Blueprint for Health Care Providers Involved in the Treatment and Monitoring of Patients with Pain, September 2018	JAN-TREX-00056534	JAN-TREX-00056546							
JA-03610	09/18/2018	FDA website: Approved Risk Evaluation and Mitigation Strategies (REMS). Opioid Analgesic REMS, available at www.accessdata.fda.gov/scripts/cder/remis/index.cfm?event=RemsDetails.page&REMS=17	JAN-TREX-00056547	JAN-TREX-00056583							
JA-03611	06/01/2012	Janssen Report: DURAGESIC (Fentanyl Transdermal System): Twelfth Risk Management Plan Progress Report	JAN-TREX-00056584	JAN-TREX-00057446							
JA-03612	03/18/2016	Morbidity and Mortality Weekly Report: CDC Guideline for Prescribing Opioids for Chronic Pain - Untied States, 2016, Recommendations and Reports, Vol. 65/No. 1	JAN-TREX-00057447	JAN-TREX-00057498							
JA-03613	08/01/2011	Bruce Moskowitz et al., Analgesic treatment for moderate-to-severe acute pain in the United STates: Patients' perspectives in the Physicians Partnering Against Pain (P3) Survey, Journal of Opiod Management 7.4/ July-August 2011	JAN-TREX-00057499	JAN-TREX-00057508							
JA-03614	07/01/2007	Michael Fleming et al., re Substance Use Disorders in a Primary Care Sample Receiving Daily Opioid Therapy, The Journal of Pain, Vol. 8, No. 7 (July) 2007 pp 573-582	JAN-TREX-00057509	JAN-TREX-00057518							
JA-03615	07/01/1905	Caleb Banta-green et al., Opioid use behaviors, mental health and pain - Development of a typology of chronic pain patients, Drug and Alcohol Dependence 104 (2009) 34-42	JAN-TREX-00057519	JAN-TREX-00057527							
JA-03616	07/02/1905	Joseph A. Boscarino et al., Risk factors for drug dependence among out-patients on opioid therapy in a large US health-care system, Addiction Research Report, Vol. 105, pp 1775-1782	JAN-TREX-00057528	JAN-TREX-00057535							
JA-03617	06/30/1905	David A. Fishbain, MD, FAPA et al., What Percentage of Chronic Nonmalignant Pain Patients Exposed to Chronic Opioid Analgesic Therapy Develop Abuse/Addiction and/or Aberrant Drug-Related Behaviors" a Structured Evidence-Based Review, Pain Medicine Vol. 9, No. 4, 2008	JAN-TREX-00057536	JAN-TREX-00057551							
JA-03618	07/02/1905	Long-term opioid management for chronic noncancer pain (Review), Cochrane Database of Systematic reviews, 2010, Issue 1, Art. No. CD006605	JAN-TREX-00057552	JAN-TREX-00057621							
JA-03619	12/12/2018	ScienceDirect website: Hydrocodone - an overview, Science Direct Topics available at www.sciencedirect.com/topics/medicine-and-dentistry/hydrocodone	JAN-TREX-00057622	JAN-TREX-00057627							
JA-03620	09/01/2018	Product information sheet for Duragesic	JAN-TREX-00057628	JAN-TREX-00057687							
JA-03621	01/09/2019	Table of Selected Studies, Research and Analysis of Safety and Efficacy of Duragesic and Nucynta	JAN-TREX-00057688	JAN-TREX-00057715							
JA-03622	07/01/1905	Finding Relief, Pain Management for -Older Adults, Conrad & Associates, LLC	JAN-TREX-00057716	JAN-TREX-00057736							
JA-03623	No Date	Table of References for Let's Talk Pain	JAN-TREX-00149919	JAN-TREX-00149919							
JA-03624	07/02/1905	Robert Buynak, et al.,Efficacy and Safety of Tapentadol Extended Release for -the Management of Chronic Low Back pain: results of a prospective, randomized, double-blind, placebo- and active- controlled Phase III Study, Expert Opinion, 11(11), 2010	JAN-MS-00074460	JAN-MS-00074477							
JA-03625	04/24/2018	Plaintiffs' First Set of Interrogatories to Johnson & Johnson, Janssen Pharmaceuticals, Inc., Ortho-McNeil-Janssen Pharmaceuticals, Inc., and Janssen Pharmaceutica, Inc.	JAN-TREX-00057737	JAN-TREX-00057746							
JA-03626	05/24/2018	Defendants Johnson & Johnson, Janssen Pharmaceuticals, Inc., Ortho-McNeil-Janssen Pharmaceuticals, Inc., and Janssen Pharmaceutica, Inc.'s Responses and Objections to Plaintiffs' First Set of Interrogatories	JAN-TREX-00057747	JAN-TREX-00057837							
JA-03627	07/20/2018	Plaintiffs' Second Set of Interrogatories to Johnson & Johnson, Janssen Pharmaceuticals, Inc.Ortho-McNeil-Janssen Pharmaceuticals, Inc. and Janssen Pharmaceutica, Inc.	JAN-TREX-00057838	JAN-TREX-00057852							
JA-03628	07/21/2018	Plaintiffs' Corrected Second Set of Interrogatories to Johnson & Johnson, Janssen Pharmaceuticals, Inc., Ortho-McNeil-Janssen Pharmaceuticals, Inc., and Janssen Pharmaceutica, Inc.	JAN-TREX-00057853	JAN-TREX-00057864							
JA-03629	08/31/2018	Defendants Johnson & Johnson, Janssen Pharmaceuticals, Inc., Ortho-McNeil-Janssen Pharmaceuticals, Inc., and Janssen Pharmaceutica, Inc.'s Responses and Objections to Plaintiffs' Second Set of Interrogatories	JAN-TREX-00057865	JAN-TREX-00057918							
JA-03630	08/31/2018	Defendants Johnson & Johnson, Janssen Pharmaceuticals, Inc., Ortho-McNeil-Janssen Pharmaceuticals, Inc, and Janssen Pharmaceutica, Inc.'s Responses and Objections to Plaintiffs' Second Set of Interrogatories	JAN-TREX-00057919	JAN-TREX-00057972							
JA-03631	09/14/2018	Defendants Johnson & Johnson, Janssen Pharmaceuticals, Inc., Ortho-McNeil-Janssen Pharmaceuticals, Inc., and Janssen Pharmaceutica, Inc.'s Amended Responses and Objections to Plaintiffs' First Set of Interrogatories	JAN-TREX-00057973	JAN-TREX-00057988							
JA-03632	11/05/2018	Defendants Johnson & Johnson, Janssen Pharmaceuticals, Inc., Ortho-McNeil-Janssen Pharmaceuticals, Inc., and Janssen Pharmaceutica, Inc.'s Supplemental Responses to Plaintiffs' First Set of Interrogatories	JAN-TREX-00057989	JAN-TREX-00058011							
JA-03633	11/06/2018	Defendants Johnson & Johnson, Janssen Pharmaceuticals, Inc., Ortho-McNeil-Janssen Pharmaceuticals, Inc., and Janssen Pharmaceutica, Inc.'s Supplemental Responses to Plaintiffs' First Set of Interrogatories, No. 13	JAN-TREX-00058012	JAN-TREX-00058019							
JA-03634	12/11/2018	Plaintiffs' Third Set of Interrogatories to Johnson & Johnson, Janssen Pharmaceuticals, Inc., Ortho-McNeil-Janssen Pharmaceuticals, Inc., and Janssen Pharmaceutica, Inc.	JAN-TREX-00058020	JAN-TREX-00058028							
JA-03635	12/14/2018	Defendants Johnson & Johnson, Janssen Pharmaceuticals, Inc., Ortho-McNeil-Janssen Pharmaceuticals, Inc., and Janssen Pharmaceutica, Inc.'s Supplemental and Amended Responses to Plaintiffs' First and Second Set of Interrogatories, Nos. 13, 19, 20, 22, 24-29, & 31	JAN-TREX-00058029	JAN-TREX-00058081							
JA-03636	12/17/2018	Defendants Johnson & Johnson, Janssen Pharmaceuticals, Inc., Ortho-McNeil-Janssen Pharmaceuticals, Inc., and Janssen Pharmaceutica, Inc.'s Supplemental and Amended Responses to Plaintiffs' First and Second Set of Interrogatories, Nos. 13, 19-20, 22, 24-29 & 31	JAN-TREX-00058082	JAN-TREX-00058134							
JA-03637	01/07/2019	Defendants Johnson & Johnson and Janssen Pharmaceuticals, Inc.'s Objections and Written Responses to Certain Topics Identified in Plaintiffs' Amended Notice of Deposition Pursuant to Rule 30(B)(6)	JAN-TREX-00058135	JAN-TREX-00058200							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-03638	01/10/2019	Defendants Johnson & Johnson, Janssen Pharmaceuticals, Inc., Ortho-McNeil-Janssen Pharmaceuticals, Inc., and Janssen Pharmaceutica, Inc.'s Responses to Plaintiffs' Third Set of Interrogatories, Nos. 32-34	JAN-TREX-00058201	JAN-TREX-00058221							
JA-03639	01/18/2019	Defendants Johnson & Johnson, Janssen Pharmaceuticals, Inc., Ortho-McNeil-Janssen Pharmaceuticals, Inc., and Janssen Pharmaceutica, Inc.'s Supplemental Responses to Plaintiffs' Second Set of Interrogatories, Interrogatory No. 24	JAN-TREX-00058222	JAN-TREX-00058231							
JA-03640	03/04/2019	Defendants Johnson & Johnson, Janssen Pharmaceuticals, Inc., Ortho-McNeil-Janssen Pharmaceuticals, Inc., and Janssen Pharmaceutica, Inc Combined Second Supplemental and Amended Responses to Plaintiffs' First, Second, and Third Set of Interrogatories, Nos. 1-4, 7-9, 19, 21, 23, 25, and 28-32	JAN-TREX-00058232	JAN-TREX-00058414							
JA-03641	03/22/2019	Defendants Johnson & Johnson, Janssen Pharmaceuticals, Inc., Ortho-McNeil-Janssen Pharmaceuticals, Inc., and Janssen Pharmaceutica, Inc Combined Second Supplemental and Amended Responses to Plaintiffs' First, Second, and Third Set of Interrogatory, Nos. 5 and 33	JAN-TREX-00058415	JAN-TREX-00058431							
JA-03642	08/01/1990	Duragesic Label	JAN-TREX-00058432	JAN-TREX-00058443							
JA-03643	01/01/1991	Duragesic Label	JAN-TREX-00058444	JAN-TREX-00058455							
JA-03644	06/01/1991	Duragesic Label	JAN-TREX-00058456	JAN-TREX-00058467							
JA-03645	06/01/1991	Duragesic Label	JAN-TREX-00058468	JAN-TREX-00058479							
JA-03646	04/01/1992	Duragesic Label	JAN-TREX-00058480	JAN-TREX-00058491							
JA-03647	03/01/1993	Duragesic Label	JAN-TREX-00058492	JAN-TREX-00058504							
JA-03648	08/01/1993	Duragesic Label	JAN-TREX-00058505	JAN-TREX-00058517							
JA-03649	01/01/1994	Duragesic Label	JAN-TREX-00058518	JAN-TREX-00058530							
JA-03650	05/01/1994	Duragesic Label	JAN-TREX-00058531	JAN-TREX-00058543							
JA-03651	06/01/1994	Duragesic Label	JAN-TREX-00058544	JAN-TREX-00058556							
JA-03652	06/01/1997	Duragesic Label	JAN-TREX-00058557	JAN-TREX-00058569							
JA-03653	04/01/1998	Duragesic Label	JAN-TREX-00058570	JAN-TREX-00058573							
JA-03654	11/01/1999	Duragesic Label	JAN-TREX-00058574	JAN-TREX-00058582							
JA-03655	01/01/2000	Duragesic Label	JAN-TREX-00058583	JAN-TREX-00058585							
JA-03656	02/01/2001	Duragesic Label	JAN-TREX-00058586	JAN-TREX-00058590							
JA-03657	05/20/2003	Duragesic Label	JAN-TREX-00058591	JAN-TREX-00058619							
JA-03658	02/04/2005	Duragesic Label	JAN-TREX-00058620	JAN-TREX-00058664							
JA-03659	02/07/2008	Duragesic Label	JAN-TREX-00058665	JAN-TREX-00058713							
JA-03660	07/31/2009	Duragesic Label	JAN-TREX-00058714	JAN-TREX-00058760							
JA-03661	07/09/2012	Duragesic Label	JAN-TREX-00058761	JAN-TREX-00058804							
JA-03662	09/23/2013	Duragesic Label	JAN-TREX-00058805	JAN-TREX-00058849							
JA-03663	04/16/2014	Duragesic Label	JAN-TREX-00058850	JAN-TREX-00058896							
JA-03664	12/16/2016	Duragesic Label	JAN-TREX-00058897	JAN-TREX-00058953							
JA-03665	01/24/2018	Duragesic Label	JAN-TREX-00058954	JAN-TREX-00059010							
JA-03666	11/20/2008	Nucynta Label	JAN-TREX-00059011	JAN-TREX-00059038							
JA-03667	03/01/2009	Nucynta Label	JAN-TREX-00059039	JAN-TREX-00059065							
JA-03668	10/01/2010	Nucynta Label	JAN-TREX-00059066	JAN-TREX-00059092							
JA-03669	07/01/2013	Nucynta Label	JAN-TREX-00059093	JAN-TREX-00059121							
JA-03670	10/01/2013	Nucynta Label	JAN-TREX-00059122	JAN-TREX-00059150							
JA-03671	12/01/2016	Nucynta Label	JAN-TREX-00059151	JAN-TREX-00059184							
JA-03672	10/01/2012	Nucynta Label	JAN-TREX-00059185	JAN-TREX-00059216							
JA-03673	11/01/2014	Nucynta Label	JAN-TREX-00059217	JAN-TREX-00059255							
JA-03674	12/01/2016	Nucynta Label	JAN-TREX-00059256	JAN-TREX-00059295							
JA-03675	08/01/2011	Nucynta ER Label	JAN-TREX-00059296	JAN-TREX-00059335							
JA-03676	07/01/2012	Nucynta ER Label	JAN-TREX-00059336	JAN-TREX-00059371							
JA-03677	08/01/2012	Nucynta ER Label	JAN-TREX-00059372	JAN-TREX-00059409							
JA-03678	04/01/2014	Nucynta ER Label	JAN-TREX-00059410	JAN-TREX-00059445							
JA-03679	12/01/2016	Nucynta ER Label	JAN-TREX-00059446	JAN-TREX-00059479							
JA-03680	05/24/2018	Defendants Johnson & Johnson, et al., Responses And Objections To Plaintiffs' First Set Of Requests For Production of Documents	JAN-TREX-00059480	JAN-TREX-00059514							
JA-03681	04/24/2018	Plaintiffs' First Set Of Requests For Production Of Documents To Johnson & Johnson et al.	JAN-TREX-00059515	JAN-TREX-00059536							
JA-03682	08/01/2017	GAO Report, re: INTERNATIONAL MAIL SECURITY: Costs and Benefits of Using Electronic Data to Screen Mail Need to Be Assessed, GAO-17-606, August 2017	JAN-TREX-00059537	JAN-TREX-00059604							
JA-03683	12/19/2018	US House of Representatives Energy and Commerce Committee Majority Staff Report, re: Red Flags and Warning Signs Ignored: Opioid Distribution and Enforcement Concerns in West Virginia, December 19, 2018	JAN-TREX-00059605	JAN-TREX-00059929							
JA-03684	01/23/2018	US Senate Permanent Subcommittee On Investigations, Committee on Homeland Security and Governmental Affairs Staff Report, re: Combatting The Opioid Crisis: Exploiting Vulnerabilities In International Mail, Report Combatting the Opioid Crisis - Exploiting Vulnerabilities in International Mail	JAN-TREX-00059930	JAN-TREX-00060029							
JA-03685	07/01/2006	U.S. Department of Justice Office of the Inspector General Evaluation and Inspections Division Review, re: Follow-Up Review of the Drug Enforcement Administration's Efforts to Control the Diversion of Controlled Pharmaceuticals, I-2006-004, July 2006	JAN-TREX-00060030	JAN-TREX-00060124							
JA-03686	06/01/2015	GAO Report re: Prescription Drugs More DEA Information about Registrants' Controlled Substances Roles Could Improve Their Understanding and Help Ensure Access, GAO-15-471, June 2015	JAN-TREX-00060125	JAN-TREX-00060215							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-03687	05/01/2014	U.S. Department of Justice Office of the Inspector General Evaluation and Inspections Division, re: The Drug Enforcement Administration's Adjudication of Registrant Actions, I-2014-003, May 2014	JAN-TREX-00060216	JAN-TREX-00060267							
JA-03688	No Date	National Law Enforcement Issue Paper	JAN-TREX-00060268	JAN-TREX-00060305							
JA-03689	09/28/2018	Office of Inspector General, United States Postal Service Audit Report: Use of Postal Service Network to Facilitate Illicit Drug Distribution, Report Number SAT-AR-18-002, September 28, 2018	JAN-TREX-00060306	JAN-TREX-00060344							
JA-03690	01/01/2003	Memorandum from Glen A. Fine to Asa Hutchinson	JAN-TREX-00060345	JAN-TREX-00060383							
JA-03691	08/01/2011	GAO Report re: Prescription Drug Control DEA Has Enhanced Efforts to Combat Diversion, but Could Better Assess and Report Program Results, GAO-11-744, August 2011	JAN-TREX-00060384	JAN-TREX-00060438							
JA-03692	05/13/2019	FDA Website: Timeline of Selected FDA Activities and Significant Events Addressing Opioid Misuse and Abuse, available at https://www.fda.gov/drugs/information-drug-class/timeline-selected-fda-activities-and-significant-events-addressing-opioid-misuse-and-abuse	JAN-TREX-00060439	JAN-TREX-00060451							
JA-03693	12/01/2014	Brooks MJ, et al., Mitigating the Safety Risks of Drugs With a Focus on Opioids: Are Risk Evaluation and Mitigation Strategies the Answer?, Mayo Clin Proc.; 89(12), pp. 1673-1684, December 2014	JAN-TREX-00060452	JAN-TREX-00060463							
JA-03694	04/01/2015	FDA Center for Drug Evaluation and Research (CDER) Guidance for Industry, re: Abuse-Deterrent Opioids-Evaluation and Labeling, April 2015	JAN-TREX-00060464	JAN-TREX-00060492							
JA-03695	06/08/2017	FDA Press Release, re: FDA requests removal of Opana ER for risks related to abuse, June 8, 2017	JAN-TREX-00060493	JAN-TREX-00060495							
JA-03696	11/01/2017	President's Commission on Combating Drug Addiction and the Opioid Crisis, re: Recommendations to Combat the Addiction Crisis, November 1, 2017	JAN-TREX-00060496	JAN-TREX-00060633							
JA-03697	11/28/2018	National Institutes of Health Almanac, National Institute on Drug Abuse (NIDA) Website: What We Do, available at https://www.nih.gov/about-nih/what-we-do/nih-almanac/national-institute-drug-abuse-nida	JAN-TREX-00060634	JAN-TREX-00060648							
JA-03698	05/01/2014	U.S. Department of Justice Office of the Inspector General Evaluation and Inspections Division Executive Summary, re: The Drug Enforcement Administration's Adjudication of Registrant Actions, I-2014-003, May 2014	JAN-TREX-00060649	JAN-TREX-00060700							
JA-03699	06/01/2015	U.S. Department of Health and Human Services, Office of Inspector General Guidance Related to Part D: Ensuring The Integrity Of Medicare Part D, OEI-03-15-00180, June 2015	JAN-TREX-00060701	JAN-TREX-00060729							
JA-03700	08/13/2019	US Department of Health and Human Services Office of Inspector General Website: Combatting the Opioid Epidemic, available at https://oig.hhs.gov/reports-and-publications/featured-topics/opioids/	JAN-TREX-00060730	JAN-TREX-00060735							
JA-03701	10/21/2015	The White House, Office of the Press Secretary Press Release, re: Fact Sheet: Obama Administration Announces Public and Private Sector Efforts to Address Prescription Drug Abuse and Heroin Use, October 21, 2015, available at https://obamawhitehouse.archives.gov/the-press-office/2015/10/21/fact-sheet-obama-administration-announces-public-and-private-sector	JAN-TREX-00060736	JAN-TREX-00060746							
JA-03702	07/03/1905	Executive Office of the President of the United States Report: Epidemic: Responding to America's Prescription Drug Abuse Crisis 2011	JAN-TREX-00060747	JAN-TREX-00060757							
JA-03703	09/01/2011	Email from Yolanda Mauriz to James Arico et al,	JAN-MS-00936536	JAN-MS-00936537							
JA-03704	07/01/2008	NEO Pathways Flashcards Set	JAN-MS-03779104	JAN-MS-03779119							
JA-03705	10/15/2019	CRC Submission for NEO Pathways website	JAN-MS-03920634	JAN-MS-03920872							
JA-03706	10/15/2019	CRC Submission for NEO Pathways website	JAN-MS-03970872	JAN-MS-03971110							
JA-03707	09/01/2010	Substance Abuse and Mental Health Services Administration re: Results from the 2009 National Survey on Drug Use and Health: Volume I. Summary of National Findings, NSDUH Series H-38A, HHS Publication, No. SMA 10-4586, 2010	JAN-TREX-00060758	JAN-TREX-00060861							
JA-03708	01/08/2013	Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality, re: The NSDUH Report: State Estimates of Nonmedical Use of Prescription Pain Relievers, January 8, 2013	JAN-TREX-00060862	JAN-TREX-00060866							
JA-03709	09/01/2012	Substance Abuse and Mental Health Services Administration, re: Results from the 2011 National Survey on Drug Use and Health: Summary of National Findings, NSDUH Series H-44, HHS Publication No. (SMA) 12-4713., 2012.	JAN-TREX-00060867	JAN-TREX-00061034							
JA-03710	09/04/2014	Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality, re: Results From 2013 National Survey on Drug Use and Health: Detailed Tables, Prevalence estimates, Standard Errors, P values, And Sample Sizes, September 4, 2014	JAN-TREX-00061035	JAN-TREX-00063294							
JA-03711	09/10/2015	Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality, re: Results From 2014 National Survey on Drug Use and Health: Detailed Tables: Prevalence estimates, Standard Errors, P values, And Sample Sizes, September 10, 2015	JAN-TREX-00063295	JAN-TREX-00065698							
JA-03712	09/01/2015	Lipari R, et al., Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality: The NSDUH Data Review: Risk and Protective Factors and Initiation of Substance Use: Results from the 2014 National Survey on Drug Use and Health, pp. 1-28, September 2015	JAN-TREX-00065699	JAN-TREX-00065740							
JA-03713	09/08/2016	Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality, re: Results From 2015 National Survey on Drug Use and Health: Detailed Tables: Prevalence estimates, Standard Errors, P values, And Sample Sizes, September 8, 2016	JAN-TREX-00065741	JAN-TREX-00069003							
JA-03714	09/01/2016	Hughes, A, et al., Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality: The NSDUH Data Review: Prescription Drug Use and Misuse in the United States: Results from the 2015 National Survey on Drug Use and Health, pp. 1-30, September 2016	JAN-TREX-00069004	JAN-TREX-00069075							
JA-03715	07/08/1905	SAMHSA, Center for Behavioral Health Statistics and Quality, re: 2015-2016 National Surveys on Drug use and Health Model-Based Estimated Totals (in Thousands) (50 States and the District of Columbia)	JAN-TREX-00069076	JAN-TREX-00069137							
JA-03716	09/07/2017	Substance Abuse and Mental Health Services Administration Center for Behavioral Health Statistics and Quality re: Results from the 2016 National Survey on Drug Use and Health Detailed Tables:Prevalence estimates, Standard Errors, P values, And Sample Sizes , September 7, 2017	JAN-TREX-00069138	JAN-TREX-00072026							
JA-03717	09/01/2017	Lipari, RN,, et al., Substance Abuse and Mental Health Services Administration, The NSDUH Data Review: Risk and Protective Factors and Estimates of Substance Use Initiation: Results from the 2016 National Survey on Drug Use and Health, pp. 1-22, September 2017	JAN-TREX-00072027	JAN-TREX-00072058							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-03718	07/09/1905	SAMHSA, Center for Behavioral Health Statistics and Quality, re: 2016-2017 National Surveys on Drug use and Health Model-Based Estimated Totals	JAN-TREX-00072059	JAN-TREX-00072122							
JA-03719	09/07/2018	Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality, re: Results From 2017 National Survey on Drug Use and Health: Detailed Tables: Prevalence estimates, Standard Errors, P values, And Sample Sizes, September 7, 2018	JAN-TREX-00072123	JAN-TREX-00074993							
JA-03720	06/24/1905	National Survey on Drug Use and Health Comparison of 2002-2003 and 2011-2012	JAN-TREX-00074994	JAN-TREX-00075043							
JA-03721	06/25/1905	National Survey on Drug Use and Health Comparison of 2002-2003 and 2013-2014	JAN-TREX-00075044	JAN-TREX-00075091							
JA-03722	06/24/1905	National Survey on Drug Use and Health Comparison of 2002-2004 and 2012-2014	JAN-TREX-00075092	JAN-TREX-00075409							
JA-03723	06/24/1905	National Survey on Drug Use and Health Comparison of 2002-2043 and 2010-2012	JAN-TREX-00075410	JAN-TREX-00075703							
JA-03724	06/30/1905	National Survey on Drug Use and Health Comparison of 2008-2010 and 2010-2012	JAN-TREX-00075704	JAN-TREX-00076047							
JA-03725	07/01/1905	National Survey on Drug Use and Health Comparison of 2009-2010 and 2010-2011	JAN-TREX-00076048	JAN-TREX-00076104							
JA-03726	07/02/1905	National Survey on Drug Use and Health Comparison of 2010-2011 and 2011-2012	JAN-TREX-00076105	JAN-TREX-00076162							
JA-03727	07/02/1905	National Survey on Drug Use and Health Comparison of 2010-2012 and 2012-2014	JAN-TREX-00076163	JAN-TREX-00076532							
JA-03728	06/27/1905	2005-2010 National Surveys on Drug use and Health Substance Use and Mental Disorders in Selected Metropolitan Statistical Areas Detailed Tables	JAN-TREX-00076533	JAN-TREX-00076646							
JA-03729	06/28/1905	2006 Results from the 2006 National Survey of Drug Use and Health National Findings	JAN-TREX-00076647	JAN-TREX-00076928							
JA-03730	06/29/1905	2007 Results from the National Survey of Drug Use and Health National Findings	JAN-TREX-00076929	JAN-TREX-00077234							
JA-03731	06/25/1905	In 1998, the VA adopted the Pain as the Fifth Vital Sign concept in conjunction with its launch of the Veterans' Health Administration National Pain Management Strategy to develop a system-wide approach to pain management.	JAN-MS-00919365	JAN-MS-00919372							
JA-03732	03/22/2010	In 2010, J&J provided \$50,080 for an educational grant related to pharmacologic therapy for the elderly to AGS (though \$13,230 was returned).	JAN-MS-00932659	JAN-MS-00932659							
JA-03733	08/25/2004	The DEA has partnered with PPSG to provide educational materials for healthcare providers, law enforcement, and regulators on policies related to opioid abuse and diversion	JAN-MS-04308093	JAN-MS-04308095							
JA-03734	12/01/2012	Imagine the Possibilities Pain Coalition Meeting Agenda: Totality Closeout Documentation	JAN-MS-01528023	JAN-MS-01528025							
JA-03735	08/14/2019	AAPM presentation: About the American Academy of Pain Medicine	JAN-TREX-00077235	JAN-TREX-00077236							
JA-03736	08/14/2019	AAPM presentation: AAPM is accredited by ACCME to provide continuing medical education to physicians	JAN-TREX-00077237	JAN-TREX-00077241							
JA-03737	03/21/2019	AAPM report of past Council of Past Presidents	JAN-TREX-00077242	JAN-TREX-00077243							
JA-03738	08/14/2019	AAPM report on Member Benefits	JAN-TREX-00077244	JAN-TREX-00077245							
JA-03739	08/14/2019	AAPM presentation: Pain Medicine Journal	JAN-TREX-00149714	JAN-TREX-00149714							
JA-03740	01/09/2019	PhRMA presentation: About PhRMA	JAN-TREX-00077246	JAN-TREX-00077249							
JA-03741	08/23/2019	AGS presentation: Benefits of Membership	JAN-TREX-00077250	JAN-TREX-00077256							
JA-03742	08/23/2019	AGS presentation: Who We Are	JAN-TREX-00077257	JAN-TREX-00077262							
JA-03743	08/23/2019	AGS presentation: About Us	JAN-TREX-00077263	JAN-TREX-00077268							
JA-03744	07/03/1905	APF - 2010 Annual Report	JAN-TREX-00077269	JAN-TREX-00077296							
JA-03745	08/14/2019	APS presentation: History of the American Pain Society	JAN-TREX-00077297	JAN-TREX-00077299							
JA-03746	08/14/2019	APS presentation: Membership Benefits	JAN-TREX-00077300	JAN-TREX-00077302							
JA-03747	08/23/2019	APS presentation: Overview	JAN-TREX-00077303	JAN-TREX-00077304							
JA-03748	08/14/2019	APS presentation: Strategic Plan	JAN-TREX-00077305	JAN-TREX-00077306							
JA-03749	08/23/2019	ASPMN presentation: History	JAN-TREX-00077307	JAN-TREX-00077309							
JA-03750	08/23/2019	ASPMN presentation: Journal	JAN-TREX-00077310	JAN-TREX-00077311							
JA-03751	08/23/2019	American Society for Pain Management Nursing Website: Mission Statement & Goals, available at http://www.aspmn.org/whatwedo/Pages/missionandgoals.aspx	JAN-TREX-00077312	JAN-TREX-00077314							
JA-03752	08/23/2019	Center for Practical Bioethics Website: Overview, available at https://www.practicalbioethics.org/about-us/overview.html	JAN-TREX-00077315	JAN-TREX-00077325							
JA-03753	08/23/2019	Federation of State Medical Boards Website: 100 Years of Service - FSMB Centennial Celebration - 1912 - 2012, available at http://centennial.fsmb.org/ceo-msg.html	JAN-TREX-00149715	JAN-TREX-00149715							
JA-03754	08/14/2019	Federation of State Medical Boards Website: About FSMB, available at https://www.fsmb.org/about-fsmb/	JAN-TREX-00077326	JAN-TREX-00077328							
JA-03755	08/14/2019	Federation of State Medical Boards Website: FSMB - Federation Credentials Verification Service FAQs, available at https://www.fsmb.org/fcvs/fcvs-faq/	JAN-TREX-00077329	JAN-TREX-00077334							
JA-03756	08/14/2019	Federation of State Medical Boards Website: FSMB - Membership Information, available at https://www.fsmb.org/about-fsmb/fsmb-member-medical-boards/	JAN-TREX-00077335	JAN-TREX-00077337							
JA-03757	07/11/1905	FSMB and NBME 2019 Bulletin of Information: United States Medical Licensing Examination	JAN-TREX-00077338	JAN-TREX-00077367							
JA-03758	02/01/2019	Joint Commission on the Accreditation of Healthcare Organizations - Fact Sheet	JAN-TREX-00149716	JAN-TREX-00149716							
JA-03759	07/10/1905	Joint Commission on the Accreditation of Healthcare Organizations - Over a Century of Quality and Safety, 1910 - 2018	JAN-TREX-00077368	JAN-TREX-00077428							
JA-03760	08/23/2019	IRS Website: Tax Exempt Organization Search for the National Hospice and Palliative Care Organization Inc., available https://apps.irs.gov/app/eos/displayAll.do?dispatchMethod=displ	JAN-TREX-00077429	JAN-TREX-00077431							
JA-03761	06/08/1905	Portenoy RK & Foley K , Chronic Use of Opioid Analgesics in Non-Malignant Pain: Report of 38 Cases, Elsevier Science Publishers (B.V.), 1986	JAN-TREX-00077432	JAN-TREX-00077447							
JA-03762	02/01/1990	Portenoy RK. 1990 Chronic Opioid Therapy in Nonmalignant Pain, Journal of Pain Symptom Management, Vol. 5 No. 18, (1 Suppl) S46-62, 1990	JAN-TREX-00077448	JAN-TREX-00077465							
JA-03763	08/23/2019	Pain & Policy Studies Group Website: About PPSG, available at https://web.archive.org/web/20190130031524/http://www.painpoli	JAN-TREX-00077466	JAN-TREX-00077468							
JA-03764	06/08/2012	Letter from Humayun J. Chaudhry to The Honorable Max Baucus	JAN-TREX-00077469	JAN-TREX-00077496							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-03765	10/01/2015	Vallerand AH, et al., Pain Management Strategies and Lessons from the Military: A Narrative Review, Pain Res Manag, Vol. 20 No. 5, September/October 2015	JAN-TREX-00077497	JAN-TREX-00077504							
JA-03766	08/20/2019	Smith P., Why are stimulant-related deaths spiking in the U.S. Salon Website, available at https://www.salon.com/2019/08/20/why-are-stimulant-related-deaths-spiking-in-the-u-s_partner/	JAN-TREX-00077505	JAN-TREX-00077509							
JA-03767	08/23/2019	Horwitz S, et al., The flow of fentanyl: In the mail, over the border, The Washington Post, available at https://www.washingtonpost.com/investigations/2019/08/23/fentanyl-flowed-through-us-postal-service-vehicles-crossing-southern-border/	JAN-TREX-00077510	JAN-TREX-00077524							
JA-03768	10/19/2018	Quentin W. et al., Fentanyl smuggled from China is killing thousands of Americans, Los Angeles Times, available at https://www.latimes.com/politics/la-na-pol-china-fentanyl-20181019-story.html	JAN-TREX-00077525	JAN-TREX-00077530							
JA-03769	10/17/2018	Christine Vestal, How Fentanyl Changes the Opioid Equation, Pew Charitable Trusts,	JAN-TREX-00077531	JAN-TREX-00077535							
JA-03770	06/25/1905	Allan L, et al., Transdermal Fentanyl Versus Sustained Release Morphine for Chronic Low Back Pain, V. 62, Suppl. 12003	JAN-TREX-00077536	JAN-TREX-00077537							
JA-03771	11/01/2015	Bunyak, R, et al., Long-term Safety and Efficacy of Tapentadol Extended Release Following up to 2 Years of Treatment in Patients With Moderate to Severe, Chronic Pain: Results of an Open-label Extension Trial, Clinical Therapeutics, Vol. 37, No. 11, 2015	JAN-TREX-00077538	JAN-TREX-00077556							
JA-03772	07/01/1905	Lange C., et al., Log-Term Safety of Controlled, Adjustable Doses of Tapentadol Extended Release (ER) and Oxycodone Controlled Release (CR): Results of a Randomized, Open-Label, Phase 3, 1-Year Trial in Patients with Chronic Low Back or Osteoarthritis Pain	JAN-TREX-00149717	JAN-TREX-00149717							
JA-03773	10/01/2010	American College of Rheumatology Abstract Supplement: Arthritis and Rheumatism	JAN-TREX-00077557	JAN-TREX-00078594							
JA-03774	05/31/2019	Cho DK & Hocevar, M., Deconstructing the Myth that Prescribed Opioids Have a Low Risk of Addiction, (with Handwritten Notes)	JAN-TREX-00078595	JAN-TREX-00078598							
JA-03775	12/01/2005	Exhibit 3 - Passik SD, et al., Monitoring outcomes during long-term opioid therapy for noncancer pain: Results with the Pain Assessment and Documentation tool, Journal of Opioid Pain Management, November-December 2005; Passik SD, et al., Opioid Analgesics in the Treatment of Chronic Intractable Pain of Non-Neoplastic Origin, Author Taub; Evaluation of Long-term Efficacy and Safety of Transdermal Fentanyl in the Treatment of Chronic Noncancer Pain, Milligan, et al	JAN-TREX-00078599	JAN-TREX-00078617							
JA-03776	05/31/2019	Deposition Exhibit 15 - Collection of Articles provided by the Witness	JAN-TREX-00078618	JAN-TREX-00078678							
JA-03777	05/01/2005	Exhibit 16 - American Academy of Psychiatry and the Law: Ethics Guidelines for the Practice of Forensic Psychiatry	JAN-TREX-00078679	JAN-TREX-00078683							
JA-03778	01/01/2015	Ohio Substance Abuse Monitoring Network; Surveillance of Drug Abuse Trends in the State of Ohio; June 2014-January 2015	JAN-TREX-00078684	JAN-TREX-00078703							
JA-03779	04/29/2014	House Committee on Energy and Commerce; Examining The Growing Problems of Prescription Drug and Heroin Abuse (Prevoznik Ex. 14)	JAN-TREX-00078704	JAN-TREX-00078729							
JA-03780	04/29/2014	Statement of J. Rannazzisi re Examining the Growing Problems of Prescription Drug and Heroin Abuse, Hearing Before the Subcommittee on Oversight and Investigations Committee on Energy and Commerce House of Representatives	JAN-TREX-00078730	JAN-TREX-00078764							
JA-03781	12/01/2004	Natalie Mizik & Robert Jacobson, Are Physicians "Easy Marks"? Quantifying the Effects of Detailing and Sampling on New Prescriptions, vol. 50, No. 12, pp. 1704-15, Dec. 2004.	JAN-TREX-00078765	JAN-TREX-00078777							
JA-03782	04/29/2014	Examining the Growing Problems of Prescription Drug and Heroin Abuse Hearing Before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce House of Representatives	JAN-TREX-00078778	JAN-TREX-00078817							
JA-03783	04/29/2014	Hearing Before the Subcommittee On Oversight And Investigations of the Committee on Energy and Commerce House of Representatives, Examining the Growing Problems of Prescription Drug and Heroin Abuse, April 29, 2014	JAN-TREX-00078818	JAN-TREX-00079006							
JA-03784	06/29/1905	Mark J. Edlund, et al., Do Users of Regularly Prescribed Opioids Have Higher Rates of Substance Use Problems Than Nonusers?, Pain Medicine, Vol. 8, pp. 647-656, 2007	JAN-TREX-00079007	JAN-TREX-00079016							
JA-03785	05/23/2017	Cicero TJ, et al., Increased use of heroin as an initiating opioid of abuse, Addictive Behaviors, 74, pp. 63-65, 05/23/2017	JAN-TREX-00079017	JAN-TREX-00079020							
JA-03786	02/21/2019	Passik, SD, Pseudoaddiction revisited: a commentary on clinical and historical considerations, Pain Manage, 1(3), pp. 239-248	JAN-TREX-00079021	JAN-TREX-00079030							
JA-03787	07/09/1905	Anne case and Angus Deaton, Mortality and Morbidity in the 21st Century, pp. 397- 476, 2017	JAN-TREX-00079031	JAN-TREX-00079110							
JA-03788	12/01/2004	Natalie Mizik, et al., Are Physicians "Easy Marks? Quantifying the Effects of Detailing and Sampling on New Prescriptions, Management Science, Vol. 50, No. 12, pp. 1704-1715, December 2004	JAN-TREX-00079111	JAN-TREX-00079123							
JA-03789	07/09/1905	Anne Case, et al., Mortality and Morbidity in the 21st Century, Brookings Papers on Economic Activity, Spring Volume, pp. 397-476, 2017	JAN-TREX-00079124	JAN-TREX-00079203							
JA-03790	01/27/2005	Berndt, Ernst R. PhD, To Inform or Persuade? Direct-to-Consumer Advertising of prescription Drugs, N. Eng. J. Med., vol. 352, No. 4, pp. 325-28, Jan. 27, 2005.	JAN-TREX-00079204	JAN-TREX-00079208							
JA-03791	03/17/2017	Case Anne and Deaton Angus, Mortality and morbidity in the 21st century, Brookings Papers on Economic Activity, Conference Version, March 17, 2017.	JAN-TREX-00079209	JAN-TREX-00079268							
JA-03792	05/10/2010	Rigg, Khary, Prescription Drug Abuse & Diversion: Role of the Pain Clinic, Journal of Drug Issues 2010	JAN-TREX-00079269	JAN-TREX-00079289							
JA-03793	04/01/2015	Vowles, Kevin, Rates of Opioid Misuse, Abuse, and Addiction in Chronic Pain: A Systemic Review and Data Synthesis, International Association for the Study of Pain, Vol. 156 No. 4, April 2015	JAN-TREX-00079290	JAN-TREX-00079297							
JA-03794	10/14/2016	Opioid history: From 'wonder drug' to abuse epidemic, CNN	JAN-TREX-00079298	JAN-TREX-00079305							
JA-03795	05/28/2014	Cicero, Theodore, PhD, et. al.; The Changing Face of Heroin Use in the United States A Retrospective Analysis of the Past 50 Years; JAMA Psychiatry; Volume 71(7); Pages 821-826; 2014	JAN-TREX-00079306	JAN-TREX-00079311							
JA-03796	07/09/1905	Stumbo, SP, et al., Patient-reported pathways to opioid use disorders and pain-related barriers to treatment engagement, Journal of Substance Abuse Treatment, Vol 73, pp. 47-54, 2017	JAN-TREX-00079312	JAN-TREX-00079319							
JA-03797	01/28/2011	Khary K. Rigg, et. al., Prescription Drug Abuse & Diversion: Role of the Pain Clinic, NIH, J. Drug Issues 2010; 40(3): pp. 681-702, 2010	JAN-TREX-00079320	JAN-TREX-00079333							
JA-03798	02/09/2001	The Ohio Substance Abuse Monitoring Network: SURVEILLANCE OF DRUG ABUSE TRENDS IN THE STATE OF OHIO June 2000 - January 2001	JAN-TREX-00079334	JAN-TREX-00079463							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-03799	01/31/2003	The Ohio Substance Abuse Monitoring Network: SURVEILLANCE OF DRUG ABUSE TRENDS IN THE STATE OF OHIO June 2002 - January 2003	JAN-TREX-00079464	JAN-TREX-00079585							
JA-03800	06/04/2004	The Ohio Substance Abuse Monitoring Network: SURVEILLANCE OF DRUG ABUSE TRENDS IN THE STATE OF OHIO January 2004 - June 2004	JAN-TREX-00079586	JAN-TREX-00079667							
JA-03801	04/17/2014	OSAM REPORT: SURVEILLANCE OF DRUG ABUSE TRENDS IN THE CLEVELAND REGION June 2010 - January 2011	JAN-TREX-00079668	JAN-TREX-00079680							
JA-03802	03/09/2016	OSAM REPORT: SURVEILLANCE OF DRUG ABUSE TRENDS IN THE STATE OF OHIO June 2011 - January 2012	JAN-TREX-00079681	JAN-TREX-00079832							
JA-03803	03/09/2016	OSAM REPORT: SURVEILLANCE OF DRUG ABUSE TRENDS IN THE STATE OF OHIO June 2012 - January 2013	JAN-TREX-00079833	JAN-TREX-00079996							
JA-03804	01/28/2016	OSAM REPORT: SURVEILLANCE OF DRUG ABUSE TRENDS IN THE STATE OF OHIO January - June 2015	JAN-TREX-00079997	JAN-TREX-00080174							
JA-03805	12/01/2017	OSAM REPORT: SURVEILLANCE OF DRUG ABUSE TRENDS IN THE STATE OF OHIO June 2016 – January 2017	JAN-TREX-00080175	JAN-TREX-00080370							
JA-03806	02/17/2017	Typewritten Notes	JAN-TREX-00080371	JAN-TREX-00080436							
JA-03807	12/15/2017	Ohio Department of Health and Human Services Substance Abuse and Mental Health Services Administration Presentation: State Targeted Response To The Opioid Crisis	JAN-TREX-00080437	JAN-TREX-00080666							
JA-03808	12/15/2017	Ohio Department of Health and Human Services Substance Abuse and Mental Health Services Administration, 2017	JAN-TREX-00080667	JAN-TREX-00080896							
JA-03809	03/18/2016	Typewritten Notes	JAN-TREX-00080897	JAN-TREX-00080949							
JA-03810	06/01/2016	Ohio Substance Abuse Monitoring Network Surveillance of Drug Abuse Trends in the State of Ohio; January - June 2016	JAN-TREX-00080950	JAN-TREX-00081141							
JA-03811	06/01/2015	Ohio Substance Abuse Monitoring Network Drug Abuse Trends in the Athens Region ; January - June 2015	JAN-TREX-00081142	JAN-TREX-00081159							
JA-03812	01/01/2015	Ohio Substance Abuse Monitoring Network: Surveillance of Drug Abuse Trends in the State of Ohio; January - June 2015	JAN-TREX-00081160	JAN-TREX-00081337							
JA-03813	01/01/2015	Ohio Substance Abuse Monitoring Network: Surveillance of Drug Abuse Trends in the State of Ohio; January - June 2015	JAN-TREX-00081338	JAN-TREX-00081512							
JA-03814	03/18/2016	CDC Trip Report: Undetermined Risk Factors for Fentanyl-Related Overdose Deaths - Ohio, 2015; 2015; State of Ohio	JAN-TREX-00081513	JAN-TREX-00081565							
JA-03815	01/01/2012	Ohio Substance Abuse Monitoring Network Report: Surveillance of Drug Abuse Trends in the State of Ohio; June 2011 - January 2012	JAN-TREX-00081566	JAN-TREX-00081717							
JA-03816	09/25/2015	Ohio Department of Public Safety, re: Daily Briefing, Bulletin 2015-254, 25 September 2015	JAN-TREX-00081718	JAN-TREX-00081727							
JA-03817	05/22/2015	Case Western Reserve University Presentation: Summit County County Children Services: Citizens Advisory Committee The Opiate & Heroin Epidemic: Ohio's New Criminal	JAN-TREX-00081728	JAN-TREX-00081768							
JA-03818	03/22/2016	Cuyahoga County Medical Examiner's Office Presentation: Heroin & Fentanyl Related Deaths in Cuyahoga County	JAN-TREX-00081769	JAN-TREX-00081793							
JA-03819	05/01/2012	Office of the Ohio Attorney General Criminal Intelligence Unit Heroin Report, May 2012	JAN-TREX-00081794	JAN-TREX-00081816							
JA-03820	01/01/2011	Ohio Substance Abuse Monitoring Network Report; June 2010 - January 2011; State of Ohio	JAN-TREX-00081817	JAN-TREX-00081922							
JA-03821	07/08/1905	Epidemic Intelligence Service Presentation: Undetermined risk factors for fentanyl-related overdose deaths — Ohio, 2015 (EpiAid 2016-003) Trip Report	JAN-TREX-00081923	JAN-TREX-00081975							
JA-03822	07/09/1905	Ohio Department of Mental Health and Addiction Services Office of Quality, Planning, and Research Ohio Substance Abuse Monitoring Network Surveillance of Drug Abuse Trends Report; June 2016-January 2017, State of Ohio	JAN-TREX-00081976	JAN-TREX-00082171							
JA-03823	10/25/2017	House Committee on Energy and Commerce; Federal Efforts to Combat the Opioid Crisis: A Status Update on CARA and Other Initiatives	JAN-TREX-00082172	JAN-TREX-00082473							
JA-03824	05/25/2017	Written Record from United States Senate, Committee on Homeland Security and Governmental Affairs, Permanent Subcommittee on Investigations, Hearing entitled "Stopping the Shipment of Synthetic Opioids: Oversight of U. S. Strategy to Combat Illicit Drugs."	JAN-TREX-00082474	JAN-TREX-00082721							
JA-03825	07/00/2017	NAS Report, "Pain Management and the Opioid Epidemic: Balancing Societal and Individual Benefits and Risks of Prescription Opioid Use"	JAN-TREX-00082722	JAN-TREX-00083203							
JA-03826	05/31/2018	Increased Use of Heroin as an Initiating Opioid of Abuse: Further Considerations and Policy Implications by T. Cicero et al, Addictive Behaviors	JAN-TREX-00083204	JAN-TREX-00083208							
JA-03827	no date	Ohio State Targeted Response DRAFT Report, Ohio	JAN-TREX-00083209	JAN-TREX-00083226							
JA-03828	10/03/2011	Ohio Department of Alcohol and Drug Addiction Services, Ohio Substance Abuse Monitoring Network: Drug Abuse Trends in the Cleveland Region, January-June 2011	JAN-TREX-00083227	JAN-TREX-00083246							
JA-03829	10/29/2015	Cleveland Department of Public Health Opioid Death Report; 2010-2014; State of Ohio	JAN-TREX-00083247	JAN-TREX-00083263							
JA-03830	06/19/2017	HIDI: Heroin Involved Death Investigations report; 06/19/2017; State of Ohio	JAN-TREX-00083264	JAN-TREX-00083304							
JA-03831	03/04/2015	Services Agreement between The Cleveland Municipal Court and Moore Counseling and Mediation Services, Inc	JAN-TREX-00083305	JAN-TREX-00083351							
JA-03832	01/01/2016	Cuyahoga County Medical Examiner's Office Presentation; Cuyahoga County Overdose Deaths 2006 - 2015	JAN-TREX-00083352	JAN-TREX-00083362							
JA-03833	07/07/1905	National Center for Injury Prevention and Control and Centers for Disease Control and Prevention Trip Report; 2015; Ohio	JAN-TREX-00083363	JAN-TREX-00083423							
JA-03834	05/07/2012	Cleveland Police, 2011 Narcotics Units Compliance Enforcement Stats	JAN-TREX-00083424	JAN-TREX-00083426							
JA-03835	01/01/2019	City of Cleveland: Law Enforcement Grant Program Package	JAN-TREX-00083427	JAN-TREX-00083444							
JA-03836	10/07/2019	National Drug Intelligence Center Presentation: National Drug Threat Assessment 2008	JAN-TREX-00083445	JAN-TREX-00083533							
JA-03837	11/13/2019	Drug Enforcement Administration Presentation: National Drug Threat Assessment Summary 2013	JAN-TREX-00083534	JAN-TREX-00083561							
JA-03838	05/27/2014	Email from Patricia Rideout to EX	JAN-TREX-00083562	JAN-TREX-00083563							
JA-03839	05/08/2018	Ohio Substance Abuse Monitoring Network, re: Surveillance of Drug Abuse Trends in the State of Ohio June 2012-January 2013	JAN-TREX-00083564	JAN-TREX-00083727							
JA-03840	08/20/2013	Cuyahoga County Medical Examiner's Office Presentation: The Cuyahoga County Heroin Epidemic	JAN-TREX-00083728	JAN-TREX-00083745							
JA-03841	11/08/2014	Thomas Gilson, M.D. Presentation: By the Numbers: The Opiate Epidemic in Cuyahoga County	JAN-TREX-00083746	JAN-TREX-00083775							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-03842	04/01/2014	Ohio Mental Health & Addiction Services Governor's Cabinet Opiate Action Team Epidemiological Report No. 3; 04/2014; Ohio	JAN-TREX-00083776	JAN-TREX-00083787							
JA-03843	10/23/2014	Alcohol, Drug Addiction, & Mental Health Services Board of Cuyahoga County Presentation: Heroin, Cocaine & Prescription Drugs—An Epidemic Among Us	JAN-TREX-00083788	JAN-TREX-00083809							
JA-03844	08/16/2012	Plain Dealer Suggested Talking Points for William M. Denihan Faces of Addiction Phone Interview	JAN-TREX-00083810	JAN-TREX-00083818							
JA-03845	07/25/2013	Cuyahoga County Opiate Task Force Meeting Minutes	JAN-TREX-00083819	JAN-TREX-00083820							
JA-03846	11/21/2013	The Heroin Epidemic in Northeast Ohio- Our Community's Action Plan	JAN-TREX-00083821	JAN-TREX-00083829							
JA-03847	03/11/2015	Cleveland Metropolitan School District Presentation: Heroin, Prescription Drugs and Alcohol - An Epidemic Among Us	JAN-TREX-00083830	JAN-TREX-00083863							
JA-03848	04/18/2014	Ohio Department of Health 2012 Ohio Overdose Deaths Report, Violence and Injury Prevention Program	JAN-TREX-00083864	JAN-TREX-00083868							
JA-03849	10/13/2016	Email from Judge Lauren C. Moore to Thomas P. Gilson	JAN-TREX-00083869	JAN-TREX-00083875							
JA-03850	07/08/1905	Ohio Department of Health, 2016 Ohio Drug Overdose Data General Findings, Fentanyl and Related Drugs Like Carfentanil as well as Cocaine Drove increase in Overdose Deaths	JAN-TREX-00083876	JAN-TREX-00083885							
JA-03851	04/17/2012	Email from R. Dissell to S. Osiecki re addiction and meeting	JAN-TREX-00083886	JAN-TREX-00083888							
JA-03852	10/01/2010	Ohio Prescription Drug Abuse Task Force: Final Report Task Force Recommendations	JAN-TREX-00083889	JAN-TREX-00083962							
JA-03853	03/25/2019	G. Caleb Alexander Supplemental Expert Report	JAN-TREX-00083963	JAN-TREX-00084077							
JA-03854	04/25/2019	Jonathan Gruber Deposition Transcript	JAN-TREX-00084078	JAN-TREX-00084574							
JA-03855	03/15/2016	CDC Morbidity and Mortality Weekly Report; 2016 March 15	JAN-TREX-00084575	JAN-TREX-00084633							
JA-03856	10/01/2016	Dowell D et al., Mandatory Provider Review And Pain Clinic Laws Reduce The Amounts Of Opioids Prescribed And Overdose Death Rates, Health Affairs, Vol. 35 (10), pp. 1876-1883	JAN-TREX-00084634	JAN-TREX-00084645							
JA-03857	10/01/2010	Unintentional Prescription Drug Poisoning Project, re: Center for Interventions, Treatment, and Addictions Research, 1 August 2010	JAN-TREX-00084646	JAN-TREX-00084721							
JA-03858	03/15/2016	CDC guideline for prescribing opioids for chronic pain - United States 2016, Centers for Disease Control	JAN-TREX-00084722	JAN-TREX-00084790							
JA-03859	06/15/2017	Ohio High Intensity Drug Trafficking Area Threat Assessment & Strategy; 2017 January 1-December 31; State of Ohio	JAN-TREX-00084791	JAN-TREX-00084862							
JA-03860	10/09/2018	Ohio Department of Health report; State of Ohio	JAN-TREX-00084863	JAN-TREX-00084931							
JA-03861	04/17/2008	Davis, W. Rees; Prescription Opioid Use, Misuse, and Diversion and Street Drug Users in New York City; National Institutes of Health; Drug, Alcohol, Depend; Pages 267-276; 2008	JAN-TREX-00084932	JAN-TREX-00084948							
JA-03862	12/06/2011	Lankenau S., et al., Initiation into Prescription Opioid Misuse among Young Injection Drug Users, Int J Drug Policy, 23(1), 37-44, 2012 January	JAN-TREX-00084949	JAN-TREX-00084965							
JA-03863	03/21/2014	Mars, Sarah et al., "Every 'Never' I Ever Said Came True" Transitions from opioid pills to heroin injecting, Int J Drug Policy, 25(2), 257-266, 03/2014	JAN-TREX-00084966	JAN-TREX-00084984							
JA-03864	05/19/2016	County of Summit, Alcohol, Drug Addiction & Mental Health Services Board, Doug Smith, Presentation:The Opiate Epidemic in Ohio	JAN-TREX-00084985	JAN-TREX-00085069							
JA-03865	10/03/2014	County of Summit, Alcohol, Drug Addiction & Mental Health Services Board, Doug Smith, Presentation:The Opiate Epidemic in Ohio	JAN-TREX-00085070	JAN-TREX-00085095							
JA-03866	10/15/2014	County of Summit, Alcohol, Drug Addiction & Mental Health Services Board, Doug Smith, Presentation:The Opiate Epidemic in Ohio	JAN-TREX-00085096	JAN-TREX-00085197							
JA-03867	01/18/2017	Ohio Substance Abuse Monitoring Network, Drug Abuse Trends in the Akron-Canton Region, page(s) 25-45	JAN-TREX-00085198	JAN-TREX-00085218							
JA-03868	07/09/1905	National Rx Drug Abuse & Heroin Summit Presentation: "Heroin" in Transition: U.S. Regional Differences and Novel Forms	JAN-TREX-00085219	JAN-TREX-00085319							
JA-03869	03/01/2012	County of Summit Alcohol, Drug Addiction & Mental Health Services Board Presentation: March [2012] Articles	JAN-TREX-00085320	JAN-TREX-00085333							
JA-03870	07/11/1905	Curriculum Vitae Dr. Charles E. Argoff	ARGOFF000984	ARGOFF001017							
JA-03871	No Date	Curriculum Vitae Dr. Steven D. Passik	JAN-MS-00618217	JAN-MS-00618231							
JA-03872	No Date	Curriculum Vitae Dr. Lynn R. Webster	WEB000001	WEB000150							
JA-03873	06/27/1905	Webster LR, Webster RM. Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the Opioid risk tool. Pain Medicine 2005;6(6):432-42.	JAN-TREX-00085334	JAN-TREX-00085344							
JA-03874	09/01/2017	Curriculum Vitae Dr. Perry G. Fine	FIN00001	FIN00081							
JA-03875	03/01/2018	Curriculum Vitae Dr. Scott M. Fishman	FISH0000001	FISH0000046							
JA-03876	06/08/1905	Portenoy RK, Foley KM: Chronic use of opioid analgesics in non-malignant pain: report of 38 cases. Pain 1986; 25:171-86.	JAN-TREX-00085345	JAN-TREX-00085360							
JA-03877	02/25/2010	Curriculum Vitae Dr. Richard Payne	JAN-MS-00402671	JAN-MS-00402708							
JA-03878	No Date	Curriculum Vitae Russell K. Portenoy, M.D.	RP-030311	RP-030432							
JA-03879	04/01/1996	"Opioids for chronic nonmalignant pain JPSM" - Portenoy RK: Opioids for chronic nonmalignant pain: a review of the critical issues. J Pain Symptom Manage 1996; 11:203-217	JAN-TREX-00085361	JAN-TREX-00085375							
JA-03880	03/30/2012	Copy Review Committee Submission for Opioid Risk Tool	JAN-MS-03763609	JAN-MS-03763615							
JA-03881	07/01/2002	PhRMA Code on Interactions with Healthcare Professionals	JAN-TREX-00085376	JAN-TREX-00085384							
JA-03882	03/01/2007	RADARS System News March/April 2007	JAN-MS-01243882	JAN-MS-01243885							
JA-03883	11/17/2006	Email from RADARS to H. Rofael	JAN-MS-01379376	JAN-MS-01379377							
JA-03884	05/01/2008	National Drug Intelligence Center Presentation: Ohio High Intensity Drug Trafficking Area Drug Market Analysis 2008	JAN-TREX-00085385	JAN-TREX-00085403							
JA-03885	04/01/2009	National Drug Intelligence Center Presentation: Ohio High Intensity Drug Trafficking Area Drug Market Analysis 2009	JAN-TREX-00085404	JAN-TREX-00085425							
JA-03886	08/14/2012	Email from Kati Chupa to Alex Gorsky	JAN-MS-00775913	JAN-MS-00775913							
JA-03887	07/12/2013	Janssen Standard Operating Procedure: JOM Customer Service Customer Master Data Process	JAN-MS-5457234	JAN-MS-5457247							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-03888	10/29/2010	PriCara label for Nucynta	JAN-MS-00236322	JAN-MS-00236322							
JA-03889	03/05/1998	Letter from Stephen W. Sherman to Jacqueline Brown	JAN-MS-00238335	JAN-MS-00238337							
JA-03890	03/20/2000	Letter from Spencer Salis to Cynthia Chianese	JAN-MS-00238338	JAN-MS-00238345							
JA-03891	09/17/2004	Letter from James Burns to Thomas Abrams	JAN-MS-00238384	JAN-MS-00238390							
JA-03892	04/22/2011	Letter from Mathilda Fienkeng to Philomena	JAN-MS-00238409	JAN-MS-00238412							
JA-03893	02/09/2001	Email from John Coleman to Dennis Fitzgerald et al	JAN-MS-00246850	JAN-MS-00246850							
JA-03894	08/01/2019	City of Cleveland Division of Police Bureau of Special Services Chart of HIDI Response Stats Non-Fatal and Fatal Heroin Overdoses	CLEVE_004293892	CLEVE_004293892							
JA-03895	05/02/2018	State of Ohio Board of Pharmacy Summary Suspension	BOP_MDL 1st Production_000115	BOP_MDL 1st Production_000119							
JA-03896	11/02/1998	Ohio State Board of Pharmacy Order	BOP_MDL 1st Production_000843	BOP_MDL 1st Production_000856							
JA-03897	06/14/2000	Ohio State Board of Pharmacy Order	BOP_MDL 1st Production_001228	BOP_MDL 1st Production_001233							
JA-03898	11/02/2010	Ohio State Board of Pharmacy Order	BOP_MDL 1st Production_001250	BOP_MDL 1st Production_001257							
JA-03899	11/04/2009	Ohio State Board of Pharmacy Order	BOP_MDL 1st Production_001877	BOP_MDL 1st Production_001899							
JA-03900	03/07/2007	Ohio State Board of Pharmacy Order	BOP_MDL 1st Production_001914	BOP_MDL 1st Production_001928							
JA-03901	01/13/1998	Ohio State Board of Pharmacy Order	BOP_MDL 1st Production_002391	BOP_MDL 1st Production_002400							
JA-03902	01/07/2003	Ohio State Board of Pharmacy Order	BOP_MDL 1st Production_002682	BOP_MDL 1st Production_002694							
JA-03903	04/06/1999	Ohio State Board of Pharmacy Order	BOP_MDL 1st Production_004897	BOP_MDL 1st Production_004909							
JA-03904	08/23/1989	Ohio State Board of Pharmacy Order	BOP_MDL 1st Production_007921	BOP_MDL 1st Production_007925							
JA-03905	10/07/1997	Ohio State Board of Pharmacy Order	BOP_MDL 1st Production_008888	BOP_MDL 1st Production_008896							
JA-03906	01/12/1997	Ohio State Board of Pharmacy Order	BOP_MDL 1st Production_008929	BOP_MDL 1st Production_008938							
JA-03907	10/20/2014	Akron Doctor Pleads Guilty to Illegally Prescribing Painkillers, Department of Justice U.S. Attorney's Office Northern District of Ohio	JAN-TREX-00085426	JAN-TREX-00085427							
JA-03908	02/13/2015	Akron Doctor Sentenced To 10 Years In Prison For Illegally Prescribing Painkillers , Even After Patients Died, Department of Justice U.S. Attorney's Office Northern District of Ohio	JAN-TREX-00085428	JAN-TREX-00085429							
JA-03909	09/28/1994	Order of the Ohio State Board of Pharmacy, State Board of Pharmacy v. Charles M. Hanifin	JAN-TREX-00085430	JAN-TREX-00085433							
JA-03910	09/19/2002	Order of the Ohio State Board of Pharmacy, In the Matter of Charles R. Wilson	JAN-TREX-00085434	JAN-TREX-00085464							
JA-03911	01/09/2001	Order of the Ohio State Board of Pharmacy, In the Matter of Dennis L. Carey	JAN-TREX-00085465	JAN-TREX-00085469							
JA-03912	09/07/2000	Order of the Ohio State Board of Pharmacy, In the Matter of Derek Edward Duckworth	JAN-TREX-00085470	JAN-TREX-00085481							
JA-03913	12/09/2010	Order of the Ohio State Board of Pharmacy, In the Matter of Henry F. Kozik	JAN-TREX-00085482	JAN-TREX-00085486							
JA-03914	12/08/1994	Order of the Ohio State Board of Pharmacy, In the Matter of John Joseph Perry	JAN-TREX-00085487	JAN-TREX-00085496							
JA-03915	03/06/1996	Order of the Ohio State Board of Pharmacy, In the Matter of Joseph Claire Salmen	JAN-TREX-00085497	JAN-TREX-00085501							
JA-03916	03/07/2007	Ohio State Board of Pharmacy Order, In the Matter of Michael J. Esber	JAN-TREX-00085502	JAN-TREX-00085506							
JA-03917	06/29/1989	Ohio State Board of Pharmacy Order, In the Matter of Stephen Deitsch	JAN-TREX-00085507	JAN-TREX-00085511							
JA-03918	06/14/2000	Ohio State Board of Pharmacy Order, In the Matter of Thomas William Foti	JAN-TREX-00085512	JAN-TREX-00085517							
JA-03919	01/13/1998	Ohio State Board of Pharmacy Order, In the Matter of William C. Cody	JAN-TREX-00085518	JAN-TREX-00085527							
JA-03920	04/02/1998	Settlement Agreement with the State Board of Pharmacy, Matthew Earl Fisher	JAN-TREX-00085528	JAN-TREX-00085531							
JA-03921	08/08/2005	Settlement Agreement with the State Board of Pharmacy, Right Aid Discount Pharmacies #'s 3086, 3088, 1186, 1659, 2304 (c/o Karen Mankoski)	JAN-TREX-00085532	JAN-TREX-00085536							
JA-03922	01/12/1997	Settlement Agreement with the State Board of Pharmacy, Robert J. Dougherty	JAN-TREX-00085537	JAN-TREX-00085541							
JA-03923	09/07/1999	Settlement Agreement with the State Board of Pharmacy, Todd R. Jaros	JAN-TREX-00085542	JAN-TREX-00085545							
JA-03924	01/01/2019	Stratfor presentation: Mexico Cartels Forecast 2019	JAN-TREX-00085546	JAN-TREX-00085552							
JA-03925	04/09/2019	National Drug Intelligence Center Presentation: National Prescription Drug Threat Assessment 2009	JAN-TREX-00085553	JAN-TREX-00085627							
JA-03926	02/10/2019	National Drug Intelligence Center Presentation: National Drug Threat Assessment 2010	JAN-TREX-00085628	JAN-TREX-00085711							
JA-03927	11/03/2009	Order of the Ohio State Board of Pharmacy, In the Matter of Justin Allan Bracken	JAN-TREX-00085712	JAN-TREX-00085723							
JA-03928	09/12/2011	Ohio State Board of Pharmacy Order, In the Matter of Nick Prentice Poore (intern)	JAN-TREX-00085724	JAN-TREX-00085732							
JA-03929	12/05/2011	Settlement Agreement with the State Board of Pharmacy, Giant Eagle #4098 (c/o Kelly Ann Chappell)	JAN-TREX-00085733	JAN-TREX-00085736							
JA-03930	09/01/2019	AMA: National Roadmap on State-Level Efforts to End the Opioid Epidemic	JAN-TREX-00149939	JAN-TREX-00149968							
JA-03931	No Date	A Plan for Attacking Ohio's Opiate Epidemic: A Call to Action	JAN-TREX-00149969	JAN-TREX-00149972							
JA-03932	08/14/2019	AAPM presentation: About the American Academy of Pain Medicine	JAN-TREX-00085737	JAN-TREX-00085738							
JA-03933	08/14/2019	AAPM presentation: Accreditation	JAN-TREX-00085739	JAN-TREX-00085743							
JA-03934	03/21/2019	AAPM presentation: AAPM Council of Past Presidents	JAN-TREX-00085744	JAN-TREX-00085745							
JA-03935	08/14/2019	AAPM presentation: Member Benefits	JAN-TREX-00085746	JAN-TREX-00085747							
JA-03936	08/14/2019	AAPM presentation: Pain Medicine Journal	JAN-TREX-00149718	JAN-TREX-00149718							
JA-03937	01/09/2019	PhRMA presentation: About PhRMA	JAN-TREX-00085748	JAN-TREX-00085751							
JA-03938	08/23/2019	AGS presentation: americangeriatrics.org/membership/benefits/other-healthcare-professional	JAN-TREX-00085752	JAN-TREX-00085758							
JA-03939	08/23/2019	AGS presentation: Who We Are	JAN-TREX-00085759	JAN-TREX-00085764							
JA-03940	08/23/2019	AGS presentation: About Us	JAN-TREX-00085765	JAN-TREX-00085770							
JA-03941	01/15/2011	APF Annual Report; 2010	JAN-TREX-00085771	JAN-TREX-00085798							
JA-03942	08/14/2019	APS presentation: History of APS	JAN-TREX-00085799	JAN-TREX-00085801							
JA-03943	08/14/2019	APS presentation: Membership Overview	JAN-TREX-00085802	JAN-TREX-00085804							
JA-03944	08/23/2019	APS presentation: About Us	JAN-TREX-00085805	JAN-TREX-00085806							
JA-03945	08/14/2019	APS presentation: Strategic Plan	JAN-TREX-00085807	JAN-TREX-00085808							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-03946	08/23/2019	ASPMN presentation: About Us	JAN-TREX-00085809	JAN-TREX-00085811							
JA-03947	08/23/2019	Pain Management Nursing presentation: Home Page	JAN-TREX-00085812	JAN-TREX-00085813							
JA-03948	08/23/2019	ASPMN presentation: Mission and Goals	JAN-TREX-00085814	JAN-TREX-00085816							
JA-03949	08/23/2019	The Center For Practical Bioethics presentation: About Us	JAN-TREX-00085817	JAN-TREX-00085827							
JA-03950	07/04/1905	FSMB presentation: Centennial Celebration 1912 - 2012	JAN-TREX-00149719	JAN-TREX-00149719							
JA-03951	08/14/2019	FSMB presentation: About the Federation of State Medical Boards	JAN-TREX-00085828	JAN-TREX-00085830							
JA-03952	08/14/2019	FSMB presentation: Federation Credentials Verification Service FAQ	JAN-TREX-00085831	JAN-TREX-00085836							
JA-03953	08/14/2019	FSMB presentation: Membership Information	JAN-TREX-00085837	JAN-TREX-00085839							
JA-03954	07/11/1905	FSMB and NBME presentation: Information on the United States Medical Licensing Examination	JAN-TREX-00085840	JAN-TREX-00085869							
JA-03955	02/01/2019	The Joint Commission presentation: Fact Sheet	JAN-TREX-00149720	JAN-TREX-00149720							
JA-03956	12/01/2018	The Joint Commission presentation: Over a century of quality and safety	JAN-TREX-00085870	JAN-TREX-00085930							
JA-03957	08/23/2019	IRS report on Tax Exempt organization: National Hospice And Palliative Care Organization Incorporated	JAN-TREX-00085931	JAN-TREX-00085933							
JA-03958	06/08/1905	Russell K. Portenoy and Kathleen M. Foley, Chronic Use of Opioid Analgesics in Non-Malignant Pain: Report of 38 Cases, Elsevier, Pain 25, pp. 171-186, 1986	JAN-TREX-00085934	JAN-TREX-00085949							
JA-03959	02/01/1990	Russell K. Portenoy, Chronic Opioid Therapy in Nonmalignant Pain, Elsevier, Volume 5 No. 1 Supplement, pp. S46-S62	JAN-TREX-00085950	JAN-TREX-00085967							
JA-03960	08/23/2019	PPSG presentation: About Pain & Policy Studies Group	JAN-TREX-00085968	JAN-TREX-00085970							
JA-03961	06/08/2012	Letter from the Federation of State Medical Boards to Senators Max Baucus and Charles Grassley	JAN-TREX-00085971	JAN-TREX-00085998							
JA-03962	10/01/2015	April H. Vallerand, Patricia Cosler, Jack Henningfield and Pam Galassini, Pain management strategies and lessons from the military: A narrative review, Pain Research and Management, Volume 20 No. 5, pp. 261-268, September/October 2015	JAN-TREX-00085999	JAN-TREX-00086006							
JA-03963	03/05/2019	Hillary Samples, Elizabeth A. Stuart and Mark Olfson, Opioid Use and Misuse and Suicidal Behaviors in a Nationally Representative Sample of US Adults, Oxford University Press, Volume 188, No. 7, pp. 1245-1253, 2019.	JAN-TREX-00086007	JAN-TREX-00086015							
JA-03964	12/19/2018	Energy and Commerce Committee, Majority Staff, report: Red Flags and Warning Signs Ignored: Opioid Distribution and Enforcement Concerns in West Virginia	JAN-TREX-00086016	JAN-TREX-00086340							
JA-03965	10/01/2002	Memorandum from Glenn A. Fine to Asa Hutchinson	JAN-TREX-00086341	JAN-TREX-00086379							
JA-03966	11/01/2004	Memorandum from the National Drug Intelligence Center to the Department of Justice	JAN-TREX-00086380	JAN-TREX-00086405							
JA-03967	02/01/2015	United States Government Accountability Office report to Congressional Requesters: Drug Shortages: Better Management of the Quota Process for Controlled Substances Needed; Coordination between DEA and FDA Should Be Improved	JAN-TREX-00086406	JAN-TREX-00086489							
JA-03968	04/18/2016	Email from John Prince to Yamilka Stivers	JAN-TREX-00086490	JAN-TREX-00086491							
JA-03969	04/01/2015	DEA report: Historical Overview of the 2005 - 2006 Fentanyl Overdose Epidemic: Will History Repeat Itself? (Part 2 of 2)	JAN-TREX-00086492	JAN-TREX-00086507							
JA-03970	05/27/2015	FBI report: Mexican Drug Trafficking Organizations Establish Direct Ties to Northern Ohio, Resulting in Increased Heroin Distribution in the Region	JAN-TREX-00086508	JAN-TREX-00086514							
JA-03971	04/01/2018	Puja Seth, Rose A. Rudd, Rita K. Noonan, Tamara M. Haegerich, Quantifying the Epidemic of Prescription Opioid Overdose Deaths, Centers for Disease Control and Prevention, Vol 108, No. 4, pp. 500-502, April 2018	JAN-TREX-00086515	JAN-TREX-00086517							
JA-03972	12/01/2003	GAO report to Congressional Requesters: Prescription Drugs: OxyContin Abuse and Diversion and Efforts to Address the Problem	JAN-TREX-00086518	JAN-TREX-00086580							
JA-03973	08/01/2004	National Drug Intelligence Center report: OxyContin Diversion, Availability, and Abuse	JAN-TREX-00086581	JAN-TREX-00086588							
JA-03974	06/25/1905	National Drug Intelligence Center report: What is OxyContin?	JAN-TREX-00086589	JAN-TREX-00086590							
JA-03975	01/01/2001	National Drug Intelligence Center report: OxyContin Diversion and Abuse	JAN-TREX-00086591	JAN-TREX-00086596							
JA-03976	04/01/2001	National Drug Intelligence Center report: Ohio: Drug Threat Assessment	JAN-TREX-00086597	JAN-TREX-00086634							
JA-03977	07/01/2002	National Drug Intelligence Center report: Ohio: Drug Threat Assessment Update	JAN-TREX-00086635	JAN-TREX-00086645							
JA-03978	06/01/2007	National Drug Intelligence Center and Ohio HIDTA report: High Intensity Drug Trafficking Area, Drug Market Analysis	JAN-TREX-00086646	JAN-TREX-00086657							
JA-03979	05/01/2008	National Drug Intelligence Center and Ohio HIDTA report: Drug Market Analysis	JAN-TREX-00086658	JAN-TREX-00086676							
JA-03980	04/01/2009	National Drug Intelligence Center and Ohio HIDTA report: Drug Market Analysis	JAN-TREX-00086677	JAN-TREX-00086698							
JA-03981	04/01/2010	National Drug Intelligence Center and Ohio HIDTA report: Drug Market Analysis 2010	JAN-TREX-00086699	JAN-TREX-00086718							
JA-03982	09/01/2011	National Drug Intelligence Center and Ohio HIDTA report: Drug Market Analysis 2011	JAN-TREX-00086719	JAN-TREX-00086746							
JA-03983	10/01/2006	National Drug Intelligence Center report: National Drug Threat Assessment 2007	JAN-TREX-00086747	JAN-TREX-00086813							
JA-03984	10/01/2007	National Drug Intelligence Center report: National Drug Threat Assessment 2008	JAN-TREX-00086814	JAN-TREX-00086902							
JA-03985	04/01/2009	National Drug Intelligence Center and DEA report: National Prescription Drug Threat Assessment 2009	JAN-TREX-00086903	JAN-TREX-00086977							
JA-03986	04/01/2009	National Drug Intelligence Center and DEA report: National Prescription Drug Threat Assessment 2009	JAN-TREX-00086978	JAN-TREX-00087052							
JA-03987	06/22/2010	National Drug Intelligence Center report: National Drug Threat Assessment 2010	JAN-TREX-00087053	JAN-TREX-00087136							
JA-03988	08/01/2011	National Drug Intelligence Center report: National Drug Threat Assessment 2011	JAN-TREX-00087137	JAN-TREX-00087208							
JA-03989	11/01/2013	DEA report: 2013 National Drug Threat Assessment Summary	JAN-TREX-00087209	JAN-TREX-00087236							
JA-03990	11/01/2014	DEA report: 2014 National Drug Threat Assessment Summary	JAN-TREX-00087237	JAN-TREX-00087298							
JA-03991	10/01/2015	DEA report: 2015 National Drug Threat Assessment Summary	JAN-TREX-00087299	JAN-TREX-00087446							
JA-03992	11/01/2016	DEA report: 2016 National Drug Threat Assessment Summary	JAN-TREX-00087447	JAN-TREX-00087640							
JA-03993	10/01/2017	DEA report: 2017 National Drug Threat Assessment Summary	JAN-TREX-00087641	JAN-TREX-00087822							
JA-03994	10/01/2018	DEA report: 2018 National Drug Threat Assessment Summary	JAN-TREX-00087823	JAN-TREX-00087986							
JA-03995	11/18/2013	DEA, DEA Announces Release Of 2013 National Drug Threat Assessment	JAN-TREX-00087987	JAN-TREX-00087989							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-03996	10/01/2000	National Drug Intelligence Center report: National Drug Threat Assessment 2001: The Domestic Perspective	JAN-TREX-00087990	JAN-TREX-00088085							
JA-03997	12/01/2001	National Drug Intelligence Center report: National Drug Threat Assessment 2002	JAN-TREX-00088086	JAN-TREX-00088205							
JA-03998	01/01/2003	National Drug Intelligence Center report: National Drug Threat Assessment 2003	JAN-TREX-00088206	JAN-TREX-00088343							
JA-03999	04/01/2004	National Drug Intelligence Center report: National Drug Threat Assessment 2004	JAN-TREX-00088344	JAN-TREX-00088521							
JA-04000	08/01/2002	National Drug Intelligence Center report: Prescription Drug Abuse and Youth	JAN-TREX-00088522	JAN-TREX-00088529							
JA-04001	02/01/2005	National Drug Intelligence Center report: National Drug Threat Assessment 2005	JAN-TREX-00088530	JAN-TREX-00088755							
JA-04002	06/05/2006	National Drug Intelligence Center report: Fentanyl: Situation Report	JAN-TREX-00088756	JAN-TREX-00088758							
JA-04003	01/01/2006	National Drug Intelligence Center report: National Drug Threat Assessment 2006	JAN-TREX-00088759	JAN-TREX-00088815							
JA-04004	03/01/2018	DEA report: NFLIS Brief: Fentanyl and Fentanyl-Related Substances Reported in NFLIS, 2015–2016	JAN-TREX-00088816	JAN-TREX-00088817							
JA-04005	05/01/2003	ODADAS report: Increases in Adderall Abuse Among High School and College-Aged Youth	JAN-TREX-00149721	JAN-TREX-00149721							
JA-04006	06/23/1905	State Medical Board of Ohio Annual Report, 2000	JAN-TREX-00088818	JAN-TREX-00088845							
JA-04007	05/28/2015	Ravenna doctor charged with illegally prescribing painkillers, Department of Justice	JAN-TREX-00149722	JAN-TREX-00149722							
JA-04008	02/28/2019	Forty-three people indicted in federal court for their roles in two separate conspiracies to sell large amounts of drugs in the Mansfield area, Department of Justice	JAN-TREX-00088846	JAN-TREX-00088848							
JA-04009	01/24/2018	USAO Press Release, re: Moreland Hills physicians indicted on charges of performing unnecessary medical tests and procedures, overbilling insurance providers and illegally distributing opioids and other drugs	JAN-TREX-00149723	JAN-TREX-00149723							
JA-04010	04/24/2014	New Jersey Doctors Sentenced To Five Years In Prison In Online Pill Mill Case, Department of Justice	JAN-TREX-00088849	JAN-TREX-00088850							
JA-04011	03/01/2018	USAO Press Release, re: Nine people indicted for ordering fentanyl and carfentanil from China and selling it in Akron and Lorain, as well as firearms and money laundering violations	JAN-TREX-00114410	JAN-TREX-00114411							
JA-04012	05/16/2019	Nine people, most from Toledo, indicted for their roles in a conspiracy to traffic large amounts of heroin, cocaine and fentanyl in Northwest Ohio, Department of Justice	JAN-TREX-00088851	JAN-TREX-00088852							
JA-04013	06/13/2017	Ohio couple charged with importing and distributing fentanyl and carfentanil, Department of Justice	JAN-TREX-00088853	JAN-TREX-00088854							
JA-04014	12/13/2018	Seven people from Northeast Ohio indicted for conspiracy to distribute carfentanil, fentanyl, heroin and cocaine, Department of Justice	JAN-TREX-00088855	JAN-TREX-00088856							
JA-04015	06/01/2008	USAO Press Release, re: Seven people indicted for conspiracy to distribute heroin, fentanyl, cocaine and crack cocaine around Youngstown and Girard, Ohio, and Farrell, Pennsylvania	JAN-TREX-00149724	JAN-TREX-00149724							
JA-04016	02/07/2019	Texas couple sentenced to prison; they were the most prolific dark net fentanyl vendor in the world at the time of their arrest last year, Department of Justice	JAN-TREX-00088857	JAN-TREX-00088859							
JA-04017	10/23/2018	Texas couple who had thousands of online sales of fentanyl and other drugs pleaded guilty to drug crimes,Department of Justice	JAN-TREX-00088860	JAN-TREX-00088861							
JA-04018	02/15/2018	USAO Press Release, re: Three from the Akron area indicted for their roles in a conspiracy in which they forged the signatures of medical professionals to obtain thousands of Oxycodone pills and other drugs	JAN-TREX-00149725	JAN-TREX-00149725							
JA-04019	04/25/2019	USAO Press Release, re: Twenty people indicted for their roles in a conspiracy to obtain large amounts of heroin, fentanyl, fentanyl analogues and sell the drugs to customers on the west side of Chicago	JAN-TREX-00114412	JAN-TREX-00114413							
JA-04020	06/18/2019	20 pounds of cocaine, fentanyl found in two Cleveland homes; 5 arrested, FOX 8 Cleveland	JAN-TREX-00088862	JAN-TREX-00088870							
JA-04021	06/27/2018	USAO Press Release, re: Twenty-five people indicted for their roles in conspiracy to traffic drugs in Elyria, including fentanyl, carfentanil, heroin, cocaine, crack cocaine and fentanyl analogues pressed to look like Percocet	JAN-TREX-00149726	JAN-TREX-00149726							
JA-04022	03/13/2019	USAO Press Release: Twenty-two people indicted for their roles in a conspiracy to traffic fentanyl, heroin, fentanyl analogues including carfentanil and other drugs, which they sold in Euclid and Cleveland to customers from across Northeast Ohio	JAN-TREX-00114414	JAN-TREX-00114415							
JA-04023	08/22/2018	Two Chinese nationals charged with operating global opioid and drug manufacturing conspiracy resulting in deaths in Akron, Department of Justice	JAN-TREX-00088871	JAN-TREX-00088874							
JA-04024	11/14/2014	Akron Doctor Charged for Illegally Distributing Prescription Painkillers, Department of Justice	JAN-TREX-00088875	JAN-TREX-00088876							
JA-04025	10/20/2014	Akron Doctor Pleads Guilty to Illegally Prescribing Painkillers, Department of Justice	JAN-TREX-00088877	JAN-TREX-00088878							
JA-04026	02/13/2015	Akron Doctor Sentenced to 10 Years In Prison For Illegally Prescribing Painkillers, Even After Patients Died, Department of Justice	JAN-TREX-00088879	JAN-TREX-00088880							
JA-04027	05/24/2018	Akron man charged with selling fentanyl that caused Wadsworth man's death, Department of Justice	JAN-TREX-00088881	JAN-TREX-00088882							
JA-04028	02/07/2019	Akron man indicted for stamping pills containing fentanyl and other drugs to look like Percocet, as well as firearms charges, Department of Justice	JAN-TREX-00088883	JAN-TREX-00088884							
JA-04029	03/16/2015	Akron physician sentenced to five years in prison for illegally distributing prescription painkillers,Department of Justice	JAN-TREX-00088885	JAN-TREX-00088886							
JA-04030	01/15/2019	California man charged after receiving a shipment of one kilogram of suspected fentanyl while staying in Cleveland, Department of Justice	JAN-TREX-00088887	JAN-TREX-00088888							
JA-04031	05/23/2019	Cleveland drug trafficker still serving time had fentanyl pills mailed to him and eluded agents after car chase, feds say, Cleveland.com	JAN-TREX-00088889	JAN-TREX-00088901							
JA-04032	07/25/2018	Elyria man indicted for trafficking fentanyl, heroin and cocaine, Department of Justice	JAN-TREX-00088902	JAN-TREX-00088903							
JA-04033	10/26/2018	Federal judge approves injunction permanently barring Akron doctor from prescribing opioids or practicing medicine, Department of Justice	JAN-TREX-00088904	JAN-TREX-00088905							
JA-04034	06/20/2019	Fifteen people indicted for their roles in a conspiracy to traffic fentanyl, heroin and crack cocaine in Lorain, Department of Justice	JAN-TREX-00088906	JAN-TREX-00088908							
JA-04035	06/24/1905	State Medical Board of Ohio Annual Report; 2002 January 1 - December 31; State of Ohio	JAN-TREX-00088909	JAN-TREX-00088949							
JA-04036	06/17/2019	Five people charged in federal court after they were arrested with nearly 20 pounds of cocaine, fentanyl and approximately \$1 million, Department of Justice	JAN-TREX-00088950	JAN-TREX-00088951							
JA-04037	03/20/2018	Former physician Richard Rydze sentenced to 10 years in prison for illegally distributing anabolic steroids, HGH, oxycodone and OxyContin, Department of Justice	JAN-TREX-00088952	JAN-TREX-00088954							
JA-04038	05/02/2017	Former Pittsburgh physician convicted of 180 counts, including conspiracy to distribute steroids, human growth hormone, oxycodone and OxyContin, Department of Justice	JAN-TREX-00088955	JAN-TREX-00088957							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-04039	03/26/2013	Former Toledo Doctor Sentenced to Five Years In Prison for Illegally Dispensing Oxycodone, Department of Justice	JAN-TREX-00088958	JAN-TREX-00088959							
JA-04040	06/25/1905	State Medical Board of Ohio Annual Report; 2003 January 1 - December 31; State of Ohio	JAN-TREX-00088960	JAN-TREX-00089001							
JA-04041	02/01/2003	Journal of American Osteopathic Association, Characteristics of physicians disciplined by the State Medical Board of Ohio, Vol. 103, No 2, pp. 81- 88	JAN-TREX-00089002	JAN-TREX-00089009							
JA-04042	04/01/2005	State Medical Board of Ohio Annual Report 2004; January 1 - December 31; State of Ohio	JAN-TREX-00089010	JAN-TREX-00089053							
JA-04043	06/23/1905	State Medical Board of Ohio Annual Report 2001; January 1 - December 31; State of Ohio	JAN-TREX-00089054	JAN-TREX-00089090							
JA-04044	06/18/1905	Thomas E. Gretter, MD, Pain Management Revisited, Your Report, Spring 1996, pp 19 - 22	JAN-TREX-00089091	JAN-TREX-00089094							
JA-04045	03/01/2004	Report of the Ohio Compassionate Care Task Force, March 2004	JAN-TREX-00089095	JAN-TREX-00089156							
JA-04046	06/19/1905	Your Report from the State Medical Board of Ohio, Spring-Summer 1997	JAN-TREX-00089157	JAN-TREX-00089176							
JA-04047	06/17/1905	Your Report from the State Medical Board of Ohio, Summer 1995	JAN-TREX-00089177	JAN-TREX-00089197							
JA-04048	07/08/1905	State Medical Board of Ohio Annual Report; 2016 January 1 - December 31; State of Ohio	JAN-TREX-00089198	JAN-TREX-00089215							
JA-04049	06/29/1905	State Medical Board of Ohio Annual Report; 2006 July 2006 - June 2007; State of Ohio	JAN-TREX-00089216	JAN-TREX-00089256							
JA-04050	06/28/1905	State Medical Board of Ohio Activity Report; 2005 January - June 2006; State of Ohio	JAN-TREX-00089257	JAN-TREX-00089295							
JA-04051	05/23/2013	State Medical Board of Ohio Formal Action Report; May 2013; State of Ohio	JAN-TREX-00089296	JAN-TREX-00089307							
JA-04052	06/19/2013	State Medical Board of Ohio Formal Action Report; June 2013; State of Ohio	JAN-TREX-00089308	JAN-TREX-00089317							
JA-04053	06/20/2019	State Medical Board of Ohio: Complaints and Investigations Key Steps, available at https://med.ohio.gov/Regulation/Complaints-and-Investigations	JAN-TREX-00089318	JAN-TREX-00089320							
JA-04054	07/24/2013	State Medical Board of Ohio Formal Action Report; July 2013; State of Ohio	JAN-TREX-00089321	JAN-TREX-00089329							
JA-04055	04/03/2013	State Medical Board of Ohio Formal Action Report; April 3, 2013; State of Ohio	JAN-TREX-00089330	JAN-TREX-00089339							
JA-04056	04/01/2013	State Medical Board of Ohio Formal Action Report; April 24, 2013; State of Ohio	JAN-TREX-00089340	JAN-TREX-00089348							
JA-04057	11/11/2018	Problem doctors went unchecked for years as the opioid crisis exploded. Here's how we found out, News 5 Cleveland	JAN-TREX-00089349	JAN-TREX-00089364							
JA-04058	10/30/2018	AG Sessions calls for state medical board 'to be more aggressive' in opioid crisis, News 5 Cleveland	JAN-TREX-00089365	JAN-TREX-00089371							
JA-04059	10/30/2018	How state regulators allowed Ohio's pill mill crisis to explode, News 5 Cleveland	JAN-TREX-00089372	JAN-TREX-00089406							
JA-04060	04/20/2011	Pill mill fight spans river, Columbus Dispatch	JAN-TREX-00089407	JAN-TREX-00089409							
JA-04061	06/23/2011	Letter from Charles Hickey to Richard Whitehouse	JAN-TREX-00089410	JAN-TREX-00089413							
JA-04062	06/01/2017	Ohio Substance Abuse Monitoring Network Presentation: Surveillance of Drug Abuse Trends in the State of Ohio	JAN-TREX-00149727	JAN-TREX-00149727							
JA-04063	02/01/2017	Ohio Substance Abuse Monitoring Network Presentation: Statewide Increases in Methamphetamine linked to Heroin	JAN-TREX-00089414	JAN-TREX-00089415							
JA-04064	07/01/2015	Ohio Board of Nursing Annual Report; July 1, 2015 - June 30, 2016; State of Ohio	JAN-TREX-00089416	JAN-TREX-00089436							
JA-04065	07/01/2010	Ohio Board of Nursing Annual Report; July 1, 2010 - June 30, 2011; State of Ohio	JAN-TREX-00089437	JAN-TREX-00089460							
JA-04066	07/01/2011	Ohio Board of Nursing Annual Report; July 1, 2011 - June 30, 2012; State of Ohio	JAN-TREX-00089461	JAN-TREX-00089481							
JA-04067	07/01/2012	Ohio Board of Nursing Annual Report; July 1, 2012 - June 30, 2013; State of Ohio	JAN-TREX-00089482	JAN-TREX-00089507							
JA-04068	07/01/2017	Ohio Board of Nursing Annual Report; July 1, 2017 - June 30, 2018; State of Ohio	JAN-TREX-00089508	JAN-TREX-00089525							
JA-04069	07/01/2013	Ohio Board of Nursing Annual Report; July 1, 2013 - June 30, 2014; State of Ohio	JAN-TREX-00089526	JAN-TREX-00089551							
JA-04070	07/01/2014	Ohio Board of Nursing Annual Report; July 1, 2014 - June 30, 2015; State of Ohio	JAN-TREX-00089552	JAN-TREX-00089578							
JA-04071	11/19/2003	Ohio Board of Nursing meeting minutes; new campaign to address the shortage of nurses in Ohio	JAN-TREX-00089579	JAN-TREX-00089626							
JA-04072	11/05/2010	The Ohio State Dental Board Annual Report; 2010 January 1 - December 31; State of Ohio	JAN-TREX-00089627	JAN-TREX-00089639							
JA-04073	09/12/2011	The Ohio State Dental Board Annual Report; 2011 January 1 - December 31; State of Ohio	JAN-TREX-00089640	JAN-TREX-00089651							
JA-04074	09/27/2012	The Ohio State Dental Board Annual Report; 2012 January 1 - December 31; State of Ohio	JAN-TREX-00089652	JAN-TREX-00089664							
JA-04075	10/05/2013	The Ohio State Dental Board Annual Report; 2013 January 1 - December 31; State of Ohio	JAN-TREX-00089665	JAN-TREX-00089674							
JA-04076	11/21/2014	The Ohio State Dental Board Annual Report; 2014 January 1 - December 31; State of Ohio	JAN-TREX-00089675	JAN-TREX-00089687							
JA-04077	08/16/2016	The Ohio State Dental Board Annual Report; FY 2015 - FY 2016; State of Ohio	JAN-TREX-00089688	JAN-TREX-00089699							
JA-04078	08/29/2017	The Ohio State Dental Board Annual Report; FY 2016 - FY 2017; State of Ohio	JAN-TREX-00089700	JAN-TREX-00089713							
JA-04079	09/28/2018	The Ohio State Dental Board Annual Report; FY 2017 - FY 2018; State of Ohio	JAN-TREX-00089714	JAN-TREX-00089726							
JA-04080	07/01/2013	State of Ohio Board of Pharmacy Annual Report; July 1, 2013 - June 30, 2014; State of Ohio	JAN-TREX-00089727	JAN-TREX-00089752							
JA-04081	07/01/2014	State of Ohio Board of Pharmacy Annual Report; July 1, 2014 - June 30, 2015; State of Ohio	JAN-TREX-00089753	JAN-TREX-00089764							
JA-04082	07/01/2015	State of Ohio Board of Pharmacy Annual Report; July 1, 2015 - June 30, 2016; State of Ohio	JAN-TREX-00089765	JAN-TREX-00089776							
JA-04083	07/01/2016	State of Ohio Board of Pharmacy Annual Report; July 1, 2016 - June 30, 2017; State of Ohio	JAN-TREX-00089777	JAN-TREX-00089788							
JA-04084	07/01/2017	State of Ohio Board of Pharmacy Annual Report; July 1, 2017 - June 30, 2018; State of Ohio	JAN-TREX-00089789	JAN-TREX-00089800							
JA-04085	06/30/1994	Ohio State Board of Pharmacy: Order of the State Board Pharmacy	JAN-TREX-00089801	JAN-TREX-00089807							
JA-04086	08/03/1999	Ohio State Board of Pharmacy: Order of the State Board Pharmacy	JAN-TREX-00089808	JAN-TREX-00089815							
JA-04087	04/21/1997	Ohio State Board of Pharmacy: Order of the State Board Pharmacy	JAN-TREX-00089816	JAN-TREX-00089827							
JA-04088	04/23/1996	Ohio State Board of Pharmacy: Order of the State Board Pharmacy	JAN-TREX-00089828	JAN-TREX-00089836							
JA-04089	11/08/2000	Order of the Board of Pharmacy	JAN-TREX-00089837	JAN-TREX-00089846							
JA-04090	06/10/2002	Order of the Board of Pharmacy	JAN-TREX-00089847	JAN-TREX-00089854							
JA-04091	07/26/1988	Order of the Board of Pharmacy	JAN-TREX-00089855	JAN-TREX-00089864							
JA-04092	09/28/1994	Order of the Board of Pharmacy	JAN-TREX-00089865	JAN-TREX-00089868							
JA-04093	09/19/2002	Order of the Board of Pharmacy	JAN-TREX-00089869	JAN-TREX-00089899							
JA-04094	09/28/1994	Order of the Board of Pharmacy	JAN-TREX-00089900	JAN-TREX-00089904							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-04095	12/09/1993	Order of the Board of Pharmacy	JAN-TREX-00089905	JAN-TREX-00089910							
JA-04096	04/12/2000	Order of the Board of Pharmacy	JAN-TREX-00089911	JAN-TREX-00089918							
JA-04097	01/11/2007	Order of the Board of Pharmacy	JAN-TREX-00089919	JAN-TREX-00090058							
JA-04098	08/09/1993	Order of the Board of Pharmacy	JAN-TREX-00090059	JAN-TREX-00090072							
JA-04099	02/14/1994	Order of the Board of Pharmacy	JAN-TREX-00090073	JAN-TREX-00090079							
JA-04100	05/05/2005	Order of the Board of Pharmacy	JAN-TREX-00090080	JAN-TREX-00090084							
JA-04101	09/10/1997	Order of the Board of Pharmacy	JAN-TREX-00090085	JAN-TREX-00090089							
JA-04102	12/17/1996	Order of the Board of Pharmacy	JAN-TREX-00090090	JAN-TREX-00090099							
JA-04103	12/01/2018	Board of Pharmacy newsletter, New Regulations for Chronic and Subacute Opioid Prescriptions	JAN-TREX-00149728	JAN-TREX-00149728							
JA-04104	01/09/2001	Order of the Board of Pharmacy	JAN-TREX-00090100	JAN-TREX-00090104							
JA-04105	09/14/2006	Order of the Board of Pharmacy	JAN-TREX-00090105	JAN-TREX-00090108							
JA-04106	09/07/2000	Order of the Board of Pharmacy	JAN-TREX-00090109	JAN-TREX-00090120							
JA-04107	10/31/1994	Order of the Board of Pharmacy	JAN-TREX-00090121	JAN-TREX-00090133							
JA-04108	03/08/2007	Order of the Board of Pharmacy	JAN-TREX-00090134	JAN-TREX-00090272							
JA-04109	03/05/1990	Order of the Board of Pharmacy	JAN-TREX-00090273	JAN-TREX-00090280							
JA-04110	01/12/1998	Order of the Board of Pharmacy	JAN-TREX-00090281	JAN-TREX-00090287							
JA-04111	10/17/1995	Order of the Board of Pharmacy	JAN-TREX-00090288	JAN-TREX-00090294							
JA-04112	03/08/2007	Order of the Board of Pharmacy	JAN-TREX-00090295	JAN-TREX-00090425							
JA-04113	04/30/1992	Order of the Board of Pharmacy	JAN-TREX-00090426	JAN-TREX-00090433							
JA-04114	03/06/2008	Order of the Board of Pharmacy	JAN-TREX-00090434	JAN-TREX-00090439							
JA-04115	06/29/1987	Order of the Board of Pharmacy	JAN-TREX-00090440	JAN-TREX-00090446							
JA-04116	08/22/1988	Order of the Board of Pharmacy	JAN-TREX-00090447	JAN-TREX-00090451							
JA-04117	05/11/2006	Order of the Board of Pharmacy	JAN-TREX-00090452	JAN-TREX-00090456							
JA-04118	11/02/2011	Order of the Board of Pharmacy	JAN-TREX-00090457	JAN-TREX-00090460							
JA-04119	03/05/2009	Order of the Board of Pharmacy	JAN-TREX-00090461	JAN-TREX-00090465							
JA-04120	01/30/1991	Order of the Board of Pharmacy	JAN-TREX-00090466	JAN-TREX-00090480							
JA-04121	12/09/2010	Order of the Board of Pharmacy	JAN-TREX-00090481	JAN-TREX-00090485							
JA-04122	07/17/2000	Order of the Board of Pharmacy	JAN-TREX-00090486	JAN-TREX-00090491							
JA-04123	07/17/2000	Order of the Board of Pharmacy	JAN-TREX-00090492	JAN-TREX-00090500							
JA-04124	12/06/1994	Order of the Board of Pharmacy	JAN-TREX-00090501	JAN-TREX-00090505							
JA-04125	07/26/1988	Order of the Board of Pharmacy	JAN-TREX-00090506	JAN-TREX-00090519							
JA-04126	12/10/2003	Order of the Board of Pharmacy	JAN-TREX-00090520	JAN-TREX-00090524							
JA-04127	07/12/2007	Order of the Board of Pharmacy	JAN-TREX-00090525	JAN-TREX-00090529							
JA-04128	12/08/1994	Order of the Board of Pharmacy	JAN-TREX-00090530	JAN-TREX-00090539							
JA-04129	01/12/2011	Order of the Board of Pharmacy	JAN-TREX-00090540	JAN-TREX-00090547							
JA-04130	07/07/1905	Ohio State Board of Pharmacy, Ohio Automated Rx Reporting System 2015 Report	JAN-TREX-00090548	JAN-TREX-00090556							
JA-04131	03/06/1996	Order of the Board of Pharmacy	JAN-TREX-00090557	JAN-TREX-00090561							
JA-04132	11/07/2000	Order of the Board of Pharmacy	JAN-TREX-00090562	JAN-TREX-00090566							
JA-04133	04/27/1995	Order of the Board of Pharmacy	JAN-TREX-00090567	JAN-TREX-00090571							
JA-04134	11/03/2009	Order of the Board of Pharmacy	JAN-TREX-00090572	JAN-TREX-00090583							
JA-04135	11/06/2009	Order of the Board of Pharmacy	JAN-TREX-00090584	JAN-TREX-00090595							
JA-04136	08/12/1997	Order of the Board of Pharmacy	JAN-TREX-00090596	JAN-TREX-00090614							
JA-04137	12/08/1994	Order of the Board of Pharmacy	JAN-TREX-00090615	JAN-TREX-00090626							
JA-04138	12/10/2001	Order of the Board of Pharmacy	JAN-TREX-00090627	JAN-TREX-00090640							
JA-04139	06/19/2000	Order of the Board of Pharmacy	JAN-TREX-00090641	JAN-TREX-00090658							
JA-04140	04/25/1995	Order of the Board of Pharmacy	JAN-TREX-00090659	JAN-TREX-00090666							
JA-04141	04/09/2003	Order of the Board of Pharmacy	JAN-TREX-00090667	JAN-TREX-00090674							
JA-04142	10/28/1993	Order of the Board of Pharmacy	JAN-TREX-00090675	JAN-TREX-00090683							
JA-04143	07/09/2015	Order of the Board of Pharmacy	JAN-TREX-00090684	JAN-TREX-00090695							
JA-04144	01/29/1988	Order of the Board of Pharmacy	JAN-TREX-00090696	JAN-TREX-00090703							
JA-04145	12/08/1995	Order of the Board of Pharmacy	JAN-TREX-00090704	JAN-TREX-00090712							
JA-04146	01/12/1998	Order of the Board of Pharmacy	JAN-TREX-00090713	JAN-TREX-00090717							
JA-04147	06/13/2000	Order of the Board of Pharmacy	JAN-TREX-00090718	JAN-TREX-00090727							
JA-04148	04/12/2007	Order of the Board of Pharmacy	JAN-TREX-00090728	JAN-TREX-00090732							
JA-04149	05/04/2000	Order of the Board of Pharmacy	JAN-TREX-00090733	JAN-TREX-00090743							
JA-04150	10/06/2000	Order of the Board of Pharmacy	JAN-TREX-00090744	JAN-TREX-00090759							
JA-04151	07/17/2000	Order of the Board of Pharmacy	JAN-TREX-00090760	JAN-TREX-00090770							
JA-04152	08/07/2000	Order of the Board of Pharmacy	JAN-TREX-00090771	JAN-TREX-00090777							
JA-04153	01/11/2002	Order of the Board of Pharmacy	JAN-TREX-00090778	JAN-TREX-00090782							
JA-04154	04/09/2003	Order of the Board of Pharmacy	JAN-TREX-00090783	JAN-TREX-00090785							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-04155	03/15/1996	Order of the Board of Pharmacy	JAN-TREX-00090786	JAN-TREX-00090818							
JA-04156	05/04/2000	Order of the Board of Pharmacy	JAN-TREX-00090819	JAN-TREX-00090828							
JA-04157	07/08/1905	Ohio Board of Pharmacy, Ohio Automated Rx Reporting System 2016 Annual Report	JAN-TREX-00090829	JAN-TREX-00090842							
JA-04158	05/13/2002	Order of the Board of Pharmacy	JAN-TREX-00090843	JAN-TREX-00090847							
JA-04159	04/14/2005	Order of the Board of Pharmacy	JAN-TREX-00090848	JAN-TREX-00090853							
JA-04160	11/10/2004	Order of the Board of Pharmacy	JAN-TREX-00090854	JAN-TREX-00090859							
JA-04161	08/23/1989	Order of the Board of Pharmacy	JAN-TREX-00090860	JAN-TREX-00090864							
JA-04162	04/08/2008	Order of the Board of Pharmacy	JAN-TREX-00090865	JAN-TREX-00091044							
JA-04163	06/14/2000	Order of the Board of Pharmacy	JAN-TREX-00091045	JAN-TREX-00091050							
JA-04164	01/13/1998	Ohio State Board Of Pharmacy, Order Of The State Board Of Pharmacy, Docket No. D-970918-006, In The Matter OF William C. Cody, R.Ph,	JAN-TREX-00091051	JAN-TREX-00091060							
JA-04165	06/12/2012	Ohio State Board Of Pharmacy, Order Of The State Board Of Pharmacy, Docket No. D-120309-241, In The Matter OF William David Hipp, R.Ph,	JAN-TREX-00091061	JAN-TREX-00091066							
JA-04166	02/27/1989	Ohio State Board Of Pharmacy, Order Of The State Board Of Pharmacy, Docket No. D-890201-094, In The Matter OF William W. Figley, R.Ph.	JAN-TREX-00091067	JAN-TREX-00091078							
JA-04167	10/26/1994	Ohio State Board Of Pharmacy, Settlement Agreement With The State Board Of Pharmacy, Docket No. D-930621-093, In The Matter OF Dale Wayne Baker, R.Ph,	JAN-TREX-00091079	JAN-TREX-00091083							
JA-04168	09/08/1997	Ohio State Board Of Pharmacy, Settlement Agreement With The State Board Of Pharmacy, Docket No. D-970423-037, In The Matter OF Henry B. Eyman, R.Ph,	JAN-TREX-00091084	JAN-TREX-00091087							
JA-04169	07/07/1998	Ohio State Board Of Pharmacy, Settlement Agreement With The State Board Of Pharmacy, Docket No. D-980210-041, In The Matter OF Jerry H. Starr, R.Ph,	JAN-TREX-00091088	JAN-TREX-00091091							
JA-04170	03/03/2003	Ohio State Board Of Pharmacy, Settlement Agreement With The State Board Of Pharmacy, Docket No. D-021119-036, In The Matter OF William Joseph Gongola, R.Ph,	JAN-TREX-00091092	JAN-TREX-00091094							
JA-04171	08/08/2005	Ohio State Board Of Pharmacy, Settlement Agreement With The State Board Of Pharmacy, Docket No. D-040518-073, D-040518-074, D-040518-076, D-040621-077 and D-041122-035, In The Matter of Rite Aid Discount Pharmacy #3086, Rite Aid #3088, Rite Aid Of Ohio, Inc. #1186, Rite Aid Discount Pharmacy #1659, Rite Aid Discount Pharmacy #2304, C/O Karen Mankowski	JAN-TREX-00091095	JAN-TREX-00091099							
JA-04172	04/03/2000	Ohio State Board Of Pharmacy, Settlement Agreement With The State Board Of Pharmacy, Docket No. D-990726-010, In The Matter OF Suellen Ogden, R.Ph.	JAN-TREX-00091100	JAN-TREX-00091129							
JA-04173	09/07/1999	Ohio State Board Of Pharmacy, Settlement Agreement With The State Board Of Pharmacy, Docket No. D-990810-013, In The Matter OF Todd R. Jaros, R.Ph.	JAN-TREX-00091130	JAN-TREX-00091133							
JA-04174	12/05/1984	Ohio State Board Of Pharmacy, The State Board Of Pharmacy vs. Henry E. Agin, R.Ph., The Matter OF Henry E. Agin, Docket No. 6-88-1	JAN-TREX-00091134	JAN-TREX-00091136							
JA-04175	12/06/2001	Ohio State Board Of Pharmacy, Summary Suspension Order/Notice Of Opportunity For Hearing Re: Alvin Dorfman, R. Ph.	JAN-TREX-00091137	JAN-TREX-00091165							
JA-04176	02/02/2004	Ohio State Board Of Pharmacy, Summary Suspension Order/Notice Of Opportunity For Hearing Re: Donald Christopher Hart, R.Ph.	JAN-TREX-00091166	JAN-TREX-00091168							
JA-04177	03/21/2012	Ohio State Board Of Pharmacy, Summary Suspension Order/Notice Of Opportunity For Hearing Re; Harold E. Fletcher	JAN-TREX-00091169	JAN-TREX-00091171							
JA-04178	09/25/1995	Ohio State Board Of Pharmacy, Summary Suspension Order Re: Peter Sung	JAN-TREX-00091172	JAN-TREX-00091192							
JA-04179	06/01/2017	State of Ohio Board Of Pharmacy, E-News Update June 2017 Edition, re: Pharmacy Technician Registration Updates	JAN-TREX-00149729	JAN-TREX-00149729							
JA-04180	01/12/2011	Pharmacist takes plea deal in pill-mill case, The Columbus Dispatch	JAN-TREX-00091193	JAN-TREX-00091196							
JA-04181	05/12/2016	DEA Report Of Theft Or Loss Of Controlled Substances: Aultman Hospital Association	JAN-TREX-00091197	JAN-TREX-00091198							
JA-04182	02/24/2016	DEA Report Of Theft Or Loss Of Controlled Substances: Cincinnati Eye Institute	JAN-TREX-00149730	JAN-TREX-00149730							
JA-04183	04/09/2015	DEA Report Of Theft Or Loss Of Controlled Substances: REM Corporation dba Johnston's Pharmacy	JAN-TREX-00091199	JAN-TREX-00091216							
JA-04184	06/12/2013	DEA Report Of Theft Or Loss Of Controlled Substances: Kmart Pharmacy	JAN-TREX-00149731	JAN-TREX-00149731							
JA-04185	01/20/2017	DEA Report Of Theft Or Loss Of Controlled Substances: Metrohealth Medical Center Unit Of The Metrohealth System	JAN-TREX-00091217	JAN-TREX-00091218							
JA-04186	08/05/2015	DEA Report Of Theft Or Loss Of Controlled Substances: Ohio Health Corporation	JAN-TREX-00091219	JAN-TREX-00091222							
JA-04187	04/21/2017	DEA Report Of Theft Or Loss Of Controlled Substances: Remedi SeniorCare of Ohio-Northeast, LLC	JAN-TREX-00149732	JAN-TREX-00149732							
JA-04188	01/01/2016	Governor's Cabinet Opiate Action Team, re: Ohio Guideline for the Management of Acute Pain Outside of Emergency Departments	JAN-TREX-00091223	JAN-TREX-00091224							
JA-04189	03/25/2014	United Stated of America v. Adolph Harper, Jr., et al., USDC for the Northern District of Ohio, Eastern Division, Case No. 5:14CR096	JAN-TREX-00091225	JAN-TREX-00091260							
JA-04190	08/08/2014	Email from Kyle Parker to BOP All	JAN-TREX-00149733	JAN-TREX-00149733							
JA-04191	09/15/2014	Letter from Tracy M. Nave to Andrew Welsh-Huggins	JAN-TREX-00091261	JAN-TREX-00091265							
JA-04192	12/10/2010	National Association Of Boards Of Pharmacy Website: State Boards of Pharmacy Take Action to Stop Licensees Involved in Unlawful Internet Drug Outlet Schemes, available at https://nabp.pharmacy/newsroom/news/state-boards-of-pharmacy-take-action-to-stop-licensees-involved-in-unlawful-internet-drug-outlet-schemes/	JAN-TREX-00091266	JAN-TREX-00091271							
JA-04193	07/09/1905	Ohio Automated RX Reporting System Annual Report: Executive Summary; 2017; State Of Ohio Board Of Pharmacy	JAN-TREX-00149734	JAN-TREX-00149734							
JA-04194	07/09/1905	Ohio Automated RX Reporting System Annual Report; 2017; State Of Ohio Board Of Pharmacy	JAN-TREX-00091272	JAN-TREX-00091284							
JA-04195	07/10/1905	Ohio Automated RX Reporting System Annual Report: Executive Summary, 2018; State Of Ohio Board Of Pharmacy	JAN-TREX-00149735	JAN-TREX-00149735							
JA-04196	07/10/1905	Ohio Automated RX Reporting System Annual Report; 2018; State Of Ohio Board Of Pharmacy	JAN-TREX-00091285	JAN-TREX-00091297							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-04197	07/06/1905	Ohio Automated RX Reporting System Biennial Report; 2013-2014; Ohio State Board of Pharmacy	JAN-TREX-00091298	JAN-TREX-00091309							
JA-04198	11/21/2011	Ohio State Board of Pharmacy Ohio Automated RX Reporting System House Bill 93 Report, re: Ohio's Dangerous Drug Database Past, Present, and Future	JAN-TREX-00091310	JAN-TREX-00091320							
JA-04199	06/01/2015	Ohio Automated RX Reporting System Semiannual Report On Opioid Prescribing In Ohio; June 2015; State Of Ohio Board Of Pharmacy	JAN-TREX-00091321	JAN-TREX-00091326							
JA-04200	01/11/2012	Ohio Bureau of Workers' Compensation, Special Investigations Department, US Attorney's Office, Southern District of Ohio Press Release re: Pharmacist Sentenced to Two Years in Prison for Illegal Distribution of Oxycodone, Structuring and Filing False Income Tax Return	JAN-TREX-00091327	JAN-TREX-00091333							
JA-04201	08/01/2004	Ohio State Board Of Pharmacy Newsletter, re: August 2004 State Board News	JAN-TREX-00091334	JAN-TREX-00091340							
JA-04202	08/01/2005	Ohio State Board Of Pharmacy Newsletter, re: August 2005 State Board News	JAN-TREX-00091341	JAN-TREX-00091346							
JA-04203	02/01/2005	Ohio State Board Of Pharmacy Newsletter, re: February 2005 State Board News	JAN-TREX-00091347	JAN-TREX-00091356							
JA-04204	10/27/2018	State Of Ohio Board Of Pharmacy Press Release: Reminder: National Prescription Drug Take Back Day	JAN-TREX-00149736	JAN-TREX-00149736							
JA-04205	08/01/2006	Ohio State Board of Pharmacy, re: Ohio State Board of Pharmacy News August 2006	JAN-TREX-00091357	JAN-TREX-00091360							
JA-04206	08/01/2014	Ohio State Board of Pharmacy, re: Ohio State Board of Pharmacy News August 2014	JAN-TREX-00091361	JAN-TREX-00091365							
JA-04207	08/01/2009	Ohio State Board of Pharmacy, re: Ohio State Board of Pharmacy News August 2009	JAN-TREX-00091366	JAN-TREX-00091369							
JA-04208	08/01/2015	State of Ohio Board of Pharmacy, re: State of Ohio Board of Pharmacy News August 2015	JAN-TREX-00091370	JAN-TREX-00091374							
JA-04209	08/01/2016	State of Ohio Board of Pharmacy, re: State of Ohio Board of Pharmacy News August 2016	JAN-TREX-00091375	JAN-TREX-00091379							
JA-04210	02/01/2015	Ohio State Board of Pharmacy, re: Ohio State Board of Pharmacy News February 2015	JAN-TREX-00091380	JAN-TREX-00091384							
JA-04211	02/01/2016	State of Ohio Board of Pharmacy, re: State of Ohio Board of Pharmacy News February 2016	JAN-TREX-00091385	JAN-TREX-00091388							
JA-04212	02/01/2017	State Of Ohio Board of Pharmacy, re: State of Ohio Board of Pharmacy News February 2017	JAN-TREX-00091389	JAN-TREX-00091393							
JA-04213	05/01/2009	Ohio State Board of Pharmacy, re: Ohio State Board of Pharmacy News May 2009	JAN-TREX-00091394	JAN-TREX-00091397							
JA-04214	05/01/2010	Ohio State Board of Pharmacy, re: Ohio State Board of Pharmacy News May 2010	JAN-TREX-00091398	JAN-TREX-00091401							
JA-04215	05/01/2011	Ohio State Board of Pharmacy, re: Ohio State Board of Pharmacy News May 2011	JAN-TREX-00091402	JAN-TREX-00091405							
JA-04216	05/01/2012	Ohio State Board of Pharmacy, re: Ohio State Board of Pharmacy News May 2012	JAN-TREX-00091406	JAN-TREX-00091410							
JA-04217	05/01/2013	Ohio State Board of Pharmacy, re: Ohio State Board of Pharmacy News May 2013	JAN-TREX-00091411	JAN-TREX-00091414							
JA-04218	05/01/2014	Ohio State Board of Pharmacy, re: Ohio State Board of Pharmacy News May 2014	JAN-TREX-00091415	JAN-TREX-00091419							
JA-04219	05/01/2017	State of Ohio Board of Pharmacy, re: State of Ohio Board of Pharmacy News May 2017	JAN-TREX-00091420	JAN-TREX-00091423							
JA-04220	05/01/2018	State of Ohio Board of Pharmacy, re:State of Ohio Board of Pharmacy News May 2018	JAN-TREX-00091424	JAN-TREX-00091428							
JA-04221	11/01/2009	Ohio State Board of Pharmacy, re: Ohio State Board of Pharmacy News November 2009	JAN-TREX-00091429	JAN-TREX-00091432							
JA-04222	11/01/2011	Ohio State Board of Pharmacy, re: Ohio State Board of Pharmacy News November 2011	JAN-TREX-00091433	JAN-TREX-00091437							
JA-04223	11/01/2012	Ohio State Board of Pharmacy, re: Ohio State Board of Pharmacy News November 2012	JAN-TREX-00091438	JAN-TREX-00091442							
JA-04224	11/01/2014	Ohio State Board of Pharmacy, re: Ohio State Board of Pharmacy News November 2014	JAN-TREX-00091443	JAN-TREX-00091446							
JA-04225	06/22/1993	Ohio State Board Of Pharmacy, Order Of The State Board Of Pharmacy, Docket No. D-921015-015, In The Matter OF Gilbert Ernest Art, Jr., R.Ph,	JAN-TREX-00091447	JAN-TREX-00091457							
JA-04226	12/01/1995	Ohio State Board Of Pharmacy, Order Of The State Board Of Pharmacy, Docket No. D-950124-033, In The Matter OF Jeffrey Scott Dannemiller, R.Ph,	JAN-TREX-00091458	JAN-TREX-00091479							
JA-04227	12/05/2001	Ohio State Board Of Pharmacy, Order Of The State Board Of Pharmacy, Docket No. D-981009-020, In The Matter OF Linden Medical Pharmacy, Inc.	JAN-TREX-00091480	JAN-TREX-00091483							
JA-04228	09/12/2011	Ohio State Board Of Pharmacy, Order Of The State Board Of Pharmacy, Docket No. D-110113-158, In The Matter OF Nick Prentice Poore, Intern	JAN-TREX-00091484	JAN-TREX-00091492							
JA-04229	05/03/2011	Ohio State Board Of Pharmacy, Order Of The State Board Of Pharmacy, Docket No. D-110118-161, In The Matter OF Ryan Michael Griffin, Intern	JAN-TREX-00091493	JAN-TREX-00091502							
JA-04230	03/03/2003	Ohio State Board Of Pharmacy, Settlement Agreement With The State Board Of Pharmacy, Docket No. D-021119-035, In The Matter OF Big Bear Pharmacy #208	JAN-TREX-00091503	JAN-TREX-00091505							
JA-04231	10/04/1999	Ohio State Board Of Pharmacy, Settlement Agreement With The State Board Of Pharmacy, Docket No. D-981208-024, In The Matter OF David Michael Sunshein, R.Ph,	JAN-TREX-00091506	JAN-TREX-00091517							
JA-04232	12/05/2011	Ohio State Board Of Pharmacy, Settlement Agreement With The State Board Of Pharmacy, Docket No. D-110714-197, In The Matter OF Giant Eagle #4098	JAN-TREX-00091518	JAN-TREX-00091521							
JA-04233	05/12/2003	Ohio State Board Of Pharmacy, Settlement Agreement With The State Board Of Pharmacy, Docket No. D-020626-065, In The Matter OF Harold Eugene Fletcher, R.Ph.	JAN-TREX-00091522	JAN-TREX-00091525							
JA-04234	02/21/2000	Ohio State Board Of Pharmacy, Settlement Agreement With The State Board Of Pharmacy, Docket No. D-990726-009, In The Matter OF Imogene Carol Maynard, R.Ph.	JAN-TREX-00091526	JAN-TREX-00091537							
JA-04235	04/06/2015	Ohio State Board Of Pharmacy, Settlement Agreement With The Ohio State Board Of Pharmacy, Case No. 2013-1218, In The Matter OF KHN Pharmacy - Huber	JAN-TREX-00091538	JAN-TREX-00091542							
JA-04236	02/09/1999	Ohio State Board Of Pharmacy, Settlement Agreement With The State Board Of Pharmacy, Docket No. D-980618-069, In The Matter OF Linda M. Mahoney, R.Ph,	JAN-TREX-00091543	JAN-TREX-00091546							
JA-04237	04/06/1998	Ohio State Board Of Pharmacy, Settlement Agreement With The State Board Of Pharmacy, Docket No. D-971210-025, In The Matter OF Matthew Earl Fisher, R.Ph,	JAN-TREX-00091547	JAN-TREX-00091550							
JA-04238	08/07/2006	Ohio State Board Of Pharmacy, Settlement Agreement With The State Board Of Pharmacy Voluntary Surrender With Disciplinary Action Pending, Docket No. D-030716-003, In The Matter OF Michael M. Fraulini, R.Ph.	JAN-TREX-00091551	JAN-TREX-00091563							
JA-04239	01/12/1997	Settlement Agreement between Ohio State Board of Pharmacy and Robert J. Dougherty	JAN-TREX-00091564	JAN-TREX-00091568							
JA-04240	11/19/1998	Settlement Agreement between Ohio State Board of Pharmacy and Steven A. Goldblatt	JAN-TREX-00091569	JAN-TREX-00091574							
JA-04241	No Date	Order in The State of Pharmacy vs. Charles A. Gilford	JAN-TREX-00091575	JAN-TREX-00091577							
JA-04242	10/03/1978	Order in The State of Pharmacy vs. Charles M. Hanifin	JAN-TREX-00091578	JAN-TREX-00091579							
JA-04243	06/28/1984	Order of the Board in The State of Pharmacy vs. Jay N. Green, R.Ph. et al.	JAN-TREX-00091580	JAN-TREX-00091586							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-04244	06/29/1905	Presentation: Prescription Drug Abuse	JAN-TREX-00091587	JAN-TREX-00091625							
JA-04245	09/27/2017	Ohio State Board of Pharmacy Press Release: Board of Pharmacy Awarded Federal Funding to Address Prescription Drug Abuse Innovative Program Will Use Data to Promote Early Intervention & Treatment	JAN-TREX-00149737	JAN-TREX-00149737							
JA-04246	04/03/2017	Ohio State Board of Pharmacy Press Release: State of Ohio Board of Pharmacy Approves Rules to Help Implement Limits on Opiate Prescriptions for Acute Pain	JAN-TREX-00149738	JAN-TREX-00149738							
JA-04247	08/31/2017	Ohio State Board of Pharmacy Press Release: Ohio's Acute Pain Prescribing Rules Effective Today	JAN-TREX-00149739	JAN-TREX-00149739							
JA-04248	09/04/2014	Ohio State Board of Pharmacy Press Release, re: The Ohio State Board of Pharmacy Awarded U.S. Department of Justice Grant to Improve Ohio's Prescription Monitoring Program	JAN-TREX-00149740	JAN-TREX-00149740							
JA-04249	05/12/2012	Omnicare pays \$50 million to settle federal case, NewsRoom	JAN-TREX-00091626	JAN-TREX-00091627							
JA-04250	02/13/2015	DOJ Press Release: Akron Doctor Sentenced To 10 Years In Prison For Illegally Prescribing Painkillers, Even After	JAN-TREX-00091628	JAN-TREX-00091629							
JA-04251	09/16/2014	Email from Eric Griffin to Peg Huwer et al.	JAN-TREX-00149741	JAN-TREX-00149741							
JA-04252	09/16/2014	Governor's office Behind pharmacy board firing, Columbus Bureau	JAN-TREX-00091630	JAN-TREX-00091631							
JA-04253	10/01/2013	Ohio Guidelines for Prescribing Opioids for the Treatment of Chronic, Non-Terminal Pain 80 mg of a Morphine Equivalent Daily Dose (MED) "Trigger Point", Ohio Governor's Cabinet, Opiate Action Team	JAN-TREX-00091632	JAN-TREX-00091633							
JA-04254	No Date	Ohio State Board of Pharmacy Press Release: Reminder: New Requirements for Reporting of Suspicious Orders and Customer Due Diligence	JAN-TREX-00149742	JAN-TREX-00149742							
JA-04255	05/12/2013	Authorities: Champion pharmacy added to area's drug problem, Youngtown News	JAN-TREX-00091634	JAN-TREX-00091639							
JA-04256	06/23/1905	State of Ohio Medical Board Press Release: A Word From the President	JAN-TREX-00091640	JAN-TREX-00091684							
JA-04257	03/11/2011	DeWine: Ohio med board must fight prescription-drug abuse harder, NewsRoom	JAN-TREX-00091685	JAN-TREX-00091686							
JA-04258	04/06/2011	Suspend Doctor, Kasich Urges, NewsRoom	JAN-TREX-00091687	JAN-TREX-00091689							
JA-04259	05/01/2012	State of Ohio Medical Board Report: Improving Patient Care Through Improving Patient Care Through Enhanced Use of OARRS	JAN-TREX-00091690	JAN-TREX-00091732							
JA-04260	10/18/2012	State medical board ousts chief, The Columbus Dispatch	JAN-TREX-00091733	JAN-TREX-00091734							
JA-04261	06/30/2014	Ohio's 2014 Opiate Conference Presentation: Don't Get Me Started	JAN-TREX-00091735	JAN-TREX-00091747							
JA-04262	10/14/1997	Ohio Legislative Service Commission Report: 122nd Final Bill Analysis	JAN-TREX-00091748	JAN-TREX-00091750							
JA-04263	04/18/2000	OSAM Network report: Statewide Increase in Heroin Use, Especially Among Younger Population	JAN-TREX-00149743	JAN-TREX-00149743							
JA-04264	06/29/2000	OSAM Network report: Surveillance of Drug Abuse Trends in The State of Ohio	JAN-TREX-00091751	JAN-TREX-00091893							
JA-04265	07/09/2000	By The Numbers, Beginning With Mexico's New No. 1, NewsRoom	JAN-TREX-00091894	JAN-TREX-00091896							
JA-04266	07/01/2002	National Drug Intelligence Center Report: Drug Threat Assessment Update	JAN-TREX-00091897	JAN-TREX-00091907							
JA-04267	07/01/2002	National Drug Intelligence Center Report: Ohio Drug Threat Assessment	JAN-TREX-00091908	JAN-TREX-00091911							
JA-04268	03/01/2004	Report: Report of the Ohio Compassionate Care Task Force	JAN-TREX-00091912	JAN-TREX-00091973							
JA-04269	05/27/2005	Police arrest 32 in NE Ohio, calling probe major drug bust, NewsRoom	JAN-TREX-00091974	JAN-TREX-00091975							
JA-04270	06/01/2007	DOJ Report: High Intensity Drug Trafficking Area Drug Market Analysis	JAN-TREX-00091976	JAN-TREX-00091987							
JA-04271	05/01/2008	DOJ, Ohio High Intensity Drug Trafficking Area Presentation: Ohio Drug Market Analysis 2008	JAN-TREX-00091988	JAN-TREX-00092006							
JA-04272	08/19/2008	Mexican gangs dominate Ohio drug trade, The Columbus Dispatch	JAN-TREX-00092007	JAN-TREX-00092012							
JA-04273	04/24/2019	Legislative Service Commission Report: Sub. H.B. 377 125th General Assembly (As Passed by the General Assembly)	JAN-TREX-00092013	JAN-TREX-00092019							
JA-04274	04/01/2009	DOJ, Ohio High Intensity Drug Trafficking Area Report: Drug Market Analysis 2009	JAN-TREX-00092020	JAN-TREX-00092041							
JA-04275	08/15/2009	Heroin high here getting cheaper, NewsRoom	JAN-TREX-00092042	JAN-TREX-00092043							
JA-04276	04/01/2010	DOJ, Ohio High Intensity Drug Trafficking Area Report: Drug Market Analysis 2010	JAN-TREX-00092044	JAN-TREX-00092063							
JA-04277	05/15/2011	DOJ, Ohio High Intensity Drug Trafficking Area Report: CY 2010 Annual Report, Ohio	JAN-TREX-00092064	JAN-TREX-00092108							
JA-04278	10/23/2010	Keep watch, NewsRoom	JAN-TREX-00092109	JAN-TREX-00092110							
JA-04279	05/20/2011	Ohio Legislative Service Commission Report: Am. Sub. H.B. 93 129th General Assembly (As Passed by the General Assembly)	JAN-TREX-00092111	JAN-TREX-00092134							
JA-04280	09/01/2011	DOJ, Ohio High Intensity Drug Trafficking Area Presentation: Drug Market Analysis 2011	JAN-TREX-00092135	JAN-TREX-00092162							
JA-04281	09/10/2012	4731.052 Diagnosis and management of chronic pain; use of controlled substances or products containing tramadol, Westlaw, Thomson Reuters	JAN-TREX-00092163	JAN-TREX-00092169							
JA-04282	12/06/2012	First Year of Operation, Local task force targets money of drug traffickers, NewsRoom	JAN-TREX-00092170	JAN-TREX-00092171							
JA-04283	08/12/2015	Kyle Soska et al., Measuring the Longitudinal Evolution of the Online Anonymous Marketplace Ecosystem, USENIX Association, 24th USENIX Security Symposium	JAN-TREX-00092172	JAN-TREX-00092188							
JA-04284	09/01/2015	OSAM Report: Much of Heroin Supply Adulterated with Fentanyl	JAN-TREX-00092189	JAN-TREX-00092190							
JA-04285	02/01/2017	U.S.-China Economic and Security Review Commission Report: Fentanyl: China's Deadly Export to the United States	JAN-TREX-00092191	JAN-TREX-00092207							
JA-04286	03/01/2017	OSAM Report: Fentanyl, and the Deadlier Carfentanil, Now Outpacing Heroin Sales in Many Areas	JAN-TREX-00092208	JAN-TREX-00092209							
JA-04287	08/22/2017	Predators and prey: Predators and prey: How business of fentanyl controls Ohio's opioid crisis, NewsRoom	JAN-TREX-00092210	JAN-TREX-00092212							
JA-04288	09/03/2017	Deadly fentanyl infiltrates USA, worsening an epidemic Synthetic, highly concentrated opioid foils authorities because it 'truly is everywhere', NewsRoom	JAN-TREX-00092213	JAN-TREX-00092215							
JA-04289	03/01/2018	OSAM Report: Increase in Fentanyl-Cut Drugs	JAN-TREX-00149744	JAN-TREX-00149744							
JA-04290	No Date	US Senate, Permanent Subcommittee on Investigations, Committe on Homeland Security and Governmental Affairs Report: Combatting the Opioid Crisis: Exploiting Vulnerabilities in International Mail	JAN-TREX-00092216	JAN-TREX-00092315							
JA-04291	01/25/2018	Testimony of Joseph Murphy, Department of State, Bureau of International Organizations International Postal Policy Unit Chief Senate Committee on Homeland Security and Governmental Affairs Permanent Subcommittee on Investigations	JAN-TREX-00092316	JAN-TREX-00092319							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-04292	05/11/2018	Mexican cartel moves into Northeast Ohio, three-year investigation sends 19 to federal prison, News 5 Cleveland	JAN-TREX-00092320	JAN-TREX-00092322							
JA-04293	02/14/2019	Congressional Research Service Report: Heroin Trafficking in the United States	JAN-TREX-00092323	JAN-TREX-00092341							
JA-04294	03/01/2019	Illegal Pill Presses: An Overlooked Threat to American Patients, National Association of Boards of Pharmacy, National Association of Drug Diversion Investigators, and The Partnership For Safe Medicines	JAN-TREX-00092342	JAN-TREX-00092374							
JA-04295	04/01/2019	China To Close Loophole On Fentanyl After U.S.Calls For Opioid Action, NPR	JAN-TREX-00092375	JAN-TREX-00092384							
JA-04296	10/01/2018	DOJ Press Release: Justice Department awards \$1.8 million to support data sharing, drug courts and other programs in Cuyahoga and Lucas County	JAN-TREX-00092385	JAN-TREX-00092387							
JA-04297	04/05/2019	DOJ Press Release: Comprehensive Opioid Abuse Site-based Program FY 2019 Competitive Grant Announcement	JAN-TREX-00092388	JAN-TREX-00092434							
JA-04298	08/20/2019	Comprehensive Opioid Abuse Program (COAP), DOJ, Bureau of Justice Assistance	JAN-TREX-00092435	JAN-TREX-00092437							
JA-04299	08/19/2010	DOJ Press Release: DEA Heads First-ever Nationwide Prescription Drug Take-back Day	JAN-TREX-00092438	JAN-TREX-00092439							
JA-04300	07/09/2011	FDA Press Release: Disposal of Unused Medicines: What You Should Know	JAN-TREX-00092440	JAN-TREX-00092442							
JA-04301	04/25/2019	FDA News Release: FDA launches public education campaign to encourage safe removal of unused opioid pain medicines from homes	JAN-TREX-00092443	JAN-TREX-00092445							
JA-04302	01/09/2019	Viral Hepatitis, Funded Partners/Programs and Budgets, CDC	JAN-TREX-00149745	JAN-TREX-00149745							
JA-04303	02/01/2019	The National Association of State Alcohol and Drug Abuse Directors (NASADAD), FY 2019 Appropriations, February 2019 Update, NASADAD	JAN-TREX-00092446	JAN-TREX-00092463							
JA-04304	08/20/2019	Infectious Diseases, Opioids and Injection Drug Use, CDC	JAN-TREX-00092464	JAN-TREX-00092466							
JA-04305	02/21/2019	Minority Aids Initiative: Substance Use Disorder Treatment for Racial/Ethnic Minority Populations at High Risk for HIV/AIDS, U.S. Department of Health & Human Services, SAMHSA	JAN-TREX-00092467	JAN-TREX-00092469							
JA-04306	07/08/1905	Center for Disease Control and Prevention (CDC) Program Guidance for Implementing Certain Components of Syringe Services Programs, 2016	JAN-TREX-00092470	JAN-TREX-00092477							
JA-04307	08/20/2019	Determination of Need for Syringe Services Programs, CDC	JAN-TREX-00092478	JAN-TREX-00092481							
JA-04308	08/20/2019	DEA Presentation: Take Back Day	JAN-TREX-00092482	JAN-TREX-00092493							
JA-04309	08/20/2019	Behavioral Health, Youth.gov	JAN-TREX-00092494	JAN-TREX-00092503							
JA-04310	02/01/2019	Building Communities of Recovery, U.S. Department of Health & Human Services SAMHSA	JAN-TREX-00092504	JAN-TREX-00092506							
JA-04311	08/20/2019	Grants for the Benefit of Homeless Individuals (GBHI), U.S. Department of Health & Human Services SAMHSA	JAN-TREX-00092507	JAN-TREX-00092508							
JA-04312	08/20/2019	Grants, HHS.gov	JAN-TREX-00092509	JAN-TREX-00092517							
JA-04313	02/15/2019	USDA and HHS Partner to Create Recovery Housing in Rural Communities, U.S. Department of Health & Human Services, SAMHSA	JAN-TREX-00092518	JAN-TREX-00092519							
JA-04314	08/20/2019	Bureau of Criminal Investigation (BCI), www.ohioattorneygeneral.gov	JAN-TREX-00092520	JAN-TREX-00092521							
JA-04315	08/20/2019	Cuyahoga County Sheriff's Department website: Cuyahoga County Sheriff, available at https://sheriff.cuyahogacounty.us	JAN-TREX-00092522	JAN-TREX-00092523							
JA-04316	08/20/2019	Ohio Department of Rehabilitation & Correction Website: Ohio Department of Rehabilitation & Correction, available at https://www.drc.ohio.gov .	JAN-TREX-00092524	JAN-TREX-00092526							
JA-04317	08/20/2019	Ohio Department of Public Safety website: Ohio Department of Public Safety, available at: https://publicsafety.ohio.gov/wps/portal/gov/odps .	JAN-TREX-00092527	JAN-TREX-00092531							
JA-04318	08/20/2019	County of Summit Website: County of Summit, The High Point of Ohio, Sheriff Steve Barry, available at: https://sheriff.summitoh.net .	JAN-TREX-00092532	JAN-TREX-00092534							
JA-04319	08/20/2019	Health.gov Website: Overview -Pathways to Safer Opioid Use, available at https://health.gov/hcq/training-pathways.asp .	JAN-TREX-00092535	JAN-TREX-00092537							
JA-04320	03/12/2019	Centers for Disease Control and Prevention Website: Rx Awareness, Campaign Resources, available at https://www.cdc.gov/rxawareness/resources/index.html	JAN-TREX-00092538	JAN-TREX-00092539							
JA-04321	09/25/2017	Centers for Disease Control and Prevention Website: CDC launches campaign to help states fight prescription opioid epidemic, available at https://www.cdc.gov/media/releases/2017/p0925-rx-awareness-campaigns.html	JAN-TREX-00092540	JAN-TREX-00092542							
JA-04322	01/01/2015	FDA Website: Disposal of Unused Medicines: What You Should Know, available at https://www.fda.gov/drugs/safe-disposal-medicines/disposal-unused-medicines-what-you-should-know	JAN-TREX-00092543	JAN-TREX-00092545							
JA-04323	08/20/2019	Up & Away Website: Up & Away Put your Medicines Up and Away, available at https://web.archive.org/web/20181121233922/https://www.upandaway.org/	JAN-TREX-00092546	JAN-TREX-00092550							
JA-04324	08/20/2019	NIDA for Teens Website: National Drug and Alcohol Facts Week NIDA for Teens, available at https://teens.drugabuse.gov/national-drug-alcohol-facts-week	JAN-TREX-00092551	JAN-TREX-00092556							
JA-04325	08/20/2019	Heart.org Website: Opioid Education for Non-Clinical Staff and Lay Responders AHA eLearning, available at https://elearning.heart.org/course/320?utm_source=google&utm_medium=cpc&utm_term..	JAN-TREX-00092557	JAN-TREX-00092559							
JA-04326	08/20/2019	Centers for Disease Control and Prevention Website: State Information Drug Overdose CDC Injury Center, available at https://www.cdc.gov/drugoverdose/states/index.html	JAN-TREX-00092560	JAN-TREX-00092563							
JA-04327	12/01/2016	Centers for Disease Control and Prevention Presentation: Addressing the Prescription Opioid Crisis; CDC Rx Awareness Campaign Overview	JAN-TREX-00092564	JAN-TREX-00092587							
JA-04328	08/20/2019	National Institute on Drug Abuse Website:Parents & Educators National Institute on Drug Abuse (NIDA), available at https://www.drugabuse.gov/parents-educators	JAN-TREX-00092588	JAN-TREX-00092592							
JA-04329	08/20/2019	Centers for Disease Control and Prevention Website: PROTECT Initiative: Advancing Children's Medication Safety Medication Safety Program, available at https://www.cdc.gov/MedicationSafety/protect/protect_Initiative.html	JAN-TREX-00092593	JAN-TREX-00092594							
JA-04330	08/20/2019	Up & Away Website:Up & Away Put your Medicines Up and Away and Out of Sight of Children, available at https://www.upandaway.org/	JAN-TREX-00092595	JAN-TREX-00092601							
JA-04331	06/07/2019	White House Press Release, Statement from the Press Secretary Regarding the Youth Opioid Prevention Ad Campaign, Issued June 7, 2018	JAN-TREX-00092602	JAN-TREX-00092603							
JA-04332	08/20/2019	NIDA for Teens Website: Teens -Drug Information NIDA for Teens, available at https://teens.drugabuse.gov/	JAN-TREX-00092604	JAN-TREX-00092607							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-04333	08/20/2019	Thetruth.com Website: What is the Opioid Epidemic?, available at https://opioids.thetruth.com/o/home	JAN-TREX-00092608	JAN-TREX-00092610							
JA-04334	08/20/2019	Substance Abuse and Mental Health Services Administration Website:Prevention Media Campaigns SAMHSA, available at https://web.archive.org/web/20181124185432/https://www.samhsa.gov/capt/tools-learning-...	JAN-TREX-00092611	JAN-TREX-00092617							
JA-04335	12/05/2017	Senate Committee on Appropriations Subcommittee on Labor, Health and Human Services, Education and Related Agencies; Department of Health and Human Services Written Testimony re: Hearing titled, "Addressing the Opioid Crisis in America: Prevention, Treatment, and Recovery."	JAN-TREX-00092618	JAN-TREX-00092630							
JA-04336	08/20/2019	SAMHSA-HRSA Website: Referral to treatment/SAMHSA-HRSA, available at https://www.integration.samhsa.gov/clinical-practice/sbirt/referral-to-treatment	JAN-TREX-00092631	JAN-TREX-00092632							
JA-04337	07/11/1905	The Substance Abuse and Mental Health Services Administration Operating plan for FY 2019	JAN-TREX-00092633	JAN-TREX-00092638							
JA-04338	08/20/2019	Substance Abuse and Mental Health Services Administration (SAMHSA) Website: State Grant Programs SAMHSA - Substance Abuse and Mental Health Services Administration, available at https://www.samhsa.gov/medication-assisted-treatment/training-materials-resources/state-...	JAN-TREX-00092639	JAN-TREX-00092642							
JA-04339	08/20/2019	Substance Abuse and Mental Health Services Administration (SAMHSA) Website: 2017 NSDUH Annual National Report CBHSQ, available at https://www.samhsa.gov/data/report/2017-nsduh-annual-national-report .	JAN-TREX-00092643	JAN-TREX-00092644							
JA-04340	03/06/2019	Cuyahoga County Medical Examiner's Office Presentation: Heroin/Fentanyl/Cocaine Related Deaths in Cuyahoga County	JAN-TREX-00092645	JAN-TREX-00092656							
JA-04341	02/01/2019 - 02/28/2019	Summit County Public Health Population Health Vital Statistics Brief: Volume 3: Drug Overdoses, Feb. 1 - Feb. 28, 2019	JAN-TREX-00092657	JAN-TREX-00092664							
JA-04342	08/20/2019	American Addiction Centers Website: Public Assistance Options for Drug & Alcohol Treatment Centers, available at https://americanaddictioncenters.org/rehab-guide/public-assistance	JAN-TREX-00092665	JAN-TREX-00092681							
JA-04343	03/01/2019	Bipartisan Policy Center Presentation: Tracking Federal Funding to Combat the Opioid Crisis	JAN-TREX-00092682	JAN-TREX-00092785							
JA-04344	08/20/2019	U.S. Department of Justice Website: Bureau of Justice Assistance -Comprehensive Opioid Abuse Program (COAP), available at https://www.bja.gov/ProgramDetails.aspx?Program_ID=72	JAN-TREX-00092786	JAN-TREX-00092788							
JA-04345	08/15/2019	Cuyahoga County Sheriff's Office receives free naloxone kits, deputy training, Cleveland.com	JAN-TREX-00092789	JAN-TREX-00092790							
JA-04346	03/06/2019	U.S. Department of Health & Human Services Website: First Responders-Comprehensive Addiction and Recovery Act SAMHSA, available at https://www.samhsa.gov/grants/grant-announcements/ti-19-004	JAN-TREX-00092791	JAN-TREX-00092793							
JA-04347	02/01/2019	The National Association of State Alcohol and Drug Abuse Directors (NASADAD) Presentation: FY 2019 Appropriations	JAN-TREX-00092794	JAN-TREX-00092811							
JA-04348	03/01/2019	U.S. Department of Justice Office of Justice Programs, FY 2020 Program Summaries	JAN-TREX-00092812	JAN-TREX-00092986							
JA-04349	08/20/2019	U.S. Department of Health & Human Services Website: SAMHSA -Substance Abuse and Mental Health Services Administration (List of grant recipients), available at https://www.samhsa.gov/grants/awards/2019/TI-18-009	JAN-TREX-00092987	JAN-TREX-00092990							
JA-04350	08/20/2019	U.S. Department of Health & Human Services Website: Opioid Overdose Prevention Toolkit SAMHSA Publications, available at https://store.samhsa.gov/product/Opioid-Overdose-Prevention-Toolkit/SMA18-4742	JAN-TREX-00092991	JAN-TREX-00092994							
JA-04351	05/09/2019	U.S. Department of Health & Human Services Website: Targeted Capacity Expansion: Medication Assisted Treatment –Prescription Drug and Opioid Addiction, available at https://www.samhsa.gov/grants/grant-announcements/ti-18-009	JAN-TREX-00092995	JAN-TREX-00092998							
JA-04352	08/20/2019	Department of Justice, Bureau of Justice Assistance Website: Who covers law enforcement overdose response costs? Working with BJA NTTAC, available at https://bjatta.bja.ojp.gov/naloxone/who-covers-law-enforcement-overdose-response-costs	JAN-TREX-00092999	JAN-TREX-00093001							
JA-04353	08/20/2019	Community Success Website: Apply Now: Improving Access to Overdose Treatment Program, available at https://www.communitysuccess.org/apply-now-improving-access-to-overdose-treatment-program	JAN-TREX-00093002	JAN-TREX-00093006							
JA-04354	08/20/2019	U.S. Department of Justice Website: Bureau of Justice Assistance -Comprehensive Opioid Abuse Program (COAP), Available at https://www.bja.gov/ProgramDetails.aspx?Program_ID=72	JAN-TREX-00093007	JAN-TREX-00093009							
JA-04355	07/09/1905	Alcohol, Drug Addiction and Mental Health Services Board (ADM Board) Presentation: 2017 Report to the Community.	JAN-TREX-00093010	JAN-TREX-00093017							
JA-04356	07/11/1905	Alcohol Drug Addiction and Mental Health Service Board Total Budget Summary for Calendar Year 2019	JAN-TREX-00093018	JAN-TREX-00093021							
JA-04357	12/01/2018	U.S. Department of Health and Human Services Draft Report on Pain Management Best practices: Updates, gaps, Inconsistencies, and Recommendations	JAN-TREX-00093022	JAN-TREX-00093089							
JA-04358	08/20/2019	Health Resources & Services Administration Website: Find Grants, available at https://data.hrsa.gov/tools/find-grants	JAN-TREX-00093090	JAN-TREX-00093092							
JA-04359	01/09/2019	Centers for Disease Control and Prevention Website: Funded Partners/Programs and Budgets Policy and Programs Division of Viral Hepatitis CDC, available at https://www.cdc.gov/hepatitis/policy/fundedpartners.htm	JAN-TREX-00149746	JAN-TREX-00149746							
JA-04360	02/01/2019	The National Association of State Alcohol and Drug Abuse Directors (NASADAD) FY 2019 Appropriations February 2019 Update	JAN-TREX-00093093	JAN-TREX-00093110							
JA-04361	09/19/2018	U.S. Department of Health & Human Services Press Release, re: HHS Awards Over \$1 Billion to Combat the Opioid Crisis	JAN-TREX-00093111	JAN-TREX-00093114							
JA-04362	04/18/2018	U.S. Department of Health & Human Services Press Release, re: HHS provides states second installment of grant awards to combat opioid crisis.	JAN-TREX-00093115	JAN-TREX-00093118							
JA-04363	03/20/2019	U.S. Department of Health & Human Services Press Release, re: HHS Releases additional \$487 million to states, territories to expand access to effective opioid treatment; 2019 SOR grants will total \$1.4 billion.	JAN-TREX-00093119	JAN-TREX-00093123							
JA-04364	08/20/2019	Centers for Disease Control and Prevention Website: Infectious Diseases, Opioids and Injection Drug Use in Persons Who Inject Drugs CDC, available at https://www.cdc.gov/pwuid/opioid-use.html	JAN-TREX-00093124	JAN-TREX-00093126							
JA-04365	02/21/2019	U.S. Department of Health & Human Services Website: Minority Aids Initiative: Substance Use Disorder Treatment for Racial/Ethnic Minority Populations at High Risk for HIV/AIDS, available at https://www.samhsa.gov/grants/grant-announcements/ti-19-008	JAN-TREX-00093127	JAN-TREX-00093129							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-04366	08/20/2019	U.S. Department of Health & Human Services Website: SAMHSA -Substance Abuse and Mental Health Services Administration, available at https://www.samhsa.gov/grants-awards-by-state/OH/2018	JAN-TREX-00093130	JAN-TREX-00093131							
JA-04367	07/29/2019	American Addiction Centers Website: Public Assistance Options for Drug & Alcohol Treatment Centers, available at https://americanaddictioncenters.org/rehab-guide/public-assistance	JAN-TREX-00093132	JAN-TREX-00093148							
JA-04368	07/11/1905	The Substance Abuse and Mental Health Services Administration Operating plan for FY 2019	JAN-TREX-00093149	JAN-TREX-00093154							
JA-04369	08/13/2019	Department of Health and Human Services Substance Abuse and Mental Health Services Administration State Opioid Response Grants Funding Opportunity Announcement (FOA) No. TI-18-015	JAN-TREX-00093155	JAN-TREX-00093235							
JA-04370	08/20/2019	U.S. Department of Health & Human Services Website: SABG SAMHSA -Substance Abuse and Mental Health Services Administration, available at https://www.samhsa.gov/grants/block-grants/sabg	JAN-TREX-00093236	JAN-TREX-00093239							
JA-04371	10/18/2017	Congressional Research Service Report, re: The Opioid Epidemic and Federal Efforts to Address It: Frequently Asked Questions	JAN-TREX-00093240	JAN-TREX-00093268							
JA-04372	03/01/2019	Bipartisan Policy Center report re: Tracking Federal Funding to Combat the Opioid Crisis	JAN-TREX-00093269	JAN-TREX-00093372							
JA-04373	10/01/2018	U.S. Department of Health and Human Services, Health Resources and Service Administration Presentation, re: HRSA's Home Visiting Program: Supporting Families Impacted by Opioid Use and Neonatal Abstinence Syndrome	JAN-TREX-00093373	JAN-TREX-00093400							
JA-04374	08/20/2019	Semel Institute for Neuroscience and Human Behavior Website: Neonatal Abstinence Syndrome, available at https://www.semel.ucla.edu/dual-diagnosis-program/News_and_Resources/Neonatal_Abstinence	JAN-TREX-00093401	JAN-TREX-00093403							
JA-04375	07/10/1905	Department of Health & Human Services Presentation, re: Maternal, Infant, and Early Childhood Home Visiting Program	JAN-TREX-00093404	JAN-TREX-00093409							
JA-04376	08/20/2019	U.S. Department of Health & Human Services Website: About Screening, Brief Intervention, and Referral to Treatment (SBIRT), available at https://www.samhsa.gov/sbirt/about	JAN-TREX-00149747	JAN-TREX-00149747							
JA-04377	08/01/2017	The National Association of State Alcohol and Drug Abuse Directors (NASADAD) FY 2018 Appropriations August 2017 Update	JAN-TREX-00093410	JAN-TREX-00093423							
JA-04378	02/01/2019	The National Association of State Alcohol and Drug Abuse Directors (NASADAD) FY 2019 Appropriations February 2019 Update	JAN-TREX-00093424	JAN-TREX-00093441							
JA-04379	08/20/2019	The White House Website: Office of National Drug Control Policy, Grants & Programs, available at https://www.whitehouse.gov/ondcp/grants-programs/	JAN-TREX-00093442	JAN-TREX-00093447							
JA-04380	08/20/2019	Substance Abuse and Mental Health Services (SAMHSA) Website: Referral to Treatment, available at https://www.integration.samhsa.gov/clinical-practice/sbirt/referral-to-treatment	JAN-TREX-00093448	JAN-TREX-00093449							
JA-04381	07/11/1905	The Substance Abuse and Mental Health Services Administration Operating plan for FY 2019	JAN-TREX-00093450	JAN-TREX-00093455							
JA-04382	08/20/2019	U.S. Department of Health & Human Services Website: SBIRT Grantees SAMHSA -Substance Abuse and Mental Health Services Administration, available at https://www.samhsa.gov/sbirt/grantees	JAN-TREX-00093456	JAN-TREX-00093463							
JA-04383	08/20/2019	Summit County Children Services Website: About Summit County Children Services, available at https://www.summitkids.org/About	JAN-TREX-00093464	JAN-TREX-00093467							
JA-04384	08/20/2019	Ohio Department of Jobs and Family Services Website: Office of Families and Children, available at http://jfs.ohio.gov/ocf/gen_stat.stm	JAN-TREX-00149748	JAN-TREX-00149748							
JA-04385	08/20/2019	Cuyahoga County, Children and Family Services Website: What we do - Children and family services, available at http://cfs.cuyahogacounty.us/en-US/What-We-Do.aspx	JAN-TREX-00093468	JAN-TREX-00093469							
JA-04386	10/11/2017	Email from Donna Barrett to Tonya Block re: AOD dollars	JAN-TREX-00093470	JAN-TREX-00093471							
JA-04387	06/09/2019	Akron Beacon Journal Website: New Probation program kicks off in Summit County - News - Akron Beacon Journal, available at https://www.ohio.com/news/20190609/new-probation-program-kicks-off-in-summit-county	JAN-TREX-00093472	JAN-TREX-00093474							
JA-04388	08/20/2019	Summit County Court of Common Please - General Division Website: Home - Adult Probation, available at http://www.summitpcourt.net/Programs/Pages/AdultProbation.aspx	JAN-TREX-00149749	JAN-TREX-00149749							
JA-04389	08/20/2019	Ohio Department of Rehabilitation & Correction Website: Targeted Community Alternatives to Prison (T-CAP), available at https://drc.ohio.gov/tcap	JAN-TREX-00093475	JAN-TREX-00093479							
JA-04390	08/20/2019	Oriana House Website: Summit County Residential Community Correction Programs, available at http://www.orianahouse.org/programs/summit/prog_residential.php	JAN-TREX-00093480	JAN-TREX-00093481							
JA-04391	08/20/2016	Hunt P, et al., The Price of Justice: New National and State-Level Estimates of the Judicial and Legal Costs of Crime to Taxpayers, Am J Crim Just (2017), Vol. 42, pp. 231–254	JAN-TREX-00093482	JAN-TREX-00093505							
JA-04392	09/01/2017	Financial Disclosure OPD-206R Form (Spanish version)	JAN-TREX-00093506	JAN-TREX-00093507							
JA-04393	09/01/2017	Financial Disclosure OPD_206R Form	JAN-TREX-00093508	JAN-TREX-00093509							
JA-04394	02/01/2019	Ohio Public Defender Indigent Client Eligibility Guidelines 2019	JAN-TREX-00149750	JAN-TREX-00149750							
JA-04395	02/01/2019	Monthly Public Defender Reimbursement (%) History from 07/1998 to 02/2019	JAN-TREX-00093510	JAN-TREX-00093513							
JA-04396	04/28/2006	Memorandum from David Bodiker to Judges et al.	JAN-TREX-00093514	JAN-TREX-00093519							
JA-04397	No Date	Ohio Public Defender Indigent Application Fee, County Auditor Monthly Remittance Form	JAN-TREX-00149751	JAN-TREX-00149751							
JA-04398	No Date	Instructions for Ohio Public Defender Indigent Application Fee, County Auditor Monthly Remittance Form	JAN-TREX-00149752	JAN-TREX-00149752							
JA-04399	No Date	Ohio Public Defender Clerk of Court Indigent Application Fee Report Form	JAN-TREX-00149753	JAN-TREX-00149753							
JA-04400	02/20/2007	Instructions for Ohio Public Defender Clerk of Court Indigent Application Fee Report	JAN-TREX-00093520	JAN-TREX-00093521							
JA-04401	08/01/2005	Indigent Application Fee Client Information Sheet (FAQ)	JAN-TREX-00093522	JAN-TREX-00093523							
JA-04402	08/03/2005	Memorandum from David Bodiker to Judges et. al.	JAN-TREX-00149754	JAN-TREX-00149754							
JA-04403	09/01/2017	Financial Disclosure Form OPD 206R Instructions	JAN-TREX-00093524	JAN-TREX-00093526							
JA-04404	02/20/2007	Ohio Administrative Code § 120.36. Application fee for indigent defendants and parties in juvenile court	JAN-TREX-00093527	JAN-TREX-00093529							
JA-04405	No Date	State of Ohio Public Defender Presentation: Office of the Ohio Public Defender County Indigent Fee/Cost Recoupment Programs	JAN-TREX-00093530	JAN-TREX-00093536							
JA-04406	02/20/2007	Ohio Public Defender Clerk of the Court Indigent Application Fee Report Version 2 Instructions	JAN-TREX-00093537	JAN-TREX-00093547							
JA-04407	No Date	Ohio Public Defender Clerk of the Court Indigent Application Fee Report Version 2 Form	JAN-TREX-00149755	JAN-TREX-00149755							
JA-04408	No Date	Form Motion for Waiver of Application Fee and Memorandum in Support	JAN-TREX-00093548	JAN-TREX-00093549							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-04409	09/01/2017	Financial Disclosure OPD-206R Form (Spanish version)	JAN-TREX-00093550	JAN-TREX-00093551							
JA-04410	09/01/2017	Financial Disclosure OPD-206R Form	JAN-TREX-00093552	JAN-TREX-00093553							
JA-04411	02/01/2019	Ohio Public Defender Indigent Client Eligibility Guidelines 2019	JAN-TREX-00149756	JAN-TREX-00149756							
JA-04412	02/01/2019	Monthly Public Defender Reimbursement (%) History from 07/1998 to 02/2019	JAN-TREX-00093554	JAN-TREX-00093557							
JA-04413	04/28/2006	Memorandum from David Bodiker to Judges et al.	JAN-TREX-00093558	JAN-TREX-00093563							
JA-04414	No Date	Ohio Public Defender Indigent Application Fee, County Auditor Monthly Remittance Form	JAN-TREX-00149757	JAN-TREX-00149757							
JA-04415	No Date	Instructions for Ohio Public Defender Indigent Application Fee, County Auditor Monthly Remittance Form	JAN-TREX-00149758	JAN-TREX-00149758							
JA-04416	No Date	Ohio Public Defender Clerk of Court Indigent Application Fee Report Form	JAN-TREX-00149759	JAN-TREX-00149759							
JA-04417	02/20/2007	Instructions for Ohio Public Defender Clerk of Court Indigent Application Fee Report	JAN-TREX-00093564	JAN-TREX-00093565							
JA-04418	08/01/2005	Indigent Application Fee Client Information Sheet (FAQ)	JAN-TREX-00093566	JAN-TREX-00093567							
JA-04419	08/03/2005	Memorandum form David Bodiker to Judges et al.	JAN-TREX-00149760	JAN-TREX-00149760							
JA-04420	09/01/2017	Financial Disclosure Form OPD 206R Instructions	JAN-TREX-00093568	JAN-TREX-00093570							
JA-04421	02/20/2007	Ohio Administrative Code § 120.36. Application fee for indigent defendants and parties in juvenile court	JAN-TREX-00093571	JAN-TREX-00093573							
JA-04422	No Date	State of Ohio Public Defender Presentation: Office of the Ohio Public Defender County Indigent Fee/Cost Recoupment Programs	JAN-TREX-00093574	JAN-TREX-00093580							
JA-04423	02/20/2007	Ohio Public Defender Clerk of the Court Indigent Application Fee Report Version 2 Instructions	JAN-TREX-00093581	JAN-TREX-00093591							
JA-04424	No Date	Ohio Public Defender Clerk of the Court Indigent Application Fee Report Version 2 Form	JAN-TREX-00149761	JAN-TREX-00149761							
JA-04425	No Date	Form Motion for Waiver of Application Fee and Memorandum in Support	JAN-TREX-00093592	JAN-TREX-00093593							
JA-04426	09/01/2017	Financial Disclosure OPD-206R Form (Spanish version)	JAN-TREX-00093594	JAN-TREX-00093595							
JA-04427	09/01/2017	Financial Disclosure OPD-206R Form	JAN-TREX-00093596	JAN-TREX-00093597							
JA-04428	02/01/2019	Ohio Public Defender Indigent Client Eligibility Guidelines 2019	JAN-TREX-00149762	JAN-TREX-00149762							
JA-04429	02/01/2019	Monthly Public Defender Reimbursement (%) History from 07/1998 to 02/2019	JAN-TREX-00093598	JAN-TREX-00093601							
JA-04430	04/28/2006	Memorandum from David Bodiker to Judges et al.	JAN-TREX-00093602	JAN-TREX-00093607							
JA-04431	No Date	Ohio Public Defender Indigent Application Fee, County Auditor Monthly Remittance Form	JAN-TREX-00149763	JAN-TREX-00149763							
JA-04432	No Date	Instructions for Ohio Public Defender Indigent Application Fee, County Auditor Monthly Remittance Form	JAN-TREX-00149764	JAN-TREX-00149764							
JA-04433	No Date	Ohio Public Defender Clerk of Court Indigent Application Fee Report Form	JAN-TREX-00149765	JAN-TREX-00149765							
JA-04434	02/20/2007	Instructions for Ohio Public Defender Clerk of Court Indigent Application Fee Report	JAN-TREX-00093608	JAN-TREX-00093609							
JA-04435	08/01/2005	Indigent Application Fee Client Information Sheet (FAQ)	JAN-TREX-00093610	JAN-TREX-00093611							
JA-04436	08/03/2005	Memorandum from David Bodiker to Judges et. al.	JAN-TREX-00149766	JAN-TREX-00149766							
JA-04437	09/01/2017	Financial Disclosure Form OPD 206R Instructions	JAN-TREX-00093612	JAN-TREX-00093614							
JA-04438	02/20/2007	Ohio Administrative Code § 120.36. Application fee for indigent defendants and parties in juvenile court	JAN-TREX-00093615	JAN-TREX-00093617							
JA-04439	No Date	State of Ohio Public Defender Presentation: Office of the Ohio Public Defender County Indigent Fee/Cost Recoupment Programs	JAN-TREX-00093618	JAN-TREX-00093624							
JA-04440	02/20/2007	Ohio Public Defender Clerk of the Court Indigent Application Fee Report Version 2 Instructions	JAN-TREX-00093625	JAN-TREX-00093635							
JA-04441	No Date	Ohio Public Defender Clerk of the Court Indigent Application Fee Report Version 2 Form	JAN-TREX-00149767	JAN-TREX-00149767							
JA-04442	No Date	Form Motion for Waiver of Application Fee and Memorandum in Support	JAN-TREX-00093636	JAN-TREX-00093637							
JA-04443	09/01/2017	Financial Disclosure OPD-206R Form (Spanish version)	JAN-TREX-00093638	JAN-TREX-00093639							
JA-04444	09/01/2017	Financial Disclosure OPD_206R Form	JAN-TREX-00093640	JAN-TREX-00093641							
JA-04445	02/01/2019	Ohio Public Defender Indigent Client Eligibility Guidelines 2019	JAN-TREX-00149768	JAN-TREX-00149768							
JA-04446	02/01/2019	Monthly Public Defender Reimbursement (%) History from 07/1998 to 02/2019	JAN-TREX-00093642	JAN-TREX-00093645							
JA-04447	04/28/2006	Memorandum from David Bodiker to Judges et al.	JAN-TREX-00093646	JAN-TREX-00093651							
JA-04448	No Date	Ohio Public Defender Indigent Application Fee, County Auditor Monthly Remittance Form	JAN-TREX-00149769	JAN-TREX-00149769							
JA-04449	No Date	Instructions for Ohio Public Defender Indigent Application Fee, County Auditor Monthly Remittance Form	JAN-TREX-00149770	JAN-TREX-00149770							
JA-04450	No Date	Ohio Public Defender Clerk of Court Indigent Application Fee Report Form	JAN-TREX-00149771	JAN-TREX-00149771							
JA-04451	02/20/2007	Instructions for Ohio Public Defender Clerk of Court Indigent Application Fee Report	JAN-TREX-00093652	JAN-TREX-00093653							
JA-04452	08/01/2005	Indigent Application Fee Client Information Sheet (FAQ)	JAN-TREX-00093654	JAN-TREX-00093655							
JA-04453	08/03/2005	Memorandum from David Bodiker to Judges et al.	JAN-TREX-00149772	JAN-TREX-00149772							
JA-04454	09/01/2017	Financial Disclosure Form OPD 206R Instructions	JAN-TREX-00093656	JAN-TREX-00093658							
JA-04455	02/20/2007	Ohio Administrative Code § 120.36. Application fee for indigent defendants and parties in juvenile court	JAN-TREX-00093659	JAN-TREX-00093661							
JA-04456	No Date	State of Ohio Public Defender Presentation: Office of the Ohio Public Defender County Indigent Fee/Cost Recoupment Programs	JAN-TREX-00093662	JAN-TREX-00093668							
JA-04457	02/20/2007	Ohio Public Defender Clerk of the Court Indigent Application Fee Report Version 2 Instructions	JAN-TREX-00093669	JAN-TREX-00093679							
JA-04458	No Date	Ohio Public Defender Clerk of the Court Indigent Application Fee Report Version 2 Form	JAN-TREX-00149773	JAN-TREX-00149773							
JA-04459	No Date	Form Motion for Waiver of Application Fee and Memorandum in Support	JAN-TREX-00093680	JAN-TREX-00093681							
JA-04460	09/11/2018	Ghertner R & Groves I, The Opioid Crisis and Economic Opportunity: Geographic and Economic Trends, ASPE Research Brief, 2018	JAN-TREX-00093682	JAN-TREX-00093703							
JA-04461	08/20/2019	Substance Abuse and Mental Health Data Archive (SAMHDA), National Survey on Drug Use and Health, https://rdas.samhsa.gov/	JAN-TREX-00093704	JAN-TREX-00093707							
JA-04462	01/13/2012	Paulozzi, LJ, et al., CDC Grand Tounds: Prescription Drug Overdoses - a U.S. Epidemic, Morbidity and Mortality Weekly Report, Vol. 61, pp. 10-13, 2012	JAN-TREX-00093708	JAN-TREX-00093715							
JA-04463	11/16/2017	Rhyan, CN, The Potential Societal Benefit of Eliminating Opioid Overdoses, Deaths, and Substance Use Disorders Exceeds \$95 Billion Per Year, Altarum	JAN-TREX-00093716	JAN-TREX-00093719							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-04464	07/09/1905	2017 Ohio Neonatal Abstinence Syndrome County Report, 2013-2017, Ohio	JAN-TREX-00149774	JAN-TREX-00149774							
JA-04465	07/10/1905	2018 Ohio Neonatal Abstinence Syndrome Report; 2018	JAN-TREX-00149775	JAN-TREX-00149775							
JA-04466	08/31/2018	Centers for Disease Control and Prevention 2018 Annual Surveillance Report of Drug-Related Risks and Outcomes - United States; 2018	JAN-TREX-00093720	JAN-TREX-00093810							
JA-04467	11/01/2017	The Council of Economic Advisers; The Underestimated Cost of the Opioid Crisis Report; 11/2017	JAN-TREX-00093811	JAN-TREX-00093824							
JA-04468	05/14/2019	Ferrise A, Who's Who of Cuyahoga County Investigation (updated), Cleveland.com, May 14, 2019	JAN-TREX-00093825	JAN-TREX-00093829							
JA-04469	10/01/2016	Florence C, et al., The Economic Burden of Prescription Opioid Overdose, Abuse and Dependence in the United States, 2013, Med Care. 54(10), pp. 901-906, October 2016	JAN-TREX-00093830	JAN-TREX-00093843							
JA-04470	09/09/2010	Jackson FM, Cuyahoga County's Corruption Investigation: A Comprehensive Guide, The Plain Dealer Cleveland.com, September 9, 2010	JAN-TREX-00093844	JAN-TREX-00093846							
JA-04471	05/14/2014	Volkow ND Presentation: America's Addiction to Opioids: Heroin and Prescription Drug Abuse, National Institute on Drug Abuse Archives, May 14, 2014	JAN-TREX-00093847	JAN-TREX-00093861							
JA-04472	04/01/2010	McCollister KE, et al., The Cost of Crime to Society: New Crime-Specific Estimates for Policy and Program Evaluation, Drug Alcohol and Depend, 108(1-2), pp. 98-109, April 1, 2010	JAN-TREX-00093862	JAN-TREX-00093887							
JA-04473	07/10/1905	Bose J, et al., Key Substance Use and Mental Health Indicators in the United States: Results from the 2017 National Survey on Drug Use and Health, Substance Abuse and Mental Health Services Administration, HHS Publication No. SMA 18-5068, NSDUH Series H-53J, 2018	JAN-TREX-00093888	JAN-TREX-00094011							
JA-04474	08/21/2014	Drug Enforcement Administration press release, DEA To Publish Final Rule Rescheduling Hydrocodone Combination Products, August 21, 2014	JAN-TREX-00094012	JAN-TREX-00094013							
JA-04475	06/22/1905	Viscusi WK, The Value of Life in Legal Contexts: Survey and Critique, American Law and Economics Review, V2 N1, pp. 195-222, 2000	JAN-TREX-00094014	JAN-TREX-00094041							
JA-04476	08/20/2019	Summit County Prosecutor, Criminal Division, The Prosecutor Site Designed by the County of Summit Department of Communications, Ilene Shapiro, Executive, August 20, 2019	JAN-TREX-00094042	JAN-TREX-00094043							
JA-04477	08/20/2019	Summit County Prosecutor, Juvenile Division, The Prosecutor Site Designed by the County of Summit Department of Communications, Ilene Shapiro, Executive, August 20, 2019	JAN-TREX-00094044	JAN-TREX-00094045							
JA-04478	08/20/2019	Summit County Prosecutor, A Message from the Prosecutor, The Prosecutor Site Designed by the County of Summit Department of Communications, Ilene Shapiro, Executive, August 20, 2019	JAN-TREX-00094046	JAN-TREX-00094050							
JA-04479	01/01/2019	Ohio Public Defender Commission, Supreme Court of Ohio, Motion, Entry, and Certification for Appointed Counsel Fees form, January 2019.	JAN-TREX-00094051	JAN-TREX-00094052							
JA-04480	01/01/2019	Ohio Public Defender Commission, Clerk's/Auditor's Transcript Fee For An Indigent Defendant form, January 2019	JAN-TREX-00149776	JAN-TREX-00149776							
JA-04481	09/01/2017	Ohio Public Defender Commission, Financial Disclosure Form (Spanish), September 2017	JAN-TREX-00094053	JAN-TREX-00094054							
JA-04482	09/01/2017	Ohio Public Defender Commission, Financial Disclosure Form, September 2017	JAN-TREX-00094055	JAN-TREX-00094056							
JA-04483	12/01/2017	Ohio Public Defender Commission, Financial Disclosure Form, December 2017	JAN-TREX-00094057	JAN-TREX-00094058							
JA-04484	07/11/1905	Ohio Public Defender Indigent Client Eligibility Guidelines 2019	JAN-TREX-00149777	JAN-TREX-00149777							
JA-04485	No date	Office of the Ohio Public Defender, Monthly Assigned Counsel Summary Sheet	JAN-TREX-00149778	JAN-TREX-00149778							
JA-04486	01/01/2019	Ohio Public Defender Commission, Monthly Operating Expenses and Caseload Report for County Public Defender Office	JAN-TREX-00094059	JAN-TREX-00094060							
JA-04487	01/01/2019	Ohio Public Defender Commission, Motion, Entry, and Certification for Appointed Counsel Fees form	JAN-TREX-00094061	JAN-TREX-00094062							
JA-04488	07/11/1905	Ohio Public Defender Commission, Chart showing Appointed Counsel Month, Payment Month, Rate, Public Defender Month, and Notes	JAN-TREX-00094063	JAN-TREX-00094066							
JA-04489	01/01/2019	Office of the Ohio Public Defender, Standards and Guidelines for Appointed Counsel Reimbursement, State Maximum Fee Schedule for Appointed Counsel Reimbursement, County Public Defender Office Reimbursement Standards, State Public Defender Billing, Payment, and Reimbursement, Ohio Revised Code, Chapter 120, January 2019	JAN-TREX-00094067	JAN-TREX-00094137							
JA-04490	01/01/2019	Ohio Public Defender Commission, Request for Court-Paid Experts and/or Expenses form	JAN-TREX-00149779	JAN-TREX-00149779							
JA-04491	01/01/2000	Ohio Public Defender Commission, Itemized Fee Statement Continuation Sheet	JAN-TREX-00149780	JAN-TREX-00149780							
JA-04492	04/28/2008	Memorandum from David Bodiker to Judges, Clerks of Court, County Commissioners, County Public Defender, County Treasurers, and County Auditors	JAN-TREX-00094138	JAN-TREX-00094143							
JA-04493	No date	Ohio Public Defender, Indigent Application Fee County Auditor Monthly Remittance Form	JAN-TREX-00149781	JAN-TREX-00149781							
JA-04494	No date	Ohio Public Defender, Instructions for Completing Ohio Public Defender Indigent Application Fee County Auditor Monthly Remittance Form	JAN-TREX-00149782	JAN-TREX-00149782							
JA-04495	No date	Ohio Public Defender, Clerk of Court Indigent Application Fee Report form	JAN-TREX-00149783	JAN-TREX-00149783							
JA-04496	No date	Ohio Public Defender, Instructions for Completing Ohio Public Defender Clerk of Court Indigent Application Fee Report	JAN-TREX-00094144	JAN-TREX-00094145							
JA-04497	08/01/2005	Office of the Ohio Public Defender, \$25 Indigent Application Fee Client Information Sheet	JAN-TREX-00094146	JAN-TREX-00094147							
JA-04498	11/06/2012	Memorandum from Tim Young to Ohio Judicial Conference, County Public Defenders, County Commissioners, County auditors, Clerk of Courts	JAN-TREX-00149784	JAN-TREX-00149784							
JA-04499	08/03/2005	Memorandum from David Bodiker to Judges, Clerks of Court, County Commissioners, County Treasurers, County Auditors, County Public Defenders	JAN-TREX-00149785	JAN-TREX-00149785							
JA-04500	09/01/2017	Office of Public Defender Commission, Instructions for Completing Financial Disclosure form OPD 206R	JAN-TREX-00094148	JAN-TREX-00094150							
JA-04501	06/29/1905	Ohio Revised Code, Section 120.36, Application fee for indigent defendants and parties in juvenile court	JAN-TREX-00094151	JAN-TREX-00094153							
JA-04502	No date	Office of Ohio Public Defender, County Indigent Fee/Cost Recoupment Programs	JAN-TREX-00094154	JAN-TREX-00094160							
JA-04503	06/29/1905	Ohio Public Defender, Instructions for Completing Ohio Public Defender Clerk of Court Indigent Application Fee Report Version 2 (Optional)	JAN-TREX-00094161	JAN-TREX-00094171							
JA-04504	No date	Ohio Public Defender, Clerk of Court Indigent Application Fee Report, Version 2 (Optional)	JAN-TREX-00149786	JAN-TREX-00149786							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-04505	01/2000 - 06/2003	Chapter 120 of the Ohio Revised Code, Ohio Public Defender, Standards and Guidelines for Appointed Counsel Reimbursement Revised January 1, 2000, State Maximum Fee Schedule For Appointed Counsel Reimbursement, Revised June 24, 2003, County Public Defender Office Reimbursement Standards, Revised January 1, 2000	JAN-TREX-00094172	JAN-TREX-00094257							
JA-04506	No date	Office of Ohio Public Defender, Motion for Waiver of Application Fee form	JAN-TREX-00094258	JAN-TREX-00094259							
JA-04507	08/15/2017	Morice J, Cuyahoga County Sheriff's Office Receives Free Naloxone Kits, Deputy Training, Cleveland.com	JAN-TREX-00094260	JAN-TREX-00094261							
JA-04508	06/24/2016	Glunt N, Summit County starts needle exchange program to prevent spread of HIV, hepatitis C, Akron Beacon Journal, June 24, 2016	JAN-TREX-00094262	JAN-TREX-00094263							
JA-04509	01/2004 - 06/2004	The Ohio Substance Abuse Monitoring Network, Executive Summary, January 2004 - June 2004	JAN-TREX-00094264	JAN-TREX-00094267							
JA-04510	06/01/2005	The Ohio Substance Abuse Monitoring Network, June 2005 Meeting Executive Summary, Ohio Department of Alcohol and Drug Addiction Services	JAN-TREX-00094268	JAN-TREX-00094270							
JA-04511	01/2008 - 06/2008	Wright State University and the University of Akron, The Ohio Substance Abuse Monitoring Network, Executive Summary, Ohio Department of Alcohol and Drug Addiction Services, January 2008-July 2008	JAN-TREX-00094271	JAN-TREX-00094273							
JA-04512	06/30/1905	Ohio Mental Health and Addiction Services, Prescription Opioids as a Primary Drug of Choice, Ohio Behavioral Health Module - State Fiscal Year 2008	JAN-TREX-00149787	JAN-TREX-00149787							
JA-04513	6/2008 - 1/2009	Wright State University School of Medicine, The Ohio Substance Abuse Monitoring Network, Executive Summary, Ohio Department of Alcohol and Drug Addiction Services, January 2008 - July 2008	JAN-TREX-00094274	JAN-TREX-00094276							
JA-04514	07/01/1905	Ohio Mental Health and Addiction Services, Prescription Opioids as a Primary Drug of Choice, Ohio Behavioral Health Module - State Fiscal Year 2009	JAN-TREX-00149788	JAN-TREX-00149788							
JA-04515	07/02/1905	Ohio Mental Health and Addiction Services, Prescription Opioids as a Primary Drug of Choice, Ohio Behavioral Health Module - State Fiscal Year 2010	JAN-TREX-00149789	JAN-TREX-00149789							
JA-04516	01/2011 - 06/2011	Ohio Department of Alcohol and Drug Addiction Services, Ohio Substance Abuse Monitoring Network, Surveillance of Drug Abuse Trends in the State of Ohio January - June 2011	JAN-TREX-00094277	JAN-TREX-00094283							
JA-04517	07/04/1905	Ohio Mental Health and Addiction Services, Prescription Opioids as a Primary Drug of Choice, Ohio Behavioral Health Module - State Fiscal Year 2012	JAN-TREX-00149790	JAN-TREX-00149790							
JA-04518	07/05/1905	Ohio Mental Health and Addiction Services, Prescription Opioids as a Primary Drug of Choice, Ohio Behavioral Health Module - State Fiscal Year 2013	JAN-TREX-00149791	JAN-TREX-00149791							
JA-04519	07/06/1905	Ohio Mental Health and Addiction Services, Prescription Opioids as a Primary Drug of Choice, Ohio Behavioral Health Module - State Fiscal Year 2014	JAN-TREX-00149792	JAN-TREX-00149792							
JA-04520	04/18/2000	Wright State University The University of Akron, Ohio Substance Abuse Monitoring Network, Statewide Increase in Heroin Use, Especially Among Younger Population, April 18, 2000	JAN-TREX-00149793	JAN-TREX-00149793							
JA-04521	04/01/2014	Ohio Department of Mental Health and Addiction Services, Increasing Heroin Overdoses in Ohio: Understanding the Issue, Epidemiological Report, No. 3, April 2014	JAN-TREX-00094284	JAN-TREX-00094295							
JA-04522	04/09/2019	Report: Opioid Prescriptions in Ohio Down, Availability Up, Cincinnati Public Radio, April 9, 2009	JAN-TREX-00094296	JAN-TREX-00094303							
JA-04523	08/01/2009	Daniulaityte R, et al., Illicit Use of Pharmaceutical Opioids Among Young Polydrug Users in Ohio, Addict Behav., 34(8), pp. 649-653, August 2009	JAN-TREX-00094304	JAN-TREX-00094314							
JA-04524	2002 - 2012	Substance Abuse Mental Health Services Administration, Center for Behavioral Health Statistics and Quality, Treatment Episode Data Set (TEDS), State Admissions to Substance Abuse Treatment Services, BHSIS Series S-72, HHS Publication No. 14-4889, 2002-2012	JAN-TREX-00094315	JAN-TREX-00094493							
JA-04525	1989 - 2019	Westlaw Search Results, Akron Beacon Journal	JAN-TREX-00094494	JAN-TREX-00094598							
JA-04526	1992 - 2018	Westlaw Search Results, Cleveland Plain Dealer	JAN-TREX-00094599	JAN-TREX-00094715							
JA-04527	1998-2008	Substance Abuse Mental Health Services Administration, Center for Behavioral Health Statistics and Quality, Treatment Episode Data Set (TEDS), State Admissions to Substance Abuse Treatment Services, DASIS Series S-55, HHS Publication No. 10-4613, 1998-2008	JAN-TREX-00094716	JAN-TREX-00094894							
JA-04528	06/2018-01/2019	Ohio Department of Mental Health and Addiction Services, Ohio Substance Abuse Monitoring Network: Surveillance of Drug Abuse Trends in the State of Ohio, June 2018-January 2019	JAN-TREX-00094895	JAN-TREX-00094922							
JA-04529	02/13/2001	Wright State University The University of Akron, Ohio Substance Abuse Monitoring Network, Increases in Methamphetamine Abuse May Be Near for Southwest, February 13, 2001	JAN-TREX-00094923	JAN-TREX-00094924							
JA-04530	02/12/2014	Email from Thomas Gilson to Stephen Stroka, et al.	JAN-TREX-00094925	JAN-TREX-00094926							
JA-04531	06/1999 -01/2000	Ohio Substance Abuse Monitoring Network, Surveillance of Drug Abuse Trends in the State of Ohio, June 1999-January 2000	JAN-TREX-00094927	JAN-TREX-00095057							
JA-04532	06/2001-01/2002	Ohio Substance Abuse Monitoring Network, Surveillance of Drug Abuse Trends in the State of Ohio, June 2001-January 2002	JAN-TREX-00095058	JAN-TREX-00095181							
JA-04533	01/01/2004	Wright State University The University of Akron, Ohio Substance Abuse Monitoring Network, Increase in Adolescents Abusing Over-the-Counter Medications Containing Dextromethorphan (DXM), January 2004	JAN-TREX-00149794	JAN-TREX-00149794							
JA-04534	01/01/2004	Wright State University The University of Akron, Ohio Substance Abuse Monitoring Network, PCP Abuse Reported in Several Areas of the State, January 2004	JAN-TREX-00149795	JAN-TREX-00149795							
JA-04535	01/01/2004	Wright State University The University of Akron, Ohio Substance Abuse Monitoring Network, Decreasing Prices of Powdered Cocaine Make it More Accessible to Diverse Users, January 2004	JAN-TREX-00149796	JAN-TREX-00149796							
JA-04536	01/01/2005	Wright State University The University of Akron, Ohio Substance Abuse Monitoring Network, Benzodiazepines and Patterns of Poly Substance Abuse Among High School and College Age Youth, January 2005	JAN-TREX-00149797	JAN-TREX-00149797							
JA-04537	01/01/2006	Wright State University The University of Akron, Ohio Substance Abuse Monitoring Network, Reports of Increases in Crack-Cocaine Injection Across the State, January 2006	JAN-TREX-00149798	JAN-TREX-00149798							
JA-04538	01/01/2006	Wright State University The University of Akron, Ohio Substance Abuse Monitoring Network, New Increases in Ecstasy Abuse Reported in Several Areas of the State, January 2006	JAN-TREX-00149799	JAN-TREX-00149799							
JA-04539	01/01/2006	Wright State University The University of Akron, Ohio Substance Abuse Monitoring Network, Crack-Cocaine Abuse Remains a Serious Problem in Urban and Rural Areas of Ohio, January 2006	JAN-TREX-00149800	JAN-TREX-00149800							
JA-04540	01/01/2008	Ohio Substance Abuse Monitoring (OSAM) Network press release, re: Continuing Increases in the Diversion of Suboxone, January 2008.	JAN-TREX-00149801	JAN-TREX-00149801							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-04541	01/01/2008	Ohio Substance Abuse Monitoring (OSAM) Network press release, re: Increasing Ecstasy Availability and Reports of Diversifying Users across the State, January 2008.	JAN-TREX-00149802	JAN-TREX-00149802							
JA-04542	06/2014 - 01/2015	Ohio Substance Abuse Monitoring (OSAM) Network press release, re: Surveillance of Drug Abuse Trends in the State of Ohio, June 2014-January 2015.	JAN-TREX-00149803	JAN-TREX-00149803							
JA-04543	01/01/2019	DEA special maps release, re: Tracking Fentanyl and Fentanyl-related Substances Reported in NFLIS-Drug by State, 2016-2017.	JAN-TREX-00095182	JAN-TREX-00095193							
JA-04544	01/24/2002	Ohio Substance Abuse Monitoring (OSAM) Network press release, re: OSAM Rapid Response Investigation Reveals Connection Between OxyContin Abuse and Heroin Addiction in Some Individuals	JAN-TREX-00149804	JAN-TREX-00149804							
JA-04545	01/01/2017	Department of Health and Human Services: Substance Abuse and Mental Health Services Administration (SAMHSA) Report; Treatment Episode Data Set (TEDS) 2005-2017; 2017 January	JAN-TREX-00095194	JAN-TREX-00095425							
JA-04546	07/26/2017	The Cuyahoga County Medical Examiners's Office detects Carfentanil in fake OxyContin pills, ABC 5 News Cleveland	JAN-TREX-00095426	JAN-TREX-00095430							
JA-04547	06/29/2000	Ohio Department of Alcohol and Drug Addiction Services Report; Surveillance of Drug Abuse Trends In The State of Ohio; June 2000	JAN-TREX-00095431	JAN-TREX-00095573							
JA-04548	06/01/2003	Ohio Substance Abuse Monitoring (OSAM) Network press release, re: Part I. Prescription Analgesic Abuse: Patterns of Prescription Analgesic Abuse and Perceived Risks, June 2003	JAN-TREX-00149805	JAN-TREX-00149805							
JA-04549	06/24/2005	Ohio Department of Alcohol and Drug Addiction Services Report; Surveillance of Drug Abuse Trends In The State of Ohio; June 2005	JAN-TREX-00095574	JAN-TREX-00095657							
JA-04550	06/01/2006	Ohio Substance Abuse Monitoring (OSAM) Network press release, re: Targeted Response Initiative on Young Heroin Users in Ohio Part II: Initiation to Heroin Use, June 2006	JAN-TREX-00149806	JAN-TREX-00149806							
JA-04551	03/01/2018	DEA Press Release, re: NFLIS Brief: Fentanyl and Fentanyl-Related Substances in NFLIS, 2015-2016	JAN-TREX-00095658	JAN-TREX-00095659							
JA-04552	05/20/2014	Ohio Department of Mental Health and Addiction Services Report; Comparing Accidental Drug Overdose Trends in Montgomery and 23 Other Ohio Counties: 2010 - June 2013	JAN-TREX-00095660	JAN-TREX-00095687							
JA-04553	05/01/2003	Ohio Substance Abuse Monitoring (OSAM) Network press release, re: Increases in Adderall Abuse Among High School and College-Aged Youth,, May 2003	JAN-TREX-00149807	JAN-TREX-00149807							
JA-04554	11/06/2002	Ohio Substance Abuse Monitoring (OSAM) Network press release, re: Methamphetamine Abuse Increasing in Stark and Summit Counties, November 2002	JAN-TREX-00149808	JAN-TREX-00149808							
JA-04555	09/27/2018	Substance Abuse and Mental Health Services Administration (SAMHSA) Report; Results From The 2017 National Survey On Drug Use And Health: Detailed Tables; September 2018	JAN-TREX-00095688	JAN-TREX-00098558							
JA-04556	10/10/2017	Email from LaMarca Lou to Loretta Ryland et al.	JAN-TREX-00098559	JAN-TREX-00098563							
JA-04557	10/01/2005	Ohio Substance Abuse Monitoring (OSAM) Network press release, re: Targeted Response Initiative on Methamphetamine Abuse in Ohio Part II: Perceived Trends in Methamphetamine Availability, October 2005	JAN-TREX-00149809	JAN-TREX-00149809							
JA-04558	05/01/2019	Ohio University, Meth and other psychostimulant-related overdose deaths grow by over 5,000 percent in Ohio, retrieved from https://www.ohio.edu/chsp/news/meth-and-other-psychostimulant-related-overdose-deaths-grow=over-5000-percent-ohio	JAN-TREX-00098564	JAN-TREX-00098567							
JA-04559	10/10/2001	Ohio Substance Abuse Monitoring (OSAM) Network press release, re:Ecstasy use Increasingly Common Outside of Traditional Venues & Appears to be Increasing in Popularity Among Minorities, October 2001	JAN-TREX-00149810	JAN-TREX-00149810							
JA-04560	10/05/2001	Ohio Substance Abuse Monitoring (OSAM) Network press release, re: Heroin Abuse Among White, Suburban Youth and Young Adults Continues to Rise and Spreads to Other Areas in Ohio, October 2001	JAN-TREX-00149811	JAN-TREX-00149811							
JA-04561	09/01/2004	Department of Health and Human Services: Substance Abuse and Mental Health Services Administration (SAMHSA) Report; Treatment Episode Data Set (TEDS) 1992-2002; 2004 September	JAN-TREX-00098568	JAN-TREX-00098800							
JA-04562	09/01/2013	Ohio Substance Abuse Monitoring (OSAM) Network press release, re: Methamphetamine Use Increasing in Multiple Regions, September 2013	JAN-TREX-00098801	JAN-TREX-00098802							
JA-04563	09/01/2015	Ohio Substance Abuse Monitoring (OSAM) Network press release, re: Much of Heroin Supply Adulterated with Fentanyl, September 2015	JAN-TREX-00098803	JAN-TREX-00098804							
JA-04564	10/15/2009	Invoice for website design and promotion, PriCara,	JAN-TREX-00098805	JAN-TREX-00099043							
JA-04565	10/15/2009	Invoice for website design and promotion, PriCara,	JAN-TREX-00099044	JAN-TREX-00099282							
JA-04566	07/01/2008	New Directions in Pain Presentation: Undertreatment of Pain: The Evidence is Compelling	JAN-TREX-00099283	JAN-TREX-00099299							
JA-04567	04/01/1996	Russell Portenoy, Opioid Therapy for Chronic Nonmalignant Pain: A review of the Critical Issues, Journal of Pain and Symptom Management, Vol. 11 No. 4, pp. 204 - 217, April 1996	JAN-TREX-00099300	JAN-TREX-00099314							
JA-04568	No Date	Curriculum Vitae Dr. Charles E. Argoff, M.D.	JAN-TREX-00099315	JAN-TREX-00099348							
JA-04569	No Date	Curriculum Vitae Steven Passik	JAN-TREX-00099349	JAN-TREX-00099362							
JA-04570	No Date	Curriculum Vitae Perry G. Fine, MD	JAN-TREX-00099363	JAN-TREX-00099443							
JA-04571	No Date	Curriculum Vitae Scott M. Fishman, M.D.	JAN-TREX-00099444	JAN-TREX-00099489							
JA-04572	No Date	PhRMA Code on Interactions with Healthcare Professionals,	JAN-TREX-00099490	JAN-TREX-00099498							
JA-04573	06/08/1905	Russell K. Portnoy, et. al., Chronic Use of Opioid Analgesics in Non-Malignant Pain: Report of 38 Cases, Pain, 25 (1986) 171-186, 1986	JAN-TREX-00099499	JAN-TREX-00099514							
JA-04574	No Date	Curriculum Vitae Russell K. Portenoy, M.D.	JAN-TREX-00099515	JAN-TREX-00099636							
JA-04575	03/30/2012	Draft advertising brochures for Janssen Pharmaceuticals	JAN-TREX-00099637	JAN-TREX-00099643							
JA-04576	No Date	Curriculum Vitae of Lynn R. Webster, M.D.	JAN-TREX-00099644	JAN-TREX-00099793							
JA-04577	06/27/1905	Lynn R. Webster, MD, et al., Predicting Aberrant Behaviors in Opioid-Treated Patients: Preliminary Validation of Opioid Risk Tool, Pain Medicine, Volume 6, Number 6, 2005	JAN-TREX-00099794	JAN-TREX-00099804							
JA-04578	No Date	Curriculum Vitae Richard Payne, MD	JAN-TREX-00099805	JAN-TREX-00099842							
JA-04579	07/08/1905	Valium (Diazepam) Label	JAN-TREX-00099843	JAN-TREX-00099857							
JA-04580	09/01/2016	Xanax (Alprazolam) Label	JAN-TREX-00099858	JAN-TREX-00099883							
JA-04581	06/01/2015	Extended-Release (ER and Long-Acting (LA) Opioid Analgesics Risk Elevation and Mitigation Strategy (REMS), FDA, 06/2015	JAN-TREX-00099884	JAN-TREX-00099928							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-04582	06/12/2019	FDA Briefing Document. Joint Meeting of the Drug Safety and Risk Management (DSaRM) Advisory Committee and Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC)	JAN-TREX-00099929	JAN-TREX-00100025							
JA-04583	10/23/2018	2017 National Survey on Drug Use and Health, Substance Abuse and Mental Health Services Administration Center for Behavioral Health Statistics and Quality, October 23, 2018	JAN-TREX-00100026	JAN-TREX-00100886							
JA-04584	05/01/1979	The Interagency Committee on New Therapies for Pain and Discomfort, Report of the White House, U.S. Department of Health, Education, and Welfare	JAN-TREX-00100887	JAN-TREX-00101150							
JA-04585	06/25/1905	L. Allan, et al., Transdermal Fentanyl Versus Sustained Release Morphine for Chronic Low Back Pain, OP0019, 2003	JAN-TREX-00101151	JAN-TREX-00101152							
JA-04586	07/07/1905	Robert Buynak, MD, Long-term Safety and Efficacy of Tapentadol Extended Release Following up to 2 Years of Treatment in Patients With Moderate to Severe, Chronic Pain: Results of an Open-Label Extension Trial, Clinical Therapeutics, Volume 37, Number 11, 2015	JAN-TREX-00101153	JAN-TREX-00101171							
JA-04587	07/01/1905	C. Lange, Long-Term Safety of Controlled, Adjustable Doeses of tapentadol Extended Release (ER) and Oxycodone Controlled release (CR: Results of a Randomized, Open-Label, Phase 3,1-Year Trial in Patients with Chronic Back or Osteoarthritis Pain, Euler, SAT0481 (2009)	JAN-TREX-00149812	JAN-TREX-00149812							
JA-04588	10/01/2010	Arthritis & Rheumatism, Volume 62, Number 10, October 2010.	JAN-TREX-00101172	JAN-TREX-00102209							
JA-04589	09/01/2010	Caleb J. Banta-Green, et. al. Opioid use behaviors, mental health and pain-Development of a typology of Chronic pain patients, Drug Alcohol Depend. 104(1-2):34-42, September 1, 2010.	JAN-TREX-00102210	JAN-TREX-00102229							
JA-04590	04/06/2010	Joesph A. Boscarino, et. al., Risk factors for drug dependence among out-patients on opioid therapy in large US Health-care system, Addiction Research Report, 105, 1776-1782, 04/06/2010	JAN-TREX-00102230	JAN-TREX-00102236							
JA-04591	07/11/2011	Joseph Boscarino, et al., Prevalence of Prescription Opioid-Use disorder Among Chronic pain Patients: Comparison of DSM-5 vs. DSM-4 Diagnostic material, Journal of Addictive Diseases, 30:185-194, 2011	JAN-TREX-00102237	JAN-TREX-00102247							
JA-04592	07/01/2014	Mark J. Edlund, et. al., The Role of Opioid Prescription in Incident Abuse and Dependence Among Individuals with Chronic Non-Cancer Pain; The Role of Opioid Prescription, Clin J Pain, 30(7): 557-564, July 2014	JAN-TREX-00102248	JAN-TREX-00102263							
JA-04593	06/30/1905	David A. Fishbain, MD, et al. What Percentage of Chroniz Nonmalignant pain Patients Exposed to Chronic Opioid Analgesic Therapy Develop Abuse/Addiction and/or Aberrant Drug-Related Behaviors? A Structured Evidence-Based Review, Pain Medicine, Volume 9, Number 4, 2008,	JAN-TREX-00102264	JAN-TREX-00102279							
JA-04594	07/01/2007	Michael F. Fleming, Substance Use Disorders in a Primary Care Sample Receiving Daily Opioid Therapy, The Journal of Pain, Vol 8, No 7, July 2007	JAN-TREX-00102280	JAN-TREX-00102289							
JA-04595	04/21/2018	C. Higgins, et al., Incidence of iatrogenic opioid dependence or abuse in patients with pain who were exposed to opioid analgesic therapy: a systematic review and meta-analysis, British Journal of Anesthesia, 120 (6): 1335-1344, April 2018	JAN-TREX-00102290	JAN-TREX-00102299							
JA-04596	06/01/2012	Silvia Minozzi, Development of Dependence following treatment with opioid analgesics for pain relief: a systematic review, Addiction, 2012	JAN-TREX-00102300	JAN-TREX-00102310							
JA-04597	07/02/1905	Meredith Noble, et. al. Long-Term opioid management for Chronic Noncancer Pain, Cochrane Pain, Issue 1. Art. No. CD006605, 2010	JAN-TREX-00102311	JAN-TREX-00102313							
JA-04598	No Date	U.S. Department of Health and Human Services, Prescription Drugs, Abuse and Addiction National Institute on Drug Abuse Research Report	JAN-TREX-00102314	JAN-TREX-00102325							
JA-04599	03/18/2016	CDC Guideline for Prescribing Opioids for Chronic Pain - United States, 2016	JAN-TREX-00102326	JAN-TREX-00102377							
JA-04600	07/11/1905	A guide to Safe use of Pain Medicine, FDA	JAN-TREX-00102378	JAN-TREX-00102382							
JA-04601	No Date	Timeline of Selected FDA Activities and Significant Events Addressing Opioid Misuse and Abuse, FDA	JAN-TREX-00102383	JAN-TREX-00102416							
JA-04602	05/05/2006	Edgar Adams, et al., A Comparison of the Abuse Liability of Tramadol, NSAIDs, and Hydrocodone in Patients with Chronic Pain, Journal of Pain and Symptom Management, Vol. 31, pp. 465-476, May 5, 2006	JAN-TREX-00102417	JAN-TREX-00102428							
JA-04603	06/29/1905	Theodore J. Cicero, PhD, The development of a Comprehensive Risk-Management Program for Prescription Opioid Analgesics: Researched Abuse, Diversion and Addiction-Related Surveillance, Pain Medicine, Volume 8, Number 2, 2007	JAN-TREX-00102429	JAN-TREX-00102442							
JA-04604	04/15/1999	Theodore J. Cicero, Edgar H. Adams, Anne Geller, James A. Inciardi, Alvaro Munoz, Sidney H. Schnoll, Edward C. Senay, George E. Woody, A postmarketing surveillance program to monitor Ultram (tramadol hydrochloride) abuse in the United States, Elsevier, Drug and Alcoho lDependence 57, pp. 7-22, 1999.	JAN-TREX-00114416	JAN-TREX-00114423							
JA-04605	06/27/1905	Theodore J. Cicero, et al., Rates of abuse of tramadol remain unchanged with the introduction of new branded and generic products: results of an abuse monitoring system, 1994-2004, Pharmacoepidemiology and Drug Safety, 14, 851-859, 2005	JAN-TREX-00102443	JAN-TREX-00102451							
JA-04606	04/01/2002	Janet S. Knisely, et. al. Tramadol post-marketing surveillance in health care professionals, Drug and Alcohol Dependence, 68, 15-22, 2002	JAN-TREX-00102452	JAN-TREX-00102459							
JA-04607	11/01/1994	William Arkinstall, et. al., Efficacy of controlled-release codeine in chronic non-malignant pain: a randomized, placebo-controlled clinical trial, Pain, 62, 169-178, 1995	JAN-TREX-00102460	JAN-TREX-00102469							
JA-04608	10/01/1998	Dellemijn PL et al., Prolonged Treatment with Transdermal Fentanyl in Neuropathic Pain, Journal of Pain and Symptom Management, 16(4), pp.220-229	JAN-TREX-00102470	JAN-TREX-00102479							
JA-04609	08/01/1997	Garcia J et al., Chronic Pain States: Pathophysiology and Medical Therapy, Seminars in Arthritis and Rheumatism, 27(1), pp. 1-16	JAN-TREX-00102480	JAN-TREX-00102495							
JA-04610	06/06/1992	Jadad AR et al., Morphine responsiveness of chronic pain: double-blind randomised crossover study with patient-controlled analgesia, Lancet, 339 (8806), pp. 1367-71	JAN-TREX-00102496	JAN-TREX-00102501							
JA-04611	01/20/1996	Moulin DE et al., Randomised trial of oral morphine for chronic non-cancer pain, Lancet, 347(8995), p. 143	JAN-TREX-00102502	JAN-TREX-00102515							
JA-04612	04/01/1993	Newshan GT et al., Pain Characteristics and Their Management in Persons with AIDS, JANAC, 4(2), pp. 53-59	JAN-TREX-00102516	JAN-TREX-00102522							
JA-04613	06/19/1905	Pappagallo M et al., Ethical Issues in the Management of Chronic Nonmalignant Pain, Seminars in Neurology, 17(3), pp. 203-211	JAN-TREX-00102523	JAN-TREX-00102533							
JA-04614	06/16/1905	Portenoy RK, Opioid Therapy for Chronic Nonmalignant Pain: Current Status, Progress in Pain Research and Management, Volume 1, pp. 247-287	JAN-TREX-00102534	JAN-TREX-00102576							
JA-04615	04/01/1994	Reidenberg MM et al., Commentary: The need for an open mind about the treatment of chronic nonmalignant pain, Clinical Pharmacology & Therapeutics, 55(4), pp. 367-69	JAN-TREX-00102577	JAN-TREX-00102580							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-04616	08/01/1991	Schug SA et al., Treatment Principles for the Use of Opioids in Pain of Nonmalignant Origin, Drugs, 42(2), pp. 228-239	JAN-TREX-00102581	JAN-TREX-00102594							
JA-04617	08/01/2002	U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Office of Applied Studies, Drug Abuse Warning Network: Development of a New Design, Methodology Report	JAN-TREX-00102595	JAN-TREX-00102720							
JA-04618	08/01/2002	U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Office of Applied Studies, Emergency Department Trends From the Drug Abuse Warning Network, Final Estimates 1994-2001	JAN-TREX-00102721	JAN-TREX-00102862							
JA-04619	02/01/2002	U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Office of Applied Studies, Emergency Department Trends from the Drug Abuse Warning Network, Preliminary Estimates January-June 2001 with Revised Estimates 1994-2000	JAN-TREX-00102863	JAN-TREX-00103006							
JA-04620	06/01/2004	U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Fact Sheet, Who Uses Data from the New DAWN?	JAN-TREX-00103007	JAN-TREX-00103008							
JA-04621	08/09/2019	U.S. Drug Enforcement Agency, Drug Scheduling	JAN-TREX-00103009	JAN-TREX-00103011							
JA-04622	06/26/1905	Nagda J et al., Chapter 4, Definitions and Classifications of Pain, in Warfield CA et al., Principles and Practice of Pain Medicine, 2d ed., pp. 51-54	JAN-TREX-00103012	JAN-TREX-00103018							
JA-04623	11/11/1998	Eisenberg DM et al., Trends in Alternative Medicine Use in the United States, 1990-1997, JAMA, 280(18), pp. 1569-1575	JAN-TREX-00103019	JAN-TREX-00103025							
JA-04624	06/26/1905	Audette J, Chapter 7 Acupuncture, in Warfield CA et al., Principles and Practice of Pain Medicine, 2d ed., pp. 785-791	JAN-TREX-00103026	JAN-TREX-00103035							
JA-04625	06/26/1905	Leskowitz E, Chapter 77, Complementary and Alternative Medicine in Pain Management, in Warfield CA et al., Principles and Practice of Pain Medicine, 2d ed., pp. 780-784	JAN-TREX-00103036	JAN-TREX-00103043							
JA-04626	06/29/1905	Brennan F et al., Pain Management: A Fundamental Human Right, Anesthesia & Analgesia, 105(1), pp. 205-221	JAN-TREX-00103044	JAN-TREX-00103060							
JA-04627	10/11/2018	Lipman AG et al., Opioid Pharmacotherapy: Introduction, Principles & Practice of Pain Medicine, 2d ed., pp. 1-53	JAN-TREX-00103061	JAN-TREX-00103113							
JA-04628	06/08/1905	Morgan JP, American Opiophobia: Customary Underutilization of Opioid Analgesics, Controversies in Alcoholism and Substance Abuse, pp. 163-173	JAN-TREX-00103114	JAN-TREX-00103124							
JA-04629	06/19/1905	The Use of Opioids for the Treatment of Chronic Pain, A Consensus Statement from the American Academy of Pain Medicine and the American Pain Society, Clinical Journal of Pain, 13(1), pp. 6-8	JAN-TREX-00103125	JAN-TREX-00103128							
JA-04630	05/02/1998	Federation of State Medical Boards of the United States, Inc., Model Guidelines for the Use of Controlled Substances for the Treatment of Pain	JAN-TREX-00103129	JAN-TREX-00103132							
JA-04631	06/20/1905	Pappagallo M, The Concept of Pseudotolerance to Opioids, Journal of Pharmaceutical Care in Pain & Symptom Control, 6(2), pp. 95-98	JAN-TREX-00103133	JAN-TREX-00103136							
JA-04632	06/26/1905	Won A, Chapter 57, Pain in the Elderly, in Warfield CA et al., Principles and Practice of Pain Medicine, 2d ed., pp. 571-79	JAN-TREX-00103137	JAN-TREX-00103148							
JA-04633	06/28/1905	U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics, Health, United States, 2006, with Chartbook on Trends in the Health of Americans	JAN-TREX-00103149	JAN-TREX-00103707							
JA-04634	06/19/1905	The Use of Opioids for the Treatment of Chronic Pain, A Consensus Statement from the American Academy of Pain Medicine and the American Pain Society, Clinical Journal of Pain, 13(1), pp. 6-8	JAN-TREX-00103708	JAN-TREX-00103711							
JA-04635	12/01/2001	National Pharmaceutical Council, Inc., and Joint Commission on Accreditation of Healthcare Organizations, Pain: Current Understanding of Assessment, Management, and Treatments	JAN-TREX-00103712	JAN-TREX-00103812							
JA-04636	06/26/1905	Warfield CA et al., Preface, Principles and Practice of Pain Medicine, 2d ed., pp. xxi-xxiii	JAN-TREX-00103813	JAN-TREX-00103818							
JA-04637	05/14/2003	Rosenblum A et al., Pain Among Chemically Dependent Patients in Methadone Maintenance and Residential Treatment Facilities, JAMA 289(18), pp. 2370-2378	JAN-TREX-00103819	JAN-TREX-00103827							
JA-04638	06/22/1905	Fishman S., The War on Pain: How Breakthroughs in the New Field of Pain Medicine Are Turning the Tide Against Suffering	JAN-TREX-00103828	JAN-TREX-00103850							
JA-04639	06/26/1905	Macres S, Chapter 62, Adjuvant Analgesics, in Warfield CA et al., Principles and Practice of Pain Medicine, 2d ed., pp. 627-38	JAN-TREX-00103851	JAN-TREX-00103865							
JA-04640	NO DATE	Index, Findng Relief References	JAN-TREX-00103866	JAN-TREX-00103868							
JA-04641	05/09/2019	U.S. Department of Health and Human Services, Pain Management Best Practices Inter-Agency Task Force Report; Updates, Gaps, Inconsistencies, and Recommendations	JAN-TREX-00103869	JAN-TREX-00103984							
JA-04642	06/01/2009	American Pain Foundation, Pain Resource Guide: Getting the Help You Need	JAN-TREX-00103985	JAN-TREX-00104016							
JA-04643	NO DATE	American Pain Foundation, Pain Notebook	JAN-TREX-00104017	JAN-TREX-00104040							
JA-04644	01/23/2019	American Pain Society, Evidence Review, APS-AAPM Clinical Guidelines for the Use of Chronic Opioid Therapy in Chronic Noncancer Pain	JAN-TREX-00149815	JAN-TREX-00149815							
JA-04645	NO DATE	American Pain Society, Pain: Current Understanding of Assessment, Management, and Treatments	JAN-TREX-00104041	JAN-TREX-00104145							
JA-04646	06/16/2005	Libby RT, Treating Doctors as Drug Dealers: The DEA's War on Prescription Painkillers, Policy Analysis, 545, pp. 1-27	JAN-TREX-00104146	JAN-TREX-00104173							
JA-04647	11/13/2003	Ballantyne JC et al., Opioid Therapy for Chronic Pain, NEJM 349(20), pp. 1943-1953	JAN-TREX-00104174	JAN-TREX-00104184							
JA-04648	06/27/1905	Lowinson JH, Substance Abuse: A Comprehensive Textbook	JAN-TREX-00104185	JAN-TREX-00104228							
JA-04649	07/07/1905	McNaughton EC et al., Assessing Abuse Potential of New Analgesic Medications Following Market Release: An Evaluation of Internet Discussion of Tapentadol Abuse, Pain Medicine 2015(16), pp. 131-140	JAN-TREX-00104229	JAN-TREX-00104238							
JA-04650	04/06/2011	Bohnert ASB et al., Association Between Opioid Prescribing Patterns and Opioid Overdose-Related Deaths, JAMA, 305(13), pp. 1315-21	JAN-TREX-00104239	JAN-TREX-00104245							
JA-04651	12/01/2009	Boudreau D et al., Trends in De-facto Long-term Opioid Therapy for Chronic Non-Cancer Pain, NIH Public Access Manuscript	JAN-TREX-00104246	JAN-TREX-00104259							
JA-04652	02/01/2013	Cepeda MS et al., Comparison of Opioid Doctor Shopping for Tapentadol and Oxycodone: A Cohort Study, Journal of Pain 14(2), pp. 158-64	JAN-TREX-00104260	JAN-TREX-00104266							
JA-04653	10/01/2013	Cepeda MS et al., Comparison of Opioid Doctor Shopping for Tapentadol and Oxycodone: Results From A Cohort Study, Journal of Pain 14(10), pp. 1227-41	JAN-TREX-00104267	JAN-TREX-00104281							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-04654	07/08/1905	Dart RC et al., Diversion and Illicit Sale of Extended Release Tapentadol in the United States, Pain Medicine 2016(17), pp. 1490-96	JAN-TREX-00104282	JAN-TREX-00104288							
JA-04655	01/01/2013	Afilalo M et al., Efficacy of Tapentadol ER for Managing Moderate to Severe Chronic Pain, Pain Physician 2013(16), pp. 27-40	JAN-TREX-00104289	JAN-TREX-00104302							
JA-04656	05/01/2010	Vorsanger G et al., Evaluation of study discontinuations with tapentadol immediate release and oxycodone immediate release in patients with low back or osteoarthritis pain, Journal of Opioid Management 6(3), pp. 169-79	JAN-TREX-00104303	JAN-TREX-00104313							
JA-04657	05/01/2014	Galia E et al., Evaluation of the tamper-resistant properties of tapenadol extended-release tablets: Results of in vitro laboratory analyses, Journal of Opioid Management 10(3), pp. 149-58	JAN-TREX-00104314	JAN-TREX-00104323							
JA-04658	02/20/2013	Jones CM et al., Research Letter, Pharmaceutical Overdose Deaths, United States, 2010, JAMA 309(7), pp. 657-59	JAN-TREX-00104324	JAN-TREX-00104326							
JA-04659	05/04/2005	Kosinski MR et al., An observational study of health-related quality of life and pain outcomes in chronic low back pain patients treated with fentanyl transdermal system, Current Medical Research and Opinion 21(6), pp. 849-62	JAN-TREX-00104327	JAN-TREX-00104341							
JA-04660	08/22/2012	Kuehn BM, Methadone Overdose Deaths Rise With Increased Prescribing for Pain JAMA 308(8), pp. 749-50	JAN-TREX-00104342	JAN-TREX-00104343							
JA-04661	02/01/1992	Zenz M, Long-Term Oral Opioid Therapy in Patients With Chronic Nonmalignant Pain, Journal of Pain and Sympton Management 7(2), pp.69-77	JAN-TREX-00104344	JAN-TREX-00104352							
JA-04662	04/24/2019	Dowell D et al., Perspective: No Shortcuts to Safer Opioid Prescribing, NEJM	JAN-TREX-00104353	JAN-TREX-00104355							
JA-04663	07/06/1905	Dart RC et al., Nonmedical Use of Tapentadol Immediate Release by College Students, Clinical Journal of Pain 2014(30), pp. 685-92	JAN-TREX-00104356	JAN-TREX-00104363							
JA-04664	06/20/1905	Collett BJ, Opioid tolerance: the clinical perspective, British Journal of Anaesthesia 1998(81), pp. 58-8	JAN-TREX-00104364	JAN-TREX-00104374							
JA-04665	07/06/1905	DennisC.Turk, PhD, ElizabethJ.Dansie, PhD, HilaryD.Wilson, PhD, BruceMoskovitz, MD, and MyoungKim,PhD, Physicians' Beliefs and Likelihood of Prescribing Opioid Tamper-Resistant Formulations for Chronic Noncancer Pain Patients, WileyPeriodicals,Inc., Volume 14, pp. 625-636, 2014	JAN-TREX-00114424	JAN-TREX-00114431							
JA-04666	07/01/2011	Vorsanger G et al., Post hoc analysis of data from a 90-day clinical trial evaluating the tolerability and efficacy of tapentadol immediate release and oxycodone immediate release for the relief of moderate to severe pain in elderly and nonelderly patients, Pain Research and Management 16(4), pp. 245-51	JAN-TREX-00104375	JAN-TREX-00104381							
JA-04667	10/04/2012	Salinas GD et al., Primary care physician attitudes and perceptions of the impact of FDA-proposed REMS policy on prescription of extended-release and long-acting opioids, Journal of Pain Research 2012(5), pp. 363-69	JAN-TREX-00104382	JAN-TREX-00104388							
JA-04668	07/07/1905	Butler SF et al., Tapentadol Abuse Potential: A Postmarketing Evaluation Using a Sample of Individuals Evaluated for Substance Abuse Treatment, Pain Medicine 2015(16), pp. 119-30	JAN-TREX-00104389	JAN-TREX-00104400							
JA-04669	06/27/1905	Allan L, Transdermal Fentanyl Versus Sustained Release Oral Morphine in Strong-Opioid Naive Patients With Chronic Low Back Pain, SPINE 30(22), pp. 2484-90	JAN-TREX-00104401	JAN-TREX-00104407							
JA-04670	07/04/1905	Warner EA, Opioids for the Treatment of Chronic Noncancer Pain, The American Journal of Medicine 2012(125), pp. 1155-61	JAN-TREX-00104408	JAN-TREX-00104414							
JA-04671	06/30/1905	Wisniewski AM et al., The Epidemiologic Association Between Opioid Prescribing, Non-Medical Use, and Emergency Department Visits, Journal of Addictive Diseases 27(1), pp. 1-11	JAN-TREX-00104415	JAN-TREX-00104426							
JA-04672	07/06/1905	Wright ER, The iatrogenic epidemic of prescription drug abuse: County-level determinants of opioid availability and abuse, Drug and Alcohol Dependence 138(2014), pp. 209-15	JAN-TREX-00104427	JAN-TREX-00104433							
JA-04673	07/01/2005	FDA Alert: Postmarket Drug Safety Information for Patients and Providers	JAN-TREX-00104434	JAN-TREX-00104435							
JA-04674	07/15/2005	FDA Safety Warnings Regarding Use of Fentanyl Transdermal (Skin) Patches	JAN-TREX-00149816	JAN-TREX-00149816							
JA-04675	09/27/2004	Civil Case Information Statement and Amended Complaint	JAN-TREX-00104436	JAN-TREX-00104467							
JA-04676	07/06/2012	Complaint	JAN-TREX-00104468	JAN-TREX-00104575							
JA-04677	12/03/2014	Order	JAN-TREX-00104576	JAN-TREX-00104577							
JA-04678	07/10/2018	Civil Docket	JAN-TREX-00104578	JAN-TREX-00104582							
JA-04679	03/28/2017	Letter from Claire McCaskill to Alex Gorsky	JAN-TREX-00104583	JAN-TREX-00104587							
JA-04680	07/10/1905	U.S. Senate Homeland Security and Government Affairs Committee, Minority Staff Report, Fueling an Epidemic (Report Two): Exposing the Financial Ties Between Opioid Manufacturers and Third Party Advocacy Groups	JAN-TREX-00104588	JAN-TREX-00104610							
JA-04681	12/23/2010	Settlement Agreement and Release	JAN-TREX-00104611	JAN-TREX-00104621							
JA-04682	11/18/2010	Opinion	JAN-TREX-00104622	JAN-TREX-00104634							
JA-04683	08/22/2018	Court Docket	JAN-TREX-00104635	JAN-TREX-00104643							
JA-04684	12/23/2010	Settlement agreement between Janssen and West Vuirginia	JAN-TREX-00104644	JAN-TREX-00104654							
JA-04685	05/08/2012	Letter from Senators Max Baucus and Charles Grassley to William Weldon	JAN-TREX-00149817	JAN-TREX-00149817							
JA-04686	05/01/2013	Letter from Derrick Johnson to Janssen Custodian of Records	JAN-TREX-00104655	JAN-TREX-00104674							
JA-04687	05/29/2012	Complaint for Violation of the Federal False Claims Act	JAN-TREX-00104675	JAN-TREX-00104712							
JA-04688	09/30/2014	The Government's Notice of Election to Decline Intervention	JAN-TREX-00149818	JAN-TREX-00149818							
JA-04689	12/29/2014	Order of Dismissal	JAN-TREX-00149819	JAN-TREX-00149819							
JA-04690	07/10/2018	Civil docket for United States v. J&J	JAN-TREX-00104713	JAN-TREX-00104717							
JA-04691	03/18/1998	Letter from Elizabeth Turek to Stephen Sherman	JAN-MS-03090755	JAN-MS-03090851							
JA-04692	04/08/1998	Letter from Elizabeth M. Turek to Stephen W. Sherman	JAN-TREX-00149821	JAN-TREX-00149822							
JA-04693	04/16/1998	Letter from Stephen W. Sherman to Elizabeth M. Turek	JAN-TREX-00104718	JAN-TREX-00104720							
JA-04694	02/29/2000	Letter from Cynthia Chianese to Spencer Salis Enclosing Duragesic Marketing Materials	JAN-MS-03090864	JAN-MS-03090883							
JA-04695	11/01/2011	CDC Press Release, re: Prescription painkiller overdoses at epidemic levels	JAN-TREX-00104721	JAN-TREX-00104723							
JA-04696	11/04/2011	CDC, Morbidity and Mortality Weekly Report, Vol. 60, No. 43, Nov. 4, 2011	JAN-TREX-00104724	JAN-TREX-00104759							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-04697	08/25/2011	Janssen, Nucynta ER tablets Risk Evaluation and Mitigation Strategy	JAN-TREX-00104760	JAN-TREX-00104807							
JA-04698	08/19/2004	Letter from Judith A. Racoosin to Tania Hillmer	JAN-TREX-00104808	JAN-TREX-00104855							
JA-04699	07/06/1905	Janssen Website: Pain Management Resources Prescribe Responsibly, available at www.prescriberesponsibly.com	JAN-TREX-00149823	JAN-TREX-00149823							
JA-04700	04/16/2008	National Association of School Nurses Press Release, re: National Association of School Nurses Launches Educational Program to Address Surge of Prescription Drug Abuse by America's Youth	JAN-TREX-00104856	JAN-TREX-00104857							
JA-04701	11/01/2015	Buynak R, et al., Long-term Safety and Efficacy of Tapentadol Extended Release Following Up to 2 Years of Treatment in Patients With Moderate to Severe, Chronic Pain: Results of an Open-label Extension Trial, Clinical Therapeutics, Vol. 37, No. 11, pp. 2420-2438	JAN-TREX-00104858	JAN-TREX-00104876							
JA-04702	07/02/1905	Buynak R, et al., Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled Phase III study, Expert Opinion Pharmacother, 11(11), pp. 1787-1804	JAN-TREX-00104877	JAN-TREX-00104894							
JA-04703	03/2011 - 04/2011	Gilron I, et al., Pregabalin for Peripheral Neuropathic Pain: A Multicenter, Enriched Enrollment Randomized Withdrawal, Placebo-controlled Trial, The Clinical Journal of Pain, 27(3), pp. 185-193	JAN-TREX-00104895	JAN-TREX-00104909							
JA-04704	06/29/1905	Katz N, et al., A 12-week, randomized, placebo-controlled trial assessing the safety and efficacy of oxymorphone extended release for opioid-naïve patients with chronic low back pain, Current Medical Research and Opinion, 23:1, pp. 117-128	JAN-TREX-00104910	JAN-TREX-00104922							
JA-04705	12/02/2010	Schwartz S, et al., Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial, Current Medical Research & Opinion, Vol. 27, No. 1, pp. 151-162, 2011	JAN-TREX-00104923	JAN-TREX-00104934							
JA-04706	07/02/1905	Wild JE, et al., Long-term Safety and Tolerability of Tapentadol Extended Release for the Management of Chronic Low Back Pain or Osteoarthritis Pain, Pain Practice, Vol. 10, Iss. 5, pp. 416-427, 2010	JAN-TREX-00104935	JAN-TREX-00104946							
JA-04707	06/27/1905	Webster LR, Opioid Risk Tool, Predicting aberrant behaviors in Opioid-treated patients, Pain Med, 6(6), p. 432, available at www.drugabuse.gov/nidamed-medical-health-professionals	JAN-TREX-00104947	JAN-TREX-00104948							
JA-04708	02/09/2009	FDA Website: A Guide to Safe Use of Pain Medicine, available at www.fda.gov/consumers/consumer-updates/guide-safe-use-pain-medicine	JAN-TREX-00104949	JAN-TREX-00104954							
JA-04709	04/09/2019	Food and Drug Administration Press Release, Statement by Douglas Throckmorton, M.D., Deputy Center Director for Regulatory Programs in FDA's Center for Drug Evaluation and Research, on New Opioid Analgesic Labeling Changes to Give Providers Better Information for How to Properly Taper Patients Who Are Physically Dependent on Opioids, April 9, 2019	JAN-TREX-00104955	JAN-TREX-00104958							
JA-04710	06/18/1905	The Use of Opioids for the Treatment of Chronic Pain, American Pain Society News, pp. 77-79	JAN-TREX-00104959	JAN-TREX-00104961							
JA-04711	07/10/1905	American Medical Association House of Delegates (I-18), Report of Reference Committee B	JAN-TREX-00104962	JAN-TREX-00105001							
JA-04712	03/21/2017	Baker, DW, History of The Joint Commission's Pain Standards: Lessons for Today's Prescription Opioid Epidemic, JAMA, Vol. 317, No. 11, pp. 117-118	JAN-TREX-00105002	JAN-TREX-00105003							
JA-04713	06/12/1905	Benedetti C, et al., Systemic Analgesics, pp. 1640-1675	JAN-TREX-00105004	JAN-TREX-00105041							
JA-04714	No Date	Bonica JJ Presentation Abstract: Treatment of Cancer Pain: Current Status and Future Needs	JAN-TREX-00149824	JAN-TREX-00149824							
JA-04715	06/01/1905	Bonica JJ, Importance of the Problem, Advances in Pain Research and Therapy, Vol. 2, pp. 1-12	JAN-TREX-00105042	JAN-TREX-00105055							
JA-04716	10/01/2013	Cepeda MS, et al., Comparison of the Risks of Opioid Abuse or Dependence Between Tapentadol and Oxycodone: Results From a Cohort Study, The Journal of Pain, Vol. 14, No. 10, pp. 1227-1241	JAN-TREX-00105056	JAN-TREX-00105070							
JA-04717	02/01/2013	Cepeda MS, et al., Comparison of Opioid Abuse or Doctor Shopping for Tapentadol and Oxycodone: A Cohort Study, The Journal of Pain, Vol. 14, No. 2, pp. 158-164	JAN-TREX-00105071	JAN-TREX-00105077							
JA-04718	06/18/1980	Cohen F, Postsurgical Pain Relief: Patients' Status and Nurses' Medication Choices, Pain, Vol. 9, pp. 265-274	JAN-TREX-00105078	JAN-TREX-00105087							
JA-04719	03/18/2016	Dowell D, et al., CDC Guideline for Prescribing Opioids for Chronic Pain -- United States, 2016, MMWR, Vol. 65, No. 1, pp. 1-49	JAN-TREX-00105088	JAN-TREX-00105139							
JA-04720	09/14/2018	CDC, MMWR, Vol. 67, No. 36, pp. 1001-1006	JAN-TREX-00105140	JAN-TREX-00105145							
JA-04721	No Date	Andraae, Michael et al; Bayesian Responder Meta-Analysis of Regional Anesthetics to Prevent Chronic Pain After Iliac Crest Bone Graft Harvesting.	JAN-TREX-00105146	JAN-TREX-00105408							
JA-04722	08/01/2014	Dart RC, et al., Nonmedical Use of Tapentadol Immediate Release by College Students, Clinical J. of Pain, Vol. 30, No. 8, pp. 685-692	JAN-TREX-00105409	JAN-TREX-00105416							
JA-04723	10/01/2000	Department of Veterans Affairs, Pain as the 5th Vital Sign Toolkit	JAN-TREX-00105417	JAN-TREX-00105473							
JA-04724	06/09/1905	Donovan M, et al., Incidence and characteristics of pain in a sample of medical-surgical inpatients, Pain, Vol. 30, pp. 69-78	JAN-TREX-00105474	JAN-TREX-00105483							
JA-04725	07/02/2014	Etropolski M, et al., Safety and Tolerability of Tapentadol Extended Release in Moderate to Severe Chronic Osteoarthritis or Low Back Pain Management: Pooled Analysis of Randomized Controlled Trials, Advanced Therapy, Vol. 31, pp. 604-620	JAN-TREX-00105484	JAN-TREX-00105500							
JA-04726	06/27/1905	Federation of State Medical Boards of the United States, Inc., Model Policy for the Use of Controlled Substances for the Treatment of Pain, Journal of Pain & Palliative Care Pharmacotherapy, Vol. 19(2), pp. 73-78	JAN-TREX-00105501	JAN-TREX-00105506							
JA-04727	03/07/2013	Galvez R, et al., Tapentadol Prolonged Release Versus Strong Opioids for Severe, Chronic Low Back Pain: Results of an Open-Label, Phase 3b Study, Advances in Therapy, 30(3), pp. 229-259	JAN-TREX-00105507	JAN-TREX-00105537							
JA-04728	03/06/2019	Health Professional for Patients in Pain Organization: Health Professionals Call on the CDC to Address Misapplication of its Guideline on Opioids for Chronic Pain through Public Clarification and Impact Evaluation, available at https://healthprofessionalsforpatientsinpain.org/the-letter-1	JAN-TREX-00149825	JAN-TREX-00149825							
JA-04729	07/03/1905	Committee on Advancing Pain Research, Care, and Education, Board on Health Sciences Policy, Institute of Medicine of the National Academies, Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research	JAN-TREX-00105538	JAN-TREX-00105920							
JA-04730	06/27/1905	Kosinski MR, et al., An observational study of health-related quality of life and pain outcomes in chronic low back pain patients treated with fentanyl transdermal system, Current Medical Research and Opinion, Vol. 21, No. 6, pp. 849-862	JAN-TREX-00105921	JAN-TREX-00105935							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-04731	02/01/1973	Marks RM, et al., Undertreatment of Medical Inpatients with Narcotic Analgesics, Annals of Internal Medicine, Vol. 78, No. 2, pp. 173-181	JAN-TREX-00105936	JAN-TREX-00105944							
JA-04732	11/12/2003	Meldrum ML, A Capsule History of Pain Management, JAMA, Vol. 290, No. 18, pp. 2470-2475	JAN-TREX-00105945	JAN-TREX-00105950							
JA-04733	08/01/2015	Nahin R, Estimates of Pain Prevalence and Severity in Adults: United States 2012, The Journal of Pain, Vol. 16, No. 8, pp. 769-780	JAN-TREX-00105951	JAN-TREX-00105962							
JA-04734	05/19/1986	U.S Department of Health & Human Services, National Institutes of Health: The Integrated Approach to the Management of Pain: National Institute of Health Consensus Development Conference Statement May 19-21, 1986, available at https://consensus.nih.gov/1986/1986painmanagement055html.htm	JAN-TREX-00149826	JAN-TREX-00149830							
JA-04735	05/01/2001	Nugent M, et al., Long-Term Observations of Patients Receiving Transdermal Fentanyl After a Randomized Trial, Journal of Pain and Symptom Management, Vol. 21, No. 5, pp. 385-391	JAN-TREX-00105963	JAN-TREX-00105969							
JA-04736	06/08/1905	Portenoy RK, et al., Chronic Use of Opioid Analgesics in Non-Malignant Pain: Report of 38 Cases, Pain, Vol. 25, pp. 171-186	JAN-TREX-00105970	JAN-TREX-00105985							
JA-04737	06/26/1905	Reid C., et al., The World Health Organization three-step analgesic ladder comes of age, Palliative Medicine, Vol. 18, pp. 175-176	JAN-TREX-00105986	JAN-TREX-00105987							
JA-04738	01/29/2019	Chronic pain patients in need of opioids take anger and frustration to Attorney General's office, Kelly Roliard	JAN-TREX-00149831	JAN-TREX-00149831							
JA-04739	07/06/1905	Accepted abstracts, PAINWeek	JAN-TREX-00105988	JAN-TREX-00106256							
JA-04740	08/19/1983	Sriwatanakui K, et al., Analysis of Narcotic Analgesic Usage in the Treatment of Postoperative Pain, JAMA, Vol. 250, No. 7, pp. 926-929	JAN-TREX-00106257	JAN-TREX-00106260							
JA-04741	01/29/2019	Stanish E, Don't Punish Pain rally held to bring attention to chronic pain patients denied medication	JAN-TREX-00106261	JAN-TREX-00106264							
JA-04742	No Date	Twycross RG, The use of narcotic analgesics in terminal illness, pp. 10-17	JAN-TREX-00106265	JAN-TREX-00106272							
JA-04743	02/01/1992	HHS, Clinical Practice Guideline: Acute Pain Management: Operative or Medical Procedures and Trauma	JAN-TREX-00106273	JAN-TREX-00106436							
JA-04744	02/01/1992	HHS, Clinical Practice Guideline: Acute Pain Management: Operative or Medical Procedures and Trauma	JAN-TREX-00106437	JAN-TREX-00106600							
JA-04745	01/30/2019	Wingerter M, Confusion over opioid prescribing rules remains as Legislature returns, The Daily Oklahoman	JAN-TREX-00106601	JAN-TREX-00106603							
JA-04746	06/12/1905	WHO Expert Committee, Cancer pain relief and palliative care	JAN-TREX-00106604	JAN-TREX-00106679							
JA-04747	06/08/1905	WHO, Cancer Pain Relief	JAN-TREX-00106680	JAN-TREX-00106758							
JA-04748	06/18/1905	WHO, Cancer pain relief: with a guide to opioid availability, 2d ed	JAN-TREX-00106759	JAN-TREX-00106828							
JA-04749	03/14/2014	Wright ER, et al., The iatrogenic epidemic of prescription drug abuse: County-level determinants of opioid availability and abuse, Drug and Alcohol Dependence, Vol. 138, pp. 209-215	JAN-TREX-00106829	JAN-TREX-00106837							
JA-04750	08/05/2019	Haentzchel H., et al., Fentanyl-TTS (Durogesic) Reduces Pain and Improves Daytime Activity and Nighttime Sleep Quality in Patients with Pain Associated with Rheumatoid Arthritis, Darmstadt, Vol. 60, 2001	JAN-TREX-00106838	JAN-TREX-00106839							
JA-04751	05/04/1998	Passik SD, et al., Substantive Abuse Issues in Cancer Patients, Oncology, Vol. 12, No. 4, pp. 517-521	JAN-TREX-00106840	JAN-TREX-00106845							
JA-04752	03/05/2004	Gan TJ, et al., Patient preferences for acute pain treatment, British Journal of Anaesthesia, 92(5), pp. 681-688	JAN-TREX-00106846	JAN-TREX-00106853							
JA-04753	12/01/2001	National Pharmaceutical Council, Inc., Pain: Current Understanding of Assessment, Management, and Treatments	JAN-TREX-00106854	JAN-TREX-00106954							
JA-04754	06/29/1905	Pyati S, et al., Perioperative Pain Management, CNS Drugs, 21(3), pp. 185-211	JAN-TREX-00106955	JAN-TREX-00106981							
JA-04755	06/25/1905	Ballantyne JC, et al., Opioid Therapy for Chronic Pain, The New England Journal of Medicine, Vol. 349, pp. 1943-1953	JAN-TREX-00106982	JAN-TREX-00106992							
JA-04756	01/23/2008	Kelly JP, et al., Prevalence and characteristics of opioid use in the US adult population, Pain, Vol. 138, pp. 507-513	JAN-TREX-00106993	JAN-TREX-00106999							
JA-04757	06/27/1905	Coluzzi F, et al., Opioid therapy for chronic noncancer pain: practice guidelines for initiation and maintenance of therapy, Minerva Anestesiol, Vol. 71, pp. 425-433	JAN-TREX-00107000	JAN-TREX-00107008							
JA-04758	10/01/2008	Hong D, et al., The Side Effects of Morphine and Hydromorphone Patient-Controlled Analgesia, Anesthesia & Analgesia, Vol. 107, No. 4, pp. 1384-1389	JAN-TREX-00107009	JAN-TREX-00107014							
JA-04759	06/28/1905	Eisenberg E, et al., Opioids for neuropathic pain (Review), Cochrane Database of Systematic Reviews, Issue 3	JAN-TREX-00107015	JAN-TREX-00107058							
JA-04760	06/30/1905	Rollason V, et al., Pharmacogenetics of analgesics: toward the individualization of prescription, Pharmacogenomics, 9(7), pp. 905-933	JAN-TREX-00107059	JAN-TREX-00107087							
JA-04761	06/26/1905	Kalso E, et al., Opioids in chronic non-cancer pain: systematic review of efficacy and safety, Pain, Vol. 112, pp. 372-380	JAN-TREX-00107088	JAN-TREX-00107096							
JA-04762	06/20/1905	Lynch EP, et al., The Impact of Postoperative Pain on the Development of Postoperative Delirium, Anesthesia Analgesic, Vol. 86, pp. 781-785	JAN-TREX-00107097	JAN-TREX-00107101							
JA-04763	10/01/2000	Frederick Perkins, et al., Chronic Pain as an Outcome of Surgery, Anesthesiology, Vol. 93, pp. 1123-1133, October 2000	JAN-TREX-00107102	JAN-TREX-00107112							
JA-04764	06/28/1905	Bhushan Bhamb, et al., Survey of Select Practice Behaviors by Primary Care Physicians on the Use of Opioids for Chronic Pain, Current Medical Research and Opinion, Vol. 22, pp. 1859-1865, 2006	JAN-TREX-00107113	JAN-TREX-00107119							
JA-04765	06/28/1905	Beth Jung et al., The Risk of Action by the Drug Enforcement Administration Against Physicians Prescribing Opioids for Pain, Pain Medicine, Volume 7, Number 4, 2006	JAN-TREX-00107120	JAN-TREX-00107124							
JA-04766	06/27/1905	Kirsten Auret et al., Underutilisation of Opioids in Elderly Patients with Chronic Pain, Drugs Aging 2005; 22 (8), p. 641-654	JAN-TREX-00107125	JAN-TREX-00107139							
JA-04767	06/30/1905	David A. Fishbain et al., What Percentage of Chronic Nonmalignant Pain Patients Exposed to Chronic Opioid Analgesic Therapy Develop Abuse/Addiction and/or Aberrant Drug-Related Behaviors? A Structured Evidence-Based Review, Pain Medicine, Volume 9, Number 4, 2008	JAN-TREX-00107140	JAN-TREX-00107155							
JA-04768	06/25/1905	Howard A. Heit, Addiction, Physical Dependence, and Tolerance: Precise Definitions to Help Clinicians Evaluate and Treat Chronic Pain Patients, Journal of Pain & Palliative Care Pharmacotherapy, Vol. 17(1) 2003	JAN-TREX-00107156	JAN-TREX-00107170							
JA-04769	06/30/1905	Douglas L. Gourlay, et al., Pain and Addiction" Managing Risk Through Comprehensive Care, Journal of Addictive Diseases, Vol. 27(3), 2008	JAN-TREX-00107171	JAN-TREX-00107178							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-04770	No Date	Definitions Related to the Use of Opioids for the Treatment of Pain: Consensus Statement of the American Academy of Pain Medicine, the American Pain Society, and the American Society of Addiction Medicine, American Society of Addiction Medicine	JAN-TREX-00107179	JAN-TREX-00107182							
JA-04771	06/23/1905	George F. Koob, et al., Drug Addiction, Dysregulation of Reward, and Allostasis, Neuropsychopharmacology, 2001, Vol. 24, No. 2	JAN-TREX-00107183	JAN-TREX-00107215							
JA-04772	02/01/2001	Eric J.Nestler et al., Molecular Basis of Long-Termplasticity Underlying Addiction, Nature Reviews, Neuroscience, Volume 2, February 2001	JAN-TREX-00107216	JAN-TREX-00107225							
JA-04773	07/01/1999	Scott M. Fishman et al., The Opioid Contract in the Management of Chronic Pain, Journal of Pain and Symptom Management, Vol. 18, No. 1, July 1999	JAN-TREX-00107226	JAN-TREX-00107236							
JA-04774	07/01/1905	Howard A.Heit, et al., Pain: Substance Abuse Issues in the Treatment of Pain	JAN-TREX-00107237	JAN-TREX-00107254							
JA-04775	06/27/1905	Douglas L. Gourlay et al., Universal Precautions in Pain Medicine: A Rational Approach to the Treatment of Chronic Pain, Pain Medicine, Volume 6, Number 2, 2005	JAN-TREX-00107255	JAN-TREX-00107260							
JA-04776	10/01/2007	Nathaniel P. Katz, et al., Challenges in the Development of Prescription Opioid Abuse-deterrent Formulations, ClinJPain, Volume 23, Number 8, October 2007	JAN-TREX-00107261	JAN-TREX-00107273							
JA-04777	02/01/2009	Roger Chou et al., Clinical Guidelines for the Use of Chronic Opioid Therapy in Chronic Noncancer Pain The Journal of Pain, Vol 10, No 2 (February), 2009, :pp. 113-130	JAN-TREX-00107274	JAN-TREX-00107313							
JA-04778	03/23/2005	Kelvin Jordan, et al., A minimal clinically important difference was derived for the Roland-Morris Disability Questionnaire for low back pain, Journal of Clinical Epidemiology 59 (2006) 45–52	JAN-TREX-00107314	JAN-TREX-00107321							
JA-04779	09/01/2001	Kroenke, K. et al., Validity of a Brief Depression Severity Measure, Journal of General Internal Medicine, Vol. 16, pp. 606-613, September 2001	JAN-TREX-00107322	JAN-TREX-00107329							
JA-04780	06/24/1905	Jeffrey Dersh, et al., Chronic Pain and Psychopathology: Research Findings and Theoretical Considerations, Psychosomatic Medicine 64:773–786 (2002)	JAN-TREX-00107330	JAN-TREX-00107343							
JA-04781	06/30/1905	Steven D. Passik, et al., Addiction-Related Assessment Tools and Pain Management: Instruments for Screening, Treatment Planning, and Monitoring Compliance, Pain Medicine, Vol. 9, No. S2, 2008	JAN-TREX-00107344	JAN-TREX-00107365							
JA-04782	No Date	Steven D. Passik, et al., Monitoring outcomes during long-term opioid therapy for noncancer pain: Results with the Pain Assessment and Documentation Too, Journal of Opioid Management, November/December 200	JAN-TREX-00107366	JAN-TREX-00107375							
JA-04783	02/27/2004	Steven D. Passik, et al., A New Tool to Assess and Document Pain Outcomes in Chronic Pain Patients Receiving Opioid Therapy	JAN-TREX-00107376	JAN-TREX-00107385							
JA-04784	01/01/2008	Mark J. Fagan, et. al., Do Internal Medicine Residents Find Pain Medication Agreements Useful?, Clin. J. Pain, Volume 24, Number 1, January 2008	JAN-TREX-00107386	JAN-TREX-00107389							
JA-04785	03/01/2004	Howard A. Heit, at al., Urine Drug Testing in Pain Medicine, Journal of Pain and Symptom Management Vol. 27, No.3, March 2004	JAN-TREX-00107390	JAN-TREX-00107397							
JA-04786	No Date	Presentation: Urine Drug Testing in Primary Care	JAN-TREX-00107398	JAN-TREX-00107400							
JA-04787	05/01/2003	Andrew Rosenblum, et al., Prevalence and Characteristics of Chronic Pain Among Chemically Dependent Patients in Methadone Maintenance and Residential Treatment Facilities, JAMA, May 14, 2003—Vol 289, No.18	JAN-TREX-00107401	JAN-TREX-00107409							
JA-04788	07/17/2008	Miriam Kunz, et al., The relation between catastrophizing and facial responsiveness to pain, Pain 140 (2008) 127–134	JAN-TREX-00107410	JAN-TREX-00107417							
JA-04789	05/12/2006	Study review, Orthopaedic Nursing May/June 2006 Volume 25 Number 3	JAN-TREX-00107418	JAN-TREX-00107427							
JA-04790	06/16/1905	Michael E. Geisser, et al., ICatastrophizing, depression and the sensory, affective and evaluative aspects of chronic pain, Pain, 59 (1994) 79-83	JAN-TREX-00107428	JAN-TREX-00107432							
JA-04791	11/26/2006	Kenneth L. Kirsh, et al., Initial development of a survey tool to detect issues of chemical coping in chronic pain patients, Palliative and Supportive Care (2007), Vol. 5, pp.219–226	JAN-TREX-00107433	JAN-TREX-00107440							
JA-04792	11/10/2003	Matthew J. Bair, et al., Depression and Pain Comorbidity, Arch Intern Med, Vol. 163, Nov. 10, 2003	JAN-TREX-00107441	JAN-TREX-00107453							
JA-04793	06/01/1997	The Clinical Journal of Pain, Journal of the American Academy of Pain Medicine, Vol. 13, No. 2, June 1997	JAN-TREX-00107454	JAN-TREX-00107476							
JA-04794	06/17/1905	Dennis C. Turk, et al., Chronic pain and depression: role of perceived impact and perceived control in different age cohorts, Pain, 61 (1995) pp. 93-101	JAN-TREX-00107477	JAN-TREX-00107485							
JA-04795	06/10/1905	Thomas E. Rudy , et al., Chronic pain and depression: toward a cognitive-behavioral mediation model, Pain, 35 (1988) pp. 129-140	JAN-TREX-00107486	JAN-TREX-00107497							
JA-04796	03/01/2009	Christopher S. Nielsen, et al., Individual Differences in Pain Sensitivity:Measurement,Causation,and Consequences, The Journal of Pain, Vol 10, No. 3, March 2009: pp. 231-237	JAN-TREX-00107498	JAN-TREX-00107504							
JA-04797	06/28/1905	Robert R. Edwards, PhD, et al., Genetic Predictors of Acute and Chronic Pain	JAN-TREX-00107505	JAN-TREX-00107511							
JA-04798	01/12/2006	Jorn Lotsch, at al., Current evidence for a genetic modulation of the response to analgesics, Pain, Vol. 121, (2006), pp. 1-5	JAN-TREX-00107512	JAN-TREX-00107516							
JA-04799	05/01/2004	Model Policy for the Use of Controlled Substances for the Treatment of Pain Federation of State Medical Boards of the United States, Inc.	JAN-TREX-00107517	JAN-TREX-00107521							
JA-04800	06/13/1905	Charles S. Cleeland, PhD, Brief Pain Inventory (Short Form), Pain Research Group	JAN-TREX-00107522	JAN-TREX-00107523							
JA-04801	12/01/2001	Pain: Current Understanding of Assessment, Management,and Treatments, National Pharmaceutical Council, Inc and Joint Commission on Accreditation of Healthcare Organizations	JAN-TREX-00107524	JAN-TREX-00107624							
JA-04802	06/05/1905	Martin Roland, et al., A Study of the Natural History of Back Pain, Spine, Vol. 8, No. 2, 1983	JAN-TREX-00107625	JAN-TREX-00107628							
JA-04803	06/24/1905	Beverly K. Phillip, et al., The Economic Impact of Opioids on Postoperative Pain Management, Journal of Clinical Anesthesia Vol. 14, pp. 354–364, 2002	JAN-TREX-00107629	JAN-TREX-00107639							
JA-04804	11/01/2005	Andrew T. Trout, at al., Evaluation of Vertebroplasty with a Validated Outcome Measure: The Roland-Morris Disability Questionnaire, AJNR AmJNeuroradiol Vol. 26, pp. 2652–2657, November/December2005	JAN-TREX-00107640	JAN-TREX-00107645							
JA-04805	06/25/1905	Progress Note Pain Assessment and Documentation Tool, Janssen Pharmaceutica Products, L.P., 2003	JAN-TREX-00107646	JAN-TREX-00107647							
JA-04806	06/25/1905	Pain Rating Scale, The Pain Society 2003	JAN-TREX-00149832	JAN-TREX-00149832							
JA-04807	01/01/1988	Donna Lee Wong, et al., Pain in Children Comparison of Assessment Scales, Pediatric Nursing, Vol. 14, No. 1	JAN-TREX-00107648	JAN-TREX-00107656							
JA-04808	06/05/1905	Wong-Baker Faces Pain Rating Scale, Wong-Baker Faces Foundation	JAN-TREX-00149833	JAN-TREX-00149833							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-04809	07/02/1905	Interagency Guideline on Opioid Dosing for Chronic Non-cancer Pain, Agency Medical Directors Group	JAN-TREX-00107657	JAN-TREX-00107715							
JA-04810	06/17/1905	Richard L. Brown, et al., Conjoint screening questionnaires for alcohol and other drug abuse: criterion validity in a primary care practice, Wisconsin Medical Journal, 1995:94(3)	JAN-TREX-00107716	JAN-TREX-00107722							
JA-04811	01/24/2001	Diagnosis and Treatment of Drug Abuse in Family Practice, Treatment	JAN-TREX-00107723	JAN-TREX-00107728							
JA-04812	No Date	Lynn R. Webster, Opioid Risk Tool (ORT), www.PreventRxAbuse.org	JAN-TREX-00149834	JAN-TREX-00149834							
JA-04813	12/01/2010	Form: Opioid Progress Report Chronic, Non-Cancer Pain, Washington State Department of Labor and Industries	JAN-TREX-00107729	JAN-TREX-00107732							
JA-04814	06/30/1905	Deborah K. Stephenson, Guideline for Physicians Working in California Opioid Treatment Programs, California Society of Addiction Medicine	JAN-TREX-00107733	JAN-TREX-00107884							
JA-04815	07/01/1905	D.A. Tompkins, et al., Drug and Alcohol Dependence, Vol. 105 (2009), pp. 154–159	JAN-TREX-00107885	JAN-TREX-00107890							
JA-04816	09/01/2002	Charles Argoff, MD, Pharmacologic management of chronic pain, Vol 102, No 9, September 2002	JAN-TREX-00107891	JAN-TREX-00107896							
JA-04817	06/26/1905	Pain: Moving from Symptom Control toward Mechanism-Specific Pharmacologic Management, Am. Intern Med. 2004; Vol. 140, pp.441-451	JAN-TREX-00107897	JAN-TREX-00107907							
JA-04818	06/25/1905	Charles E. Argoff, MD, et al., Targeted Topical Peripheral Analgesics in the Management of Pain	JAN-TREX-00107908	JAN-TREX-00107912							
JA-04819	07/15/2008	Eduardo E. Benarroch, MD, et al., Descending monoaminergic pain modulation, Neurology 71, July 15, 2008	JAN-TREX-00107913	JAN-TREX-00107917							
JA-04820	01/01/2009	Brendan Bingham, et al., The molecular basis of pain and its clinical implications in rheumatology	JAN-TREX-00107918	JAN-TREX-00107927							
JA-04821	01/01/2006	Robert Raffa, Pharmacological aspects of successful long-term analgesia, Clin. Rheumatol (2006) 25 (Suppl 1): S9–S15	JAN-TREX-00107928	JAN-TREX-00107934							
JA-04822	06/29/1905	Robert H. Dworkin, at al., Pharmacologic management of neuropathic pain: Evidence-based recommendations, Pain, Vol. 132 (2007), pp. 237–251	JAN-TREX-00107935	JAN-TREX-00107949							
JA-04823	04/01/1997	Practice Guidelines for Chronic Pain Management, Anesthesiology, Bol. 86, No. 4, Apr. 1997	JAN-TREX-00107950	JAN-TREX-00107959							
JA-04824	06/01/2004	Practice Guidelines for Acute Pain Management in the Perioperative Setting, Anesthesiology 2004;100: pp. 1573–81	JAN-TREX-00107960	JAN-TREX-00107968							
JA-04825	01/04/2006	Xiaochun Jin, et al., Acute p38-Mediated Modulation of Tetrodotoxin-Resistant Sodium Channels in Mouse Sensory Neurons by Tumor Necrosis Factor-ff, The Journal of Neuroscience, January 4,2006, Vol. 26, pp. 246–255	JAN-TREX-00107969	JAN-TREX-00107978							
JA-04826	06/22/1905	Michael Costigan, et al., Pain: Molecular Mechanisms, The Journal of Pain, Vol 1, No. 3 (Fall), Suppl 1, 2000: pp 35-44	JAN-TREX-00107979	JAN-TREX-00107988							
JA-04827	07/13/2007	Linda R. Watkins, et al., “Listening” and “talking” to neurons: Implications of immune activation for pain control and increasing the efficacy of opioids	JAN-TREX-00107989	JAN-TREX-00108010							
JA-04828	11/02/2007	Mark R. Hutchinson, et al., Opioid-Induced Glial Activation: Mechanisms of Activation and Implications for Opioid Analgesia, Dependence, and Reward, The Scientific World Journal (2007) 7(S2), pp. 98–111	JAN-TREX-00108011	JAN-TREX-00108024							
JA-04829	10/01/1995	Prasad Koka, et al., Human Immunodeficiency Virus 1 Envelope Proteins Induce Interleukin 1,Tumor Necrosis Factor cx, and Nitric Oxide in Glial Cultures Derived from Fetal, Neonatal, and Adult Human Brain, J. Exp. Med., Volume 182, October 1995, pp. 941-952	JAN-TREX-00108025	JAN-TREX-00108035							
JA-04830	06/17/1905	Exposure to gp120 of HIV-I Induces an Increased Release of Arachidonic Acid in Rat Primary Neuronal Cell Culture Followed by NMDA Receptor-mediated Neu rotoxicity, European Journal of Neuroscience, Vol. 7, pp. 1353-1359, 1995	JAN-TREX-00108036	JAN-TREX-00108042							
JA-04831	06/19/1905	Sabino Vesce, et al., HIV-1 gpl20 glycoprotein affects the astrocyte control of extracellular glutamate by both inhibiting the uptake and stimulating the release of the amino acid, FEBS Letters, vol. 411 (1997), pp. 107-10	JAN-TREX-00108043	JAN-TREX-00108045							
JA-04832	05/11/2008	Alfonso Romero-Sandoval, at al., A comparison of spinal Iba1 and GFAP expression in rodent models of acute and chronic pain, www.sciencedirect.com	JAN-TREX-00108046	JAN-TREX-00108056							
JA-04833	08/14/2003	letters to nature, Nature, Vol. 424, 14 August 2003	JAN-TREX-00108057	JAN-TREX-00108062							
JA-04834	08/01/1999	R. J. Mannion, et al., Neurotrophins: Peripherally and centrally acting modulators of tactile stimulus-induced inflammatory pain hypersensitivity, Proc. Natl. Acad. Sci. USA Vol. 96,pp.9385–9390, August 1999	JAN-TREX-00108063	JAN-TREX-00108068							
JA-04835	09/26/2002	Ru-RongJi, et al., p38 MAPK Activation by NGF in Primary Sensory Neurons after Inflammation Increases TRPV1 Levels and Maintains Heat Hyperalgesia, Neuron, Vol.36, pp. 57–68, September 26, 2002	JAN-TREX-00108069	JAN-TREX-00108080							
JA-04836	05/15/2001	Allan Gottschak, et al., New Concepts in Acute Pain Therapy: Preemptive Analgesia, American family Physician, Vol. 63, No. 10	JAN-TREX-00108081	JAN-TREX-00108086							
JA-04837	06/19/1905	A. Stubhaug, et al., Longterm treatment of chronic neuropathic pain with the NMDA (N-methyl-D-aspartate) receptor antagonist ketamine, Acta Anaesthesiol Scand 1997; 41: 329-331	JAN-TREX-00108087	JAN-TREX-00108089							
JA-04838	10/12/1998	Denes Budai, et al., Endogenous Opioid Peptides Actingatm-Opioid Receptors in the Dorsal Horn Contribute to Midbrain Modulation of Spinal Nociceptive Neurons, The American Physiological Society	JAN-TREX-00108090	JAN-TREX-00108100							
JA-04839	02/01/2002	KarlaP.ZeitZ, at al., The 5-HT3 Subtype of Serotonin Receptor Contributes to Nociceptive Processing via a Novel Subset of Myelinated and Unmyelinated Nociceptors, The Journal of Neuroscience, February 1, 2002, Vol. 22(3): pp. 1010–1019	JAN-TREX-00108101	JAN-TREX-00108110							
JA-04840	07/20/1987	Fleetwood-Walker, S.M., et al., Antinociceptive Actions of Descending Dopaminergic Tracts on Cat and Rat Dorsal Horn Somatosensory Neurones, Journal of Physiology, (1988), 399, pp. 335-348, July 20, 1987	JAN-TREX-00108111	JAN-TREX-00108124							
JA-04841	10/23/2007	Coffeen, Ulises et al., Dopamine Receptors in the Anterior Insular Cortex Modulate Long-term Nociception in the Rat, European Journal of Pain, 12 (2008), pp. 535-543, October 23, 2007	JAN-TREX-00108125	JAN-TREX-00108133							
JA-04842	No Date	Reference Table beginning with Passik SD.	JAN-TREX-00108134	JAN-TREX-00108140							
JA-04843	07/25/2012	Letter from Physicians for Responsible Opioid Prescribing to the Food and Drug Administration	JAN-TREX-00108141	JAN-TREX-00108147							
JA-04844	01/01/2014	Food and Drug Administration, Guidance for Industry and FDA Staff Dear Health Care Provider Letters: Improving Communication of Important Safety Information, January 2014	JAN-TREX-00108148	JAN-TREX-00108167							
JA-04845	03/01/2005	Food and Drug Administration, Guidance for Industry Development and Use of Risk Minimization Action Plans, March 2005	JAN-TREX-00108168	JAN-TREX-00108194							
JA-04846	03/22/2005	Food and Drug Administration, Guidance for Industry Good Pharmacovigilance Practices and Pharmacoepidemiologic Assessment, March 22, 2005	JAN-TREX-00108195	JAN-TREX-00108217							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-04847	03/01/2005	Food and Drug Administration, Guidance for Industry Premarketing Risk Assessment, March 2005	JAN-TREX-00108218	JAN-TREX-00108245							
JA-04848	05/12/2001	Laurie Allan, et al., Randomised Crossover Trial of Transdermal Fentanyl and Sustained Release Oral Morphine for Treating Chronic Non Cancer Pain, BMJ, Vol. 322, pp. 1-7. May 12, 2001	JAN-TREX-00108246	JAN-TREX-00108252							
JA-04849	04/05/2000	David Joranson, et al., Trends in Medical Use and Abuse of Opioid Analgesics, JAMA, Vol. 283, No. 13, pp. 1710-1714, April 5, 2000	JAN-TREX-00108253	JAN-TREX-00108257							
JA-04850	12/14/2000	Keith Milligan, et al., Evaluation of Long-term Efficacy and Safety of Transdermal Fentanyl in the Treatment of Chronic Noncancer Pain, Journal of Pain, Vol. 2, pp. 197-204, December 14, 2000	JAN-TREX-00108258	JAN-TREX-00108265							
JA-04851	10/04/1997	Richard Simpson, et al., Transdermal Fentanyl as Treatment for Chronic Low Back Pain, Journal of Pain and Symptom Management, Vol. 14, pp. 218-224, October 4, 1997	JAN-TREX-00108266	JAN-TREX-00108272							
JA-04852	12/12/2002	James Zacny, et al., College on Problems of Drug Dependence Task Force on Prescription Opioid Non-medical Use and Abuse: Position Statement, Drug and Alcohol Dependence, 69(2003), pp. 215-232, December 12, 2002	JAN-TREX-00108273	JAN-TREX-00108290							
JA-04853	11/01/1996	Drug Utilization report, Ohio, 1996.	JAN-TREX-00120132	JAN-TREX-00120999							
JA-04854	01/15/1998	Drug Utilization report, Ohio, 1997.	JAN-TREX-00121000	JAN-TREX-00121816							
JA-04855	01/15/1999	Drug Utilization report, Ohio, 1998.	JAN-TREX-00121817	JAN-TREX-00122840							
JA-04856	01/15/2000	Drug Utilization report, Ohio, 1999.	JAN-TREX-00122841	JAN-TREX-00123847							
JA-04857	01/15/2001	Drug Utilization report, Ohio, 2000.	JAN-TREX-00123848	JAN-TREX-00124773							
JA-04858	01/15/2002	Drug Utilization report, Ohio, 2001.	JAN-TREX-00124774	JAN-TREX-00125676							
JA-04859	01/15/2003	Drug Utilization report, Ohio, 2002.	JAN-TREX-00125677	JAN-TREX-00126588							
JA-04860	01/15/2004	Drug Utilization report, Ohio, 2003.	JAN-TREX-00126589	JAN-TREX-00127484							
JA-04861	01/15/2005	Drug Utilization report, Ohio, 2004.	JAN-TREX-00127485	JAN-TREX-00128141							
JA-04862	01/15/2006	Drug Utilization report, Ohio, 2005.	JAN-TREX-00128142	JAN-TREX-00129002							
JA-04863	01/15/2007	Drug Utilization report, Ohio, 2006.	JAN-TREX-00129003	JAN-TREX-00129795							
JA-04864	01/15/2008	Drug Utilization report, Ohio, 2007.	JAN-TREX-00129796	JAN-TREX-00130561							
JA-04865	01/15/2009	Drug Utilization report, Ohio, 2008.	JAN-TREX-00130562	JAN-TREX-00131303							
JA-04866	01/15/2010	Drug Utilization report, Ohio, 2009.	JAN-TREX-00131304	JAN-TREX-00132090							
JA-04867	01/15/2011	Drug Utilization report, Ohio, 2010.	JAN-TREX-00132091	JAN-TREX-00133042							
JA-04868	01/15/2012	Drug Utilization report, Ohio, 2011.	JAN-TREX-00133043	JAN-TREX-00133943							
JA-04869	01/15/2013	Drug Utilization report, Ohio, 2012.	JAN-TREX-00133944	JAN-TREX-00135895							
JA-04870	07/05/1905	Drug Utilization report, Ohio, 2013	JAN-TREX-00135896	JAN-TREX-00137999							
JA-04871	07/06/1905	Drug Utilization report, Ohio, 2014	JAN-TREX-00138000	JAN-TREX-00140176							
JA-04872	07/07/1905	Drug Utilization report, Ohio, 2015	JAN-TREX-00140177	JAN-TREX-00142377							
JA-04873	07/08/1905	Drug Utilization report, Ohio, 2016	JAN-TREX-00142378	JAN-TREX-00144566							
JA-04874	07/09/1905	Drug Utilization report, Ohio, 2017	JAN-TREX-00144567	JAN-TREX-00146847							
JA-04875	07/10/1905	Drug Utilization report, Ohio, 2018	JAN-TREX-00146848	JAN-TREX-00149113							
JA-04876	07/11/1905	Drug Utilization report, Ohio, 2019	JAN-TREX-00149114	JAN-TREX-00149692							
JA-04877	05/01/2017	GCOAT: Action Guide to Address Opioid Abuse	JAN-TREX-00149973	JAN-TREX-00149992							
JA-04878	No Date	GCOAT: Expanding Ohio's Opioid Prescribing Guidelines.	JAN-TREX-00149993	JAN-TREX-00149994							
JA-04879	06/01/2018	GCOAT: Action Guide to Address Opioid Abuse	JAN-TREX-00149995	JAN-TREX-00150014							
JA-04880	07/01/2015	GCOAT: Health Resource Toolkit for Addressing Opioid Abuse	JAN-TREX-00150015	JAN-TREX-00150030							
JA-04881	07/10/1905	Medical Mutual: 2018 Prescription Drug Formulary	JAN-TREX-00150031	JAN-TREX-00150200							
JA-04882	01/01/2017	Medical Mutual: Agreement with County of Summit.	JAN-TREX-00150201	JAN-TREX-00150254							
JA-04883	07/09/1905	Medical Mutual: 2017 Prescription Drug Formulary	JAN-TREX-00150255	JAN-TREX-00150403							
JA-04884	01/01/2018	Medical Mutual: Medical Policy regarding Pain Management Medications.	JAN-TREX-00150404	JAN-TREX-00150411							
JA-04885	07/11/2018	Email from Margaret Carr to Jim Dustin.	JAN-TREX-00150412	JAN-TREX-00150412							
JA-04886	07/12/2017	Email from Lorrie Goodnight to Records.	JAN-TREX-00150413	JAN-TREX-00150414							
JA-04887	07/16/2018	Email from Kathy Pietz to Margaret Carr.	JAN-TREX-00150415	JAN-TREX-00150417							
JA-04888	07/13/2018	Email from Kathy Pietz to Margaret Carr.	JAN-TREX-00150418	JAN-TREX-00150426							
JA-04889	07/24/2018	Medical Mutual: : County of Summit: Utilization Chapter Detail	JAN-TREX-00150427	JAN-TREX-00150427							
JA-04890	01/09/2018	Purchase Order, County of Summit, Ohio.	JAN-TREX-00150428	JAN-TREX-00150464							
JA-04891	12/21/2018	Notice of Videotaped 30(b)(6) Deposition of the County of Summit.	JAN-TREX-00150465	JAN-TREX-00150476							
JA-04892	09/15/2010	Ohio Department of Job and Family Services Drug Utilization Review Board Quarterly Meeting	JAN-TREX-00150477	JAN-TREX-00150479							
JA-04893	06/29/2011	Ohio Department of Job and Family Services P&T Committee Meeting Minutes	JAN-TREX-00150480	JAN-TREX-00150566							
JA-04894	05/08/2012	Ohio Department of Job and Family Services Drug Utilization Review Board Quarterly Meeting	JAN-TREX-00150567	JAN-TREX-00150586							
JA-04895	05/21/2013	Ohio Department of Job and Family Services Drug Utilization Review Board Quarterly Meeting	JAN-TREX-00150587	JAN-TREX-00150596							
JA-04896	06/12/2013	Ohio Department of Job and Family Services P&T Committee Meeting Minutes	JAN-TREX-00150597	JAN-TREX-00150681							
JA-04897	11/18/2014	Ohio Department of Medicaid Drug Utilization Review Board Quarterly Meeting	JAN-TREX-00150682	JAN-TREX-00150683							
JA-04898	04/08/2015	Ohio Department of Medicaid P&T Committee Meeting Minutes	JAN-TREX-00150684	JAN-TREX-00150704							
JA-04899	05/17/2016	Ohio Department of Medicaid Drug Utilization Review Board Quarterly Meeting	JAN-TREX-00150705	JAN-TREX-00150706							
JA-04900	03/20/2014	5162.71 Implementation of Systems to Improve Health and Reduce Health Disparities. Ohio Revised Code Annotated.	JAN-TREX-00150707	JAN-TREX-00150707							
JA-04901	09/11/2019	Drug Utilization Review Board: pharmacy.medicaid.ohio.gov	JAN-TREX-00150708	JAN-TREX-00150709							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-04902	07/01/1992	Cleveland Plain Dealer: Druggist, Pharmacy Targeted in Fraud Probe.	JAN-TREX-00150710	JAN-TREX-00150712							
JA-04903	10/01/2010	Ohio Prescription Drug Abuse Task Force: Final Report: Task Force Recommendations	JAN-TREX-00150713	JAN-TREX-00150787							
JA-04904	06/10/2015	Ohio Department of Medicaid P&T Committee Meeting Minutes	JAN-TREX-00150788	JAN-TREX-00151018							
JA-04905	05/19/2010	Ohio Department of Job and Family Services Drug Utilization Review Board Quarterly Meeting	JAN-TREX-00151019	JAN-TREX-00151021							
JA-04906	05/24/2006	Ohio Department of Medicaid Drug Utilization Review Board Agenda	JAN-TREX-00151022	JAN-TREX-00151022							
JA-04907	05/11/2005	Ohio Department of Job and Family Services Drug Utilization Review Board Quarterly Meeting	JAN-TREX-00151023	JAN-TREX-00151025							
JA-04908	No Date	Cincinnati Children's Project: Limiting Prescribed Opioid Doses Through Standardized Plan Efforts	JAN-TREX-00151026	JAN-TREX-00151040							
JA-04909	09/01/2012	Ohio Department of Job and Family Services: A Drug Utilization Review of Duplicative Long-Acting Opiate Use	JAN-TREX-00151041	JAN-TREX-00151042							
JA-04910	04/03/2010	Columbus Dispatch: Ohio Taking Aim at Opiates	JAN-TREX-00151043	JAN-TREX-00151045							
JA-04911	No Date	Ohio Department of Medicaid: Timeline: Collective Action to Address the Opioid Crisis in Ohio 2011-2015; 2016-2020	JAN-TREX-00151046	JAN-TREX-00151047							
JA-04912	11/16/2011	Opiate Cabinet Action Team Leads Meeting	JAN-TREX-00151048	JAN-TREX-00151048							
JA-04913	02/15/2012	Opiate Cabinet Action Team: Team Leads Meeting Minutes	JAN-TREX-00151049	JAN-TREX-00151051							
JA-04914	03/21/2012	Opiate Cabinet Action Team: Team Leads Meeting Minutes	JAN-TREX-00151052	JAN-TREX-00151054							
JA-04915	05/16/2012	Govenor's Cabinet Opiate Action Team: Team Leads Meeting Minutes	JAN-TREX-00151055	JAN-TREX-00151056							
JA-04916	06/14/2012	Govenor's Cabinet Opiate Action Team: Team Leads Meeting Minutes	JAN-TREX-00151057	JAN-TREX-00151059							
JA-04917	07/25/2012	Govenor's Cabinet Opiate Action Team: Team Leads Meeting Minutes	JAN-TREX-00151060	JAN-TREX-00151061							
JA-04918	01/09/2012	Opiate Cabinet Action Team: Treatment Workgroup Meeting Minutes	JAN-TREX-00151062	JAN-TREX-00151063							
JA-04919	04/16/2012	Govenor's Cabinet Opiate Action Team: Team Leads Meeting Minutes/Provider/Consumer Fraud Coordinated Services Program	JAN-TREX-00151064	JAN-TREX-00151066							
JA-04920	10/03/2018	Ohio Department of Medicaid, Pharmacy & Therapeutics Committee By-Laws	JAN-TREX-00151067	JAN-TREX-00151070							
JA-04921	02/03/2011	Article: Sen. Brown: Crack Down on Medicaid Prescription Drug Fraud by Preventing "Doctor Shopping" and "Pharmacy Hopping."; https://www.brown.senate.gov/newsroom/press/release/sen-brown-crack-down-on-medicaid-prescription-drug-fraud-by-preventing-doctor-shopping-and-pharmacy-hopping	JAN-TREX-00151071	JAN-TREX-00151072							
JA-04922	07/20/2003	Columbus Dispatch: Waiting List Puts Methadone on Streets	JAN-TREX-00151073	JAN-TREX-00151077							
JA-04923	01/23/2018	Wiggam S., Testimony on the Drug Trafficking Deterrence Act	JAN-TREX-00151078	JAN-TREX-00151078							
JA-04924	12/21/2017	Ohio House of Representatives Website, Rep. Wiggam Announces Drug Trafficking Deterrence Act, available at www.ohiohouse.gov/scott-wiggam/press/rep-wiggam-announces-drug-trafficking-deterrence-act	JAN-TREX-00151079	JAN-TREX-00151080							
JA-04925	04/26/2012	Prescription drug abuse remains target of local lawmaker, Akron Legal News	JAN-TREX-00151081	JAN-TREX-00151082							
JA-04926	03/20/2014	Implementation of systems to improve health and reduce health disparities, Ohio Revised Code s 5162.71	JAN-TREX-00151083	JAN-TREX-00151083							
JA-04927	06/05/2019	Current Legislative Priorities; https://www.ohiopharmacists.org/aws/OPA/pt/sd/news_article/02887/_Parent/layout_interior_details/true	JAN-TREX-00151084	JAN-TREX-00151087							
JA-04928	07/01/1992	Druggist, Pharmacy Targeted in Fraud Probe, Plain Dealer (Cleveland)	JAN-TREX-00151088	JAN-TREX-00151090							
JA-04929	01/19/2017	Federal Court: Oxycodone ring members sentenced, Examiner (Independence, MO)	JAN-TREX-00151091	JAN-TREX-00151092							
JA-04930	12/13/2016	Federal Court: Women sentenced in oxycodone schemes, Examiner (Independence, MO)	JAN-TREX-00151093	JAN-TREX-00151094							
JA-04931	10/01/2010	Ohio Prescription Drug Abuse Task Force, Task Force Recommendations, Final Report	JAN-TREX-00151095	JAN-TREX-00151169							
JA-04932	05/12/1988	Governor's Task Force on Prescription Drug Abuse, Final Report	JAN-TREX-00151170	JAN-TREX-00151190							
JA-04933	06/30/2011	Action Plan for Improving Access to Prescription Drug Monitoring Programs Through Health Information Technology	JAN-TREX-00151191	JAN-TREX-00151210							
JA-04934	06/28/1905	Inciardi J., et al., The Diversion Prescription Drugs by Health Care Workers in Cincinnati, Ohio, Substance Use & Misuse, Vol. 41, pp. 255-264	JAN-TREX-00151211	JAN-TREX-00151220							
JA-04935	01/01/1986	The Ohio State Medical Journal, Vol. 82, No. 1	JAN-TREX-00151221	JAN-TREX-00151266							
JA-04936	05/01/1986	Doctor: Are You Being Duped? Beware! Some substance abusers are counting on you . . . , The Ohio State Medical Journal	JAN-TREX-00151267	JAN-TREX-00151272							
JA-04937	11/01/1989	Governor's Office of Criminal Justice Services, Understanding the Enemy: An Informational Overview of Substance Abuse in Ohio	JAN-TREX-00151273	JAN-TREX-00151340							
JA-04938	07/08/1905	OARRS Annual Report	JAN-TREX-00151341	JAN-TREX-00151354							
JA-04939	No Date	Cincinnati Children's Presentation: Limiting Prescribed Opioid Doses Through Standardized Plan Efforts	JAN-TREX-00151355	JAN-TREX-00151369							
JA-04940	09/01/2012	Griffith, JRK, A Drug Utilization Review of Duplicative Long-Acting Opiate Use	JAN-TREX-00151370	JAN-TREX-00151371							
JA-04941	04/03/2010	Ohio Taking Aim at Opiates, Columbus Dispatch (Ohio)	JAN-TREX-00151372	JAN-TREX-00151374							
JA-04942	2011 - 2015	Timeline: Collective Action to Address the Opioid Crisis in Ohio	JAN-TREX-00151375	JAN-TREX-00151376							
JA-04943	11/16/2011	Governor's Cabinet Opiate Action Team- Team Leads Meeting Minutes	JAN-TREX-00151377	JAN-TREX-00151377							
JA-04944	02/15/2012	Governor's Cabinet Opiate Action Team- Team Leads Meeting Minutes	JAN-TREX-00151378	JAN-TREX-00151380							
JA-04945	03/21/2012	Governor's Cabinet Opiate Action Team- Team Leads Meeting Minutes	JAN-TREX-00151381	JAN-TREX-00151383							
JA-04946	05/16/2012	Governor's Cabinet Opiate Action Team- Team Leads Meeting Minutes	JAN-TREX-00151384	JAN-TREX-00151385							
JA-04947	06/14/2012	Governor's Cabinet Opiate Action Team- Team Leads Meeting Minutes	JAN-TREX-00151386	JAN-TREX-00151388							
JA-04948	07/25/2012	Governor's Cabinet Opiate Action Team- Team Leads Meeting Minutes	JAN-TREX-00151389	JAN-TREX-00151390							
JA-04949	01/09/2012	Governor's Cabinet Opiate Action Team- Treatment Workgroup Meeting Minutes	JAN-TREX-00151391	JAN-TREX-00151392							
JA-04950	06/03/2019	July Legislative Update: Narcotics Abuse Prevention, Dispensing Fees, E-Prescribing Controlled Substances, Ohio Pharmacists Association	JAN-TREX-00151393	JAN-TREX-00151396							
JA-04951	07/11/1905	Ohio Administrative Code 4715-6-03: Prescribing for subacute and chronic pain	JAN-TREX-00151397	JAN-TREX-00151402							
JA-04952	04/13/2018	Ohio Administrative Code 4715-6-03: Prescribing for subacute and chronic pain	JAN-TREX-00151403	JAN-TREX-00151408							
JA-04953	06/25/1905	The "Perfect Storm": Drug Abuse Converges in the Heartland, Vital Signs	JAN-TREX-00151409	JAN-TREX-00151410							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-04954	07/11/1905	Ohio General Information: Number of Unintentional Drug Overdose Deaths Involving Specific Drugs As Mentioned on Death Certificate, by Year, Ohio 2005-2017	JAN-TREX-00151411	JAN-TREX-00151417							
JA-04955	06/18/1905	Utilization Spreadsheet	JAN-TREX-00151418	JAN-TREX-00152285							
JA-04956	06/19/1905	Utilization Spreadsheet	JAN-TREX-00152286	JAN-TREX-00153102							
JA-04957	06/20/1905	Utilization Spreadsheet	JAN-TREX-00153103	JAN-TREX-00154126							
JA-04958	06/21/1905	Utilization Spreadsheet	JAN-TREX-00154127	JAN-TREX-00155133							
JA-04959	06/22/1905	Utilization Spreadsheet	JAN-TREX-00155134	JAN-TREX-00156059							
JA-04960	06/23/1905	Utilization Spreadsheet	JAN-TREX-00156060	JAN-TREX-00156962							
JA-04961	06/24/1905	Utilization Spreadsheet	JAN-TREX-00156963	JAN-TREX-00157874							
JA-04962	06/25/1905	Utilization Spreadsheet	JAN-TREX-00157875	JAN-TREX-00158770							
JA-04963	06/26/1905	Utilization Spreadsheet	JAN-TREX-00158771	JAN-TREX-00159427							
JA-04964	06/27/1905	Utilization Spreadsheet	JAN-TREX-00159428	JAN-TREX-00160288							
JA-04965	06/28/1905	Utilization Spreadsheet	JAN-TREX-00160289	JAN-TREX-00161081							
JA-04966	06/29/1905	Utilization Spreadsheet	JAN-TREX-00161082	JAN-TREX-00161847							
JA-04967	06/30/1905	Utilization Spreadsheet	JAN-TREX-00161848	JAN-TREX-00162589							
JA-04968	07/01/1905	Utilization Spreadsheet	JAN-TREX-00162590	JAN-TREX-00163376							
JA-04969	07/02/1905	Utilization Spreadsheet	JAN-TREX-00163377	JAN-TREX-00164328							
JA-04970	07/03/1905	Utilization Spreadsheet	JAN-TREX-00164329	JAN-TREX-00165229							
JA-04971	07/04/1905	Utilization Spreadsheet	JAN-TREX-00165230	JAN-TREX-00167181							
JA-04972	07/05/1905	Utilization Spreadsheet	JAN-TREX-00167182	JAN-TREX-00169285							
JA-04973	07/06/1905	Utilization Spreadsheet	JAN-TREX-00169286	JAN-TREX-00171462							
JA-04974	07/07/1905	Utilization Spreadsheet	JAN-TREX-00171463	JAN-TREX-00173663							
JA-04975	07/08/1905	Utilization Spreadsheet	JAN-TREX-00173664	JAN-TREX-00175852							
JA-04976	07/09/1905	Utilization Spreadsheet	JAN-TREX-00175853	JAN-TREX-00178133							
JA-04977	07/10/1905	Utilization Spreadsheet	JAN-TREX-00178134	JAN-TREX-00180399							
JA-04978	07/11/1905	Utilization Spreadsheet	JAN-TREX-00180400	JAN-TREX-00180978							
JA-04979	05/20/1986	State of Ohio, Executive Department, Office of the Governor, Columbus, Executive Order 86-25, Creating the Govenor's Task Force on Prescription Drug Abuse.	JAN-TREX-00180979	JAN-TREX-00180982							
JA-04980	05/01/2002	US GAO, Report to the Subcommittee on Oversight and Investigations, Committee on Energy and Commerce, House of Representatives; Prescription Drugs: State Monitoring Programs Provide Useful Tool to Reduce Diversion.	JAN-TREX-00180983	JAN-TREX-00181009							
JA-04981	09/06/2019	Ohio Senate, 133rd General Assembly: 33 Senators with One Goal: Serve all Ohioans; http://www.ohiosenate.gov/about	JAN-TREX-00181010	JAN-TREX-00181015							
JA-04982	09/06/2019	The Role of an Ohio Representative, The Ohio House of Representatives; http://www.ohiohouse.gov/education/role-of-an-ohio-representative	JAN-TREX-00181016	JAN-TREX-00181016							
JA-04983	09/01/2007	Pharmacy Times: Prescription-overdose Deaths Surpass Car-accident Deaths;	JAN-TREX-00181017	JAN-TREX-00181018							
JA-04984	08/01/2004	Pharmacy Times: Prescription-Monitoring Programs	JAN-TREX-00181019	JAN-TREX-00181021							
JA-04985	03/29/2017	Borchardt, Jackie, cleveland.com ., Article: Ohio lawmakers push opioid prescription restrictions, online addiction counsel.	JAN-TREX-00181022	JAN-TREX-00181024							
JA-04986	09/06/2019	The Ohio Senate 133rd General Assembly: Burke's Bill Creating New Tools in the Fight Against prescription Drug Abuse Signed into Law; http://www.ohiosenate.gov/senators/burke/news/burkes-bill-creating-new-tools-in-the-fight-against-prescritpion-drug-abuse-signed-into-law	JAN-TREX-00181025	JAN-TREX-00181027							
JA-04987	12/21/2017	New Opioid Legislation Introduced in Ohio, The Statehouse News Bureau	JAN-TREX-00181028	JAN-TREX-00181029							
JA-04988	05/13/2014	Democrats say Ohio's heroin epidemic should be declared a public health emergency, cleveland.com	JAN-TREX-00181030	JAN-TREX-00181031							
JA-04989	09/22/2018	Lawmakers: More to be done in addressing opioid crisis, Journal-News	JAN-TREX-00181032	JAN-TREX-00181044							
JA-04990	06/06/2018	Lawmakers on different paths to solve opioid crisis, nbc4i.com , available at www.nbc4i.com/news/politics/ohio-statehouse-newsroom/lawmakers-on-different-pa...	JAN-TREX-00181045	JAN-TREX-00181048							
JA-04991	06/07/2019	Lawmakers consider expanding immunity for Good Samaritans in face of opioid epidemic, nbc4i.com , available at www.nbc4i.com/news/politics/lawmakers-consider-expanding-immunity-for-good-sa...	JAN-TREX-00181049	JAN-TREX-00181051							
JA-04992	04/22/2018	Opioid deaths prompt Ohio to reimagine classroom lessons, starting with kindergarten, Washington Post	JAN-TREX-00181052	JAN-TREX-00181057							
JA-04993	09/01/2016	Ohio House Democrats Call for Action to Battle Opioid Abuse, The Statehouse News Bureau	JAN-TREX-00181058	JAN-TREX-00181059							
JA-04994	06/12/1905	U.S. Department of Health and Human Services, National Institute on Drug Abuse, National Household Survey on Drug Abuse: Main Findings 1990	JAN-TREX-00181060	JAN-TREX-00181338							
JA-04995	No Date	Summa Health Presentation: Carfentanil and Current Opioid Trends in Summit County, Ohio	JAN-TREX-00181339	JAN-TREX-00181348							
JA-04996	06/16/1905	Portenoy, R., Opioid Therapy for Chronic Nonmalignant Pain: Current Status, Progress in Pain Research and Management, Vol. 1, pp. 247-287, 1994	JAN-TREX-00181934	JAN-TREX-00181976							
JA-04997	05/08/2019	Letter from Giuseppe W. Pappalardo, Tucker Ellis LLP to File. (PRIVILEGED AND CONFIDENTIAL).	JAN-TREX-00181349	JAN-TREX-00181371							
JA-04998	05/01/1997	Ohio Medicine newspaper, a publication of the Ohio State Medical Association.	JAN-TREX-00181372	JAN-TREX-00181390							
JA-04999	07/01/1997	Ohio Medicine newspaper, a publication of the Ohio State medical Association.	JAN-TREX-00181391	JAN-TREX-00181408							
JA-05000	08/01/1997	Ohio Medicine newspaper, a publication of the Ohio State Medical Association.	JAN-TREX-00181409	JAN-TREX-00181427							
JA-05001	04/16/1997	USA Today: Legal Risks Make Drugs a Rare Remedy.	JAN-TREX-00181428	JAN-TREX-00181429							
JA-05002	07/18/1997	Richmond Times: Drug War Hits Pain Sufferers, Doctors Lament Suspicion That Accompanies Some Treatment.	JAN-TREX-00181430	JAN-TREX-00181432							
JA-05003	07/27/1997	Washington Post: First Do No Harm: When it comes to treating severe pain with narcotics, which should take precedence: a patient's need for relief or a government's concerns about abuse.	JAN-TREX-00181433	JAN-TREX-00181441							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-05004	12/07/1997	AMA: House of Delegates: Proceedings, 51st Interim Meeting.	JAN-TREX-00181442	JAN-TREX-00181444							
JA-05005	08/01/1998	Ohio Medicine newspaper, a publication of the Ohio State Medical Association.	JAN-TREX-00181445	JAN-TREX-00181466							
JA-05006	06/22/1998	Columbus Dispatch: Pain Management, Fear of Agonizing Death Encourages Suicide.	JAN-TREX-00181467	JAN-TREX-00181468							
JA-05007	09/23/1998	Cortex News Network: Coalition Opposes Hyde/Nickles Legal Drug Abuse Prevention Act.	JAN-TREX-00181469	JAN-TREX-00181471							
JA-05008	06/21/1995	Ohio Medical Association: Pain, The Fifth Vital Sign: a Physician Reference on Pain Treatment in Ohio.	JAN-TREX-00181472	JAN-TREX-00181526							
JA-05009	02/17/1999	Akron Beacon Journal (Ohio): Slow Gain in the War on Pain, Surveys Say Not Enough Done to Monitor and Treat Physical Suffering; Research Turns Slowly to Practice.	JAN-TREX-00181527	JAN-TREX-00181529							
JA-05010	07/01/1999	Ohio Medicine newspaper, a publication of the Ohio State Medical Association.	JAN-TREX-00181530	JAN-TREX-00181555							
JA-05011	12/01/1999	Ohio Medicine newspaper, a publication of the Ohio State Medical Association.	JAN-TREX-00181556	JAN-TREX-00181578							
JA-05012	06/20/1999	AMA: House of Delegates: Proceedings, 148th Annual Meeting.	JAN-TREX-00181579	JAN-TREX-00181589							
JA-05013	08/09/1999	New Orleans Times Picayune: Laws Shield Doctors From Prosecution for Prescribing Powerful Pain Medicines.	JAN-TREX-00181590	JAN-TREX-00181592							
JA-05014	02/01/2000	Ohio Medicine newspaper, a publication of the Ohio State Medical Association.	JAN-TREX-00181593	JAN-TREX-00181618							
JA-05015	06/07/2000	Cleveland Plain Dealer: Pain Relief Should Be Nonpartisan.	JAN-TREX-00181619	JAN-TREX-00181621							
JA-05016	08/21/2001	Pittsburgh Post-Gazette: OxyContin: We're Missing the Point.	JAN-TREX-00181622	JAN-TREX-00181623							
JA-05017	06/17/2001	AMA: House of Delegates: Proceedings, 150th Annual Meeting.	JAN-TREX-00181624	JAN-TREX-00181625							
JA-05018	No Date	A Joint Statement from 21 Health Organizations and the Drug Enforcement Administration: Promotion Pain Relief and Preventing Abuse of Pain Medications: A Critical Balancing Act.	JAN-TREX-00181626	JAN-TREX-00181626							
JA-05019	06/14/1993 - 06/19/2003	American Medical Association Proceedings of the House of Delegates, 152nd Annual Meeting. p. 579	JAN-TREX-00181627	JAN-TREX-00181628							
JA-05020	10/19/2003	Hidden Pain in Pain Pill, The Los Angeles Times	JAN-TREX-00181629	JAN-TREX-00181631							
JA-05021	09/28/2004	Painful Remedy? Patients, advocates and government spar over tighter controls on painkillers, Sane Diego Union-Tribune	JAN-TREX-00181632	JAN-TREX-00181637							
JA-05022	12/04/2004 - 12/07/2004	American Medical Association Proceedings of the House of Delegates, 58th Interim Meeting, pp. 122-128	JAN-TREX-00181638	JAN-TREX-00181645							
JA-05023	12/21/2004	Specialists Decry DEA Reversal on Pain Drugs; New Rules Called A 'Step Backward', Washington Post	JAN-TREX-00181646	JAN-TREX-00181648							
JA-05024	11/16/2004	Dispensing of Controlled Substances for the Treatment of Pain, Federal Register Doc 04-25469, Vol. 69, No. 220	JAN-TREX-00181649	JAN-TREX-00181651							
JA-05025	No Date	DEA Last Acts Partnership, Prescription Pain Medications: Frequently Asked Questions and Answers for Health Care Professionals, and Law Enforcement Personnel	JAN-TREX-00181652	JAN-TREX-00181699							
JA-05026	06/10/2006 - 06/14/2006	American Medical Association Proceedings of the House of Delegates, 155th Annual Meeting, pp. 37-41	JAN-TREX-00181700	JAN-TREX-00181705							
JA-05027	12.15/2007	Ault A., DEA rule allows multiple scrips for pain meds, Internal Medicine News, Vol. 40, Iss. 24	JAN-TREX-00181706	JAN-TREX-00181708							
JA-05028	06/23/2007 - 06/27/2007	AMA Proceedings of the House of Delegates, 156th Annual Meeting, pp. 431-440	JAN-TREX-00181709	JAN-TREX-00181719							
JA-05029	06/14/2008 - 06/17/2008	AMA Proceedings of the House of Delegates, 157th Annual Meeting, pp. 41-45, 238-239, 505	JAN-TREX-00181720	JAN-TREX-00181728							
JA-05030	11/08/2008 - 11/10/2008	AMA Proceedings of the House of Delegates, 62nd Interim Meeting, pp. 1, 260-278	JAN-TREX-00181729	JAN-TREX-00181748							
JA-05031	04/30/2010	Governor creates task force for pill problem, News Herald (Port Clinton, OH)	JAN-TREX-00181749	JAN-TREX-00181750							
JA-05032	11/24/2010	Piketon 'pill mill' ordinance might prove effective, Chillicothe Gazette (Chillicothe, OH)	JAN-TREX-00181751	JAN-TREX-00181753							
JA-05033	02/10/2011	Bill aims to shut down Ohio 'pill mills', Advocate (Newark, OH)	JAN-TREX-00181754	JAN-TREX-00181756							
JA-05034	06/18-2011 - 06/21/2011	AMA Proceedings of the House of Delegates, 160th Annual Meeting, p. 5	JAN-TREX-00181757	JAN-TREX-00181758							
JA-05035	06/01/2012	AMA Board of Trustees Annual Report, pp. 27, 52-55	JAN-TREX-00181759	JAN-TREX-00181763							
JA-05036	07/04/1995	Resolutions, AMA Annual Meeting, p. 439	JAN-TREX-00181764	JAN-TREX-00181764							
JA-05037	12/17/2013	New bills target drug prescriptions in Ohio Choking off pipeline to end overdoses, Cleveland Plain Dealer	JAN-TREX-00181765	JAN-TREX-00181768							
JA-05038	07/05/1995	AMA, Reference Committee on Amendments to Contitution and Bylaws, AMA Proceedings of the House of Delegates, 2013 Annual Meeting, pp. 505, 631	JAN-TREX-00181769	JAN-TREX-00181770							
JA-05039	10/25/2013	FDA backs tighter control for narcotic painkillers: Patients would need more visits to doctor to get refills, St. Paul Pioneer Press	JAN-TREX-00181771	JAN-TREX-00181773							
JA-05040	11/01/2013	Reference Committee on Amendments to Constitution and Bylaws, AMA Proceedings of the House of Delegates 2013 Annual Meeting, pp. 225, 282-283, 290	JAN-TREX-00181774	JAN-TREX-00181777							
JA-05041	07/05/1995	Reports of the Council on Science and Public Health, AMA 2013 Interim Meeting, pp. 147, 154-165	JAN-TREX-00181778	JAN-TREX-00181790							
JA-05042	07/05/1995	American Medical Association Reports of the Board of Trustees	JAN-TREX-00181791	JAN-TREX-00181795							
JA-05043	10/29/2013	U.S. shift on painkillers was years in the making, International Herald Tribune	JAN-TREX-00181796	JAN-TREX-00181799							
JA-05044	07/07/1995	American Medical Association Reports of the Board of Trustees	JAN-TREX-00181800	JAN-TREX-00181802							
JA-05045	07/07/1995	American Medical Association Joint Council Reports	JAN-TREX-00181803	JAN-TREX-00181808							
JA-05046	05/11/2016	Confronting a Crisis: An Open Letter to America's Physicians on the Opioid Epidemic, HuffPost Life	JAN-TREX-00181809	JAN-TREX-00181818							
JA-05047	07/08/1995	American Medical Association Resolution 19. Pain as the Fifth Vital Sign	JAN-TREX-00181819	JAN-TREX-00181822							
JA-05048	07/08/1995	American Medical Association Reports of Reference Committees House of Delegates, 2016 Annual Meeting, pp. 471-530	JAN-TREX-00181823	JAN-TREX-00181828							
JA-05049	07/08/1995	American Medical Association Resolution 918 Ensuring Cancer Patient Access to Pain Medication	JAN-TREX-00181829	JAN-TREX-00181831							
JA-05050	06/16/2016	AMA Drops Pain as Vital Sign, Pain Network News	JAN-TREX-00181832	JAN-TREX-00181849							
JA-05051	07/09/1995	American Medical Association 2017 Annual Meeting Resolutions	JAN-TREX-00181850	JAN-TREX-00181851							
JA-05052	07/10/1995	American Medical Association Annual Meeting 17. Evaluating Actions by Pharmacy Benefit Manager and Payer Policies on Patient Care	JAN-TREX-00181852	JAN-TREX-00181857							
JA-05053	11/01/2018	American Medical Association Resolutions	JAN-TREX-00181858	JAN-TREX-00181858							
JA-05054	07/10/1995	American Medical Association 2018 Interim Meeting, Pg 43-48	JAN-TREX-00181859	JAN-TREX-00181864							
JA-05055	11/01/2018	American Medical Association Resolution 235 Inappropriate Use of CDC Guidelines for Prescribing Opioids	JAN-TREX-00181865	JAN-TREX-00181868							
JA-05056	07/07/1995	AMA Policy: Protection for Physicians Who Prescribe Pain Medication H-120.960	JAN-TREX-00181869	JAN-TREX-00181870							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-05057	No Date	AMA Policy: Pain Control in Long-Term Care H-280.958	JAN-TREX-00181871	JAN-TREX-00181871							
JA-05058	06/29/1905	Report 6 of the Council on Science and Public Health (A-07)	JAN-TREX-00181872	JAN-TREX-00181888							
JA-05059	09/12/2016	American Medical Association House of Delegates Resolution: 803	JAN-TREX-00181889	JAN-TREX-00181891							
JA-05060	07/04/1905	AMA Policy: Pain Management Standards and Performance Measures D-295.966	JAN-TREX-00181892	JAN-TREX-00181892							
JA-05061	03/25/2019	Texas Medical Association Resolution 302: Numerical Recording of Subjective Pain	JAN-TREX-00181893	JAN-TREX-00181896							
JA-05062	07/04/1905	AMA Policy: Pain Management D-120.976	JAN-TREX-00181897	JAN-TREX-00181897							
JA-05063	07/08/1905	AMA Policy: Promoting Pain Relief and Preventing Abuse of Controlled Substances D-120.971	JAN-TREX-00181898	JAN-TREX-00181898							
JA-05064	No Date	AMA Policy: Promotion of Better Pain Care D-160.981	JAN-TREX-00181899	JAN-TREX-00181900							
JA-05065	07/05/1905	American Psychiatric Association, Substance-Related and Addictive Disorders, 2013	JAN-TREX-00181985	JAN-TREX-00181986							
JA-05066	N/A	Specific Janssen Call Notes	JAN-TREX-00181901	JAN-TREX-00181901							
JA-05067	06/29/2012	Email from Elizabeth Haranas to Li-Chia Ong Chansanchai et al	CHI_000512642	CHI_000512887							
JA-05068	07/04/1905	Ohio Department of Health report, Ohio's Opioid Epidemic: An Overview of the Problem	CLEVE_000117817	CLEVE_000117902							
JA-05069	10/01/2010	Ohio Prescription Drug Abuse Task Force report, Final Report Task Force Recommendations, October 1, 2010	CLEVE_000117903	CLEVE_000117977							
JA-05070	02/28/2017	The Feds Are About to Stick It to Pain Patients in a Big Way, Vice	JAN-TREX-00052627	JAN-TREX-00052643							
JA-05071	10/01/2010	Ohio Department of Health, Office of Healthy Ohio Bureau of Health Promotion and Risk Reduction Violence and Injury Prevention Program, The Burden of Poisoning in Ohio, 1999-2008	CUYAH_000018361	CUYAH_000018488							
JA-05072	10/17/2013	Ohio House of Representatives, Prescription Drug Addiction and Healthcare Reform Legislative Study, Committee Chairman's Report, October 17, 2013	CUYAH_012549329	CUYAH_012549344							
JA-05073	09/05/2013	Cuyahoga County Opiate Action Team Presentation: The Scope of the Problem	CUYAH_012616469	CUYAH_012616469							
JA-05074	10/20101	Ohio Department of Heath, Office of the Healthy Ohio Bureau of Health Promotion and Risk Reduction Violence and Injury Prevention Program, The Burden of Poisoning in Ohio, 1999-2008	CUYAH_013361276	CUYAH_013361403							
JA-05075	02/27/2017	Cuyahoga County Board of Health and Opiate Task Force Presentation: Ohio's Opioid Drug Overdose Epidemic: Contributing Factors and Ongoing Prevention Efforts	CUYAH_014199744	CUYAH_014199744							
JA-05076	06/13/1905	Ohio Drug Utilization Review 1991	JAN-TREX-00182494	JAN-TREX-00183711							
JA-05077	06/14/1905	Ohio Drug Utilization Review 1992	JAN-TREX-00183712	JAN-TREX-00185007							
JA-05078	06/15/1905	Ohio Drug Utilization Review 1993	JAN-TREX-00185008	JAN-TREX-00186246							
JA-05079	06/16/1905	Ohio Drug Utilization Review 1994	JAN-TREX-00186247	JAN-TREX-00187474							
JA-05080	06/17/1905	Ohio Drug Utilization Review 1995	JAN-TREX-00187475	JAN-TREX-00188374							
JA-05081	07/06/1905	Epstein AJ, et al., Information technology and agency in physicians' prescribing decisions, RAND Journal of Economics, Vol. 45, No. 2, pp. 422-448	JAN-TREX-00114432	JAN-TREX-00114459							
JA-05082	01/01/2004	Position Paper on Utilizing Prescription Medications for the Treatment of Intractable Pain	JAN-TREX-00114460	JAN-TREX-00114474							
JA-05083	06/29/2018	DEA Press Release, re: Five indicted for running a pill mill in Hamilton	JAN-TREX-00114475	JAN-TREX-00114477							
JA-05084	11/05/2016	Ohio Task Force Commanders Website: Two indicted, one already jailed for alleged 'pill mill' with North Olmsted office, available at otca.net/two-indicted-one-already-jailed-for-alleged-pill-mill-with-north-olmsted-office	JAN-TREX-00114478	JAN-TREX-00114481							
JA-05085	03/15/2006	Memorandum from Director, National Institute of Drug Abuse to the Surgeon General	JAN-TREX-00114482	JAN-TREX-00114483							
JA-05086	04/01/2015	FDA Guidance for Industry, Abuse-Deterrent Opioids -- Evaluation and Labeling	JAN-TREX-00114484	JAN-TREX-00114512							
JA-05087	05/13/2019	FDA Website: Timeline of Selected FDA Activities and Significant Events Addressing Opioids Misuse and Abuse, available at www.fda.gov/drugs/information-drug-class/timeline-selected-fda-activities-and-sig...	JAN-TREX-00114513	JAN-TREX-00114525							
JA-05088	06/01/2015	HHS OIG, Ensuring the Integrity of Medicare Part D, Part D Program Integrity Portfolio (OEI-03-15-00180)	JAN-TREX-00114526	JAN-TREX-00114554							
JA-05089	05/01/2014	DOJ OIG, The Drug Enforcement Administration's Adjudication of Registrant Actions, I-2014-003	JAN-TREX-00114555	JAN-TREX-00114606							
JA-05090	08/13/2019	NIH, The NIH Almanac: National Institute on Drug Abuse (NIDA), available at www.nih.gov/about-nih/what-we-do/nih-almanac/national-institute-drug-abuse-nida	JAN-TREX-00114607	JAN-TREX-00114621							
JA-05091	07/03/1905	Executive Office of the President of the United States, Epidemic: Responding to America's Prescription Drug Abuse Crisis	JAN-TREX-00114622	JAN-TREX-00114632							
JA-05092	08/13/2019	HHS OIG, Combatting the Opioid Epidemic, available at www.oig.hhs.gov/reports-and-publications/featured-topics/opioids	JAN-TREX-00114633	JAN-TREX-00114638							
JA-05093	07/01/2018	HHS OIG Data Brief,Opioids in Ohio Medicaid: Review of Extreme Use and Prescribing, OEI-05-18-00010	JAN-TREX-00114639	JAN-TREX-00114671							
JA-05094	05/13/2019	Fact Sheet: Obama Administration Announces Public and Private Sector Efforts to Address Prescription Drug Abuse and Heroin Use, available at obamawhitehouse.archives.gov/the-press-office/2015/10/21/fact-sheet-obama-admi...	JAN-TREX-00114672	JAN-TREX-00114682							
JA-05095	2011 - 2018	Ohio Governor's Cabinet, Opiate Action Team, Combatting the Opiate Crisis in Ohio	JAN-TREX-00114683	JAN-TREX-00114789							
JA-05096	01/01/2014	Ohio Governor's Cabinet, Opiate Action Team, Ohio Guidelines for Emergency and Acute Care Facility Opioid and Other Controlled Substances (OOCs) Prescribing	JAN-TREX-00149886	JAN-TREX-00149886							
JA-05097	07/10/1905	Ohio Governor's Cabinet, Opiate Action Team, New Strategies to Combat the Opiate Crisis in Ohio (2018)	JAN-TREX-00114790	JAN-TREX-00114792							
JA-05098	10/01/2010	Ohio Prescription Drug Abuse Task Force, Ohio Prescription Drug Abuse Task Force: Final Report Task Force Recommendations	JAN-TREX-00114793	JAN-TREX-00114868							
JA-05099	10/01/2013	Ohio Governor's Cabinet, Opiate Action Team, Ohio Guidelines for Prescribing Opioids for the Treatment of Chronic, Non-Terminal Pain 80 mg of a Morphine Equivalent Daily Dose (MED) "Trigger Point"	JAN-TREX-00114869	JAN-TREX-00114870							
JA-05100	No Date	Ohio Governor's Opiate Action Team, Attacking Ohio's Opiate Epidemic	JAN-TREX-00114871	JAN-TREX-00114872							
JA-05101	04/06/2015	Agreement between Cuyahoga County and Medical Mutual Services, L.L.C	JAN-TREX-00149887	JAN-TREX-00149887							
JA-05102	No Date	County of Cuyahoga (EPO)	JAN-TREX-00114873	JAN-TREX-00114945							
JA-05103	01/01/2017	Agreement between CaremarkPCS Health, L.L.C., Health Action Council, and the Cooperative Council of Governments	JAN-TREX-00149888	JAN-TREX-00149888							
JA-05104	09/27/2017	Email from Laura A. Smith to Holly Woods, et al.	JAN-TREX-00114946	JAN-TREX-00114950							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-05105	07/10/1905	Cuyahoga Benefits Enrollment Guide, 2018	JAN-TREX-00114951	JAN-TREX-00114974							
JA-05106	02/05/206	Cuyahoga County Internal Audit Report, Health Care Benefits Program - Phase 1: January 1, 2011 - June 30, 2015	JAN-TREX-00149889	JAN-TREX-00149889							
JA-05107	03/22/2017	Email from Holly Woods to Tracey Jaycox	JAN-TREX-00114975	JAN-TREX-00114988							
JA-05108	04/16/2018	Email from Thomas Lyden to Lisa Duliba, et al.	JAN-TREX-00114989	JAN-TREX-00114990							
JA-05109	06/22/2017	Email from Thomas P. Gilson to Michael Houser	JAN-TREX-00114991	JAN-TREX-00114992							
JA-05110	06/27/2017	Email from Michael Houser to Thomas Gilson, et al.	JAN-TREX-00149890	JAN-TREX-00149890							
JA-05111	06/16/2017	Email from Kevin Gregory to Holly Woods	JAN-TREX-00114993	JAN-TREX-00114994							
JA-05112	04/17/2017	Email from Health Action Council to Holly Woods	JAN-TREX-00114995	JAN-TREX-00114997							
JA-05113	04/01/2018	Organizational chart: Human Resources Department Functional Reporting Areas and Dirt Reports	JAN-TREX-00149891	JAN-TREX-00149891							
JA-05114	11/09/2016	Email from Patrick Smock to Holly Woods	JAN-TREX-00114998	JAN-TREX-00115047							
JA-05115	01/30/2018	Email from Benefits to Holly Woods	JAN-TREX-00115048	JAN-TREX-00115051							
JA-05116	11/21/2011	Winsley W and Droz D, Ohio Dangerous Drug Database Past, Present, and Future Ohio State Board of Pharmacy House Bill 93 Report, Ohio State Board of Pharmacy, November 21, 2011	JAN-TREX-00115052	JAN-TREX-00115062							
JA-05117	2013-2014	Ohio Automated RX Reporting System, 2013-2014 Biennial Report, Ohio State Board of Pharmacy + 2013-2014 Biennial Report	JAN-TREX-00115063	JAN-TREX-00115074							
JA-05118	07/07/1905	Ohio Automated RX Reporting System, 2015 Report, State of Ohio Board of Pharmacy	JAN-TREX-00115075	JAN-TREX-00115083							
JA-05119	07/08/1905	Ohio Automated RX Reporting System, 2016 Annual Report, State of Ohio Board of Pharmacy	JAN-TREX-00115084	JAN-TREX-00115097							
JA-05120	07/09/1905	Ohio Automated RX Reporting System, 2017 Annual Report Executive Summary, State of Ohio Board of Pharmacy	JAN-TREX-00149892	JAN-TREX-00149892							
JA-05121	07/09/1905	Ohio Automated RX Reporting System, 2017 Annual Report, State of Ohio Board of Pharmacy	JAN-TREX-00115098	JAN-TREX-00115110							
JA-05122	07/10/1905	Ohio Automated RX Reporting System, 2018 Annual Report Executive Summary, State of Ohio Board of Pharmacy	JAN-TREX-00149893	JAN-TREX-00149893							
JA-05123	07/10/1905	Ohio Automated RX Reporting System, 2018 Annual Report, State of Ohio Board of Pharmacy	JAN-TREX-00115111	JAN-TREX-00115123							
JA-05124	2010 - 2018	Chart: Report of prescriptions per county, 2010-2018	JAN-TREX-00149894	JAN-TREX-00149894							
JA-05125	06/01/2015	Ohio Automated RX Reporting System, Semiannual Report on Opioid Prescribing in Ohio June 2015, State of Ohio Board of Pharmacy	JAN-TREX-00115124	JAN-TREX-00115129							
JA-05126	05/11/2005	Ohio Department of Job and Family Services Drug Utilization Review Board Quarterly Meeting May 11, 2005 draft Minutes	JAN-TREX-00115130	JAN-TREX-00115132							
JA-05127	10/01/2006	Memorandum from Bob Reid to P&T Committee Members	JAN-TREX-00115133	JAN-TREX-00115135							
JA-05128	05/24/2006	Ohio Department of Job and Family Services Utilization Review (DUR) Board Agenda, May 24, 2006	JAN-TREX-00149895	JAN-TREX-00149895							
JA-05129	10/07/2009	Ohio Department of Job and Family Services (ODJFS) P&T Committee Meeting Minutes, October 7, 2009	JAN-TREX-00115136	JAN-TREX-00115138							
JA-05130	04/21/2010	Ohio Department of Job and Family Services (ODJFS) P&T Committee Meeting Minutes, April 21, 2010	JAN-TREX-00115139	JAN-TREX-00115142							
JA-05131	11/17/2010	Ohio Department of Job and Family Services Drug Utilization Review (DUR) Board Agenda, November 17, 2010	JAN-TREX-00115143	JAN-TREX-00115145							
JA-05132	06/25/2010	Letter from Michael Barnes to Ohio Medicaid Pharmaceutical & Therapeutics Committee Members	JAN-TREX-00115146	JAN-TREX-00115147							
JA-05133	02/01/2011	Medicaid Integrity Program Ohio Comprehensive Program Integrity Review Final Report, Department of Health and Human Services Centers for Medicare & Medicaid Services, February 2011	JAN-TREX-00115148	JAN-TREX-00115161							
JA-05134	02/01/2011	Medicaid Integrity Program Ohio Comprehensive Program Integrity Review Final Report, Department of Health and Human Services Centers for Medicare & Medicaid Services, February 2011	JAN-TREX-00115162	JAN-TREX-00115175							
JA-05135	04/11/2012	Ohio Department of Job and Family Services (ODJFS) P&T Committee Meeting Minutes, April 11, 2012	JAN-TREX-00115176	JAN-TREX-00115197							
JA-05136	10/10/2012	Ohio Department of Job and Family Services (ODJFS) P&T Committee Meeting Minutes, October 10, 2012	JAN-TREX-00115198	JAN-TREX-00115203							
JA-05137	01/09/2013	Ohio Department of Job and Family Services (ODJFS) P&T Committee Meeting Minutes, January 9, 2013	JAN-TREX-00115204	JAN-TREX-00115211							
JA-05138	04/10/203	Ohio Department of Job and Family Services (ODJFS) P&T Committee Meeting Minutes, April 10, 2013	JAN-TREX-00115212	JAN-TREX-00115221							
JA-05139	10/09/2013	Ohio Department of Job and Family Services (ODJFS) P&T Committee Meeting Minutes, October 9, 2013	JAN-TREX-00115222	JAN-TREX-00115233							
JA-05140	08/20/2013	Ohio Automated RX Reporting System (OARRS) Overview of Opioid Prescribing Metrics and Detailed Metrics, Revised 08/20/2013	JAN-TREX-00149896	JAN-TREX-00149896							
JA-05141	08/01/2014	Medicaid Integrity Program Ohio Comprehensive Program Integrity Review Final Report, Department of Health and Human Services Centers for Medicare & Medicaid Services, August 2014	JAN-TREX-00115234	JAN-TREX-00115246							
JA-05142	07/06/1905	The Ohio Department of Medicaid Program Integrity Report 2014	JAN-TREX-00115247	JAN-TREX-00115264							
JA-05143	03/01/2013	The Ohio Department of Medicaid Ohio Medical Assistance Provider Agreement for Managed Care Plan	JAN-TREX-00115265	JAN-TREX-00115468							
JA-05144	10/08/2014	Ohio Department of Medicaid (ODM) P&T Committee Meeting Minutes, October 8, 2014	JAN-TREX-00115469	JAN-TREX-00115476							
JA-05145	07/06/1905	The Ohio Department of Medicaid Program Integrity Report 2014	JAN-TREX-00115477	JAN-TREX-00115494							
JA-05146	08/01/2014	Medicaid Integrity Program Ohio Comprehensive Program Integrity Review Final Report, Department of Health and Human Services Centers for Medicare & Medicaid Services, August 2014	JAN-TREX-00115495	JAN-TREX-00115507							
JA-05147	07/07/1905	The Ohio Department of Medicaid Program Integrity Report 2015	JAN-TREX-00115508	JAN-TREX-00115524							
JA-05148	01/01/2015	The Ohio Department of Medicaid Ohio Medical Assistance Provider Agreement for Managed Care Plan	JAN-TREX-00115525	JAN-TREX-00115747							
JA-05149	01/14/2015	Ohio Department of Medicaid (ODM) P&T Committee Meeting Minutes, January 14, 2015	JAN-TREX-00115748	JAN-TREX-00115759							
JA-05150	01/01/2015	The Ohio Department of Medicaid Ohio Medical Assistance Provider Agreement for Managed Care Plan	JAN-TREX-00115760	JAN-TREX-00115980							
JA-05151	07/01/2015	The Ohio Department of Medicaid Ohio Medical Assistance Provider Agreement for Managed Care Plan	JAN-TREX-00115981	JAN-TREX-00116208							
JA-05152	10/14/2015	Ohio Department of Medicaid (ODM) Pharmacy & Therapeutics Committee Quarterly Meeting October 14, 2015 Minutes	JAN-TREX-00116209	JAN-TREX-00116217							
JA-05153	07/07/1905	The Ohio Department of Medicaid Program Integrity Report 2015	JAN-TREX-00116218	JAN-TREX-00116234							
JA-05154	07/10/1905	Timeline: Collective Action to Address the Opioid Crisis in Ohio 2016 - 2020, Collective Action to Address the Opioid Crisis in Ohio 2011 - 2015, Ohio Department of Medicaid	JAN-TREX-00116235	JAN-TREX-00116236							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-05155	07/03/1905	Ohio Department of Medicaid, ACS Rx Delivery Services, SmartPA Criteria Proposal, Analgesics: Opioids Preferred Drug List	JAN-TREX-00116237	JAN-TREX-00116270							
JA-05156	02/01/2016	Department of Health and Human Services, Centers for Medicare & Medicaid Services, Center for Program Integrity, Ohio Focused Program Integrity Review, Final Report.	JAN-TREX-00116271	JAN-TREX-00116293							
JA-05157	07/01/2015	Ohio Department of Medicaid, Ohio Medical Assistance Provider Agreement for Managed Care Plan.	JAN-TREX-00116294	JAN-TREX-00116519							
JA-05158	01/13/2016	Ohio Department of Medicaid (ODM), Pharmacy & Therapeutics Committee Quarterly Meeting Minutes.	JAN-TREX-00116520	JAN-TREX-00116525							
JA-05159	07/01/2016	Ohio Department of Medicaid, Ohio Medical Assistance Provider Agreement for Managed Care Plan.	JAN-TREX-00116526	JAN-TREX-00116779							
JA-05160	08/10/2016	Ohio Department of Medicaid (ODM), Pharmacy & Therapeutics Committee Quarterly Meeting Minutes.	JAN-TREX-00116780	JAN-TREX-00116786							
JA-05161	02/01/2016	Department of Health and Human Services, Centers for Medicare & Medicaid Services, Center for Program Integrity, Ohio Focused Program Integrity Review, Final Report.	JAN-TREX-00116787	JAN-TREX-00116809							
JA-05162	07/31/2018	Ohio Department of Medicaid Fee-for-Service, Pharmacy Claims Review Provider Manual.	JAN-TREX-00116810	JAN-TREX-00116821							
JA-05163	07/09/1905	2017 Ohio Medicaid Fraud Control Unit Annual Report	JAN-TREX-00116822	JAN-TREX-00116867							
JA-05164	07/01/2016	Ohio Department of Medicaid, Ohio Medical Assistance Provider Agreement for Managed Care Plan.	JAN-TREX-00116868	JAN-TREX-00117111							
JA-05165	03/01/2017	Ohio Department of Medicaid, Preferred Drug List Changes.	JAN-TREX-00149897	JAN-TREX-00149897							
JA-05166	07/01/2017	Ohio Department of Medicaid, Ohio Medical Assistance Provider Agreement for Managed Care Plan.	JAN-TREX-00117112	JAN-TREX-00117337							
JA-05167	09/01/2017	Ohio Department of Medicaid, Preferred Drug List Changes.	JAN-TREX-00117338	JAN-TREX-00117340							
JA-05168	07/09/1905	2017 Ohio Medicaid Fraud Control Unit Annual Report	JAN-TREX-00117341	JAN-TREX-00117386							
JA-05169	10/18/2017	Letter from Shawn Ryan, President, Ohio Society of Addiction Medicine, et al to Mary Applegate, Medical Director, Ohio Department of Medicaid.	JAN-TREX-00117387	JAN-TREX-00117390							
JA-05170	11/01/2017	Letter from Brian Neale, Director, Center for Medicare & Medicaid Services to State Medicaid Director.	JAN-TREX-00117391	JAN-TREX-00117404							
JA-05171	07/09/1905	Cincinnati Children's Project: Limiting Prescribed Opioid Doses Through Standardized Plan Efforts.	JAN-TREX-00117405	JAN-TREX-00117419							
JA-05172	03/24/2017	Ohio Medicaid NCPDP Payer Sheet	JAN-TREX-00117420	JAN-TREX-00117441							
JA-05173	08/09/2017	Ohio Department of Medicaid: Presentation: Building Dynamic and Functional Interagency Collaboration.	JAN-TREX-00117442	JAN-TREX-00117452							
JA-05174	No Date	Ohio Department of Medicaid web page, Managed Care Policy.	JAN-TREX-00149898	JAN-TREX-00149898							
JA-05175	06/01/2018	Ohio Department of Medicaid, Template: Request for Rx Prior Authorization:Long Acting or Short-Acting Opioid Medication.	JAN-TREX-00117453	JAN-TREX-00117454							
JA-05176	07/10/1905	Ohio Department of Medicaid, Managed Care Quality Strategy.	JAN-TREX-00117455	JAN-TREX-00117589							
JA-05177	12/01/2017	Ohio Department of Medicaid, Preferred Drug List Changes.	JAN-TREX-00117590	JAN-TREX-00117594							
JA-05178	01/01/2018	Ohio Department of Medicaid, Ohio Medical Assistance Provider Agreement for Managed Care Plan.	JAN-TREX-00117595	JAN-TREX-00117845							
JA-05179	01/10/2018	Ohio Department of Medicaid, Pharmacy & Therapeutics Committee Meeting Minutes.	JAN-TREX-00117846	JAN-TREX-00117856							
JA-05180	04/01/2018	Ohio Department of Medicaid, Ohio Medical Assistance Provider Agreement for Managed Care Plan.	JAN-TREX-00117857	JAN-TREX-00118107							
JA-05181	04/11/2018	Ohio Department of Medicaid, Pharmacy & Therapeutics Committee Meeting Minutes.	JAN-TREX-00118108	JAN-TREX-00118123							
JA-05182	06/01/2018	Ohio Department of Medicaid, Preferred Drug List Changes.	JAN-TREX-00149899	JAN-TREX-00149899							
JA-05183	07/01/2018	Ohio Department of Medicaid, Ohio Medical Assistance Provider Agreement for Managed Care Plan.	JAN-TREX-00118124	JAN-TREX-00118357							
JA-05184	07/11/2018	Ohio Department of Medicaid, Pharmacy & Therapeutics Committee Meeting Minutes.	JAN-TREX-00118358	JAN-TREX-00118368							
JA-05185	08/08/2018	National Conference of State Legislatures (NCSL), Recent Medicaid Prescription Drug Laws and Strategies.	JAN-TREX-00118369	JAN-TREX-00118419							
JA-05186	10/01/2018	Ohio Department of Medicaid, Ohio Medicaid Fee-For-Service Pharmacy Benefit Management Program.	JAN-TREX-00118420	JAN-TREX-00118533							
JA-05187	10/03/2018	Ohio Department of Medicaid, Pharmacy & Therapeutics Committee Meeting Minutes.	JAN-TREX-00118534	JAN-TREX-00118547							
JA-05188	10/03/2018	Ohio Department of Medicaid, Pharmacy & Therapeutics Committee By-Laws.	JAN-TREX-00118548	JAN-TREX-00118551							
JA-05189	No Date	Ohio Department of Medicaid (ODM) Initiatives.	JAN-TREX-00118552	JAN-TREX-00118564							
JA-05190	06/26/2018	Ohio Auditor of State, Dave Yost: The Opioid Crisis: The impact on the Medicaid population is stretching the state's safety net.	JAN-TREX-00118565	JAN-TREX-00118581							
JA-05191	06/01/2018	Ohio Attorney General's Insurer Task Force on Opioid Reduction, Report and Recommendations.	JAN-TREX-00118582	JAN-TREX-00118609							
JA-05192	08/14/2018	Ohio Department of Medicaid Quarterly Clinical Report, Q2 2018.	JAN-TREX-00118610	JAN-TREX-00118655							
JA-05193	01/01/2019	Ohio Department of Medicaid: Effective Treatment for Opiate Use Disorders: Removing Barriers to Medication Assisted Treatment.	JAN-TREX-00118656	JAN-TREX-00118658							
JA-05194	01/01/2019	Ohio Department of Medicaid, Ohio Medical Assistance Provider Agreement for Managed Care Plan.	JAN-TREX-00118659	JAN-TREX-00118917							
JA-05195	01/01/2019	Ohio Department of Medicaid, Preferred Drug Lists: Fee-for-Service Preferred Drug List.	JAN-TREX-00118918	JAN-TREX-00119030							
JA-05196	11/30/2018	Ohio Department of Medicaid, Preferred Drug List.	JAN-TREX-00119031	JAN-TREX-00119034							
JA-05197	01/16/2019	Ohio Department of Medicaid, Pharmacy & Therapeutics Committee.	JAN-TREX-00119035	JAN-TREX-00119052							
JA-05198	02/01/2019	Ohio Department of Medicaid, Ohio Medical Assistance Provider Agreement for Managed Care Plan.	JAN-TREX-00119053	JAN-TREX-00119309							
JA-05199	03/12/2019	Letter from Roxanne Richardson, Ohio Department of Medicaid to Contracted Medicaid Managed Care Plans (MCPs).	JAN-TREX-00149900	JAN-TREX-00149900							
JA-05200	04/01/2019	Ohio Department of Medicaid, Preferred Drug Lists: Fee-for-Service Preferred Drug List.	JAN-TREX-00119310	JAN-TREX-00119423							
JA-05201	04/10/2019	ODM P&T Committee Meeting Minutes	JAN-TREX-00119424	JAN-TREX-00119444							
JA-05202	07/01/2019	ODM Ohio Medical Assistance Provider Agreement for Managed Care Plan	JAN-TREX-00119445	JAN-TREX-00119687							
JA-05203	07/10/2019	ODM P&T Committee Meeting Minutes	JAN-TREX-00119688	JAN-TREX-00119702							
JA-05204	07/11/1905	ODM Webiste; DUR Board Overview, available at https://pharmacy.medicaid.ohio.gov/drug-utilization-review-board	JAN-TREX-00119703	JAN-TREX-00119704							
JA-05205	07/11/1905	ODM Webiste; DUR Board Digest, available at https://pharmacy.medicaid.ohio.gov/drug-utilization-review-digest	JAN-TREX-00149901	JAN-TREX-00149901							
JA-05206	07/10/1905	ODM Drug Utilization Review Board Oversight Sheet	JAN-TREX-00119705	JAN-TREX-00119706							
JA-05207	07/10/1905	ODM P&T Committee Info Sheet for Interested Party Presentations	JAN-TREX-00119707	JAN-TREX-00119708							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-05208	04/08/2019	The Center for Community Solutions Website: Engineering Outcomes: Managed care and value-based design in Ohio Medicaid, available at https://www.communitysolutions.com/research/engineering-outcomes-managed-care-value-based-design-ohio-medicaid/	JAN-TREX-00119709	JAN-TREX-00119721							
JA-05209	07/11/1905	Ohio Department of Medicaid Website: Managed Care Policy Guidance, available at https://medicaid.ohio.gov/Managed-Care/For-Managed-Care-Plans#1910241-guidance	JAN-TREX-00119722	JAN-TREX-00119723							
JA-05210	07/11/1905	Ohio Department of Medicaid Step Therapy Exemption Request Form	JAN-TREX-00119724	JAN-TREX-00119726							
JA-05211	07/11/1905	Ohio Department of Medicaid Website: About Us, available at https://medicaid.ohio.gov/MEDICAID-101/About-Us	JAN-TREX-00149902	JAN-TREX-00149902							
JA-05212	07/10/1905	ODM Drug Coverage Information Sheet	JAN-TREX-00119727	JAN-TREX-00119728							
JA-05213	07/10/1905	ODM P&T Committee Information Sheet for Drug Manufacturer Presentations	JAN-TREX-00149903	JAN-TREX-00149903							
JA-05214	07/11/1905	ODM Website: DUR Board info, available at https://pharmacy.medicaid.ohio.gov/drug-utilization-review-board	JAN-TREX-00119729	JAN-TREX-00119730							
JA-05215	07/11/1905	ODM Website: DUR Board Meeting Minutes, available at https://pharmacy.medicaid.ohio.gov/dur-board-meeting-minute-archive	JAN-TREX-00119731	JAN-TREX-00119733							
JA-05216	07/11/1905	ODM Website: Ohio Medicaid Covered Services, available at https://medicaid.ohio.gov/FOR-OHIOANS/Covered-Services	JAN-TREX-00119734	JAN-TREX-00119735							
JA-05217	07/11/1905	ODM P&T Committee Conflict of Interest Policy Sheet	JAN-TREX-00119736	JAN-TREX-00119737							
JA-05218	07/11/1905	ODM Website: P&T PDL Archive, available at https://pharmacy.medicaid.ohio.gov/pt-pdl-archive	JAN-TREX-00119738	JAN-TREX-00119739							
JA-05219	07/11/1905	ODM Website: P&T Committee Overview, available at https://pharmacy.medicaid.ohio.gov/pharmacy-therapeutics-committee	JAN-TREX-00119740	JAN-TREX-00119741							
JA-05220	07/11/1905	ODM Website: Prior Authorization Criteria Update, available at https://pharmacy.medicaid.ohio.gov/pa-criteria-update-history	JAN-TREX-00119742	JAN-TREX-00119743							
JA-05221	07/11/1905	ODM Website: P&T Committee Overview, available at https://pharmacy.medicaid.ohio.gov/pharmacy-therapeutics-committee	JAN-TREX-00119744	JAN-TREX-00119746							
JA-05222	No Date	My Ohio Legislature web page, Senate Bill 261	JAN-TREX-00149904	JAN-TREX-00149904							
JA-05223	01/01/2019	Molina Healthcare of Ohio Preferred Drug List (Formulary)	JAN-TREX-00119747	JAN-TREX-00119809							
JA-05224	07/11/1905	ODM P&T Committee By-Laws	JAN-TREX-00119810	JAN-TREX-00119813							
JA-05225	05/19/2015	US Rep Brad Wenstrup Website: VA on board with OARRS, available at https://wenstrup.house.gov/updates/documentsingle.aspx?DocumentID=398755	JAN-TREX-00119965	JAN-TREX-00119966							
JA-05226	05/01/1997	Ohio Medicine, A Publication of the Ohio State Medical Association	JAN-TREX-00119967	JAN-TREX-00119985							
JA-05227	03/01/2011	Ohio's Opiate Epidemic, Behavioral Health: Developing A Better Understanding, Vol. Seven, Issue II	JAN-TREX-00119986	JAN-TREX-00119988							
JA-05228	05/20/1986	Executive Order 86-25 from Ohio Governor, "Creating the Governor's Task Force on Prescription Drug Abuse"	JAN-TREX-00120052	JAN-TREX-00120055							
JA-05229	05/01/2002	GAO Report to the Subcommittee on Oversight and Investigations, Committee on Energy and Commerce, House of Representatives: "Prescription Drugs: State Monitoring Programs Provide Useful Tool to Reduce Diversion"	JAN-TREX-00120056	JAN-TREX-00120082							
JA-05230	07/11/1905	Ohio Senate Website: About, available at http://www.ohiosenate.gov/about	JAN-TREX-00120083	JAN-TREX-00120088							
JA-05231	07/11/1905	Ohio House of Representatives Website: Role of a Representative, available at http://www.ohiohouse.gov/education/role-of-an-ohio-representative	JAN-TREX-00149905	JAN-TREX-00149905							
JA-05232	09/01/2007	Prescription-overdose Deaths Surpass Car-accident Deaths, Pharmacy Times	JAN-TREX-00120089	JAN-TREX-00120090							
JA-05233	08/01/2004	Prescription-Monitoring Programs, Pharmacy Times	JAN-TREX-00120091	JAN-TREX-00120093							
JA-05234	03/29/2017	Ohio Lawmakers push opioid prescription restrictions, online addiction counseling, The Plain Dealer (Cleveland.com)	JAN-TREX-00120094	JAN-TREX-00120096							
JA-05235	12/12/2012	Ohio Senate Website: Burke's Bill Creating New Tools in the Fight Against Presription Drug Abuse Signed Into Law, available at http://www.ohiosenate.gov/senators/burke/news/burkes-bill-creating-new-tools-in-the-fight-against-prescription-drug-abuse-signed-into-law	JAN-TREX-00120097	JAN-TREX-00120099							
JA-05236	12/21/2017	New Opioid Legislation Introduced in Ohio, Statehouse News Bureau	JAN-TREX-00120100	JAN-TREX-00120101							
JA-05237	05/13/2014	Democrats say Ohio's heroin epidemic should be declared a public health emergency, Cleveland.com	JAN-TREX-00120102	JAN-TREX-00120103							
JA-05238	09/22/2018	Butler County Journal-News, Lawmakers: More to be done in addressing opioid crisis	JAN-TREX-00120104	JAN-TREX-00120116							
JA-05239	06/06/2018	Lawmakers on Different Paths to Solve Opioid Crisis, Ohio Statehouse Newsroom	JAN-TREX-00120117	JAN-TREX-00120120							
JA-05240	06/07/2019	Lawmakers consider expanding immunity for Good Samaritans in face of opioid epidemic, NBC4i.com	JAN-TREX-00120121	JAN-TREX-00120123							
JA-05241	09/06/2019	Opioid deaths prompt Ohio to reimagine classroom lessons, starting with kindergarten, The Washington Post	JAN-TREX-00120124	JAN-TREX-00120129							
JA-05242	09/01/2016	Ohio House Democrats Call for Action to Battle Opioid Abuse, The Statehouse News Bureau	JAN-TREX-00120130	JAN-TREX-00120131							
JA-05243	02/10/2007	Email from Christine Rauschkolb to Dennis Fitzgerald, David Upmalis, Ravi Desiraju and Ron Kuntz	JAN-MS-01008014	JAN-MS-01008014							
JA-05244	02/01/2004	Littlejohn, C., et al., Chronic Non-cancer Pain and Opioid Dependence, Journal of the Royal Society of Medicine, Vol. 97, pp. 62-65	JAN-TREX-00190075	JAN-TREX-00190078							
JA-05245	07/09/1905	National Automobile Dealers Association (NADA) data including the Annual Financial Profile of America's Franchised New-Car Dealerships Report for 2017, https://www.nada.org/2017NADAdata/ (accessed August 19, 2019) and electronic file "2017 NADA State Data Sheets.xlsx" received from NADA Economist, Patrick Manzi, August 13, 2019.	JAN-TREX-00109620	JAN-TREX-00109658							
JA-05246	07/09/1905	National Automobile Dealers Association (NADA) data including the Annual Financial Profile of America's Franchised New-Car Dealerships Report for 2017, https://www.nada.org/2017NADAdata/ (accessed August 19, 2019) and electronic file "2017 NADA State Data Sheets.xlsx" received from NADA Economist, Patrick Manzi, August 13, 2019.	JAN-TREX-00109659	JAN-TREX-00109661							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-05247	07/09/1905	National Automobile Dealers Association (NADA) data including the Annual Financial Profile of America's Franchised New-Car Dealerships Report for 2017, https://www.nada.org/2017NADAdata/ (accessed August 19, 2019) and electronic file "2017 NADA State Data Sheets.xlsx" received from NADA Economist, Patrick Manzi, August 13, 2019.	JAN-TREX-00109662	JAN-TREX-00109663							
JA-05248	1996-2017	Polk confidential light-vehicle registrations from R.L. Polk & Co., a foundation of IHS Markit automotive solutions, 1996–2017.	JAN-TREX-00109664	JAN-TREX-00109679							
JA-05249	1996-2016	U.S. Department of Transportation, National Highway Traffic Safety Administration, Traffic Safety Facts 1996-Traffic Safety Facts 2016, https://crashstats.nhtsa.dot.gov/#/DocumentTypeList/11 (accessed July 31, 2019).	JAN-TREX-00109680	JAN-TREX-00109894							
JA-05250	1996-2016	U.S. Department of Transportation, National Highway Traffic Safety Administration, Traffic Safety Facts 1996-Traffic Safety Facts 2016, https://crashstats.nhtsa.dot.gov/#/DocumentTypeList/11 (accessed July 31, 2019).	JAN-TREX-00109895	JAN-TREX-00110113							
JA-05251	1996-2016	U.S. Department of Transportation, National Highway Traffic Safety Administration, Traffic Safety Facts 1996-Traffic Safety Facts 2016, https://crashstats.nhtsa.dot.gov/#/DocumentTypeList/11 (accessed July 31, 2019).	JAN-TREX-00110114	JAN-TREX-00110333							
JA-05252	1996-2016	U.S. Department of Transportation, National Highway Traffic Safety Administration, Traffic Safety Facts 1996-Traffic Safety Facts 2016, https://crashstats.nhtsa.dot.gov/#/DocumentTypeList/11 (accessed July 31, 2019).	JAN-TREX-00110334	JAN-TREX-00110559							
JA-05253	1996-2016	U.S. Department of Transportation, National Highway Traffic Safety Administration, Traffic Safety Facts 1996-Traffic Safety Facts 2016, https://crashstats.nhtsa.dot.gov/#/DocumentTypeList/11 (accessed July 31, 2019).	JAN-TREX-00110560	JAN-TREX-00110779							
JA-05254	1996-2016	U.S. Department of Transportation, National Highway Traffic Safety Administration, Traffic Safety Facts 1996-Traffic Safety Facts 2016, https://crashstats.nhtsa.dot.gov/#/DocumentTypeList/11 (accessed July 31, 2019).	JAN-TREX-00110780	JAN-TREX-00110999							
JA-05255	1996-2016	U.S. Department of Transportation, National Highway Traffic Safety Administration, Traffic Safety Facts 1996-Traffic Safety Facts 2016, https://crashstats.nhtsa.dot.gov/#/DocumentTypeList/11 (accessed July 31, 2019).	JAN-TREX-00111000	JAN-TREX-00111219							
JA-05256	1996-2016	U.S. Department of Transportation, National Highway Traffic Safety Administration, Traffic Safety Facts 1996-Traffic Safety Facts 2016, https://crashstats.nhtsa.dot.gov/#/DocumentTypeList/11 (accessed July 31, 2019).	JAN-TREX-00111220	JAN-TREX-00111449							
JA-05257	1996-2016	U.S. Department of Transportation, National Highway Traffic Safety Administration, Traffic Safety Facts 1996-Traffic Safety Facts 2016, https://crashstats.nhtsa.dot.gov/#/DocumentTypeList/11 (accessed July 31, 2019).	JAN-TREX-00111450	JAN-TREX-00111647							
JA-05258	1996-2016	U.S. Department of Transportation, National Highway Traffic Safety Administration, Traffic Safety Facts 1996-Traffic Safety Facts 2016, https://crashstats.nhtsa.dot.gov/#/DocumentTypeList/11 (accessed July 31, 2019).	JAN-TREX-00111648	JAN-TREX-00111869							
JA-05259	1996-2016	U.S. Department of Transportation, National Highway Traffic Safety Administration, Traffic Safety Facts 1996-Traffic Safety Facts 2016, https://crashstats.nhtsa.dot.gov/#/DocumentTypeList/11 (accessed July 31, 2019).	JAN-TREX-00111870	JAN-TREX-00112091							
JA-05260	1996-2016	U.S. Department of Transportation, National Highway Traffic Safety Administration, Traffic Safety Facts 1996-Traffic Safety Facts 2016, https://crashstats.nhtsa.dot.gov/#/DocumentTypeList/11 (accessed July 31, 2019).	JAN-TREX-00112092	JAN-TREX-00112313							
JA-05261	1996-2016	U.S. Department of Transportation, National Highway Traffic Safety Administration, Traffic Safety Facts 1996-Traffic Safety Facts 2016, https://crashstats.nhtsa.dot.gov/#/DocumentTypeList/11 (accessed July 31, 2019).	JAN-TREX-00112314	JAN-TREX-00112535							
JA-05262	1996-2016	U.S. Department of Transportation, National Highway Traffic Safety Administration, Traffic Safety Facts 1996-Traffic Safety Facts 2016, https://crashstats.nhtsa.dot.gov/#/DocumentTypeList/11 (accessed July 31, 2019).	JAN-TREX-00112536	JAN-TREX-00112767							
JA-05263	1996-2016	U.S. Department of Transportation, National Highway Traffic Safety Administration, Traffic Safety Facts 1996-Traffic Safety Facts 2016, https://crashstats.nhtsa.dot.gov/#/DocumentTypeList/11 (accessed July 31, 2019).	JAN-TREX-00112768	JAN-TREX-00112999							
JA-05264	1996-2016	U.S. Department of Transportation, National Highway Traffic Safety Administration, Traffic Safety Facts 1996-Traffic Safety Facts 2016, https://crashstats.nhtsa.dot.gov/#/DocumentTypeList/11 (accessed July 31, 2019).	JAN-TREX-00113000	JAN-TREX-00113231							
JA-05265	1996-2016	U.S. Department of Transportation, National Highway Traffic Safety Administration, Traffic Safety Facts 1996-Traffic Safety Facts 2016, https://crashstats.nhtsa.dot.gov/#/DocumentTypeList/11 (accessed July 31, 2019).	JAN-TREX-00113232	JAN-TREX-00113479							
JA-05266	1996-2016	U.S. Department of Transportation, National Highway Traffic Safety Administration, Traffic Safety Facts 1996-Traffic Safety Facts 2016, https://crashstats.nhtsa.dot.gov/#/DocumentTypeList/11 (accessed July 31, 2019).	JAN-TREX-00113480	JAN-TREX-00113717							
JA-05267	1996-2016	U.S. Department of Transportation, National Highway Traffic Safety Administration, Traffic Safety Facts 1996-Traffic Safety Facts 2016, https://crashstats.nhtsa.dot.gov/#/DocumentTypeList/11 (accessed July 31, 2019).	JAN-TREX-00113718	JAN-TREX-00113955							
JA-05268	1996-2016	U.S. Department of Transportation, National Highway Traffic Safety Administration, Traffic Safety Facts 1996-Traffic Safety Facts 2016, https://crashstats.nhtsa.dot.gov/#/DocumentTypeList/11 (accessed July 31, 2019).	JAN-TREX-00113956	JAN-TREX-00114193							
JA-05269	1996-2016	U.S. Department of Transportation, National Highway Traffic Safety Administration, Traffic Safety Facts 1996-Traffic Safety Facts 2016, https://crashstats.nhtsa.dot.gov/#/DocumentTypeList/11 (accessed July 31, 2019).	JAN-TREX-00114194	JAN-TREX-00114409							
JA-05270	06/08/2012	FSMB Senate Finance Committee Letter Response	OKAG-00020937	OKAG-00020964							
JA-05271	05/21/1986	NIH Report, The Integrated Approach to the Management of Pain	JAN-TREX-00195172	JAN-TREX-00195184							
JA-05272	06/27/1905	J. Devulder, U. Richarz and S. Natara, Impact of long-term use of opioids on quality of life in patients with chronic, non-malignant pain, <i>Librapharm</i> , Volume 21, pp. 1555-1568, 2005	JAN-TREX-00195185	JAN-TREX-00195198							
JA-05273	04/08/1977	George I., Engel, The Need for a New Medical Model: A Challenge for Biomedicine, <i>JSTOR</i> , Volume 196, No. 4286, pp. 129-136, 1977.	JAN-TREX-00195199	JAN-TREX-00195207							
JA-05274	06/13/1905	David A. Fishbain, M.D., F.A.P.A., Myron Goldberg, Ph.D., Renee Steele Rosomoff, R.N., and Hubert Rosomoff, M.D., Completed Suicide in Chronic Pain, <i>Raven Press, Ltd.</i> , Volume 7, No. 1, pp. 29-36, 1991.	JAN-TREX-00195208	JAN-TREX-00195215							
JA-05275	10/02/2015	Frank Brennan, The US Congressional “Decade on Pain Control and Research” 2001–2011: A Review, <i>Taylor & Francis Group, LLC</i> , Volume 29:3, pp. 212-227, 2015.	JAN-TREX-00195216	JAN-TREX-00195232							
JA-05276	06/10/1905	USDHHS presentation, Problems of Drug Dependence 1987	JAN-TREX-00195233	JAN-TREX-00195880							
JA-05277	06/06/1905	Randal France, Bruno Urban and Francis Keefe, Long-Term Use of Narcotic Analgesics in Chronic Pain, <i>Pergamon Press</i> , Volume 19, No. 12, pp. 1379-1382, 1984	JAN-TREX-00195881	JAN-TREX-00195884							
JA-05278	07/03/1905	David A. Fishbain, MD, FAPA, Daniel Bruns, PsyD, John E. Lewis, PhD, John Mark Disorbio, EdD, Jinrun Gao, MS, MBA and Laura J. Meyer, PhD, Predictors of Homicide–Suicide Affirmation in Acute and Chronic Pain Patients, <i>Wiley Periodicals</i> , Volume 12, pp. 127-137, 2011	JAN-TREX-00195885	JAN-TREX-00195895							
JA-05279	07/11/1905	AMA presentation, Council on Legislation Sunset Review of 2009 House Policies	JAN-TREX-00195896	JAN-TREX-00196098							
JA-05280	08/01/2002	DEA and American Pain Foundation, AMA et al report, Promoting Pain Relief and Preventing Abuse of Pain Medications: A Critical Balancing Act	JAN-TREX-00196099	JAN-TREX-00196099							
JA-05281	09/16/2019	Resume of Joshua P. Cohen, Ph.D.	JAN-TREX-00196100	JAN-TREX-00196111							
JA-05282	02/01/2018	Katherine Young and Rachel Garfield, Snapshots of Recent State Initiatives in Medicaid Prescription Drug Cost Control, <i>Kaiser Family Foundation</i> , February 2018 Issue	JAN-TREX-00196112	JAN-TREX-00196127							

Ex. No.	Date	Description	BegBates	EndBates	901 Stip	Admission Stip	Plaintiffs' Objections	Defendants' Objections	Offered	Admitted	Not Admitted
JA-05283	08/01/2017	HealthAffairs presentation, Medicaid Best Price: The Medicaid best price policy requires drug manufacturers to give Medicaid programs the best price among nearly all purchasers.	JAN-TREX-00196128	JAN-TREX-00196131							
JA-05284	06/11/2019	FDA meeting materials, June 11-12, 2019: Joint Meeting of the Drug Safety and RiskManagement Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee	JAN-TREX-00196132	JAN-TREX-00196139							
JA-05285	07/11/1905	AMA report, Council on Legislation Sunset Review of 2009 House Policies	JAN-TREX-00196140	JAN-TREX-00196342							
JA-05286	05/09/2019	USDHHS report, Pain Management: Best Practices	JAN-TREX-00196343	JAN-TREX-00196458							
JA-05287	12/31/1987	Health: Patient Care;Physicians Said to Persist in Undertreating Pain and Ignoring the Evidence, New York Times	JAN-TREX-00196459	JAN-TREX-00196461							
JA-05288	07/03/1905	Institute of Medicine report, Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research.	JAN-TREX-00196462	JAN-TREX-00196843							
JA-05289	08/01/2019	Urban Institute report, State Variation in Medicaid Prescriptions for Opioid Use Disorder from 2011 to 2018	JAN-TREX-00196844	JAN-TREX-00196864							
JA-05290	09/01/2019	AMA report, National Roadmap on State-Level Efforts to End the Opioid Epidemic: Leading-edge Practices and Next Steps	JAN-TREX-00196865	JAN-TREX-00196894							
JA-05291	07/11/1905	Supplemental Materials Considered by Joshua P. Cohen, M.D.	JAN-TREX-00196895	JAN-TREX-00196916							
JA-05292	08/01/2013	SAMHSA report, Associations of Nonmedical Pain Reliever Use and Initiation of Heroin Use in the United States	JAN-TREX-00196917	JAN-TREX-00196932							
JA-05293	07/10/1905	Mark Edmund Rose,BS,MA, Are Prescription Opioids Driving the Opioid Crisis? Assumptions vs Facts, Oxford Press, Volume 19, pp. 793-807, 2018	JAN-TREX-00196933	JAN-TREX-00196947							
JA-05294	05/31/2014	Center for Evidence-Based Practices at Case Western Reserve University Presentation: Facing the Opiate Epidemic: How We Got Here and What We Need to Do Next	SUMMIT_000822287	SUMMIT_000822346							
JA-05295	08/24/2019	Twitter: ONDCP on Twitter. ".@realdonaldtrump was right. China continues to pour poison into our communities. More than 23,000 kilograms of Chinese fentanyl seized at Mexico's largest seaport. FINAL DESTINATION: USA. https://t/co/6n0LVeWRKH", available at https://twitter.com/ONDCP/status/1165288934060019712	JAN-TREX-00181902	JAN-TREX-00181933							
JA-05296	05/00/1979	Interagency Committee on New Therapies for Pain and Discomfort, Report to the White House	JAN-TREX-00197230	JAN-TREX-00197493							
JA-05297	05/29/2008	JAN-MS-00406028: Smart Moves Smart Choices	JAN-MS-00406028	JAN-MS-00406028							
JA-05298	N/A	JAN-MS-00500637: Smart Moves, Smart Choices PowerPoint	JAN-MS-00500637	JAN-MS-00500637							
JA-05299	N/A	JAN-MS-00500670: Smart Moves Smart Choices: A Prescription Drug Abuse Education Program	JAN-MS-00500670	JAN-MS-00500673							
JA-05300	N/A	JAN-MS-00500674: Smart Moves Smart Choices: A Prescription Drug Abuse Education Program	JAN-MS-00500674	JAN-MS-00500675							
JA-05301	05/31/2012	JAN-MS-00927238: Email from Bert Wickey to Robyn Kohn et al.	JAN-MS-00927238	JAN-MS-00927239							